PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GEIGER, HJ				GEIGER, HJ			THE ROAD OUT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1152	1152						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933329				2022-12-28	WOS:A1994PL21200001
J	PAVLIDIS, P; RAMASWAMI, M; TANOUYE, MA				PAVLIDIS, P; RAMASWAMI, M; TANOUYE, MA			THE DROSOPHILA EASILY SHOCKED GENE - A MUTATION IN A PHOSPHOLIPID SYNTHETIC PATHWAY CAUSES SEIZURE, NEURONAL FAILURE, AND PARALYSIS	CELL			English	Article							CHOLINE KINASE; ETHANOLAMINE KINASE; ESCHERICHIA-COLI; SODIUM-CHANNELS; RAT-LIVER; MELANOGASTER; EXPRESSION; PROTEIN; SEQUENCE; CLONING	We have characterized easily shocked (eas), a Drosophila ''bang-sensitive'' paralytic mutant. Electrophysiological recordings from flight muscles in the giant fiber pathway of adult eas flies reveal that induction of paralysis with electrical stimulation results in a brief seizure, followed by a failure of the muscles to respond to giant fiber stimulation. Molecular cloning, germline transformation, and biochemical experiments show that eas mutants are defective in the gene for ethanolamine kinase, which is required for a pathway of phosphatidylethanolamine synthesis. Assays of phospholipid composition reveal that total phosphatidylethanolamine is decreased in eas mutants. The data suggest that eas bang sensitivity is due to an excitability defect caused by altered membrane phospholipid composition.	UNIV CALIF BERKELEY,DEPT ENVIRONM SCI POLICY & MANAGEMENT,BERKELEY,CA 94720; TATA INST FUNDAMENTAL RES,MOLEC BIOL UNIT,BOMBAY 400005,MAHARASHTRA,INDIA	University of California System; University of California Berkeley; Tata Institute of Fundamental Research (TIFR)	PAVLIDIS, P (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.		Pavlidis, Paul/H-8406-2013	Pavlidis, Paul/0000-0002-0426-5028; Ramaswami, Mani/0000-0001-7631-0468				ALNAES E, 1975, J PHYSL, V248, P306; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENZER S, 1971, J AMER MED ASSOC, V218, P1015, DOI 10.1001/jama.218.7.1015; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURT AM, 1975, ANAL BIOCHEM, V65, P215, DOI 10.1016/0003-2697(75)90506-0; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DOWNER RGH, 1985, COMPREHENSIVE INSECT, P78; EXTON JH, 1994, CURR OPIN CELL BIOL, V6, P226, DOI 10.1016/0955-0674(94)90140-6; FALK DR, 1984, MUTAT RES, V126, P25, DOI 10.1016/0027-5107(84)90166-0; FAST PG, 1966, LIPIDS, V1, P209, DOI 10.1007/BF02531874; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORTE M, 1981, P NATL ACAD SCI-BIOL, V78, P7195, DOI 10.1073/pnas.78.11.7195; GANETZKY B, 1982, GENETICS, V100, P597; Gorczyca M., 1984, Journal of Neurogenetics, V1, P289, DOI 10.3109/01677068409107093; HALL JC, 1985, COMPREHENSIVE INSECT, V9, P287; HEILIG JS, 1991, EMBO J, V10, P809, DOI 10.1002/j.1460-2075.1991.tb08013.x; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, FEBS LETT, V304, P229, DOI 10.1016/0014-5793(92)80625-Q; IKEDA K, 1980, J NEUROCYTOL, V9, P799, DOI 10.1007/BF01205020; JACKSON FR, 1985, J NEUROSCI, V5, P1144; JAN YN, 1978, P NATL ACAD SCI USA, V75, P515, DOI 10.1073/pnas.75.1.515; JONES KR, 1990, NEURON, V4, P711, DOI 10.1016/0896-6273(90)90197-N; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KENNEDY EP, 1957, ANNU REV BIOCHEM, V26, P119, DOI 10.1146/annurev.bi.26.070157.001003; KING DG, 1980, J NEUROCYTOL, V9, P753, DOI 10.1007/BF01205017; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; MARTIN JH, 1993, PRINCIPLES NEURAL SC, P777; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGEE TP, 1993, PROTEIN LIPID INTERA, P163; MIDOZIC M, 1992, GENE EXPRESSION NEUR, P397; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OLSEN RW, 1976, BRAIN RES, V102, P283, DOI 10.1016/0006-8993(76)90883-0; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PORTER TJ, 1990, J BIOL CHEM, V265, P414; RAMABRAHMAM P, 1981, ARCH BIOCHEM BIOPHYS, V207, P55, DOI 10.1016/0003-9861(81)90007-2; ROBERTSON HM, 1988, GENETICS, V118, P461; ROYDEN CS, 1987, CELL, V51, P165, DOI 10.1016/0092-8674(87)90144-9; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBIGER M, 1994, NEURON, V12, P373, DOI 10.1016/0896-6273(94)90278-X; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SHELLEY RM, 1971, J INSECT PHYSIOL, V17, P545, DOI 10.1016/0022-1910(71)90032-1; Skipski V.P., 1969, METHOD ENZYMOL, V14, P530; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; Sundler R., 1984, Biomembranes, V12, P563; SURDEJ P, 1990, BIOL CELL, V68, P105, DOI 10.1016/0248-4900(90)90295-E; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TANOUYE MA, 1980, J NEUROPHYSIOL, V44, P405, DOI 10.1152/jn.1980.44.2.405; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; ULANE RE, 1982, LUNG DEV BIOL CLIN P, V1, P295; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5135, DOI 10.1021/bi00722a013; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; Wu C F, 1992, Ion Channels, V3, P261; WU CF, 1980, NATURE, V286, P814, DOI 10.1038/286814a0; YEAGLE PL, 1989, FASEB J, V3, P1833, DOI 10.1096/fasebj.3.7.2469614; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0; [No title captured]	61	147	152	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					23	33		10.1016/0092-8674(94)90397-2	http://dx.doi.org/10.1016/0092-8674(94)90397-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923374				2022-12-28	WOS:A1994PK58500005
J	COHEN, JHM				COHEN, JHM			GRESHAMS-LAW	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					966	966		10.1016/S0140-6736(94)92328-0	http://dx.doi.org/10.1016/S0140-6736(94)92328-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934385				2022-12-28	WOS:A1994PJ28700072
J	RANDALL, MD				RANDALL, MD			ENDOTHELINS - FROM LABORATORY TO CLINIC	LANCET			English	Editorial Material											RANDALL, MD (corresponding author), UNIV NOTTINGHAM,QUEENS MED CTR,SCH MED,DEPT PHYSIOL & PHARMACOL,NOTTINGHAM NG7 2UH,ENGLAND.							CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; DASHWOOD MR, 1993, CARDIOVASC PHARM S8, V22, pS343; DOUGLAS SA, 1993, J CARDIOVASC PHARM, V22, pS371, DOI 10.1097/00005344-199322008-00097; DOUGLAS SA, 1994, CIRC RES, V75, P190, DOI 10.1161/01.RES.75.1.190; GARDINER SM, 1994, BRIT J PHARMACOL, V112, P823, DOI 10.1111/j.1476-5381.1994.tb13153.x; HUGGINS JP, 1993, PHARMACOL THERAPEUT, V59, P55, DOI 10.1016/0163-7258(93)90041-B; MCMAHON EG, 1991, J CARDIOVASC PHARM, V17, pS29, DOI 10.1097/00005344-199100177-00009; OHLSTEIN EH, 1993, J CARDIOVASC PHARM, V22, pS321, DOI 10.1097/00005344-199322008-00084; RANDALL MD, 1991, PHARMACOL THERAPEUT, V50, P73, DOI 10.1016/0163-7258(91)90073-U; VALLANCE P, 1989, LANCET, V2, P997; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZAMORA MR, 1990, LANCET, V336, P1144, DOI 10.1016/0140-6736(90)92766-B; [No title captured]; 1991, LANCET, V337, P79	14	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					832	833		10.1016/S0140-6736(94)92819-3	http://dx.doi.org/10.1016/S0140-6736(94)92819-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916393				2022-12-28	WOS:A1994PH25300003
J	WICKS, C; SOMASUNDARAM, S; BJARNASON, I; MENZIES, IS; ROUTLEY, D; POTTER, D; TAN, KC; WILLIAMS, R				WICKS, C; SOMASUNDARAM, S; BJARNASON, I; MENZIES, IS; ROUTLEY, D; POTTER, D; TAN, KC; WILLIAMS, R			COMPARISON OF ENTERAL FEEDING AND TOTAL PARENTERAL-NUTRITION AFTER LIVER-TRANSPLANTATION	LANCET			English	Article							INTESTINAL PERMEABILITY; DISEASE; SURGERY; HUMANS; RATS; GUT	Total parenteral nutrition is used for nutritional support in patients undergoing orthotopic liver transplantation but is associated with complications. We compared the efficacy and tolerability of early enteral feeding with total parenteral nutrition after liver transplantation. 24 patients were studied: 14 received enteral feeding and 10 total parenteral nutrition. A double-lumen enteral tube was used to deliver the feed directly into the jejunum with the second lumen of the tube being used for gastric aspiration. Enteral feeding was started post-operatively within 18 h, was well-tolerated, and of comparable efficacy to total parenteral nutrition. The median number of days for patients to start eating (4) and to achieve 70% of estimated requirements orally (5) did not differ significantly between the two groups. Mid-arm circumference, triceps skinfold thickness, and biceps skinfold thickness were, by comparison with pre-operative values, maintained on the tenth postoperative day in both groups. Early postoperative absorptive capacity, as assessed by a combined carbohydrate test, was reduced significantly in both groups but insufficiently to be of nutritional concern. Intestinal mucosal integrity, as assessed by an intestinal permeability test, was maintained throughout. We conclude that the practical aspects of enteral feeding after liver transplantation are surmountable and that enteral feeding is as effective at maintaining nutritional status as total parenteral nutrition, and has potential benefits in terms of reduced complications and costs.	UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,LONDON SE5 9RS,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT CLIN BIOCHEM,LONDON SE5 9RS,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT ANAESTHESIA,LONDON SE5 9RS,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT LIVER TRANSPLANT SURG,LONDON SE5 9RS,ENGLAND; ST THOMAS HOSP,DEPT CHEM PATHOL,LONDON,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust				Somasundaram, Siva/0000-0002-3833-4845; opoku, anita/0000-0001-7243-8157				ALVERDY JC, 1988, SURGERY, V104, P185; BISHOP CW, 1987, J AM DIET ASSOC, V87, P469; BUDILLON G, 1985, J HEPATOL, V1, P513, DOI 10.1016/S0168-8278(85)80749-2; BURKE DJ, 1989, ARCH SURG-CHICAGO, V124, P1396; DICECCO SR, 1989, MAYO CLIN PROC, V64, P95, DOI 10.1016/S0025-6196(12)65308-7; DIETZ EA, 1990, SURGERY, V102, P411; FERRY DM, 1989, GASTROENTEROLOGY, V97, P61, DOI 10.1016/0016-5085(89)91416-9; FREUND HR, 1990, JPEN-PARENTER ENTER, V14, P39, DOI 10.1177/014860719001400139; HASS JD, 1981, NUTRITION CANCER ETI; HUGHES CA, 1980, CLIN SCI, V59, P317, DOI 10.1042/cs0590317; LEVOYER T, 1992, ARCH SURG-CHICAGO, V127, P26; MAXTON DG, 1989, CLIN SCI, V77, P401, DOI 10.1042/cs0770401; MAYNARD ND, 1991, BRIT MED J, V303, P1007, DOI 10.1136/bmj.303.6809.1007; MCCULLOUGH AJ, 1991, SEMIN LIVER DIS, V11, P265, DOI 10.1055/s-2008-1040445; MINAMI H, 1984, GASTROENTEROLOGY, V86, P1592; ODWYER ST, 1988, ARCH SURG-CHICAGO, V123, P1459; OHRI SK, 1994, GASTROENTEROLOGY, V106, P318, DOI 10.1016/0016-5085(94)90588-6; OKEEFE SJ, 1980, LANCET, V2, P615; OTAMIRI T, 1987, ACTA CHIR SCAND, V153, P51; PAYNEJAMES JJ, 1991, BR J INTENS CARE, V1, P135; ROUMEN RMH, 1993, J VASC SURG, V17, P734, DOI 10.1016/0741-5214(93)90118-6; RYAN JA, 1982, JPEN J PARENTER ENTE, V8, P187; SCHROEDER D, 1991, JPEN-PARENTER ENTER, V15, P376, DOI 10.1177/0148607191015004376; SIGALET DL, 1992, TRANSPLANTATION, V53, P1103, DOI 10.1097/00007890-199205000-00024; TEAHON K, 1992, GUT, V33, P320, DOI 10.1136/gut.33.3.320; THOMPSON DG, 1990, MED INT, V78, P3231; WAGMAN LD, 1986, ANN SURG, V204, P524, DOI 10.1097/00000658-198611000-00003; WEINSIER RL, 1982, JPEN-PARENTER ENTER, V6, P421, DOI 10.1177/0148607182006005421; WOOLFSON AMJ, 1989, CLIN NUTR, V8, P15, DOI 10.1016/0261-5614(89)90020-4; ZIEGLER TR, 1988, ARCH SURG-CHICAGO, V123, P1313	30	132	146	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					837	840		10.1016/S0140-6736(94)92824-X	http://dx.doi.org/10.1016/S0140-6736(94)92824-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916398				2022-12-28	WOS:A1994PH25300008
J	ARONHEIM, A; ENGELBERG, D; LI, NX; ALALAWI, N; SCHLESSINGER, J; KARIN, M				ARONHEIM, A; ENGELBERG, D; LI, NX; ALALAWI, N; SCHLESSINGER, J; KARIN, M			MEMBRANE TARGETING OF THE NUCLEOTIDE EXCHANGE FACTOR SOS IS SUFFICIENT FOR ACTIVATING THE RAS SIGNALING PATHWAY	CELL			English	Article							RECEPTOR TYROSINE KINASES; SACCHAROMYCES-CEREVISIAE CDC25; EPIDERMAL GROWTH-FACTOR; GENE-PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; MAMMALIAN RAS; TRANSDUCTION; GRB2; PHOSPHORYLATION	Activation of growth factor receptors results in tyrosine autophosphorylation and recruitment of SH2 domain-containing effecters, including Grb2. Grb2 recruitment mediates activation of the Ras nucleotide exchanger Sos by an unknown mechanism. To examine the role of membrane recruitment, we prepared Sos derivatives containing either myristoylation or farnesylation signals. This resulted in plasma membrane targeting of Sos and stimulation of the Ras signaling pathway, including ERK and AP-1 activities leading to oncogenic transformation. Sos derivatives with nonfunctional myristoylation or farnesylation sequences were inactive. Farnesylation of Sos also activated pas signaling in yeast. In both mammalian cells and yeast, membrane-targeted Sos derivatives lacking the C-terminal region were considerably more active. Therefore, targeting of Sos to the plasma membrane in the vicinity of Ras appears to be the primary mechanism leading to activation of the Ras pathway. A secondary mechanism could involve relief of the inhibitory effect of the Sos C-terminal region.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT MED,PROGRAM BIOMED SCI,LA JOLLA,CA 92093; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	University of California System; University of California San Diego; New York University	ARONHEIM, A (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.			Aronheim, Ami/0000-0002-8575-4092				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DEBELL KE, 1992, J IMMUNOL, V149, P2271; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ENGELBERG D, 1990, EMBO J, V9, P641, DOI 10.1002/j.1460-2075.1990.tb08156.x; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARREAU H, 1990, FEBS LETT, V269, P53, DOI 10.1016/0014-5793(90)81117-7; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1994, IN PRESS MOL CELL BI; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAWSON T, 1993, CURR BIOL, V3, P4345; PETITJEAN A, 1990, GENETICS, V124, P797; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SEGAL M, 1992, J BIOL CHEM, V267, P22747; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUSA M, 1992, J BIOL CHEM, V267, P22951; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	65	425	445	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					949	961		10.1016/0092-8674(94)90271-2	http://dx.doi.org/10.1016/0092-8674(94)90271-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923364				2022-12-28	WOS:A1994PJ29400007
J	BERNHARD, JD				BERNHARD, JD			THE SWEAT SUITE	LANCET			English	Editorial Material							GLAND-FUNCTION; DISORDERS; BIOLOGY				BERNHARD, JD (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV DERMATOL,WORCESTER,MA, USA.							CHAMPION RH, 1992, TXB DERMATOLOGY, P1745; Inaba M., 1992, HUMAN BODY ODOR ETIO; KLIGMAN AM, 1963, BRIT J DERMATOL, V75, P307, DOI 10.1111/j.1365-2133.1963.tb13567.x; PORTER AMW, 1993, J HUM EVOL, V25, P417, DOI 10.1006/jhev.1993.1059; SATO K, 1989, J AM ACAD DERMATOL, V20, P713, DOI 10.1016/S0190-9622(89)70081-5; SATO K, 1989, J AM ACAD DERMATOL, V20, P537, DOI 10.1016/S0190-9622(89)70063-3	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					767	768		10.1016/S0140-6736(94)92336-1	http://dx.doi.org/10.1016/S0140-6736(94)92336-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916068				2022-12-28	WOS:A1994PG17800005
J	YEN, LM; DAO, LM; DAY, NPJ; WALLER, DJ; BETHELL, DB; SON, LH; HIEN, TT; WHITE, NJ				YEN, LM; DAO, LM; DAY, NPJ; WALLER, DJ; BETHELL, DB; SON, LH; HIEN, TT; WHITE, NJ			ROLE OF QUININE IN THE HIGH MORTALITY OF INTRAMUSCULAR INJECTION TETANUS	LANCET			English	Article								There has been considerable uncertainty about the risks and severity of tetanus after intramuscular quinine, a widely used treatment of severe malaria in the rural tropics. We have compared the clinical features and outcome of tetanus in which injection was the only apparent site of infection with tetanus acquired by other routes in patients admitted to the Centre for Tropical Diseases, Ho Chi Minh City, Vietnam. In 1081 consecutive patients with tetanus treated between Jan 26, 1989, and May 27, 1991, 27 followed intramuscular quinine and 15 followed injections of other drugs. Overall mortality was 26% (285/1081). Mortality in patients who had not had preceding injections was 24% (250/1039) compared with 96% (26/27) in the quinine group (relative risk 4.0, 95% Cl 3.5-4.6) (p < 0.0001), and 60% (9/15) in the other injections group (2.5, 1.6-3.8) (p < 0.005). 21 patients (78%) in the quinine group died within 72 h of admission compared with 5 (33%) in the other intramuscular injections group(p < 0.01) and 4 (7%) of 54 matched controls (p < 0.0001). Tetanus that follows intramuscular injections has a poor prognosis, but when it follows intramuscular quinine it is usually rapidly fatal.	CHO QUAN HOSP, WELLCOME TRUST CLIN RES UNIT, HO CHI MINH CITY OX3 9DU, VIETNAM; CHO QUAN HOSP, CTR TROP DIS, HO CHI MINH CITY, VIETNAM; JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD, ENGLAND	University of Oxford			White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKRY N, 1991, J PHARMACOL EXP THER, V258, P613; BRETTLE RP, 1992, J INFECTION, V25, P121, DOI 10.1016/0163-4453(92)93874-P; CHERUBIN CE, 1967, ANN INTERN MED, V67, P23, DOI 10.7326/0003-4819-67-1-23; FLETCHER W, 1923, STUDIES I MED RES KU, P24; FRANCIS E, 1914, B HYG LAB, V95, P1; ROSS Ronald, 1914, Journal of Tropical Medicine and Hygiene, V17, P286; SEMPLE D, 1911, SCI MEMOIRS GOVERN I, V43, P60; 1990, T R SOC TROP MED S2, V84, P1	8	38	38	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 17	1994	344	8925					786	787		10.1016/S0140-6736(94)92342-6	http://dx.doi.org/10.1016/S0140-6736(94)92342-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916074				2022-12-28	WOS:A1994PG17800011
J	PORTEGIES, P; ENTING, RH; DEJONG, MD; DANNER, SA; REISS, P; GOUDSMIT, J; LANGE, JMA				PORTEGIES, P; ENTING, RH; DEJONG, MD; DANNER, SA; REISS, P; GOUDSMIT, J; LANGE, JMA			AIDS DEMENTIA COMPLEX AND DIDANOSINE	LANCET			English	Letter							ZIDOVUDINE		UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT VIROL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,NATL AIDS THERAPY EVALUAT CTR,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	PORTEGIES, P (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT NEUROL,1105 AZ AMSTERDAM,NETHERLANDS.							BALIS FM, 1992, J INFECT DIS, V165, P99, DOI 10.1093/infdis/165.1.99; DARBYSHIRE JH, 1992, LANCET, V340, P1346, DOI 10.1016/0140-6736(92)92524-J; GRAY F, 1994, AIDS, V8, P489, DOI 10.1097/00002030-199404000-00011; PORTEGIES P, 1989, BRIT MED J, V299, P819, DOI 10.1136/bmj.299.6703.819; PORTEGIES P, 1993, AIDS, V7, P669, DOI 10.1097/00002030-199305000-00010	5	27	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					759	759		10.1016/S0140-6736(94)92252-7	http://dx.doi.org/10.1016/S0140-6736(94)92252-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915809				2022-12-28	WOS:A1994PF18700060
J	MACSWEENEY, STR; ELLIS, M; WORRELL, PC; GREENHALGH, RM; POWELL, JT				MACSWEENEY, STR; ELLIS, M; WORRELL, PC; GREENHALGH, RM; POWELL, JT			SMOKING AND GROWTH-RATE OF SMALL ABDOMINAL AORTIC-ANEURYSMS	LANCET			English	Note							MORTALITY	Smoking is an important risk factor for abdominal aortic aneurysm. Limiting the growth rate of small aneurysms has the potential to prevent them reaching a size at which surgical repair is considered. In 43 patients, with small aneurysms, growth rates were studied by serial ultrasound over 3 years. The median expansion rate of these small aneurysms was 0.13 cm per year. Growth rates were higher in those who continued to smoke (0.16 vs 0.09 cm per year in those who no longer smoked, p = 0.038). Higher growth rates were significantly correlated with the concentration of serum cotinine. Stopping smoking could reduce the growth rate of small abdominal aortic aneurysms.			MACSWEENEY, STR (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON W6 8RF,ENGLAND.		Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				ADISESHIAH M, 1993, LANCET, V341, P215; ELLIS M, 1991, BRIT J SURG, V78, P614, DOI 10.1002/bjs.1800780529; FEYERABEND C, 1980, ANALYST, V105, P998, DOI 10.1039/an9800500998; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HARRIS PL, 1992, BMJ-BRIT MED J, V305, P697, DOI 10.1136/bmj.305.6855.697; JENKINS AM, 1986, BRIT J SURG, V73, P395, DOI 10.1002/bjs.1800730528; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; MACSWEENEY STR, 1993, BRIT J SURG, V80, P582, DOI 10.1002/bjs.1800800510; STRACHAN DP, 1991, BRIT J SURG, V78, P401, DOI 10.1002/bjs.1800780407	9	145	145	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					651	652		10.1016/S0140-6736(94)92087-7	http://dx.doi.org/10.1016/S0140-6736(94)92087-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915350				2022-12-28	WOS:A1994PE38600012
J	KING, M; ELLIOTT, C				KING, M; ELLIOTT, C			CAIRO - DAMP SQUIB OR ROMAN CANDLE	LANCET			English	Editorial Material																		Brown L., 1994, VITAL SIGNS 1994; DEWAAL A, 1994, TIMES LITERARY  0701; KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; KING M, 1993, LANCET, V341, P669, DOI 10.1016/0140-6736(93)90431-F; KING MH, 1991, DEMOGRAPHIC TRAP; MASKELL K, 1993, LANCET, V342, P1027, DOI 10.1016/0140-6736(93)92883-U; PLNSTRUPANDERSE.P, 1993, WORLD FOOD TRENDS TH; 1992, HUMAN DEV REPORT; 1990, STATE FOOD AGR	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					528	528		10.1016/S0140-6736(94)91906-2	http://dx.doi.org/10.1016/S0140-6736(94)91906-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914621				2022-12-28	WOS:A1994PC53500017
J	STRANDGAARD, S; PAULSON, OB				STRANDGAARD, S; PAULSON, OB			CEREBROVASCULAR CONSEQUENCES OF HYPERTENSION	LANCET			English	Article							ANTIHYPERTENSIVE TREATMENT; BLOOD-PRESSURE; STROKE; INFARCTION		RIGSHOSP, DEPT NEUROL, DK-2100 COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen	STRANDGAARD, S (corresponding author), HERLEV HOSP, DEPT MED & NEPHROL B, DK-2730 HERLEV, DENMARK.		Paulson, Olaf B./N-6924-2016	Paulson, Olaf B./0000-0001-7712-8596				[Anonymous], 1991, JAMA, V265, P3255; BRITTON M, 1986, STROKE, V17, P861, DOI 10.1161/01.STR.17.5.861; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DONNAN GA, 1992, LANCET, V339, P473, DOI 10.1016/0140-6736(92)91070-O; FUJII K, 1992, HYPERTENSION, V19, P713, DOI 10.1161/01.HYP.19.6.713; HACHINSKI VC, 1987, ARCH NEUROL-CHICAGO, V44, P21, DOI 10.1001/archneur.1987.00520130013009; HANKEY GJ, 1987, MED J AUSTRALIA, V146, P412, DOI 10.5694/j.1326-5377.1987.tb120332.x; IRIE K, 1993, STROKE, V24, P1844, DOI 10.1161/01.STR.24.12.1844; LEDINGHAM JGG, 1979, Q J MED, V48, P25; MOYER JH, 1952, AM J MED SCI, V224, P377, DOI 10.1097/00000441-195210000-00002; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PAULSON OB, 1994, HYPERTENSION PATHOPH; SANDERCOCK P, 1992, LANCET, V339, P537, DOI 10.1016/0140-6736(92)90348-7; SPENCE JD, 1986, STROKE, V17, P808, DOI 10.1161/01.STR.17.5.808; STRANDGAARD S, 1987, LANCET, V2, P658; Strandgaard Svend, 1993, P675; YAO H, 1992, STROKE, V23, P1673, DOI 10.1161/01.STR.23.11.1673	18	58	59	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	1994	344	8921					519	521		10.1016/S0140-6736(94)91903-8	http://dx.doi.org/10.1016/S0140-6736(94)91903-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914618				2022-12-28	WOS:A1994PC53500014
J	MELNICK, J; DUL, JL; ARGON, Y				MELNICK, J; DUL, JL; ARGON, Y			SEQUENTIAL INTERACTION OF THE CHAPERONES BIP AND GRP94 WITH IMMUNOGLOBULIN-CHAINS IN THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							GLUCOSE-REGULATED PROTEIN; BINDING-SPECIFICITY; BIP; HSP90; GLYCOPROTEIN; CELLS; ASSOCIATION; ABUNDANT; ATPASE; GENES	During their transit through the endoplasmic reticulum, newly synthesized light and heavy chains of immunoglobulins associate with two endoplasmic reticulum stress proteins. BiP/GRP78, a member of the HSP70 family, binds these polypeptides, presumably through promiscuously exposed hydrophobic sequences(1,2), soon after their translocation into the endoplasmic reticulum(3,4). GRP94, another endoplasmic reticulum stress protein(5,6) homologous to HSP90(7-11), also associates,vith unassembled immunoglobulin chains(12), but its interaction is biochemically, kinetically and structurally distinct from BiP's. We report here that whereas BiP preferentially binds an early disulphide intermediate of light chain and dissociates within a few minutes, GRP94 exclusively binds fully oxidized molecules and dissociates with a half-time of 50 min. These results indicate that GRP94 is itself a chaperone which acts after BiP.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University								BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOGEN B, 1989, SCAND J IMMUNOL, V29, P273, DOI 10.1111/j.1365-3083.1989.tb01125.x; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; COWAN NJ, 1974, J MOL BIOL, V90, P691, DOI 10.1016/0022-2836(74)90533-6; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOCH G, 1986, J CELL SCI, V86, P217; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WU GE, 1983, CELL, V33, P77, DOI 10.1016/0092-8674(83)90336-7	27	361	370	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					373	375		10.1038/370373a0	http://dx.doi.org/10.1038/370373a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	7913987				2022-12-28	WOS:A1994PA30400056
J	AZEM, A; KESSEL, M; GOLOUBINOFF, P				AZEM, A; KESSEL, M; GOLOUBINOFF, P			CHARACTERIZATION OF A FUNCTIONAL GROEL(14)(GROES(7))(2) CHAPERONIN HETERO-OLIGOMER	SCIENCE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; CENTRAL CAVITY; GROEL; RECONSTITUTION; PURIFICATION; HYDROLYSIS; BINDING; HSP60	Chaperonins GroEL and GroES form two types of hetero-oligomers in vitro that can mediate the folding of proteins. Chemical cross-linking and electron microscopy showed that in the presence of adenosine triphosphate (ATP), two GroES(7) rings can successively bind a single GroEL(14) core oligomer. The symmetric GroEL(14)(GroES(7))(2) chaperonin, whose central cavity appears obstructed by two GroES(7) rings, can nonetheless stably bind and assist the ATP-dependent refolding of RuBisCO enzyme. Thus, unfolded proteins first bind and possibly fold on the external envelope of the chaperonin hetero-oligomer.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BOT,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MEMBRANE & ULTRASTRUCT RES,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem				Goloubinoff, Pierre/0000-0002-4802-0807				AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; DARAWSHE S, 1991, EUR J BIOCHEM, V201, P169, DOI 10.1111/j.1432-1033.1991.tb16270.x; ELLIS RJ, 1993, NATURE, V366, P213, DOI 10.1038/366213a0; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRIMM R, 1993, J BIOL CHEM, V268, P5220; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	30	145	147	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					653	656		10.1126/science.7913553	http://dx.doi.org/10.1126/science.7913553			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	7913553				2022-12-28	WOS:A1994NZ53800031
J	SUPPARATPINYO, K; KHAMWAN, C; BAOSOUNG, V; NELSON, KE; SIRISANTHANA, T				SUPPARATPINYO, K; KHAMWAN, C; BAOSOUNG, V; NELSON, KE; SIRISANTHANA, T			DISSEMINATED PENICILLIUM-MARNEFFEI INFECTION IN SOUTHEAST-ASIA	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PATIENT; THAILAND; MYCOSIS; CHINA	Disseminated infection with the fungal pathogen Penicillium marneffei is, after extrapulmonary tuberculosis and cryptococcal meningitis, the third most common opportunistic infection in HIV disease in northern Thailand. We report the clinical, microbiological, and therapeutic features of a large series of HIV-infected adults with disseminated P marneffei infection. From August, 1987, to June, 1992, 92 patients with Pmarneffei infection confirmed by culture were seen at Chiang Mai University Hospital, of whom 86 were also infected with HIV. Clinical information was available for 80 of these patients. The most common presenting symptoms and signs were fever (92%), anaemia (77%), weight loss (76%), and skin lesions (71%). 87% of patients presenting with skin lesions had generalised papules with central umbilication. Presumptive diagnosis was made in 50 patients by microscopic examination of Wright's-stained bone-marrow aspirate and/or touch smears of skin biopsy or lymph-node biopsy specimens. Most patients who were diagnosed responded initially to amphotericin or itraconazole, whereas most who were not diagnosed and treated died. 12 patients relapsed within 6 months of cessation of treatment. P marneffei has become an important pathogen of HIV-associated opportunistic infection in Thailand.	CHIANG MAI UNIV,FAC MED,DEPT MED,INFECT DIS SECT,CHIANG MAI 50002,THAILAND; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD	Chiang Mai University; Johns Hopkins University								ANCELLE T, 1988, Bulletin de la Societe Francaise de Mycologie Medicale, V17, P73; [Anonymous], 1959, BULL SOC MYCOL FR; CHAN JKC, 1989, ACTA CYTOL, V33, P523; CHAN YF, 1990, J BONE JOINT SURG BR, V72, P500, DOI 10.1302/0301-620X.72B3.2341456; CHIEWCHANVIT S, 1991, MYCOSES, V34, P245, DOI 10.1111/j.1439-0507.1991.tb00652.x; DENG ZL, 1985, AM J CLIN PATHOL, V84, P323, DOI 10.1093/ajcp/84.3.323; DENG ZL, 1988, REV INFECT DIS, V10, P640; DISALVO AF, 1973, AM J CLIN PATHOL, V60, P259; HILMARSDOTTIR I, 1993, J ACQ IMMUN DEF SYND, V6, P466; HOCKEY LJ, 1982, J CLIN MICROBIOL, V16, P1080, DOI 10.1128/JCM.16.6.1080-1085.1982; HULSHOF CMJ, 1990, EUR J CLIN MICROBIOL, V9, P370, DOI 10.1007/BF01973751; JAYANETRA P, 1984, AM J TROP MED HYG, V33, P637, DOI 10.4269/ajtmh.1984.33.637; JONES PD, 1992, CLIN INFECT DIS, V15, P744, DOI 10.1093/clind/15.4.744; LI JS, 1991, CHINESE MED J-PEKING, V104, P247; MA KF, 1991, ACTA CYTOL, V35, P557; PAUTLER KB, 1984, SABOURAUDIA, V22, P433; PETO TEA, 1988, J INFECTION, V16, P285, DOI 10.1016/S0163-4453(88)97700-6; PIEHL MR, 1988, ARCH PATHOL LAB MED, V112, P1262; SATHAPATAYAVONGS B, 1989, J INFECTION, V19, P84, DOI 10.1016/S0163-4453(89)95136-0; SIRISANTHANA V, 1993, PEDIATR INFECT DIS J, V12, P1021, DOI 10.1097/00006454-199312000-00013; SO SY, 1985, AM REV RESPIR DIS, V131, P662, DOI 10.1164/arrd.1985.131.4.662; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; SUPPARATPINYO K, 1993, ANTIMICROB AGENTS CH, V37, P2407, DOI 10.1128/AAC.37.11.2407; TSANG DNC, 1991, REV INFECT DIS, V13, P766; TSANG DNC, 1988, HISTOPATHOLOGY, V13, P311, DOI 10.1111/j.1365-2559.1988.tb02041.x; TSUI WMS, 1992, HISTOPATHOLOGY, V20, P287, DOI 10.1111/j.1365-2559.1992.tb00985.x; VIVIANI MA, 1993, EUR J EPIDEMIOL, V9, P79, DOI 10.1007/BF00463094; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; YUEN WC, 1986, BRIT J SURG, V73, P1007, DOI 10.1002/bjs.1800731224; 1987, MMWR S1S, V36, pS1	30	403	458	2	24	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					110	113		10.1016/S0140-6736(94)91287-4	http://dx.doi.org/10.1016/S0140-6736(94)91287-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912350	hybrid			2022-12-28	WOS:A1994NV73200015
J	BERREBI, A; KOBUCH, WE; BESSIERES, MH; BLOOM, MC; ROLLAND, M; SARRAMON, MF; ROQUES, C; FOURNIE, A				BERREBI, A; KOBUCH, WE; BESSIERES, MH; BLOOM, MC; ROLLAND, M; SARRAMON, MF; ROQUES, C; FOURNIE, A			TERMINATION OF PREGNANCY FOR MATERNAL TOXOPLASMOSIS	LANCET			English	Article							CONGENITAL TOXOPLASMOSIS	Termination of pregnancy is usually recommended to pregnant women who have infection with Toxoplasma gondii before 26 weeks of pregnancy if the fetus is infected. No prospective studies are available on the outcome if such pregnancies are allowed to continue with anti-parasitic treatment. We prospectively studied 163 mothers with acute toxoplasma infection before 28 weeks of amenorrhoea. All received anti-parasitic treatment with 9 million IU spiramycin orally. 23 also received pyrimethamine and sulphadiazine. All had cordocentesis and regular obstetric ultrasound examinations. The 162 liveborn infants were followed up for 15 to 71 months. 3 fetuses died in utero. 27 of 162 liveborn infants had proven congenital toxoplasmosis: 10 had one or more clinical signs of congenital toxoplasmosis; 5 had isolated or multiple intracranial calcifications; 7 had peripheral chorioretinitis; and 2 had moderate ventricular dilations. All 27 are free from symptoms and have normal neurological development at 15 to 71 months of age. We conclude that in first and second trimester pregnancies with acute fetal toxoplasma infection, the pregnancy need not be interrupted if repeated fetal ultrasound is normal, and antiparasitic treatment is given.	CHU RANGUEIL,DEPT MICROBIOL PARASITOL,TOULOUSE,FRANCE; UNIV TOULOUSE,DEPT PEDIAT,TOULOUSE,FRANCE	CHU de Toulouse; Universite de Toulouse	BERREBI, A (corresponding author), UNIV TOULOUSE,CHU LA GRAVE,DEPT OBSTET & GYNECOL,PL LANGE,F-31052 TOULOUSE,FRANCE.							Berrebi A., 1993, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V22, P261; CARDOZA JD, 1988, RADIOLOGY, V169, P711, DOI 10.1148/radiology.169.3.3055034; COUVREUR J, 1991, ARCH FR PEDIATR, V48, P397; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DAFFOS F, 1992, 11E SEM DIAGN ANT MA, P9; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; DESMONTS G, 1985, LANCET, V1, P500; Dorangeon P. H., 1992, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V21, P549; HOHFELD P, 1989, J PEDIATR, V115, P765; KOPPE JG, 1974, EUR J OBSTET GYN R B, V4, P101, DOI 10.1016/0028-2243(74)90029-X; Kraubig H., 1966, P104; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; THALHAMMER O, 1957, TOXOPLASMOSE BEI MEN, P1; WILSON CB, 1980, AM J OBSTET GYNECOL, V138, P357, DOI 10.1016/0002-9378(80)90129-5; 1988, NEW ENGL J MED, V318, P313	15	62	68	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					36	39		10.1016/S0140-6736(94)91054-5	http://dx.doi.org/10.1016/S0140-6736(94)91054-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912304				2022-12-28	WOS:A1994NU91700017
J	FRANCIS, CY; WHORWELL, PJ				FRANCIS, CY; WHORWELL, PJ			BRAN AND IRRITABLE-BOWEL-SYNDROME - TIME FOR REAPPRAISAL	LANCET			English	Article								Whilst following up large numbers of patients with irritable bowel syndrome we got the impression that wholemeal wheat and bran products made people with the condition worse rather than better. One hundred consecutive new referrals, all of whom had tried bran, were questioned to resolve this issue. 55% of patients were made worse by bran whereas only 10% had found it helpful. With the exception of fruit, other forms of dietary fibre were not as detrimental and proprietary supplements were found to be beneficial. All symptoms of irritable bowel syndrome were exacerbated by bran, with bowel disturbance most often adversely affected, followed by abdominal distension and pain. The results of this study suggest that the use of bran in irritable bowel syndrome should be reconsidered. The study also raises the possibility that excessive consumption of bran in the community may actually be creating patients with irritable bowel syndrome by exacerbating mild, noncomplaining cases.	UNIV S MANCHESTER HOSP, DEPT MED, MANCHESTER M20 8LR, LANCS, ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital				Whorwell, Peter/0000-0002-5220-8474				DICKINSON RJ, 1982, LANCET, V2, P393; HARVEY RF, 1987, LANCET, V1, P963; HEATON KW, 1993, EUR J GASTROEN HEPAT, V5, P567, DOI 10.1097/00042737-199308000-00001; LYNN RB, 1993, NEW ENGL J MED, V329, P1940, DOI 10.1056/NEJM199312233292608; PAINTER NS, 1972, BRIT MED J, V2, P46, DOI 10.1136/bmj.2.5804.46-b; PAINTER NS, 1976, LANCET, V1, P540; RITCHIE J, 1982, PRACTITIONER, V226, P633; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; 1980, MED ASPECTS DIETARY	9	208	215	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	1994	344	8914					39	40		10.1016/S0140-6736(94)91055-3	http://dx.doi.org/10.1016/S0140-6736(94)91055-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912305				2022-12-28	WOS:A1994NU91700018
J	KOVACS, JA; KOVACS, AAS				KOVACS, JA; KOVACS, AAS			PCP PROPHYLAXIS IN PEDIATRIC HIV-INFECTION - TIME FOR A CHANGE	LANCET			English	Editorial Material							PNEUMOCYSTIS-CARINII PNEUMONIA; CHILDREN		UNIV SO CALIF,LOS ANGELES CTY MED CTR,COMPREHENS MATERNAL CHILD HIV MANAGEMENT & RES CT,LOS ANGELES,CA 90033	University of Southern California	KOVACS, JA (corresponding author), NIH,DEPT CRIT CARE MED,BETHESDA,MD 20892, USA.		Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				CHANOCK SJ, 1994, PEDIATRICS, V93, P519; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; FREDERICK T, 1994, 1ST NAT C HUM RETR R, P693; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; KOVACS A, 1993, 33RD ICAAC, P828; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; 1991, JAMA-J AM MED ASSOC, V265, P1637; 1994, BRIT MED J, V308, P437; 1989, MMWR-MORBID MORTAL W, V38, P1; 1993 CTR DIS CONTR P	10	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					5	6		10.1016/S0140-6736(94)91042-1	http://dx.doi.org/10.1016/S0140-6736(94)91042-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912309				2022-12-28	WOS:A1994NU91700005
J	GEPPERT, M; BOLSHAKOV, VY; SIEGELBAUM, SA; TAKEI, K; DECAMILLI, P; HAMMER, RE; SUDHOF, TC				GEPPERT, M; BOLSHAKOV, VY; SIEGELBAUM, SA; TAKEI, K; DECAMILLI, P; HAMMER, RE; SUDHOF, TC			THE ROLE OF RAB3A IN NEUROTRANSMITTER RELEASE	NATURE			English	Article							GTP-BINDING PROTEIN; SYNAPTIC VESICLES; TRANSMITTER RELEASE; SYNAPSIN-I; PROBABILITY; EXOCYTOSIS; PLASTICITY; RECEPTOR; NEURONS; MICE	THE small GTP-binding protein Rab3A is a Rab family member(1-3) that is abundant in brain synaptic vesicles(4,5). Here we show that mice in which the rab3A gene has been mutated by homologous recombination do not express Rab3A but are viable and fertile. Electrophysiological recordings in hippocampal CA1 pyramidal cells indicate that most of their synaptic parameters are also normal, although synaptic depression after short trains of repetitive stimuli (15-30 stimuli at 14 Hz) is significantly increased. Levels of the Rab3A-binding protein rabphilin are decreased by 70%, but expression of more than 20 other synaptic proteins is unchanged. No compensatory changes were detected in other GTP-binding proteins or in proteins that interact with Rab3. Rab3A thus appears not to be essential for synaptic vesicle exocytosis but to play a role in the recruitment of synaptic vesicles for exocytosis during repetitive stimulation.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, CTR NEUROBIOL & BEHAV, DEPT PHARMACOL, NEW YORK, NY 10032 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University				Takei, Kohji/0000-0002-6555-9425; Hammer, Robert E./0000-0001-5487-7551				BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BAUMERT M, 1993, BIOCHEM J, V293, P157, DOI 10.1042/bj2930157; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; FYKSE EM, 1993, J NEUROSCI, V13, P4997; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; Peters A., 1991, FINE STRUCTURE NERVO; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Sambrook J, 1989, MOL CLONING LABORATO; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKEI K, 1992, J NEUROSCI, V12, P489; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0	30	412	420	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 9	1994	369	6480					493	497		10.1038/369493a0	http://dx.doi.org/10.1038/369493a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	7911226				2022-12-28	WOS:A1994NQ28600060
J	FORMAN, D; PIKE, MC; DAVEY, G; DAWSON, S; BAKER, K; CHILVERS, CED; OLIVER, RTD; COUPLAND, C; CARTWRIGHT, RA; ELWOOD, PC; BIRCH, J; TYRELL, C; BRETT, R; BUSH, T; ISBELL, V; CORNWELL, A; STEER, R; THISTLETHWAITE, S; GELLMAN, H; HUGHES, J; LLEWELLYN, M; ARDERNJONES, A; ALLEN, A; HILTON, E; LLOYD, B; MCVEIGH, S; THORNE, M; TROWBRIDGE, P; REID, S				FORMAN, D; PIKE, MC; DAVEY, G; DAWSON, S; BAKER, K; CHILVERS, CED; OLIVER, RTD; COUPLAND, C; CARTWRIGHT, RA; ELWOOD, PC; BIRCH, J; TYRELL, C; BRETT, R; BUSH, T; ISBELL, V; CORNWELL, A; STEER, R; THISTLETHWAITE, S; GELLMAN, H; HUGHES, J; LLEWELLYN, M; ARDERNJONES, A; ALLEN, A; HILTON, E; LLOYD, B; MCVEIGH, S; THORNE, M; TROWBRIDGE, P; REID, S			ETIOLOGY OF TESTICULAR CANCER - ASSOCIATION WITH CONGENITAL-ABNORMALITIES, AGE AT PUBERTY, INFERTILITY, AND EXERCISE	BRITISH MEDICAL JOURNAL			English	Article							GERM-CELL TUMORS; RISK-FACTORS; CARCINOMA INSITU; DOWNS-SYNDROME; UNITED-STATES; YOUNG MEN; TESTIS; EPIDEMIOLOGY; CRYPTORCHIDISM; VASECTOMY	Objective-To determine the risk of testicular cancer associated with undescended testis, inguinal hernia, age at puberty, marital status, infertility, vasectomy, and amount of exercise. Design-A population based case-control study with a questionnaire administered by an interviewer and with relevant supplementary data extracted from general practitioners' notes. Setting-Nine health regions within England and Wales. Subjects-794 men, aged 15-49 years, with a testicular germ cell tumour diagnosed between 1 January 1984 and 1 January 1987; each had an age matched (within one year) control selected from the list of their general practitioner. Results-There was a significant association of testicular cancer with undescended testis (odds ratio 3.82; 95% confidence interval 2.24 to 6.52) and inguinal hernia (1.91; 1.12 to 3.23). The excess risk associated with undescended testis was eliminated in men who had had an orchidopexy before the age of 10 years. There were positive associations with early age at voice breaking, early age at starting to shave, and infertility. There was a significant association with a sedentary lifestyle and a moderate protective effect of exercise. There was no association with vasectomy. Conclusion-This study confirms previous reports that developmental urogenital abnormalities result in an increased risk of testicular cancer. The trend to perform orchidopexy at younger ages may reduce the risk associated with undescended testis. The increased risks associated with early age at puberty and low amounts of exercise may be related to effects of exposure to endogenous hormones. Changes in both of these factors may partly contribute to the increasing rates of testicular cancer observed in the past few decades.	MRC,EPIDEMIOL UNIT,CARDIFF,WALES; UNIV MANCHESTER,DEPT EPIDEMIOL & SOCIAL ONCOL,MANCHESTER,LANCS,ENGLAND; FREEDOM FIELDS HOSP,PLYMOUTH ONCOL UNIT,PLYMOUTH,DEVON,ENGLAND; UNIV LEEDS,LEUKAEMIA RES FUND CTR,LEEDS,ENGLAND; INST CANC RES,EPIDEMIOL SECT,SUTTON,SURREY,ENGLAND; UNIV NOTTINGHAM,SCH MED,DEPT EPIDEMIOL & PUBL HLTH MED,NOTTINGHAM NG7 2RD,ENGLAND; ROYAL LONDON HOSP,DEPT MED ONCOL,LONDON E1 1BB,ENGLAND	University of Manchester; University of Leeds; University of London; Institute of Cancer Research - UK; University of Nottingham; Barts Health NHS Trust; Royal London Hospital	FORMAN, D (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.			Coupland, Carol/0000-0002-2327-3306				BEITINS IZ, 1991, J CLIN ENDOCR METAB, V72, P1350, DOI 10.1210/jcem-72-6-1350; BENSON RC, 1991, MAYO CLIN PROC, V66, P372, DOI 10.1016/S0025-6196(12)60660-0; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BRAUN DL, 1985, AM J PEDIAT HEMATOL, V7, P208; Breslow N. E., 1980, SCI PUBLICATION, V32; BROWN LM, 1986, INT J EPIDEMIOL, V15, P164, DOI 10.1093/ije/15.2.164; BROWN LM, 1986, CANCER RES, V46, P4812; CALE ARJ, 1990, BRIT MED J, V300, P370, DOI 10.1136/bmj.300.6721.370; CHILVERS C, 1986, J PEDIATR SURG, V21, P691, DOI 10.1016/S0022-3468(86)80389-X; CHILVERS C, 1989, UROLOGICAL GENITAL C, P396; CHILVERS C, 1992, EUROPEAN UROLOGY UPD, V1, P74; COGGON D, 1986, BRIT J IND MED, V43, P381; COLDMAN AJ, 1982, BRIT J CANCER, V46, P749, DOI 10.1038/bjc.1982.267; DAVIS E, 1981, J ACM, V28, P721, DOI 10.1145/322276.322284; DEPUE RH, 1983, J NATL CANCER I, V71, P1151; DEPUE RH, 1986, J NATL CANCER I, V77, P830, DOI 10.1093/jnci/77.3.830; Doll R, 1992, Clin Oncol (R Coll Radiol), V4, P257, DOI 10.1016/S0936-6555(05)81065-9; FORMAN D, IN PRESS CANCER SURV; FORMAN D, 1970, PROGR CLIN BIOL RES, V357, P245; FORMAN D, 1989, UROLOGICAL GENITAL C, P289; FRISCH RE, 1981, JAMA-J AM MED ASSOC, V246, P1559, DOI 10.1001/jama.246.14.1559; GERSHMAN ST, 1988, INT J EPIDEMIOL, V17, P738, DOI 10.1093/ije/17.4.738; GRAHAM S, 1972, CANCER, V29, P1242, DOI 10.1002/1097-0142(197205)29:5<1242::AID-CNCR2820290517>3.0.CO;2-R; GRAHAM S, 1977, J NATL CANCER I, V58, P1225; HANSEN PV, 1989, CANCER, V64, P956, DOI 10.1002/1097-0142(19890815)64:4<956::AID-CNCR2820640431>3.0.CO;2-3; HASEN J, 1980, HORM RES, V12, P345, DOI 10.1159/000179141; HAUGHEY BP, 1989, AM J EPIDEMIOL, V130, P25, DOI 10.1093/oxfordjournals.aje.a115319; HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503; JOHNSON DE, 1987, UROLOGY, V30, P199, DOI 10.1016/0090-4295(87)90231-7; LYNGE E, 1993, EUR J CANCER, V29A, P1064, DOI 10.1016/S0959-8049(05)80226-6; MCDOWALL ME, 1986, J EPIDEMIOL COMMUN H, V40, P26, DOI 10.1136/jech.40.1.26; MILLS PK, 1984, LANCET, V1, P207; MORRISON AS, 1976, J NATL CANCER I, V56, P731, DOI 10.1093/jnci/56.4.731; MOSS AR, 1986, AM J EPIDEMIOL, V124, P39, DOI 10.1093/oxfordjournals.aje.a114369; MUSTACCHI P, 1976, J NATL CANCER I, V56, P717, DOI 10.1093/jnci/56.4.717; NEWELL GR, 1987, J NATL CANCER I, V78, P881; OLIVER RTD, 1990, CANCER SURV, V9, P263; OPSTAD PK, 1992, J CLIN ENDOCR METAB, V74, P1176, DOI 10.1210/jc.74.5.1176; PEARCE N, 1987, CANCER, V59, P1677, DOI 10.1002/1097-0142(19870501)59:9<1677::AID-CNCR2820590926>3.0.CO;2-Q; PIKE MC, 1986, LANCET, V1, P1246; POTTERN LM, 1985, J NATL CANCER I, V74, P377; PRYOR JP, 1983, BRIT J UROL, V55, P780, DOI 10.1111/j.1464-410X.1983.tb03425.x; RAJPERTDEMEYTS E, 1993, EUR UROL, V23, P54; ROSS RK, 1979, BRIT J CANCER, V39, P284, DOI 10.1038/bjc.1979.53; SASAGAWA I, 1993, ARCH ANDROLOGY, V30, P93, DOI 10.3109/01485019308987740; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SKAKKEBAEK NE, 1978, HISTOPATHOLOGY, V2, P157, DOI 10.1111/j.1365-2559.1978.tb01706.x; STONE JM, 1991, CANCER, V68, P211, DOI 10.1002/1097-0142(19910701)68:1<211::AID-CNCR2820680139>3.0.CO;2-Q; STRADER CH, 1988, AM J EPIDEMIOL, V127, P1013, DOI 10.1093/oxfordjournals.aje.a114877; STRADER CH, 1988, AM J EPIDEMIOL, V128, P56, DOI 10.1093/oxfordjournals.aje.a114958; SWERDLOW AJ, 1989, INT J CANCER, V43, P549, DOI 10.1002/ijc.2910430403; SWERDLOW AJ, 1988, BRIT J IND MED, V45, P225; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; TANNER JM, 1978, FETUS MAN PHYSICAL G; TARONE RE, 1991, J NATL CANCER I, V83, P1497, DOI 10.1093/jnci/83.20.1497; THORNHILL JA, 1987, BRIT J UROL, V59, P367, DOI 10.1111/j.1464-410X.1987.tb04660.x; WANDERAS EH, 1990, BRIT J UROL, V66, P315, DOI 10.1111/j.1464-410X.1990.tb14935.x; 1986, BRIT MED J, V293, P1401; 1993, SERIES MBI, V20	60	220	225	2	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1393	1399		10.1136/bmj.308.6941.1393	http://dx.doi.org/10.1136/bmj.308.6941.1393			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	7912596				2022-12-28	WOS:A1994NP42000012
J	JOSEPH, AM				JOSEPH, AM			IS CONGRESS BLOWING SMOKE AT THE VA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOSEPH, AM (corresponding author), VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,1 VET DR,MINNEAPOLIS,MN 55417, USA.			Joseph, Anne/0000-0002-3440-2679				ALLEN A, 1989, VA PRACT         FEB, P15; DAWLEY HH, 1989, VA PRACT         APR, P47; JOSEPH A, 1988, JAMA-J AM MED ASSOC, V260, P1551, DOI 10.1001/jama.1988.03410110059012; JOSEPH AM, 1992, JAMA-J AM MED ASSOC, V267, P87; LUCK TC, 1990, VA PRACT         JAN, P71; MCALLISTER B, 1992, WASHINGTON POST 0604, pA27; SIROTA AD, 1987, VA PRACT         FEB, P11; 1990, 1090142 US DEP VET A; 1992, SMOKE FREE ENV SMO S, V1; 1993, MA1314 JOINT COMM AC; 1990, 1090141 US DEP VET A; 1992, EPA600690006F PUBL; 1986, HLTH CONSEQUENCES IN; 1993, FY1992 US DEP VET AF; 1993, ESTABLISHING PATIENT	15	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1215	1216		10.1001/jama.272.15.1215	http://dx.doi.org/10.1001/jama.272.15.1215			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933352				2022-12-28	WOS:A1994PL21200038
J	WATERS, S				WATERS, S			A THIN GREEN LINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1086	1086						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK124	7933302				2022-12-28	WOS:A1994PK12400002
J	CHANG, EC; BARR, M; WANG, Y; JUNG, V; XU, HP; WIGLER, MH				CHANG, EC; BARR, M; WANG, Y; JUNG, V; XU, HP; WIGLER, MH			COOPERATIVE INTERACTION OF S-POMBE PROTEINS REQUIRED FOR MATING AND MORPHOGENESIS	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; GENE-PRODUCT; SEXUAL-DIFFERENTIATION; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; EXCHANGE FACTOR; HUMAN ONCOGENE; CELL POLARITY	We isolated two S. pombe genes, scd1 and scd2, that are required for normal morphology and mating. scd1 and scd1 are homologous to CDC24 and BEM1, respectively, of S. cerevisiae. Epistasis analyses indicate that scd2 and rest converge upon scd1, which, in turn, interacts with cdc42sp, a RHO-like GTPase. Studies with the yeast two-hybrid system indicate that scd2 forms complexes with both scd1 and cdc42sp. Furthermore, biochemical studies indicate that the interaction between scd1 and scd2 is direct. The yeast two-hybrid data further suggest that scd1, scd2, cdc42sp, and ras1, in its GTP-bound state, act cooperatively to form a protein complex.			CHANG, EC (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Wigler, Michael/0000-0003-4396-1971				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS JM, 1992, ONCOGENE, V7, P611; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; DOWNWARD J, 1992, NATURE, V358, P282, DOI 10.1038/358282a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAWELL E, 1992, GENE, V114, P153, DOI 10.1016/0378-1119(92)90724-4; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUKUI Y, 1988, MOL GEN GENET, V215, P26, DOI 10.1007/BF00331298; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; FUKUI Y, 1985, EMBO J, V4, P687, DOI 10.1002/j.1460-2075.1985.tb03684.x; FUKUI Y, 1989, MOL CELL BIOL, V9, P5617, DOI 10.1128/MCB.9.12.5617; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1973, GENETICS, V74, P267; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN CS, 1990, GENETICS, V124, P807; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAWAMUKAI M, 1992, MOL BIOL CELL, V3, P167, DOI 10.1091/mbc.3.2.167; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MIYAMOTO S, 1991, BIOCHEM BIOPH RES CO, V181, P604, DOI 10.1016/0006-291X(91)91233-3; MOLZ L, 1989, GENETICS, V122, P773; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NADINDAVIS SA, 1986, EMBO J, V5, P2963, DOI 10.1002/j.1460-2075.1986.tb04593.x; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AL, 1993, CELL, V70, P389; RIDLEY AL, 1993, CELL, V70, P401; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; XU HP, 1990, CELL REGUL, V1, P763, DOI 10.1091/mbc.1.10.763; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	59	255	259	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					131	141		10.1016/0092-8674(94)90406-5	http://dx.doi.org/10.1016/0092-8674(94)90406-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923372				2022-12-28	WOS:A1994PK58500014
J	WIEGMANN, K; SCHUTZE, S; MACHLEIDT, T; WITTE, D; KRONKE, M				WIEGMANN, K; SCHUTZE, S; MACHLEIDT, T; WITTE, D; KRONKE, M			FUNCTIONAL DICHOTOMY OF NEUTRAL AND ACIDIC SPHINGOMYELINASES IN TUMOR-NECROSIS-FACTOR SIGNALING	CELL			English	Article							FACTOR-KAPPA-B; PROTEIN-KINASE-C; TNF RECEPTOR; MOLECULAR-CLONING; GENE-EXPRESSION; PHOSPHOLIPASE-C; HL-60 CELLS; HUMAN-URINE; ACTIVATION; CERAMIDE	Ceramide produced by sphingomyelinases (SMases) has been recognized as an important second messenger in growth factor receptor signaling. Tumor necrosis factor (TNF), through binding to the 55 kDa TNF receptor (TNF-R55), rapidly activates two distinct types of SMase, a membrane-associated neutral (N-)SMase, and an endosomal acidic (A-)SMase. N-SMase and A-SMase are activated independently by different cytoplasmic domains of TNF-R55. Each type of SMase specifically couples to select pathways of TNF signaling. Ceramide generated by N-SMase directs the activation of proline-directed serine/threonine protein kinase(s) and phospholipase A(2). In contrast, A-SMase triggers the activation of NF-kappa B. No apparent crosstalk was detected between N-SMase and A-SMase pathways, indicating that ceramide action depends on the topology of its production. These results suggest that N-SMase and A-SMase control important yet dissociable and nonoverlapping pathways of TNF receptor signal transduction.			WIEGMANN, K (corresponding author), TECH UNIV MUNICH, INST MED MIKROBIOL & HYG, D-81675 MUNICH, GERMANY.		Schütze, Stefan/C-8596-2011					BALLOU LR, 1992, IMMUNOL TODAY, V13, P339, DOI 10.1016/0167-5699(92)90167-6; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BERG T, 1985, EXP CELL RES, V161, P285, DOI 10.1016/0014-4827(85)90086-2; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; CALLAHAN JW, 1983, J NEUROSCI RES, V10, P151, DOI 10.1002/jnr.490100205; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FAURE R, 1992, J BIOL CHEM, V267, P11215; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FINCO TS, 1993, J BIOL CHEM, V268, P17676; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU J, 1994, J BIOL CHEM, V269, P3047; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P1009; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; QUINTERN LE, 1991, METHOD ENZYMOL, V197, P536; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAO BG, 1976, J LIPID RES, V17, P506; RAO GR, 1981, BIOCHEM J, V198, P9, DOI 10.1042/bj1980009; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; SAINTJOANIS B, 1989, MOL GEN GENET, V219, P453, DOI 10.1007/BF00259619; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; YANG ZH, 1993, J BIOL CHEM, V268, P20520	57	664	678	1	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					1005	1015		10.1016/0092-8674(94)90275-5	http://dx.doi.org/10.1016/0092-8674(94)90275-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923351				2022-12-28	WOS:A1994PJ29400011
J	KESSEL, E				KESSEL, E			QUINACRINE STERILIZATION REVISITED	LANCET			English	Editorial Material											KESSEL, E (corresponding author), OREGON HLTH SCI UNIV,DEPT PUBL HLTH & PREVENT MED,PORTLAND,OR 97201, USA.							Archer J D, 1984, JAMA, V252, P1054; BENAGIANO G, 1994, LANCET, V344, P689, DOI 10.1016/S0140-6736(94)92125-3; BENAGIANO G, 1994, LANCET, V343, P1425, DOI 10.1016/S0140-6736(94)92547-X; GODAL T, 1994, SCIENCE, V264, P1864, DOI 10.1126/science.8009212; HIEU DT, 1993, LANCET, V342, P213, DOI 10.1016/0140-6736(93)92302-A; KESSEL E, IN PRESS 8TH P WORLD; KESSLER DA, 1989, NEW ENGL J MED, V320, P281, DOI 10.1056/NEJM198902023200504; POLLACK AE, 1994, ADV CONTRACEPT, V10, P43, DOI 10.1007/BF01986529; TICE RR, 1990, EVALUATION MUTAGENIC; 1994, LANCET, V343, P987	10	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					698	700						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915769				2022-12-28	WOS:A1994PF18700002
J	STEWART, THM				STEWART, THM			POSTMASTECTOMY RADIOTHERAPY - MORE THAN A LOCAL MATTER	LANCET			English	Editorial Material							BREAST-CANCER				STEWART, THM (corresponding author), OTTAWA GEN HOSP,DEPT MED,OTTAWA K1H 8L6,ON,CANADA.							CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; OVERGAARD M, 1990, INT J RADIAT ONCOL, V19, P1121, DOI 10.1016/0360-3016(90)90214-5; PREHN TR, 1994, CANCER RES, V54, P908; RAGAZ J, 1993, P AN M AM SOC CLIN, V12, P60; ROTSTEIN S, 1985, INT J RADIAT ONCOL, V11, P921, DOI 10.1016/0360-3016(85)90114-2; STEWART THM, 1993, CLIN EXP METASTAS, V11, P295, DOI 10.1007/BF00058049; STEWART THM, 1992, CELLULAR IMMUNE MECHANISMS AND TUMOR DORMANCY, P213; STEWART THM, 1994, LANCET, V343, P402; STJERNSW.J, 1974, LANCET, V2, P1285, DOI 10.1016/S0140-6736(74)90142-1	10	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					351	352		10.1016/S0140-6736(94)91396-X	http://dx.doi.org/10.1016/S0140-6736(94)91396-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914302				2022-12-28	WOS:A1994PA30300005
J	MILLER, FH				MILLER, FH			INFANT RESUSCITATION, A US UK DIVIDE	LANCET			English	Editorial Material											MILLER, FH (corresponding author), BOSTON UNIV,SCH LAW,BOSTON,MA 02215, USA.							BRAHAMS D, 1992, LANCET, V339, P1472, DOI 10.1016/0140-6736(92)92052-H	1	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1584	1585		10.1016/S0140-6736(94)93051-1	http://dx.doi.org/10.1016/S0140-6736(94)93051-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911914				2022-12-28	WOS:A1994NU35400004
J	SEMBA, RD; MIOTTI, PG; CHIPHANGWI, JD; SAAH, AJ; CANNER, JK; DALLABETTA, GA; HOOVER, DR				SEMBA, RD; MIOTTI, PG; CHIPHANGWI, JD; SAAH, AJ; CANNER, JK; DALLABETTA, GA; HOOVER, DR			MATERNAL VITAMIN-A-DEFICIENCY AND MOTHER-TO-CHILD TRANSMISSION OF HIV-1	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; A-DEFICIENCY; INFECTION; RISK; ASSOCIATION; INFANTS; WOMEN	Studies show that around 10-40% HIV-positive women will give birth to children who are also infected. However, the risk factors for transmission from mother to child are not well understood and the effects of maternal nutritional status are unknown. We conducted a study of vitamin A status in pregnant women as a risk factor for mother-to-child transmission of HIV in Malawi. Serum vitamin A, height, weight, CD4 T-cell counts, and duration of breastfeeding were measured in 338 HIV-positive mothers whose infant's HIV serostatus was known. Mother-to-child transmission of HIV was 21.9% among mothers whose infants survived to 12 months of age. Mean vitamin A concentration in 74 mothers who transmitted HIV to their infants was lower than that in 264 mothers who did not transmit HIV to their infants (0.86 [0.03] vs 1.07 [0.02], p<0.0001). We divided HIV positive mothers to 4 groups, those with vitamin A concentrations of less than 0.70, between 0.70 and 1.05, between 1.05 and 1.40, and greater than or equal to 1.40 mu mol/L. The mother-to-child transmission rates for each group were 32.4%, 26.2%, 16.0%, and 7.2%, respectively (p<0.0001). Maternal CD4 cell counts, CD4%, and CD4/CD8 ratio were also associated with increased mother-to-child transmission of HIV. Maternal age, body-mass index, and breastfeeding practices were not significantly associated with higher mother-to-child transmission. Our study suggests that maternal vitamin A deficiency contributes to mother-to-child transmission of HIV.	DEPT INT HLTH,DIV HUMAN NUTR,BALTIMORE,MD 21287; MALAWI MED COLL,BLANTYRE,MALAWI; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,PROGRAM INFECT DIS,BALTIMORE,MD	University of Malawi; Johns Hopkins University	SEMBA, RD (corresponding author), DANA CTR,DEPT IMMUNOL & INFECT DIS,600 N WOLFE ST,BALTIMORE,MD 21287, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030042, R55HD030042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI026499, R21AI033874] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26499, AI33874] Funding Source: Medline; NICHD NIH HHS [HD30042] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAUM MK, 1991, J ACQ IMMUN DEF SYND, V4, P1122; BEACH RS, 1992, AIDS, V6, P701, DOI 10.1097/00002030-199207000-00013; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BOYLAN L, 1991, EPIDEMIOL REV, V13, P143, DOI 10.1093/oxfordjournals.epirev.a036067; BRAY GA, 1978, INT J OBESITY, V2, P99; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; CAMPOS FACS, 1987, AM J CLIN NUTR, V46, P91, DOI 10.1093/ajcn/46.1.91; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Dushimimana A., 1992, 8 INT C AIDS AMST; GAL I, 1974, AM J CLIN NUTR, V27, P688, DOI 10.1093/ajcn/27.7.688; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P976; LEPAGE P, 1993, AM J EPIDEMIOL, V137, P589, DOI 10.1093/oxfordjournals.aje.a116716; MIOTTI PG, 1992, J INFECT DIS, V165, P1116, DOI 10.1093/infdis/165.6.1116; MIOTTI PG, 1993, 9TH INT C AIDS BERL; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SEMBA RD, 1993, LANCET, V341, P5, DOI 10.1016/0140-6736(93)92478-C; SEMBA RD, 1992, J NUTR, V122, P101, DOI 10.1093/jn/122.1.101; SEMBA RD, 1993, ARCH INTERN MED, V153, P2149, DOI 10.1001/archinte.153.18.2149; SEMBA RD, 1994, IN PRESS CLIN INFECT; SOMMER A, 1987, AM J CLIN NUTR, V45, P977, DOI 10.1093/ajcn/45.5.977; TANG AM, 1993, AM J EPIDEMIOL, V138, P937, DOI 10.1093/oxfordjournals.aje.a116814; Wallingford JC, 1986, VITAMIN A DEFICIENCY, P101; 1988, LANCET, V2, P1043; 1992, LANCET, V339, P1007	29	309	316	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1593	1597		10.1016/S0140-6736(94)93056-2	http://dx.doi.org/10.1016/S0140-6736(94)93056-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911919	hybrid			2022-12-28	WOS:A1994NU35400009
J	VERONESI, U; LUINI, A; MARIANI, L; DELVECCHIO, M; ALVEZ, D; ANDREOLI, C; GIACOBONE, A; MERSON, M; PACETTI, G; RASELLI, R; SACCOZZI, R				VERONESI, U; LUINI, A; MARIANI, L; DELVECCHIO, M; ALVEZ, D; ANDREOLI, C; GIACOBONE, A; MERSON, M; PACETTI, G; RASELLI, R; SACCOZZI, R			EFFECT OF MENSTRUAL PHASE ON SURGICAL-TREATMENT OF BREAST-CANCER	LANCET			English	Article							PERIPHERAL-BLOOD; CYCLE; SURVIVAL; SURGERY; DISEASE	1175 premenopausal women whose date of last menstrual period was known were followed up for up to 20 years (average 8 years) after surgery for breast cancer. 525 patients were in the follicular phase and 650 in the luteal phase. We observed 192 unfavourable events among patients operated on during the follicular phase (36.6%) and 192 among patients operated on during the luteal phase (29.6%). The effect of phase was restricted to patients with positive axillary nodes. The 5-year relapse-free survival was 75.5% in 246 node-positive patients operated on during the luteal phase and 63.3% in 190 node-positive patients who had surgery during the follicular phase. The hazard ratio at Cox multivariate analysis was 1.329 for all patients (p=0.006) and 1.431 for node-positive patients (p=0.03). In our study, premenopausal patients with breast cancer and positive axillary nodes operated on during the luteal phase had a significantly better prognosis than patients operated on during the follicular phase. It may be that the processes of cell metastases, such as loss of adhesiveness, may be enhanced by high concentrations of unopposed oestrogens or by reduced activity of natural killer cells during the first half of the menstrual cycle.			VERONESI, U (corresponding author), IST NAZL STUDIO & CURA TUMORI,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Mariani, Luigi/AAB-9464-2019; Mariani, Luigi/C-2580-2017	Mariani, Luigi/0000-0001-6208-4084				BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; GOLDHIRSCH A, 1991, LANCET, V338, P691; HRUSHESKY WJM, 1989, LANCET, V2, P949; LIPPMAN ME, 1986, BREAST CANCER RES TR, V7, P59, DOI 10.1007/BF01806790; LOW SC, 1991, LANCET, V338, P691, DOI 10.1016/0140-6736(91)91265-V; MOYER DL, 1979, CELLS UTERINE FLUID; MURPHY LJ, 1990, ENDOCR REV, V11, P443, DOI 10.1210/edrv-11-3-443; POWLES J, 1991, LANCET, V338, P620; SENIE RT, 1991, ANN INTERN MED, V115, P337, DOI 10.7326/0003-4819-115-5-337; SULKE AN, 1985, BRIT MED J, V290, P884, DOI 10.1136/bmj.290.6472.884; WHITE D, 1982, BRIT J CANCER, V46, P611, DOI 10.1038/bjc.1982.245	11	85	87	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1545	1547		10.1016/S0140-6736(94)92942-4	http://dx.doi.org/10.1016/S0140-6736(94)92942-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911875				2022-12-28	WOS:A1994NR32900012
J	GLANTZ, SA; BEGAY, ME				GLANTZ, SA; BEGAY, ME			TOBACCO INDUSTRY CAMPAIGN CONTRIBUTIONS ARE AFFECTING TOBACCO CONTROL POLICY-MAKING IN CALIFORNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PACS	Objective.-To test the hypothesis that tobacco industry campaign contributions are influencing the behavior of members of the California legislature. Design.-Multivariate simultaneous-equations regression was used to analyze data on campaign contributions from the tobacco industry to members of the California legislature in 1991 and 1992, members' tobacco control policy positions, and members' personal characteristics. Data Sources.-The following sources were analyzed: campaign contributions from disclosure statements filed with the California Fair Political Practices Commission; constituent attitudes on tobacco control from the California Tobacco Survey; legislators' personal characteristics, from a survey of key informants conducted by the California Journal; and the tobacco policy score, a survey of key informants working on tobacco issues in the state legislature. Specific voting on tobacco-related bills was also analyzed. Setting.-California legislature in 1991 and 1992. Patients or Other Participants.-All members of the California legislature in 1991 and 1992. Main Outcome Measures.-Tobacco policy score, campaign contributions, and votes on individual tobacco-related bills. Results.-The tobacco industry is having a statistically detectable effect on behavior of members of the California legislature on tobacco policymaking. On a scale of 0 to 10, a legislator's tobacco policy score dropped tie, became more protobacco industry) by -0.11 for every $1000 in tobacco campaign contributions, after accounting for the fact that a more protobacco position was associated with greater contributions ($1855 for each -1.0 reduction in score). Members who were rated as effective received larger contributions from the industry. Members rated higher in integrity and intelligence were more antitobacco (higher scores) and Republicans more protobacco (lower scores) after taking into account the effects of contributions from the industry. Constituent attitudes were not reflected in legislators' perceived behavior. Conclusion.-Tobacco industry campaign contributions influence California legislators in matters related to tobacco policymaking, independent of constituents' support for tobacco control.			GLANTZ, SA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,BOX 0124,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEGAY M, 1994, TWILIGHT PROPOSITION; BEGAY ME, 1993, AM J PUBLIC HEALTH, V83, P1214, DOI 10.2105/AJPH.83.9.1214; BEGAY ME, 1992, TOBACCO IND POLITICA; BURNS D, 1992, TOBACCO USE CALIFORN; DREW E, 1983, POLITICS MONEY; Fenno RichardF., 1978, HOMESTYLE HOUSE MEMB; GERBER E, 1991, THESIDS U MICHIGAN A; GLANTZ S, 1993, TOBACCO BIOL POLITIC; GLANTZ S, 1990, PRIMER APPLIED REGRE, pCH5; GLANTZ SA, 1994, AM J PUBLIC HEALTH, V84, P1081, DOI 10.2105/AJPH.84.7.1081; GRENZKE JM, 1989, AM J POLIT SCI, V33, P1, DOI 10.2307/2111251; JACKSON B, 1988, HONEST GRAFT; Jewell MalcolmE., 1982, REPRESENTATION STATE; Kingdon, 1989, CONGRESSMENS VOTING; Pierce JP, 1994, TOBACCO USE CALIFORN; PRICE C, 1991, CALIF J, V22, P343; SKOLNICK AA, 1994, JAMA-J AM MED ASSOC, V271, P1387, DOI 10.1001/jama.271.18.1387; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2723; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2721, DOI 10.1001/jama.267.20.2721; TAYLOR P, 1984, SMOKE RING; WRIGHT JR, 1985, AM POLIT SCI REV, V79, P400, DOI 10.2307/1956656; ZEIGER R, 1992, CALIF J, V23, P173; 1991, 1991 1992 DIRECTORY; 1993, HLTH LETT, V9, P1; 1993, LOBBYING EXPENDITURE; 1988, SAS ETS USERS GUIDE; 1993, PRICE ADM	27	71	71	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1176	1182		10.1001/jama.272.15.1176	http://dx.doi.org/10.1001/jama.272.15.1176			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL212	7933347				2022-12-28	WOS:A1994PL21200031
J	DURCH, JS; KLERMAN, LV				DURCH, JS; KLERMAN, LV			OVERCOMING IMMUNIZATION BARRIERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											DURCH, JS (corresponding author), NATL ACAD SCI,INST MED,COMM OVERCOMING BARRIERS IMMUNIZAT,WASHINGTON,DC 20418, USA.							[Anonymous], OVERCOMING BARRIERS; 1994, MMWR-MORBID MORTAL W, V42, P985; 1994, MMWR-MORBID MORTAL W, V43, P556; 1993, MMWR-MORBID MORTAL W, V42, P1	4	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1092	1092						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK124	7933306				2022-12-28	WOS:A1994PK12400006
J	ROBILLARD, PY; HULSEY, TC; PERIANIN, J; JANKY, E; MIRI, EH; PAPIERNIK, E				ROBILLARD, PY; HULSEY, TC; PERIANIN, J; JANKY, E; MIRI, EH; PAPIERNIK, E			ASSOCIATION OF PREGNANCY-INDUCED HYPERTENSION WITH DURATION OF SEXUAL COHABITATION BEFORE CONCEPTION	LANCET			English	Article							PRE-ECLAMPSIA; PREECLAMPSIA; CONTRACEPTION; IMMUNOLOGY; ANTIBODIES; PATERNITY	Pregnancy-induced hypertension affects at least 10% of all pregnancies. An association with first pregnancy or a change in paternity for subsequent pregnancies has been suggested. We studied the duration of sexual cohabitation with the father prior to conception and the incidence of pregnancy-induced hypertension. During a five-month period, 1011 consecutive women who delivered in an obstetric unit were interviewed about paternity and duration of sexual cohabitation before conception. Obstetric charts were abstracted to identify three groups: those with pregnancy-induced hypertension, chronic hypertension, and normal blood pressure. The incidence of pregnancy-induced hypertension was 11.9% among primigravidae, 4.7% among same-paternity multigravidae, and 24.0% among new-paternity multigravidae. For both primigravidae and multigravidae, length of sexual cohabitation before conception was inversely related to the incidence of pregnancy-induced hypertension (p<0.0001). Similar results were observed after control for race, education, maternal age, marital status, and number of pregnancies. Pregnancy-induced hypertension may be a problem of primipaternity rather than primigravidity. Furthermore, an extended duration of sexual cohabitation before conception may protect against pregnancy-induced hypertension.	UNIV HOSP POINTE PITRE, CHRU, GYNAECOL OBSTET UNIT, F-97159 POINTE A PITRE, Guadeloupe, FRANCE; MED UNIV S CAROLINA, CHILDRENS HOSP, DIV NEONATOL, CHARLESTON, SC 29425 USA; MATERN PORT ROYAL, F-75674 PARIS 14, FRANCE	CHU Guadeloupe; Medical University of South Carolina; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	ROBILLARD, PY (corresponding author), UNIV HOSP POINTE A PITRE, CHRU, PAEDIAT UNIT, BP 465, F-97159 POINTE A PITRE, Guadeloupe, FRANCE.		Robillard, Pierre-Yves/AAD-9774-2021					[Anonymous], PREECLAMPSIA; Beer A E, 1985, Birth Defects Orig Artic Ser, V21, P131; BEER AE, 1989, JAMA-J AM MED ASSOC, V262, P3184, DOI 10.1001/jama.262.22.3184; BEER AE, 1990, IMMUNOLOGICAL DIS, P329; BRONSON R, 1984, FERTIL STERIL, V42, P171; CHARBIT Y, 1984, CARIBBEAN FAMILY STR; CHNG PK, 1982, BRIT J OBSTET GYNAEC, V89, P862, DOI 10.1111/j.1471-0528.1982.tb05042.x; DAVEY DA, 1986, CLIN EXP HYPERTENS B, V5, P97, DOI 10.3109/10641958609023478; FEENEY JG, 1980, EUR J OBSTET GYN R B, V11, P35, DOI 10.1016/0028-2243(80)90051-9; GOLDBERG JM, 1990, AM J OBSTET GYNECOL, V163, P65, DOI 10.1016/S0002-9378(11)90669-3; IKEDIFE D, 1980, BRIT MED J, V280, P985, DOI 10.1136/bmj.280.6219.985-a; KANBOURSHAKIR A, 1990, P NATL ACAD SCI USA, V87, P444, DOI 10.1073/pnas.87.1.444; KLONOFFCOHEN HS, 1989, JAMA-J AM MED ASSOC, V262, P3143, DOI 10.1001/jama.262.22.3143; MARTI JJ, 1977, AM J OBSTET GYNECOL, V128, P489, DOI 10.1016/0002-9378(77)90030-8; MASSIAH H, 1983, WOMEN HEADS HOUSEHOL; NEED JA, 1975, BRIT MED J, V1, P548, DOI 10.1136/bmj.1.5957.548; REDMAN CWG, 1991, SEMIN PERINATOL, V15, P257; ROBILLARD PY, 1993, J REPROD IMMUNOL, V24, P1, DOI 10.1016/0165-0378(93)90032-D; ROBILLARD PY, IN PRESS INT J FETOM; SAFTLAS AF, 1990, AM J OBSTET GYNECOL, V163, P460, DOI 10.1016/0002-9378(90)91176-D; SERHAL PF, 1987, LANCET, V2, P744; SPECK EH, 1980, PREGNANCY HYPERTENS, P45; 1990, RESULTATS RECENSEMEN; 1994, LANCET, V344, P969	24	246	254	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	1994	344	8928					973	975		10.1016/S0140-6736(94)91638-1	http://dx.doi.org/10.1016/S0140-6736(94)91638-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934427				2022-12-28	WOS:A1994PK97800006
J	KASTNER, P; GRONDONA, JM; MARK, M; GANSMULLER, A; LEMEUR, M; DECIMO, D; VONESCH, JL; DOLLE, P; CHAMBON, P				KASTNER, P; GRONDONA, JM; MARK, M; GANSMULLER, A; LEMEUR, M; DECIMO, D; VONESCH, JL; DOLLE, P; CHAMBON, P			GENETIC-ANALYSIS OF RXR-ALPHA, DEVELOPMENTAL FUNCTION - CONVERGENCE OF RXR AND RAR SIGNALING PATHWAYS IN HEART AND EYE MORPHOGENESIS	CELL			English	Article							REPLICATION-DEFECTIVE RETROVIRUS; 9-CIS RETINOIC ACID; CARDIAC MORPHOGENESIS; CLONAL ANALYSIS; RECEPTOR-GAMMA; MUTANT MICE; MOUSE; EXPRESSION; TRANSACTIVATION; TRANSCRIPTION	A null mutation was generated in the mouse RXR alpha gene by targeted disruption. Growth deficiency occurred in heterozygote mice. Null mutants died in utero and displayed myocardial and ocular malformations. These malformations belong to the fetal vitamin A deficiency syndrome, supporting the idea that RXR alpha is involved in retinoid signaling in vivo. A phenotypic synergy was observed when the RXR alpha mutation was introduced into RAR alpha or RAR gamma mutant backgrounds: RXR alpha null mutants and RXR alpha(+/-)/RAR gamma(-/-) double mutants displayed similar ocular defects, which became more severe in RXR alpha(-/-)/RAR gamma(+/-) and RXR alpha(-/-)/RAR gamma(-/-) mutants. Furthermore, RXR alpha/RAR double mutants exhibited several malformations not seen in single mutants. This functional convergence strongly suggests that RXR alpha/RAR heterodimers mediate retinoid signaling in vivo.			KASTNER, P (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Dolle, Pascal/A-8037-2010; Grondona, Jesus M./F-1650-2011	Dolle, Pascal/0000-0002-9294-9090; Grondona, Jesus M./0000-0003-1781-1486; Decimo, Didier/0000-0002-0390-1205				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BLOMHOFF RB, 1994, VITAMIN A HLTH DISEA; CHALLICE CE, 1974, TISSUE CELL, V6, P447, DOI 10.1016/0040-8166(74)90037-8; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COULOMBRE AJ, 1977, HDB TERATOLOGY, P329; COULOMBRE JL, 1969, INVEST OPHTH VISUAL, V8, P251; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HERO I, 1990, INVEST OPHTH VIS SCI, V31, P197; JOHNSTON MC, 1979, EXP EYE RES, V29, P27, DOI 10.1016/0014-4835(79)90164-7; Kastner P., 1994, Vitamin A in health and disease., P189; Kaufman M.H., 1992, ATLAS MOUSE DEV; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAND MF, 1992, ANNU REV NEUROSCI, V15, P1, DOI 10.1146/annurev.ne.15.030192.000245; LEGRAND J, 1986, THYROID HORMONE META, V8, P503; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LIU Q, 1993, MOL ENDOCRINOL, V7, P651, DOI 10.1210/me.7.5.651; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOHNES D, 1994, IN PRESS DEVELOPMENT; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Mann I, 1937, DEV ABNORMALITIES EY; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHARMSTRONG N, 1994, P NATL ACAD SCI USA, V91, P7286, DOI 10.1073/pnas.91.15.7286; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MENDELSOHN C, 1994, IN PRESS DEV BIOL; MENDELSOHN C, 1994, IN PRESS DEVELOPMENT; MIKAWA T, 1992, DEV DYNAM, V195, P133, DOI 10.1002/aja.1001950208; MIKAWA T, 1992, DEV DYNAM, V193, P11, DOI 10.1002/aja.1001930104; MOENS CB, 1993, DEVELOPMENT, V119, P485; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NODEN DM, 1991, DEVELOPMENT, V111, P867; ORO AE, 1992, DEVELOPMENT, V115, P449; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUMYANTSEV PP, 1977, INT REV CYTOL, V51, P187; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SPORN MB, 1994, RETINOIDS, P319; STEPHAN F, 1954, TRAITE ZOOL, V12, P854; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; WARKANY J, 1946, ARCH OPHTHALMOL-CHIC, V35, P150, DOI 10.1001/archopht.1946.00890200155008; WILSON JG, 1949, AM J ANAT, V85, P113, DOI 10.1002/aja.1000850106; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202	56	592	606	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					987	1003		10.1016/0092-8674(94)90274-7	http://dx.doi.org/10.1016/0092-8674(94)90274-7			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923367				2022-12-28	WOS:A1994PJ29400010
J	KENT, LA; GILL, GV; WILLIAMS, G				KENT, LA; GILL, GV; WILLIAMS, G			MORTALITY AND OUTCOME OF PATIENTS WITH BRITTLE DIABETES AND RECURRENT KETOACIDOSIS	LANCET			English	Article							INSULIN INFUSION; COMPLICATIONS; MANAGEMENT; MELLITUS; WOMEN	The long-term outlook of patients with brittle insulin-dependent diabetes is uncertain. We assessed the outcome of a group of young female patients with diabetes and recurrent ketoacidosis originally investigated in 1979-85 and reassessed after a mean of 10.5 (SD 1.4) years. 7 of the 33 patients could not be traced. 5 (19%) of the remaining 26 had died. Causes of death were not certain, but were probably ketoacidosis (2), hypoglycaemia (2), and renal failure (1). Of the 21 survivors, only 2 (10%) were still considered to have brittle diabetes. Diabetic complications were common (67%), and were more frequent than in a matched control group of stable patients with diabetes (25%). Brittle diabetic patients also had lower quality-of-life scores, more frequent psychosocial disruptions, and were on higher insulin doses (77 [39] vs 47 [15] U per day, p = 0.007) than controls. Pregnancy complications had occurred in 13 of 28 (46%) pregnancies in severely unstable patients compared with 2 of 27 (7%) in stable controls. Patients with brittle diabetes have a tendency to become more stable with time, but have a higher risk of death, more microvascular and pregnancy complications, and a poorer quality of life.	WALTON HOSP, CTR DIABET, LIVERPOOL L9 1AE, MERSEYSIDE, ENGLAND; ROYAL LIVERPOOL UNIV HOSP, DIABET CLIN, LIVERPOOL, MERSEYSIDE, ENGLAND; ROYAL LIVERPOOL UNIV HOSP, DEPT MED, LIVERPOOL, MERSEYSIDE, ENGLAND	Walton Centre; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool								BARNES PJ, 1989, BRIT MED J, V299, P695, DOI 10.1136/bmj.299.6701.695; BENEDETTI MM, 1987, DIABETES RES CLIN PR, V3, P307, DOI 10.1016/S0168-8227(87)80055-4; DCCT Res Grp, 1988, DIABETES CARE, V11, P725; DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; Gill G, 1986, Diabet Med, V3, P284; GILL G, 1989, DIABETIC MED, V6, P448, DOI 10.1111/j.1464-5491.1989.tb01203.x; GILL GV, 1992, J ROY SOC MED, V85, P259; GILL GV, 1991, BRIT MED J, V303, P285, DOI 10.1136/bmj.303.6797.285; GILL GV, BRITTLE DIABETES, P29; HINKLE LE, 1949, AM J MED SCI, V217, P130, DOI 10.1097/00000441-194902000-00002; HOME PD, 1982, ACTA ENDOCRINOL-COP, V101, P414, DOI 10.1530/acta.0.1010414; Husband D J, 1984, Diabet Med, V1, P99; HUSBAND DJ, 1986, DIABETES RES CLIN EX, V3, P193; JONES RB, 1984, BRIT MED J, V289, P1381, DOI 10.1136/bmj.289.6455.1381-b; MORAN G, 1991, J AM ACAD CHILD PSY, V30, P926, DOI 10.1097/00004583-199111000-00010; PECK FB, 1956, DIABETES, V5, P44, DOI 10.2337/diab.5.1.44; PICKUP J, 1983, DIABETES CARE, V6, P279, DOI 10.2337/diacare.6.3.279; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SCHADE DS, 1986, NEW ENGL J MED, V315, P147, DOI 10.1056/NEJM198607173150302; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEEL JM, 1987, BRIT MED J, V294, P859, DOI 10.1136/bmj.294.6576.859; TATTERSALL R, 1985, BRIT MED J, V291, P555, DOI 10.1136/bmj.291.6495.555; TATTERSALL R, 1991, BRIT MED J, V302, P1240, DOI 10.1136/bmj.302.6787.1240; TATTERSALL R, 1977, CLIN ENDOCRINOL META, V6, P403, DOI 10.1016/S0300-595X(77)80045-5; TAYLOR R, 1984, DIABETOLOGIA, V27, P441, DOI 10.1007/BF00273908; Williams D R, 1985, Diabet Med, V2, P27; WILLIAMS G, 1985, DIABETES CARE, V8, P21, DOI 10.2337/diacare.8.1.21; WILLIAMS G, 1988, DIABETES RES CLIN EX, V7, P13; WILLIAMS G, 1987, AM J MED, V82, P1247, DOI 10.1016/0002-9343(87)90234-8; WOOD DF, 1990, BRIT MED J, V301, P1143, DOI 10.1136/bmj.301.6761.1143	30	55	55	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 17	1994	344	8925					778	781		10.1016/S0140-6736(94)92340-X	http://dx.doi.org/10.1016/S0140-6736(94)92340-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916072				2022-12-28	WOS:A1994PG17800009
J	MCMANUS, C				MCMANUS, C			DEPARTMENT OF THEATRICAL MEDICINE	LANCET			English	Editorial Material											MCMANUS, C (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,ACAD DEPT PSYCHIAT,LONDON W2 1PG,ENGLAND.							Benedetti Jean, 1989, STANISLAVSKI INTRO; Goffman E, 1971, PRESENTATION SELF EV; Harrop John, 1992, ACTING; Hewstone M, 1989, CAUSAL ATTRIBUTION; MCMANUS IC, 1993, BRIT MED J, V306, P1322, DOI 10.1136/bmj.306.6888.1322; Stearns C. W., 1865, SHAKESPEARES MED KNO	6	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					767	767		10.1016/S0140-6736(94)92335-3	http://dx.doi.org/10.1016/S0140-6736(94)92335-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916067				2022-12-28	WOS:A1994PG17800004
J	CHEN, S; ROSEMAN, AM; HUNTER, AS; WOOD, SP; BURSTON, SG; RANSON, NA; CLARKE, AR; SAIBIL, HR				CHEN, S; ROSEMAN, AM; HUNTER, AS; WOOD, SP; BURSTON, SG; RANSON, NA; CLARKE, AR; SAIBIL, HR			LOCATION OF A FOLDING PROTEIN AND SHAPE CHANGES IN GROEL-GROES COMPLEXES IMAGED BY CRYOELECTRON MICROSCOPY	NATURE			English	Article							CHAPERONIN GROEL; CENTRAL CAVITY; BINDING; SURFACE; CYCLE; ATP	PROTEIN folding mediated by the molecular chaperone GroEL occurs by its binding to non-native polypeptide substrates and is driven by ATP hydrolysis(1). Both of these processes are influenced by the reversible association of the co-protein, GroES (refs 2-4). GroEL and other chaperonin 60 molecules(5) are large, cylindrical oligomers consisting of two stacked heptameric rings of subunits(6,7); each ring forms a cage-like structure(8) thought to bind polypeptides in a central cavity(8-10). Chaperonins play a passive role in folding by binding or sequestering folding proteins to prevent their aggregation(11-13), but they may also actively unfold substrate proteins trapped in misfolded forms, enabling them to assume productive folding conformations(14-16). Biochemical studies show that GroES improves the efficiency of GroEL function(2,3,17), but the structural basis for this is unknown. Here we report the first direct visualization, by cryo-electron microscopy, of a non-native protein substrate (malate dehydrogenase) bound to the mobile, outer domains at one end of GroEL. Addition of GroES to GroEL in the presence of ATP causes a dramatic hinge opening of about 60 degrees. GroES binds to the equivalent surface of the GroEL outer domains, but on the opposite end of the GroEL oligomer to the protein substrate.	UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND; UNIV BRISTOL,CTR MOLEC RECOGNIT,BRISTOL BS8 1TD,ENGLAND	University of Bristol; University of Bristol	CHEN, S (corresponding author), UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,MALET ST,LONDON WC1E 7HX,ENGLAND.		Wood, Stephen P/B-1438-2009; Roseman, Alan/AAE-6689-2019	Ranson, Neil/0000-0002-3640-5275; Roseman, Alan/0000-0002-4783-2619	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FISHER MT, 1994, J BIOL CHEM, V269, P13629; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARRIS JR, IN PRESS J STRUCT BI; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HUTCHINSON EG, 1989, EMBO J, V8, P1485, DOI 10.1002/j.1460-2075.1989.tb03532.x; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; NILSSON B, 1991, ANNU REV MICROBIOL, V45, P607; PERALTA D, 1994, FEBS LETT, V339, P40; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT R, 1994, SCIENCE, V265, P656; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	27	330	332	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					261	264		10.1038/371261a0	http://dx.doi.org/10.1038/371261a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	7915827				2022-12-28	WOS:A1994PG29000057
J	SCHUMPELICK, V; TREUTNER, KH; ARLT, G				SCHUMPELICK, V; TREUTNER, KH; ARLT, G			INGUINAL-HERNIA REPAIR IN ADULTS	LANCET			English	Article							COOPER LIGAMENT REPAIR; PREPERITONEAL APPROACH; GROIN HERNIA; HERNIORRHAPHY; HERNIOPLASTY; SIGMOIDOSCOPY; PREVENTION; EXPERIENCE; MANAGEMENT; DIAGNOSIS				SCHUMPELICK, V (corresponding author), RHEIN WESTFAL TH AACHEN,FAC MED,CHIRURG KLIN,DEPT SURG,PAUWELSSTR 30,D-52057 AACHEN,GERMANY.							AMID PK, 1993, AM J SURG, V165, P369, DOI 10.1016/S0002-9610(05)80847-5; ARREGUI ME, 1993, SURG CLIN N AM, V73, P513; BEHNIA R, 1992, SURG GYNECOL OBSTET, V174, P277; BENDAVID R, 1989, WORLD J SURG, V13, P522, DOI 10.1007/BF01658865; BERLINER SD, 1984, SURG CLIN N AM, V64, P197; BOGOJAVLENSKY S, 1989, 18TH ANN M AM ASS GY; Corbitt J D Jr, 1991, Surg Laparosc Endosc, V1, P23; DEVLIN HB, 1986, BRIT J SURG, V73, P123, DOI 10.1002/bjs.1800730217; FONG Y, 1992, SURG GYNECOL OBSTET, V174, P399; GER R, 1990, AM J SURG, V159, P370, DOI 10.1016/S0002-9610(05)81273-5; GILBERT AI, 1989, AM J SURG, V157, P331, DOI 10.1016/0002-9610(89)90564-3; GILBERT AI, 1993, SURG GYNECOL OBSTET, V177, P126; GILBERT AI, 1992, AM J SURG, V163, P331, DOI 10.1016/0002-9610(92)90015-J; GLASSOW F, 1976, AM J SURG, V131, P306, DOI 10.1016/0002-9610(76)90122-7; HAHNPEDERSEN J, 1994, BRIT J SURG, V81, P569, DOI 10.1002/bjs.1800810430; HORTON MD, 1993, AM J SURG, V165, P595, DOI 10.1016/S0002-9610(05)80442-8; HOURLAY P, IN PRESS INGUINAL HE; KINGSNORTH AN, 1992, BRIT J SURG, V79, P1068, DOI 10.1002/bjs.1800791026; KUX M, 1994, CHIRURG, V65, P59; LICHTENSTEIN IL, 1993, SURG CLIN N AM, V73, P529; LOVETT J, 1989, AM J SURG, V158, P615, DOI 10.1016/0002-9610(89)90206-7; MACFADYEN BV, 1993, SURG ENDOSC-ULTRAS, V7, P155, DOI 10.1007/BF00594097; NYHUS LM, 1993, SURG CLIN N AM, V73, P487; PANOS RG, 1992, SURG GYNECOL OBSTET, V175, P315; Popp L W, 1991, J Laparoendosc Surg, V1, P83, DOI 10.1089/lps.1991.1.83; READ RC, 1993, SURG CLIN N AM, V73, P545; REID I, 1994, BRIT J SURG, V81, P91, DOI 10.1002/bjs.1800810132; RIS HB, 1987, CHIRURG, V59, P93; RUBIN BG, 1987, ARCH SURG-CHICAGO, V122, P296; RUTKOW IM, 1992, ARCH SURG-CHICAGO, V127, P1271; RUTKOW IM, 1993, SURGERY, V114, P3; RUTKOW IM, 1993, SURG CLIN N AM, V73, P413; RUTLEDGE RH, 1993, SURG CLIN N AM, V73, P471; RUTLEDGE RH, 1988, SURGERY, V103, P1; SCHAAP HM, 1992, SURG GYNECOL OBSTET, V174, P460; SCHUMPELICK V, 1990, CHIRURG, V61, P526; SCHUMPELICK V, 1990, ATLAS HERNIA SURGERY; SCHUMPELICK V, IN PRESS INGUINAL HE; SERPELL JW, 1990, ANN ROY COLL SURG, V72, P299; SHULMAN AG, 1992, AM SURGEON, V58, P255; SHULTZ L, 1990, J LAPAROENDOSC SURG, V1, P40; STARLING JR, 1989, WORLD J SURG, V13, P586, DOI 10.1007/BF01658875; STOKER D, 1994, LANCET, V343, P1243, DOI 10.1016/S0140-6736(94)92148-2; STOPPA RE, 1989, WORLD J SURG, V13, P545, DOI 10.1007/BF01658869; TOENS C, 1990, CHIRURG, V61, P109; WANTZ GE, 1993, SURG GYNECOL OBSTET, V176, P497; WANTZ GE, 1989, WORLD J SURG, V13, P516, DOI 10.1007/BF01658864; WANTZ GE, 1993, SURG CLIN N AM, V73, P571; WASSMER FA, 1988, SEM HOP PARIS, V64, P2595; WELSH DRJ, 1993, SURG CLIN N AM, V73, P451; 1993, CLIN GUIDELINES MANA	51	136	149	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					375	379						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914310				2022-12-28	WOS:A1994PA30300013
J	CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; BRETT, SE; RITTER, JM				CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; BRETT, SE; RITTER, JM			SEX-DIFFERENCES IN ENDOTHELIAL FUNCTION IN NORMAL AND HYPERCHOLESTEROLEMIC SUBJECTS	LANCET			English	Note							DEPENDENT VASODILATION; L-ARGININE; VESSELS	Acetylcholine stimulates endothelial synthesis of nitric oxide from L-arginine. To investigate the influence of sex on endothelial function, we measured vasodilator responses to brachial artery administration of acetylcholine in hypercholesterolaemic and control men and women. Mean response to acetylcholine was impaired (55% of that in controls at 15 mu g/min) in hypercholesterolaemic men but not in hypercholesterolaemic women. L-arginine normalised responses to acetylcholine in hypercholesterolaemic men, but had similar effects in hypercholesterolaemic and control women. These results suggest that women are protected against adverse effects of hypercholesterolaemia on the L-arginine/nitric-oxide pathway.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT CLIN PHARMACOL,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT ENDOCRINOL & CHEM PATHOL,LONDON SE1 9RT,ENGLAND	University of London; King's College London; University of London; King's College London				Chowienczyk, Phil/0000-0003-4507-038X; Watts, Gerald/0000-0003-2276-1524				CALVER A, 1991, CLIN SCI, V81, P695, DOI 10.1042/cs0810695; CASINO PR, 1993, CIRCULATION, V88, P2541, DOI 10.1161/01.CIR.88.6.2541; CHOWIENCZYK PJ, 1994, CLIN SCI, V87, P45, DOI 10.1042/cs0870045; CHOWIENCZYK PJ, 1992, LANCET, V340, P1430, DOI 10.1016/0140-6736(92)92621-L; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; IMAIZUMI T, 1992, HYPERTENSION, V20, P511, DOI 10.1161/01.HYP.20.4.511; JACOBS M, 1990, BRIT J PHARMACOL, V100, P21, DOI 10.1111/j.1476-5381.1990.tb12045.x; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; WEINER C, 1993, ENDOTHELIUM, V1, pS1	10	73	73	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					305	306		10.1016/S0140-6736(94)91342-0	http://dx.doi.org/10.1016/S0140-6736(94)91342-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914265				2022-12-28	WOS:A1994NZ23300011
J	JENNEY, M				JENNEY, M			LIMITATION OF THERAPY IN THE TREATMENT OF CHILDHOOD-CANCER - TOXICITY VERSUS CURE	LANCET			English	Editorial Material							ACUTE LYMPHOBLASTIC-LEUKEMIA; CRANIAL RADIATION; METHOTREXATE; DISEASE				JENNEY, M (corresponding author), UNIV MINNESOTA,DEPT PEDIAT,DIV HEMATOL ONCOL,MINNEAPOLIS,MN 55455, USA.							BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CLAYTON PE, 1988, LANCET, V1, P460; MILHERN RK, 1991, J CLIN ONCOL, V9, P1348; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; OCHS J, 1991, J CLIN ONCOL, V9, P145, DOI 10.1200/JCO.1991.9.1.145; ODRISCOLL BR, 1990, NEW ENGL J MED, V323, P378, DOI 10.1056/NEJM199008093230604; ROWLAND JH, 1984, J CLIN ONCOL, V2, P1327, DOI 10.1200/JCO.1984.2.12.1327; SHALET SM, 1989, ARCH DIS CHILD, V64, P1635, DOI 10.1136/adc.64.11.1635; STEINHERZ LJ, 1991, JAMA-J AM MED ASSOC, V266, P1672, DOI 10.1001/jama.266.12.1672; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P520, DOI 10.1200/JCO.1993.11.3.520	10	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					210	211		10.1016/S0140-6736(94)92991-2	http://dx.doi.org/10.1016/S0140-6736(94)92991-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913151				2022-12-28	WOS:A1994NY06000003
J	MAXWELL, S; CRUICKSHANK, A; THORPE, G				MAXWELL, S; CRUICKSHANK, A; THORPE, G			RED WINE AND ANTIOXIDANT ACTIVITY IN SERUM	LANCET			English	Letter							LOW-DENSITY-LIPOPROTEIN				MAXWELL, S (corresponding author), QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WHITEHEAD TP, 1992, ANAL CHIM ACTA, V266, P265, DOI 10.1016/0003-2670(92)85052-8	5	292	301	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					193	194		10.1016/S0140-6736(94)92795-2	http://dx.doi.org/10.1016/S0140-6736(94)92795-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912786				2022-12-28	WOS:A1994NW81000048
J	CARROLL, SB; GATES, J; KEYS, DN; PADDOCK, SW; PANGANIBAN, GEF; SELEGUE, JE; WILLIAMS, JA				CARROLL, SB; GATES, J; KEYS, DN; PADDOCK, SW; PANGANIBAN, GEF; SELEGUE, JE; WILLIAMS, JA			PATTERN-FORMATION AND EYESPOT DETERMINATION IN BUTTERFLY WINGS	SCIENCE			English	Article							PRECIS-COENIA LEPIDOPTERA; LIMB DEVELOPMENT; IMAGINAL DISKS; DROSOPHILA-MELANOGASTER; ENGRAILED GENE; HOMEOBOX GENE; EXPRESSION; WINGLESS; PROTEIN; ENCODES	Butterfly wings display pattern elements of many types and colors. To identify the molecular processes underlying the generation of these patterns, several butterfly cognates of Drosophila appendage patterning genes have been cloned and their expression patterns have been analyzed. Butterfly wing patterns are organized by two spatial coordinate systems. One system specifies positional information with respect to the entire wing field and is conserved between fruit flies and butterflies. A second system, superimposed on the general system and involving several of the same genes, operates within each wing subdivision to elaborate discrete pattern elements. Eyespots, which form from discrete developmental organizers, are marked by Distal-less gene expression. These circular pattern elements appear to be generated by a process similar to, and perhaps evolved from, proximodistal pattern formation in insect appendages.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	CARROLL, SB (corresponding author), UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706, USA.		Boekhoff-Falk, Grace E/B-2240-2008	Boekhoff-Falk, Grace E/0000-0002-9877-8309				CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; Cohen Stephen M., 1993, P747; COLEMAN KG, 1987, GENE DEV, V1, P19, DOI 10.1101/gad.1.1.19; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; DIASBENJUMEA F, 1993, CELL, V75, P741; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; DOLLE P, 1992, DIFFERENTIATION, V49, P93, DOI 10.1111/j.1432-0436.1992.tb00773.x; FRENCH V, 1992, DEVELOPMENT, V116, P103; GARCIABELLIDO A, 1975, CIBA F S, V29, P16; HUI CC, 1992, P NATL ACAD SCI USA, V89, P167, DOI 10.1073/pnas.89.1.167; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KLESSIG DF, 1983, PLANT MOL BIOL REP, V1, P12; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Nijhout H.F., 1991, DEV EVOLUTION BUTTER; NIJHOUT HF, 1985, J EMBRYOL EXP MORPH, V86, P191; NIJHOUT HF, 1980, DEV BIOL, V80, P275, DOI 10.1016/0012-1606(80)90404-2; NIJHOUT HF, 1988, DEVELOPMENT, V102, P377; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PATEL NH, 1989, DEVELOPMENT, V107, P201; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SPENCER FA, 1982, CELL, V28, P45; STEVENS ME, 1986, DEV BIOL, V117, P326, DOI 10.1016/0012-1606(86)90375-1; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1988, EMBO J, V7, P1355, DOI 10.1002/j.1460-2075.1988.tb02951.x; WILLIAMS JA, 1993, BIOESSAYS, V15, P167; WILLIAMS JA, 1991, GENE DEV, V5, P248; WILLIAMS JA, 1994, NATURE, V368, P298; WILLIAMS JJ, UNPUB; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YAMAMOTO RT, 1993, J ECON ENTOMOL, V621, P1427	45	287	294	0	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					109	114		10.1126/science.7912449	http://dx.doi.org/10.1126/science.7912449			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	7912449				2022-12-28	WOS:A1994NV30100038
J	TURKOF, E; TAMBWEKAR, S; MANSUKHANI, K; MILLESI, H; MAYR, N				TURKOF, E; TAMBWEKAR, S; MANSUKHANI, K; MILLESI, H; MAYR, N			INTRAOPERATIVE SPINAL ROOT STIMULATION TO DETECT MOST PROXIMAL SITE OF LEPROUS ULNAR NEURITIS	LANCET			English	Note							MUSCLE	In 10 patients with leprous ulnar neuritis, we investigated the most proximal site of lesion in the affected nerves. Spinal roots C8 and T1 were stimulated intraoperatively to evoke efferent mixed compound nerve action potentials which were recorded from the exposed ulnar nerves. The site at which amplitudes reached a maximum was considered the most proximal site of lesion. Nerve damage was found far proximally from the thickened segments in otherwise inconspicuous sections. Epineuriotomy within these apparently unaffected segments revealed fibrosis of the interfascicular epineurium in 9 patients, which is an indication for microsurgical interfascicular neurolysis.	UNIV VIENNA,ALLGEMEINES KRANKENHAUS WIEN,NEUROL KLIN,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,SURG CLIN,DEPT PLAST & RECONSTRUCT SURG,VIENNA,AUSTRIA; LUDWIG BOLTZMANN INST EXPTL PLAST SURG,VIENNA,AUSTRIA; KEM HOSP BOMBAY,DEPT PLAST & RECONSTRUCT SURG,BOMBAY,MAHARASHTRA,INDIA; KEM HOSP BOMBAY,DEPT NEUROL,BOMBAY,MAHARASHTRA,INDIA; UNIV VIENNA,NEUROL CLIN,VIENNA,AUSTRIA	University of Vienna; University of Vienna; Ludwig Boltzmann Institute; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; University of Vienna								[Anonymous], 1993, Wkly Epidemiol Rec, V68, P181; ENNA CD, 1974, J NEUROSURG, V40, P734, DOI 10.3171/jns.1974.40.6.0734; GIRAUDEAU P, 1982, ACTA LEPROL GENEVE, V86, P227; MCLEOD JG, 1975, BRAIN, V98, P203, DOI 10.1093/brain/98.2.203; MERTON PA, 1982, LANCET, V2, P597; PANDYA JN, 1976, INT J LEPROSY, V46, P47; PEREIRA JH, 1991, LANCET, V338, P1239, DOI 10.1016/0140-6736(91)92105-B; SUNDERLAND S, 1973, BRAIN, V96, P865, DOI 10.1093/brain/96.4.865	8	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1604	1605		10.1016/S0140-6736(94)93059-7	http://dx.doi.org/10.1016/S0140-6736(94)93059-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911922				2022-12-28	WOS:A1994NU35400012
J	ZACHARSKI, LR				ZACHARSKI, LR			WARFARIN TREATMENT IN BREAST-CANCER	LANCET			English	Letter							PATHWAYS; TISSUE				ZACHARSKI, LR (corresponding author), DEPT VET AFFAIRS,MED & REG OFF CTR,WHITE RIVER JCT,VT 05009, USA.							COSTANTINI V, 1991, CANCER RES, V51, P354; LEBEAU B, 1991, LUNG CANCER S, V7, P129; LEVINE, 1994, LANCET, V343, P886; ZACHARSKI LR, 1993, JNCI-J NATL CANCER I, V85, P1225, DOI 10.1093/jnci/85.15.1225; ZACHARSKI LR, 1992, SEMIN THROMB HEMOST, V18, P104, DOI 10.1055/s-2007-1002415; ZACHARSKI LR, 1993, THROMB HAEMOSTASIS, V69, P1234	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1568	1568		10.1016/S0140-6736(94)92967-X	http://dx.doi.org/10.1016/S0140-6736(94)92967-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911887				2022-12-28	WOS:A1994NR32900036
J	MARK, T; DOUGHERTY, D				MARK, T; DOUGHERTY, D			UNDERSTANDING ESTIMATES OF NATIONAL-HEALTH EXPENDITURES UNDER HEALTH SYSTEM REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MARK, T (corresponding author), US CONGRESS,OFF TECHNOL ASSESSMENT,HLTH PROGRAM,WASHINGTON,DC 20501, USA.							OTAH594 PUBL	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1399	1399						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP690	7933408				2022-12-28	WOS:A1994PP69000006
J	GRANOFF, DM; HOLMES, SJ; BEISHE, RB; OSTERHOLM, MT; MCHUGH, JE; ANDERSON, EL				GRANOFF, DM; HOLMES, SJ; BEISHE, RB; OSTERHOLM, MT; MCHUGH, JE; ANDERSON, EL			EFFECT OF CARRIER PROTEIN PRIMING ON ANTIBODY-RESPONSES TO HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINES IN INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED EPITOPIC SUPPRESSION; CAPSULAR POLYSACCHARIDE; IMMUNOGENICITY; IMMUNIZATION; DIPHTHERIA; IGG; INDUCTION; DISEASE	Objective.-To assess the effect of priming with diphtheria and tetanus toroid vaccine (DT) at 1 month of age on the anticapsular polyribosylribitol phosphate (PRP) antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-tetanus toroid conjugate (PRP-T) or PRP oligosaccharide-cross-reactive mutant diphtheria toxin conjugate (HbOC). Design.-Randomized controlled trial with serum samples assayed blindly. Participants and Setting.-Healthy infants enrolled in private pediatric practices; 94 (91%) of 103 infants had prevaccination and postvaccination serum samples available for analysis. Interventions.-Two groups received DT vaccination at 1 month of age and subsequent injections of PRP-T or HbOC conjugate vaccines at 2, 4, and 6 months of age. The control groups were not vaccinated with DT but received PRP-T or HbOC at the same ages as the carrier-primed groups. Infants in all groups were given a booster injection of unconjugated PRP at 12 months of age to assess induction of immunologic memory. Main Outcome Measure.-Concentrations of serum antibody to PRP. Main Results.-The DT-primed infants given PRP-T had twofold to threefold higher geometric mean anti-PRP antibody responses after one (P less than or equal to.01), two (P less than or equal to.01), or three (P=.06) doses of conjugate vaccine than the infants of the unprimed group. The primed infants also had threefold higher memory antibody responses to the booster PRP injection given at 12 months of age (concentration of 24.4 vs 8.4 mu g/mL in infants not primed with DT; P<.01). The DT-primed infants given HbOC had twofold to threefold higher antibody responses after one (P=.07) or two (P<.01) doses of conjugate vaccine than the unprimed HbOC group, but there were no significant differences after the third dose of conjugate vaccine or after the PRP booster injection. Conclusions.-Vaccination with DT at 1 month of age increases the magnitude of the anti-PRP antibody responses to conjugate vaccination. With HbOC, the effect of carrier priming was present for up to 6 months of age, whereas in infants vaccinated with PRP-T, enhanced immunity was present for at least 12 months.	WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, DIV INFECT DIS, ST LOUIS, MO 63110 USA; CTR DIS CONTROL & PREVENT, NATL IMMUNIZATION PROGRAM, ATLANTA, GA 30333 USA; ST LOUIS UNIV, SCH MED, DEPT PEDIAT, NIAID, VACCINE EVALUAT UNIT, ST LOUIS, MO 63104 USA; ST LOUIS UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63104 USA; MINNESOTA DEPT HLTH, ACUTE DIS EPIDEMIOL SECT, MINNEAPOLIS, MN USA; CHILDRENS CLIN, WAYATA, MN USA; CHIRON CORP, BIOCENE CLIN RES, EMERYVILLE, CA 94608 USA	Washington University (WUSTL); Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Saint Louis University; Saint Louis University; Minnesota Department of Health (MHD); Novartis	GRANOFF, DM (corresponding author), CHILDRENS HOSP OAKLAND, RES INST, 747 52ND ST, OAKLAND, CA 94609 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F33AI008851, R01AI017962, R01AI021842] Funding Source: NIH RePORTER; NIAID NIH HHS [F33 AI 08851, AI 21842, AI 17962] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; Avery OT, 1929, J EXP MED, V50, P533, DOI 10.1084/jem.50.4.533; BARINGTON T, 1994, INFECT IMMUN, V62, P9, DOI 10.1128/IAI.62.1.9-14.1994; BARINGTON T, 1993, INFECT IMMUN, V61, P432, DOI 10.1128/IAI.61.2.432-438.1993; Bixler G S Jr, 1989, Contrib Microbiol Immunol, V10, P18; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; DENGROVE J, 1986, PEDIATR RES, V20, P735, DOI 10.1203/00006450-198608000-00007; DONNELLY JJ, 1994, DEV CLIN USES HAEMOP, P71; EINHORN MS, 1986, LANCET, V2, P299; GARDNER P, 1993, NEW ENGL J MED, V328, P1252, DOI 10.1056/NEJM199304293281708; GRANOFF DM, 1993, J INFECT DIS, V168, P663, DOI 10.1093/infdis/168.3.663; GRANOFF DM, 1986, J INFECT DIS, V154, P257, DOI 10.1093/infdis/154.2.257; GRANOFF DM, 1992, J PEDIATR-US, V121, P187, DOI 10.1016/S0022-3476(05)81186-2; GRANOFF DM, 1994, IN PRESS ANN NY ACAD; HERZENBERG LA, 1982, J EXP MED, V155, P1730, DOI 10.1084/jem.155.6.1730; HOLMES SJ, 1991, J PEDIATR-US, V118, P364, DOI 10.1016/S0022-3476(05)82148-1; INSEL RA, 1986, J EXP MED, V163, P262, DOI 10.1084/jem.163.2.262; JENNINGS HJ, 1983, ADV CARBOHYD CHEM BI, V41, P155, DOI 10.1016/S0065-2318(08)60058-X; KREEFTENBERG JG, 1985, J BIOL STAND, V13, P229, DOI 10.1016/S0092-1157(85)80006-8; LIEBERMAN JM, 1993, PEDIATRRES, V33, P174; MIYAMURA K, 1974, J BIOL STAND, V2, P203, DOI 10.1016/0092-1157(74)90016-X; MURPHY TV, 1993, JAMA-J AM MED ASSOC, V269, P246, DOI 10.1001/jama.269.2.246; PARKE JC, 1991, J PEDIATR-US, V118, P184, DOI 10.1016/S0022-3476(05)80480-9; PEETERS CCAM, 1991, INFECT IMMUN, V59, P3504, DOI 10.1128/IAI.59.10.3504-3510.1991; ROBBINS JB, 1989, CURR TOP MICROBIOL, V146, P169; ROY R, 1984, CAN J BIOCHEM CELL B, V62, P270, DOI 10.1139/o84-037; SCHLESINGER Y, 1992, JAMA-J AM MED ASSOC, V267, P1489, DOI 10.1001/jama.267.11.1489; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; SCHNEERSON R, 1984, INFECT IMMUN, V45, P582, DOI 10.1128/IAI.45.3.582-591.1984; SCHUTZE MP, 1989, J IMMUNOL, V142, P2635; SCHUTZE MP, 1985, J IMMUNOL, V135, P2319; URCHIDA T, 1972, SCIENCE, V175, P901; WATTS C, 1993, J EXP MED, V178, P1459, DOI 10.1084/jem.178.4.1459; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; 1993, PEDIATRICS, V92, P80	35	54	57	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1116	1121		10.1001/jama.272.14.1116	http://dx.doi.org/10.1001/jama.272.14.1116			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK124	7933324				2022-12-28	WOS:A1994PK12400031
J	DUNAIEF, JL; STROBER, BE; GUHA, S; KHAVARI, PA; ALIN, K; LUBAN, J; BEGEMANN, M; CRABTREE, GR; GOFF, SP				DUNAIEF, JL; STROBER, BE; GUHA, S; KHAVARI, PA; ALIN, K; LUBAN, J; BEGEMANN, M; CRABTREE, GR; GOFF, SP			THE RETINOBLASTOMA PROTEIN AND BRG1 FORM A COMPLEX AND COOPERATE TO INDUCE CELL-CYCLE ARREST	CELL			English	Article							LARGE T-ANTIGEN; TRANSCRIPTION FACTOR E2F; SV40 LARGE-T; GENE-PRODUCT; SUSCEPTIBILITY GENE; BINDING PROTEIN; SNF6 PROTEINS; E1A PRODUCTS; EXPRESSION; DOMAIN	The retinoblastoma tumor suppressor protein (RB) binds several cellular proteins involved in cell cycle progression. Using the yeast two-hybrid system, we found that RB bound specifically to the protein BRG1. BRG1 shares extensive sequence similarity to Drosophila brahma, an activator of homeotic gene expression, and the yeast transcriptional activator SNF2/SWI2. BRG1 contains an RB-binding motif found in viral oncoproteins and bound to the A/B pocket and the hypophosphorylated form of RB. BRG1 did not bind RB in viral oncoprotein-transformed cells. Coimmunoprecipitation experiments suggested BRG1 associates with the RB family in vivo. In the human carcinoma cell line SW13, BRG1 exhibited tumor suppressor activity by inducing formation of flat, growth-arrested cells. This activity depended on the ability of BRG1 to cooperate and complex with RB, as both an RB-nonbinding mutant of BRG1 and the sequestration of RB by adenovirus E1A protein abolished flat cell formation.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032; STANFORD UNIV,DEPT DEV BIOL,STANFORD,CA 94305	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University; Stanford University	DUNAIEF, JL (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032, USA.		Strober, Bruce/AAQ-6953-2020	Strober, Bruce/0000-0002-8394-2057; Luban, Jeremy/0000-0001-5650-4054	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007616] Funding Source: NIH RePORTER; NHLBI NIH HHS [MSTP 5T35HL07616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1992, NATURE, V359, P270, DOI 10.1038/359270a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUBAN J, 1992, J VIROL, V66, P5157, DOI 10.1128/JVI.66.8.5157-5160.1992; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RANDAZZO FM, 1994, DEV BIOL, V161, P229, DOI 10.1006/dbio.1994.1023; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSUCHIYA E, 1992, EMBO J, V11, P4017, DOI 10.1002/j.1460-2075.1992.tb05495.x; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	66	539	551	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					119	130		10.1016/0092-8674(94)90405-7	http://dx.doi.org/10.1016/0092-8674(94)90405-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923370				2022-12-28	WOS:A1994PK58500013
J	GOTZSCHE, PC				GOTZSCHE, PC			IS THERE LOGIC IN THE PLACEBO	LANCET			English	Article							PAIN				GOTZSCHE, PC (corresponding author), RIGSHOSP, NORDIC COCHRANE CTR, RES & DEV SECRETARIAT, 9 BLEGDAMSVEJ, DK-2100 COPENHAGEN 0, DENMARK.							Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; GAM AN, 1993, PAIN, V52, P63, DOI 10.1016/0304-3959(93)90114-5; KENNEDY W P, 1961, Med World, V95, P203; PECK C, 1991, THEOR MED, V12, P247, DOI 10.1007/BF00489609; SHAPIRO AK, 1968, PSYCHIAT QUART, V42, P653, DOI 10.1007/BF01564309; SHEPHERD M, 1993, PSYCHOL MED, V23, P569, DOI 10.1017/S0033291700025356; WARE JE, 1993, BRIT MED J, V306, P1429, DOI 10.1136/bmj.306.6890.1429; Wulff H. R., 1986, PHILOS MED	8	117	117	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	1994	344	8927					925	926						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934350				2022-12-28	WOS:A1994PJ28700014
J	GRISHAM, MB				GRISHAM, MB			OXIDANTS AND FREE-RADICALS IN INFLAMMATORY BOWEL-DISEASE	LANCET			English	Article							REACTIVE OXYGEN METABOLITES; NITRIC-OXIDE; EXPERIMENTAL COLITIS; CROHNS-DISEASE; COPPER-ZINC; SUPEROXIDE; MECHANISMS; DECREASE; INJURY; COLON				GRISHAM, MB (corresponding author), LOUISIANA STATE UNIV,MED CTR,DEPT PHYSIOL & BIOPHYS,1501 KINGS HIGHWAY,SHREVEPORT,LA 71130, USA.				NIDDK NIH HHS [DK 43785, DK 47663] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK043785] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNFELTRONNE I, 1990, GASTROENTEROLOGY, V98, P1162, DOI 10.1016/0016-5085(90)90329-Y; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOUGHTONSMITH NK, 1993, LANCET, V342, P338, DOI 10.1016/0140-6736(93)91476-3; EMERIT J, 1989, FREE RADICAL BIO MED, V7, P145, DOI 10.1016/0891-5849(89)90005-1; Grisham M, 1990, CAN J GASTROENTEROL, V4, P295, DOI 10.1155/1990/324287; GRISHAM MB, 1988, DIGEST DIS SCI, V33, pS6, DOI 10.1007/BF01538126; GRISHAM MB, 1990, INFLAMMATION, V14, P669, DOI 10.1007/BF00916370; GRISHAM MB, 1993, CURR OPIN GASTROEN, V9, P971, DOI 10.1097/00001574-199309060-00013; GRISHAM MB, 1989, DIGEST DIS SCI, V34, P575; GRISHAM MB, 1992, REACTIVE OXYGEN META; GRISHAM MB, IN PRESS J PHARM EXP; HARRIS ML, 1992, PHARMACOL THERAPEUT, V53, P375, DOI 10.1016/0163-7258(92)90057-7; KESHAVARZIAN A, 1992, DIGEST DIS SCI, V37, P1866; KESHAVARZIAN A, 1992, GASTROENTEROLOGY, V103, P177, DOI 10.1016/0016-5085(92)91111-G; KESHAVARZIAN A, 1990, GUT, V31, P786, DOI 10.1136/gut.31.7.786; Klebanoff SJ., 1992, INFLAMMATION BASIC P, P541; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MULDER TPJ, 1991, GUT, V32, P1146, DOI 10.1136/gut.32.10.1146; OSHITANI N, 1993, GUT, V34, P936, DOI 10.1136/gut.34.7.936; SIMMONDS NJ, 1992, GASTROENTEROLOGY, V103, P186, DOI 10.1016/0016-5085(92)91112-H; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEITZMAN SA, 1990, BLOOD, V76, P655	22	436	453	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					859	861		10.1016/S0140-6736(94)92831-2	http://dx.doi.org/10.1016/S0140-6736(94)92831-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916405				2022-12-28	WOS:A1994PH25300015
J	REHMAN, I; QUINN, AG; HEALY, E; REES, JL				REHMAN, I; QUINN, AG; HEALY, E; REES, JL			HIGH-FREQUENCY OF LOSS OF HETEROZYGOSITY IN ACTINIC KERATOSES, A USUALLY BENIGN DISEASE	LANCET			English	Note							SQUAMOUS-CELL CARCINOMA; SKIN	Actinic keratoses (AKs) are focal areas of dysplasia with low risk of progression to squamous cell cancer; many regress spontaneously. Using polymerase-chain-reaction microsatellite analysis, we found that loss of heterozygosity on several chromosome arms, including 17p, 17q, 9p, 9q, and 13q, was common in AKs. More than half the AKs examined showed loss of heterozygosity at four or more loci. The apparent genetic instability of these lesions contrasts with their benign clinical course.	UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,ENGLAND	Newcastle University - UK				Healy, Eugene/0000-0001-5591-6970				CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; KNUDSON A, 1991, ORIGINS OF HUMAN CANCER, P17; KWA RE, 1992, J AM ACAD DERMATOL, V26, P1, DOI 10.1016/0190-9622(92)70001-V; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; QUINN AG, 1994, CANCER RES, V54, P4756; WEINBERG RA, 1991, ORIGINS OF HUMAN CANCER, P1; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	10	60	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					788	789		10.1016/S0140-6736(94)92343-4	http://dx.doi.org/10.1016/S0140-6736(94)92343-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916075				2022-12-28	WOS:A1994PG17800012
J	KAMM, MA				KAMM, MA			OBSTETRIC DAMAGE AND FECAL INCONTINENCE	LANCET			English	Review							ANAL-SPHINCTER DEFECTS; FECAL INCONTINENCE; VAGINAL DELIVERY; PREVALENCE; CHILDBIRTH; ENDOSONOGRAPHY; DENERVATION; INNERVATION; INJURY	Anal incontinence for gas or faeces affects up to 11% of adults, and occurs frequently in 2%. The commonest cause in healthy women is unrecognised damage to the anal sphincter during childbirth; 13% of women having their first vaginal delivery develop incontinence or urgency, and 30% have structural changes shown by anal endosonography. The commonest predisposing cause of damage is the use of forceps. When a third-degree tear occurs, 85% of women have persistent structural sphincter defects and 50% remain symptomatic despite primary repair after delivery. Structural damage associated with childbirth is more important than neurological factors. The characterisation of this sphincter damage has led to improved treatment, including successful surgical repair.			KAMM, MA (corresponding author), ST MARKS HOSP,CITY RD,LONDON EC1V 2PS,ENGLAND.							BARTOLO DCC, 1983, BRIT J SURG, V70, P664, DOI 10.1002/bjs.1800701108; BARTOLO DCC, 1983, GASTROENTEROLOGY, V85, P68; BEK KM, 1992, BRIT J OBSTET GYNAEC, V99, P724, DOI 10.1111/j.1471-0528.1992.tb13870.x; BURNETT SJD, 1991, BRIT J SURG, V78, P448, DOI 10.1002/bjs.1800780419; CARRARO PS, 1994, BRIT J SURG, V81, P140, DOI 10.1002/bjs.1800810151; DEEN KI, 1993, GUT, V34, P685, DOI 10.1136/gut.34.5.685; DENIS P, 1992, GASTROEN CLIN BIOL, V16, P344; ENGEL AF, 1994, BRIT J SURG, V81, P1231, DOI 10.1002/bjs.1800810853; FLESHMAN JW, 1991, DIS COLON RECTUM, V34, P1061, DOI 10.1007/BF02050062; JAMESON JS, IN PRESS BR J SURG; LAW PJ, 1991, BRIT J SURG, V78, P312, DOI 10.1002/bjs.1800780315; NIELSEN MB, 1993, AM J ROENTGENOL, V160, P771, DOI 10.2214/ajr.160.4.8456663; PARKS AG, 1977, GUT, V18, P656, DOI 10.1136/gut.18.8.656; SNOOKS SJ, 1986, INT J COLORECTAL DIS, V1, P20, DOI 10.1007/BF01648831; SNOOKS SJ, 1984, LANCET, V2, P546; SORENSEN M, 1993, BRIT J SURG, V80, P392, DOI 10.1002/bjs.1800800343; SPEAKMAN CTM, 1991, GUT, V32, P345, DOI 10.1136/gut.32.4.345; SULTAN AH, 1994, BRIT J OBSTET GYNAEC, V101, P22, DOI 10.1111/j.1471-0528.1994.tb13005.x; SULTAN AH, 1993, INT J GYNECOL OBSTET, V43, P263, DOI 10.1016/0020-7292(93)90514-W; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, CLIN RADIOL, V49, P368, DOI 10.1016/S0009-9260(05)81819-7; SULTAN AH, 1993, BRIT J SURG, V80, P508, DOI 10.1002/bjs.1800800435; SULTAN AH, 1994, BRIT MED J, V308, P887, DOI 10.1136/bmj.308.6933.887; Sultan AH, 1993, J OBSTET GYNECOL, V13, P484; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P895, DOI 10.1016/0016-5085(92)90175-X	25	233	238	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					730	733		10.1016/S0140-6736(94)92213-6	http://dx.doi.org/10.1016/S0140-6736(94)92213-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915781				2022-12-28	WOS:A1994PF18700015
J	CHAN, SK; JAFFE, L; CAPOVILLA, M; BOTAS, J; MANN, RS				CHAN, SK; JAFFE, L; CAPOVILLA, M; BOTAS, J; MANN, RS			THE DNA-BINDING SPECIFICITY OF ULTRABITHORAX IS MODULATED BY COOPERATIVE INTERACTIONS WITH EXTRADENTICLE, ANOTHER HOMEOPROTEIN	CELL			English	Article							HUMAN PROTOONCOGENE PBX1; MAGNETIC-RESONANCE SPECTROSCOPY; DROSOPHILA HOMEODOMAIN PROTEINS; HOMEOTIC GENE-EXPRESSION; FUNCTIONAL SPECIFICITY; ANTENNAPEDIA HOMEODOMAIN; ECTOPIC EXPRESSION; VISCERAL MESODERM; CRYSTAL-STRUCTURE; HOMEOBOX GENES	The Ultrabithorax (Ubx) and Antennapedia (Antp) genes of Drosophila encode homeodomain proteins that have very similar DNA binding specificities in vitro but specify the development of different segmental patterns in vivo. We describe cooperative interactions between Ubx protein and a divergent homeodomain protein, extradenticle (exd), that selectively increases the affinity of Ubx, but not Antp, for a particular DNA target. We also provide evidence that Ubx and exd bind to neighboring sites on this DNA and interact directly to stabilize the DNA-bound form of Ubx. Thus, the ability of different homeotic genes to specify distinct segmental patterns may depend on cooperative interactions with proteins such as exd that selectively modulate their otherwise similar DNA binding specificities.	COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	Columbia University; Baylor College of Medicine	CHAN, SK (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.		Capovilla, Maria/O-8483-2016	Capovilla, Maria/0000-0002-1308-7964	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054510] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW DJ, 1992, NEW BIOL, V4, P5; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BILLETER M, 1990, J MOL BIOL, V214, P183, DOI 10.1016/0022-2836(90)90155-F; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESSAIN S, 1992, EMBO J, V11, P991, DOI 10.1002/j.1460-2075.1992.tb05138.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JOHNSON A, 1993, TRANSCRIPTIONAL REGU; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; RAUSKOLB C, 1994, IN PRESS EMBO; REUTER R, 1990, DEVELOPMENT, V110, P1031; SMITH MC, 1988, J BIOL CHEM, V263, P7211; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XU T, 1993, DEVELOPMENT, V117, P1223; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZENG WL, 1993, DEVELOPMENT, V118, P339	49	341	342	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					603	615		10.1016/0092-8674(94)90525-8	http://dx.doi.org/10.1016/0092-8674(94)90525-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915199				2022-12-28	WOS:A1994PD69300009
J	BENNET, NE				BENNET, NE			HYPERTENSION IN THE ELDERLY	LANCET			English	Article							QUALITY-OF-LIFE; BLOOD-PRESSURE; ANTIHYPERTENSIVE AGENTS; TRIAL; MORBIDITY; MORTALITY				BENNET, NE (corresponding author), UNIV MASSACHUSETTS, MED CTR, DEPT MED, HYPERTENS & CLIN TRIALS UNIT, 55 LAKE AVE N, WORCESTER, MA 01655 USA.							AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1970, JAMA, V213, P1143; APPLEGATE WB, 1991, ARCH INTERN MED, V151, P1817, DOI 10.1001/archinte.151.9.1817; APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; APPLEGATE WB, 1992, ARCH INTERN MED, V152, P1162, DOI 10.1001/archinte.152.6.1162; APPLEGATE WB, 1993, AM J HYPERTENS, V6, pS277, DOI 10.1093/ajh/6.7.277S; BETO JA, 1992, AM J HYPERTENS, V5, P125, DOI 10.1093/ajh/5.3.125; BLACK HR, 1994, HYPERTENSION, V23, P275; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; MANN SJ, 1992, ARCH INTERN MED, V152, P1977, DOI 10.1001/archinte.152.10.1977; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; WEINBERGER MH, 1991, HYPERTENSION, V18, P67, DOI 10.1161/01.HYP.18.1.67; 1993, ARHC INTERN MED, V153, P154; 1981, MED J AUSTRALIA, V2, P398; 1993, PHS931513 NAT CTR HL, P33; 1986, VITAL HLTH STATISTIC, V11	21	29	29	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					447	449		10.1016/S0140-6736(94)91773-6	http://dx.doi.org/10.1016/S0140-6736(94)91773-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914568				2022-12-28	WOS:A1994PB76100013
J	HOLT, PG				HOLT, PG			A POTENTIAL VACCINE STRATEGY FOR ASTHMA AND ALLIED ATOPIC DISEASES DURING EARLY-CHILDHOOD	LANCET			English	Editorial Material							NATURAL IMMUNE-RESPONSE; T-CELL CLONES; IGE RESPONSES; PROTEIN ANTIGENS; INDUCED TOLERANCE; IFN-GAMMA; SUPPRESSION; SENSITIZATION; INHALATION; ALLERGEN				HOLT, PG (corresponding author), INST CHILD HLTH RES, DIV CELL BIOL, POB 855, PERTH, WA 6872, AUSTRALIA.		Holt, Patrick G/H-1548-2011	Holt, Patrick G/0000-0003-1193-0935				CHAPMAN MD, 1980, J IMMUNOL, V125, P587; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; HANSON DG, 1981, J IMMUNOL, V127, P1518; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; HOLT PG, 1987, IMMUNOLOGY, V60, P97; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P255, DOI 10.1111/j.1365-2222.1989.tb02380.x; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; HOYNE GF, 1993, IMMUNOLOGY, V78, P534; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; NELSON D, 1991, PEDIATR ALLERGY IMMU, V4, P170; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PENE J, 1988, J IMMUNOL, V141, P1218; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SEDGWICK JD, 1984, EUR J IMMUNOL, V14, P893, DOI 10.1002/eji.1830141006; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; VANASPEREN PP, 1989, ACTA PAEDIATR SCAND, V78, P239; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Wells HG, 1911, J INFECT DIS, V8, P66, DOI 10.1093/infdis/8.1.66; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; ZHANG ZY, 1990, J IMMUNOL, V144, P4163	27	154	160	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					456	458		10.1016/S0140-6736(94)91776-0	http://dx.doi.org/10.1016/S0140-6736(94)91776-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914570				2022-12-28	WOS:A1994PB76100016
J	MILLER, JD				MILLER, JD			SWELLING AND BLOOD-FLOW IN THE INJURED CHILDS BRAIN	LANCET			English	Editorial Material							HEAD-INJURY; METABOLISM				MILLER, JD (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH, MIDLOTHIAN, SCOTLAND.							ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SCHRODER ML, 1993, J NEUROTRAUMA S, V10, pS57; SHARPLES PM, 1991, ARCH DIS CHILD, V66, P1326, DOI 10.1136/adc.66.11.1326; SHARPLES PM, IN PRESS J NEUROL NE; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	13	9	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					421	422						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914562				2022-12-28	WOS:A1994PB76100005
J	VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; LONNQVIST, J; EHNHOLM, C				VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; LONNQVIST, J; EHNHOLM, C			SERUM-CHOLESTEROL CONCENTRATION AND MORTALITY FROM ACCIDENTS, SUICIDE, AND OTHER VIOLENT CAUSES	BRITISH MEDICAL JOURNAL			English	Article							DEATH; RISK	Objective-To study the association of mortality from accidents, suicides, and other violent deaths with serum cholesterol concentration. Design-Baseline measurements in two randomly chosen independent cohorts were carried out in 1972 and 1977. Mortality was monitored over 10-15 years through the national death registry. Setting-Eastern Finland. Subjects-The two cohorts comprised men (n=10898) and women (n=11534) born between 1913 and 1947. There were 193 deaths due to accidents, suicides, and violence among men and 43 among women. Main outcome measure-Mortality from accidents, suicides, and other violent deaths was used as the end point. Deaths from these causes were pooled together in the analyses. Results-Serum cholesterol concentration was not associated with mortality from accidents, suicides, and other violent deaths in the univariate analyses or in the proportional hazards regression analyses including smoking, systolic blood pressure, alcohol drinking, and education. In both genders smoking was more prevalent among those who died from accidents, suicides, and other violent causes than from other causes. Frequent use of alcohol increased mortality from these causes. Conclusion-The risk of accidents, suicides, and other violent deaths was not related to serum cholesterol concentration, whereas such deaths were more prevalent in smokers and alcohol drinkers.			VARTIAINEN, E (corresponding author), NATL PUBL HLTH INST,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.							[Anonymous], COMMUNITY CONTROL CA; COX DR, 1972, J R STAT SOC B, V34, P187; KROMHOUT D, 1992, LANCET, V340, P317, DOI 10.1016/0140-6736(92)92415-C; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; SCHUIT AJ, 1993, LANCET, V341, P827, DOI 10.1016/0140-6736(93)90600-L; SMITH GD, 1992, LANCET, V340, P709; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SMITH GD, 1990, BRIT MED J, V301, P552; 1990, SAS USERS GUIDE STAT	12	53	53	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					445	447						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920128	Green Published			2022-12-28	WOS:A1994PC40400018
J	MCCORMICK, J				MCCORMICK, J			HEALTH PROMOTION - THE ETHICAL DIMENSION	LANCET			English	Editorial Material							CORONARY HEART-DISEASE; PRIMARY PREVENTION; MORTALITY; SMOKING; TRIALS; MEN				MCCORMICK, J (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT COMMUNITY HLTH & GEN PRACTICE,199 PEARSE ST,DUBLIN 2,IRELAND.							COCHRANE AL, 1971, BRIT MED BULL, V27, P3, DOI 10.1093/oxfordjournals.bmb.a070810; HOLLAND WW, 1993, BRIT MED J, V306, P1222, DOI 10.1136/bmj.306.6887.1222; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; MANT D, 1994, BRIT J GEN PRACT, V44, P51; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MCCORMICK J, 1988, LANCET, V2, P839; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; SELTZER CC, 1989, J CLIN EPIDEMIOL, V42, P743, DOI 10.1016/0895-4356(89)90070-X; SKRABANEK P, 1990, J MED ETHICS, V16, P187, DOI 10.1136/jme.16.4.187; SKRABANEK P, IN PRESS DEATH HUMAN; STRANDBERG TE, 1991, JAMA-J AM MED ASSOC, V266, P1225, DOI 10.1001/jama.266.9.1225; TURNER RG, 1993, BRIT MED J, V307, P939, DOI 10.1136/bmj.307.6909.939; 1994, BRIT MED J, V308, P313; 1994, BRIT MED J, V308, P308; 1992, BRIT MED J, V305, P1369	17	35	35	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					390	391						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	PA303	7914313				2022-12-28	WOS:A1994PA30300016
J	QUIRING, R; WALLDORF, U; KLOTER, U; GEHRING, WJ				QUIRING, R; WALLDORF, U; KLOTER, U; GEHRING, WJ			HOMOLOGY OF THE EYELESS GENE OF DROSOPHILA TO THE SMALL EYE GENE IN MICE AND ANIRIDIA IN HUMANS	SCIENCE			English	Article							HOMEOBOX-CONTAINING GENE; PAIRED BOX GENE; HUMAN PAX6 GENE; STRUCTURAL-ANALYSIS; EXPRESSION PATTERN; MOLECULAR-GENETICS; NEURAL-TUBE; SEQUENCE; DNA; MELANOGASTER	A Drosophila gene that contains both a paired box and a homeobox and has extensive sequence homology to the mouse Pax-6 (Small eye) gene was isolated and mapped to chromosome IV in a region close to the eyeless locus. Two spontaneous mutations, ey(2) and ey(R), contain transposable element insertions into the cloned gene and affect gene expression, particularly in the eye primordia. This indicates that the cloned gene encodes ey. The finding that ey of Drosophila, Small eye of the mouse, and human Aniridia are encoded by homologous genes suggests that eye morphogenesis is under similar genetic control in both vertebrates and insects, in spite of the large differences in eye morphology and mode of development.	UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND	University of Basel								ASHBURNER M, 1989, DROSOPHILA LABORATOR; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURGLIN TR, GUIDEBOOK HOMEOBOX G, P25; CALLAERTS P, UNPUB; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOZIER C, 1993, CELL GROWTH DIFFER, V4, P281; DRIVER A, 1989, MOL GEN GENET, V220, P49, DOI 10.1007/BF00260854; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROMMER G, 1994, CHROMOSOMA, V103, P82, DOI 10.1007/BF00352316; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOGAN BLM, 1988, DEVELOPMENT, V103, P115; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; JURGENS G, 1993, DEV DROSOPHILA MELAN, V1, P702; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; LEEMANS R, UNPUB; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOOSLI F, UNPUB; MARTIN P, 1992, ONCOGENE, V7, P1721; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; OHARE K, 1983, P NATL ACAD SCI-BIOL, V80, P6917, DOI 10.1073/pnas.80.22.6917; OHARE K, 1991, MOL GEN GENET, V225, P17, DOI 10.1007/BF00282637; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; PLATE L, 1924, ALLGEMEINE ZOOLOGIE; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALLDORF U, UNPUB; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435	54	864	889	1	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					785	789		10.1126/science.7914031	http://dx.doi.org/10.1126/science.7914031			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7914031				2022-12-28	WOS:A1994PA37200034
J	DERKX, FHM; SCHALEKAMP, MADH				DERKX, FHM; SCHALEKAMP, MADH			RENAL-ARTERY STENOSIS AND HYPERTENSION	LANCET			English	Article							RENOVASCULAR HYPERTENSION; ANGIOPLASTY; DIAGNOSIS; CAPTOPRIL; TESTS				DERKX, FHM (corresponding author), ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT INTERNAL MED 1,ROOM L242,DR MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.							[Anonymous], 1987, Arch Intern Med, V147, P820; BLAUFOX MD, 1990, HYPERTENSION PATHOPH, P1509; DAVIDSON RA, 1992, JAMA-J AM MED ASSOC, V268, P3353, DOI 10.1001/jama.268.23.3353; DEAN RH, 1981, ARCH SURG-CHICAGO, V116, P1408; DERKX FHM, 1993, NETH J MED, V43, pS12; DERKX FHM, 1993, J HYPERTENS, V11, pS200; DERKX FHM, 1987, RENOVASCULAR HYPERTE, P295; DORROS G, 1993, CATHET CARDIOVASC DI, V3, P191; ELLIOTT WJ, 1993, ARCH INTERN MED, V153, P755, DOI 10.1001/archinte.153.6.755; FOMMEI E, 1993, EUR J NUCL MED, V20, P617; HUDSPETH DA, 1993, J VASC SURG, V18, P389; HUNT JC, 1974, ARCH INTERN MED, V133, P988, DOI 10.1001/archinte.133.6.988; Marks L S, 1975, Urol Clin North Am, V2, P311; MAY AG, 1963, SURGERY, V53, P5213; NEIMAN HL, 1985, ANGIOGRAPHY VASCULAR, P1; Pickering T, 1990, HYPERTENSION PATHOPH, P1539; PICKERING TG, 1985, J HYPERTENS, V3, pS291; PLOUIN PF, 1993, HYPERTENSION, V21, P89, DOI 10.1161/01.HYP.21.1.89; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; SIMON G, 1994, AM J HYPERTENS, V7, P1; VANJAARSVELD BC, 1994, NETH J MED, V44, pA65; WEIBULL H, 1993, J VASC SURG, V18, P841, DOI 10.1016/0741-5214(93)90340-R; WENTING GJ, 1984, BMJ-BRIT MED J, V288, P886, DOI 10.1136/bmj.288.6421.886	23	183	192	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					237	239		10.1016/S0140-6736(94)93002-3	http://dx.doi.org/10.1016/S0140-6736(94)93002-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913161	Green Submitted			2022-12-28	WOS:A1994NY06000014
J	FEDSON, DS				FEDSON, DS			ADULT IMMUNIZATION - SUMMARY OF THE NATIONAL VACCINE ADVISORY-COMMITTEE REPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; CHANGING EPIDEMIOLOGY; MISSED OPPORTUNITIES; RUBELLA; TRANSMISSION; RESURGENCE; INFLUENZA; POLICIES; MEASLES; IMPACT	In January 1994 the National Vaccine Advisory Committee adopted a report that reviewed the status of adult immunization in the United States. Vaccine-preventable infections of adults represent a continuing cause of morbidity and mortality. Their major impact is among older persons. Effective and safe vaccines against these diseases are available, but they are poorly used. Several reasons account for low immunization levels among adults, including inadequate awareness by health care providers and the public of the importance and benefits of vaccination. Health care providers often fail to take advantage of opportunities to immunize adults during office, clinic, and hospital contacts and fail to organize programs in medical settings that ensure adults are offered the vaccines they need. Inadequate reimbursement for adult immunization by public and private health insurers and a lack of federal programs to support vaccine delivery are also major problems. The National Vaccine Advisory Committee's report includes five goals and 18 recommendations for improving adult immunization. To reach the Public Health Service adult immunization goals for the year 2000, the Committee recommends (1) improvements in public and provider education; (2) major changes in clinical practice; (3) increased financial support by public and private health insurers; (4) improved surveillance of vaccine-preventable diseases and vaccine production and delivery; and (5) support for research on vaccine-preventable diseases, new and improved vaccines, immunization practices, and international programs for adult immunization.			FEDSON, DS (corresponding author), NATL VACCINE PROGRAM OFF,ROCKWALL 2 BLDG,SUITE 1075,5600 FISHERS LN,ROCKVILLE,MD 20852, USA.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDERSON K, 1993, OPTIONS CONTROL INFL, V2, P109; [Anonymous], 1989, GUIDE CLIN PREVENTIV; ATKINSON WL, 1991, AM J MED, V91, pS320, DOI 10.1016/0002-9343(91)90389-F; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; BARTON MB, 1990, AM J PUBLIC HEALTH, V80, P534, DOI 10.2105/AJPH.80.5.534; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; Fedson D S, 1992, Clin Geriatr Med, V8, P183; GARDNER P, 1993, NEW ENGL J MED, V328, P1252, DOI 10.1056/NEJM199304293281708; GOODMAN AK, 1987, AM J PUBLIC HEALTH, V77, P725, DOI 10.2105/AJPH.77.6.725; HINMAN AR, 1986, AM J DIS CHILD, V140, P528, DOI 10.1001/archpedi.1986.02140200038022; HOWSON CP, 1992, JAMA-J AM MED ASSOC, V267, P392, DOI 10.1001/jama.267.3.392; LEE SH, 1992, JAMA-J AM MED ASSOC, V267, P2616, DOI 10.1001/jama.267.19.2616; MARINER WK, 1992, HEALTH AFFAIR, V11, P255, DOI 10.1377/hlthaff.11.1.255; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MITCHELL VS, 1993, CHILDRENS VACCINE IN; Neustadt RE, 1978, SWINE FLU AFFAIR DEC, P48; PETER G, 1992, NEW ENGL J MED, V327, P1794, DOI 10.1056/NEJM199212173272507; SOSIN DM, 1989, PEDIATRICS, V84, P779; WHARTON M, 1990, ARCH INTERN MED, V150, P47, DOI 10.1001/archinte.150.1.47; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1990, MMWR MORBID MORTAL W, V39, P725; 1994, MMWR MORBID MORTAL W, V43, P144; 1993, JORDAN REPORT ACCELE; 1993, MMWR MORBID MORTAL W, V42, P601; 1991, MMWR MORBID MORTAL W, V40, P1; 1993, MMWR MORBID MORTAL W, V42, P847; 1994, GUIDE ADULT IMMUNIZA; 1994, ADULT IMMUNIZATION; 1994, MMWR MORBID MORTAL W, V43, P1; 1991, DHHS PHS9150212 PUBL; 1993, MMWR MORBID MORTAL W, V42, P501; 1993, MMWR MORBID MORTAL W, V42, P840; 1993, MMWR MORBID MORTAL W, V42, P768; 1994, MMWR MORBID MORTAL W, V43, P57	37	119	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1133	1137		10.1001/jama.272.14.1133	http://dx.doi.org/10.1001/jama.272.14.1133			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK124	7933327				2022-12-28	WOS:A1994PK12400034
J	KADHIM, MA; LORIMORE, SA; HEPBURN, MD; GOODHEAD, DT; BUCKLE, VJ; WRIGHT, EG				KADHIM, MA; LORIMORE, SA; HEPBURN, MD; GOODHEAD, DT; BUCKLE, VJ; WRIGHT, EG			ALPHA-PARTICLE-INDUCED CHROMOSOMAL INSTABILITY IN HUMAN BONE-MARROW CELLS	LANCET			English	Note							LEUKEMIA; RADON; EXPOSURE	alpha-particles, which are ionising radiation of high linear-energy-transfer emitted, for example, from radon or plutonium, pass through tissue as highly structured tracks. Single target cells in the path of the tracks might be damaged by even Tow-dose alpha-irradiation. We found non-clonal cytogenetic aberrations, characterised by a high frequency of chromatid aberrations with chromosome aberrations, in clonal descendants of haemopoietic stem cells after exposure to alpha-particles of bone marrow cells from two of four haematologically normal individuals (up to 25% abnormal metaphases). The data are consistent with a transmissible genetic instability induced in a stem cell resulting in a diversity of aberrations in its clonal progeny many cell divisions later.	MRC,RADIOBIOL UNIT,DIDCOT OX11 0RD,OXON,ENGLAND; NINEWELLS HOSP & MED SCH,DEPT HAEMATOL,DUNDEE,SCOTLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	MRC Harwell; University of Dundee; University of Oxford								ALEXANDER FE, 1990, LANCET, V335, P1336; ALEXANDER FE, 1990, LANCET, V336, P1461, DOI 10.1016/0140-6736(90)93176-P; DIONIAN J, 1986, NRPBR196 NAT RAD PRO; GOODHEAD DT, 1988, HEALTH PHYS, V55, P231, DOI 10.1097/00004032-198808000-00015; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; HOLYOAKE TL, 1993, LEUKEMIA, V7, P207; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; LORIMORE SA, 1993, INT J RADIAT BIOL, V63, P655, DOI 10.1080/09553009314450851; LUCIE NP, 1989, LANCET, V2, P99; RICHARDSON RB, 1991, BRIT J RADIOL, V64, P608, DOI 10.1259/0007-1285-64-763-608	10	184	191	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					987	988		10.1016/S0140-6736(94)91643-8	http://dx.doi.org/10.1016/S0140-6736(94)91643-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934432				2022-12-28	WOS:A1994PK97800011
J	SCHEINBERG, IH; STERNLIEB, I				SCHEINBERG, IH; STERNLIEB, I			IS NON-INDIAN CHILDHOOD CIRRHOSIS CAUSED BY EXCESS DIETARY COPPER	LANCET			English	Article							STORAGE DISEASE; LIVER	Indian childhood cirrhosis is generally believed to be caused by toxic excesses of hepatic copper derived from milk boiled in copper vessels. Sporadic cases of a disorder indistinguishable from Indian childhood cirrhosis have appeared in other countries where the toxic hepatic copper has been thought to be derived from drinking water. In published reports of seven 2-year-old or younger infants with non-Indian childhood cirrhosis (five of whom died), the copper content of their drinking water-which the authors considered the essential, if not the sole,aetiological factor-ranged from 0.05 to 6.8 mg Cu/L. We identified three Massachusetts towns in which between 1969 and 1991 there were 64 124 child-years of exposure of children under the age of 6 years to drinking water that contained between 8.5 and 8.8 mg Cu/L. Data from the Massachusetts Department of Public Health showed that there were 135 deaths among these children, but no deaths from cirrhosis or any form of liver disease. These data, and evidence of a genetic aetiology in three of the seven infants reported previously, suggest that non-Indian childhood cirrhosis is an inherited disorder.	ST LUKES ROOSEVELT HOSP,NEW YORK,NY 10019	Mount Sinai St. Luke's; Mount Sinai West	SCHEINBERG, IH (corresponding author), COLUMBIA UNIV,NATL CTR STUDY WILSONS DIS,432 W 58TH ST,SUITE 614,NEW YORK,NY 10019, USA.							ADAMSON M, 1992, GASTROENTEROLOGY, V102, P1771, DOI 10.1016/0016-5085(92)91742-M; ALJAJEH IA, 1994, VIRCHOWS ARCH, V424, P225; GOLDFISCHER S, 1980, AM J PATHOL, V99, P715; LEFKOWITCH JH, 1982, NEW ENGL J MED, V307, P271, DOI 10.1056/NEJM198207293070502; Lim C T, 1979, J Singapore Paediatr Soc, V21, P99; MULLERHOCKER J, 1987, VIRCHOWS ARCH A, V411, P379, DOI 10.1007/BF00713384; MULLERHOCKER J, 1988, PATHOL RES PRACT, V183, P39, DOI 10.1016/S0344-0338(88)80157-2; TANNER MS, 1983, LANCET, V2, P992; TANNER MS, 1986, RECENT ADV PAEDIATRI, V8, P103; WALKERSMITH J, 1973, ARCH DIS CHILD, V48, P476, DOI 10.1136/adc.48.6.476; WEISS M, 1989, ACTA PAEDIATR SCAND, V79, P152; 1993, LEAD COPPER REPORT E; 1991, US FED REG, V56, P26460; [No title captured]	14	55	55	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					1002	1004		10.1016/S0140-6736(94)91649-7	http://dx.doi.org/10.1016/S0140-6736(94)91649-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934386				2022-12-28	WOS:A1994PK97800017
J	VARENDI, H; PORTER, RH; WINBERG, J				VARENDI, H; PORTER, RH; WINBERG, J			DOES THE NEWBORN BABY FIND THE NIPPLE BY SMELL	LANCET			English	Note							LACTATING FEMALES; FED INFANTS; MOTHER	We studied the involvement of naturally occurring odours in guiding the baby to the nipple. One breast of each participating mother was washed immediately after delivery. The newborn infant was placed prone between the breasts. Of 30 infants, 22 spontaneously selected the unwashed breast. The washing procedure had no effect on breast temperature. We concluded that the infants responded to olfactory differences between the washed and unwashed breasts.	INRA,COMPORTEMENT ANIM LAB,CNRS,URA 1291,F-37380 NOUZILLY,FRANCE; KAROLINSKA INST,KAROLINSKA HOSP,INST WOMEN & CHILD HLTH,S-10401 STOCKHOLM,SWEDEN	Centre National de la Recherche Scientifique (CNRS); INRAE; Karolinska Institutet; Karolinska University Hospital	VARENDI, H (corresponding author), TARTU STATE UNIV,CHILDRENS HOSP,6 LUNINI STR,2400 TARTU,ESTONIA.							GOLDMAN AS, 1987, PEDIATR RES, V22, P493, DOI 10.1203/00006450-198711000-00001; HOFER MA, 1976, PHYSIOL BEHAV, V17, P131, DOI 10.1016/0031-9384(76)90279-1; Macfarlane A, 1975, Ciba Found Symp, P103; MAKIN JW, 1989, CHILD DEV, V60, P803, DOI 10.2307/1131020; PORTER RH, 1991, PHYSIOL BEHAV, V50, P907, DOI 10.1016/0031-9384(91)90413-I; PORTER RH, 1992, INFANT BEHAV DEV, V15, P85, DOI 10.1016/0163-6383(92)90008-T; RIGHARD L, 1990, LANCET, V336, P1105, DOI 10.1016/0140-6736(90)92579-7; SCHAAL B, 1980, REPROD NUTR DEV, V20, P843, DOI 10.1051/rnd:19800510; TEICHER MH, 1978, PHYSIOL BEHAV, V21, P553, DOI 10.1016/0031-9384(78)90130-0; WIDSTROM AM, 1987, ACTA PAEDIATR SCAND, V76, P566, DOI 10.1111/j.1651-2227.1987.tb10522.x	10	132	134	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					989	990		10.1016/S0140-6736(94)91645-4	http://dx.doi.org/10.1016/S0140-6736(94)91645-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK978	7934434				2022-12-28	WOS:A1994PK97800013
J	EDMONDSON, RA; COHEN, AT; DAS, SK; WAGNER, MB; KAKKAR, VV				EDMONDSON, RA; COHEN, AT; DAS, SK; WAGNER, MB; KAKKAR, VV			LOW-MOLECULAR-WEIGHT HEPARIN VERSUS ASPIRIN AND DIPYRIDAMOLE AFTER FEMOROPOPLITEAL BYPASS-GRAFTING	LANCET			English	Article							MUSCLE CELL-PROLIFERATION; PLUS DIPYRIDAMOLE; PATENCY; RESTENOSIS	Low-molecular weight heparin has theoretical advantages over aspirin and dipyridamole in maintaining vascular-graft patency by Virtue of its better antithrombotic effect and antiproliferative activity on vascular smooth-muscle cells. We tested the hypothesis that low-molecular weight heparin would be more effective than aspirin and dipyridamole in maintaining graft patency in patients undergoing femoropopliteal bypass grafting. Patients were randomised to receive either a daily injection of 2500 IU low-molecular weight heparin, or 300 mg aspirin with 100 mg dipyridamole 8 hourly for 3 months. 94 patients were randomised to low-molecular weight heparin and 106 to aspirin and dipyridamole. Patients were stratified according to indication for surgery and were followed up for 1 year. Kaplan-Meier estimate of graft patency showed 87% graft survival on low-molecular-weight heparin and 72% on aspirin and dipyridamole at 6 months. At 12 months, the respective figures were 78% and 64%. Stratified survival analysis showed that this benefit was confined to those having salvage surgery (log rank test p=0.0006); for those having surgery for claudication there was no significant benefit. No major bleeding events occurred in either group. We conclude that low-molecular weight heparin is better than aspirin and dipyridamole in maintaining femoropopliteal-graft patency in patients with critical limb ischaemia undergoing salvage surgery. This treatment should have considerable cost benefits.	THROMBOSIS RES INST,LONDON SW3 6LR,ENGLAND	Thrombosis Research Institute			Wagner, Mario/F-9430-2015	Wagner, Mario/0000-0002-3661-4851				[Anonymous], 1994, BMJ, V308, P159; AU YPT, 1992, CIRC RES, V70, P1062, DOI 10.1161/01.RES.70.5.1062; BERGQVIST D, 1991, MAINTENANCE ARTERIAL, P441; CHESEBRO JH, 1982, NEW ENGL J MED, V307, P73, DOI 10.1056/NEJM198207083070201; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DONALDSON DR, 1985, VASCULAR SURG, V19, P224, DOI 10.1177/153857448501900405; FERRELL M, 1992, CIRCULATION, V85, P1630, DOI 10.1161/01.CIR.85.4.1630; FORBES JF, 1991, EPIDEMIOLOGY PERIPHE, P235; GOLDMAN M, 1984, VASCULAR SURG, V18, P217, DOI 10.1177/153857448401800404; GREEN RM, 1982, SURGERY, V92, P1016; HARKER LA, 1992, ANN INTERN MED, V116, P731, DOI 10.7326/0003-4819-116-9-731; KAKKAR VV, 1985, BRIT J SURG, V72, P786, DOI 10.1002/bjs.1800721006; MACKEY WC, 1986, SURGERY, V99, P26; ROSENBERG RD, 1993, THROMB HAEMOSTASIS, V70, P10; RUGGIERO HA, 1982, CLIN CARDIOL, V5, P215, DOI 10.1002/clc.4960050303; UNDERWOOD MJ, 1994, BMJ-BRIT MED J, V308, P71, DOI 10.1136/bmj.308.6921.71; WHITTEMORE AD, 1981, ANN SURG, V193, P35, DOI 10.1097/00000658-198101000-00006; WILSON NV, 1991, BRIT J SURG, V78, P1381, DOI 10.1002/bjs.1800781136; 1992, LANCET, V339, P900; 1991, CIRCULATION S4, V84, P1	20	86	86	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					914	918		10.1016/S0140-6736(94)92269-1	http://dx.doi.org/10.1016/S0140-6736(94)92269-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934346				2022-12-28	WOS:A1994PJ28700010
J	FITZSIMONS, RB				FITZSIMONS, RB			FACIOSCAPULOHUMERAL DYSTROPHY - THE ROLE OF INFLAMMATION	LANCET			English	Editorial Material							MUSCULAR-DYSTROPHY; REGION; CELLS; FSHD; ARM				FITZSIMONS, RB (corresponding author), MOORFIELDS EYE HOSP,LONDON,ENGLAND.							ASHTON N, 1969, CORNEOPLASTIC SURGER, P586; BROUWER OF, 1992, BRAIN, V115, P1587, DOI 10.1093/brain/115.5.1587; COPEMAN PWM, 1971, BRIT J DERMATOL, V85, P205, DOI 10.1111/j.1365-2133.1971.tb07218.x; FITZSIMONS RB, 1987, BRAIN, V110, P631, DOI 10.1093/brain/110.3.631; GRIGGS RC, 1993, NEUROLOGY, V43, P2369, DOI 10.1212/WNL.43.11.2369; KORF BR, 1985, ANN NEUROL, V17, P513, DOI 10.1002/ana.410170516; MARKS RM, 1986, J INVEST DERMATOL, V87, P519, DOI 10.1111/1523-1747.ep12455604; MUNSAT TL, 1972, NEUROLOGY, V22, P335, DOI 10.1212/WNL.22.4.335; POWERS JM, 1992, J NEUROPATH EXP NEUR, V51, P630, DOI 10.1097/00005072-199211000-00007; PRINEAS JW, 1993, BRAIN, V116, P681, DOI 10.1093/brain/116.3.681; WIJMENGA C, 1993, HUM MOL GENET, V2, P1667, DOI 10.1093/hmg/2.10.1667; WINOKUR ST, 1993, AM J HUM GENET, V53, P874	12	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					902	903		10.1016/S0140-6736(94)92263-2	http://dx.doi.org/10.1016/S0140-6736(94)92263-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934342				2022-12-28	WOS:A1994PJ28700004
J	WITZTUM, JL				WITZTUM, JL			THE OXIDATION HYPOTHESIS OF ATHEROSCLEROSIS	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; LDL; ATHEROGENESIS; CHOLESTEROL; INDUCTION; CELLS; MICE				WITZTUM, JL (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HODIS HN, 1994, J LIPID RES, V35, P669; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; NAVAB M, 1994, CORONARY ARTERY DIS, V5, P198, DOI 10.1097/00019501-199403000-00003; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; RANKIN SM, 1991, J LIPID RES, V32, P449; REAVEN P, IN PRESS ENDOCRINOLO; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAMBRANO GR, 1994, P NATL ACAD SCI USA, V91, P3265, DOI 10.1073/pnas.91.8.3265; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBERG D, 1993, NEW ENGL J MED, V328, P1587; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; WITZTUM JL, 1993, BRIT HEART J, V69, pS12; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; 1994, NEW ENGL J MED, V330, P1029	21	1144	1227	0	22	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					793	795		10.1016/S0140-6736(94)92346-9	http://dx.doi.org/10.1016/S0140-6736(94)92346-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916078				2022-12-28	WOS:A1994PG17800015
J	POPE, M; BETJES, MGH; ROMANI, N; HIRMAND, H; CAMERON, PU; HOFFMAN, L; GEZELTER, S; SCHULER, G; STEINMAN, RM				POPE, M; BETJES, MGH; ROMANI, N; HIRMAND, H; CAMERON, PU; HOFFMAN, L; GEZELTER, S; SCHULER, G; STEINMAN, RM			CONJUGATES OF DENDRITIC CELLS AND MEMORY T-LYMPHOCYTES FROM SKIN FACILITATE PRODUCTIVE INFECTION WITH HIV-1	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; EPIDERMAL LANGERHANS CELLS; FEMALE RHESUS MACAQUES; IMMUNE-RESPONSES; ADHESION MOLECULE; LYMPHOID-TISSUE; GENITAL-TRACT; HUMAN BLOOD; AIDS; LYMPHADENOPATHY	Experimentally, a productive infection with HIV-1 requires that virus be administered to T cells that are activated by mitogens. We describe a productive milieu for HIV-1 within the confines of normal skin that does not require standard stimuli. The milieu consists of dendritic cells and T cells that emigrate from skin and produce distinctive stable, nonproliferating conjugates. These conjugates, upon exposure to each of seven different HIV-1 isolates, begin to release high levels of virus progeny within 4 days. Numerous infected syncytia, comprised of both dendritic and T cells, rapidly develop. We propose that conjugates of dendritic cells and T cells, as found in the external linings of organs involved in sexual transmission of HIV-1, represent an important site for the productive phase of HIV-1 infection. Because the affected T cells carry the memory phenotype, this site additionally provides a mechanism for the chronic depletion of CD4(+) memory cells in HIV-1 disease.	VRIJE UNIV AMSTERDAM, DEPT CELL BIOL, 1081 BT AMSTERDAM, NETHERLANDS; CORNELL UNIV, COLL MED, DIV PLAST SURG, NEW YORK, NY 10021 USA; UNIV INNSBRUCK, DEPT DERMATOL, A-6020 INNSBRUCK, AUSTRIA	Vrije Universiteit Amsterdam; Cornell University; University of Innsbruck	POPE, M (corresponding author), ROCKEFELLER UNIV, CELLULAR PHYSIOL & IMMUNOL LAB, NEW YORK, NY 10021 USA.		Steinman, Ralph/F-7729-2012; Cameron, Paul/H-3474-2011	Romani, Nikolaus/0000-0003-1614-9128; Cameron, Paul Urquhart/0000-0002-1906-6945; Betjes, Michiel/0000-0001-9435-6208	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007012, R37AI007012, P01AI024775] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07012, AI24775] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; ARMSTRONG JA, 1984, LANCET, V2, P370; ASJO B, 1993, J VIROL, V67, P4395; BERGER R, 1992, J INVEST DERMATOL, V99, P271, DOI 10.1111/1523-1747.ep12616619; BHARDWAJ N, 1994, INFECT IMMUN, V62, P135, DOI 10.1128/IAI.62.1.135-144.1994; BIBERFELD P, 1986, AM J PATHOL, V125, P436; CAMERON PU, 1994, AIDS RES HUM RETROV, V10, P61, DOI 10.1089/aid.1994.10.61; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CHEN LL, 1978, J CELL BIOL, V79, P184, DOI 10.1083/jcb.79.1.184; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CIMARELLI A, 1994, J ACQ IMMUN DEF SYND, V7, P230; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DANIELS TE, 1984, J INVEST DERMATOL, V82, P21, DOI 10.1111/1523-1747.ep12259038; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ENK AH, 1993, J IMMUNOL, V150, P3698; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; FOSTER CA, 1990, J EXP MED, V171, P997, DOI 10.1084/jem.171.4.997; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; HANNA MG, 1968, J IMMUNOL, V101, P949; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUMPHREY JH, 1984, EUR J IMMUNOL, V14, P859, DOI 10.1002/eji.1830140916; INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717; INABA K, 1986, J EXP MED, V163, P247, DOI 10.1084/jem.163.2.247; KALTER DC, 1991, J IMMUNOL, V146, P3396; KAPLAN G, 1987, J EXP MED, V165, P763, DOI 10.1084/jem.165.3.763; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; MACKAY CR, 1988, EUR J IMMUNOL, V18, P1681, DOI 10.1002/eji.1830181105; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MILLER CJ, 1992, LAB INVEST, V67, P628; MILLER CJ, 1992, AM J PATHOL, V141, P655; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; MILLER CJ, 1993, LAB INVEST, V68, P129; MURRAY HW, 1985, NEW ENGL J MED, V313, P1504, DOI 10.1056/NEJM198512123132403; NESTLE FO, 1994, CELL IMMUNOL, V156, P220, DOI 10.1006/cimm.1994.1166; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; NUOVO GJ, 1993, AM J PATHOL, V143, P40; ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANCHOLI P, 1992, IMMUNOLOGY, V76, P217; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; RACZ P, 1986, PROG ALLERGY, V37, P81; REKA S, 1993, CYTOKINE, V5, P305, DOI 10.1016/1043-4666(93)90061-9; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SPIEGEL H, 1992, AM J PATHOL, V140, P15; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; STOSSEL H, 1990, J EXP MED, V172, P1471, DOI 10.1084/jem.172.5.1471; SZAKAL AK, 1989, ANNU REV IMMUNOL, V7, P91, DOI 10.1146/annurev.immunol.7.1.91; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VANNOESEL CJM, 1990, J CLIN INVEST, V86, P293, DOI 10.1172/JCI114698; WOOD GS, 1983, J IMMUNOL, V131, P212; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	61	463	472	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 12	1994	78	3					389	398		10.1016/0092-8674(94)90418-9	http://dx.doi.org/10.1016/0092-8674(94)90418-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	7914836				2022-12-28	WOS:A1994PC40500006
J	KRUMLAUF, R				KRUMLAUF, R			HOX GENES IN VERTEBRATE DEVELOPMENT	CELL			English	Review							DROSOPHILA HOMEOTIC GENES; ZINC-FINGER GENE; EMBRYONAL CARCINOMA-CELLS; HUMAN PROTOONCOGENE PBX1; CENTRAL-NERVOUS-SYSTEM; MURINE HOX-4.2 GENE; RETINOIC ACID; HOMEOBOX GENE; TRANSGENIC MICE; TARGETED DISRUPTION				KRUMLAUF, R (corresponding author), NATL INST MED RES, MRC, DEV NEUROBIOL LAB, MILL HILL, LONDON NW7 1AA, ENGLAND.		Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927				AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; AWGULEWITSCH A, 1992, NATURE, V358, P341, DOI 10.1038/358341a0; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BEEMAN RW, 1989, DEV BIOL, V133, P196, DOI 10.1016/0012-1606(89)90311-4; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; CONDIE BG, 1993, DEVELOPMENT, V119, P579; CONLON RA, 1992, DEVELOPMENT, V116, P357; DECAMILLIS M, 1992, GENE DEV, V6, P223, DOI 10.1101/gad.6.2.223; DEKKER EJ, 1993, MECH DEVELOP, V40, P3, DOI 10.1016/0925-4773(93)90083-A; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; EID R, 1993, DEV DYNAM, V196, P205, DOI 10.1002/aja.1001960307; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; GAUNT SJ, 1991, BIOESSAYS, V13, P505, DOI 10.1002/bies.950131004; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; GERARD M, 1993, EMBO J, V12, P3539, DOI 10.1002/j.1460-2075.1993.tb06028.x; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1992, DEVELOPMENT, V116, P1059; GRAHAM A, 1991, DEVELOPMENT, V112, P255; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HOLLAND PWH, 1994, J MAR BIOL ASSOC UK, V74, P49, DOI 10.1017/S0025315400035657; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; Kaufman T C, 1990, Adv Genet, V27, P309; KAUFMAN TC, 1980, GENETICS, V27, P309; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KRESS C, 1990, DEVELOPMENT, V109, P775; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; KRUMLAUF R, 1993, IN PRESS CURR OPIN G, V3; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MCKAY IJ, 1994, IN PRESS DEVELOPMENT, V121; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; MUNKE M, 1986, CYTOGENET CELL GENET, V42, P236, DOI 10.1159/000132284; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Paro R, 1993, CURR OPIN CELL BIOL, V5, P999, DOI 10.1016/0955-0674(93)90084-4; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1993, MOL CELL BIOL, V13, P257; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; SALSER SJ, 1994, TRENDS GENET, V10, P159, DOI 10.1016/0168-9525(94)90092-2; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1988, NUCLEIC ACIDS RES, V16, P5379, DOI 10.1093/nar/16.12.5379; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; SOININEN R, 1992, MECH DEVELOP, V39, P111, DOI 10.1016/0925-4773(92)90030-N; STRUHL G, 1984, NATURE, V308, P454, DOI 10.1038/308454a0; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TREMML G, 1992, DEVELOPMENT, V116, P447; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VOGELS R, 1993, DEVELOPMENT, V118, P71; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; ZHANG M, 1994, IN PRESS DEVELOPMENT, V121; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	128	1723	1762	5	196	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					191	201		10.1016/0092-8674(94)90290-9	http://dx.doi.org/10.1016/0092-8674(94)90290-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	7913880				2022-12-28	WOS:A1994NZ24200004
J	STEVENS, MJ; BELL, DR; BLOME, SA; BEGBIE, SD				STEVENS, MJ; BELL, DR; BLOME, SA; BEGBIE, SD			PROLONGED HYPOGONADISM AFTER PULSED GONADOTROPIN-RELEASING-HORMONE AGONIST FOR PROSTATE-CANCER	LANCET			English	Letter											STEVENS, MJ (corresponding author), ROYAL N SHORE HOSP,DEPT CLIN ONCOL,ST LEONARDS,NSW 2065,AUSTRALIA.							COMITE F, 1981, NEW ENGL J MED, V305, P1546, DOI 10.1056/NEJM198112243052602; DEZIEGLER D, 1989, J CLIN ENDOCR METAB, V68, P1111, DOI 10.1210/jcem-68-6-1111; LINDE R, 1981, NEW ENGL J MED, V305, P663, DOI 10.1056/NEJM198109173051203; SHEARER RJ, 1992, BRIT J UROL, V69, P521, DOI 10.1111/j.1464-410X.1992.tb15601.x	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					274	275		10.1016/S0140-6736(94)93043-0	http://dx.doi.org/10.1016/S0140-6736(94)93043-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913195				2022-12-28	WOS:A1994NY06000064
J	MUIRHEAD, CR				MUIRHEAD, CR			RADON RISKS	LANCET			English	Editorial Material							INDOOR RADON; LUNG-CANCER				MUIRHEAD, CR (corresponding author), NATL RADIOL PROTECT BOARD,CHILTON,OXON,ENGLAND.			Muirhead, Colin/0000-0001-5394-1267				[Anonymous], 1988, IARC MONOGRAPHS EVAL, V43; [Anonymous], 1993, ANN ICRP, V65; BLOT WJ, 1990, J NATL CANCER I, V82, P1025, DOI 10.1093/jnci/82.12.1025; LUBIN JH, 1994, NIH943644 PUBL; PERSHAGEN G, 1994, NEW ENGL J MED, V330, P159, DOI 10.1056/NEJM199401203300302; STIDLEY CA, 1993, HEALTH PHYS, V65, P234, DOI 10.1097/00004032-199309000-00001; 1990, NRPB1 NAT RAD PROT B; 1988, HLTH RISKS RADON OTH; 1993, NRPB4 NAT RAD PROT B; 1991, COMP DOSIMETRY RADON	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					143	144		10.1016/S0140-6736(94)92751-0	http://dx.doi.org/10.1016/S0140-6736(94)92751-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912759				2022-12-28	WOS:A1994NW81000003
J	VERMEER, BJ; VANDERSPEKKEIJSER, LMT; FIBBE, WE				VERMEER, BJ; VANDERSPEKKEIJSER, LMT; FIBBE, WE			SKIN BIOPSIES IN BONE-MARROW TRANSPLANTATION	LANCET			English	Editorial Material							VERSUS-HOST DISEASE; ACUTE GRAFT; RECIPIENTS		LEIDEN UNIV,MED CTR,DEPT HAEMATOL,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	VERMEER, BJ (corresponding author), LEIDEN UNIV,MED CTR,DEPT DERMATOL,LEIDEN,NETHERLANDS.							DARMSTADT GL, 1992, J INVEST DERMATOL, V99, P397, DOI 10.1111/1523-1747.ep12616112; HEPBURN NC, 1993, Q J MED, V86, P715; HOOD AF, 1987, ARCH DERMATOL, V123, P745, DOI 10.1001/archderm.123.6.745; LAMPERT IA, 1982, CLIN EXP IMMUNOL, V50, P123; LEBOIT PE, 1989, J AM ACAD DERMATOL, V20, P236, DOI 10.1016/S0190-9622(89)70028-1; LERNER KG, 1974, TRANSPLANT P, V6, P367; LEVER R, 1986, BRIT J DERMATOL, V114, P161, DOI 10.1111/j.1365-2133.1986.tb02794.x; SALE GE, 1977, AM J PATHOL, V89, P621; VOLCPLATZER B, 1988, J INVEST DERMATOL, V91, P162, DOI 10.1111/1523-1747.ep12464407	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					75	76		10.1016/S0140-6736(94)91277-7	http://dx.doi.org/10.1016/S0140-6736(94)91277-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912389				2022-12-28	WOS:A1994NV73200005
J	DALVA, MB; KATZ, LC				DALVA, MB; KATZ, LC			REARRANGEMENTS OF SYNAPTIC CONNECTIONS IN VISUAL-CORTEX REVEALED BY LASER PHOTOSTIMULATION	SCIENCE			English	Article							CAT STRIATE CORTEX; CLUSTERED HORIZONTAL CONNECTIONS; INTRINSIC CONNECTIONS; AREA 17; FUNCTIONAL ARCHITECTURE; CEREBRAL-CORTEX; LOCAL CIRCUITS; AXONAL ARBORS; BRAIN-SLICES; LAYER-III	Assessing patterns of synaptic connections in the developing mammalian neocortex has relied primarily on anatomical studies. In a physiological approach described here, the patterns of synaptic connections in slices of developing ferret visual cortex were determined with scanning laser photostimulation. Functional synaptic inputs to pyramidal cells in cortical layers 2 and 3 originating from sites close to the neuronal cell body appeared at least 2 weeks before eye opening, prior to the formation of long-range horizontal connections. Extensive long-range horizontal connections appeared in the next 10 days of development. The number of local connections peaked at the time of eye opening; the number of these connections subsequently declined to the level found in the adult while the specificity of long-distance connections increased. Thus, the relative influence of local connections on the activity of layer 2 and layer 3 neurons declines as the cortex matures while the influence of longer range connections increases substantially.			DALVA, MB (corresponding author), DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA.			Dalva, Matthew/0000-0002-7737-8787	NATIONAL EYE INSTITUTE [R01EY007960] Funding Source: NIH RePORTER; NEI NIH HHS [EY07960] Funding Source: Medline; PHS HHS [T32-6M08441] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; ARMSTRONGJAMES M, 1988, CEREBRAL CORTEX DEV, V7, pCH8; BURKHALTER A, 1993, J NEUROSCI, V13, P1916, DOI 10.1523/jneurosci.13-05-01916.1993; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; CALLAWAY EM, 1992, J NEUROSCI, V12, P570; CAMPBELL G, 1992, J NEUROSCI, V12, P1847; Dalva M. B., 1992, Society for Neuroscience Abstracts, V18, P1455; DURACK J, UNPUB; EDELMAN GM, 1988, NEURAL DARWINISIM TH; FARBER IC, 1983, SCIENCE, V222, P1025, DOI 10.1126/science.6648515; FRIAUF E, 1990, J NEUROSCI, V10, P2601; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HATA Y, 1993, NEUROPHYSIOLOGY, V69, P40; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HIRSCH JA, 1993, J PHYSIOL-LONDON, V461, P247, DOI 10.1113/jphysiol.1993.sp019512; JONES EG, 1984, CEREBRAL CORTEX CELL, V1, pCH8; KATZ LC, 1989, J NEUROSCI, V9, P1389; KATZ LC, 1987, J NEUROSCI, V7, P1223; KATZ LC, 1991, EUR J NEUROSCI, V3, P1, DOI 10.1111/j.1460-9568.1991.tb00805.x; KATZ LC, IN PRESS J NEUROSCI; KAUR C, 1989, ACTA ANAT, V136, P204; KISVARDAY ZF, 1986, EXP BRAIN RES, V64, P541, DOI 10.1007/BF00340492; KISVARDAY ZF, 1992, NEUROSCIENCE, V46, P275, DOI 10.1016/0306-4522(92)90050-C; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P2830; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; LUBKE J, 1992, J COMP NEUROL, V323, P42, DOI 10.1002/cne.903230105; LUND JS, 1977, J COMP NEUROL, V176, P149, DOI 10.1002/cne.901760203; LUND JS, 1975, J COMP NEUROL, V159, P305, DOI 10.1002/cne.901590303; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MALSBURG CV, 1973, KYBERNETIK, V14, P85, DOI 10.1007/BF00288907; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MCGUIRE BA, 1991, J COMP NEUROL, V305, P370, DOI 10.1002/cne.903050303; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MILLER KD, 1994, J NEUROSCI, V14, P409; MISSON JP, 1991, GLIA, V4, P138, DOI 10.1002/glia.440040205; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; ROCKLAND KS, 1982, SCIENCE, V215, P1532, DOI 10.1126/science.7063863; ROCKLAND KS, 1985, J COMP NEUROL, V241, P225, DOI 10.1002/cne.902410209; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; TSO DY, 1986, J NEUROSCI, V6, P1160; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; WILCOX M, 1990, J ORG CHEM, V55, P1585, DOI 10.1021/jo00292a038	48	114	150	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 8	1994	265	5169					255	258		10.1126/science.7912852	http://dx.doi.org/10.1126/science.7912852			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7912852				2022-12-28	WOS:A1994NV95700043
J	SMITH, JC; CRANSTON, D; OBRIEN, T; GUILLEBAUD, J; HINDMARSH, J; TURNER, AG				SMITH, JC; CRANSTON, D; OBRIEN, T; GUILLEBAUD, J; HINDMARSH, J; TURNER, AG			FATHERHOOD WITHOUT APPARENT SPERMATOZOA AFTER VASECTOMY	LANCET			English	Note								Fatherhood after vasectomy is rare. We describe 6 cases of DNA-proven fatherhood after vasectomy in association with persistently negative semen examination. All vasectomy patients and their partners should be counselled about the small possibility of late failure, and warning of failure should be recorded.	CHURCHILL HOSP,ELLIOT SMITH CLIN,OXFORD,ENGLAND; MARGARET PYKE CTR STUDY & TRAINING FAMILY PLANNING,LONDON,ENGLAND; S CLEVELAND HOSP,MIDDLESBROUGH,CLEVELAND,ENGLAND; PETERBOROUGH DIST GEN HOSP,PETERBOROUGH,LINCS,ENGLAND; STAMFORD HOSP,PETERBOROUGH,LINCS,ENGLAND	University of Oxford; University of London; University College London	SMITH, JC (corresponding author), CHURCHILL HOSP,DEPT UROL,OXFORD OX3 7LJ,ENGLAND.		Cranston, David/K-7063-2019					BUNGE RG, 1968, J UROLOGY, V100, P762, DOI 10.1016/S0022-5347(17)62620-X; Esho J O, 1974, Urology, V3, P211, DOI 10.1016/S0090-4295(74)80018-X; PHILP T, 1984, BRIT MED J, V289, P77, DOI 10.1136/bmj.289.6437.77; Pugh R C, 1969, Br J Urol, V41, P340, DOI 10.1111/j.1464-410X.1969.tb11894.x; SMITH JC, 1971, LANCET, V1, P38; TEMPLE JG, 1970, LANCET, V2, P1258; THOMSON JA, 1993, BRIT MED J, V307, P299, DOI 10.1136/bmj.307.6899.299	7	46	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					30	30		10.1016/S0140-6736(94)91052-9	http://dx.doi.org/10.1016/S0140-6736(94)91052-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912302				2022-12-28	WOS:A1994NU91700015
J	SILVERMAN, WA				SILVERMAN, WA			PATIENTS PREFERENCES AND RANDOMIZED TRIALS	LANCET			English	Editorial Material																		BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; GORE SM, 1994, LANCET, V343, P58, DOI 10.1016/S0140-6736(94)90913-X; HENSHAW RC, 1993, BRIT MED J, V307, P714, DOI 10.1136/bmj.307.6906.714	3	16	16	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1586	1586		10.1016/S0140-6736(94)93053-8	http://dx.doi.org/10.1016/S0140-6736(94)93053-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911916				2022-12-28	WOS:A1994NU35400006
J	THOMAS, DP				THOMAS, DP			VIRAL CONTAMINATION OF BLOOD PRODUCTS	LANCET			English	Editorial Material							HEMOPHILIA-A; PARVOVIRUS-B19; TRANSMISSION; CONCENTRATE				THOMAS, DP (corresponding author), BIO PROD LAB, ELSTREE, HERTS, ENGLAND.							LYON DJ, 1989, LANCET, V1, P1085; MANNUCCI PM, 1994, ANN INTERN MED, V120, P1, DOI 10.7326/0003-4819-120-1-199401010-00001; MANNUCCI PM, 1993, VIROLOGICAL SAFETY A, P253; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MORTIMER PP, 1983, LANCET, V2, P482; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; PEERLINCK K, 1993, THROMB HAEMOSTASIS, V69, P115; PEERLINCK K, 1993, LANCET, V341, P179, DOI 10.1016/0140-6736(93)90044-H; PROWSE C, 1993, BRIT MED J, V307, P561, DOI 10.1136/bmj.307.6903.561-e; SANTAGOSTINO E, 1994, LANCET, V343, P798, DOI 10.1016/S0140-6736(94)91878-3; TEMPERLEY IJ, 1992, LANCET, V340, P1466; WILLIAMS MD, 1990, VOX SANG, V58, P177, DOI 10.1111/j.1423-0410.1990.tb02086.x	12	12	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	1994	343	8913					1583	1584		10.1016/S0140-6736(94)93050-3	http://dx.doi.org/10.1016/S0140-6736(94)93050-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911913				2022-12-28	WOS:A1994NU35400003
J	CARMEL, R				CARMEL, R			APPROACH TO A LOW VITAMIN-B-12 LEVEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							COBALAMIN DEFICIENCY; PERNICIOUS-ANEMIA				CARMEL, R (corresponding author), UNIV SO CALIF, LOS ANGELES, CA USA.							CARMEL R, 1979, ARCH INTERN MED, V139, P47, DOI 10.1001/archinte.139.1.47; CARMEL R, 1990, AM J HEMATOL, V34, P108, DOI 10.1002/ajh.2830340206; CARMEL R, 1988, ARCH INTERN MED, V148, P1715, DOI 10.1001/archinte.148.8.1715; FAIRBANKS VF, 1983, MAYO CLIN PROC, V58, P541; GAFFNEY GW, 1957, J GERONTOL, V12, P32, DOI 10.1093/geronj/12.1.32; MARCUS DL, 1987, J AM GERIATR SOC, V35, P635, DOI 10.1111/j.1532-5415.1987.tb04339.x; PENNYPACKER LC, 1992, J AM GERIATR SOC, V40, P1197, DOI 10.1111/j.1532-5415.1992.tb03641.x	7	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1233	1233						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933355				2022-12-28	WOS:A1994PN06800002
J	FRANK, DA; GREENBERG, ME				FRANK, DA; GREENBERG, ME			CREB - A MEDIATOR OF LONG-TERM-MEMORY FROM MOLLUSKS TO MAMMALS	CELL			English	Review							APLYSIA SENSORY NEURONS; PROTEIN-SYNTHESIS; PHOSPHORYLATED CREB; FACILITATION; SENSITIZATION; TRANSCRIPTION; POTENTIATION; EXPRESSION; INVITRO; MUTANT		HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	FRANK, DA (corresponding author), CHILDRENS HOSP,DEPT NEUROL,DIV NEUROSCI,BOSTON,MA 02115, USA.							ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BACKSAI BJ, 1993, SCIENCE, V260, P222; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; FOLKERS E, 1993, P NATL ACAD SCI USA, V90, P8123, DOI 10.1073/pnas.90.17.8123; FREY U, 1991, NEUROSCI LETT, V129, P111, DOI 10.1016/0304-3940(91)90732-9; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUANG YY, 1994, CELL, V79; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; RAYPORT SG, 1986, J NEUROSCI, V6, P759; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; TULLY T, 1994, CELL, V79; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; YIN JCP, 1994, CELL, V79	30	316	326	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					5	8		10.1016/0092-8674(94)90394-8	http://dx.doi.org/10.1016/0092-8674(94)90394-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923377				2022-12-28	WOS:A1994PK58500002
J	WEBSTER, J; PISCITELLI, G; POLLI, A; FERRARI, CI; ISMAIL, I; SCANLON, MF				WEBSTER, J; PISCITELLI, G; POLLI, A; FERRARI, CI; ISMAIL, I; SCANLON, MF			A COMPARISON OF CABERGOLINE AND BROMOCRIPTINE IN THE TREATMENT OF HYPERPROLACTINEMIC AMENORRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOPAMINE AGONIST; DOUBLE-BLIND; NULL HYPOTHESIS; CV 205-502; PROLACTIN; DISORDERS; NONERGOT	Background. Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic amenorrhea. We designed a study to compare its safety and efficacy with those of bromocriptine, which has been the standard therapy. Methods. A total of 459 women with hyperprolactinemic amenorrhea were treated with either cabergoline (0.5 to 1.0 mg twice weekly) or bromocriptine (2.5 to 5.0 mg twice daily), administered in a double-blind fashion for 8 weeks and subsequently in an open fashion for 16 weeks, during which adjustments in the dose were made according to the response. Of the 459 women, 279 had microprolactinomas, 3 had macroprolactinomas, 1 had a craniopharyngioma, 167 had idiopathic hyperprolactinemia, and the remainder had an empty sella. Clinical and biochemical status was assessed at 2-week intervals for 8 weeks and monthly thereafter for a total of 6 months, with an additional assessment at 14 weeks. Results. Stable normoprolactinemia was achieved in 186 of the 223 women treated with cabergoline (83 percent) and 138 of the 236 women treated with bromocriptine (59 percent, P<0.001). Seventy-two percent of the women treated with cabergoline and 52 percent of those treated with bromocriptine had ovulatory cycles or became pregnant during treatment (P<0.001). Amenorrhea persisted in 7 percent of the cabergoline-treated women and 16 percent of the bromocriptine-treated women. Adverse effects were recorded in 68 percent of the women taking cabergoline and 78 percent of those taking bromocriptine (P = 0.03); 3 percent discontinued taking cabergoline, and 12 percent stopped taking bromocriptine (P<0.001) because of drug intolerance. Gastrointestinal symptoms were significantly less frequent, less severe, and shorter-lived in the women treated with cabergoline. Conclusions. Cabergoline is more effective and better tolerated than bromocriptine in women with hyperprolactinemic amenorrhea.	UNIV WALES COLL MED,DEPT MED,ENDOCRINOL METAB & DIABET SECT,CARDIFF CF4 4XN,S GLAM,WALES; FARMITALIA CARLO ERBA SPA,PHARM,MILAN,ITALY; FATEBENEFRATELLI HOSP,ENDOCRINE UNIT,MILAN,ITALY	Cardiff University			Ismail, Ikram Shah/A-6329-2009; ISMAIL, IKRAM SHAH/B-8651-2010	ISMAIL, IKRAM SHAH/0000-0001-8796-1936				BLACKWELDER WC, 1984, CONTROL CLIN TRIALS, V5, P97, DOI 10.1016/0197-2456(84)90116-8; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CICCARELLI E, 1989, J CLIN ENDOCR METAB, V69, P725, DOI 10.1210/jcem-69-4-725; Cox DR., 1989, ANAL BINARY DATA; CROSIGNANI PG, 1990, BAILLIERE CLIN OB GY, V4, P441, DOI 10.1016/S0950-3552(05)80303-7; CUTLER S J, 1958, J Chronic Dis, V8, P699, DOI 10.1016/0021-9681(58)90126-7; FERRARI C, 1989, J CLIN ENDOCR METAB, V68, P1201, DOI 10.1210/jcem-68-6-1201; FERRARI C, 1986, J CLIN ENDOCR METAB, V63, P941, DOI 10.1210/jcem-63-4-941; FERRARI C, 1992, ACTA ENDOCRINOL-COP, V126, P489, DOI 10.1530/acta.0.1260489; HO KY, 1988, DRUGS, V36, P67, DOI 10.2165/00003495-198836010-00005; HOMBURG R, 1990, CLIN ENDOCRINOL, V32, P565, DOI 10.1111/j.1365-2265.1990.tb00899.x; MATTEI AM, 1988, J CLIN ENDOCR METAB, V66, P193, DOI 10.1210/jcem-66-1-193; VANCE ML, 1984, ANN INTERN MED, V100, P78, DOI 10.7326/0003-4819-100-1-78; VANDERHEIJDEN PFM, 1991, EUR J OBSTET GYN R B, V40, P111, DOI 10.1016/0028-2243(91)90101-P; VERHELST JA, 1991, ACTA ENDOCRINOL-COP, V125, P385, DOI 10.1530/acta.0.1250385; WEBSTER J, 1992, CLIN ENDOCRINOL, V37, P534, DOI 10.1111/j.1365-2265.1992.tb01485.x; 1991, BRIT MED J, V302, P1367	18	467	488	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					904	909		10.1056/NEJM199410063311403	http://dx.doi.org/10.1056/NEJM199410063311403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	7915824				2022-12-28	WOS:A1994PJ41900003
J	OZEL, M; XI, YG; BALDAUF, E; DIRINGER, H; POCCHIARI, M				OZEL, M; XI, YG; BALDAUF, E; DIRINGER, H; POCCHIARI, M			SMALL VIRUS-LIKE STRUCTURE IN BRAINS FROM CASES OF SPORADIC AND FAMILIAL CREUTZFELDT-JAKOB-DISEASE	LANCET			English	Note							PROTEIN	We have previously observed small virus-like particles in the brain of hamsters with experimental scrapie. Here we report that small virus-like structures can be isolated from brains of patients with Creutzfeldt-Jakob disease and identified by electronmicroscopy.	BUNDESGESUNDHEITSAMT,ROBERT KOCH INST,D-13353 BERLIN,GERMANY; IST SUPER SANITA,VIROL LAB,I-00161 ROME,ITALY	Robert Koch Institute; Istituto Superiore di Sanita (ISS)			Pocchiari, Maurizio/J-8443-2018	Pocchiari, Maurizio/0000-0002-7269-2486				DIRINGER H, 1983, EUR J BIOCHEM, V134, P555, DOI 10.1111/j.1432-1033.1983.tb07602.x; DIRINGER H, 1992, EXP CLIN IMMUNOGENET, V9, P212; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; OZEL M, 1994, LANCET, V343, P894, DOI 10.1016/S0140-6736(94)90010-8; POCCHIARI M, 1993, ANN NEUROL, V34, P802, DOI 10.1002/ana.410340608; POCCHIARI M, 1994, MOL ASPECTS MED, V15, P195, DOI 10.1016/0098-2997(94)90042-6	6	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					923	924		10.1016/S0140-6736(94)92272-1	http://dx.doi.org/10.1016/S0140-6736(94)92272-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934349				2022-12-28	WOS:A1994PJ28700013
J	MINDRINOS, M; KATAGIRI, F; YU, GL; AUSUBEL, FM				MINDRINOS, M; KATAGIRI, F; YU, GL; AUSUBEL, FM			THE A-THALIANA DISEASE RESISTANCE GENE RPS2 ENCODES A PROTEIN CONTAINING A NUCLEOTIDE-BINDING SITE AND LEUCINE-RICH REPEATS	CELL			English	Article							MEMBRANE-SPANNING PROTEINS; MOLECULAR-CLONING; ADENYLATE-CYCLASE; ARABIDOPSIS; IDENTIFICATION; AVIRULENCE; RECOGNITION; SUPPRESSION; EXPRESSION; MUTATIONS	In plants, resistance to a pathogen is frequently correlated with a genetically defined interaction between a plant resistance gene and a corresponding pathogen avirulence gene. A simple model explains these gene-for-gene interactions: avirulence gene products generate signals (ligands), and resistance genes encode cognate receptors. The A. thaliana RPS2 gene confers resistance to the bacterial pathogen P. syringae carrying the avirulence gene avrRpt2. A map-based positional cloning strategy was used to identify RPS2. The identification of RPS2 was verified using a newly developed transient assay for RPS2 function and by genetic complementation in transgenic plants. RPS2 encodes a novel 105 kDa protein containing a leucine zipper, a nucleotide-binding site, and 14 imperfect leucine-rich repeats.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	MINDRINOS, M (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114, USA.			Katagiri, Fumiaki/0000-0001-6893-3788	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048707, R37GM048707] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48707] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENT AF, 1994, IN PRESS SCIENCE; BRAUN T, 1991, EMBO J, V10, P1886; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KEEN NT, 1992, PLANT MOL BIOL, V19, P109, DOI 10.1007/BF00015609; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KONOZ C, 1986, MOL GEN GENET, V204, P33; KUNKEL BN, 1993, PLANT CELL, V5, P865, DOI 10.1105/tpc.5.8.865; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LINDGREN PB, 1986, J BACTERIOL, V168, P512, DOI 10.1128/jb.168.2.512-522.1986; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MEYER K, 1994, SCIENCE, V264, P145; MINDRINOS M, 1994, IN PRESS ADV MOL GEN, V3; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; Sambrook J, 1989, MOL CLONING LABORATO; STASKAWICZ B, 1987, J BACTERIOL, V169, P5789, DOI 10.1128/jb.169.12.5789-5794.1987; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; Swanson J., 1988, Molecular Plant-Microbe Interactions, V1, P5, DOI 10.1094/MPMI-1-005; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; TRAUT TW, 1994, EUR J BIOCHEM, V229, P9; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; YU GL, 1993, MOL PLANT MICROBE IN, V6, P434, DOI 10.1094/MPMI-6-434	45	589	735	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					1089	1099		10.1016/0092-8674(94)90282-8	http://dx.doi.org/10.1016/0092-8674(94)90282-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923358				2022-12-28	WOS:A1994PJ29400018
J	CORDNER, SM; LOFF, B				CORDNER, SM; LOFF, B			800 YEARS OF CORONERS - HAVE THEY A FUTURE	LANCET			English	Article									UNIV LONDON KINGS COLL,LONDON WC2R 2LS,ENGLAND	University of London; King's College London	CORDNER, SM (corresponding author), VICTORIAN INST FORENS PATHOL,57-83 KAVANAGH ST,S MELBOURNE,VIC 3205,AUSTRALIA.		Loff, Bebe/G-9241-2014	Loff, Bebe/0000-0003-1963-6503				BREND WA, 1915, INQUIRY STATISTICS D, P66; DYER C, 1987, BRIT MED J, V294, P564, DOI 10.1136/bmj.294.6571.564; Hunnisett R.F., 1961, MEDIEVAL CORONER; JOHNSTONE G, 1992, AFTERMATH DEATH, P164; KNAPMAN P, 1985, THURSTONS CORONERSHI, P1; KNIGHT B, 1990, MED LEGAL J, V2, P65; LEADBEATTER S, 1993, BRIT MED J, V306, P1018, DOI 10.1136/bmj.306.6884.1018; MATTHEWS P, 1993, JERVIS OFFICE DUTIES, P3; 1971, CMND 4810; 1989, AM J FOREN MED PATH, V1, P88; 1986, CORONERS COURTS ENGL; 1993, STATISTICS DEATHS RE; 1986, DEATHS COMMUNITY	13	10	11	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					799	801		10.1016/S0140-6736(94)92348-5	http://dx.doi.org/10.1016/S0140-6736(94)92348-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916080				2022-12-28	WOS:A1994PG17800017
J	BALFOUR, TW				BALFOUR, TW			WHERE HAS ALL THE APPENDICITIS GONE	LANCET			English	Editorial Material											BALFOUR, TW (corresponding author), CITY HOSP NOTTINGHAM,DEPT SURG,NOTTINGHAM,ENGLAND.							DONNAN SPB, 1986, AETIOLOGY ACUTE APPE, P16; LOGAN RFA, 1991, OXFORD TXB PUBLIC HL, V3, P333; MCCAHY P, 1994, ANN ROY COLL SURG, V76, P282	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					700	700		10.1016/S0140-6736(94)92201-2	http://dx.doi.org/10.1016/S0140-6736(94)92201-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915770				2022-12-28	WOS:A1994PF18700003
J	ORAHILLY, S; HATTERSLEY, A; VAAG, A; GRAY, H				ORAHILLY, S; HATTERSLEY, A; VAAG, A; GRAY, H			INSULIN-RESISTANCE AS THE MAJOR CAUSE OF IMPAIRED GLUCOSE-TOLERANCE - A SELF-FULFILLING PROPHESY	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; TYROSINE KINASE DOMAIN; GLUCOKINASE GENE; RECEPTOR GENE; NONSENSE MUTATION; SKELETAL-MUSCLE; PATIENT; YOUNG; LOAD	Non-insulin-dependent diabetes (NIDDM) is a heterogeneous state involving various degrees of beta-cell dysfunction and insulin resistance, although the relative importance of these two factors is controversial. Several single gene disorders of carbohydrate metabolism have their main pathophysiological defect largely restricted to the beta-cell or to insulin-sensitive tissues. We have noted that with insulin resistance the fasting plasma glucose is often normal and severe hyperglycaemia occurs after a glucose load. By contrast, in glucokinase-deficient diabetes, which is characterised by reduced insulin secretion, the reverse is the case. Supportive evidence showing that beta-cell dysfunction and insulin resistance may have different effects on fasting and post-prandial glucose concentrations comes from studies of identical twins of NIDDM patients, hemi-pancreatectomised normal subjects, and insulin-resistant Asian subjects. NIDDM is usually preceded by a period of less severe hyperglycemia, referred to as impaired glucose tolerance (IGT). Studies of the IGT phase usually conclude that insulin resistance is the major abnormality and is thus the primary defect in NIDDM. However, the definition of IGT is based on the 2 h plasma glucose after an oral glucose-tolerance test without consideration of the fasting glucose concentrations (provided these concentrations are non-diabetic). Our observations suggest that this definition of IGT may result in the over-representation of insulin-resistant individuals and the under-representation of subjects with beta-cell dysfunction in any cross sectional study of IGT. The belief that the prediabetic state of IGT is dominated by insulin resistance may be a self-fulfilling prophesy because of the excessive emphasis put on the post-prandial rather than the fasting state.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QQ, CAMBS, ENGLAND; UNIV BIRMINGHAM, DEPT MED, BIRMINGHAM, ENGLAND; ODENSE UNIV HOSP, DEPT INTERNAL MED, ODENSE, DENMARK	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Birmingham; University of Southern Denmark; Odense University Hospital	ORAHILLY, S (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, CAMBRIDGE CB2 2QQ, CAMBS, ENGLAND.		O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Hattersley, Andrew/0000-0001-5620-473X; Vaag, Allan Arthur/0000-0002-3690-2191	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; DEFRONZO RA, 1983, DIABETES, V32, P35, DOI 10.2337/diab.32.1.35; FELIG P, 1970, NEW ENGL J MED, V282, P166; FERRANNINI E, 1985, DIABETES, V34, P580, DOI 10.2337/diabetes.34.6.580; FINK RI, 1992, METABOLISM, V41, P897, DOI 10.1016/0026-0495(92)90174-9; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; HAGER J, IN PRESS DIABETES; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; HOLROYDE MJ, 1976, BIOCHEM J, V153, P363, DOI 10.1042/bj1530363; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; KATAGIRI H, 1992, LANCET, V340, P1316, DOI 10.1016/0140-6736(92)92494-Z; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; KROOK A, 1993, LANCET, V342, P277, DOI 10.1016/0140-6736(93)91820-C; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MODAN M, 1989, DIABETES, V38, P1630, DOI 10.2337/diabetes.38.12.1630; MOLL, 1993, MOLLER DE, P49; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1994, DIABETES, V43, P247, DOI 10.2337/diabetes.43.2.247; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; SAKURA H, 1992, J CLIN ENDOCR METAB, V75, P1571, DOI 10.1210/jc.75.6.1571; STOFFEL M, 1992, NAT GENET, V2, P153, DOI 10.1038/ng1092-153; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; TURNER RC, 1976, LANCET, V1, P1272; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; WATTRE S, 1993, SCAND J CLIN LAB INV, V53, P2	33	65	65	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	1994	344	8922					585	589		10.1016/S0140-6736(94)91969-0	http://dx.doi.org/10.1016/S0140-6736(94)91969-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914964				2022-12-28	WOS:A1994PD42400013
J	TREASURE, T				TREASURE, T			WHERE DID I GO WRONG	LANCET			English	Editorial Material											TREASURE, T (corresponding author), ST GEORGE HOSP,DEPT CARDIOTHORAC SURG,LONDON,ENGLAND.							ANDERSON J, 1994, BR HEART J S5, V71, pP317; ANDERSON J, 1994, BR HEART J S5, V71, pP209; DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914; PARSONNET V, 1989, CIRCULATION, V79, P3	4	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					419	420		10.1016/S0140-6736(94)91763-9	http://dx.doi.org/10.1016/S0140-6736(94)91763-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914560				2022-12-28	WOS:A1994PB76100003
J	LAGA, M; ALARY, M; NZILA, N; MANOKA, AT; TULIZA, M; BEHETS, F; GOEMAN, J; STLOUIS, M; PIOT, P				LAGA, M; ALARY, M; NZILA, N; MANOKA, AT; TULIZA, M; BEHETS, F; GOEMAN, J; STLOUIS, M; PIOT, P			CONDOM PROMOTION, SEXUALLY-TRANSMITTED DISEASES TREATMENT, AND DECLINING INCIDENCE OF HIV-1 INFECTION IN FEMALE ZAIRIAN SEX WORKERS	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; PROSTITUTES; TRANSMISSION; AFRICA	The control of sexually transmitted diseases, including HIV-1, among sex workers and their clients in urban areas in developing countries, is considered a valuable and cost-effective intervention to contain the spread of HIV-1. The effect of a programme of STD treatment combined with condom promotion on HIV-1 incidence has so far not been measured. During an intervention including condom promotion, as well as monthly sexually transmitted disease screening and treatment among 531 initially HIV-1 negative female sex workers in Kinshasa, Zaire, 70 became infected with HIV-1 (incidence of 8.0 per 100 women-years [wy]). A decline of HIV-1 incidence was observed over time, from 11.7/100 wy during the first 6 months, to 4.4/100 wy over the last 6 months, 3 years later (p = 0.003). Simultaneously, regular use of condoms with clients went up from 11% to 52% and 68%, after 6 and 36 months of intervention, respectively. Risk factors for HIV-1 seroconversion after multivariate analysis included irregular condom use (RR 1.6 [95% Cl 1.1-2.8]), gonorrhoea (RR 2.5 [1.1-6.4]), trichomoniasis (RR 1.7 [1.1-2.8]), and genital ulcer disease (RR 2.5 [1.1-6.4]), during the probable period of acquisition of HIV-1. In women who attended more than 90% of their clinic appointments, the HIV-1 incidence was 2.7/100 wy compared to 7.1, 20.3, and 44.1 per 100 wy among women who attended 76-90%, 50-75%, and less than 50% of the monthly appointments, respectively (p < 0.0001). These trends remained after controlling for reported condom use and number of clients. This study confirms earlier findings that STDs facilitate transmission of HIV-1 and shows that a clinic-based intervention consisting of STD care and condom promotion can result in a major decline of HIV-1 incidence among female sex workers.	MINIST HLTH, PROJET SIDA, KINSHASA, DEM REP CONGO; CTR DIS CONTROL, DIV HIV AIDS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	LAGA, M (corresponding author), INST TROP MED, WHO,COLLABORATING CTR AIDS,DEPT INFECT & IMMUN, DIV MICROBIOL, NATL ST 155, B-2000 ANTWERP, BELGIUM.							ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; NZILA N, 1991, AIDS, V5, P715, DOI 10.1097/00002030-199106000-00011; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414	6	352	357	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 23	1994	344	8917					246	248		10.1016/S0140-6736(94)93005-8	http://dx.doi.org/10.1016/S0140-6736(94)93005-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913164				2022-12-28	WOS:A1994NY06000017
J	LEVINE, DS				LEVINE, DS			BARRETTS-ESOPHAGUS AND P53	LANCET			English	Editorial Material							SUPPRESSOR GENE; ADENOCARCINOMA; ESOPHAGUS; DYSPLASIA; 17P				LEVINE, DS (corresponding author), UNIV WASHINGTON,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA, USA.							BLOUNT PL, 1991, CANCER RES, V51, P5482; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; JANKOWSKI J, 1992, GUT, V33, P1033, DOI 10.1136/gut.33.8.1033; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; NESHAT K, 1994, GASTROEN CLIN BIOL, V18, pD71; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; RAMEL S, 1992, GASTROENTEROLOGY, V102, P1220; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; YOUNES M, 1993, GASTROENTEROLOGY, V105, P1637, DOI 10.1016/0016-5085(93)91058-P	11	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					212	213		10.1016/S0140-6736(94)92993-9	http://dx.doi.org/10.1016/S0140-6736(94)92993-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913153				2022-12-28	WOS:A1994NY06000005
J	THOMPSON, J				THOMPSON, J			UK IMMIGRATION FOR OVERSEAS DOCTORS	LANCET			English	Editorial Material											THOMPSON, J (corresponding author), NICHOLSON GRAHAM & JONES,LONDON,ENGLAND.							1993, CONSULTATION PROPOSA	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					74	75		10.1016/S0140-6736(94)91276-9	http://dx.doi.org/10.1016/S0140-6736(94)91276-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912388				2022-12-28	WOS:A1994NV73200004
J	BRIDBORD, K; WILLOUGHBY, A				BRIDBORD, K; WILLOUGHBY, A			VITAMIN-A AND MOTHER-TO-CHILD HIV-1 TRANSMISSION	LANCET			English	Editorial Material									NICHHD,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	BRIDBORD, K (corresponding author), NICHHD,FOGARTY INT CTR,INT STUDIES BRANCH,BETHESDA,MD 20892, USA.							GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; 1993, 13 MILLION HIV POSIT	2	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1585	1586		10.1016/S0140-6736(94)93052-X	http://dx.doi.org/10.1016/S0140-6736(94)93052-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911915				2022-12-28	WOS:A1994NU35400005
J	NAKAOKA, H; PEREZ, DM; BAEK, KJ; DAS, T; HUSAIN, A; MISONO, K; IM, MJ; GRAHAM, RM				NAKAOKA, H; PEREZ, DM; BAEK, KJ; DAS, T; HUSAIN, A; MISONO, K; IM, MJ; GRAHAM, RM			G(H) - A GTP-BINDING PROTEIN WITH TRANSGLUTAMINASE ACTIVITY AND RECEPTOR SIGNALING FUNCTION	SCIENCE			English	Article							PIG LIVER TRANSGLUTAMINASE; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; ALPHA-1-ADRENERGIC RECEPTOR; CDNA CLONES; IDENTIFICATION; RECONSTITUTION; PURIFICATION; FAMILY; ALPHA(1)-ADRENOCEPTOR	The alpha(1)-adrenergic receptors activate a phospholipase C enzyme by coupling to members of the large molecular size (approximately 74 to 80 kilodaltons) G alpha(h) family of guanosine triphosphate (GTP)-binding proteins. Rat liver G alpha(h) is now shown to be a tissue transglutaminase type II (TGase II). The transglutaminase activity of rat liver TGase II expressed in COS-1 cells was inhibited by the nonhydrolyzable GTP analog guanosine 5'-O-(3-thiotriphosphate) or by alpha(1)-adrenergic receptor activation. Rat liver TGase II also mediated alpha(1)-adrenergic receptor stimulation of phospholipase C activity. Thus, G alpha(h) represents a new class of GTP-binding proteins that participate in receptor signaling and may be a component of a complex regulatory network in which receptor-stimulated GTP binding switches the function of G alpha(h) from transglutamination to receptor signaling.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Husain, Ahsan/J-6861-2012	Husain, Ahsan/0000-0003-3426-3469				ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BERNSTEIN G, 1992, CELL, V70, P411; BIRCKBICHLER PJ, 1985, HYBRIDOMA, V4, P179, DOI 10.1089/hyb.1985.4.179; DAS T, 1993, J BIOL CHEM, V268, P27398; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IM MJ, 1992, J BIOL CHEM, V267, P8887; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1201, P1; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; NAKAOKA H, UNPUB; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; TAKEUCHI Y, 1992, FEBS LETT, V307, P177, DOI 10.1016/0014-5793(92)80762-6; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WU DQ, 1992, J BIOL CHEM, V267, P25798	24	527	539	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 10	1994	264	5165					1593	1596		10.1126/science.7911253	http://dx.doi.org/10.1126/science.7911253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	7911253				2022-12-28	WOS:A1994NQ28500037
J	DRACUP, K; BAKER, DW; DUNBAR, SB; DACEY, RA; BROOKS, NH; JOHNSON, JC; OKEN, C; MASSIE, BM				DRACUP, K; BAKER, DW; DUNBAR, SB; DACEY, RA; BROOKS, NH; JOHNSON, JC; OKEN, C; MASSIE, BM			MANAGEMENT OF HEART-FAILURE .2. COUNSELING, EDUCATION, AND LIFE-STYLE MODIFICATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							IMPAIRED VENTRICULAR-FUNCTION; CARDIAC REHABILITATION; MYOCARDIAL-INFARCTION; EXERCISE PERFORMANCE; PATIENT EDUCATION; META-ANALYSIS; ABNORMALITIES; RESPONSES; SYMPTOMS; ALCOHOL	Objective-This article reviews the role of counseling, education, dietary modifications, and exercise for patients with heart failure due to left ventricular systolic dysfunction. Data Sources.-We reviewed studies published in English between 1966 and 1993 and referenced in MEDLINE or EMBASE. We used the search terms heart failure, congestive; congestive heart failure; heart failure; cardiac failure; and dilated cardiomyopathy in conjunction with terms for the specific areas of interest. Where data were lacking, we relied on opinions of panel members and peer reviewers. Study Selection and Data Synthesis.-Studies were reviewed to determine whether patients had heart failure due to systolic dysfunction (left ventricular ejection fraction, <0.35 to 0.40) and whether clinical outcomes were reported. Studies that reported only intermediate outcomes leg, hemodynamics) were not reviewed. Conclusion.-Counseling and education can improve patient outcomes and decrease unnecessary hospitalizations. Patients with mild to moderate heart failure should be restricted to 3 g/d of sodium initially. Those who are unresponsive to this dosage or who have more severe disease should be advised to consume 2 g/d or less. Patients should be strongly advised to drink no more than 30 mL/d of alcohol or, preferably, to abstain completely. Exercise training is safe and can improve exercise duration and symptoms. Adherence to the treatment plan should be stressed and monitored at each visit. Clinicians should inform patients of the seriousness of their disease and their prognosis, but they should emphasize that patients can continue to remain active and enjoy a reasonable quality of life.	RAND CORP,HLTH SCI PROGRAM,SANTA MONICA,CA; UNIV CALIF LOS ANGELES,HARBOR MED CTR,DIV GEN INTERNAL MED,TORRANCE,CA 90509; EMORY UNIV,NELL HODGSON WOODRUFF SCH NURSING,ATLANTA,GA 30322; MENDED HEARTS INC,BOULDER,CO; CLIN PRACTICE GAIDELINE PANEL,BOULDER,CO; UNIV PENN,DIV GERIATR MED,PHILADELPHIA,PA; VET ADM MED CTR,PHILADELPHIA,PA 19104; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA	RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Emory University; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	DRACUP, K (corresponding author), UNIV CALIF LOS ANGELES,SCH NURSING,FACTOR BLDG,4-238,10833 LE CONTE AVE,LOS ANGELES,CA 90024, USA.				PHS HHS [282-91-0064] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARVAN S, 1988, AM J CARDIOL, V62, P197, DOI 10.1016/0002-9149(88)90211-1; COATS AJS, 1990, LANCET, V335, P63, DOI 10.1016/0140-6736(90)90536-E; COCKCROFT A, 1987, POSTGRAD MED J, V63, P637, DOI 10.1136/pgmj.63.742.637; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1991, NEW ENGL J MED, V325, P351; CONN EH, 1982, AM J CARDIOL, V49, P296, DOI 10.1016/0002-9149(82)90504-5; CONVERTINO VA, 1989, AVIAT SPACE ENVIR MD, V60, P653; CONWAY N, 1968, AM HEART J, V76, P581, DOI 10.1016/0002-8703(68)90145-2; DAHL LK, 1972, AM J CLIN NUTR, V25, P231; DIMATTEO MR, ACHIEVING PATIENT CO; DRACUP K, 1992, J HEART LUNG TRANSPL, V11, P273; DRACUP K, 1986, ARCH INTERN MED, V146, P1757, DOI 10.1001/archinte.146.9.1757; DRACUP K, 1991, AM J CARDIOL, V68, P31, DOI 10.1016/0002-9149(91)90705-P; DUBACH P, 1989, CARDIOLOGY, V76, P368, DOI 10.1159/000174520; DYCKNER T, 1986, ACTA MED SCAND S, V707, P27; ESTEY A, 1991, PATIENT EDUC COUNS, V18, P165, DOI 10.1016/0738-3991(91)90008-S; FLETCHER SW, 1979, ARCH INTERN MED, V139, P635, DOI 10.1001/archinte.139.6.635; FRANCIOSA JA, 1984, AM J CARDIOL, V53, P127, DOI 10.1016/0002-9149(84)90696-9; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; GIANNUZZI P, 1992, CHEST, V101, pS315, DOI 10.1378/chest.101.5_Supplement.315S; GIBBS JSR, 1990, J AM COLL CARDIOL, V15, P52, DOI 10.1016/0735-1097(90)90174-N; GOULD L, 1971, J AMER MED ASSOC, V218, P1799, DOI 10.1001/jama.218.12.1799; Hawthorne M H, 1994, Prog Cardiovasc Nurs, V9, P22; Healy M, 1984, Nurs Times, V80, P41; HOPKINS BE, 1972, MED J AUSTRALIA, V1, P370, DOI 10.5694/j.1326-5377.1972.tb46840.x; HUBBARD P, 1984, NURS RES, V33, P266; HULKA BS, 1976, AM J PUBLIC HEALTH, V66, P847, DOI 10.2105/AJPH.66.9.847; JAARSMA T, IN PRESS HEART LUNG; JUGDUTT BI, 1988, J AM COLL CARDIOL, V12, P362, DOI 10.1016/0735-1097(88)90407-X; Julian Desmond G., 1988, CARDIOLOGY; Kannel W B, 1989, Cardiol Clin, V7, P1; Kellermann J J, 1986, Adv Cardiol, V34, P131; KELLERMANN JJ, 1990, CARDIOLOGY, V77, P130, DOI 10.1159/000174593; KOCH M, 1992, CHEST, V101, pS231, DOI 10.1378/chest.101.5_Supplement.231S; KRISETHERTON PM, 1982, J AM DIET ASSOC, V80, P55; LEE AP, 1979, CIRCULATION, V60, P1519, DOI 10.1161/01.CIR.60.7.1519; LIPKIN DP, 1986, BRIT MED J, V292, P1030, DOI 10.1136/bmj.292.6527.1030; LIPKIN DP, 1986, BRIT HEART J, V55, P439; MEYER TE, 1991, J INTERN MED, V230, P407, DOI 10.1111/j.1365-2796.1991.tb00465.x; MINOTTI JR, 1990, J CLIN INVEST, V86, P751, DOI 10.1172/JCI114771; MINOTTI JR, 1992, CHEST, V101, pS333; MINOTTI JR, 1991, J CLIN INVEST, V88, P2077, DOI 10.1172/JCI115537; MOLGAARD H, 1990, INT J CARDIOL, V26, P373, DOI 10.1016/0167-5273(90)90098-P; MULLEN PD, 1992, PATIENT EDUC COUNS, V19, P143, DOI 10.1016/0738-3991(92)90194-N; MULLEN PD, 1985, PREV MED, V14, P753, DOI 10.1016/0091-7435(85)90070-2; NAYLOR MD, 1990, RES NURS HEALTH, V13, P327, DOI 10.1002/nur.4770130509; NAYLOR MD, 1990, NURS RES, V39, P156; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PADGETT D, 1988, J CLIN EPIDEMIOL, V41, P1007, DOI 10.1016/0895-4356(88)90040-6; REGAN TJ, 1990, JAMA-J AM MED ASSOC, V264, P377, DOI 10.1001/jama.264.3.377; RIDEOUT E, 1986, J ADV NURS, V11, P429, DOI 10.1111/j.1365-2648.1986.tb01270.x; ROSENBERG SG, 1971, HSMHA HEALTH REP, V86, P793, DOI 10.2307/4594300; Saltin B., 1968, CIRCULATION, V38, P1, DOI 10.1161/01.CIR.38.1.1; SCALVINI S, 1993, CARDIOLOGY, V80, P417; SNIVELY WD, 1974, NURS FORUM, V13, P59, DOI 10.1111/j.1744-6198.1974.tb01249.x; SUGRUE DD, 1992, ANN INTERN MED, V117, P117, DOI 10.7326/0003-4819-117-2-117; SULLIVAN MJ, 1989, CIRCULATION, V79, P324, DOI 10.1161/01.CIR.79.2.324; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506; SULLIVAN MJ, 1988, CIRCULATION, V77, P552, DOI 10.1161/01.CIR.77.3.552; SWAIN MA, 1981, RES NURS HEALTH, V4, P213, DOI 10.1002/nur.4770040107; TOBIN JR, 1978, ARCH INTERN MED, V138, P453, DOI 10.1001/archinte.138.3.453; TUCKER RM, 1980, MAYO CLIN PROC, V55, P261; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x; WEBER KT, 1986, CARDIOPULMONARY EXER, P290; WILSON JR, 1983, AM J CARDIOL, V51, P1358, DOI 10.1016/0002-9149(83)90312-0; 1988, ANN INTERN MED, V109, P671; 1987, NEW ENGL J MED, V316, P1429; 1990, LANCET, V336, P975; 1991, JAMA-J AM MED ASSOC, V269, P3015	69	108	108	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1442	1446		10.1001/jama.272.18.1442	http://dx.doi.org/10.1001/jama.272.18.1442			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP690	7933427				2022-12-28	WOS:A1994PP69000033
J	BATES, AS; FITZGERALD, JF; DITTUS, RS; WOLINSKY, FD				BATES, AS; FITZGERALD, JF; DITTUS, RS; WOLINSKY, FD			RISK-FACTORS FOR UNDERIMMUNIZATION IN POOR URBAN INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN SERVICES; CARE UTILIZATION; SOCIAL NETWORKS; PRENATAL-CARE; CHILDRENS USE; IMMUNIZATION; HEALTH; MOTHERS; OPPORTUNITIES; VACCINATIONS	Objective.-To assess risk factors for underimmunization in poor urban infants. Design.-Prospective cohort study. Setting.-A large municipal teaching hospital in the Midwest. Participants.-A total of 464 healthy, full-term newborn infants delivered at a large municipal teaching hospital who were to be discharged to the care of their mothers. Mothers were interviewed 24 to 72 hours post partum regarding personal and financial characteristics and 9 to 12 months later to determine where immunizations had been received. Main Outcome Measures.-Immunization status at 3 and 7 months of age. Results.-Despite availability of free vaccine to most patients, only 67% had received their first set of immunizations by 3 months of age, and only 29% were up-to-date by 7 months of age. Marital status, coresidence with the infant's grandmother, adequacy of prenatal care, and perceived barriers to care were significant independent predictors of initiation of immunizations by 3 months and completion of immunization by 7 months. Poverty was also an independent predictor of immunization status at 7 months. Perceived susceptibility to common symptoms and perceived benefit of medical care to prevent disease were inversely related to immunization status at 7 months. Conclusions.-These data suggest that poor urban infants of single mothers and of mothers who received inadequate prenatal care, and those not living with their grandmother should be targeted for tracking and follow-up to ensure adequate immunization. The provision of free vaccine alone will not guarantee adequate immunization coverage of poor urban children.	INDIANA UNIV,SCH MED,REGENSTRIEF INST HLTH CARE,DEPT MED,INDIANAPOLIS,IN 46202; RICHARD L ROUDEBUSH VET ADM MED CTR,INDIANAPOLIS,IN 46202; BOWEN RES CTR,INDIANAPOLIS,IN	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	BATES, AS (corresponding author), INDIANA UNIV,SCH MED,REGENSTRIEF INST HLTH CARE,DEPT PEDIAT,1001 W 10TH ST,FLOOR 5,INDIANAPOLIS,IN 46202, USA.		Wolinsky, Fredric D/F-9231-2011	Wolinsky, Fredric/0000-0002-0916-4955	NIA NIH HHS [R37AG09692] Funding Source: Medline; BHP HRSA HHS [D28PE55009, T32PE15001] Funding Source: Medline; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE015001, D28PE055009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009692] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); BHP HRSA HHS; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1993, ACCESS HLTH CARE AM; BATES AS, 1994, MED CARE, V32, P832, DOI 10.1097/00005650-199408000-00006; BATES AS, IN PRESS MED CARE; Becker M H, 1977, J Community Health, V3, P125, DOI 10.1007/BF01674234; BERKANOVIC E, 1974, J HEALTH SOC BEHAV, V15, P93, DOI 10.2307/2137188; BOBO JK, 1993, PEDIATRICS, V91, P308; BUTZ AM, 1993, PEDIATRICS, V92, P50; COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; DAWKINS C, 1988, PUBLIC HEALTH NURS, V5, P7, DOI 10.1111/j.1525-1446.1988.tb00553.x; FIELDING JE, 1994, JAMA-J AM MED ASSOC, V271, P525, DOI 10.1001/jama.271.7.525; GORTMAKER SL, 1982, J HEALTH SOC BEHAV, V23, P25, DOI 10.2307/2136387; HOCHBAUM G, 1958, PHS572; HORWITZ SM, 1985, MED CARE, V23, P946, DOI 10.1097/00005650-198508000-00002; KESSNER DM, 1973, I MED CONTRASTS HLTH, V1; KVIZ FJ, 1985, RES NURS HEALTH, V8, P381, DOI 10.1002/nur.4770080411; LE CT, 1986, AM J DIS CHILD, V140, P615; MARKS JS, 1979, PEDIATRICS, V64, P304; MCCONNOCHIE KM, 1992, PEDIATRICS, V89, P1019; MCDONALD CJ, 1988, M D COMPUT, V5, P34; MCDONALD TP, 1985, MED CARE, V23, P986; MUELLER DP, 1980, SOC SCI MED-MED SOC, V14, P147, DOI 10.1016/0160-7979(80)90028-4; NEWACHECK PW, 1986, MED CARE, V24, P30, DOI 10.1097/00005650-198601000-00004; PEAR R, 1993, NY TIMES        0806, V116, pA1; POPE SK, 1993, JAMA-J AM MED ASSOC, V269, P1396, DOI 10.1001/jama.269.11.1396; RICH S, 1993, WASHINGTON POST 0401, V116, pA14; RILEY AW, 1993, MED CARE, V31, P767, DOI 10.1097/00005650-199309000-00002; Sprauer M A, 1993, Indiana Med, V86, P14; STCLAIR PA, 1989, MED CARE, V27, P823, DOI 10.1097/00005650-198908000-00006; SZILAGYI PG, 1992, PEDIATRICS, V90, P871; SZILAGYI PG, 1993, PEDIATRICS, V91, P1; TESSLER R, 1978, MED CARE, V16, P33, DOI 10.1097/00005650-197801000-00003; TINSLEY BJ, 1989, J DEV BEHAV PEDIATR, V10, P236; WOODS DR, 1992, PUBLIC HEALTH REP, V107, P252; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833; 1992, MMWR-MORBID MORTAL W, V10, P888; 1990, PHS9150212 US DEP HL; 1993, MMWR-MORBID MORTAL W, V42, P952; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1992, MMWR-MORBID MORTAL W, V41, P1103; 1991, MMWR-MORBID MORTAL W, V40, P36; 1993, JAMA-J AM MED ASSOC, V269, P1817; 1992, FED REGISTER, V57, P5455	43	125	125	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1105	1110		10.1001/jama.272.14.1105	http://dx.doi.org/10.1001/jama.272.14.1105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK124	7933322				2022-12-28	WOS:A1994PK12400029
J	DSOUZA, D; WU, KK; HELLUMS, JD; PHILLIPS, MD				DSOUZA, D; WU, KK; HELLUMS, JD; PHILLIPS, MD			PLATELET ACTIVATION AND ARTERIAL THROMBOSIS	LANCET			English	Discussion							VONWILLEBRAND-FACTOR; SHEAR-STRESS; WHOLE-BLOOD; ARIC HEMOSTASIS; AGGREGATION; ACID; INSUFFICIENCY; PLASMA; RISK		UNIV TEXAS, SCH MED, DIV HEMATOL, HOUSTON, TX 77030 USA; UNIV TEXAS, SCH MED, DEPT MED, HOUSTON, TX 77030 USA; UNIV TEXAS, SCH MED, VASC RES CTR, HOUSTON, TX 77030 USA; RICE UNIV, BIOMED ENGN LAB, HOUSTON, TX 77251 USA	University of Texas System; University of Texas System; University of Texas System; Rice University			Wu, Kenneth Kun-Yu/B-1070-2010					ABRAMS CS, 1990, BLOOD, V75, P128; ALEVRIADOU BR, 1993, BLOOD, V81, P1263; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AULT KA, 1989, CYTOMETRY, V10, P448, DOI 10.1002/cyto.990100413; BELVAL TK, 1986, BIOPHYS J, V50, P479, DOI 10.1016/S0006-3495(86)83485-3; BROWN CH, 1975, J LAB CLIN MED, V86, P462; CORTES J, 1993, THROMB HAEMOSTASIS, V69, P1155; DEMARCO L, 1986, J CLIN INVEST, V77, P1272, DOI 10.1172/JCI112430; DEWITZ TS, 1978, MICROVASC RES, V16, P263, DOI 10.1016/0026-2862(78)90059-6; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; JANSSON JH, 1991, BRIT HEART J, V66, P351; JEN CYJ, 1984, J LAB CLIN MED, V103, P115; Kaplan K L, 1980, Prog Hemost Thromb, V5, P153; MEADE TW, 1985, BRIT MED J, V290, P428, DOI 10.1136/bmj.290.6466.428; MEYER D, 1993, THROMB HAEMOSTASIS, V70, P99; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; PAPP AC, 1989, THROMB HAEMOSTASIS, V61, P15; PHILLIPS MD, 1988, BLOOD, V72, P1898; REILLY IAG, 1986, CIRCULATION, V73, P1300, DOI 10.1161/01.CIR.73.6.1300; STEWART ME, 1983, LANCET, V2, P479; STRONY J, 1990, CIRCULATION, V81, P1106, DOI 10.1161/01.CIR.81.3.1106; TENCATE JW, 1978, THROMB HAEMOSTASIS, V39, P223; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; VREEKEN J, 1971, LANCET, V2, P1394; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; WU KK, 1990, THROMB HAEMOSTASIS, V64, P521; WU KK, 1975, STROKE, V6, P521, DOI 10.1161/01.STR.6.5.521; WU KK, 1974, LANCET, V2, P924; WU KK, 1976, THROMB HAEMOSTASIS, V35, P702, DOI 10.1055/s-0038-1647968; WU KKY, 1978, ANN INTERN MED, V88, P7, DOI 10.7326/0003-4819-88-1-7	30	44	44	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	1994	344	8928					991	995						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934435				2022-12-28	WOS:A1994PK97800014
J	ASAI, T; BATES, DB; KOGOMA, T				ASAI, T; BATES, DB; KOGOMA, T			DNA-REPLICATION TRIGGERED BY DOUBLE-STRANDED BREAKS IN ESCHERICHIA-COLI - DEPENDENCE ON HOMOLOGOUS RECOMBINATION FUNCTIONS	CELL			English	Article							ESCHERICHIA-COLI; RECBCD ENZYME; BACTERIOPHAGE-LAMBDA; RECD MUTANTS; GENETIC-RECOMBINATION; PURIFIED SUBUNITS; INITIATION SITE; EXONUCLEASE-V; CHI; REPAIR	Homologous recombination-dependent DMA replication (RDR) of a lambda cos site-carrying plasmid is demonstrated in E. coli cells when the cells express lambda terminase that introduces a double-stranded break into the cos site. RDR occurs in normal wild-type cells if the plasmid also contains the recombination hotspot chi. chi is dispensable when cells are induced for the SOS. response or contain a recD mutation. recBC sbcA mutant cells are also capable of RDR induction. A recN mutation greatly reduces RDR in normal cells, but not in SOS-induced cells. RDR proceeds by the theta mode or rolling circle mode of DNA synthesis, yielding covalently closed circular plasmid monomers or linear plasmid multimers, respectively. Previously described inducible stable DNA replication is considered to be a special type of RDR that starts exclusively from specific sites (oriMs) on the chromosome.	UNIV NEW MEXICO, SCH MED, DEPT CELL BIOL, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, SCH MED, DEPT MICROBIOL, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, SCH MED, CTR CANC RES & TREATMENT, ALBUQUERQUE, NM 87131 USA	University of New Mexico; University of New Mexico; University of New Mexico				Bates, David/0000-0002-0870-055X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022092] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM022092-22, GM22092] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; ASAI T, 1994, J MOL BIOL, V235, P1459, DOI 10.1006/jmbi.1994.1101; ASAI T, 1993, EMBO J, V12, P3287, DOI 10.1002/j.1460-2075.1993.tb05998.x; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BAILONE A, 1988, MOL GEN GENET, V214, P389, DOI 10.1007/BF00330471; BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CLARK AJ, 1993, J BACTERIOL, V175, P7673, DOI 10.1128/JB.175.23.7673-7682.1993; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; COHEN A, 1986, J BACTERIOL, V167, P327, DOI 10.1128/jb.167.1.327-335.1986; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; DABERT P, 1992, P NATL ACAD SCI USA, V89, P12073, DOI 10.1073/pnas.89.24.12073; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; FAULDS D, 1979, J MOL BIOL, V131, P681, DOI 10.1016/0022-2836(79)90197-9; FEISS M, 1983, LAMBDA, V2, P305; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GILLEN JR, 1981, J BACTERIOL, V145, P521, DOI 10.1128/JB.145.1.521-532.1981; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; HUISMAN O, 1983, J BACTERIOL, V153, P169, DOI 10.1128/JB.153.1.169-175.1983; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; KANNAN P, 1990, CURR MICROBIOL, V21, P7, DOI 10.1007/BF02090093; Kobayashi I, 1992, Adv Biophys, V28, P81, DOI 10.1016/0065-227X(92)90023-K; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1994, IN PRESS MICROBIOL R; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; KREUZER KN, 1994, IN PRESS MOL BIOL T, V4; KUSANO K, 1989, J MOL BIOL, V209, P623, DOI 10.1016/0022-2836(89)90000-4; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; KUZMINOV A, 1994, EMBO J, V13, P2764, DOI 10.1002/j.1460-2075.1994.tb06570.x; LOVETT ST, 1988, GENETICS, V120, P37; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; MAGEE TR, 1992, EMBO J, V11, P4219, DOI 10.1002/j.1460-2075.1992.tb05516.x; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MASTERSON C, 1992, J BIOL CHEM, V267, P13564; MEYEROWITZ EM, 1980, GENE, V11, P271, DOI 10.1016/0378-1119(80)90067-0; Miller J.H., 1972, EXPT MOL GENETICS; Mosig G, 1983, BACTERIOPHAGE, V4, P120; MURIALDO H, 1988, MOL GEN GENET, V213, P42, DOI 10.1007/BF00333396; MURIALDO H, 1984, GENE, V30, P183, DOI 10.1016/0378-1119(84)90119-7; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PICKSLEY SM, 1984, MOL GEN GENET, V195, P267, DOI 10.1007/BF00332758; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RINKEN R, 1992, J BACTERIOL, V174, P1172, DOI 10.1128/jb.174.4.1172-1178.1992; RINKEN R, 1992, J BACTERIOL, V174, P5424, DOI 10.1128/JB.174.16.5424-5429.1992; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SILBERSTEIN Z, 1987, J BACTERIOL, V169, P3131, DOI 10.1128/jb.169.7.3131-3137.1987; SINGER M, 1989, MICROBIOL REV, V53, P1; SMITH GR, 1988, MICROBIOL REV, V52, P1; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; STAHL FW, 1990, GENETICS, V126, P519; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; THALER DS, 1988, ANNU REV GENET, V22, P169, DOI 10.1146/annurev.ge.22.120188.001125; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; WILLETTS NS, 1969, J BACTERIOL, V100, P231, DOI 10.1128/JB.100.1.231-239.1969; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; YAGIL E, 1985, GENET RES, V45, P1, DOI 10.1017/S0016672300021911	67	101	102	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					1051	1061		10.1016/0092-8674(94)90279-8	http://dx.doi.org/10.1016/0092-8674(94)90279-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923355	Green Accepted			2022-12-28	WOS:A1994PJ29400015
J	PATRIARCA, PA				PATRIARCA, PA			POLIO OUTBREAKS - A TALE OF TORMENT	LANCET			English	Editorial Material											PATRIARCA, PA (corresponding author), US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD, USA.							ANDERSON RM, 1985, NATURE, V318, P323, DOI 10.1038/318323a0; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; PATRIARCA PA, 1993, LANCET, V342, P1461, DOI 10.1016/0140-6736(93)92936-N; VANNIEKERK ABW, 1994, LANCET, V344, P661, DOI 10.1016/S0140-6736(94)92090-7; 1993, 33RD INT C ANT AG CH	5	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					630	631		10.1016/S0140-6736(94)92079-6	http://dx.doi.org/10.1016/S0140-6736(94)92079-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915344				2022-12-28	WOS:A1994PE38600004
J	MARAN, A; MAITRA, RK; KUMAR, A; DONG, BH; XIAO, W; LI, GY; WILLIAMS, BRG; TORRENCE, PF; SILVERMAN, RH				MARAN, A; MAITRA, RK; KUMAR, A; DONG, BH; XIAO, W; LI, GY; WILLIAMS, BRG; TORRENCE, PF; SILVERMAN, RH			BLOCKAGE OF NF-KAPPA-B SIGNALING BY SELECTIVE ABLATION OF AN MESSENGER-RNA TARGET BY 2-5A ANTISENSE CHIMERAS	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; CONSTITUTIVE EXPRESSION; BETA-INTERFERON; RNA; GENE; 2',5'-OLIGOADENYLATE; CELLS; RESISTANCE; INDUCTION; PROMOTER	Activation of 2-5A-dependent ribonuclease by 5'-phosphorylated, 2',5'-linked oligoadenylates, known as 2-5A, is one pathway of interferon action. Unaided uptake into HeLa cells of 2-5A linked to an antisense oligonucleotide resulted in the selective ablation of messenger RNA for the double-stranded RNA (dsRNA)-dependent protein kinase PKR. Similarly, purified, recombinant human 2-5A-dependent ribonuclease was induced to selectively cleave PKR messenger RNA. Cells depleted of PKR activity were unresponsive to activation of nuclear factor-kappa B (NF-kappa B) by the dsRNA poly(l):poly(C), which provides direct evidence that PKR is a transducer for the dsRNA signaling of NF-kappa B.	CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; NIDDKD,BIOMED CHEM SECT,BETHESDA,MD 20892	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028253, R01AI034039, R21AI034039] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44059] Funding Source: Medline; NIAID NIH HHS [AI 34039-02, AI 28253] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAYLEY PJ, 1982, BIOCHEM BIOPH RES CO, V108, P1243, DOI 10.1016/0006-291X(82)92133-7; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; DONG BH, 1994, J BIOL CHEM, V269, P14153; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HAUGH MC, 1983, EUR J BIOCHEM, V132, P77, DOI 10.1111/j.1432-1033.1983.tb07327.x; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; Kinjo J E, 1992, Drug Des Discov, V8, P241; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOVACS T, 1993, BIOORG CHEM, V21, P192, DOI 10.1006/bioo.1993.1017; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A., UNPUB; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LESIAK K, 1993, BIOCONJUGATE CHEM, V4, P467, DOI 10.1021/bc00024a008; Maitra R., UNPUB; MARAN A, UNPUB; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SILVERMAN RH, 1987, LYMPHOKINES INTERFER, P149; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WELLS JA, 1984, J BIOL CHEM, V259, P1363; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; XANTHOUDAKIS S, 1989, J BIOL CHEM, V264, P1139; Xiao W., UNPUB; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	37	217	225	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					789	792		10.1126/science.7914032	http://dx.doi.org/10.1126/science.7914032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7914032				2022-12-28	WOS:A1994PA37200035
J	BRAKS, JAM; MARTENS, GJM				BRAKS, JAM; MARTENS, GJM			7B2 IS A NEUROENDOCRINE CHAPERONE THAT TRANSIENTLY INTERACTS WITH PROHORMONE CONVERTASE PC2 IN THE SECRETORY PATHWAY	CELL			English	Article							PITUITARY POLYPEPTIDE 7B2; SUBTILISIN-LIKE PROTEASE; PROCESSING ENDOPROTEASES; ENDOCRINE PROTEIN; CDNA SEQUENCE; CELLS; RAT; GENE; BIOSYNTHESIS; IDENTIFICATION	The neuroendocrine polypeptide 7B2 is a highly conserved secretory protein selectively present in prohormone-producing cells equipped with a regulated secretory pathway. We find that the amino-terminal half of 7B2 is distantly related to chaperonins, a subclass of molecular chaperones. When incubated in vitro with newly synthesized pituitary proteins, recombinant 7B2 specifically associates with prohormone convertase PC2. Metabolic cell labeling combined with coimmunoprecipitation studies showed that, in vivo, the precursor form of 7B2 interacts with the preform of PC2. Pulse-chase analysis revealed that this association is transient in that it commences early in the secretory pathway, while dissociation in the later stages appears to coincide with the cleavages of 7B2, proPC2, and prohormone. Our results suggest that 7B2 is a novel type of molecular chaperone preventing premature activation of proPC2 in the regulated secretory pathway.			BRAKS, JAM (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT ANIM PHYSIOL,TOERNOOIVELD,6525 ED NIJMEGEN,NETHERLANDS.		Martens, Gerard JM/D-1925-2010	Martens, Gerard/0000-0003-1761-4570				ALARCON C, 1993, J BIOL CHEM, V268, P4276; AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; AYOUBI TAY, 1991, CELL TISSUE RES, V264, P329, DOI 10.1007/BF00313970; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BRAKS JAM, 1992, FEBS LETT, V305, P45, DOI 10.1016/0014-5793(92)80652-W; BRAYTON KA, 1988, DNA-J MOLEC CELL BIO, V7, P713, DOI 10.1089/dna.1988.7.713; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CULLINAN WE, 1991, ENZYME, V45, P285, DOI 10.1159/000468902; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLEMBOTSKI CC, 1982, J BIOL CHEM, V257, P493; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; IGUCHI H, 1987, PEPTIDES, V8, P593, DOI 10.1016/0196-9781(87)90030-1; JENKS BG, 1993, SCIENCE, V10, P1; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MARCINKIEWICZ M, 1987, CELL TISSUE RES, V250, P205, DOI 10.1007/BF00214673; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MARTENS GJM, 1988, FEBS LETT, V234, P160, DOI 10.1016/0014-5793(88)81324-3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MARTENS GJM, 1989, EUR J BIOCHEM, V181, P75, DOI 10.1111/j.1432-1033.1989.tb14695.x; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MBIKAY M, 1989, INT J PEPT PROT RES, V33, P39; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SEEMULLER U, 1980, H-S Z PHYSIOL CHEM, V361, P1841; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SENATOROV VV, 1993, J NEUROENDOCRINOL, V5, P533, DOI 10.1111/j.1365-2826.1993.tb00518.x; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEEL JH, 1988, ENDOCRINOLOGY, V122, P270, DOI 10.1210/endo-122-1-270; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDUIJNHOVEN HLP, 1991, J IMMUNOL METHODS, V142, P187, DOI 10.1016/0022-1759(91)90106-P; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	58	192	195	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					263	273		10.1016/0092-8674(94)90296-8	http://dx.doi.org/10.1016/0092-8674(94)90296-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	7913882				2022-12-28	WOS:A1994NZ24200010
J	SHIANG, R; THOMPSON, LM; ZHU, YZ; CHURCH, DM; FIELDER, TJ; BOCIAN, M; WINOKUR, ST; WASMUTH, JJ				SHIANG, R; THOMPSON, LM; ZHU, YZ; CHURCH, DM; FIELDER, TJ; BOCIAN, M; WINOKUR, ST; WASMUTH, JJ			MUTATIONS IN THE TRANSMEMBRANE DOMAIN OF FGFR3 CAUSE THE MOST COMMON GENETIC FORM OF DWARFISM, ACHONDROPLASIA	CELL			English	Article							GROWTH-FACTOR RECEPTOR; GRADIENT GEL-ELECTROPHORESIS; SINGLE-BASE CHANGES; HOMOZYGOUS ACHONDROPLASIA; IMMUNOGLOBULIN DOMAIN; HUNTINGTONS-DISEASE; EXPRESSION PATTERN; HUMAN CHROMOSOME-4; DNA; FAMILY	Achondroplasia (ACH) is the most common genetic form of dwarfism. This disorder is inherited as an autosomal dominant trait, although the majority of cases are sporadic. A gene for ACH was recently localized to 4p16.3 by linkage analyses. The ACH candidate region includes the gene encoding fibroblast growth factor receptor 3 (FGFR3), which was originally considered as a candidate for the Huntington's disease gene. DNA studies revealed point mutations in the FGFR3 gene in ACH heterozygotes and homozygotes. The mutation on 15 of the 16 ACH-affected chromosomes was the same, a G-->A transition, at nucleotide 1138 of the cDNA. The mutation on the only ACH-affected chromosome 4 without the G-->A transition at nucleotide 1138 had a G-->C transversion at this same position. Both mutations result in the substitution of an arginine residue for a glycine at position 380 of the mature protein, which is in the transmembrane domain of FGFR3.	UNIV CALIF IRVINE, COLL MED, DEPT PEDIAT, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, HUMAN GENOME RES CTR, IRVINE, CA 92717 USA	University of California System; University of California Irvine	SHIANG, R (corresponding author), UNIV CALIF IRVINE, COLL MED, DEPT BIOL CHEM, IRVINE, CA 92717 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025631] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00834] Funding Source: Medline; NINDS NIH HHS [NS25631] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAXENDALE S, 1993, NAT GENET, V4, P181, DOI 10.1038/ng0693-181; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; EISEMANN A, 1991, ONCOGENE, V6, P1195; FRANCOMANO CA, 1994, HUM MOL GENET, V3, P787, DOI 10.1093/hmg/3.5.787; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; Gorlin RJ, 1990, PLAST RECONSTR SURG; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HECHT JT, 1987, AM J HUM GENET, V41, P454; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEMERRER M, 1994, NAT GENET, V6, P318; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; MACDONALD ME, 1991, SOMAT CELL MOLEC GEN, V17, P421, DOI 10.1007/BF01233067; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PAULI RM, 1983, AM J MED GENET, V16, P459, DOI 10.1002/ajmg.1320160404; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; STANESCU R, 1990, AM J MED GENET, V37, P412, DOI 10.1002/ajmg.1320370323; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELINOV M, 1994, NAT GENET, V6, P314, DOI 10.1038/ng0394-314; WEBER B, 1991, NUCLEIC ACIDS RES, V19, P6263, DOI 10.1093/nar/19.22.6263; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; ZUO JA, 1993, HUM MOL GENET, V2, P889, DOI 10.1093/hmg/2.7.889	39	964	1039	4	85	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					335	342		10.1016/0092-8674(94)90302-6	http://dx.doi.org/10.1016/0092-8674(94)90302-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	7913883				2022-12-28	WOS:A1994NZ24200016
J	LAYTON, AM; IBBOTSON, SH; DAVIES, JA; GOODFIELD, MJD				LAYTON, AM; IBBOTSON, SH; DAVIES, JA; GOODFIELD, MJD			RANDOMIZED TRIAL OF ORAL ASPIRIN FOR CHRONIC VENOUS LEG ULCERS	LANCET			English	Note								The effect of oral aspirin on the healing rate of chronic venous leg ulcers was compared with that of placebo in a double-blind randomised trial. 20 subjects with chronic venous leg ulcers were randomised to daily enteric-coated aspirin 300 mg or placebo, and standardised compression bandaging. 4 months of treatment achieved ulcer healing in 38% of the patients receiving aspirin compared with 0% of those receiving placebo (p<0.007). 52% of the aspirin-treated group showed significant reduction in ulcer size compared with 26% of placebo recipients (p<0.007). Reduction in ulcer surface area was significantly better in the aspirin-treated group at 2 (p<0.01) and 4 months (p<0.002) compared with that in the placebo group.	GEN INFIRM,ACAD UNIT DERMATOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; GEN INFIRM,ACAD UNIT MED,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; Leeds General Infirmary; University of Leeds			Ibbotson, Sally H/H-7061-2019	Ibbotson, Sally H/0000-0001-5685-752X; Layton, Alison/0000-0003-0473-3319				ALINOVI A, 1986, J AM ACAD DERMATOL, V15, P186, DOI 10.1016/S0190-9622(86)70154-0; COLGAN MP, 1990, BRIT MED J, V300, P972, DOI 10.1136/bmj.300.6730.972; ERIKSSON G, 1984, ENV HEALING ROLE OCC, P45; GOODFIELD MJD, 1986, BRIT J DERMATOL, V115, P521, DOI 10.1111/j.1365-2133.1986.tb05761.x; HIGGINS EJ, 1989, BRIT J DERMATOL, V120, P322; SHRAIBMAN JG, 1987, PHLEBOLOGY, V2, P265; SKENE AI, 1992, BRIT MED J, V305, P1119, DOI 10.1136/bmj.305.6862.1119	7	75	76	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					164	165		10.1016/S0140-6736(94)92759-6	http://dx.doi.org/10.1016/S0140-6736(94)92759-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912767				2022-12-28	WOS:A1994NW81000011
J	ROSEN, SD; PAULESU, E; FRITH, CD; FRACKOWIAK, RSJ; DAVIES, GJ; JONES, T; CAMICI, PG				ROSEN, SD; PAULESU, E; FRITH, CD; FRACKOWIAK, RSJ; DAVIES, GJ; JONES, T; CAMICI, PG			CENTRAL NERVOUS PATHWAYS MEDIATING ANGINA-PECTORIS	LANCET			English	Article							CORTEX; BRAIN; PAIN; LOCALIZATION; RAT	The central nervous pathways of angina pectoris have never been identified in vivo in man. We used positron emission tomography to examine the changes in regional cerebral blood flow associated with angina pectoris. Dynamic positron emission tomography with O-15-labelled water was used in 12 patients with angina and angiographically proven coronary artery disease to measure regional cerebral blood flow changes during angina induced by intravenous dobutamine. All subjects had typical retrosternal chest pain accompanied by ischaemic electrocardiographic changes during dobutamine infusion. Compared to the resting state, angina was associated with increased regional cerebral blood flow in the hypothalamus (percentage change in regional cerebral blood now +6.5 and Z score 7.2) periaquaductal grey (+2.6 and 4.0), bilaterally in the thalamus (left: +2.7 and 4.3; right + 3.7 and 4.7) and lateral prefrontal cortex (left +11.5 and 7.6; right +8.5 and 7.8) and left inferior anterocaudal cingulate cortex (+9.4 and 6.6). In contrast, it was reduced bilaterally in the mid-rostrocaudal cingulate cortex (left -3.7 and 6.3; right -4.7 and 4.6) and fusiform gyrus (left -3.2 and 4.0; right -3.3 and 3.7), right posterior cingulate (-3.9 and 5.8) and left parietal cortices(-4.8 and 6.3). Several minutes after stopping dobutamine infusion, when the patients no longer experienced angina and the electrocardiographic changes had resolved, thalamic, but not cortical activation could be seen. We propose that the central structures activated constitute the pathways for perception of anginal pain and that the thalamus may act as a gate to afferent pain signals, with cortical activation being necessary for the sensation of pain. This method of investigation may form a basis for research into anomalies of visceral pain perception such as silent myocardial ischaemia.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND	Imperial College London	ROSEN, SD (corresponding author), MRC,CTR CLIN SCI,CYCLOTRON UNIT,LONDON W12 0HS,ENGLAND.		Frackowiak, Richard/H-4383-2011; Frith, Chris D/A-2171-2009; Rosen, Stuart/AAE-4649-2020; Camici, Paolo/AAN-1959-2020; Frackowiak, Richard S/I-1809-2013; PAULESU, ERALDO/C-2737-2017	Frackowiak, Richard/0000-0002-3151-822X; Frith, Chris D/0000-0002-8665-0690; Camici, Paolo/0000-0001-5584-0750; PAULESU, ERALDO/0000-0002-9224-754X				[Anonymous], 1993, NEUROBIOLOGY CINGULA; AVERSANO T, 1993, PAIN, V32, P93; CAMICI P, 1986, CIRCULATION, V74, P81, DOI 10.1161/01.CIR.74.1.81; FRANCOISFRANCK CA, 1899, B ACAD MED, V41, P565; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; GABRIEL M, 1991, EXP BRAIN RES, V86, P585; Heberden W., 1786, MED T COLL PHYSICIAN, V2, P59; Hill J A, 1986, Cardiol Clin, V4, P621; HURLEY KM, 1991, J COMP NEUROL, V308, P249, DOI 10.1002/cne.903080210; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; Keefer CS, 1928, ARCH INTERN MED, V41, P769, DOI 10.1001/archinte.1928.00130180002001; MALLIANI A, 1989, TXB PAIN, P128; MALLIANI A, 1987, SILENT ISCHEMIA CURR, P19; MELLER ST, 1992, NEUROSCIENCE, V48, P501, DOI 10.1016/0306-4522(92)90398-L; MORECRAFT RJ, 1992, J COMP NEUROL, V323, P341, DOI 10.1002/cne.903230304; OPIE LH, 1991, DRUGS HEART, P14; Raichle M. E., 1987, HDB PHYSL NERVOUS SY, V1, P643; SPINKS TJ, 1992, PHYS MED BIOL, V37, P1637, DOI 10.1088/0031-9155/37/8/002; TAKAO Y, 1992, EUR J PHARMACOL, V215, P245, DOI 10.1016/0014-2999(92)90034-2; Talairach I., 1988, COPLANAR STEREOTACTI; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; TERREBERRY RR, 1983, BRAIN RES, V278, P245, DOI 10.1016/0006-8993(83)90246-9; WHITE JC, 1957, CIRCULATION, V16, P644, DOI 10.1161/01.CIR.16.4.644	25	194	201	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					147	150		10.1016/S0140-6736(94)92755-3	http://dx.doi.org/10.1016/S0140-6736(94)92755-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912763				2022-12-28	WOS:A1994NW81000007
J	NIJHOUT, HF				NIJHOUT, HF			GENES ON THE WING	SCIENCE			English	Editorial Material							PATTERN-FORMATION				NIJHOUT, HF (corresponding author), DUKE UNIV,DEPT ZOOL,DURHAM,NC 27708, USA.							CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; COUSO JP, 1994, DEVELOPMENT, V120, P621; DOHRMANN C E, 1988, Journal of Research on the Lepidoptera, V27, P151; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; Lawrence P., 1992, MAKING FLY GENETICS; Nijhout H.F., 1991, DEV EVOLUTION BUTTER; NIJHOUT HF, 1980, DEV BIOL, V80, P267, DOI 10.1016/0012-1606(80)90403-0; NIJHOUT HF, 1990, PROC R SOC SER B-BIO, V239, P81, DOI 10.1098/rspb.1990.0009; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1993, BIOESSAYS, V15, P567, DOI 10.1002/bies.950150902	10	25	27	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					44	45		10.1126/science.7912450	http://dx.doi.org/10.1126/science.7912450			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	7912450				2022-12-28	WOS:A1994NV30100022
J	CLARK, DA				CLARK, DA			DOES IMMUNOLOGICAL INTERCOURSE PREVENT PREECLAMPSIA	LANCET			English	Editorial Material							PREGNANCY; CELLS; PREECLAMPSIA; TROPHOBLAST; GROWTH				CLARK, DA (corresponding author), MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA.							BURROWS TD, 1993, HUM REPROD, V8, P475, DOI 10.1093/oxfordjournals.humrep.a138075; CASPI E, 1994, AM J REPROD IMMUNOL, V31, P19, DOI 10.1111/j.1600-0897.1994.tb00842.x; CLARK DA, IN PRESS HUM REPROD; FEENEY JG, 1977, LANCET, V1, P874; HEYBORNE KD, 1992, J IMMUNOL, V149, P2872; KAJINO T, 1988, AM J REPROD IMMUNOL, V17, P91; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; KLONOFFCOHEN HS, 1989, JAMA-J AM MED ASSOC, V262, P3143, DOI 10.1001/jama.262.22.3143; LABARRERE C, 1985, AM J REPROD IM MIC, V7, P149; LICHTIG C, 1985, AM J CLIN PATHOL, V83, P633, DOI 10.1093/ajcp/83.5.633; MARTI JJ, 1977, AM J OBSTET GYNECOL, V128, P489, DOI 10.1016/0002-9378(77)90030-8; MASAKI T, 1991, SEMIN PERINATOL, V15, P27; NAGARKATTI PS, 1983, J IMMUNOL, V131, P638; ROBERTS JM, 1991, SEMIN PERINATOL, V15, P86; SAITO S, 1993, INT IMMUNOL, V5, P559, DOI 10.1093/intimm/5.5.559; SMARASON AK, 1993, BRIT J OBSTET GYNAEC, V100, P943, DOI 10.1111/j.1471-0528.1993.tb15114.x; STRICKLAND DM, 1986, AM J OBSTET GYNECOL, V154, P146, DOI 10.1016/0002-9378(86)90412-6; WOOD ML, 1988, TRANSPLANT P, V20, P1200; 1994, LANCET, V344, P973	19	26	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					969	970		10.1016/S0140-6736(94)91634-9	http://dx.doi.org/10.1016/S0140-6736(94)91634-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934423				2022-12-28	WOS:A1994PK97800002
J	CIECHANOVER, A				CIECHANOVER, A			THE UBIQUITIN-PROTEASOME PROTEOLYTIC PATHWAY	CELL			English	Review							N-END RULE; MOLECULAR-WEIGHT PROTEASES; CONJUGATING ENZYMES; TRANSCRIPTIONAL REGULATOR; TERMINAL HYDROLASE; ACTIVATING ENZYME; E6 ONCOPROTEIN; GENE ENCODES; PROTEIN; DEGRADATION		TECHNION ISRAEL INST TECHNOL,FAC MED,RAPPAPORT FAMILY INST RES MED SCI,IL-31096 HAIFA,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	CIECHANOVER, A (corresponding author), TECHNION ISRAEL INST TECHNOL,FAC MED,DEPT BIOCHEM,IL-31096 HAIFA,ISRAEL.		Ciechanover, Aaron J/C-9166-2017					BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DICK LR, 1994, J IMMUNOL, V152, P3884; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; EYTAN E, 1993, J BIOL CHEM, V268, P4668; GASZYNSKA M, 1993, NATURE, V365, P264; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIROD PA, 1993, J BIOL CHEM, V268, P955; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HERSHKO A, 1991, J BIOL CHEM, V266, P376; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOU D, 1994, J BIOL CHEM, V269, P14244; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LENK SE, 1992, J CELL BIOL, V118, P301, DOI 10.1083/jcb.118.2.301; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MADLURA K, 1994, SCIENCE, V265, P1454; MADURA K, 1993, J BIOL CHEM, V268, P12046; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; YEWDELL J, 1994, J IMMUNOL, V152, P1163	61	1571	1667	4	128	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					13	21		10.1016/0092-8674(94)90396-4	http://dx.doi.org/10.1016/0092-8674(94)90396-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923371				2022-12-28	WOS:A1994PK58500004
J	CROSS, CE; VANDERVLIET, A; ONEILL, CA; EISERICH, JP				CROSS, CE; VANDERVLIET, A; ONEILL, CA; EISERICH, JP			REACTIVE OXYGEN SPECIES AND THE LUNG	LANCET			English	Article							OXIDATIVE STRESS; RESPIRATORY-TRACT; INJURY; ACID; CELL; GLUTATHIONE; RECEPTORS; TOXICITY; DISEASE		UNIV CALIF DAVIS,DEPT INTERNAL MED,DAVIS,CA; UNIV CALIF DAVIS,DEPT HUMAN PHYSIOL,DAVIS,CA	University of California System; University of California Davis; University of California System; University of California Davis	CROSS, CE (corresponding author), UNIV CALIF DAVIS,DIV PULM CRIT CARE,PROFESS BLDG,4301 X ST,ROOM 2120,SACRAMENTO,CA 95817, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047628, T32HL007013] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07013, HL47628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER KB, 1990, J CLIN INVEST, V85, P75, DOI 10.1172/JCI114436; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; BALLA G, 1992, J BIOL CHEM, V267, P18148; BARNARD ML, 1993, AM J PHYSIOL, V265, pL340, DOI 10.1152/ajplung.1993.265.4.L340; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; BRITIGAN BE, 1991, J CLIN INVEST, V88, P1092, DOI 10.1172/JCI115408; BROWN LAS, 1994, AM J PHYSIOL, V266, pL172, DOI 10.1152/ajplung.1994.266.2.L172; BUCCA C, 1989, RESPIRATION, V55, P214, DOI 10.1159/000195737; BUHL R, 1994, CHEM-BIOL INTERACT, V91, P147, DOI 10.1016/0009-2797(94)90035-3; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; CLERCH LB, 1994, J CLIN INVEST, V93, P2482, DOI 10.1172/JCI117257; CROSS CE, IN PRESS ENV HLTH PE; CRYSTAL RG, 1991, AM J MED, V91, pS39, DOI 10.1016/0002-9343(91)90282-3; GARNIER P, 1994, AM J RESP CRIT CARE, V149, pA148; GHIO AJ, 1994, AM J PHYSIOL, V266, pL382, DOI 10.1152/ajplung.1994.266.4.L382; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HOLROYD KJ, 1993, THORAX, V48, P985, DOI 10.1136/thx.48.10.985; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KOOY NW, 1994, AM J RESP CRIT CARE, V149, pA814; LEWISMOLOCK Y, 1994, AM J RESP CELL MOL, V10, P133, DOI 10.1165/ajrcmb.10.2.8110468; MERCER RR, 1994, AM J RESP CELL MOL, V10, P613, DOI 10.1165/ajrcmb.10.6.8003339; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; MUNDAY R, 1989, FREE RADICAL BIO MED, V7, P659, DOI 10.1016/0891-5849(89)90147-0; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; ORRENIUS S, 1992, ANN NEUROL, V32, pS33, DOI 10.1002/ana.410320708; PEDEN DB, 1993, AM REV RESPIR DIS, V148, P455, DOI 10.1164/ajrccm/148.2.455; PRICE LT, 1993, PEDIATR RES, V34, P577, DOI 10.1203/00006450-199311000-00005; PRITCHARD RJ, 1994, AM J RESP CRIT CARE, V149, pA840; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHWARTZ J, 1994, AM J CLIN NUTR, V59, P110, DOI 10.1093/ajcn/59.1.110; SHI M, 1994, AM J RESPIR CRIT CAR, V149, pA569; SMITH LJ, 1993, AM REV RESPIR DIS, V147, P1461, DOI 10.1164/ajrccm/147.6_Pt_1.1461; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; VANDERVLIET A, 1992, CHEM-BIOL INTERACT, V85, P95, DOI 10.1016/0009-2797(92)90055-P; YOO JH, 1994, J CLIN INVEST, V93, P297, DOI 10.1172/JCI116959	38	102	105	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					930	933		10.1016/S0140-6736(94)92275-6	http://dx.doi.org/10.1016/S0140-6736(94)92275-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934352				2022-12-28	WOS:A1994PJ28700016
J	ROOKUS, MA; VANLEEUWEN, FE				ROOKUS, MA; VANLEEUWEN, FE			ORAL-CONTRACEPTIVES AND RISK OF BREAST-CANCER IN WOMEN AGED 20-54 YEARS	LANCET			English	Article							YOUNG-WOMEN; METAANALYSIS	Although the use of oral contraceptives (OCs) is not generally associated with increased risk of breast cancer, higher risks have been reported for some subgroups of users. We have carried out a population-based case-control study in the Netherlands to assess the effect of timing and duration of OC use on the risk of breast cancer developing at various ages. 918 women with breast cancer (20-54 years at diagnosis) were pair-matched by age with controls randomly selected from municipal registries. Information on OC use obtained from women and their prescribers was combined according to standard decision rules. Overall, long-term use of OCs (greater than or equal to 12 years) had an associated relative risk (RR) of 1.3 (95% CI 0.9-1.9; test for trend in risk with months of use p = 0.03). This positive trend was found in both the youngest (<36 years; p = 0.08) and the oldest (46-54 years, p = 0.004) age groups, but not in women aged 36-45 years. The RR of developing breast cancer before age 36 was 2.1 (1.0-4.5) for 4 or more years of OC use compared with shorter use. In women younger than 36, risk increased for longer OC use before age 20 (1.44 per year, p = 0.04). Recent use (previous 3 years) was associated with increased risk in women of 46-54 (RR 1.9 [0.9-4.1], p = 0.02). We conclude that 4 or more years of OC use, especially if partly before age 20, is associated with an increased risk of breast cancer developing at an early age. There is limited evidence that the excess risk disappears as the cohort of young OC users ages, but this issue needs confirmation.	NETHERLANDS CANC INST,DEPT EPIDEMIOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute								BERNSTEIN L, 1990, ORAL CONTRACEPTIVES, P169; BRESLOW NE, 1980, STATISTICAL METHODS; DELGADORODRIGUEZ M, 1991, REV EPIDEMIOL SANTE, V39, P165; EWERTZ M, 1992, EUR J CANCER, V28A, P1176, DOI 10.1016/0959-8049(92)90481-G; KOLS A, 1982, POPULATION REP, V10, pA189; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; MCPHERSON K, 1986, J EPIDEMIOL COMMUN H, V40, P289, DOI 10.1136/jech.40.4.289; MCPHERSON K, 1987, BRIT J CANCER, V56, P653, DOI 10.1038/bjc.1987.261; MEIRIK O, 1986, LANCET, V2, P650; NISCHAN P, 1993, AM J EPIDEMIOL, V138, P697, DOI 10.1093/oxfordjournals.aje.a116907; PAUL C, 1990, INT J CANCER, V46, P366, DOI 10.1002/ijc.2910460305; PIKE MC, 1981, BRIT J CANCER, V43, P72, DOI 10.1038/bjc.1981.10; PIKE MC, 1983, LANCET, V2, P926; ROMIEU I, 1990, CANCER-AM CANCER SOC, V66, P2253, DOI 10.1002/1097-0142(19901201)66:11<2253::AID-CNCR2820661102>3.0.CO;2-G; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; RUSHTON L, 1992, BRIT J OBSTET GYNAEC, V99, P239, DOI 10.1111/j.1471-0528.1992.tb14506.x; SKEGG DCG, 1988, AM J EPIDEMIOL, V127, P205, DOI 10.1093/oxfordjournals.aje.a114796; STADEL BV, 1986, AM J EPIDEMIOL, V123, P373, DOI 10.1093/oxfordjournals.aje.a114252; THOMAS DB, 1991, CONTRACEPTION, V43, P597, DOI 10.1016/0010-7824(91)90006-2; THOMAS DB, 1992, BRIT J CANCER, V65, P108, DOI 10.1038/bjc.1992.20; THOMAS DB, 1991, CANCER CAUSE CONTROL, V2, P309; VANDERVANGE N, 1987, CONTEMP OBSTET GYNEC, P315; VANLEEUWEN FE, 1992, CONTRACEPTION, V45, P399, DOI 10.1016/0010-7824(92)90154-L; VESSEY MP, 1989, BRIT J CANCER, V59, P613, DOI 10.1038/bjc.1989.124; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P121; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; WINGO PA, 1990, ORAL CONTRACEPTIVES, P67; 1989, LANCET, V1, P973; 1987, TNM CLASSIFICATION M	29	91	92	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					844	851		10.1016/S0140-6736(94)92826-6	http://dx.doi.org/10.1016/S0140-6736(94)92826-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916400				2022-12-28	WOS:A1994PH25300010
J	VANNIEKERK, ABW; VRIES, JB; BAARD, J; SCHOUB, BD; CHEZZI, C; BLACKBURN, NK				VANNIEKERK, ABW; VRIES, JB; BAARD, J; SCHOUB, BD; CHEZZI, C; BLACKBURN, NK			OUTBREAK OF PARALYTIC POLIOMYELITIS IN NAMIBIA	LANCET			English	Article							SOUTH-AFRICA; VACCINE; POLIOVIRUSES	The last confirmed case of poliomyelitis in Namibia had been reported in 1988. However, between Nov 8, 1993, and Jan 7, 1994, 27 cases of paralytic poliomyelitis were confirmed in the country. The outbreak was limited to the south health region; at least 80% of infants in this region have received four doses of oral poliovaccine (OPV) by the age of 1 year. Acute flaccid paralysis (AFP) was the predominant clinical presentation during the outbreak. The patients' ages ranged from 13 months to 12 years; 24 were younger than 5 years. Of the 26 patients whose vaccine status was known, 14 had received four doses of OPV, 6 had one or two doses, and 6 no vaccine. Genotypic analysis showed 86% homology of outbreak isolates with a 1982 Namibian isolate and west African isolates. Factors that may have had a role in the outbreak include establishment of a pool of susceptible people, rapid urbanisation, inadequate sanitation, poor water supply, and possible endemicity of poliovirus in neighbouring areas. Epidemics can occur in areas of high vaccine coverage. Our findings emphasise the need to improve AFP surveillance activities and the estimation of vaccine coverage to identify areas of potential susceptibility for outbreaks.	KATATURA HOSP,DEPT PAEDIAT,WINDHOEK,NAMIBIA; NAMIBIAN MINIST HLTH & SOCIAL SERV,WINDHOEK,NAMIBIA		VANNIEKERK, ABW (corresponding author), NATL INST VIROL,PRIVATE BAG X4,JOHANNESBURG 2131,SOUTH AFRICA.							HESSE RR, 1987, VIROLOGY, V160, P311; JOHNSON S, 1984, T ROY SOC TROP MED H, V78, P26, DOI 10.1016/0035-9203(84)90166-4; KIMFARLEY RJ, 1984, LANCET, V2, P1322; NOTTAY BK, 1981, VIROLOGY, V108, P405, DOI 10.1016/0042-6822(81)90448-7; OTTEN MW, 1992, AM J EPIDEMIOL, V135, P381, DOI 10.1093/oxfordjournals.aje.a116299; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; SCHOUB BD, 1992, T ROY SOC TROP MED H, V86, P83, DOI 10.1016/0035-9203(92)90453-J; SCHOUB BD, 1988, J INFECT DIS, V157, P836, DOI 10.1093/infdis/157.4.836; SLATER PE, 1990, LANCET, V335, P1192, DOI 10.1016/0140-6736(90)92705-M; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; YANG CF, 1991, VIRUS RES, V20, P159; 1991, EPI NEWSLETTER, V13, P5; 1992, WEEKLY EPIDEMIOL REC, V67, P113; 1993, WEEKLY EPIDEMIOL REC, V68, P225; 1992, WEEKLY EPIDEMIOL REC, V67, P325; 1989, MANUAL MANAGERS IMMU; 1991, WEEKLY EPIDEMIOL REC, V66, P49; 1988, WEEKLY EPIDEMIOL REC, V63, P161	18	34	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					661	664		10.1016/S0140-6736(94)92090-7	http://dx.doi.org/10.1016/S0140-6736(94)92090-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915353				2022-12-28	WOS:A1994PE38600015
J	MOYA, C; ANTO, JM; TAYLOR, AJN; COSTA, A; FENOLLAR, J; MAYORDOMO, C; DOMENECH, E; MITJANS, L; VANACLOCHA, H; MARTI, JV; SALAS, D; SANTOLARIA, E; VILLANUEVA, V; GOBERNA, R; MORELL, F; PARKER, JB; POZO, F; SUNYER, J; GIL, J; HERNANDEZ, L; MARTIN, C; ROMERO, S; ARANDA, I; ANDREO, L; SOLE, A; VILAR, JL; CORRIN, B				MOYA, C; ANTO, JM; TAYLOR, AJN; COSTA, A; FENOLLAR, J; MAYORDOMO, C; DOMENECH, E; MITJANS, L; VANACLOCHA, H; MARTI, JV; SALAS, D; SANTOLARIA, E; VILLANUEVA, V; GOBERNA, R; MORELL, F; PARKER, JB; POZO, F; SUNYER, J; GIL, J; HERNANDEZ, L; MARTIN, C; ROMERO, S; ARANDA, I; ANDREO, L; SOLE, A; VILAR, JL; CORRIN, B			OUTBREAK OF ORGANIZING PNEUMONIA IN TEXTILE PRINTING SPRAYERS	LANCET			English	Article							ORGANIZING PNEUMONIA	Eight textile printing factories in Valencia, Spain, with a total workforce of 257 using spraying techniques were investigated as a result of severe interstitial lung disease occurring in three employees, one of whom died. Clinical and radiological data together with biopsy from 71 (27.6%) workers with abnormal respiratory features indicated the occurrence of an outbreak of organising pneumonia resulting in 6 deaths. Epidemiological analysis included the 22 workers who fulfilled the radiological case definition based on chest radiograph and computed tomographic scan showing widespread nodular opacities or confluent patchy consolidation with a lung biopsy corresponding to organising pneumonia. The overall attach rate was 8.9%. Only 2 of the 22 cases never worked in factories A or B. Those who had only worked in factory A had the highest risk of being a case (RR = 24.3; 95% CI = 5.7 - 104.4). The relationship of case status to period of employment suggested an abrupt change in exposure conditions in the period when Acramin FWR was substituted by Acramin FWN. Although the precise toxicological mechanism is unknown, it is proposed that the lung disease was caused by spraying procedures delivered a respirable aerosol of Acramin FWN to distal airways and pulmonary parenchyma.	UNIV AUTONOMA BARCELONA,INST MUNICIPAL INVEST MED,DEPT EPIDEMIOL & PUBL HLTH,E-08003 BARCELONA,SPAIN; NATL HEART & LUNG INST,DEPT OCCUPAT & ENVIRONM MED,LONDON,ENGLAND; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,AREA SALUD ALCOI,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,SERV EPIDEMIOL,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,SERV PROGRAMMAS ESPECIALES,UNIDAD SALUD LABORAL,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,DIRECCIO GEN SALUT PUBL,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,SERV SEGURIDAD & HIGIENE,VALENCIA,SPAIN; HOSP GEN VALLE HEBRON,SERV PNEUMOL,BARCELONA,SPAIN; NIOSH,DIV RESP DIS STUDIES,CINCINNATI,OH; MINIST SANIDAD & CONSUMO,DIRECC GEN ORDENAC INVEST & FORMAC,MADRID,SPAIN; HOSP GEN ALICANTE,SECC NEUMOL,ALACANT,SPAIN; HOSP GEN ALICANTE,SERV ANAT PATOL,ALACANT,SPAIN; HOSP GEN ALICANTE,SERV IMMUNOL,ALACANT,SPAIN; HOSP VIRGEN LIRIOS,MED INTERNA SERV,ALACANT,SPAIN; HOSP VIRGEN LIRIOS,SERV RADIOL,ALACANT,SPAIN; HOSP LA FE,SERV NEUMOL,E-46009 VALENCIA,SPAIN; HOSP DR PESET,SERV RADIOL,VALENCIA,SPAIN; ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT LUNG PATHOL,LONDON SW3 6NP,ENGLAND	Autonomous University of Barcelona; Imperial College London; Hospital Universitari Vall d'Hebron; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); General University Hospital of Alicante; General University Hospital of Alicante; General University Hospital of Alicante; Hospital Universitari i Politecnic La Fe; Imperial College London			Sunyer, Jordi/G-6909-2014; Aranda, F. Ignacio/H-5029-2011; ARANDA, FRANCISCO I/L-5525-2015; Anto, J M/H-2676-2014	Sunyer, Jordi/0000-0002-2602-4110; Aranda, F. Ignacio/0000-0003-2338-2286; ARANDA, FRANCISCO I/0000-0003-2338-2286; Anto, J M/0000-0002-4736-8529				BRESLOW N, 1980, INT AGENCY RES CANCE, V32, P299; DAVISON AG, 1983, Q J MED, V52, P382; EPLER GR, 1992, CHEST, V102, pS2, DOI 10.1378/chest.102.1_Supplement.2S; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; KHAN H, 1989, STATISTICAL METHODS; SANZ P, 1993, LANCET, V342, P240, DOI 10.1016/0140-6736(93)92330-V; SPITERI MA, 1992, LANCET, V340, P281, DOI 10.1016/0140-6736(92)92366-N; 1992, MMWR-MORBID MORTAL W, V41, P965; 1993, MMWR-MORBID MORTAL W, V42, P885	9	53	54	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					498	502		10.1016/S0140-6736(94)91896-1	http://dx.doi.org/10.1016/S0140-6736(94)91896-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914612				2022-12-28	WOS:A1994PC53500007
J	SNOW, R; HAJRI, S; MASSAI, R; LI, XF				SNOW, R; HAJRI, S; MASSAI, R; LI, XF			CONCERNED ABOUT REPRODUCTIVE HEALTH - STRENGTHEN THE HRP	LANCET			English	Editorial Material									CTR RECH REPROD HUMAINE,TUNIS 2080,TUNISIA; INST CHILENO MED REPROD,SANTIAGO,CHILE; FAMILY PLANNING RES INST ZHEJIANG,HANGZHOU,PEOPLES R CHINA		SNOW, R (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT POPULAT & INT HLTH,BOSTON,MA 02115, USA.							Alexander N, 1992, STEROID HORMONES UTE; ELIAS CJ, 1993, 6 POP COUNC PROGR DI; Germaine A, 1994, POPULATION POLICIES, P27; MAULDIN WP, 1988, STUD FAMILY PLANN, V19, P335, DOI 10.2307/1966628; RICHTER J, 1994, POWER DECISION SOCIA, P205; Sen Gita, 1994, POPULATION POLICIES; TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856; 1994, 3 INT C POP DEV PREP	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					459	460		10.1016/S0140-6736(94)91777-9	http://dx.doi.org/10.1016/S0140-6736(94)91777-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB761	7914571				2022-12-28	WOS:A1994PB76100017
J	TRIOZZI, PL				TRIOZZI, PL			AUTOLOGOUS BONE-MARROW AND PERIPHERAL-BLOOD PROGENITOR TRANSPLANT FOR BREAST-CANCER	LANCET			English	Editorial Material							HIGH-DOSE CHEMOTHERAPY; SUPPORT; THERAPY				TRIOZZI, PL (corresponding author), OHIO STATE UNIV,CTR COMPREHENS CANC,COLUMBUS,OH 43210, USA.							ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; COIFFIER B, 1994, J CLIN ONCOL, V12, P226, DOI 10.1200/JCO.1994.12.1.226; DAVIDSON NE, 1992, J CLIN ONCOL, V10, P517, DOI 10.1200/JCO.1992.10.4.517; ECKHOLM E, 1993, NY TIMES        1230, pA12; ECKHOLM E, 1993, NEW YORK TIMES  0920, pA1; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; HRYNIUK WM, 1987, SEMIN ONCOL, V14, P65; NEIDHART JA, 1991, BREAST CANCER RES TR, V20, pS15, DOI 10.1007/BF01908240; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; 1993, AUTOLOGOUS BONE MARR; 1992, LANCET, V339, P71	13	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					418	419		10.1016/S0140-6736(94)91762-0	http://dx.doi.org/10.1016/S0140-6736(94)91762-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914559				2022-12-28	WOS:A1994PB76100002
J	JANKOVIC, M; BROUWERS, P; VALSECCHI, MG; VANVELDHUIZEN, A; HUISMAN, J; KAMPHUIS, R; KINGMA, A; MOR, W; VANDONGENMELMAN, J; FERRONATO, L; MANCINI, MA; SPINETTA, JJ; MASERA, G				JANKOVIC, M; BROUWERS, P; VALSECCHI, MG; VANVELDHUIZEN, A; HUISMAN, J; KAMPHUIS, R; KINGMA, A; MOR, W; VANDONGENMELMAN, J; FERRONATO, L; MANCINI, MA; SPINETTA, JJ; MASERA, G			ASSOCIATION OF 1800 CGY CRANIAL IRRADIATION WITH INTELLECTUAL FUNCTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							LONG-TERM SURVIVORS; CENTRAL NERVOUS-SYSTEM; ACUTE LYMPHOCYTIC-LEUKEMIA; CHILDHOOD LEUKEMIA; COGNITIVE FUNCTION; RADIATION; SEQUELAE; NEUROTOXICITY; METHOTREXATE; PROPHYLAXIS	Cranial radiation therapy in childhood acute lymphoblastic leukaemia has been associated with adverse neuropsychological effects, such as low intelligence. However, records show that these associations usually occur when the dose of radiation used is 2400 cGy. We investigated whether a lower dose of 1800 cGy had the same adverse effects on long-term survivors and whether high doses of methotrexate but no radiation therapy would have a more beneficial effect. We evaluated 203 children for six years in a multi-centre European study. The patients were divided into two groups: 129 children treated with 1800 cGy of cranial radiation therapy and 74 children who received high-dose methotrexate but no radiation therapy. We used full scale intelligence quotient, verbal, and performance IQ tests to assess the patient's intelligence. We found a significant decline in full scale intelligence quotient in the irradiated group that increased with the length of time from diagnosis. Younger age at diagnosis was associated with lower full scale intelligence quotient in the radiated group. Our results indicate that a radiation dose of 1800 cGy can have negative effects on neurocognitive function and we continue to question the benefit of low-dose cranial radiation therapy.	NCI,PEDIAT BRANCH,BETHESDA,MD 20892; UNIV MILAN,INST BIOMETRY & MED STAT,I-20122 MILAN,ITALY; UNIV AMSTERDAM,DEPT PAEDIAT,AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PSYCHOL MED,AMSTERDAM,NETHERLANDS; LEIDEN UNIV,DEPT PAEDIAT,LEIDEN,NETHERLANDS; UNIV GRONINGEN,9700 AB GRONINGEN,NETHERLANDS; ST ANNA CHILDRENS HOSP,VIENNA,AUSTRIA; UNIV ROTTERDAM,DEPT PAEDIAT,ROTTERDAM,NETHERLANDS; UNIV PADUA,I-35100 PADUA,ITALY; UNIV BOLOGNA,I-40126 BOLOGNA,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Milan; University of Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Leiden University; Leiden University - Excl LUMC; University of Groningen; Saint Anna Children's Hospital; Erasmus University Rotterdam; University of Padua; University of Bologna	JANKOVIC, M (corresponding author), UNIV MILAN,S GERARDO HOSP MONZA,DEPT PAEDIAT,VIA DONIZETTI 106,I-20052 MONZA,ITALY.		Valsecchi, Maria Grazia/K-8891-2016	Valsecchi, Maria Grazia/0000-0001-5574-3504				BROUWERS P, 1984, J CLIN NEUROPSYCHOL, V6, P325, DOI 10.1080/01688638408401222; BROUWERS P, 1990, AM J PEDIAT HEMATOL, V12, P174; BROUWERS P, 1992, DEV PEDIAT PSYCHOSOC, P79; BROUWERS P, 1991, HDB CLIN TRIALS NEUR, P45; CHESSELLS JM, 1990, ARCH DIS CHILD, V65, P416, DOI 10.1136/adc.65.4.416; COUSENS P, 1988, J CHILD PSYCHOL PSYC, V29, P839, DOI 10.1111/j.1469-7610.1988.tb00757.x; HALBERG FE, 1992, INT J RADIAT ONCOL, V22, P13, DOI 10.1016/0360-3016(92)90976-O; JANKOVIC M, 1991, NEURO ONCOLOGY, P365; JANNOUN L, 1983, ARCH DIS CHILD, V58, P953, DOI 10.1136/adc.58.12.953; JANNOUN L, 1978, AM J PEDIAT HEMATOL, V4, P293; MEADOWS AT, 1984, P AN M AM SOC CLIN, V3, P71; MOORE IMK, 1991, CANCER, V68, P1913; MOSS HA, 1981, AM J MED, V71, P47, DOI 10.1016/0002-9343(81)90257-6; MULHERN RK, 1988, J CLIN ONCOL, V6, P315, DOI 10.1200/JCO.1988.6.2.315; MULHERN RK, 1992, J CONSULT CLIN PSYCH, V60, P477; MULHERN RK, 1991, J CLIN ONCOL, V9, P1348, DOI 10.1200/JCO.1991.9.8.1348; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1300; OCHS J, 1991, J CLIN ONCOL, V9, P145, DOI 10.1200/JCO.1991.9.1.145; PFEFFERBAUMLEVINE B, 1984, AM J PEDIAT HEMATOL, V6, P123; POPLACK DG, 1985, CLINICS ONCOL, V4, P263; RICCARDI R, 1985, J CLIN ONCOL, V3, P12, DOI 10.1200/JCO.1985.3.1.12; RIEHM H, 1990, ACUTE LEUKEMIAS, V2, P439; RIMM IJ, 1987, CANCER, V59, P1506, DOI 10.1002/1097-0142(19870415)59:8<1506::AID-CNCR2820590819>3.0.CO;2-P; RUBENSTEIN CL, 1990, J DEV BEHAV PEDIATR, V11, P301; SAID JA, 1989, J CONSULT CLIN PSYCH, V57, P251, DOI 10.1037/0022-006X.57.2.251; TAMAROFF M, 1985, P ASCO, V4, P165; VECCHI V, 1993, CANCER, V72, P2157; Veerman A J, 1990, Haematol Blood Transfus, V33, P473; Williams J M, 1986, Arch Clin Neuropsychol, V1, P183, DOI 10.1016/0887-6177(86)90018-1	29	138	139	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					224	227		10.1016/S0140-6736(94)92997-1	http://dx.doi.org/10.1016/S0140-6736(94)92997-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913156	Green Submitted			2022-12-28	WOS:A1994NY06000009
J	UGURLUOGLU, A; HOFMANN, S; KATZENSCHLAGER, R; EHRINGER, H				UGURLUOGLU, A; HOFMANN, S; KATZENSCHLAGER, R; EHRINGER, H			DETECTION OF SYMPTOMLESS POSTOPERATIVE DEEP-VEIN THROMBOSIS	LANCET			English	Letter							VENOUS THROMBOSIS; DIAGNOSIS; LIMITATIONS; ACCURACY				UGURLUOGLU, A (corresponding author), UNIV VIENNA,DEPT MED ANGIOL,WAEHRINGER GUERTEL 18,A-1090 VIENNA,AUSTRIA.							KRINGS W, 1990, RADIOLOGE, V30, P525; ROSE SC, 1990, RADIOLOGY, V175, P639, DOI 10.1148/radiology.175.3.2188293; YUCEL EK, 1991, RADIOLOGY, V179, P443, DOI 10.1148/radiology.179.2.2014289	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					126	126						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912357				2022-12-28	WOS:A1994NV73200037
J	SIPE, JC; ROMINE, JS; KOZIOL, JA; MCMILLAN, R; ZYROFF, J; BEUTLER, E				SIPE, JC; ROMINE, JS; KOZIOL, JA; MCMILLAN, R; ZYROFF, J; BEUTLER, E			CLADRIBINE IN TREATMENT OF CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS	LANCET			English	Article							STATUS SCALE EDSS; 2-CHLORODEOXYADENOSINE; 2-CHLORO-2'-DEOXYADENOSINE; IMMUNOSUPPRESSION	Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role. The nucleoside drug cladribine is a potent lympholytic agent with few side-effects. We have studied its efficacy and safety in a randomised double-blind trial. 51 patients (48 entered as matched pairs) received four monthly courses of 0.7 mg/kg cladribine or placebo (saline) given through a surgically implanted central line. Neurologists with no knowledge of which medication the patient was receiving examined the patients monthly and noted two rating scale scores (Kurtzke and Scripps). Cerebrospinal fluid and brain magnetic resonance imaging (MRI) examinations were done at 6 and 12 months. Average neurological scores, demyelinated volumes on MRI, and concentrations of oligoclonal bands in cerebrospinal fluid were stable or improved in the patients receiving cladrabine but continued to deteriorate in patients on placebo. Mean paired (placebo minus matched cladribine) differences at 12 months relative to baseline were 1.0 (SE 0.4) for the Kurtzke scores, - 13.9 (2.3) for the Scripps scores, 4.57 (1.17) mL for demyelinated volumes, and 7.3 (3.3) arbitrary units for concentrations of oligoclonal bands. Cladribine was generally well tolerated and clinically significant toxicity occurred in only 1 patient, in whom severe marrow suppression developed with complete recovery after several months. 1 patient died of newly acquired hepatitis B, an event unlikely to be related to cladribine, We conclude that the immunosuppressive drug cladribine influences favourably the course of chronic progressive MS.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED SBR3, LA JOLLA, CA 92037 USA; SCRIPPS CLIN & RES FDN, DIV NEUROL, LA JOLLA, CA USA; Scripps Clinic, DEPT RADIOL, LA JOLLA, CA USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Macedo, Ana/L-9912-2018	Macedo, Ana/0000-0002-6978-8989	NCRR NIH HHS [RR00833] Funding Source: Medline; NINDS NIH HHS [NS30218] Funding Source: Medline; FDA HHS [FD-R-000280] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030218] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FDA HHS; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BEUTLER E, 1994, ACTA HAEMATOL-BASEL, V91, P10; BEUTLER E, 1991, LEUKEMIA LYMPHOMA, V5, P1, DOI 10.3109/10428199109068099; CARSON DA, 1984, P NATL ACAD SCI-BIOL, V81, P2232, DOI 10.1073/pnas.81.7.2232; CARSON DA, 1983, BLOOD, V62, P737; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; GOODKIN DE, 1992, NEUROLOGY, V42, P859, DOI 10.1212/WNL.42.4.859; HAFLER DA, 1988, NEUROLOGY, V38, P42; KOZIOL JA, 1983, STAT MED, V1, P83; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LAU JYN, 1991, LANCET, V337, P802, DOI 10.1016/0140-6736(91)91433-U; LILIEMARK J, 1992, J CLIN ONCOL, V10, P1514, DOI 10.1200/JCO.1992.10.10.1514; LUEG E, 1992, CAN MED ASSOC J, V147, P1155; MORIYAMA T, 1990, SCIENCE, V248, P361, DOI 10.1126/science.1691527; PATY DW, 1993, NEUROLOGY, V43, P622; PIRO LD, 1992, BLOOD, V79, P843; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; SCHIRMER M, 1993, EXP HEMATOL, V21, P1091; SIPE JC, 1984, NEUROLOGY, V34, P1368, DOI 10.1212/WNL.34.10.1368; SNEDECOR GW, 1980, STATISTICAL METHODS, P464; SNEDECOR GW, 1980, STATISTICAL METHODS, P243; TINDALL R, 1988, NEUROLOGY, V38, P53; WEINER HL, 1988, ANN NEUROL, V23, P211, DOI 10.1002/ana.410230302	24	252	259	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					9	13		10.1016/S0140-6736(94)91046-4	http://dx.doi.org/10.1016/S0140-6736(94)91046-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912347				2022-12-28	WOS:A1994NU91700009
J	RUETZ, S; GROS, P				RUETZ, S; GROS, P			PHOSPHATIDYLCHOLINE TRANSLOCASE - A PHYSIOLOGICAL-ROLE FOR THE MDR2 GENE	CELL			English	Article							MULTIDRUG-RESISTANCE GENE; EXCHANGING HOMOLOGOUS DOMAINS; PRODUCT P-GLYCOPROTEIN; PLASMA-MEMBRANE; MONOCLONAL-ANTIBODIES; CANALICULAR MEMBRANE; TRANSMEMBRANE DOMAIN; FUNCTIONAL-ANALYSIS; COMPLEMENTARY-DNA; SENSITIVE METHOD	P-glycoproteins (P-gps) encoded by the mouse mdr2 and mdr3 genes were expressed in secretory vesicles (SVs) from the yeast mutant sec6-4, and their capacity to function as a lipid translocase/flippase was tested. An assay that uses a fluorescent phosphatidylcholine (PC) analog was developed to quantitate asymmetric lipid distribution in the outer and inner leaflets of the lipid bilayer of these vesicles. Mdr2 expression in SVs caused a time- and temperature-dependent enhancement of PC translocation to the inner leaflet of the membrane. The Mdr2-mediated effect was specific since expression of Mdr3 in these vesicles was without effect on the membrane distribution of PC. Increased Mdr2-mediated PC translocation was strictly ATP and Mg2+ dependent, was abrogated by the ATPase inhibitor vanadate and the P-gp modulator verapamil, but was insensitive to the presence of excess of the multidrug resistance drugs colchicine and vinblastine.			RUETZ, S (corresponding author), MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,PQ,CANADA.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BERR F, 1993, J BIOL CHEM, V268, P3976; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLEMAN R, 1987, BIOCHEM J, V244, P249, DOI 10.1042/bj2440249; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Gros P, 1993, Int Rev Cytol, V137C, P169; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1994, CURR BIOL, V4, P259, DOI 10.1016/S0960-9822(00)00059-2; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LEE TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOWRY RR, 1974, LIPIDS, V9, P491, DOI 10.1007/BF02534277; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P1889, DOI 10.1021/bi00406a014; OLSON P, 1979, BIOCHIM BIOPHYS ACTA, V455, P12; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RAYMOND M, 1994, MOL CELL BIOL, V14, P277, DOI 10.1128/MCB.14.1.277; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERVALK P, 1990, ANN ONCOL, V1, P56; WALSORTH NC, 1987, J CELL BIOL, V105, P163; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; YUSA K, 1989, CANCER RES, V49, P5002	56	549	562	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1071	1081		10.1016/0092-8674(94)90446-4	http://dx.doi.org/10.1016/0092-8674(94)90446-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	7912658				2022-12-28	WOS:A1994NV42500015
J	EITAN, S; SOLOMON, A; LAVIE, V; YOLES, E; HIRSCHBERG, DL; BELKIN, M; SCHWARTZ, M				EITAN, S; SOLOMON, A; LAVIE, V; YOLES, E; HIRSCHBERG, DL; BELKIN, M; SCHWARTZ, M			RECOVERY OF VISUAL RESPONSE OF INJURED ADULT-RAT OPTIC NERVES TREATED WITH TRANSGLUTAMINASE	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; AXONAL REGENERATION; NEURITE GROWTH; OLIGODENDROCYTES; MYELIN	Failure of axons of the central nervous system in adult mammals to regenerate spontaneously after injury is attributed in part to inhibitory molecules associated with oligodendrocytes. Regeneration of central nervous system axons in fish is correlated with the presence of a transglutaminase. This enzyme dimerizes interleukin-2, and the product is cytotoxic to oligodendrocytes in vitro. Application of this nerve-derived transglutaminase to rat optic nerves, in which the injury had caused the loss of visual evoked potential response to light, promoted the recovery of that response within 6 weeks after injury. Transmission electron microscopy analysis revealed the concomitant appearance of axons in the distal stump of the optic nerve.	WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,CHAIM SHEBA MED CTR,GOLDSCHLEGER EYE INST,TEL HASHOMER,ISRAEL	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine			Belkin, Michael/AAK-4728-2020; Solomon, Arieh/AAF-4361-2021					AGUAYO AJ, 1990, J EXP BIOL, V153, P199; ASSIA E, 1989, BRAIN RES, V476, P205, DOI 10.1016/0006-8993(89)91240-7; BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; CAJAL SRY, 1954, DEGENERATION REGENER, V1; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DORFMAN LJ, 1987, NEUROLOGY, V37, P123, DOI 10.1212/WNL.37.1.123; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; EIZENBERG O, UNPUB; FACCHIANO F, 1993, TRENDS BIOCHEM SCI, V18, P327, DOI 10.1016/0968-0004(93)90066-V; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GRAFSTEIN B, 1982, EXP NEUROL, V76, P318, DOI 10.1016/0014-4886(82)90212-6; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; KEIRSTEAD SA, 1989, SCIENCE, V246, P255, DOI 10.1126/science.2799387; KIERNAN JA, 1979, BIOL REV, V54, P155, DOI 10.1111/j.1469-185X.1979.tb00871.x; LAVIE V, 1990, J COMP NEUROL, V298, P293, DOI 10.1002/cne.902980304; RICHARDSON PM, 1982, J NEUROCYTOL, V11, P949, DOI 10.1007/BF01148310; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; SCHWARTZ M, 1985, SCIENCE, V228, P600, DOI 10.1126/science.3983646; SIVRON T, 1994, J COMP NEUROL, V343, P237, DOI 10.1002/cne.903430205; SO KF, 1985, BRAIN RES, V328, P349, DOI 10.1016/0006-8993(85)91047-9	23	111	115	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 17	1994	264	5166					1764	1768		10.1126/science.7911602	http://dx.doi.org/10.1126/science.7911602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR600	7911602				2022-12-28	WOS:A1994NR60000044
J	LUCAS, SB; DECOCK, KM; HOUNNOU, A; PEACOCK, C; DIOMANDE, M; HONDE, M; BEAUMEL, A; KESTENS, L; KADIO, A				LUCAS, SB; DECOCK, KM; HOUNNOU, A; PEACOCK, C; DIOMANDE, M; HONDE, M; BEAUMEL, A; KESTENS, L; KADIO, A			CONTRIBUTION OF TUBERCULOSIS TO SLIM DISEASE IN AFRICA	BRITISH MEDICAL JOURNAL			English	Article							AIDS; HIV; UGANDA; INFECTIONS; DIARRHEA	Objectives-To assess the contribution of tuberculosis to the aetiology of the HIV wasting syndrome (slim) in Africa, a condition usually considered an enteropathy. Methods-Clinical examination and representative necropsy study of adult patients positive for HIV. Setting-Hospital medical wards in Abidjan, Ivory Coast. Subjects-Adults positive for HIV. Main outcome measures-CD4 T lymphocyte counts before death, clinical and anthropometric data, and gross and microscopic pathology. Results-Necropsy was done on 212 HIV positive adults. Tuberculosis was found in 41 of 93 with the clinical HIV wasting syndrome and in 32 of 119 without (odds ratio 2.1, 95% confidence interval 1.2 to 4.0). A significant association existed between the prevalence of tuberculosis at necropsy and the degree of cadaveric wasting (no wasting 25% (15/59); moderate wasting 40% (23/58); skeletal wasting 44% (42/95); P=0.02). Wasting was also associated with a history of chronic diarrhoea, but no association existed between diarrhoea and tuberculosis. Median CD4 T lymphocyte counts were lowest in wasted patients irrespective of findings at necropsy and in those with chronic diarrhoea (<60x10(6)/l). Conclusion-Wasting and chronic diarrhoea are late stage manifestations of HIV disease in Africa. The importance of tuberculosis as a contributing factor in the pathogenesis of the slim syndrome has been underestimated. In nearly half of patients dying with severe wasting, tuberculosis was the dominant pathological finding.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341; PROJET RETRO CI,ABIDJAN,COTE IVOIRE; UNIV HOSP ABIDJAN,ABIDJAN,COTE IVOIRE; INST TROP MED,B-2000 ANTWERP,BELGIUM	Centers for Disease Control & Prevention - USA; Institute of Tropical Medicine (ITM)	LUCAS, SB (corresponding author), UNIV LONDON UNIV COLL,SCH MED,DEPT HISTOPATHOL,LONDON WC1E 6JJ,ENGLAND.							COLEBUNDERS R, 1988, GUT, V29, P1687, DOI 10.1136/gut.29.12.1687; COLEBUNDERS RL, 1991, AIDS, V5, pS103; CONLON CP, 1990, AM J TROP MED HYG, V42, P83, DOI 10.4269/ajtmh.1990.42.83; DEAN AD, 1990, EPI INFO; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1993, LANCET, V342, P437, DOI 10.1016/0140-6736(93)92853-L; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DECOCK KM, 1993, AM J PUBLIC HEALTH, V83, P1385, DOI 10.2105/AJPH.83.10.1385; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; KAPEMBWA MS, 1991, CLIN SCI, V81, P327, DOI 10.1042/cs0810327; KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006; KEUSCH GT, 1990, ANNU REV NUTR, V10, P475, DOI 10.1146/annurev.nu.10.070190.002355; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; LUCAS SB, 1989, J CLIN PATHOL, V42, P885, DOI 10.1136/jcp.42.8.885-b; LUCS SB, 1993, AIDS, V7, P1569; NAHLEN BL, 1993, AIDS, V7, P183, DOI 10.1097/00002030-199302000-00005; NAMBUYA A, 1988, J CLIN PATHOL, V41, P93, DOI 10.1136/jcp.41.1.93; NELSON AM, 1993, AIDS, V7, P1241, DOI 10.1097/00002030-199309000-00014; Scalcini M, 1991, Bull Int Union Tuberc Lung Dis, V66, P37; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SEWANKAMBO N, 1987, AIDS, V1, P9; SMITH PD, 1992, ANN INTERN MED, V116, P63, DOI 10.7326/0003-4819-116-1-63; World Health Organisation, 1986, WKLY EPIDEM REC, V61, P69	23	106	106	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1531	1533		10.1136/bmj.308.6943.1531	http://dx.doi.org/10.1136/bmj.308.6943.1531			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	7912597	Green Published			2022-12-28	WOS:A1994NR11000018
J	NGAI, J; DOWLING, MM; BUCK, L; AXEL, R; CHESS, A				NGAI, J; DOWLING, MM; BUCK, L; AXEL, R; CHESS, A			THE FAMILY OF GENES ENCODING ODORANT RECEPTORS IN THE CHANNEL CATFISH	CELL			English	Article							BETA-ADRENERGIC-RECEPTOR; SENSITIVE ADENYLATE-CYCLASE; LIGAND-BINDING SPECIFICITY; ACID OLFACTORY RECEPTOR; NUCLEOTIDE SUBSTITUTIONS; OVERDOMINANT SELECTION; AMINO-ACIDS; EXPRESSION; NEURONS; CILIA	The anatomical and numerical simplicity of the fish olfactory system has led us to examine the family of olfactory receptors expressed in the catfish. We have identified a family of genes encoding seven transmembrane domain receptors that share considerable homology with the odorant receptors of the rat. The size of the catfish receptor repertoire appears to be far smaller than in mammals. Analysis of the nucleotide sequences suggests that these receptor genes have undergone positive Darwinian selection to generate enhanced diversity within the putative odorant-binding domains. Individual receptor clones anneal with 0.5%-2% of the olfactory neurons, suggesting that a single cell expresses only a small subset of distinct odorant receptors. Each cell, therefore, possesses a unique identity defined by the receptors it expresses. These data suggest that the brain may discriminate among odors by determining which neurons have been activated.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute			Dowling, Michael M./AAE-5263-2020	Dowling, Michael M./0000-0001-5058-6589; Axel, Richard/0000-0002-3141-4076	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NIGMS NIH HHS [T-32 GM07367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRUCH RC, 1988, COMP BIOCHEM PHYS B, V91, P535, DOI 10.1016/0305-0491(88)90018-1; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAGAN RH, 1978, P NATL ACAD SCI USA, V75, P4679, DOI 10.1073/pnas.75.10.4679; CAPRIO J, 1989, J GEN PHYSIOL, V93, P245, DOI 10.1085/jgp.93.2.245; CAPRIO J, 1984, J GEN PHYSIOL, V84, P403, DOI 10.1085/jgp.84.3.403; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; Doving K.B., 1986, Progress in Sensory Physiology, V6, P39; FESENKO EE, 1983, BIOCHIM BIOPHYS ACTA, V759, P250, DOI 10.1016/0304-4165(83)90320-3; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HARA T J, 1975, Progress in Neurobiology (Oxford), V5, P271, DOI 10.1016/0301-0082(75)90014-3; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; JUKES T H, 1969, P21; KALINOSKI DL, 1992, BIOCHEM J, V281, P449, DOI 10.1042/bj2810449; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MAEDA N, 1986, ANNU REV GENET, V20, P81; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NEI M, 1986, MOL BIOL EVOL, V3, P418; NEI M, 1989, MOL BIOL EVOL, V6, P290; NGAI J, 1993, CELL, V72; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; REHNBERG BG, 1986, J COMP PHYSIOL A, V159, P61, DOI 10.1007/BF00612496; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; RHEIN LD, 1983, J NEUROCHEM, V41, P569, DOI 10.1111/j.1471-4159.1983.tb04777.x; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; TANAKA T, 1989, MOL BIOL EVOL, V6, P447; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	44	327	345	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					657	666						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7916654	Bronze			2022-12-28	WOS:A1993KR43600003
J	GEORGOPOULOS, K; BIGBY, M; WANG, JH; MOLNAR, A; WU, P; WINANDY, S; SHARPE, A				GEORGOPOULOS, K; BIGBY, M; WANG, JH; MOLNAR, A; WU, P; WINANDY, S; SHARPE, A			THE IKAROS GENE IS REQUIRED FOR THE DEVELOPMENT OF ALL LYMPHOID LINEAGES	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; NATURAL-KILLER-CELLS; DENDRITIC EPIDERMAL-CELLS; BONE-MARROW; PRECURSOR CELLS; LYMPHOCYTES-T; EXPRESSION; THYMUS; MOUSE; MICE	The Ikaros gene encodes a family of early hematopoietic- and lymphocyte-restricted transcription factors. Mice homozygous for a germline mutation in the Ikaros DNA-binding domain lack not only T and B lymphocytes and natural killer cells but also their earliest defined progenitors. In contrast, the erythroid and myeloid lineages were intact in these mutant mice. We propose that Ikaros promotes differentiation of pluripotential hematopoietic stem cell(s) into the lymphocyte pathways. In the absence of a functional Ikaros gene, these stem cells are exclusively diverted into the erythroid and myeloid lineages.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV IMMUNOL RES,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	GEORGOPOULOS, K (corresponding author), MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039795] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI033062, R01-AI33062-62] Funding Source: Medline; NIAMS NIH HHS [AR39795-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; ASNARNOW DM, 1988, CELL, V55, P837; BIGBY M, 1987, J INVEST DERMATOL, V89, P495, DOI 10.1111/1523-1747.ep12460983; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; FIFE A, 1994, J CLIN PATHOL, V47, P82, DOI 10.1136/jcp.47.1.82; FLEMING WH, 1993, J CELL BIOL, V122, P897, DOI 10.1083/jcb.122.4.897; GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; HACKETT J, 1986, J IMMUNOL, V136, P3124; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARDY RR, 1986, IMMUNOL REV, V93, P53, DOI 10.1111/j.1600-065X.1986.tb01502.x; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HESTDAL K, 1991, J IMMUNOL, V147, P22; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NILSSON SK, 1994, EXP HEMATOL, V22, P377; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SPANGRUDE GJ, 1989, IMMUNOL TODAY, V10, P344, DOI 10.1016/0167-5699(89)90192-8; VISSER JWM, 1983, CELL TISSUE KINET, V16, P385; WARD HP, 1971, MEDICINE, V50, P357, DOI 10.1097/00005792-197109000-00001; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0	36	753	772	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					143	156		10.1016/0092-8674(94)90407-3	http://dx.doi.org/10.1016/0092-8674(94)90407-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923373				2022-12-28	WOS:A1994PK58500015
J	STEFANSKI, D; WORSLEY, K				STEFANSKI, D; WORSLEY, K			10-DAY WINDOW ON THE WORLD	LANCET			English	Editorial Material											STEFANSKI, D (corresponding author), MONASH UNIV,DEPT PHYSIOL,MED POPULAT AWARENESS,CLAYTON,VIC 3168,AUSTRALIA.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					936	937		10.1016/S0140-6736(94)92277-2	http://dx.doi.org/10.1016/S0140-6736(94)92277-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934353				2022-12-28	WOS:A1994PJ28700018
J	ASSEMAN, P; MCFADDEN, E; BAUCHART, JJ; LOUBEYRE, C; THERY, C				ASSEMAN, P; MCFADDEN, E; BAUCHART, JJ; LOUBEYRE, C; THERY, C			WHY DO BETA-BLOCKERS HELP IN IDIOPATHIC DILATED CARDIOMYOPATHY - FREQUENCY MISMATCH	LANCET			English	Article							HUMAN HEART-FAILURE; HUMAN VENTRICULAR MYOCARDIUM; FAILING HUMAN MYOCARDIUM; CALCIUM; EXPRESSION; CONTRACTILITY; METOPROLOL; BLOCKADE				ASSEMAN, P (corresponding author), UNIV LILLE,HOP CARDIOIOG,F-59037 LILLE,FRANCE.							BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; BREALL JA, 1993, J AM COLL CARDIOL, V21, P471, DOI 10.1016/0735-1097(93)90691-S; CORABOEUF E, 1992, THERAPIE, V47, P171; EISING GP, 1994, J AM COLL CARDIOL, V23, P97; FOWLER MB, 1986, CIRCULATION, V74, P1290, DOI 10.1161/01.CIR.74.6.1290; GILBERT EM, 1991, CIRCULATION S2, V84, P1868; GO LW, 1993, CIRCULATION, V88, P624; GWATHMEY JK, 1990, J CLIN INVEST, V85, P1599, DOI 10.1172/JCI114611; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HAJJAR RJ, 1992, CIRCULATION, V86, P1819, DOI 10.1161/01.CIR.86.6.1819; HASENFUSS G, 1993, CIRCULATION, V88, P407; HASENFUSS G, 1992, CIRC RES, V70, P1226; HEILBRUNN SM, 1989, CIRCULATION, V79, P483, DOI 10.1161/01.CIR.79.3.483; LECHAT P, IN PRESS CIRCULATION; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; MORAVEC CS, 1993, CIRCULATION, V88, P408; MULIERI LA, 1992, CIRCULATION, V85, P1743, DOI 10.1161/01.CIR.85.5.1743; PIESKE B, 1993, CIRCULATION, V88, P373; RASMUSSEN RP, 1990, BIOCHEM PHARMACOL, V39, P691, DOI 10.1016/0006-2952(90)90147-D; REINECKE H, 1993, CIRCULATION, V88, P408; SATO H, 1993, CIRCULATION, V88, P2215, DOI 10.1161/01.CIR.88.5.2215; VAHL CF, 1994, CIRC RES, V74, P952, DOI 10.1161/01.RES.74.5.952; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R	24	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					803	804		10.1016/S0140-6736(94)92350-7	http://dx.doi.org/10.1016/S0140-6736(94)92350-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916082				2022-12-28	WOS:A1994PG17800019
J	STEEL, JM				STEEL, JM			SUCH A NICE GIRL	LANCET			English	Editorial Material							SUBCUTANEOUS-INSULIN-RESISTANCE; BRITTLE; MANAGEMENT; ETIOLOGY; THERAPY				STEEL, JM (corresponding author), VICTORIA HOSP,KIRKCALDY,FIFE,SCOTLAND.							BROSSARD JH, 1993, DIABETIC MED, V10, P174, DOI 10.1111/j.1464-5491.1993.tb00037.x; Campbell I W, 1984, Diabetes Res, V1, P83; GILL GV, 1985, DIABETOLOGIA, V28, P579, DOI 10.1007/BF00281992; PICKUP J, 1983, DIABETES CARE, V6, P279, DOI 10.2337/diacare.6.3.279; PICKUP JC, 1981, BRIT MED J, V282, P347, DOI 10.1136/bmj.282.6261.347; SCHADE DS, 1986, NEW ENGL J MED, V315, P147, DOI 10.1056/NEJM198607173150302; SCHADE DS, 1985, DIABETES CARE, V8, P12, DOI 10.2337/diacare.8.1.12; SCHADE DS, 1985, DIABETES CARE, V8, P5, DOI 10.2337/diacare.8.1.5; TATTERSALL RB, 1977, CLIN ENDOCRINOL META, V6, P406; WILLIAMS G, 1983, DIABETES, V32, P466, DOI 10.2337/diabetes.32.5.466; WILLIAMS G, 1985, DIABETES CARE, V6, P21; WOOD DF, 1990, BRIT MED J, V301, P1143, DOI 10.1136/bmj.301.6761.1143	12	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					765	766		10.1016/S0140-6736(94)92333-7	http://dx.doi.org/10.1016/S0140-6736(94)92333-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916065				2022-12-28	WOS:A1994PG17800002
J	TURKASPA, I; MAOR, Y; DOR, J; MASHIACH, S				TURKASPA, I; MAOR, Y; DOR, J; MASHIACH, S			FREQUENCY OF INTERCOURSE FOR COUPLES TRYING TO CONCEIVE	LANCET			English	Editorial Material							OLIGOZOOSPERMIC MEN; SEMEN CHARACTERISTICS; INFERTILE MEN; PARAMETERS; INTERVAL; MOTILE; SPERM				TURKASPA, I (corresponding author), TEL AVIV UNIV,CHAIM SHEBA MED CTR,DEPT OBSTET & GYNECOL,INFERTIL & INVITRO FERTILIZAT UNIT,IL-52621 TEL HASHOMER,ISRAEL.			Maor, Yasmin/0000-0001-7258-3434				ACOSTA AA, 1988, OBSTET GYNECOL SURV, V44, P1; BAKER HWG, 1981, INT J ANDROL, V4, P609, DOI 10.1111/j.1365-2605.1981.tb00743.x; BRASCH JG, 1994, FERTIL STERIL, V62, P150; CHECK JH, 1985, FERTIL STERIL, V44, P416; COOPER TG, 1993, HUM REPROD, V8, P1251, DOI 10.1093/oxfordjournals.humrep.a138236; GLASS RH, 1986, REPRODUCTIVE ENDOCRI, P571; GULMEZ I, 1991, ANDROLOGIA, V23, P167; HORNSTEIN MD, 1992, FERTIL STERIL, V58, P433; Hotchkiss RS, 1941, J UROLOGY, V45, P875, DOI 10.1016/S0022-5347(17)71125-1; MATILSKY M, 1993, HUM REPROD, V8, P71, DOI 10.1093/oxfordjournals.humrep.a137877; SILBER SJ, 1989, HUM REPROD, V4, P947, DOI 10.1093/oxfordjournals.humrep.a137018; TURKASPA I, 1990, FERTIL STERIL, V54, P906; TURKASPA I, 1994, FERTIL STERIL, V62, P370	13	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					766	766		10.1016/S0140-6736(94)92334-5	http://dx.doi.org/10.1016/S0140-6736(94)92334-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916066				2022-12-28	WOS:A1994PG17800003
J	BERKOWITZ, CD				BERKOWITZ, CD			HOMEOPATHT - KEEPING AN OPEN MIND	LANCET			English	Editorial Material											BERKOWITZ, CD (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT PEDIAT,TORRANCE,CA 90509, USA.							CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; JACOBS J, 1994, PEDIATRICS, V93, P719; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; PALAFOX N, 1980, CROSS CULTURAL CARIN; REILLY DT, 1986, LANCET, V2, P881; WAPNIR RA, 1991, J PEDIATR, V118, P553; 1981, PUBLIC HLTH LETT, V3, P37	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					701	702		10.1016/S0140-6736(94)92203-9	http://dx.doi.org/10.1016/S0140-6736(94)92203-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915771				2022-12-28	WOS:A1994PF18700005
J	CLARKE, KW; GRAY, D; KEATING, NA; HAMPTON, JR				CLARKE, KW; GRAY, D; KEATING, NA; HAMPTON, JR			DO WOMEN WITH ACUTE MYOCARDIAL-INFARCTION RECEIVE THE SAME TREATMENT AS MEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; THROMBOLYSIS; MORTALITY; PROGNOSIS; GENDER; POLICY	Objective-To determine whether women with acute myocardial infarction in the Nottingham health district receive the same therapeutic interventions as their male counterparts. Design-Retrospective study. Setting-University and City Hospitals, Nottingham. Patients-All patients admitted with a suspected myocardial infarction during 1989 and 1990. Main outcome measures-Route and timing of admission to hospital, ward of admission, treatment, interventions in hospital, and mortality. Results-Women with myocardial infarction took longer to arrive in hospital than men. They were less likely to be admitted to the coronary care unit and were therefore also less likely to receive thrombolytic treatment. They seemed to have more severe infarcts, with higher Killip classes, and had a slightly higher mortality during admission. They were less likely than men to receive secondary prophylaxis by being discharged taking beta blockers or aspirin. Conclusions-Survival chances both in hospital and after discharge in women with acute myocardial infarction are reduced because they do not have the same opportunity for therapeutic intervention as men.	UNIV NOTTINGHAM, BRITISH HEART FDN, DEPT MATH, CARDIOVASC STAT UNIT, NOTTINGHAM NG7 2RD, ENGLAND	University of Nottingham	CLARKE, KW (corresponding author), UNIV NOTTINGHAM HOSP, NOTTINGHAM NG7 2UH, ENGLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; [Anonymous], 1986, Lancet, V2, P57; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GRAY D, 1993, INT J EPIDEMIOL, V22, P222, DOI 10.1093/ije/22.2.222; HAMPTON JR, 1985, MED INT, P848; KANNEL WB, 1987, CORONARY HEART DISEA, P208; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MULCAHY R, 1993, BRIT J CARDIOLOGY, V1, P35; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; ROWLEY JM, 1992, BRIT HEART J, V67, P255; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; VEMURA K, 1988, WORLD HLTH STAT Q, V41, P155; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; 1993, MORTALITY STATISTICS	19	158	162	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	1994	309	6954					563	566		10.1136/bmj.309.6954.563	http://dx.doi.org/10.1136/bmj.309.6954.563			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	7916228	Green Published			2022-12-28	WOS:A1994PF33000014
J	JACQZAIGRAIN, E; DAOUD, P; BURTIN, P; DESPLANQUES, L; BEAUFILS, F				JACQZAIGRAIN, E; DAOUD, P; BURTIN, P; DESPLANQUES, L; BEAUFILS, F			PLACEBO-CONTROLLED TRIAL OF MIDAZOLAM SEDATION IN MECHANICALLY VENTILATED NEWBORN BABIES	LANCET			English	Article							ARTIFICIAL-VENTILATION; ANESTHESIA; FENTANYL; INFANTS; PAIN; PHARMACOKINETICS; ANALGESIA; INDUCTION; INFUSION; CHILDREN	Although midazolam is used for sedation of mechanically ventilated newborn babies, this treatment has not been evaluated in a randomised trial, We have done a prospective placebo-controlled study of the effects of midazolam on haemodynamic variables and sedation as judged by a five-item behaviour score. 46 newborn babies on mechanical ventilation for respiratory distress syndrome were randomly assigned to receive midazolam (n=24) or placebo (n=22) as a continuous infusion. Doses of midazolam were calculated to obtain plasma concentrations between 200 and 1000 ng/mL within 24 h of starting treatment and to maintain these values throughout the study. Haemodynamic and ventilatory variables were noted every hour, as were complications and possible side-effects of treatment. Mean (SD) duration of inclusion was 7.87 (30.9) h. 1 patient in the treatment group and 7 in the placebo group were withdrawn because of inadequate sedation (p < 0.05). Midazolam gave a significantly better sedative effect than placebo, as estimated by the behaviour score (p < 0.05). Heart rate and blood pressure were reduced by treatment but remained within the normal range for gestational age and there was no effect on ventilatory indices. The incidence of complications was similar in the two groups. No midazolam-related side-effects were noted. Continuous infusion of midazolam at doses adapted to gestational age induces effective sedation in newborn babies on mechanical ventilation, with positive effects on haemodynamic variables. The course of the respiratory distress syndrome was not influenced by this treatment. Midazolam was given over only a few days and the limited effects on heart rate and blood pressure that we report should not encourage long-term administration.	HOP ROBERT DEBRE,DEPT PAEDIAT INTENS CARE,F-75019 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	JACQZAIGRAIN, E (corresponding author), HOP ROBERT DEBRE,DEPT CLIN PHARMACOL,F-75019 PARIS,FRANCE.		Jacqz-Aigrain, Evelyne/AAW-7089-2021	Jacqz-Aigrain, Evelyne/0000-0002-4285-7067				ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; BARRIER G, 1989, INTENS CARE MED, V15, pS37, DOI 10.1007/BF00260882; BENSHLOMO I, 1990, BRIT J ANAESTH, V64, P45, DOI 10.1093/bja/64.1.45; BOOKER PD, 1986, BRIT J ANAESTH, V58, P1104, DOI 10.1093/bja/58.10.1104; BURTIN P, 1991, LANCET, V337, P1545, DOI 10.1016/0140-6736(91)93235-2; CRAIG KD, 1984, SOC SCI MED, V19, P1331, DOI 10.1016/0277-9536(84)90021-2; CREVOISIER C, 1983, BR J CLIN PHARM, V16, P51; FRAGEN RJ, 1979, ANESTHESIOLOGY, V51, P172; GEMELLI M, 1990, EUR J PEDIATR, V149, P318, DOI 10.1007/BF02171556; GREENOUGH A, 1983, J PEDIATR-US, V103, P769, DOI 10.1016/S0022-3476(83)80483-1; HARTWIG S, 1991, EUR J PEDIATR, V150, P784, DOI 10.1007/BF02026712; HEIKKILA H, 1984, ACTA ANAESTH SCAND, V28, P683, DOI 10.1111/j.1399-6576.1984.tb02145.x; JACQZAIGRAIN E, 1992, EUR J CLIN PHARMACOL, V42, P329; Kuban KCK, 1993, J INTENSIVE CARE MED, V8, P157, DOI 10.1177/088506669300800402; PAYNE K, 1989, EUR J CLIN PHARMACOL, V37, P267, DOI 10.1007/BF00679782; PERLMAN JM, 1985, NEW ENGL J MED, V312, P1353, DOI 10.1056/NEJM198505233122104; PERSSON MP, 1988, CLIN PHARMACOL THER, V43, P324; PUGLISI CV, 1985, J CHROMATOGR, V344, P199, DOI 10.1016/S0378-4347(00)82020-4; REVES JG, 1979, CAN ANAESTH SOC J, V26, P402, DOI 10.1007/BF03006455; REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017; RITZ R, 1991, Intensive Care Medicine, V17, pS11, DOI 10.1007/BF01731148; ROBIEUX I, 1991, J PEDIATR-US, V118, P971, DOI 10.1016/S0022-3476(05)82220-6; ROSEN DA, 1990, 10TH UPDATE INTENSIV, P758; SHELLY MP, 1991, EUR J ANAESTH, V8, P21; STORK EK, 1985, PEDIATR RES, V18, pA321; TOLIA V, 1991, J PEDIATR-US, V119, P467, DOI 10.1016/S0022-3476(05)82066-9; VACANTI JP, 1984, J PEDIATR SURG, V19, P672, DOI 10.1016/S0022-3468(84)80351-6	28	77	78	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					646	650		10.1016/S0140-6736(94)92085-0	http://dx.doi.org/10.1016/S0140-6736(94)92085-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915348				2022-12-28	WOS:A1994PE38600010
J	EISENBERG, M				EISENBERG, M			IMPROVING OUT-OF-HOSPITAL RESUSCITATION	LANCET			English	Editorial Material							AMERICAN-HEART-ASSOCIATION; CARDIAC-ARREST; HEALTH-PROFESSIONALS; STATEMENT; SURVIVAL				EISENBERG, M (corresponding author), UNIV WASHINGTON,MED CTR,EMERGENCY MED SERV,SEATTLE,WA 98195, USA.							BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BENSON NH, 1994, ANN EMERG MED, V23, P1047, DOI 10.1016/S0196-0644(94)70102-4; CLARK JJ, 1994, ANN EMERG MED, V23, P1022, DOI 10.1016/S0196-0644(94)70097-4; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; DULL SM, 1994, ANN EMERG MED, V23, P997, DOI 10.1016/S0196-0644(94)70093-1; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1994, ANN EMERG MED, V23, P1049, DOI 10.1016/S0196-0644(94)70103-2; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; PARTRIDGE JF, 1967, LANCET, V2, P271; PEPE PE, 1994, ANN EMERG MED, V23, P1037, DOI 10.1016/S0196-0644(94)70100-8; ROTTENBERG EM, 1994, ANN EMERG MED, V23, P1027, DOI 10.1016/S0196-0644(94)70098-2; SHUSTER M, 1994, ANN EMERG MED, V23, P1014, DOI 10.1016/S0196-0644(94)70096-6; SOSNA DP, 1994, ANN EMERG MED, V23, P1042, DOI 10.1016/S0196-0644(94)70101-6; WHITE RD, 1994, ANN EMERG MED, V23, P1009, DOI 10.1016/S0196-0644(94)70095-8	15	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					561	562		10.1016/S0140-6736(94)91961-5	http://dx.doi.org/10.1016/S0140-6736(94)91961-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914956				2022-12-28	WOS:A1994PD42400005
J	KENYON, C				KENYON, C			IF BIRDS CAN FLY, WHY CANT WE - HOMEOTIC GENES AND EVOLUTION	CELL			English	Review							HOX HOMEOBOX GENES; RETINOIC ACID; EARLY EMBRYOGENESIS; DROSOPHILA EMBRYOS; SEGMENTAL IDENTITY; PATTERN-FORMATION; BITHORAX COMPLEX; NERVOUS-SYSTEM; C-ELEGANS; EXPRESSION				KENYON, C (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							AKAM M, 1994, NATURE, V367, P410, DOI 10.1038/367410a0; AKAM M, 1987, DEVELOPMENT, V101, P1; ALTABA AR, 1989, NATURE, V341, P33; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BEEMAN RW, 1987, NATURE, V327, P247, DOI 10.1038/327247a0; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CHOW KL, 1994, IN PRESS DEVELOPMENT; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; DUSH MK, 1992, DEV BIOL, V151, P273, DOI 10.1016/0012-1606(92)90232-6; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; HUTTER H, 1994, IN PRESS DEVELOPMENT; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KASTURY K, 1994, IN PRESS GENOMICS; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KESSEL M, 1992, DEVELOPMENT, V115, P487; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence P., 1992, MAKING FLY GENETICS; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MORGAN BA, 1994, IN PRESS DEVELOPMENT; NARDELLIHAEFLIG.D, 1994, IN PRESS DEVELOPMENT; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PATEL NH, 1989, DEVELOPMENT, V107, P201; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; RUBENSTEIN JLR, 1994, IN PRESS CURR TOPICS, V29; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SALSER SJ, 1994, TRENDS GENET, V10, P159, DOI 10.1016/0168-9525(94)90092-2; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SHANKLAND M, 1994, IN PRESS BIOESSAYS; SHENK MA, 1993, DEVELOPMENT, V117, P657; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; STUART JJ, 1991, NATURE, V350, P72, DOI 10.1038/350072a0; TEAR G, 1990, DEVELOPMENT, V110, P915; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; ZHOU JJ, 1993, GENE DEV, V7, P343	60	106	108	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					175	180		10.1016/0092-8674(94)90288-7	http://dx.doi.org/10.1016/0092-8674(94)90288-7			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	7913878				2022-12-28	WOS:A1994NZ24200002
J	FROMMEL, D; TEKLEHAIMANOT, R; VERDIER, M; NEGESSE, Y; BULTO, T; DENIS, F				FROMMEL, D; TEKLEHAIMANOT, R; VERDIER, M; NEGESSE, Y; BULTO, T; DENIS, F			HIV-INFECTION AND LEPROSY - A 4-YEAR SURVEY IN ETHIOPIA	LANCET			English	Note							VIRUS	Between 1988 and 1992 three cross-sectional surveys for antibodies to HIV were done in 644 Ethiopian patients with histologically proven leprosy. Whereas the frequency of HIV-1 infection gradually increased from 3.2% to 6.5%, the clinical presentation, number of new patients, and frequency of relapse did not differ between HIV negative and positive patients. Thus HIV appears unlikely to have a significant impact on the incidence of leprosy in sub-Sahelian populations.	UNIV ADDIS ABABA,FAC MED,DEPT MED,ADDIS ABABA,ETHIOPIA; CHU LIMOGES,DEPT VIROL,LIMOGES,FRANCE; ALL AFRICA LEPROSY & REHABIL TRAINING CTR,ADDIS ABABA,ETHIOPIA; INST PASTEUR,CNRS,URA 1459,LYON,FRANCE	Addis Ababa University; CHU Limoges; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	FROMMEL, D (corresponding author), ARMAUER HANSEN RES INST,POB 1005,ADDIS ABABA,ETHIOPIA.			VERDIER, Mireille/0000-0002-8162-4856				DUNCAN ME, 1981, LEPROSY REV, V52, P245; FROMMEL D, 1993, AM J TROP MED HYG, V49, P435, DOI 10.4269/ajtmh.1993.49.435; KHOD, 1993, KHODAKEVICH L, P319; LEONARD G, 1990, J ACQ IMMUN DEF SYND, V3, P1109; LUCAS S, 1993, LEPROSY REV, V64, P97; TEKLEHAIMANOT R, 1991, AIDS, V5, P108, DOI 10.1097/00002030-199101000-00019; 1993, ETHIOP J HLTH DEV, V7, P33; 1992, LEPROSY CONTROL ETHI; 1988, LEPROSY CONTROL ETHI	9	30	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					165	166		10.1016/S0140-6736(94)92760-X	http://dx.doi.org/10.1016/S0140-6736(94)92760-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912768				2022-12-28	WOS:A1994NW81000012
J	GLUCK, R; MISCHLER, R; FINKEL, B; QUE, JU; SCARPA, B; CRYZ, SJ				GLUCK, R; MISCHLER, R; FINKEL, B; QUE, JU; SCARPA, B; CRYZ, SJ			IMMUNOGENICITY OF NEW VIROSOME INFLUENZA VACCINE IN ELDERLY PEOPLE	LANCET			English	Article							ANTIBODY-RESPONSE; VIRUS; IMMUNIZATION; HOSPITALIZATIONS; HEMAGGLUTININ; VOLUNTEERS; REDUCTION; EPIDEMIC; EFFICACY; YOUNG	The safety and immunogenicity of a new virosome influenza vaccine was compared to commercial whole-virus vaccine and subunit vaccine in elderly people. The virosome vaccine was made by extracting the haemagglutinin from influenza virus and incorporating it into the membrane of liposomes composed of phosphatidylcholine (PC) and phosphatidylethanolamine (PE). 126 residents of a nursing home, aged 63-102, were randomised to receive one of the vaccines. All three were well tolerated and caused a significant rise in the geometric mean anti-haemagglutinin inhibiting (HAI) antibody titre to the 3 vaccine components (H1N1 Singapore, H3N2 Belling, and B/Yamagata). The virosome formulation caused the highest geometric mean titres in addition to significantly (p=0.039-0.0016) higher rates of more than four-fold or more titre rises to all 3 vaccine components. The percentage of those immunised who achieved protective levels of antibody (HAI greater than or equal to 40) was significantly (p=0.035-0.0017) higher for the H1N1 and B/Yamagata strains following immunisation with virosome formulation. Participants with non-protective baseline titres to the H1N1 or B/Yamagata strains were more likely (p = 0.0049-0.006) to achieve protective levels of antibodies after immunisation with the virosome vaccine. Immunisation with the virosome formulation did not result in a significant rise in anti-PC or anti-PE antibodies.	SWISS SERUM & VACCINE INST,CH-3001 BERN,SWITZERLAND; UNIV CAGLIARI,IST IGIENE & MED PREVENT,CAGLIARI,ITALY	University of Cagliari								ARDEN NH, 1986, J INFECT DIS, V153, P805, DOI 10.1093/infdis/153.4.805; ARDEN NH, 1986, OPTIONS CONTROL INFL, P155; ARVIEUX J, 1991, CLIN EXP IMMUNOL, V84, P466; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; BEYER WEP, 1989, VACCINE, V7, P385, DOI 10.1016/0264-410X(89)90150-3; COUCH RB, 1986, J INFECT DIS, V153, P431, DOI 10.1093/infdis/153.3.431; ERSHLER WB, 1988, GERIATRICS, V43, P79; GLATHE H, 1993, VACCINE, V11, P702, DOI 10.1016/0264-410X(93)90252-S; GLEZEN WP, 1980, JAMA-J AM MED ASSOC, V243, P1345; GLUCK R, 1992, J CLIN INVEST, V90, P2491, DOI 10.1172/JCI116141; GROOTHUIS JR, 1991, PEDIATRICS, V87, P823; GUINK NE, 1989, VACCINE, V7, P147; KEREN G, 1988, J MED VIROL, V25, P85, DOI 10.1002/jmv.1890250112; KOHN RR, 1982, JAMA-J AM MED ASSOC, V247, P2793, DOI 10.1001/jama.247.20.2793; LOH D, 1979, J EXP MED, V150, P1067, DOI 10.1084/jem.150.5.1067; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; PALACHE AM, 1993, VACCINE, V11, P3, DOI 10.1016/0264-410X(93)90333-S; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; REICHELDERFER PS, 1989, DRUG NEWS PERSPECTIV, V2, P99; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; SUNDQUIST B, 1988, VACCINE, V6, P49, DOI 10.1016/0264-410X(88)90014-X; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; YASUDA T, 1977, P NATL ACAD SCI USA, V74, P1234, DOI 10.1073/pnas.74.3.1234; ZEI T, 1991, VACCINE, V9, P613, DOI 10.1016/0264-410X(91)90184-8; 1980, EUROPEAN PHARMACOPOE; 1992, JAMA-J AM MED ASSOC, V268, P2360; 1989, JAMA-J AM MED ASSOC, V261, P3220	29	143	150	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					160	163		10.1016/S0140-6736(94)92758-8	http://dx.doi.org/10.1016/S0140-6736(94)92758-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912766				2022-12-28	WOS:A1994NW81000010
J	RUSSELL, JA				RUSSELL, JA			CANCER-THERAPY - TIME TO LEARN THE IMMUNOBABBLE	LANCET			English	Editorial Material							HIGH-DOSE INTERLEUKIN-2; TUMOR-INFILTRATING LYMPHOCYTES; ACTIVATED KILLER-CELLS; TRIAL				RUSSELL, JA (corresponding author), TOM BAKER CANC CLIN,CALGARY,AB,CANADA.							ATKINS MB, 1993, J CLIN ONCOL, V11, P661, DOI 10.1200/JCO.1993.11.4.661; CURTI BD, 1993, J CLIN ONCOL, V11, P652, DOI 10.1200/JCO.1993.11.4.652; KIM JA, 1993, 37TH ANN C ADV BIOL; LARSON SM, 1993, ACTA ONCOL, V32, P709, DOI 10.3109/02841869309096125; MARINCOLA FM, 1993, J IMMUNOTHER, V13, P282, DOI 10.1097/00002371-199305000-00008; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; UCHIDA A, 1993, CANCER IMMUNOL IMMUN, V11, P75; YEUNG AW, 1994, CANCER, V71, P3633	10	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					145	146		10.1016/S0140-6736(94)92753-7	http://dx.doi.org/10.1016/S0140-6736(94)92753-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912761				2022-12-28	WOS:A1994NW81000005
J	HAYNES, WG; WEBB, DJ				HAYNES, WG; WEBB, DJ			CONTRIBUTION OF ENDOGENOUS GENERATION OF ENDOTHELIN-1 TO BASAL VASCULAR TONE	LANCET			English	Article							RECEPTOR ANTAGONIST; ETA RECEPTOR; RESPONSES; POTENT; BQ-123; CELLS	Endothelin-1 is an endothelium-derived vasoconstrictor peptide, possibly involved in the pathophysiology of cardiovascular disease. We examined the contribution of endogenously generated endothelin-1 to maintenance of peripheral vascular tone in healthy subjects by local intraarterial administration of an inhibitor of endothelin converting enzyme, phosphoramidon, and of a selective endothelin receptor A antagonist, BQ-123. Brachial artery infusion of local doses of proendothelin-1, the precursor to endothelin-1, caused a slow-onset dose-dependent forearm vasoconstriction which was abolished by co-infusion of phosphoramidon. Phosphoramidon did not affect responses to endothelin-1. Phosphoramidon caused slow-onset vasodilatation when infused alone, with blood flow increasing by 37% at 90 min (p = 0.03). Vasoconstriction to endothelin-1 was abolished by co-infusion of BQ-123 (p = 0.006), with forearm blood flow tending to increase. Infusion of BQ-123 alone caused progressive vasodilatation, with blood flow increasing by 64% after 60 min (p = 0.007). These results show that endogenous production of endothelin-1 contributes to the maintenance of vascular tone. Endothelin converting enzyme inhibitors and receptor antagonists may have therapeutic potential as vasodilators.			HAYNES, WG (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Haynes, William G/D-5374-2013	Haynes, William G/0000-0003-1004-6136				Altman DG, 1991, PRACTICAL STAT MED R, P426; BAZIL MK, 1992, J CARDIOVASC PHARM, V20, P940, DOI 10.1097/00005344-199212000-00014; BENJAMIN N, 1989, J PHYSIOL-LONDON, V412, P543, DOI 10.1113/jphysiol.1989.sp017630; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; DOUGLAS SA, 1992, EUR J PHARMACOL, V221, P315, DOI 10.1016/0014-2999(92)90718-J; HAYNES WG, 1993, CLIN SCI, V84, P485, DOI 10.1042/cs0840485; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; IKEGAWA R, 1991, FEBS LETT, V293, P45, DOI 10.1016/0014-5793(91)81149-3; MCMAHON EG, 1991, J CARDIOVASC PHARM, V17, pS29, DOI 10.1097/00005344-199100177-00009; NISHIKIBE M, 1993, LIFE SCI, V52, P717, DOI 10.1016/0024-3205(93)90233-S; OLLINS GM, 1989, MOL CELL ENDOCRINOL, V61, P201; POLLOCK DM, 1993, AM J PHYSIOL, V264, P222; WATANABE Y, 1991, J CARDIOVASC PHARM, V17, pS503, DOI 10.1097/00005344-199100177-00143; WEBB DJ, 1993, LANCET, V342, P1439, DOI 10.1016/0140-6736(93)92928-M; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	15	505	509	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					852	854		10.1016/S0140-6736(94)92827-4	http://dx.doi.org/10.1016/S0140-6736(94)92827-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916401				2022-12-28	WOS:A1994PH25300011
J	MANT, D				MANT, D			CHRONIC FATIGUE SYNDROME	LANCET			English	Editorial Material											MANT, D (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON,ENGLAND.							ANDERSON N, 1994, BRIT MED J, V308, P1298; BASS C, 1993, BRIT J PSYCHIAT, V162, P472, DOI 10.1192/bjp.162.4.472; DAVID A, 1993, LANCET, V342, P1247, DOI 10.1016/0140-6736(93)92234-K; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; Heller J., 1962, CATCH 22; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; PRINCE K, 1994, BRIT MED J, V308, P1300; TANNOCK C, 1994, BRIT MED J, V308, P1300; THOMAS PK, 1993, BMJ-BRIT MED J, V306, P1557, DOI 10.1136/bmj.306.6892.1557; WILSON A, 1994, BRIT MED J, V308, P756, DOI 10.1136/bmj.308.6931.756	10	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					834	835		10.1016/S0140-6736(94)92821-5	http://dx.doi.org/10.1016/S0140-6736(94)92821-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916395				2022-12-28	WOS:A1994PH25300005
J	CAFORIO, ALP; KEELING, PJ; ZACHARA, E; MESTRONI, L; CAMERINI, F; MANN, JM; BOTTAZZO, GF; MCKENNA, WJ				CAFORIO, ALP; KEELING, PJ; ZACHARA, E; MESTRONI, L; CAMERINI, F; MANN, JM; BOTTAZZO, GF; MCKENNA, WJ			EVIDENCE FROM FAMILY STUDIES FOR AUTOIMMUNITY IN DILATED CARDIOMYOPATHY	LANCET			English	Article							I DIABETES-MELLITUS; CARDIAC ANTIBODIES; AUTOANTIBODIES; ASSOCIATION	Organ-specific antibodies are found in patients with autoimmune disease and their symptom-free relatives many years before clinical onset. Organ-specific cardiac antibodies can be found in patients with dilated cardiomyopathy (DCM) and their relatives, which supports the idea that DCM is an autoimmune disease. We did non-invasive cardiological assessment and antibody screening in 342 symptom-free relatives (170 male, 172 female, mean [SD] age 31 [16] years). 177 relatives were from 33 families with more than 1 affected individual (familial DCM) and 165 relatives from 31 families with only 1 affected member (non-familial DCM). The frequency of cardiac antibodies was higher among relatives of DCM patients than in controls (20% vs 3.5%, p = 0.0001). In 37 (58%) of the families studied, cardiac antibodies were found in the proband and/or in at least 1 family member and were more common in familial than in non-familial DCM (24% vs 15%, p = 0.036). Antibody-positive relatives were younger (26 [15] vs 33 [17] years, p = 0.01) and had a larger mean echocardiographic left ventricular end-systolic dimension (35 [6] vs 32 [6], p = 0.01 mm) and reduced percentage fractional shortening compared with antibody-negative relatives (31 [6] vs 34 [6], p = 0.008). Presence of cardiac-specific autoantibodies in symptom-free DCM relatives provides evidence of autoimmunity in a subset of our patients (58%), including familial and nonfamilial forms of DCM. These antibodies are associated with mild left ventricular systolic dysfunction on echocardiography and may be early markers for relatives at risk of DCM.	ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT CARDIOVASC PATHOL,LONDON SW17 0RE,ENGLAND; UNIV PADUA,INST CLIN MED,DEPT CARDIOL,PADUA,ITALY; LONDON HOSP,COLL MED,DEPT IMMUNOL,LONDON E1 1BB,ENGLAND; SAN CAMILLO HOSP,ROME,ITALY; INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY; UNIV HOSP TRIESTE,TRIESTE,ITALY	St Georges University London; St Georges University London; University of Padua; University of London; Queen Mary University London; International Center for Genetic Engineering & Biotechnology (ICGEB)			Caforio, Alida/AAC-3223-2019; McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460; Mestroni, Luisa/0000-0003-1116-2286; Caforio, Alida Linda Patrizia/0000-0002-4901-5655				Aretz HT, 1985, AM J CARDIOL PATHOL, V1, P1; BRANDENBURG RO, 1981, CIRCULATION, V64, pA437; CAFORIO ALP, 1992, TISSUE ANTIGENS, V39, P236, DOI 10.1111/j.1399-0039.1992.tb01941.x; CAFORIO ALP, 1992, CIRCULATION, V85, P1734, DOI 10.1161/01.CIR.85.5.1734; CAFORIO ALP, 1991, LANCET, V337, P1111, DOI 10.1016/0140-6736(91)92784-Y; CAFORIO ALP, 1990, J AM COLL CARDIOL, V15, P1527, DOI 10.1016/0735-1097(90)92821-I; CARLQUIST JF, 1991, CIRCULATION, V83, P515, DOI 10.1161/01.CIR.83.2.515; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; KARJALAINEN J, 1989, NEW ENGL J MED, V320, P881, DOI 10.1056/NEJM198904063201401; KLEIN R, 1984, CLIN EXP IMMUNOL, V58, P283; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; MAGNUSSON Y, 1990, J CLIN INVEST, V86, P1658, DOI 10.1172/JCI114888; MAISCH B, 1983, AM J CARDIOL, V52, P1072, DOI 10.1016/0002-9149(83)90535-0; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MESTRONI L, 1990, AM J CARDIOL, V65, P1449, DOI 10.1016/0002-9149(90)91353-8; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; NEUMANN DA, 1990, J AM COLL CARDIOL, V16, P839; SCHULTHEISS HP, 1985, J MOL CELL CARDIOL, V17, P603, DOI 10.1016/S0022-2828(85)80029-8; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; SRIKANTA S, 1983, NEW ENGL J MED, V308, P322, DOI 10.1056/NEJM198302103080607; ZACHARA E, 1993, BRIT HEART J, V69, P129; 1978, AM J CARDIOL, V0041, P00130	23	124	126	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					773	777		10.1016/S0140-6736(94)92339-6	http://dx.doi.org/10.1016/S0140-6736(94)92339-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916071				2022-12-28	WOS:A1994PG17800008
J	DOUGLAS, NJ; POLO, O				DOUGLAS, NJ; POLO, O			PATHOGENESIS OF OBSTRUCTIVE SLEEP APNOEA/HYPOPNOEA SYNDROME	LANCET			English	Article							APNEA HYPOPNEA SYNDROME; UPPER AIRWAY; DAYTIME SLEEPINESS; NORMAL HUMANS; SNORERS; MEN; AGE; DIMENSIONS; PHARYNX; SITES		UNIV TURKU,DEPT PHYSIOL,TURKU,FINLAND	University of Turku	DOUGLAS, NJ (corresponding author), UNIV EDINBURGH,ROYAL INFIRM,DEPT MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.		Douglas, Neil/B-1491-2013					BRADLEY TD, 1986, NEW ENGL J MED, V315, P1327, DOI 10.1056/NEJM198611203152105; BROOKS LJ, 1992, AM REV RESPIR DIS, V146, P1394, DOI 10.1164/ajrccm/146.6.1394; BROWN IG, 1985, AM REV RESPIR DIS, V132, P211; BURGER CD, 1992, AM REV RESPIR DIS, V145, P846, DOI 10.1164/ajrccm/145.4_Pt_1.846; CHABAN R, 1988, LARYNGOSCOPE, V98, P641; CHESHIRE K, 1992, ARCH INTERN MED, V152, P538, DOI 10.1001/archinte.152.3.538; DAVIES RJO, 1990, EUR RESPIR J, V3, P509; DAVIES RJO, 1993, J APPL PHYSIOL, V74, P1123, DOI 10.1152/jappl.1993.74.3.1123; DOUGLAS NJ, 1993, THORAX, V48, P719, DOI 10.1136/thx.48.7.719; GLEADHILL IC, 1991, AM REV RESPIR DIS, V143, P1300, DOI 10.1164/ajrccm/143.6.1300; GOULD GA, 1988, AM REV RESPIR DIS, V128, P874; GUILLEMINAULT C, 1991, CHEST, V99, P40, DOI 10.1378/chest.99.1.40; HARALDSSON PO, 1990, ORL J OTO-RHINO-LARY, V52, P57, DOI 10.1159/000276104; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; HORNER RL, 1989, EUR RESPIR J, V2, P613; HUDGEL DW, 1988, AM REV RESPIR DIS, V138, P1542, DOI 10.1164/ajrccm/138.6.1542; Jennum, 1992, J Sleep Res, V1, P240; KIMOFF RJ, 1994, AM J RESP CRIT CARE, V149, P707, DOI 10.1164/ajrccm.149.3.8118640; LAKS L, 1992, American Review of Respiratory Disease, V145, pA865; MARTIN SE, 1994, AM J RESP CRIT CARE, V149, pA147; MATHUR R, 1993, AM REV RESPIR DIS, V147, pA233; MEZZANOTTE WS, 1992, J CLIN INVEST, V89, P1571, DOI 10.1172/JCI115751; PARTINEN M, 1990, CHEST, V97, P27, DOI 10.1378/chest.97.1.27; PHILLIPSON EA, 1993, NEW ENGL J MED, V328, P1271, DOI 10.1056/NEJM199304293281712; RODENSTEIN DO, 1990, THORAX, V45, P722, DOI 10.1136/thx.45.10.722; SHELTON KE, 1993, AM REV RESPIR DIS, V148, P462, DOI 10.1164/ajrccm/148.2.462; SMITH PL, 1988, J APPL PHYSIOL, V64, P789, DOI 10.1152/jappl.1988.64.2.789; STAUFFER JL, 1989, AM REV RESPIR DIS, V140, P724, DOI 10.1164/ajrccm/140.3.724; STEWART DA, 1992, AM REV RESPIR DIS, V146, P1389, DOI 10.1164/ajrccm/146.6.1389; STRADLING JR, 1990, BRIT MED J, V300, P75, DOI 10.1136/bmj.300.6717.75; SURATT PM, 1988, AM REV RESPIR DIS, V137, P889, DOI 10.1164/ajrccm/137.4.889; WHITE DP, 1985, J APPL PHYSIOL, V58, P365, DOI 10.1152/jappl.1985.58.2.365; YILDIRIM N, 1991, AM REV RESPIR DIS, V144, P845, DOI 10.1164/ajrccm/144.4.845; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	34	111	116	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					653	655		10.1016/S0140-6736(94)92088-5	http://dx.doi.org/10.1016/S0140-6736(94)92088-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915351				2022-12-28	WOS:A1994PE38600013
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - CURRENT TRENDS AND SOME PROSPECTS FOR THE FUTURE .1.	BRITISH MEDICAL JOURNAL			English	Article								Cancer control encompasses the whole spectrum from prevention and early diagnosis to treatment and palliation, The key to the future of cancer control will be to establish multidisciplinary approaches to each type of cancer across this spectrum. For primary prevention this requires some understanding of the causes of each cancer. Although understanding of the aetiology of cancer has greatly improved, prospects for the primary prevention of many common cancers remain remote. Other approaches currently under evaluation include chemoprevention and the use of biomarkers. The identification of predisposing genes for some of the common cancers may have a considerable impact on the ability to recognise those at risk. Overall, however, mortality trends indicate that reduction of smoking remains the main priority for cancer prevention in the United Kingdom. For primary care teams, brief interventions to reduce smoking are likely to achieve the greatest benefit. This should be seen as part of broader policies aimed at achieving change in the whole population. The government must acknowledge its major responsibility to cancer prevention by banning all forms of advertising and promotion of tobacco.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							Doll R, 1981, THE CAUSES OF CANCER; Pike M. C., 1991, INTRO CELLULAR MOL B, P49	2	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					449	452		10.1136/bmj.309.6952.449	http://dx.doi.org/10.1136/bmj.309.6952.449			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920130	Green Published			2022-12-28	WOS:A1994PC40400020
J	BHATTACHARYA, I				BHATTACHARYA, I			ENDOSCOPIC ULTRASONOGRAPHY - TOWARDS A MORE PERFECT UNION	LANCET			English	Editorial Material											BHATTACHARYA, I (corresponding author), MICHAEL REESE HOSP & MED CTR,CHICAGO,IL 60616, USA.							ELMOUAAOUY A, 1992, Z GASTROENTEROL, V30, P486; LAOUDI F, 1992, ENDOSCOPY, V24, P658; MILLER LS, 1993, GASTROENTEROLOGY, V105, P31, DOI 10.1016/0016-5085(93)90007-Y; PALAZZO L, 1993, ENDOSCOPY, V25, P143, DOI 10.1055/s-2007-1010273; ROSCH T, 1992, GASTROENTEROLOGY, V102, P188; ROSCH T, 1994, ENDOSCOPY, V26, P148, DOI 10.1055/s-2007-1008941; ROSCH T, 1992, NEW ENGL J MED, V326, P1721, DOI 10.1056/NEJM199206253262601; WANG KK, 1993, GASTROENTEROLOGY, V105, P283, DOI 10.1016/0016-5085(93)90039-F; WARSHAW AL, 1990, ARCH SURG-CHICAGO, V125, P230; WIERSEMA MJ, 1993, GASTROINTEST ENDOSC, V39, P336; 1987, LANCET, V2, P431	11	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					349	350		10.1016/S0140-6736(94)91394-3	http://dx.doi.org/10.1016/S0140-6736(94)91394-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914300				2022-12-28	WOS:A1994PA30300003
J	HORTON, R				HORTON, R			THE CONTEXT OF CONSENT	LANCET			English	Editorial Material							TRIALS											BRAHAMS D, 1994, LANCET, V343, P1494, DOI 10.1016/S0140-6736(94)92599-2; Brazier M., 1992, MED PATIENTS LAW; DAWES PJD, 1994, J ROY SOC MED, V87, P149; HORTON R, 1994, LANCET, V343, P1029; SAW KC, 1994, J ROY SOC MED, V87, P143; SILVERMAN WA, 1994, LANCET, V343, P1586, DOI 10.1016/S0140-6736(94)93053-8; THORNTON HM, 1992, LANCET, V339, P44, DOI 10.1016/0140-6736(92)90157-X; WEAR S, 1993, INFORMED CONSENT PAT; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; 1994, WOMEN HLTH RES	10	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 23	1994	344	8917					211	212		10.1016/S0140-6736(94)92992-0	http://dx.doi.org/10.1016/S0140-6736(94)92992-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913152				2022-12-28	WOS:A1994NY06000004
J	WEISS, APC				WEISS, APC			THERMAL REGULATORY TESTING FOR PAIN DYSFUNCTION SYNDROMES	LANCET			English	Editorial Material							REFLEX SYMPATHETIC DYSTROPHY				WEISS, APC (corresponding author), BROWN UNIV,SCH MED,DEPT ORTHOPED,PROVIDENCE,RI 02912, USA.							AMADIO PC, 1988, J BONE JOINT SURG AM, V70A, P944, DOI 10.2106/00004623-198870060-00024; COOKE ED, 1993, J ROY SOC MED, V86, P690; HOLDER LE, 1984, RADIOLOGY, V152, P517, DOI 10.1148/radiology.152.2.6739825; KOMAN LA, 1984, J HAND SURG-AM, V9A, P305, DOI 10.1016/S0363-5023(84)80214-2; LINSON MA, 1983, J HAND SURG-AM, V8, P153, DOI 10.1016/S0363-5023(83)80006-9; POCHACZEVSKY R, 1987, AM J SPORT MED, V15, P243, DOI 10.1177/036354658701500309; POLLOCK FE, 1993, J HAND SURG-AM, V18A, P847; WERNER R, 1989, J HAND SURG-AM, V14A, P520, DOI 10.1016/S0363-5023(89)80016-4; 1986, PAIN S3, V26, pS29	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					209	210		10.1016/S0140-6736(94)92990-4	http://dx.doi.org/10.1016/S0140-6736(94)92990-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913150				2022-12-28	WOS:A1994NY06000002
J	GLYNN, JR				GLYNN, JR			HELICOBACTER-PYLORI AND THE HEART	LANCET			English	Editorial Material							ADULT LIFE; INFANCY				GLYNN, JR (corresponding author), LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1,ENGLAND.							BARKER DJP, 1989, LANCET, V2, P577; BENSHLOMO Y, 1991, LANCET, V337, P1489, DOI 10.1016/0140-6736(91)93190-K; MENDALL MA, 1994, BRIT HEART J, V71, P437; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MERTENS TE, 1993, LANCET, V342, P418, DOI 10.1016/0140-6736(93)92820-J; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; WHITAKER CJ, 1993, EPIDEMIOL INFECT, V111, P63, DOI 10.1017/S0950268800056685	7	29	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					146	146		10.1016/S0140-6736(94)92754-5	http://dx.doi.org/10.1016/S0140-6736(94)92754-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912762				2022-12-28	WOS:A1994NW81000006
J	CAPLICE, NM; WEST, MJ; CAMPBELL, GR; CAMPBELL, J				CAPLICE, NM; WEST, MJ; CAMPBELL, GR; CAMPBELL, J			INHIBITION OF HUMAN VASCULAR SMOOTH-MUSCLE CELL-GROWTH BY HEPARIN	LANCET			English	Note							EXPRESSION	We examined the inhibitory effect of heparin on vascular smooth muscle cell (VSMC) outgrowth from cultured coronary artery explants of primary atherosclerotic lesions and of undiseased regions from the same patients, compared with explant outgrowth from control patients (idiopathic cardiomyopathy) with no evidence of atherosclerosis. For undiseased tissue regardless of origin, heparin significantly delayed half-maximum percentage explant outgrowth time (mean difference from control treatment 2.1 [SE 0.8] days for atherosclerosis patients and 2.3 [1.0] days for control patients). For plaque tissue, hepa rin had no such effect. Thus the proliferative state of the cells involved in outgrowth may influence the activity of heparin.	UNIV QUEENSLAND,DEPT ANAT SCI,VASC BIOL RES CTR,BRISBANE,QLD,AUSTRALIA	University of Queensland	CAPLICE, NM (corresponding author), UNIV QUEENSLAND,PRINCE CHARLES HOSP,DEPT MED,BRISBANE,QLD 4032,AUSTRALIA.		CAMPBELL, GORDON/AAK-7979-2021; west, malcolm J/C-9425-2009	CAMPBELL, GORDON/0000-0003-1263-1988; west, malcolm J/0000-0002-7629-5277; Caplice, Noel/0000-0001-5445-1016				AU YPT, 1992, CIRC RES, V70, P1062, DOI 10.1161/01.RES.70.5.1062; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P21, DOI 10.1002/jcp.1041240105; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHAN P, 1993, LANCET, V341, P341, DOI 10.1016/0140-6736(93)90139-8; CLOWES AW, 1988, J CELL BIOL, V107, P1939, DOI 10.1083/jcb.107.5.1939; CLOWES AW, 1992, CIRC RES, V70, P1128, DOI 10.1161/01.RES.70.6.1128; LEVINE S, 1985, AM J CARDIOL, V55, P673, DOI 10.1016/0002-9149(85)90134-1; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427	8	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					97	98		10.1016/S0140-6736(94)91283-1	http://dx.doi.org/10.1016/S0140-6736(94)91283-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912394				2022-12-28	WOS:A1994NV73200011
J	THOMPSON, WG				THOMPSON, WG			DOUBTS ABOUT BRAN	LANCET			English	Editorial Material							IRRITABLE BOWEL SYNDROME				THOMPSON, WG (corresponding author), UNIV OTTAWA,OTTAWA CIVIC HOSP,DIV GASTROENTEROL,DIGEST DIS RES GRP,OTTAWA,ON,CANADA.							BANNISTER JJ, 1987, GUT, V28, P1246, DOI 10.1136/gut.28.10.1246; Burkitt D P, 1972, Lancet, V2, P1408; CANN PA, 1984, GUT, V25, P168, DOI 10.1136/gut.25.2.168; Heaton K W, 1989, PATHOGENESIS FUNCTIO, P79; JONES VA, 1982, LANCET, V2, P1115; MITCHELL CM, 1987, GASTROENTEROLOGY, V92, P1282, DOI 10.1016/S0016-5085(87)91099-7; PEARSON DJ, 1986, BRIT MED J, V292, P221, DOI 10.1136/bmj.292.6515.221; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423; [No title captured]	9	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					3	3		10.1016/S0140-6736(94)91039-1	http://dx.doi.org/10.1016/S0140-6736(94)91039-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912300				2022-12-28	WOS:A1994NU91700002
J	SCHNITZER, JJ; ROY, SM				SCHNITZER, JJ; ROY, SM			HEALTH-SERVICES IN GAZA UNDER THE AUTONOMY PLAN	LANCET			English	Article							WEST BANK; ISRAEL	The Gaza Strip now has limited self-rule. Its people inherit a health-care system provided by four sectors-the Israeli government, the UN Relief and Works Agency, nongovernmental organisations, and private facilities. They also inherit a legacy of health indices comparing unfavourably with those of Israel, huge numbers of refugees, a looming water crisis, civil unrest, and a health care expenditure bill (as a proportion of gross domestic product) that will be unsustainable. Four plans have been drawn up for health services in autonomous Gaza but none is exactly right.	HARVARD UNIV,CTR MIDDLE EASTERN STUDIES,CAMBRIDGE,MA 02138	Harvard University	SCHNITZER, JJ (corresponding author), MASSACHUSETTS GEN HOSP,PEDIAT SURG SERV,BOSTON,MA 02114, USA.							ANDERSSON G, 1986, LANCET, V2, P577; BARGHOUTHI M, 1993, PALESTINIAN HLTH; BELLISARI A, 1994, J PALESTINE STUD, V23, P52, DOI 10.1525/jps.1994.23.2.00p0052r; BRUINS HJ, 1992, WATER GAZA STRIP; GIACMAN R, 1993, HLTH CONDITIONS SERV; GREENHOUSE S, 1993, NY TIMES        1002, P2; HAUSMAN LJ, 1993, SECURING PEACE MIDDL; LASCH E E, 1990, Harefuah, V118, P522; LASCH EE, 1983, ISRAEL J MED SCI, V19, P995; LILIENFIELD LS, 1986, NEW ENGL J MED, V315, P595, DOI 10.1056/NEJM198608283150932; Nixon A. E, 1990, STATUS PALESTINIAN C; ROY S, 1986, GAZA STRIP SURVEY; ROY SM, 1993, J PALESTINE STUD, V22, P20, DOI 10.1525/jps.1993.22.4.00p00037; SCHNITZER JJ, 1993, SURG GYNECOL OBSTET, V176, P172; Schnitzker JJ, 1992, PSRQ, V2, P25; TULCHINSKY T, 1989, AM J PUBLIC HEALTH, V79, P1648, DOI 10.2105/AJPH.79.12.1648; TULCHINSKY TH, 1990, ISRAEL J MED SCI, V26, P438; TULCHINSKY TH, 1990, REV INFECT DIS, V12, P951; VERMUND SH, 1985, LANCET, V2, P1121; 1993, HLTH CONDITIONS ARAB; 1994, SPECIAL TECHNICAL AS; 1993, REPORT GAZA STRIP; 1993, INTERIM ACTION PLAN; 1991, 1991 WORLD BANK WORL; 1990, MED WAR, V6, P140; 1993, DEV OCCUPIED TERRITO; 1993, EMERGENCY ASSISTANCE	27	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1614	1617		10.1016/S0140-6736(94)93063-5	http://dx.doi.org/10.1016/S0140-6736(94)93063-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NU354	7911926				2022-12-28	WOS:A1994NU35400016
J	ASTROW, AB				ASTROW, AB			TIMING OF BREAST-CANCER SURGERY - NODES, HORMONES, AND RETROSPECTOSCOPY	LANCET			English	Editorial Material							PREMENOPAUSAL WOMEN; MENSTRUAL-CYCLE; MASTECTOMY; SURVIVAL				ASTROW, AB (corresponding author), ST VINCENTS HOSP & MED CTR,DEPT MED,NEW YORK,NY 10011, USA.							BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; HRUSHESKY WJM, 1989, LANCET, V2, P52; MCGUIRE WL, 1991, ANN INTERN MED, V115, P401, DOI 10.7326/0003-4819-115-5-401; NATHAN B, 1993, BRIT J SURG, V80, P43, DOI 10.1002/bjs.1800800115; SAAD Z, 1994, BRIT J SURG, V81, P217, DOI 10.1002/bjs.1800810219; STONELAKE PS, 1993, BRIT J CANCER, V67, P16	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1517	1518		10.1016/S0140-6736(94)92933-5	http://dx.doi.org/10.1016/S0140-6736(94)92933-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911866				2022-12-28	WOS:A1994NR32900003
J	STAESSEN, JA; LAUWERYS, RR; IDE, G; ROELS, HA; VYNCKE, G; AMERY, A				STAESSEN, JA; LAUWERYS, RR; IDE, G; ROELS, HA; VYNCKE, G; AMERY, A			RENAL-FUNCTION AND HISTORICAL ENVIRONMENTAL CADMIUM POLLUTION FROM ZINC SMELTERS	LANCET			English	Article							GENERAL-POPULATION; BLOOD-PRESSURE; CREATININE; HEALTH; EXPOSURE; METALS; SERUM; LEAD	We investigated whether there was an association between renal function and cadmium pollution in areas with different exposures. Cadmium was measured in the soil and in vegetables in 10 districts, 6 of which were close to zinc smelters; and renal function and the concentrations of metals in blood and urine were measured in 703 randomly selected residents. 6 polluted areas, compared with 4 others showed higher cadmium concentrations in the soil (4.86 vs 0.81 ppm) and in locally grown vegetables, such as celery (2.43 vs 0.68 ppm) and beans (0.42 vs 0.15 ppm). Residents in polluted areas had higher urinary cadmium (10.5 vs 7.9 nmol/24 hours) and copper (0.16 vs 0.14 mu mol/24 hours); higher serum creatinine (100 vs 97 mu mol/L) urinary excretions of beta(2)-microglobulin (109 vs 95 mu g/24 hours), retinol-binding-protein (136 vs 118 mu g/24 hours), and N-acetyl-beta-glucosaminidase (1.78 vs 1.38 U/24 hours). Serum zinc (12.2 vs 12.6 mu mol/L and creatinine clearance (87 vs 92 mL/min) were reduced in the 6 polluted areas. In all 10 districts, cadmium in the soil was positively correlated with cadmium in celery (r=0.77), in beans (r=0.67), and in residents' urine (r=0.76). The creatinine clearance was inversely correlated with cadmium in soil (r=-0.78), in celery (r=-0.90), and in beans (r=-0.70). Past emissions from zinc smelters gave rise to contamination of the environment with cadmium, which gets into the food chain and has the potential to cause renal dysfunction and alterations in zinc and copper homeostatis.	KATHOLIEKE UNIV LEUVEN, DEPT MOLEC & CARDIOVASC RES, HYPERTENS & CARDIOVASC REHABIL UNIT, LOUVAIN, BELGIUM; UNIV CATHOLIQUE LOUVAIN, IND TOXICOL & OCCUPAT MED UNIT, BRUSSELS, BELGIUM; LISEC, ECOL & FORESTRY RES CTR, GHENT, BELGIUM; MINIST FLEMISH COMMUNITY, PROV HLTH INSPECTORATE LIMBURG, HASSELT, BELGIUM	KU Leuven; Universite Catholique Louvain			Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				ADAMS RG, 1969, Q J MED, V38, P425; [Anonymous], 1980, CLASSIFICATION OCCUP; AXELSSON B, 1968, ARCH ENVIRON HEALTH, V17, P24, DOI 10.1080/00039896.1968.10665182; BARTELS H, 1971, CLIN CHIM ACTA, V32, P81, DOI 10.1016/0009-8981(71)90467-0; BERNARD A, 1984, EXPERIENTIA, V40, P143, DOI 10.1007/BF01963577; BERNARD AM, 1983, CLIN CHEM, V29, P1007; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Ewers U, 1993, Gesundheitswesen, V55, P318; Friberg L, 1950, ACTA MED SCAND  S240, V138, P1, DOI DOI 10.1111/J.0954-6820.1950.TB10091.X; HILBRANDS LB, 1991, KIDNEY INT, V40, P1171, DOI 10.1038/ki.1991.331; KARLSSON FA, 1980, SCAND J CLIN LAB I S, V154, P27; KELSON J, 1978, CLIN CHEM, V25, P240; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; LAUWERYS RR, 1979, ENVIRON HEALTH PERSP, V28, P137, DOI 10.2307/3428916; MORGAN H, 1988, SCI TOTAL ENVIRON, V75, P135, DOI 10.1016/0048-9697(88)90162-3; NAGAWA K, 1984, ENVIRON RES, V33, P29; NORDBERG GF, 1991, ENVIRON HEALTH PERSP, V91, P3, DOI 10.1289/ehp.91913; ONOSAKA S, 1981, TOXICOLOGY, V22, P91, DOI 10.1016/0300-483X(81)90109-8; OVERSTEYNS M, 1992, TIJDSCHR GENEESKUNDE, V48, P311; PERSIJN JP, 1976, J CLIN CHEM CLIN BIO, V14, P421; ROELS HA, 1989, BRIT J IND MED, V46, P755; Saito H, 1977, Contrib Nephrol, V6, P1; SCOKART PO, 1983, WATER AIR SOIL POLL, V20, P451, DOI 10.1007/BF00208519; SHERLOCK JC, 1983, CADMIUM 83, P107; STAESSEN J, 1991, AM J EPIDEMIOL, V134, P257, DOI 10.1093/oxfordjournals.aje.a116079; STAESSEN J, 1988, J HYPERTENS, V6, P965, DOI 10.1097/00004872-198812000-00003; STAESSEN J, 1991, BR J IND MED, V45, P710; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; STAESSEN JA, 1992, ENVIRON RES, V58, P25, DOI 10.1016/S0013-9351(05)80202-6; TUCKER S, 1975, CLIN CHIM ACTA, V32, P333; WATANABE H, 1973, 24 KANK HOK REP, P122	32	83	85	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	1994	343	8912					1523	1527		10.1016/S0140-6736(94)92936-X	http://dx.doi.org/10.1016/S0140-6736(94)92936-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911869				2022-12-28	WOS:A1994NR32900006
J	FRANTZ, TD; RASGON, BM; QUESENBERRY, CP				FRANTZ, TD; RASGON, BM; QUESENBERRY, CP			ACUTE EPIGLOTTITIS IN ADULTS - ANALYSIS OF 129 CASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To characterize the clinical features of acute epiglottitis in adults and to identify factors associated with airway intervention. Design.-Case series. Setting.-Northern California health maintenance organization. Participants.-A total of 129 patients aged 18 years or older with laryngoscopically confirmed acute epiglottitis admitted from November 1986 through October 1991. Results.-The mean patient age was 47 years (range, 18 to 85 years) and the male-to-female ratio was 1.8 to 1.0 (P<.001). The most common symptoms were sore throat (95% and odynophagia (94%); the most common signs were muffled voice and evidence of pharyngitis. Nineteen patients (15%) received airway intervention, including seven with tracheotomy and 12 with endotracheal intubation. The remaining 110 patients recovered fully without airway intervention. In multivariate analysis, factors associated with airway intervention were strider (relative risk [RR], 6.2; 95% confidence interval [CI], 1.7 to 22.9) and sitting erect (RR, 4.8; 95% CI, 1.3 to 16.1). Six (12%) of 52 blood cultures yielded Haemophilus influenzae type b. Major complications occurred in six patients (5%), but no deaths occurred. Conclusion.-Most adults who have acute epiglottitis can be managed conservatively and have low morbidity and mortality.	KAISER PERMANENTE MED CTR,DEPT HEAD & NECK SURG,OAKLAND,CA 94611; KAISER PERMANENTE MED CARE PROGRAM,DIV RES,OAKLAND,CA 94611	Kaiser Permanente; Kaiser Permanente								BAXTER FJ, 1988, CAN J ANAESTH, V35, P428, DOI 10.1007/BF03010869; DEEB ZE, 1985, LARYNGOSCOPE, V95, P289; FRANTZ TD, 1993, OTOLARYNG HEAD NECK, V109, P457, DOI 10.1177/019459989310900311; KHILANANI U, 1984, AM J MED SCI, V287, P65, DOI 10.1097/00000441-198401000-00022; OSSOFF RH, 1980, LARYNGOSCOPE, V90, P1155, DOI 10.1288/00005537-198007000-00011; SHAPIRO J, 1988, JAMA-J AM MED ASSOC, V259, P563, DOI 10.1001/jama.259.4.563; SHEIKH KH, 1989, WESTERN J MED, V151, P520; SHIH L, 1988, ANN OTO RHINOL LARYN, V97, P527, DOI 10.1177/000348948809700517; SMITH MFM, 1986, NEW ENGL J MED, V314, P1133; STANLEY RE, 1988, J LARYNGOL OTOL, V102, P1017, DOI 10.1017/S0022215100107157; WOLF M, 1990, LARYNGOSCOPE, V100, P183	11	118	120	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1358	1360		10.1001/jama.272.17.1358	http://dx.doi.org/10.1001/jama.272.17.1358			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933397				2022-12-28	WOS:A1994PP02000031
J	LEVETOWN, M; POLLACK, MM; CUERDON, TT; RUTTIMANN, UE; GLOVER, JJ				LEVETOWN, M; POLLACK, MM; CUERDON, TT; RUTTIMANN, UE; GLOVER, JJ			LIMITATIONS AND WITHDRAWALS OF MEDICAL INTERVENTION IN PEDIATRIC CRITICAL CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOT-RESUSCITATE ORDERS; INTENSIVE-CARE; ILL PATIENTS; ETHICS	Objective.-To investigate the use and implementation in pediatric intensive care units (PICUs) of three levels of restriction of medical intervention: do not resuscitate (DNR), additional limitations of medical interventions beyond DNR, and withdrawal of care. Design.-Consecutive patients admitted between December 1989 and January 1992. Setting.-A total of 16 PICUs randomly selected to represent variability in size, teaching status, and presence or absence of a pediatric intensivist and unit coordination. Main Outcome Measures.-Profiles of children undergoing restrictions of medical interventions including the influence of chronic disease, the justifications for restrictions, and description of implementation practices. Patients.-All pediatric admissions undergoing restrictions (n = 119) drawn from 5415 consecutive PICU admissions. Results.-A total of 94 (79%) of the restriction patients died during the PICU course, representing 38% of all deaths. A total of 73 restrictions (61%) resulted from acute disease, most involving the central nervous system or respiratory system. Restrictions were evenly divided between DNR (39%), additional limitations of medical intervention beyond DNR (27%), and withdrawals of medical intervention (34%). Survival decreased with increasing levels of restriction from 35% of DNR patients to 9% of patients with additional limitations and 2% of withdrawal patients. Imminent death was cited as the justification for restrictions in 70% of cases, no relational potential was cited in 22%, and excessive burden was cited in 8%. Conclusions.-Restrictions of medical intervention were used in all PICUs surveyed. Although severe chronic disease was common among restriction patients, acute disease was the predominant event precipitating placement of restrictions. Imminent death, not quality of life or excessive burden, was the most common justification.	CHILDRENS NATL MED CTR,DEPT CRIT CARE MED,WASHINGTON,DC 20010; CHILDRENS NATL MED CTR,CTR HLTH SERV & CLIN RES,CHILDRENS RES INST,WASHINGTON,DC; CHILDRENS NATL MED CTR,DEPT PEDIAT,WASHINGTON,DC; GEORGE WASHINGTON UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC 20052; GEORGE WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,WASHINGTON,DC; GEORGE WASHINGTON UNIV,SCH MED,DEPT HLTH CARE SCI,WASHINGTON,DC; NIAAA,BETHESDA,MD	Children's National Health System; Children's National Health System; Children's National Health System; George Washington University; George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)					PHS HHS [MCH-110584] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams FH, 1989, HEART DISEASE INFANT; American College of Physicians Ethics Manual, 1989, ANN INTERN MED, V111, P327; [Anonymous], 1985, CHILD ABUSE AMENDMEN; [Anonymous], 1990, CRIT CARE MED, V18, P1435; ARRAS JD, 1984, HASTINGS CENT REP, V14, P25, DOI 10.2307/3561882; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; HAINES IE, 1990, MED J AUSTRALIA, V153, P225, DOI 10.5694/j.1326-5377.1990.tb136867.x; JECKER NS, 1991, HASTINGS CENT REP, V21, P5, DOI 10.2307/3563315; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; LANTOS JD, 1993, CRIT CARE MED, V21, P52, DOI 10.1097/00003246-199301000-00012; MINK RB, 1992, PEDIATRICS, V89, P961; Nelson L J, 1989, Law Med Health Care, V17, P316; NELSON LJ, 1992, CRIT CARE MED, V20, P427, DOI 10.1097/00003246-199203000-00022; POLLACK MM, 1987, NEW ENGL J MED, V316, P134, DOI 10.1056/NEJM198701153160304; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; RUDOLPH AE, 1991, PEDIATRICS; SCHAFFNER KF, 1988, CRIT CARE MED, V16, P1069, DOI 10.1097/00003246-198810000-00022; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Smith, 1982, RECOGNIZABLE PATTERN; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WHITELAW A, 1986, LANCET, V2, P328; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; 1987, GUIDELINES TERMINATI; 1992, CODE MED ETHICS CURR	28	50	53	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1271	1275		10.1001/jama.272.16.1271	http://dx.doi.org/10.1001/jama.272.16.1271			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933372				2022-12-28	WOS:A1994PN06800033
J	PARRATT, J; TAGGART, M; WRAY, S				PARRATT, J; TAGGART, M; WRAY, S			ABOLITION OF CONTRACTIONS IN THE MYOMETRIUM BY ACIDIFICATION IN-VITRO	LANCET			English	Note							METABOLIC INHIBITION; INTRACELLULAR PH; FORCE PRODUCTION; UTERINE; RAT	Uterine dystocia, often of unknown cause, remains one of the commonest causes of emergency caesarean section. We have tested the hypothesis that small acidic changes in pH, that can occur during labour contractions, can decrease contractions and contribute to dystocia. We simultaneously recorded intracellular pH (pH(i)) and force in human myometrium: acidification abolished contractions. Such effects of pH(i) on uterine contractile acitivity may be of clinical significance. Blood flow reduces during each uterine contraction; the resulting fall in pH(i) could lead to inefficient uterine action in some labours and failure to progress (ie, dystocia).	UNIV LIVERPOOL,DEPT PHYSIOL,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool			Taggart, Michael/A-1288-2012; wray, susan/B-1197-2009	Taggart, Michael/0000-0002-9981-2783; Wray, Susan/0000-0002-0086-1359				BEISCHER NA, 1986, OBSTETRICS NEWBORN, P443; BRAR HS, 1988, AM J OBSTET GYNECOL, V158, P952, DOI 10.1016/0002-9378(88)90100-7; GREISS FC, 1965, AM J OBSTET GYNECOL, V93, P917, DOI 10.1016/0002-9378(65)90150-X; HARRISON N, 1994, J PHYSIOL-LONDON, V476, P349, DOI 10.1113/jphysiol.1994.sp020136; PHOENIX J, 1993, J REPROD FERTIL, V97, P507; TAGGART M, 1993, PFLUG ARCH EUR J PHY, V423, P527, DOI 10.1007/BF00374951; TAGGART MJ, 1993, J PHYSIOL-LONDON, V472, P23, DOI 10.1113/jphysiol.1993.sp019933; WRAY S, 1990, J PHYSIOL-LONDON, V423, P411, DOI 10.1113/jphysiol.1990.sp018030; WRAY S, 1992, EXP PHYSIOL, V77, P307, DOI 10.1113/expphysiol.1992.sp003590; WRAY S, 1993, AM J PHYSIOL, V264, pC1, DOI 10.1152/ajpcell.1993.264.1.C1	10	31	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					717	718		10.1016/S0140-6736(94)92209-8	http://dx.doi.org/10.1016/S0140-6736(94)92209-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915777				2022-12-28	WOS:A1994PF18700011
J	COLOVER, J				COLOVER, J			FUNCTIONAL DUALISM IN THE NERVOUS-SYSTEM	LANCET			English	Editorial Material							VISUAL-SYSTEM; ORGANIZATION; CELLS				COLOVER, J (corresponding author), UNITED MED & DENT SCH, RAYNE INST, DEPT IMMUNOL, ST THOMAS CAMPUS, LONDON SE1 7EH, ENGLAND.							BEHAN M, 1992, J COMP NEUROL, V315, P230, DOI 10.1002/cne.903150209; BEHRMAN S, 1958, BRAIN, V81, P529, DOI 10.1093/brain/81.4.529; Cushing H, 1916, J NERV MENT DIS, V44, P312; Hartline HK, 1938, AM J PHYSIOL, V121, P400, DOI 10.1152/ajplegacy.1938.121.2.400; Head H, 1905, BRAIN, V28, P99, DOI 10.1093/brain/28.2.99; HUBEL DH, 1985, NATURE, V315, P325, DOI 10.1038/315325a0; IKEDA H, 1988, DOC OPHTHALMOL, V69, P175, DOI 10.1007/BF00153699; IKEDA H, 1972, J PHYSIOL-LONDON, V227, P769, DOI 10.1113/jphysiol.1972.sp010058; IKEDA T, 1985, POLAR BIOL, V4, P1, DOI 10.1007/BF00286811; JAIN KK, 1993, J ROY SOC MED, V86, P133; MCCONNELL SK, 1986, J COMP NEUROL, V250, P109, DOI 10.1002/cne.902500110; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; SHIPP S, 1985, NATURE, V315, P322, DOI 10.1038/315322a0; ZEKI S, 1990, COLD SPRING HARB SYM, V55, P651	14	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 3	1994	344	8923					670	671		10.1016/S0140-6736(94)92092-3	http://dx.doi.org/10.1016/S0140-6736(94)92092-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915355				2022-12-28	WOS:A1994PE38600017
J	YUSUF, S; ZUCKER, D; PEDUZZI, P; FISHER, LD; TAKARO, T; KENNEDY, JW; DAVIS, K; KILLIP, T; PASSAMANI, E; NORRIS, R; MORRIS, C; MATHUR, V; VARNAUSKAS, E; CHALMERS, TC				YUSUF, S; ZUCKER, D; PEDUZZI, P; FISHER, LD; TAKARO, T; KENNEDY, JW; DAVIS, K; KILLIP, T; PASSAMANI, E; NORRIS, R; MORRIS, C; MATHUR, V; VARNAUSKAS, E; CHALMERS, TC			EFFECT OF CORONARY-ARTERY BYPASS GRAFT-SURGERY ON SURVIVAL - OVERVIEW OF 10-YEAR RESULTS FROM RANDOMIZED TRIALS BY THE CORONARY-ARTERY BYPASS GRAFT-SURGERY TRIALISTS COLLABORATION	LANCET			English	Article							DISEASE	We carried out a systematic overview using individual patient data from the seven randomised trials that have compared a strategy of initial coronary artery bypass graft (CABG) surgery with one of initial medical therapy to assess the effects on mortality in patients with stable coronary heart disease (stable angina not severe enough to necessitate surgery on grounds of symptoms alone, or myocardial infarction). 1324 patients were assigned CABG surgery and 1325 medical management between 1972 and 1984. The proportion of patients in the medical treatment group who had undergone CABG surgery was 25% at 5 years, 33% at 7 years, and 41% at 10 years: 93.7% of patients assigned to the surgery group underwent CABG surgery. The CABG group had significantly lower mortality than the medical treatment group at 5 years (10.2 vs 15.8%; odds ratio 0.61 [95% CI 0.48-0.77], p=0.0001), 7 years (15.8 vs 21.7%; 0.68 [0.56-0.83], p<0.001), and 10 years (26.4 vs 30.5%; 0.83 [0.70-0.98]; p=0.03). The risk reduction was greater in patients with left main artery disease than in those with disease in three vessels or one or two vessels (odds ratios at 5 years 0.32, 0.58, and 0.77, respectively). Although relative risk reductions in subgroups defined by other baseline characteristics were similar, the absolute benefits of CABG surgery were most pronounced in patients in the highest risk categories. This effect was most evident when several prognostically important clinical and angiographic risk factors were integrated to stratify patients by risk levels and the extension of survival at 10 years was examined (change in survival -1.1 [SE 3.1] months in low-risk group, 5.0 [4.2] months in moderate-risk group, and 8.8 [5.4] months in high-risk group; p for trend < 0.003). A strategy of initial CABG surgery is associated with lower mortality than one of medical management with delayed surgery if necessary, especially in high-risk and medium-risk patients with stable coronary heart disease. In low-risk patients, the limited data show a non-significant trend towards greater mortality with CABG.	NHLBI,BETHESDA,MD; MCMASTER UNIV,HAMILTON,ON,CANADA; HEBREW UNIV JERUSALEM,JERUSALEM,ISRAEL; VET AFFAIRS COOPERAT STUDIES PROGRAM,W HAVEN,CT; UNIV WASHINGTON,SEATTLE,WA; BETH ISRAEL HOSP,NEW YORK,NY; GREEN LANE HOSP,AUCKLAND,NEW ZEALAND; OREGON HLTH SCI UNIV,PORTLAND,OR; TEXAS HEART INST,HOUSTON,TX; GOTHENBURG UNIV,GOTHENBURG,SWEDEN; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; TUFTS UNIV,BOSTON,MA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); McMaster University; Hebrew University of Jerusalem; University of Washington; University of Washington Seattle; Oregon Health & Science University; Texas Heart Institute; University of Gothenburg; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University				Yusuf, Salim/0000-0003-4776-5601				BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; Favaloro R G, 1968, Ann Thorac Surg, V5, P334; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; IRWIN JO, 1949, J HYG-CAMBRIDGE, V47, P188, DOI 10.1017/S0022172400014443; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KENNEDY JN, 1992, CIRCULATION, V86, P1; KLOSTER FE, 1979, NEW ENGL J MED, V300, P149, DOI 10.1056/NEJM197901253000401; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Mathur V S, 1977, Cardiovasc Clin, V8, P131; MUHLBAIER LH, 1992, CIRCULATION, V86, P198; NORRIS RM, 1981, CIRCULATION, V63, P785, DOI 10.1161/01.CIR.63.4.785; PEDUZZI PN, 1982, CONTROL CLIN TRIALS, V3, P47, DOI 10.1016/0197-2456(82)90018-6; TAKARO T, 1976, CIRCULATION, V54, P107; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1985, NEW ENGL J MED, V393, P217; 1988, BRIT MED J, V296, P320; 1983, CIRCULATION, V68, P939; 1984, NEW ENGL J MED, V311, P1333	20	1543	1621	0	34	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					563	570		10.1016/S0140-6736(94)91963-1	http://dx.doi.org/10.1016/S0140-6736(94)91963-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914958				2022-12-28	WOS:A1994PD42400007
J	EKBOM, A; WAKEFIELD, AJ; ZACK, M; ADAMI, HO				EKBOM, A; WAKEFIELD, AJ; ZACK, M; ADAMI, HO			PERINATAL MEASLES INFECTION AND SUBSEQUENT CROHNS-DISEASE	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; MORTALITY	Although the aetiology of Crohn's disease is unknown, morphological and epidemiological studies have implicated measles virus as a potential component cause, particularly when exposure occurs in utero or early in life. An increased incidence of Crohn's disease among people born during measles epidemics would support this hypothesis. We identified all individuals born in four counties in central Sweden in 1945-54 who had had Crohn's disease diagnosed before the age of 30 years. Yearly reports compiled in these counties revealed that five measles epidemics had affected all four counties during the trial period. After adjusting for monthly differences in the number of livebirths in the four counties, we calculated the expected number of patients with Crohn's disease and ulcerative colitis born during the 3-month period after the peaks of the epidemics. The number of people with Crohn's disease significantly exceeded that expected: 57 versus 39.0 (standardised incidence ratio 1.46, 95% CI 1.11-1.89). For patients with ulcerative colitis, the observed number (42) was close to that expected (46.8). Our results strengthen the hypothesis that measles is related to Crohn's disease and that the perinatal period is a time of vulnerability.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; ROYAL FREE HOSP,SCH MED,INFLAMMATORY BOWEL DIS STUDY GRP,LONDON,ENGLAND; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30341	Harvard University; Harvard T.H. Chan School of Public Health; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Centers for Disease Control & Prevention - USA	EKBOM, A (corresponding author), UNIV UPPSALA HOSP,CANC EPIDEMIOL UNIT,S-75185 UPPSALA,SWEDEN.							AABY P, 1988, LANCET, V1, P516; EKBOM A, 1990, AM J EPIDEMIOL, V132, P1111, DOI 10.1093/oxfordjournals.aje.a115754; EKBOM A, 1991, GASTROENTEROLOGY, V100, P350, DOI 10.1016/0016-5085(91)90202-V; EKBOM A, 1991, AM J EPIDEMIOL, V134, P876, DOI 10.1093/oxfordjournals.aje.a116162; EVANS JG, 1965, GUT, V6, P311, DOI 10.1136/gut.6.4.311; GARLAND CF, 1981, GASTROENTEROLOGY, V81, P1115; LOCKHARTMUMMERY HE, 1960, GUT, V1, P87, DOI 10.1136/gut.1.2.87; LUNDEE AS, 1980, DHHS PHS801358 PUBL; MORGAN KL, 1987, LANCET, V1, P1017; NORLEN BJ, 1970, SCAND J GASTROENTERO, V5, P385; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; POSER CM, 1990, J NEUROL SCI, V95, P214; REMINGTON JS, 1983, INFECT DIS, P45; Samuelsson S., 1976, THESIS U UPPSALA UPP; SONNENBERG A, 1986, DIS COLON RECTUM, V29, P854, DOI 10.1007/BF02555363; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; 1945, UNTITLED NATALITY ST	17	133	133	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					508	510		10.1016/S0140-6736(94)91898-8	http://dx.doi.org/10.1016/S0140-6736(94)91898-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914614				2022-12-28	WOS:A1994PC53500009
J	FALLOWFIELD, LJ; HALL, A; MAGUIRE, P; BAUM, M; AHERN, RPA				FALLOWFIELD, LJ; HALL, A; MAGUIRE, P; BAUM, M; AHERN, RPA			PSYCHOLOGICAL EFFECTS OF BEING OFFERED CHOICE OF SURGERY FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									CHRISTIE HOSP, CANC RES CAMPAIGN, PSYCHOL MED GRP, MANCHESTER M20 9BX, LANCS, ENGLAND; ROYAL MARSDEN HOSP, LONDON SW3 6JJ, ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Royal Marsden NHS Foundation Trust	FALLOWFIELD, LJ (corresponding author), UCL, SCH MED,DEPT ONCOL,CANC RES CAMPAIGN, COMMUN & COUNSELLING RES CTR, 3RD FLOOR, LONDON W1P 7PL, ENGLAND.			A'Hern, Roger/0000-0003-0593-8391; Fallowfield, Lesley/0000-0003-0577-4518				ASHCROFT JJ, 1985, J ROY SOC MED, V78, P43; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; LUKER K, 1993, PREFERENCES INFORMAT; MORRIS J, 1988, SOC SCI MED, V26, P583, DOI 10.1016/0277-9536(88)90021-4; WILSON RG, 1988, BMJ-BRIT MED J, V297, P1167, DOI 10.1136/bmj.297.6657.1167	5	166	167	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					448	448		10.1136/bmj.309.6952.448	http://dx.doi.org/10.1136/bmj.309.6952.448			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920129	Green Published			2022-12-28	WOS:A1994PC40400019
J	TODD, MJ; VIITANEN, PV; LORIMER, GH				TODD, MJ; VIITANEN, PV; LORIMER, GH			DYNAMICS OF THE CHAPERONIN ATPASE CYCLE - IMPLICATIONS FOR FACILITATED PROTEIN-FOLDING	SCIENCE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; MOLECULAR CHAPERONES; CENTRAL CAVITY; GROEL; HYDROLYSIS; DEHYDROGENASE	The Escherichia coli chaperonins GroEL and GroES facilitate protein folding in an adenosine triphosphate (ATP)-dependent manner. After a single cycle of ATP hydrolysis by the adenosine triphosphatase (ATPase) activity of GroEL, the bi-toroidal GroEL formed a stable asymmetric ternary complex with GroES and nucleotide (bulletlike structures). With each subsequent turnover, ATP was hydrolyzed by one ring of GroEL in a quantized manner, completely releasing the adenosine diphosphate and GroES that were tightly bound to the other ring as a result of the previous turnover. The catalytic cycle involved formation of a symmetric complex (football-like structures) as an intermediate that accumulated before the rate-determining hydrolytic step. After one to two cycles, most of the substrate protein dissociated still in a nonnative state, which is consistent with intermolecular transfer of the substrate protein between toroids of high and low affinity. A unifying model for chaperonin-facilitated protein folding based on successive rounds of binding and release, and partitioning between committed and kinetically trapped intermediates, is proposed.	DUPONT CO INC, DEPT CENT RES & DEV, EXPTL STN, WILMINGTON, DE 19880 USA	DuPont								AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; CREIGHTON TE, 1994, NAT STRUCT BIOL, V1, P135, DOI 10.1038/nsb0394-135; ELLIS RJ, 1993, NATURE, V366, P213, DOI 10.1038/366213a0; ELLIS RJ, 1993, MOL CHAPERONES; ELOVE GA, 1991, ACS SYM SER, V470, P50; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; PIERCE J, 1985, APPL ENVIRON MICROB, V49, P1094, DOI 10.1128/AEM.49.5.1094-1100.1985; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; SAIBIL H, 1993, CURR OPIN STRUC BIOL, V3, P207, DOI 10.1016/S0959-440X(05)80154-X; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHLOSS JV, 1982, METHOD ENZYMOL, V90, P522; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHULTES V, 1991, FEBS LETT, V290, P235, DOI 10.1016/0014-5793(91)81268-D; SOMERVILLE CR, 1984, MOL GEN GENET, V193, P214, DOI 10.1007/BF00330670; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TESCHNER W, 1987, BIOCHEMISTRY-US, V26, P2791, DOI 10.1021/bi00384a021; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, UNPUB; TRUSCOTT KN, 1994, EUR J BIOCHEM, V222, P277, DOI 10.1111/j.1432-1033.1994.tb18866.x; TSUPRUN VL, 1992, BIOCHIM BIOPHYS ACTA, V1099, P67, DOI 10.1016/0005-2728(92)90188-8; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	57	442	447	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 29	1994	265	5172					659	666		10.1126/science.7913555	http://dx.doi.org/10.1126/science.7913555			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	7913555				2022-12-28	WOS:A1994NZ53800033
J	ARONSON, DC; MOORMANVOESTERMANS, CGM; TIELVANBUUL, MMC; VOS, A				ARONSON, DC; MOORMANVOESTERMANS, CGM; TIELVANBUUL, MMC; VOS, A			A RARE COMPLICATION OF ACUTE APPENDICITIS - COMPLETE BILATERAL DISTAL URETERAL OBSTRUCTION	LANCET			English	Article								Three children treated for appendicitis developed anuria and acute renal insufficiency several days after appendicectomy. Associated hydronephrosis or hydroureters were present in two. At cystoscopy, marked swelling of the trigonum and ureteric orifices was seen. One patient developed unilateral acute tubular necrosis, a complication not reported before. Recognition of this rare complication of acute appendicitis, which need not be accompanied by hydronephrosis, should lead to prompt decompression by the introduction of ureteric stents.	UNIV AMSTERDAM,ACAD MED CTR,DEPT NUCL MED,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	ARONSON, DC (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,PEDIAT SURG CTR AMSTERDAM,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.							AWAZU M, 1989, J PEDIATR-US, V114, P179, DOI 10.1016/S0022-3476(89)80781-4; COOK GT, 1969, J UROLOGY, V101, P212, DOI 10.1016/S0022-5347(17)62315-2; de Jong M, 1978, Ned Tijdschr Geneeskd, V122, P974; DRUMMOND KN, 1979, NELSON TXB PEDIATRIC, P1531; Hoffman HL, 1932, LANCET, V1, P778; Howze CP, 1944, J UROLOGY, V52, P319, DOI 10.1016/S0022-5347(17)70266-2; KAPLAN GW, 1974, J PEDIATR SURG, V9, P559, DOI 10.1016/S0022-3468(74)80029-1; Kottmeier PK, 1986, PEDIATR SURG, P989; MAKKER SP, 1972, NEW ENGL J MED, V287, P535, DOI 10.1056/NEJM197209142871104; NOBLE J, 1990, UROLOGY, V36, P513, DOI 10.1016/0090-4295(90)80190-X; PELTOKALLIO P, 1981, ARCH SURG-CHICAGO, V116, P153; Richie J P, 1975, Urology, V6, P689, DOI 10.1016/0090-4295(75)90796-7; STUART RG, 1982, J UROLOGY, V128, P1009, DOI 10.1016/S0022-5347(17)53321-2	13	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					99	100		10.1016/S0140-6736(94)91284-X	http://dx.doi.org/10.1016/S0140-6736(94)91284-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912395				2022-12-28	WOS:A1994NV73200012
J	GOUGH, AKS; LILLEY, J; EYRE, S; HOLDER, RL; EMERY, P				GOUGH, AKS; LILLEY, J; EYRE, S; HOLDER, RL; EMERY, P			GENERALIZED BONE LOSS IN PATIENTS WITH EARLY RHEUMATOID-ARTHRITIS	LANCET			English	Article							LOW-DOSE CORTICOSTEROIDS; DISEASE-ACTIVITY; MINERAL DENSITY; FRACTURE; CALCIUM; WOMEN; MASS	Generalised osteoporosis is a feature of established rheumatoid arthritis but whether this is a consequence of treatment, immobility, or disease activity has been unclear. We estimated bone mineral density by dual energy x-ray absorptiometry on 148 patients with early rheumatoid arthritis before treatment with corticosteroids or disease-modifying drugs and 730 normal controls. Scans were done at 12-month intervals in patients and at 0 and 12 months an 50 of the controls matched for menopausal status. At presentation, bone mineral density of patients did not differ from controls. However, patients with disease for less than 6 months had significantly higher spinal bone mineral density than those of longer duration. Over the next 12 months, bone mineral density loss was greater in patients with rheumatoid arthritis compared with controls; significantly so for early disease (eg, - 2.4 [0.8] vs - 0.6 [0.4] g/cm(2), p < 0.05 in the spine and - 4.3 [0.8] vs - 0.4 [0.5] g/cm(2), p < 0.001 in the trochanter). For the lumbar spine, only disease activity was significantly associated with this bone mineral density loss. For patients with active disease over 2 years, mean bone mineral density loss at each site was between 5.5 and 10% (p < 0.01 compared to patients with inactive disease). Suppression of disease activity stabilised this bone loss. In patients with rheumatoid arthritis significant amounts of generalised skeletal bone were test early in the disease and the loss was associated with disease activity. These findings have implications for the management of patients with rheumatoid arthritis and possibly other inflammatory diseases.	UNIV BIRMINGHAM,DEPT RHEUMATOL,BIRMINGHAM B15 2TT,ENGLAND; UNIV BIRMINGHAM,DEPT MATH & STAT,BIRMINGHAM,ENGLAND; QUEEN ELIZABETH HOSP,DEPT NUCL MED,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham			emery, paul/B-3560-2013					ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BEAT AM, 1991, J RHEUMATOL, V18, P804; BROZIK M, 1992, J RHEUMATOL, V19, P63; COMPSTON JE, 1988, ANN RHEUM DIS, V47, P660, DOI 10.1136/ard.47.8.660; COMPSTON JE, 1987, GUT, V28, P410, DOI 10.1136/gut.28.4.410; EGGELMEIJER F, 1993, BRIT J RHEUMATOL, V32, P387; FELDER M, 1991, RHEUMATOL INT, V11, P41, DOI 10.1007/BF00290250; FILLIBEN JJ, 1975, TECHNOMETRICS, V17, P111, DOI 10.2307/1268008; FRIES JF, 1982, J RHEUMATOL, V74, P786; GOUGH AKS, 1994, ANN RHEUM DIS, V53, P14, DOI 10.1136/ard.53.1.14; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; HOOYMAN JR, 1984, ARTHRITIS RHEUM-US, V27, P1353, DOI 10.1002/art.1780271205; KENNEDY AC, 1975, SCAND J RHEUMATOL, V4, P73, DOI 10.3109/03009747509095618; LAAN RFJM, 1993, ANN RHEUM DIS, V52, P21, DOI 10.1136/ard.52.1.21; LAAN RFJM, 1992, BRIT J RHEUMATOL, V31, P91; LEBOFF MS, 1991, J RHEUMATOL, V18, P339; Lilley J, 1991, Osteoporos Int, V1, P141, DOI 10.1007/BF01625443; MCCONKEY B, 1962, Q J MED, V124, P419; MELLISH RWE, 1987, ANN RHEUM DIS, V46, P830, DOI 10.1136/ard.46.11.830; NG KC, 1984, ANN RHEUM DIS, V43, P370, DOI 10.1136/ard.43.3.370; OKA M, 1975, SCAND J RHEUMATOL, V4, P28; REID DM, 1982, BMJ-BRIT MED J, V285, P330, DOI 10.1136/bmj.285.6338.330; RITCHIE DM, 1968, Q J MED, V37, P393; SAMBROOK PN, 1987, ARTHRITIS RHEUM, V30, P721, DOI 10.1002/art.1780300701; SAMBROOK PN, 1989, ANN RHEUM DIS, V48, P535, DOI 10.1136/ard.48.7.535; SAMBROOK PN, 1985, ANN RHEUM DIS, V44, P580, DOI 10.1136/ard.44.9.580; SPECTOR TD, 1993, BRIT MED J, V306, P558, DOI 10.1136/bmj.306.6877.558; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852; VERSTRAETEN A, 1989, CLIN EXP RHEUMATOL, V7, P351	30	570	586	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					23	27		10.1016/S0140-6736(94)91049-9	http://dx.doi.org/10.1016/S0140-6736(94)91049-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912297				2022-12-28	WOS:A1994NU91700012
J	LEE, PR				LEE, PR			THE EVOLUTION OF PUBLIC-HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LEE, PR (corresponding author), US PHS,WASHINGTON,DC 20201, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1315	1315		10.1001/jama.272.17.1315	http://dx.doi.org/10.1001/jama.272.17.1315			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933380				2022-12-28	WOS:A1994PP02000005
J	JUNGERS, P; DEVILLIER, P; SALOMON, H; CERISIER, JE; COUROUCE, A				JUNGERS, P; DEVILLIER, P; SALOMON, H; CERISIER, JE; COUROUCE, A			RANDOMIZED PLACEBO-CONTROLLED TRIAL OF RECOMBINANT INTERLEUKIN-2 IN CHRONIC UREMIC PATIENTS WHO ARE NONRESPONDERS TO HEPATITIS-B VACCINE	LANCET			English	Note							CHRONIC-RENAL-FAILURE; HEMODIALYSIS-PATIENTS; IMMUNE-RESPONSES	Natural interleukin-2 at low dose has been reported to overcome the non-responsiveness of patients with chronic uraemia to hepatitis B vaccine. Therefore, we revaccinated 52 previous such non-responders (24 on maintenance dialysis) with 20 mu g of recombinant preS2-containing hepatitis B vaccine with human recombinant interleukin-2 (1 MU) or placebo (randomly allocated). Seroconversion rates (74 vs 80%, respectively) and proportion of patients who elicited anti-HBs titres of 10 mlU/mL or more (56 vs 68%) were similar in both groups. Our results do not confirm local injection of interleukin-2 as an effective immunoadjuvant to hepatitis B vaccine in uraemic patients.	ROUSSEL UCLAF,DEPT IMMUNOL,ROMAINVILLE,FRANCE; PASTEUR MERLEUX,SERUMS & VACCINS,DEPT MED,MARNES COQUETTE,FRANCE; INST NATL TRANSFUS SANGUINE,F-75015 PARIS,FRANCE		JUNGERS, P (corresponding author), HOP NECKER ENFANTS MALAD,DEPT NEPHROL,F-75743 PARIS 15,FRANCE.							BENHAMOU E, 1984, CLIN NEPHROL, V21, P143; BLANKENSTIJN PJ, 1993, J AM SOC NEPHROL, V4, pA334; CROSNIER J, 1981, LANCET, V1, P797; DUMANN H, 1990, KIDNEY INT, V38, P1164, DOI 10.1038/ki.1990.328; JUNGERS P, 1994, J INFECT DIS, V169, P399, DOI 10.1093/infdis/169.2.399; KOHLER H, 1984, KIDNEY INT, V25, P124, DOI 10.1038/ki.1984.18; KURZ P, 1986, KIDNEY INT, V29, P1209, DOI 10.1038/ki.1986.129; MEUER SC, 1989, LANCET, V1, P15; MEUER SC, 1987, J CLIN INVEST, V80, P743, DOI 10.1172/JCI113129; ROSE RM, 1992, J INFECT DIS, V165, P775, DOI 10.1093/infdis/165.4.775b	10	60	63	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					856	857		10.1016/S0140-6736(94)92829-0	http://dx.doi.org/10.1016/S0140-6736(94)92829-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916403				2022-12-28	WOS:A1994PH25300013
J	FINESTONE, HM; CENTER, DB				FINESTONE, HM; CENTER, DB			ACTING IN MEDICAL-PRACTICE	LANCET			English	Editorial Material									UNIV WESTERN ONTARIO,HURON COLL,DEPT PHILOSOPHY,LONDON N6A 3K7,ON,CANADA	Western University (University of Western Ontario)	FINESTONE, HM (corresponding author), UNIV WESTERN ONTARIO HOSP,DEPT PHYS MED & REHABIL,POB 5339,339 WINDERMERE RD,LONDON N6A 5A5,ON,CANADA.							DESOUSA OR, 1987, RELATIONSHIP EMOTION; Eisenberg Nancy, 1987, EMPATHY ITS DEV; STEPHENS GG, 1990, HUM MED, V6, P255	3	15	15	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					801	802		10.1016/S0140-6736(94)92349-3	http://dx.doi.org/10.1016/S0140-6736(94)92349-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916081				2022-12-28	WOS:A1994PG17800018
J	BUDGETT, R				BUDGETT, R			ABC OF SPORTS MEDICINE - THE OVERTRAINING SYNDROME	BRITISH MEDICAL JOURNAL			English	Article									NORTHWICK PK HOSP & CLIN RES CTR,BRITISH OLYMP MED CTR,HARROW,MIDDX,ENGLAND	Imperial College London	BUDGETT, R (corresponding author), BRITISH OLYMP ASSOC,HARROW,MIDDX,ENGLAND.								0	18	19	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					465	468		10.1136/bmj.309.6952.465	http://dx.doi.org/10.1136/bmj.309.6952.465			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920134	Green Published			2022-12-28	WOS:A1994PC40400026
J	DOWNEY, GP; BAVIN, PJ; DEERY, ARS; CROW, J; GRIFFITHS, PD; EMERY, VC; WALKER, PG				DOWNEY, GP; BAVIN, PJ; DEERY, ARS; CROW, J; GRIFFITHS, PD; EMERY, VC; WALKER, PG			RELATION BETWEEN HUMAN PAPILLOMAVIRUS TYPE-16 AND POTENTIAL FOR PROGRESSION OF MINOR-GRADE CERVICAL DISEASE	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; INFECTION; SMEAR; ATYPIA; DNA; CANCER; WOMEN; RISK	We have previously reported that among 200 women referred for colposcopy with smears suggesting mild dyskaryosis, medium or high copy numbers of human papiliomavirus type 16 (HPV16) DNA identified patients with current high-grade cervical disease. We have followed up 95 women from that group who had histologically proven mild-grade cervical disease (cervical intraepithelial neoplasia grade 1, n = 37) or wart virus infection (n = 12) or who had no evidence of cervical abnormality at study entry (n = 43). Kaplan-Meier survival analysis of the 70 months' follow-up was used to identify baseline features that might affect the risk of progression. 3 women were lost to follow-up; data were available for the remaining 92. Among the whole group the probability of remaining free of high-grade cervical disease was 0.71. Women with a histological diagnosis of minor-grade disease were more likely to progress to high-grade disease than those with no evidence of abnormality (proportion disease-free 0.52 vs 0.90, p=0.004). Stratification of the group according to median age (28 years) revealed a weak association between age and disease progression (p=0.04). There was no difference in disease-free probability between HPV16-positive and HPV16-negative women (0.75 vs 0.65, p=0.19). Nor was there a significant difference in disease-free probability when the group was stratified by HPV16 viral burden. These data show that a histological diagnosis of minor grade cervical disease is a better long-term predictor of disease progression than is HPV16 positivity, irrespective of copy number. These findings do not support the simple view that HPV16 alone is the cause of high-grade cervical disease, including cancer.	ROYAL FREE HOSP, SCH MED, DIV COMMUN DIS, LONDON NW3 2QG, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT OBSTET & GYNAECOL, LONDON NW3 2QG, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT CYTOL, LONDON NW3 2QG, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT HISTOPATHOL, LONDON NW3 2QG, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Emery, Vincent/G-8928-2013	Emery, Vincent/0000-0001-5893-9756				BAVIN PJ, 1993, BRIT J CANCER, V67, P602, DOI 10.1038/bjc.1993.110; BUXTON EJ, 1991, BRIT J OBSTET GYNAEC, V98, P1273, DOI 10.1111/j.1471-0528.1991.tb15401.x; CAMPION MJ, 1986, LANCET, V2, P237; CRUM CP, 1984, INT J GYNECOL PATHOL, V3, P376; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; EVANS AS, 1985, BRIT J OBSTET GYNAEC, V92, P165, DOI 10.1111/j.1471-0528.1985.tb01069.x; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1067, DOI 10.1111/j.1471-0528.1989.tb03382.x; GISSMANN L, 1984, CANCER SURV, V3, P161; HAUSEN HZ, 1984, PROG MED VIROL, V30, P170; HIRSCHOWITZ L, 1992, BRIT MED J, V304, P1209, DOI 10.1136/bmj.304.6836.1209; KOSS LG, 1963, CANCER, V16, P1160, DOI 10.1002/1097-0142(196309)16:9<1160::AID-CNCR2820160910>3.0.CO;2-4; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; MCCORMICK JS, 1989, LANCET, V2, P207; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; MITCHELL H, 1986, LANCET, V1, P573; NUOVO GJ, 1990, OBSTET GYNECOL, V75, P1006; NUOVO GJ, 1989, OBSTET GYNECOL, V74, P673; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAFI MI, 1991, BRIT J OBSTET GYNAEC, V98, P490, DOI 10.1111/j.1471-0528.1991.tb10349.x; WALKER EM, 1986, LANCET, V2, P672	21	26	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					432	435		10.1016/S0140-6736(94)91768-X	http://dx.doi.org/10.1016/S0140-6736(94)91768-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914563				2022-12-28	WOS:A1994PB76100008
J	WERLER, MM; LOUIK, C; SHAPIRO, S; MITCHELL, AA				WERLER, MM; LOUIK, C; SHAPIRO, S; MITCHELL, AA			OVULATION INDUCTION AND RISK OF NEURAL-TUBE DEFECTS	LANCET			English	Note							CLOMIPHENE	The relation between use of ovulation-inducing drugs and risk of neural tube defects (NTDs) was studied in a case-control surveillance programme. The frequency of any use of such drugs during the 6 months before the last menstrual period or during pregnancy was 3.0% for 1034 mothers of infants and fetuses with NTDs (cases) and 2.8% for 4081 mothers of those with other major congenital malformations (controls) (relative risk 1.1, 95% CI 0.8-1.7). Relative risks for clomiphene and for hormones were 0.8 (0.5-1.3) and 1.5 (0.7-3.4), respectively. These data suggest that use of ovulation-inducing drugs before conception does not increase the risk of NTDs.			WERLER, MM (corresponding author), BOSTON UNIV,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Werler, Martha/0000-0003-3392-6814; Mitchell, Allen/0000-0003-0950-6799; Louik, Carol/0000-0001-5429-5084	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027697] Funding Source: NIH RePORTER; NICHD NIH HHS [NICHD R01-HD27697] Funding Source: Medline; PHS HHS [MCJ-2505667] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CUCKLE H, 1989, LANCET, V2, P1281; FIELD B, 1974, LANCET, V2, P1511; GLASSNER MJ, 1990, J REPROD MED, V35, P175; HARLAP S, 1976, LANCET, V2, P961; MILI F, 1991, AM J EPIDEMIOL, V134, P748; MILLS LJ, 1990, LANCET, V335, P103; MILUNSKY A, 1990, TERATOLOGY, V42, P467, DOI 10.1002/tera.1420420502; ROBERT E, 1991, REPROD TOXICOL, V5, P83, DOI 10.1016/0890-6238(91)90115-V; SINGH M, 1978, J PEDIATR-US, V93, P152, DOI 10.1016/S0022-3476(78)80634-9	9	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					445	446		10.1016/S0140-6736(94)91772-8	http://dx.doi.org/10.1016/S0140-6736(94)91772-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914567				2022-12-28	WOS:A1994PB76100012
J	ALVAREZ, FJ; DELRIO, MC				ALVAREZ, FJ; DELRIO, MC			DRUGS AND DRIVING	LANCET			English	Editorial Material											ALVAREZ, FJ (corresponding author), UNIV VALLADOLID,FAC MED,DEPT PHARMACOL & THERAPEUT,DRUGS & ALCOHOL RES GRP,VALLADOLID,SPAIN.		Alvarez, Francisco/GZL-1953-2022; Alvarez, F. Javier/E-7204-2016; Alvarez, F. Javier/X-2294-2019	Alvarez, F. Javier/0000-0002-7566-5678; Alvarez, F. Javier/0000-0002-7566-5678				DEGIER JJ, 1993, IHP9339 U LIMB I HUM; 1985, JAMA-J AM MED ASSOC, V257, P2618; 1985, EUROPEAN HLTH ALL SE, V1; 1991, OFF J EEC; 1991, III916390EN; 1986, JAMA-J AM MED ASSOC, V255, P522; 1992, OFF J EEC; 1992, EUROPEAN COMMISSION	8	24	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					282	282						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914258				2022-12-28	WOS:A1994NZ23300004
J	KENNEDY, SM				KENNEDY, SM			WHEN IS A DISEASE OCCUPATIONAL	LANCET			English	Editorial Material									UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia	KENNEDY, SM (corresponding author), UNIV BRITISH COLUMBIA,OCCUPAT HYG PROGRAMME,VANCOUVER,BC,CANADA.							CORDES LG, 1981, ANN INTERN MED, V95, P688, DOI 10.7326/0003-4819-95-6-688; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503	2	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					4	5		10.1016/S0140-6736(94)91041-3	http://dx.doi.org/10.1016/S0140-6736(94)91041-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912306				2022-12-28	WOS:A1994NU91700004
J	COWLEY, S; PATERSON, H; KEMP, P; MARSHALL, CJ				COWLEY, S; PATERSON, H; KEMP, P; MARSHALL, CJ			ACTIVATION OF MAP KINASE KINASE IS NECESSARY AND SUFFICIENT FOR PC12 DIFFERENTIATION AND FOR TRANSFORMATION OF NIH 3T3 CELLS	CELL			English	Article							NERVE GROWTH-FACTOR; SIGNAL-REGULATED KINASE; RAF-1 PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; TRANSCRIPTION FACTOR; TYROSINE KINASE; IN-VITRO; RAS; TRANSDUCTION; CASCADE	The MAP kinase pathway is activated by a wide variety of external signals leading to cell proliferation or differentiation. However, it is not clear whether activation of this pathway is required for cellular responses or whether it is only one branch point in signal transduction. To investigate these questions, we generated constitutively activated and interfering mutants of MAP kinase kinase 1. The activated mutants stimulated PC12 cell neuronal differentiation and transformed NIH 3T3 cells. The interfering mutants inhibited growth factor-induced PC12 differentiation, growth factor stimulation of proliferation, and reverted v-src- and ras-transformed cells. These results therefore show that, depending on cellular context, activation of MAP kinase kinase is necessary and sufficient for cell differentiation or proliferation.			COWLEY, S (corresponding author), INST CANC RES,CHESTER BEATTY LABS,DEPT CELL & MOLEC BIOL,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.			Cowley, Sally/0000-0003-0297-6675				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANCOCK JF, 1988, ONCOGENE, V3, P187; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUGHES DA, 1993, SCIENCE, V260, P1937; KUNG HF, 1986, EXP CELL RES, V162, P363, DOI 10.1016/0014-4827(86)90341-1; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAU AF, 1979, P NATL ACAD SCI USA, V76, P3904, DOI 10.1073/pnas.76.8.3904; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEEVES SJ, 1993, THESIS U LONDON; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1985, PROC R SOC SER B-BIO, V226, P99, DOI 10.1098/rspb.1985.0084; MASHALL C, 1994, CURR OPIN CELL BIOL, V4, P82; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SETH A, 1991, J BIOL CHEM, V266, P23521; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANHOOFF COM, 1989, J CELL BIOL, V108, P1115, DOI 10.1083/jcb.108.3.1115; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	57	1905	1951	1	98	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					841	852		10.1016/0092-8674(94)90133-3	http://dx.doi.org/10.1016/0092-8674(94)90133-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	7911739				2022-12-28	WOS:A1994NT33100009
J	BAKER, DW; KONSTAM, MA; BOTTORFF, M; PITT, B				BAKER, DW; KONSTAM, MA; BOTTORFF, M; PITT, B			MANAGEMENT OF HEART-FAILURE .1. PHARMACOLOGICAL TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CONVERTING-ENZYME-INHIBITORS; DOUBLE-BLIND; CONTROLLED TRIAL; ACE INHIBITORS; ENALAPRIL; CAPTOPRIL; THERAPY; HYPERTENSION; FUROSEMIDE; TOLERANCE	Objective.-This review of the pharmacologic treatment of heart failure due to left ventricular systolic dysfunction summarizes the recommendations of the expert panel for the Agency for Health Care Policy and Research Heart Failure Guideline. It provides specific advice to help guide practitioners through clinical decision making. Data Sources.-Data were obtained from English-language studies and referenced in MEDLINE or EMBASE between 1966 and 1993. We used the search terms heart failure, congestive; congestive heart failure; heart failure; cardiac failure; and dilated cardiomyopathy in conjunction with terms for the specific treatments. Where data were lacking, we relied on opinions of panel members and peer reviewers. Study Selection.-Only large prospective trials were used to estimate treatment efficacy. Smaller trials, case series, and case reports were reviewed for the incidence of adverse effects. Data Extraction and Synthesis.-Randomized clinical trials were reviewed for inclusion and exclusion criteria, patient outcomes, adverse effects, and eight categories of study quality using a defined list of study flaws. Conclusion.-Angiotensin-converting enzyme (ACE) inhibitors should be given to all patients unless specific contraindications exist. Diuretics should be used judiciously early in treatment to prevent excessive diuresis that could prevent titration of ACE inhibitors to target doses. Digoxin has not been shown to affect the natural history of heart failure and should be reserved for patients who remain symptomatic after treatment with ACE inhibitors and diuretics. Isosorbide dinitrate and hydralazine hydrochloride should be tried in patients who cannot tolerate ACE inhibitors or who have refractory symptoms.	TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; RAND CORP, HLTH SCI PROGRAM, SANTA MONICA, CA USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, DIV GEN INTERNAL MED, TORRANCE, CA 90509 USA; TUFTS UNIV, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, DEPT RADIOL, BOSTON, MA USA; UNIV CINCINNATI, COLL PHARM, CINCINNATI, OH 45267 USA; UNIV MICHIGAN, SCH MED, ANN ARBOR, MI USA	Tufts Medical Center; RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Tufts University; Tufts University; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan								BARNETT DB, 1993, CONGESTIVE HEART FAI; BRATER DC, 1984, KIDNEY INT, V26, P183, DOI 10.1038/ki.1984.153; BRAUNWALD E, 1991, NEW ENGL J MED, V325, P351, DOI 10.1056/NEJM199108013250508; BROGDEN RN, 1988, DRUGS, V36, P540, DOI 10.2165/00003495-198836050-00003; BUSSMANN WD, 1987, J CARDIOVASC PHARM, V9, pS50, DOI 10.1097/00005344-198700002-00012; CHALMERS JP, 1987, J CARDIOVASC PHARM, V9, pS89, DOI 10.1097/00005344-198700003-00021; CHRISTOPH I, 1991, PROG CARDIOL, V4, P3; CLELAND JGF, 1987, KIDNEY INT, V31, pS220; CLELAND JGF, 1988, EUR HEART J, V9, P132, DOI 10.1093/oxfordjournals.eurheartj.a062466; CODY RJ, 1992, AM J CARDIOL, V69, pG141, DOI 10.1016/0002-9149(92)91262-3; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1983, J AM COLL CARDIOL, V2, P755; CRANTOCK L, 1991, J GASTROEN HEPATOL, V6, P528, DOI 10.1111/j.1440-1746.1991.tb00899.x; DENHAM MJ, 1988, EUR J CLIN PHARMACOL, V35, P143; DIBIANCO R, 1989, NEW ENGL J MED, V321, P476; DRACUP K, IN PRESS JAMA; EDMONDS CJ, 1972, LANCET, V11, P8; ELKAYAM U, 1991, ANN INTERN MED, V114, P667, DOI 10.7326/0003-4819-114-8-667; FRANCIOSA JA, 1985, J AM COLL CARDIOL, V5, P101, DOI 10.1016/S0735-1097(85)80090-5; FRANK GJ, 1989, CARDIOLOGY, V76, P56, DOI 10.1159/000174560; HASFORD J, 1991, INT J CARDIOL, V31, P287, DOI 10.1016/0167-5273(91)90379-4; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; JENNINGS G, 1984, MED J AUSTRALIA, V141, P723; KJEKSHUS J, 1988, AM J CARDIOL, V62, pA67, DOI 10.1016/S0002-9149(88)80088-2; KLEBER FX, 1991, AM J CARDIOL, V68, pD121; KUPPER AJF, 1986, EUR J CLIN PHARMACOL, V30, P341, DOI 10.1007/BF00541540; LEWIS GR, 1989, AM J CARDIOL, V63, pD12, DOI 10.1016/0002-9149(89)90411-6; MAGNANI B, 1986, POSTGRAD MED J, V62, P153; MARCUS FI, 1985, J AM COLL CARDIOL, V5, pA82, DOI 10.1016/S0735-1097(85)80466-6; MCGRATH BP, 1985, BRIT HEART J, V54, P405; ONEILL CJA, 1988, EUR J CLIN PHARMACOL, V35, P143, DOI 10.1007/BF00609243; PACKER M, 1989, CARDIOLOGY, V76, P50, DOI 10.1159/000174559; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; REMES J, 1986, ANN CLIN RES, V18, P124; RIEGGER GAJ, 1990, J CARDIOVASC PHARM, V15, pS41, DOI 10.1097/00005344-199000152-00008; RIEGGER GAJ, 1991, EUR HEART J, V12, P705, DOI 10.1093/eurheartj/12.6.705; SHARPE DN, 1984, CIRCULATION, V70, P271, DOI 10.1161/01.CIR.70.2.271; SUKI WN, 1989, ARCH INTERN MED, V149, P669, DOI 10.1001/archinte.149.3.669; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; VASKO MR, 1985, ANN INTERN MED, V102, P314, DOI 10.7326/0003-4819-102-3-314; WARNER NJ, 1989, AM J CARDIOL, V63, pD33, DOI 10.1016/0002-9149(89)90415-3; WHIGHT C, 1974, MED J AUSTRALIA, V2, P831, DOI 10.5694/j.1326-5377.1974.tb93704.x; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	44	59	59	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1361	1366		10.1001/jama.272.17.1361	http://dx.doi.org/10.1001/jama.272.17.1361			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933398				2022-12-28	WOS:A1994PP02000032
J	TANG, MLK; KEMP, AS; THORBURN, J; HILL, DJ				TANG, MLK; KEMP, AS; THORBURN, J; HILL, DJ			REDUCED INTERFERON-GAMMA SECRETION IN NEONATES AND SUBSEQUENT ATOPY	LANCET			English	Article							CORD BLOOD IGE; IMMUNOGLOBULIN-E; NATURAL-HISTORY; EARLY-CHILDHOOD; DISEASE; DERMATITIS; PREDICTION; CHILDREN; INTERLEUKIN-4; RECEPTOR	Low interferon-gamma (IFN-gamma) secretion has been found in individuals with active atopic disease. Whether this is a cause or result of the disease process is uncertain. Cord blood IFN-gamma secretion was examined in 35 neonates who were then prospectively followed up for 1 year for the development of atopic disease. Infants who developed either symptoms of atopic disease or a positive IgE-mediated skin prick test at 12 months of age produced significantly less IFN-gamma at birth compared with those who did not (p = 0.005). This reduced secretion of IFN-gamma at birth indicates that the defect in interferon secretion is a primary component of the atopic state rather than an effect of the disease process.	ROYAL CHILDRENS HOSP,DEPT IMMUNOL,MELBOURNE,VIC,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT ALLERGY,MELBOURNE,VIC,AUSTRALIA; MERCY MATERN HOSP,DEPT NEONATAL PEDIAT,MELBOURNE,VIC,AUSTRALIA	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne				Tang, Mimi/0000-0002-3839-5293				BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DING AH, 1988, J IMMUNOL, V141, P2407; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; HIDE DW, 1991, CLIN EXP ALLERGY, V21, P739, DOI 10.1111/j.1365-2222.1991.tb03204.x; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; LIPTAY S, 1992, CLIN PEDIATR, V31, P241, DOI 10.1177/000992289203100411; MERRETT T, 1992, CLIN EXP ALLERGY, V22, P506, DOI 10.1111/j.1365-2222.1992.tb00155.x; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; REINHOLD U, 1990, LANCET, V335, P1282, DOI 10.1016/0140-6736(90)91347-D; REINHOLD U, 1988, INT ARCH ALLER A IMM, V87, P120, DOI 10.1159/000234661; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; RUIZ RGG, 1990, LANCET, V336, P808, DOI 10.1016/0140-6736(90)93267-S; RUIZ RGG, 1991, CLIN EXP ALLERGY, V21, P467, DOI 10.1111/j.1365-2222.1991.tb01687.x; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG MLK, 1994, IN PRESS CLIN EXP IM; VANASPEREN PP, 1989, ACTA PAEDIATR SCAND, V78, P239; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x	21	367	371	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					983	985		10.1016/S0140-6736(94)91641-1	http://dx.doi.org/10.1016/S0140-6736(94)91641-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934430				2022-12-28	WOS:A1994PK97800009
J	YIN, JCP; WALLACH, JS; DELVECCHIO, M; WILDER, EL; ZHOU, H; QUINN, WG; TULLY, T				YIN, JCP; WALLACH, JS; DELVECCHIO, M; WILDER, EL; ZHOU, H; QUINN, WG; TULLY, T			INDUCTION OF A DOMINANT-NEGATIVE CREB TRANSGENE SPECIFICALLY BLOCKS LONG-TERM-MEMORY IN DROSOPHILA	CELL			English	Article							APLYSIA SENSORY NEURONS; LEUCINE ZIPPER; TRANSCRIPTION FACTORS; PROTEIN-SYNTHESIS; BINDING-PROTEINS; CDNA CLONES; GENE; MELANOGASTER; ELEMENT; FACILITATION	Consolidated memory after olfactory learning in Drosophila consists of two components, a cycloheximide-sensitive, long-term memory (LTM) and a cycloheximide-insensitive, anesthesia-resistant memory (ARM). Using an inducible transgene that expresses a dominant negative member of the fly CREB family, LTM was specifically and completely blocked only after induction, while ARM and learning were unaffected. These results suggest that LTM formation requires de novo gene expression probably mediated by CREB family genes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Howard Hughes Medical Institute	YIN, JCP (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025621] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32245] Funding Source: Medline; NINDS NIH HHS [NS25621] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGRANOFF BERNARD W., 1966, BRAIN RES, V1, P303, DOI 10.1016/0006-8993(66)90095-3; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BACKSAI BJ, 1993, SCIENCE, V260, P222; BADDELEY A, 1976, PSYCHOL MEMORY; BARONDES SH, 1968, NATURE, V218, P271; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYNTON S, 1992, GENETICS, V131, P655; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; Ebbinghaus, 1885, GEDACHTNIS; FOLKERS E, 1993, P NATL ACAD SCI USA, V90, P8123, DOI 10.1073/pnas.90.17.8123; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; Huang Y Y, 1994, Learn Mem, V1, P74; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KANDEL ER, 1987, SYNAPTIC FUNCTION, P471; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; PARKER VP, 1985, MOL CELL BIOL, V5, P3058, DOI 10.1128/MCB.5.11.3058; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; ROSENZWEIG MR, 1984, NEUROBIOLOGY LEARNIN, P263; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Sokal R. R, 1981, BIOMETRY; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1993, J NEUROGENET, V9, P65; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	49	796	828	2	42	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					49	58		10.1016/0092-8674(94)90399-9	http://dx.doi.org/10.1016/0092-8674(94)90399-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923376				2022-12-28	WOS:A1994PK58500007
J	CERUTTI, PA				CERUTTI, PA			OXYRADICALS AND CANCER	LANCET			English	Article							ACTIVATION; P53; MUTATION; INVITRO; GENE; RAS				CERUTTI, PA (corresponding author), SWISS INST EXPTL CANC RES,DEPT CARCINOGENESIS,CH BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALESSI DR, 1993, ONCOGENE, V8, P2015; AMSTAD P, 1994, J BIOL CHEM, V269, P1606; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; DAYAGROSJEAN L, 1993, CANCER RES, V53, P1625; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FORNACE A, 1989, MOL CELL BIOL, V9, P190; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; KAINA B, 1990, LIFE SCI, P632; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LU X, 1993, CELL, V75, P1; MENKES M, 1986, NEW ENGL J MED, P1250; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOGELSTEIN B, 1993, CELL, V73, P523; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	25	456	466	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					862	863		10.1016/S0140-6736(94)92832-0	http://dx.doi.org/10.1016/S0140-6736(94)92832-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916406				2022-12-28	WOS:A1994PH25300016
J	FRESHNEY, NW; RAWLINSON, L; GUESDON, F; JONES, E; COWLEY, S; HSUAN, J; SAKLATVALA, J				FRESHNEY, NW; RAWLINSON, L; GUESDON, F; JONES, E; COWLEY, S; HSUAN, J; SAKLATVALA, J			INTERLEUKIN-1 ACTIVATES A NOVEL PROTEIN-KINASE CASCADE THAT RESULTS IN THE PHOSPHORYLATION OF HSP27	CELL			English	Article							TUMOR-NECROSIS-FACTOR; HEAT-SHOCK PROTEIN; FACTOR INCREASE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHORBOL ESTER; SKELETAL-MUSCLE; MAPKAP KINASE-2; CELLS; FIBROBLASTS; IDENTIFICATION	An IL-1-stimulated protein kinase cascade resulting in phosphorylation of the small heat shock protein hsp27 has been identified in KB cells. It is distinct from the p42 MAP kinase cascade. An upstream activator kinase phosphorylated a 40 kDa kinase (p40) upon threonine and tyrosine residues, which in turn phosphorylated a 50 kDa kinase (p50) upon threonine (and some serine) residues. p50 phosphorylated hsp27 upon serine. p40 and p50 were purified to near homogeneity. All three components were inactivated by protein phosphatase 2A, and p40 was inactivated by protein tyrosine phosphatase 1B. The substrate specificity of p40 differed from that of p42 and p54 MAP kinases. The upstream activator was not a MAP kinase kinase. p50 resembled MAPKAPK-2 and may be identical.	BABRAHAM INST,DEPT DEV & SIGNALLING,CYTOKINE LAB,CAMBRIDGE CB2 4AT,CAMBS,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research			Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Freshney, Norman/0000-0002-6342-341X; Cowley, Sally/0000-0003-0297-6675				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1994, FEBS LETT, V338, P31, DOI 10.1016/0014-5793(94)80111-8; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CARPER SW, 1990, NUCLEIC ACIDS RES, V18, P6457, DOI 10.1093/nar/18.21.6457; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1991, BLOOD, V77, P1627; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1992, J BIOL CHEM, V267, P7718; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KRACHT M, 1994, IN PRESS BIOCH J; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LIU J, 1994, J BIOL CHEM, V269, P3047; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; RAPP UR, 1991, ONCOGENE, V6, P495; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SATO N, 1986, J NATL CANCER I, V76, P113; SHIROO M, 1990, Cytokine, V2, P13, DOI 10.1016/1043-4666(90)90038-U; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; XHOU M, 1993, J BIOL CHEM, V268, P35	48	795	818	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					1039	1049		10.1016/0092-8674(94)90278-X	http://dx.doi.org/10.1016/0092-8674(94)90278-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923354				2022-12-28	WOS:A1994PJ29400014
J	MCMENAMIN, C; PIMM, C; MCKERSEY, M; HOLT, PG				MCMENAMIN, C; PIMM, C; MCKERSEY, M; HOLT, PG			REGULATION OF IGE RESPONSES TO INHALED ANTIGEN IN MICE BY ANTIGEN-SPECIFIC GAMMA-DELTA T-CELLS	SCIENCE			English	Article							NATURAL IMMUNE-RESPONSE; ALPHA-BETA; INTRAEPITHELIAL LYMPHOCYTES; PROTEIN ANTIGENS; SUPPRESSION; INHALATION; SENSITIZATION; TOLERANCE; INDUCTION; RECEPTOR	Indirect evidence implicates gamma delta T cells in the cross-regulation of CD4 alpha beta T cell responses. Adoptive transfer of small numbers of gamma delta T cells from ovalbumin (OVA)-tolerant mice selectively suppressed T(H)2- dependent immunoglobulin E (IgE) antibody production without affecting parallel IgG responses. Challenge of these gamma delta T cells in vitro with specific antigen resulted in production of high levels of interferon gamma. The effects of the gamma delta T cells may be mediated by direct inhibition of OVA-specific CD4(+) T(H)2 cell proliferation or selection for specific CD4 T(H)2 cells.	INST CHILD HLTH RES,DIV CELL BIOL,PERTH,WA 6872,AUSTRALIA	Telethon Kids Institute; University of Western Australia			Holt, Patrick G/H-1548-2011	Holt, Patrick G/0000-0003-1193-0935				AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; CARDING SR, 1990, J EXP MED, V172, P1225, DOI 10.1084/jem.172.4.1225; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FOX PC, 1981, IMMUNOLOGY, V43, P227; FUJIHASHI K, 1992, J EXP MED, V175, P695, DOI 10.1084/jem.175.3.695; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GORCZYNSKI RM, 1994, IMMUNOLOGY, V81, P27; HOLT PG, 1987, IMMUNOLOGY, V60, P97; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P255, DOI 10.1111/j.1365-2222.1989.tb02380.x; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; KAUFMANN SHE, 1993, P NATL ACAD SCI USA, V90, P9620, DOI 10.1073/pnas.90.20.9620; KUBO R, 1989, J IMMUNOL, V142, P2236; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; MASON DW, 1988, IMMUNOLOGY, V65, P249; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MCMENAMIN C, 1991, IMMUNOLOGY, V74, P234; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; PTAK W, 1992, J IMMUNOL, V149, P3503; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SEDGWICK JD, 1985, CELL IMMUNOL, V94, P182, DOI 10.1016/0008-8749(85)90095-4; SKEEN MJ, 1993, J EXP MED, V178, P985, DOI 10.1084/jem.178.3.985; STEWART GA, 1987, INT ARCH ALLER A IMM, V83, P44, DOI 10.1159/000234329; YAMAMOTO S, 1993, INFECT IMMUN, V61, P2154, DOI 10.1128/IAI.61.5.2154-2161.1993	29	362	366	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1869	1871		10.1126/science.7916481	http://dx.doi.org/10.1126/science.7916481			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7916481				2022-12-28	WOS:A1994PH25800034
J	SCHEKMAN, R				SCHEKMAN, R			TRANSLOCATION GETS A PUSH	CELL			English	Review							ENDOPLASMIC-RETICULUM MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; PREPROTEIN TRANSLOCASE; SECA; PHOSPHOLIPIDS; POLYPEPTIDES; YEAST; ATPASE; SEC61P				SCHEKMAN, R (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.							ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIM YJ, 1994, CELL, V78, P845; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885	28	22	23	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					911	913		10.1016/0092-8674(94)90265-8	http://dx.doi.org/10.1016/0092-8674(94)90265-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923360				2022-12-28	WOS:A1994PJ29400001
J	SAVEN, A; FOON, KA; PIRO, LD				SAVEN, A; FOON, KA; PIRO, LD			2-CHLORODEOXYADENOSINE-INDUCED COMPLETE REMISSIONS IN LANGERHANS-CELL HISTIOCYTOSIS	ANNALS OF INTERNAL MEDICINE			English	Note							ONCOLOGY-GROUP; TOXICITY		UNIV KENTUCKY, MED CTR, LUCILLE P MARKEY CANC CTR, LEXINGTON, KY 40536 USA	University of Kentucky	SAVEN, A (corresponding author), SCRIPPS CLIN & RES FDN, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							CARRERA CJ, 1990, J CLIN INVEST, V86, P1480, DOI 10.1172/JCI114865; CARRERA CJ, 1990, BLOOD S, V76, pA260; GOLDE DW, 1974, NATURE, V247, P373, DOI 10.1038/247373a0; GROOPMAN JE, 1981, ANN INTERN MED, V94, P95, DOI 10.7326/0003-4819-94-1-95; KOMP DM, 1991, SEMIN ONCOL, V18, P18; KOMP DM, 1981, CANCER, V47, P798, DOI 10.1002/1097-0142(19810215)47:4<798::AID-CNCR2820470427>3.0.CO;2-J; Lavin P T, 1987, Hematol Oncol Clin North Am, V1, P35; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; SAVEN A, 1994, ANN INTERN MED, V120, P784, DOI 10.7326/0003-4819-120-9-199405010-00010; SAVEN A, 1994, NEW ENGL J MED, V330, P691; SAVEN A, 1993, NEW ENGL J MED, V329, P734, DOI 10.1056/NEJM199309023291013; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; SIPE JC, 1994, LANCET, V344, P9, DOI 10.1016/S0140-6736(94)91046-4; URBA WJ, 1989, BLOOD, V73, P38	14	49	52	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1994	121	6					430	432		10.7326/0003-4819-121-6-199409150-00006	http://dx.doi.org/10.7326/0003-4819-121-6-199409150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF337	7914398				2022-12-28	WOS:A1994PF33700006
J	DEVITT, JE				DEVITT, JE			BREAST-CANCER - HAVE WE MISSED THE FOREST BECAUSE OF THE TREE	LANCET			English	Editorial Material																		EVANS I, 1994, LANCET, V343, P1085; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459	2	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					734	735		10.1016/S0140-6736(94)92214-4	http://dx.doi.org/10.1016/S0140-6736(94)92214-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915782				2022-12-28	WOS:A1994PF18700016
J	HOFFSTEIN, V				HOFFSTEIN, V			BLOOD-PRESSURE, SNORING, OBESITY, AND NOCTURNAL HYPOXEMIA	LANCET			English	Article							SLEEP-APNEA SYNDROME; CARDIOVASCULAR RISK-FACTORS; SYSTEMIC HYPERTENSION; MEN; HYPOXEMIA; DISEASE; SNORERS	The association between snoring and blood pressure is still a matter for debate, partly because of uncertainty about the definition of snoring and partly because confounding factors may affect systemic blood pressure such as obesity, sleep apnoea, and nocturnal hypoxaemia. To isolate the contribution of each of these factors, 1415 patients (389 females, 1026 males) referred to a sleep disorders centre were studied. A full history was obtained with particular attention to cardiovascular disease and medications. The patients had nocturnal polysomnography including objective measurement of snorning, and blood pressure was measured in the morning. 18% of non-snorers had hypertension as did 20% of heavy snorers (not significantly different). Multivariate linear regression analysis showed that snoring was not a significant determinant of blood pressure. Only age, male sex, apnoea/hypopnoea index, and body mass index contributed significantly to the variability of blood pressure. We conclude that snoring in the absence of sleep apnoea is not associated with raised blood pressure.			HOFFSTEIN, V (corresponding author), ST MICHAELS HOSP, DEPT MED, 30 BOND ST, TORONTO M5B 1W8, ON, CANADA.							ALI NJ, 1992, CHEST, V101, P526; GISLASON T, 1987, ACTA MED SCAND, V222, P415; GISLASON T, 1993, CHEST, V103, P1147, DOI 10.1378/chest.103.4.1147; HEDNER JA, 1992, AM REV RESPIR DIS, V146, P1240, DOI 10.1164/ajrccm/146.5_Pt_1.1240; HOFFSTEIN V, IN PRESS SLEEP; IWASE N, 1992, AM REV RESPIR DIS, V146, P1402, DOI 10.1164/ajrccm/146.6.1402; JENNUM P, 1992, CHEST, V102, P1371, DOI 10.1378/chest.102.5.1371; JENNUM P, 1993, INT J EPIDEMIOL, V22, P439, DOI 10.1093/ije/22.3.439; KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16; KOSKENVUO M, 1985, LANCET, V1, P893; LUGARESI E, 1980, SLEEP, V3, P221, DOI 10.1093/sleep/3.3-4.221; MARRONE O, 1993, CHEST, V103, P722, DOI 10.1378/chest.103.3.722; MATEIKA JH, 1992, AM REV RESPIR DIS, V145, P141, DOI 10.1164/ajrccm/145.1.141; PARTINEN M, 1985, LANCET, V2, P1325; RAUSCHER H, 1992, CHEST, V102, P367, DOI 10.1378/chest.102.2.367; RINGLER J, 1990, J APPL PHYSIOL, V69, P2143, DOI 10.1152/jappl.1990.69.6.2143; SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597; SERIES F, 1993, CHEST, V103, P1769, DOI 10.1378/chest.103.6.1769; STOOHS R, 1992, J APPL PHYSIOL, V72, P583, DOI 10.1152/jappl.1992.72.2.583; STRADLING JR, 1990, BRIT MED J, V300, P75, DOI 10.1136/bmj.300.6717.75; TILKIAN AG, 1976, ANN INTERN MED, V85, P714, DOI 10.7326/0003-4819-85-6-714; WALLER PC, 1989, LANCET, V1, P143	22	53	72	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 3	1994	344	8923					643	645		10.1016/S0140-6736(94)92084-2	http://dx.doi.org/10.1016/S0140-6736(94)92084-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915347				2022-12-28	WOS:A1994PE38600009
J	DOVAL, HC; NUL, DR; GRANCELLI, HO; PERRONE, SV; BORTMAN, GR; CURIEL, R				DOVAL, HC; NUL, DR; GRANCELLI, HO; PERRONE, SV; BORTMAN, GR; CURIEL, R			RANDOMIZED TRIAL OF LOW-DOSE AMIODARONE IN SEVERE CONGESTIVE-HEART-FAILURE	LANCET			English	Article							PLACEBO-CONTROLLED TRIAL; VENTRICULAR ARRHYTHMIAS; MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; DILATED CARDIOMYOPATHY; DOUBLE-BLIND; TACHYCARDIA; MORTALITY; DESIGN; DEATH	In severe heart failure many deaths are sudden and are presumed to be due to ventricular arrhythmias. The GESICA trial evaluated the effect of low-dose amiodarone on two-year mortality in patients with severe heart failure. Our prospective multicentre trial included 516 patients on optimal standard treatment for heart failure. Patients were randomised to 300 mg/day amiodarone(260) or to standard treatment (256). Intention-to-treat analysis showed 87 deaths in the amiodarone group (33.5%) compared with 106 in the control group (41.4%) (risk reduction 28%; 95% CI 4%-45%; log rank test p = 0.024). There were reductions in both sudden death (risk reduction 27%; p = 0.16) and death due to progressive heart failure (risk reduction 23%; p = 0.16). Fewer patients in the amiodarone group died or were admitted to hospital due to worsening heart failure (119 versus 149 in the control group; risk reduction 31%; 95% CI 13-46%; p = 0.0024). The decrease in mortality and hospital admission was present in all subgroups examined and independent of the presence of non-sustained ventricular tachycardia. Side-effects were reported in 17 patients (6.1%); amiodarone was withdrawn in 12. Low-dose amiodarone proved to be an effective and reliable treatment, reducing mortality and hospital admission in patients with severe heart failure independently of the presence of complex ventricular arrythmias.	HOSP MUNICIPAL ARGERICH, BUENOS AIRES, DF, ARGENTINA; HOSP EPANOL, INST CARDIOL, BUENOS AIRES, DF, ARGENTINA; SANATORIO GUEMES HOSP PRIVADO, BUENOS AIRES, DF, ARGENTINA; FDN FAVALORO, BUENOS AIRES, DF, ARGENTINA		DOVAL, HC (corresponding author), HOSP ITALIANO BUENOS AIRES, INST CORAZON, BUENOS AIRES, DF, ARGENTINA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; BIGGER JT, 1987, CIRCULATION, V75, P28; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CHAKKO CS, 1985, AM HEART J, V109, P497, DOI 10.1016/0002-8703(85)90554-X; CLELAND JGF, 1987, BRIT HEART J, V57, P436; FLEISS JL, 1990, CIRCULATION, V81, P684, DOI 10.1161/01.CIR.81.2.684; FREEDMAN MD, 1991, J CLIN PHARMACOL, V31, P1061, DOI 10.1002/j.1552-4604.1991.tb03673.x; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; KASKI JC, 1981, CIRCULATION, V64, P273, DOI 10.1161/01.CIR.64.2.273; KERIN NZ, 1991, J CLIN PHARMACOL, V31, P1044, DOI 10.1002/j.1552-4604.1991.tb03671.x; KERIN NZ, 1991, J CLIN PHARMACOL, V31, P1112, DOI 10.1002/j.1552-4604.1991.tb03681.x; MASON JW, 1989, AM J MED, V86, P2, DOI 10.1016/0002-9343(89)90220-9; NADEMANEE K, 1992, J AM COLL CARDIOL, V20, P1063, DOI 10.1016/0735-1097(92)90358-T; NERI R, 1987, AM HEART J, V113, P707, DOI 10.1016/0002-8703(87)90711-3; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; OLSHAUSEN KV, 1988, AM J CARDIOL, V61, P146, DOI 10.1016/0002-9149(88)91321-5; PACKER M, 1985, CIRCULATION, V72, P681, DOI 10.1161/01.CIR.72.4.681; PACZKOWSKI D, 1989, POL J PHARMACOL PHAR, V41, P359; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; PRATT CM, 1985, AM J CARDIOL, V56, P67, DOI 10.1016/0002-9149(85)90568-5; SINGH SN, 1991, J CLIN PHARMACOL, V31, P1109, DOI 10.1002/j.1552-4604.1991.tb03680.x; WILSON JR, 1983, J AM COLL CARDIOL, V2, P403, DOI 10.1016/S0735-1097(83)80265-4; WILSON JS, 1991, AM HEART J, V121, P158, DOI 10.1016/0002-8703(91)90969-O; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	29	689	711	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	1994	344	8921					493	498		10.1016/S0140-6736(94)91895-3	http://dx.doi.org/10.1016/S0140-6736(94)91895-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914611				2022-12-28	WOS:A1994PC53500006
J	LLOYD, EL				LLOYD, EL			ABC OF SPORTS MEDICINE - TEMPERATURE AND PERFORMANCE .1. COLD	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,EDINBURGH,MIDLOTHIAN,SCOTLAND; BRITISH ASSOC SPORT & MED,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh	LLOYD, EL (corresponding author), PRINCESS MARGARET ROSE ORTHOPAED HOSP,EDINBURGH,MIDLOTHIAN,SCOTLAND.								0	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					531	534		10.1136/bmj.309.6953.531	http://dx.doi.org/10.1136/bmj.309.6953.531			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	7916227	Green Published			2022-12-28	WOS:A1994PD30800033
J	GELEIJNSE, JM; WITTEMAN, JCM; BAK, AAA; DENBREEIJEN, JH; GROBBEE, DE				GELEIJNSE, JM; WITTEMAN, JCM; BAK, AAA; DENBREEIJEN, JH; GROBBEE, DE			REDUCTION IN BLOOD-PRESSURE WITH A LOW-SODIUM, HIGH POTASSIUM, HIGH MAGNESIUM SALT IN OLDER SUBJECTS WITH MILD-TO-MODERATE HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article							SUPPLEMENTATION; RESTRICTION; POPULATION; ROTTERDAM; DISEASE; TRIALS; AGE	Objective-To examine the effect of a reduced sodium and increased potassium and magnesium intake on blood pressure. Design-Randomised double blind placebo controlled trial. Setting-General population of a suburb of Rotterdam. Subjects-100 men and women between 55 and 75 years of age with untreated mild to moderate hypertension. Interventions-During 24 weeks the intervention group received a mineral salt (sodium: potassium: magnesium 8:6:1) and foods prepared with the mineral salt. Controls received common salt and foods. Main outcome measure-Change in blood pressure. Results-Complete follow up was achieved for 97 of the 100 randomised subjects. Systolic blood pressure (mean of measurements at weeks 8, 16, and 24) fell by 7.6 mm Hg (95% confidence interval 4.0 to 11.2) and diastolic blood pressure by 3.3 mm Hg (0.8 to 5.8) in the mineral salt group compared with the controls, with a 28% decrease in urinary sodium excretion and a 22% increase in urinary potassium excretion. Twenty five weeks after the study the difference in blood pressure between the groups was no longer detectable. Conclusion-Replacing common sodium salt by a low sodium, high potassium, high magnesium mineral salt could offer a valuable non-pharmacological approach to lowering blood pressure in older people with mild to moderate hypertension.			GELEIJNSE, JM (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Grobbee, Diederick/C-7651-2014; Geleijnse, Johanna Marianna M/B-5749-2012	Grobbee, Diederick/0000-0003-4472-4468; Geleijnse, Johanna Marianna M/0000-0001-7638-0589				BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; CAPPUCCIO FP, 1991, J HYPERTENS, V9, P465, DOI 10.1097/00004872-199105000-00011; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; ELLIOTT P, 1989, J HUM HYPERTENS, V3, P323; GELEIJNSE JM, 1990, BMJ-BRIT MED J, V300, P899, DOI 10.1136/bmj.300.6729.899; GROBBEE DE, 1987, J HYPERTENS, V5, P115, DOI 10.1097/00004872-198702000-00016; GROBBEE DE, 1986, BRIT MED J, V293, P27, DOI 10.1136/bmj.293.6538.27; GROBBEE DE, 1994, TXB HYPERTENSION, P539; GROBBEE DE, 1991, HYPERTENSION S1, V17, P109; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; JEFFERY RW, 1984, AM J PUBLIC HEALTH, V74, P492, DOI 10.2105/AJPH.74.5.492; KARPPANEN H, 1984, Journal of Cardiovascular Pharmacology, V6, P236; KHAW KT, 1982, LANCET, V2, P1127; KHAW KT, 1988, CIRCULATION, V77, P53, DOI 10.1161/01.CIR.77.1.53; Kristjansson I., 1992, GEOTHERMICS, V21, P765, DOI 10.1016/0375-6505(92)90029-9; Nevo-Table, 1986, DUTCH FOOD COMPOSITI; RYAN MP, 1984, ANN CLIN RES S43, V16, P818; STAMLER R, 1991, HYPERTENSION S1, V17, P16; VANDENBRANDT PA, 1990, BIJDFRAGE VOEDINGSMI; WIDMAN L, 1993, AM J HYPERTENS, V6, P41, DOI 10.1093/ajh/6.1.41; WITTEMAN JCM, 1994, AM J CLIN NUTR, V60, P129, DOI 10.1093/ajcn/60.1.129	22	117	123	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					436	440		10.1136/bmj.309.6952.436	http://dx.doi.org/10.1136/bmj.309.6952.436			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920126	Green Published			2022-12-28	WOS:A1994PC40400016
J	SCHLUGER, NW; CONDOS, R; LEWIS, S; ROM, WN				SCHLUGER, NW; CONDOS, R; LEWIS, S; ROM, WN			AMPLIFICATION OF DNA OF MYCOBACTERIUM-TUBERCULOSIS FROM PERIPHERAL-BLOOD OF PATIENTS WITH PULMONARY TUBERCULOSIS	LANCET			English	Note							POLYMERASE CHAIN-REACTION; IMMUNODEFICIENCY-VIRUS INFECTION; DIAGNOSIS	Sputum examination for rapid diagnosis of pulmonary tuberculosis is not always satisfactory. We examined peripheral blood with the polymerase chain reaction (PCR). Blood samples were collected from 8 consecutive patients with suspected pulmonary tuberculosis and from 18 healthy controls, half of whom were tuberculin skin-test positive. All 8 patients had evidence of circulating Mycobacterium tuberculosis DNA in the lymphocyte fraction of peripheral blood, and positive sputum cultures indicating active pulmonary tuberculosis. None of the healthy controls had positive PCR results. This PCR technique may prove useful for the rapid diagnosis of tuberculosis.	NYU,MED CTR,BELLEVUE CHEST SERV,NEW YORK,NY; NYU,MED CTR,DIV PULM & CRIT CARE MED,NEW YORK,NY	New York University; New York University			Schluger, Neil/ABA-1793-2021	Rom, William/0000-0002-8793-7028; Lewis, Stuart/0000-0001-5418-9388	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008743] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08743-01] Funding Source: Medline; PHS HHS [M01-0096] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		COUSINS DV, 1992, J CLIN MICROBIOL, V30, P255, DOI 10.1128/JCM.30.1.255-258.1992; EISENACH KD, 1991, AM REV RESPIR DIS, V144, P1160, DOI 10.1164/ajrccm/144.5.1160; FUJIWARA H, 1986, AM REV RESPIR DIS, V133, P73, DOI 10.1164/arrd.1986.133.1.73; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; Mattar S, 1992, Enferm Infecc Microbiol Clin, V10, P29; SCHLUGER NW, 1994, CHEST, V105, P1116, DOI 10.1378/chest.105.4.1116; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; TOOSSI Z, 1990, J CLIN INVEST, V85, P1777, DOI 10.1172/JCI114635; WALKER DA, 1992, THORAX, V47, P690, DOI 10.1136/thx.47.9.690	9	59	60	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					232	233		10.1016/S0140-6736(94)92999-8	http://dx.doi.org/10.1016/S0140-6736(94)92999-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913158				2022-12-28	WOS:A1994NY06000011
J	MARSH, JCW; SOCIE, G; SCHREZENMEIER, H; TICHELLI, A; GLUCKMAN, E; LJUNGMAN, P; MCCANN, SR; RAGHAVACHAR, A; MARIN, P; HOWS, JM; BACIGALUPO, A				MARSH, JCW; SOCIE, G; SCHREZENMEIER, H; TICHELLI, A; GLUCKMAN, E; LJUNGMAN, P; MCCANN, SR; RAGHAVACHAR, A; MARIN, P; HOWS, JM; BACIGALUPO, A			HEMATOPOIETIC GROWTH-FACTORS IN APLASTIC-ANEMIA - A CAUTIONARY NOTE	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; SAA WORKING PARTY; ANTILYMPHOCYTE GLOBULIN; ANEMIA; GRANULOCYTE; METHYLPREDNISOLONE	We are concerned about the inappropriate use of haemopoietic growth factors in patients with severe aplastic anaemia (SAA). The treatment of choice for this disorder is bone-marrow transplantation from an HLA-identical sibling donor if the patient is younger than 45 years, but it must be done soon after onset before the patient becomes sensitised by multiple red-cell and platelet transfusions. Other patients should immunosuppressive therapy with antithymocyte alone or with cyclosporin or oxymetholone. Haemopoietic growth factors may have a role in stimulation of granulopoiesis after immunosuppressive therapy, but there is no evidence that they can correct the underlying stem-cell defect in SAA, and therefore no justification for their use alone in newly diagnosed SAA. Such treatment is harmful because it delays bone-marrow transplantation, or immunosuppressive therapy in older patients and those without suitable donors, thus reducing the chances of a successful outcome.	HOP ST LOUIS,SERV HEMATOL,PARIS,FRANCE; UNIV ULM,MED KLIN & POLIKLIN,W-7900 ULM,GERMANY; UNIV BASEL HOSP,CH-4031 BASEL,SWITZERLAND; HUDDINGE SJUKHUS,MED KLINIKEN,HUDDINGE,SWEDEN; ST JAMES HOSP,DEPT HAEMATOL,DUBLIN 8,IRELAND; HOSP CLIN BARCELONA,SERV HEMATOL,BARCELONA,SPAIN; SOUTHMEAD GEN HOSP,DEPT HAEMATOL,BRISTOL,AVON,ENGLAND; OSPED SAN MARTINO GENOVA,DIV EMATOL 2,GENOA,ITALY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Ulm University; University of Basel; Trinity College Dublin; University of Barcelona; Hospital Clinic de Barcelona; Southmead Hospital; University of Genoa; IRCCS AOU San Martino IST	MARSH, JCW (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT HAEMATOL,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.		Ljungman, Per/M-4946-2019					BACIGALUPO A, 1993, BRIT J HAEMATOL, V83, P145, DOI 10.1111/j.1365-2141.1993.tb04645.x; BACIGALUPO A, 1993, EXP HEMATOL, V21, P1081; CAMITTA BM, 1976, BLOOD, V48, P63; CHAMPLIN RE, 1989, BLOOD, V73, P694; CHAMPLIN RE, 1989, BLOOD, V73, P601; DEPLANQUE MM, 1989, BRIT J HAEMATOL, V73, P121; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; GANSER A, 1990, BLOOD, V76, P1287; HIRAYAMA Y, 1994, BR JHAEMATOL, V85, P676; HOWS JM, 1991, IMMUNOL LETT, V29, P77, DOI 10.1016/0165-2478(91)90204-N; KOJIMA S, 1991, BLOOD, V77, P937; KOJIMA S, 1992, NEW ENGL J MED, V326, P1294; KOJIMA S, 1992, BLOOD, V79, P2256; RAGHAVACHAR A, 1992, CYTOKINES HEMOPOIESI, V2, P555; SCHREZENMEIER H, 1993, BRIT J HAEMATOL, V85, P371, DOI 10.1111/j.1365-2141.1993.tb03181.x; SCHREZENMEIER H, 1993, BLOOD S1, V82, P1455; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; STARK R, 1993, BRIT J HAEMATOL, V83, P560, DOI 10.1111/j.1365-2141.1993.tb04691.x; STEWARD WP, 1993, LANCET, V342, P153, DOI 10.1016/0140-6736(93)91350-U; STORB R, 1991, BONE MARROW TRANSPL, V8, P69; STORB R, 1980, ANN INTERN MED, V91, P30; TICHELLI A, 1992, BLOOD, V80, P337; 1992, LANCET, V339, P395	23	41	42	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					172	173		10.1016/S0140-6736(94)92763-4	http://dx.doi.org/10.1016/S0140-6736(94)92763-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912771				2022-12-28	WOS:A1994NW81000015
J	GIANNAKOULOPOULOS, X; SEPULVEDA, W; KOURTIS, P; GLOVER, V; FISK, NM				GIANNAKOULOPOULOS, X; SEPULVEDA, W; KOURTIS, P; GLOVER, V; FISK, NM			FETAL PLASMA-CORTISOL AND BETA-ENDORPHIN RESPONSE TO INTRAUTERINE NEEDLING	LANCET			English	Article							GESTATIONAL-AGE; INTRAHEPATIC VEIN; BLOOD-GASES; CORD; SURGERY; STRESS; FETUS; PH; ANESTHESIA; FENTANYL	The purpose of this study was to investigate whether the fetus mounts a hormonal stress response to a potentially painful procedure, intrauterine needling. Cortisol and beta-endorphin concentrations in fetal plasma obtained during uncomplicated fetal blood sampling or intrauterine transfusions by needling the fetal intra-abdominal portion of the umbilical vein (intrahepatic vein) were compared to hormone concentrations in fetal plasma obtained by the conventional technique of needling the placental cord insertion, which is not innervated. Cortisol and beta-endorphin concentrations did not increase within 10 minutes of fetal abdominal needling (n = 15). However, more prolonged needling during transfusion at the intrahepatic vein was associated with an increase in fetal plasma cortisol (median increase 48 nmol/L; 95% Cl, 23-86) and beta-endorphin (207 pg/mL; 113-307) concentrations compared to transfusion at the placental cord insertion (p < 0.005 for both hormones). The magnitude of rise in hormone increased linearly with the duration of needling (cortisol, r = 0.80; beta-endorphin, r = 0.88; p < 0.05 for both). These data suggest that the fetus mounts a hormonal stress response to invasive procedures. They raise the possibility that the human fetus feels pain in utero, and may benefit from anaesthesia or analgesia for invasive procedures.	QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,CTR FETAL CARE,LONDON W6 0XG,ENGLAND; QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,DEPT CHEM PATHOL,LONDON W6 0XG,ENGLAND	Imperial College London; Imperial College London			Fisk, Nicholas/B-2126-2009	Fisk, Nicholas/0000-0003-0031-7975				ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; COULTER CL, 1993, J CLIN ENDOCR METAB, V76, P1234, DOI 10.1210/jc.76.5.1234; DAFFOS F, 1985, AM J OBSTET GYNECOL, V153, P655, DOI 10.1016/S0002-9378(85)80254-4; DAWES GS, 1988, CAN J PHYSIOL PHARM, V66, P541, DOI 10.1139/y88-084; DONALDSON A, 1991, CLIN ENDOCRINOL, V35, P1; ECONOMIDES D L, 1988, Fetal Therapy, V3, P158; FISK NM, 1989, FETAL MONITORING, P46; FITZGERALD M, 1987, NATURE, V326, P603, DOI 10.1038/326603a0; FITZGERALD M, 1988, DEV MED CHILD NEUROL, V30, P520; FOX SB, 1990, PLACENTA, V11, P59, DOI 10.1016/S0143-4004(05)80443-6; GENSER G, 1976, ANN J OBSTET GYNECOL, V124, P43; GHIDINI A, 1993, AM J OBSTET GYNECOL, V168, P1139; HANNA CE, 1993, J CLIN ENDOCR METAB, V76, P384, DOI 10.1210/jc.76.2.384; LACOUMENTA S, 1987, BRIT J ANAESTH, V59, P713, DOI 10.1093/bja/59.6.713; MAURI A, 1990, ACTA ENDOCRINOL-COP, V123, P637, DOI 10.1530/acta.0.1230637; NICOLAIDES KH, 1987, AM J OBSTET GYNECOL, V157, P50, DOI 10.1016/S0002-9378(87)80344-7; NICOLAIDES KH, 1989, AM J OBSTET GYNECOL, V161, P996, DOI 10.1016/0002-9378(89)90770-9; NICOLINI U, 1988, PRENATAL DIAG, V8, P665, DOI 10.1002/pd.1970080906; NICOLINI U, 1990, OBSTET GYNECOL, V76, P47; PEPE GJ, 1990, ENDOCR REV, V11, P151, DOI 10.1210/edrv-11-1-151; RADUNOVIC N, 1992, AM J OBSTET GYNECOL, V167, P740, DOI 10.1016/S0002-9378(11)91581-6; ROGERS MC, 1992, NEW ENGL J MED, V326, P55, DOI 10.1056/NEJM199201023260109; RUTH V, 1993, AM J PERINAT, V10, P115, DOI 10.1055/s-2007-994641; STARK RI, 1986, ENDOCRINOLOGY, V119, P755, DOI 10.1210/endo-119-2-755; VENN RF, 1990, J CONTROL RELEASE, V13, P113, DOI 10.1016/0168-3659(90)90002-B; WARDLAW SL, 1979, J CLIN ENDOCR METAB, V49, P888, DOI 10.1210/jcem-49-6-888; WOLF AR, 1993, LANCET, V342, P319, DOI 10.1016/0140-6736(93)91468-2; ZOSMER N, 1993, OBSTET GYNECOL, V82, P504	30	166	179	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					77	81		10.1016/S0140-6736(94)91279-3	http://dx.doi.org/10.1016/S0140-6736(94)91279-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912391				2022-12-28	WOS:A1994NV73200007
J	COGGON, D; INSKIP, H; WINTER, P; PANNETT, B				COGGON, D; INSKIP, H; WINTER, P; PANNETT, B			LOBAR PNEUMONIA - AN OCCUPATIONAL-DISEASE IN WELDERS	LANCET			English	Article							MORTALITY; SHIPYARD	We have used data from three analyses of occupational mortality for England and Wales to investigate a suspected hazard of pneumonia in welders. Mortality from the disease was consistently raised in welders aged 15-64, with standardised mortality ratios of 184 (95% Cl 150-224) in 1959-63 and 157 (121-200) in 1970-72. Analysis of data for 1979-80 and 1982-90 showed that the increased risk is attributable mainly to an excess of pneumococcal and unspecified lobar pneumonia (proportional mortality ratio 255, 95% Cl 192-332). No excess occurred in men above retirement age (65). A possible explanation of these findings is that welding fume reversibly increases the susceptibility of the lung to pneumonic infection. The observation of a similar mortality pattern in moulders and coremakers points to the metallic component of the fume as a possible culprit, but ozone or oxides of nitrogen could also be implicated. There are grounds for lobar pneumonia to be considered an occupational disease in welders.			COGGON, D (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				[Anonymous], 1980, CLASSIFICATION OCCUP; BEAUMONT JJ, 1980, AM J EPIDEMIOL, V112, P775; COFFIN DL, 1968, ARCH ENVIRON HEALTH, V16, P633, DOI 10.1080/00039896.1968.10665119; COLLEN MF, 1947, J IND HYG TOXICOL, V29, P113; COTES JE, 1989, BRIT J IND MED, V46, P292; DOIG A. T., 1964, ANN OCCUP HYG, V7, P223; EHRLICH R, 1966, BACTERIOL REV, V30, P604, DOI 10.1128/MMBR.30.3.604-614.1966; FAWER RF, 1982, BRIT J IND MED, V39, P149; MCMILLAN GHG, 1983, J SOC OCCUP MED, V33, P75; MILHAM S, 1983, DHHS NIOSH83116 PUBL; NEWHOUSE ML, 1985, BRIT J IND MED, V42, P406; PARKES WR, 1982, OCCUPATIONAL LUNG DI; POLEDNAK AP, 1981, ARCH ENVIRON HEALTH, V36, P235, DOI 10.1080/00039896.1981.10667630; Puntoni R, 1979, Ann N Y Acad Sci, V330, P353, DOI 10.1111/j.1749-6632.1979.tb18738.x; 1971, ENGLAND WALES 1961 O; 1958, ENGLAND WALES 1951 2, V1; 1978, OCCUPATIONAL MORTALI	17	81	82	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					41	43		10.1016/S0140-6736(94)91056-1	http://dx.doi.org/10.1016/S0140-6736(94)91056-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912307				2022-12-28	WOS:A1994NU91700019
J	TUDDENHAM, EGD				TUDDENHAM, EGD			THROMBOPHILIA - THE NEW FACTOR IS OLD FACTOR-V	LANCET			English	Editorial Material							PROTEIN-C				TUDDENHAM, EGD (corresponding author), CLIN RES CTR,HAEMOSTASIS RES GRP,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.		Tuddenham, Edward/AAS-6196-2020	Tuddenham, Edward/0000-0001-8955-2909				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; GRIFFIN JH, 1993, BLOOD, V82, P1989; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MAJERUS PW, 1994, NATURE, V369, P14, DOI 10.1038/369014a0; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801	8	19	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1515	1516		10.1016/S0140-6736(94)92932-7	http://dx.doi.org/10.1016/S0140-6736(94)92932-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911865				2022-12-28	WOS:A1994NR32900002
J	GRANTER, SR; BARNHILL, RL; HEWINS, ME; DURAY, PH				GRANTER, SR; BARNHILL, RL; HEWINS, ME; DURAY, PH			IDENTIFICATION OF BORRELIA-BURGDORFERI IN DIFFUSE FASCIITIS WITH PERIPHERAL EOSINOPHILIA BORRELIAL FASCIITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SHULMAN SYNDROME; AMPLIFICATION; INFECTION; MORPHEA	Objective.-To determine if spirochetes could be localized in biopsy specimens of patients with diffuse fasciitis and peripheral eosinophilia. Patients.-Tissue from two patients received in consultation and retrieved from hospital flies. One patient had a history of tick bite and erythema migrans. Setting.-Tertiary care center and pathology consultation practice. Methods.-Multiple tissue sections were examined for spirochetes using the modified Dieterle or Steiner technique. One case was examined using rabbit polyclonal antibodies against Borrelia burgdorferi. One case had sufficient tissue to study for B burgdorferi DNA by polymerase chain reaction. Results.-We identified two cases of diffuse fasciitis associated with peripheral eosinophilia in which spirochetal organisms were identified. The two patients had positive or borderline B burgdorferi serological findings. Deep biopsy was diagnostic of diffuse fasciitis with eosinophilia. In one patient, multiple organisms were seen using a modified Dieterle silver stain, and B burgdorferi-specific DNA was amplified by polymerase chain reaction. In the other patient, no unequivocal organisms were detected on silver stain; however, organisms were detected using rabbit polyclonal antibodies against B burgdorferi. Conclusion.-Some cases of what has previously been described as ''eosinophilic'' fasciitis may be an expression of Lyme disease, and we propose the more specific term borrelial fasciitis to describe such lesions.	HARVARD UNIV, SCH MED, BOSTON, MA USA; IMUGEN INC, DIV DIAGNOST REFERENCE, NORWOOD, MA USA	Harvard University; Harvard Medical School	GRANTER, SR (corresponding author), BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV DERMATOPATHOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.							ABERER E, 1991, DERMATOLOGICA, V182, P145, DOI 10.1159/000247767; ABERER E, 1991, J CLIN MICROBIOL, V29, P764, DOI 10.1128/JCM.29.4.764-772.1991; ASBRINK E, 1985, ACTA PATH MICRO IM B, V93, P161; BUECHNER SA, 1993, J AM ACAD DERMATOL, V29, P190, DOI 10.1016/0190-9622(93)70166-Q; CIMINO GD, 1991, NUCLEIC ACIDS RES, V19, P99, DOI 10.1093/nar/19.1.99; Duray P, 1985, LAB MED, V16, P685, DOI DOI 10.1093/LABMED/16.11.685; DURAY PH, IN PRESS ADV PATHOL; GRAHMANN F, 1989, LYME BORRELIOSIS, V2, P172; HIRAI K, 1992, LANCET, V340, P1472, DOI 10.1016/0140-6736(92)92663-Z; MARSCH WC, 1993, BRIT J DERMATOL, V128, P674, DOI 10.1111/j.1365-2133.1993.tb00264.x; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; SCHEMPP C, 1993, J INVEST DERMATOL, V100, P717, DOI 10.1111/1523-1747.ep12472369; SEPP N, 1988, J AM ACAD DERMATOL, V18, P1361, DOI 10.1016/S0190-9622(88)80117-8; Shulman L, 1974, J RHEUMATOL, V1, P46; STANEK G, 1987, LANCET, V1, P1490, DOI 10.1016/S0140-6736(87)92235-5; Steere AC, 1983, NEW ENGL J MED, V308, P740; WIENECKE R, 1993, J CUTAN PATHOL, V20, P385, DOI 10.1111/j.1600-0560.1993.tb00658.x	18	28	29	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1283	1285		10.1001/jama.272.16.1283	http://dx.doi.org/10.1001/jama.272.16.1283			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933373				2022-12-28	WOS:A1994PN06800035
J	LAHAD, A; MALTER, AD; BERG, AO; DEYO, RA				LAHAD, A; MALTER, AD; BERG, AO; DEYO, RA			THE EFFECTIVENESS OF 4 INTERVENTIONS FOR THE PREVENTION OF LOW-BACK-PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LUMBAR INTERVERTEBRAL-DISK; SECONDARY PREVENTION; RISK-FACTORS; FOLLOW-UP; WORK-ENVIRONMENT; INJURY; PROGRAM; STRENGTH; INDUSTRY; COMPLAINTS	Objective.-Low back pain affects 60% to 80% of US adults at some time during their lives. This review evaluates the effectiveness of four strategies to prevent low back-pain for asymptomatic individuals: back and aerobic exercises, education, mechanical supports (corsets), and risk factor modification. Data Sources.-The MEDLINE database was searched for all relevant articles published in English between 1966 and 1993. Bibliographies of identified articles were searched to ensure that all pertinent articles had been gathered and back pain specialists reviewed our final bibliography for completeness. Study Selection and data Extraction.-A total of 190 articles were identified, and the 64 that contained original data about preventing low back pain were reviewed. Studies were graded according to strength of study design. Data Synthesis.-There is limited evidence based on randomized trials and epidemiological studies that exercises to strengthen back or abdominal muscles and to improve overall fitness can decrease the incidence and duration of low back pain episodes. There is minimal evidence to support the use of educational strategies to prevent low back pain and insufficient evidence to recommend about the use of mechanical supports. Although there is no evidence supporting risk factor modification for preventing low back pain (smoking cessation and weight loss), there are other reasons to recommend the interventions. Conclusion.-There is limited evidence to recommend exercise to prevent low back pain in asymptomatic individuals, but there is insufficient evidence to recommend other prevention strategies. These conclusions should be viewed cautiously since they are primarily based on studies conducted in the workplace rather than in clinical settings.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT HLTH SERV, BACK PAIN OUTCOMES ASSESSMENT TEAM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT FAMILY MED, SEATTLE, WA 98195 USA; VET AFFAIRS MED CTR, SEATTLE, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)					AHRQ HHS [5-T32 HS 00034-05, HS-06344] Funding Source: Medline; BHP HRSA HHS [3-T32 PE 10002-1002-06] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		AHLGREN SA, 1978, PROSTHET ORTHOT INT, V2, P101, DOI 10.3109/03093647809177777; ALARANTA H, 1988, SCAND J REHABIL MED, V20, P133; AMOSUN SL, 1991, CENT AFR J MED, V37, P120; Andersson G, 1991, OCCUPATIONAL LOW BAC, P95; ANDERSSON GBJ, 1992, J MANIP PHYSIOL THER, V15, P43; BASFORD JR, 1988, ORTHOPEDICS, V11, P285; BATTIE MC, 1991, SPINE, V16, P1015, DOI 10.1097/00007632-199109000-00001; BATTIE MC, 1989, SPINE, V14, P141, DOI 10.1097/00007632-198902000-00001; BATTIE MC, 1990, SPINE, V15, P768, DOI 10.1097/00007632-199008000-00006; BATTIE MC, 1989, SPINE, V14, P851, DOI 10.1097/00007632-198908000-00014; BATTIE MC, 1991, ORTHOP CLIN N AM, V22, P273; BIERINGSORENSEN F, 1984, SPINE, V9, P106, DOI 10.1097/00007632-198403000-00002; BIGOS SJ, 1992, SPINE, V17, P922, DOI 10.1097/00007632-199208000-00009; BIGOS SJ, 1991, SPINE, V16, P1, DOI 10.1097/00007632-199101000-00001; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BODEN SD, 1990, SPINE, V15, P571, DOI 10.1097/00007632-199006000-00026; BOSHUIZEN HC, 1993, SPINE, V18, P35, DOI 10.1097/00007632-199301000-00007; CADY LD, 1985, J OCCUP ENVIRON MED, V27, P110; CADY LD, 1979, J OCCUP ENVIRON MED, V21, P269; CHAFFIN DB, 1974, J OCCUP ENVIRON MED, V16, P248; COX JM, 1987, J MANIP PHYSIOL THER, V10, P239; DALTROY LH, 1993, HEALTH EDUC QUART, V20, P43, DOI 10.1177/109019819302000106; DALTROY LH, 1991, AM J IND MED, V20, P505, DOI 10.1002/ajim.4700200406; DAMKOT DK, 1984, SPINE, V9, P395, DOI 10.1097/00007632-198405000-00012; DEHLIN O, 1981, SCAND J REHABIL MED, V13, P1; DEHLIN O, 1978, SCAND J REHABIL MED, V10, P201; DEYO RA, 1989, SPINE, V14, P501, DOI 10.1097/00007632-198905000-00005; DEYO RA, 1990, ANN INTERN MED, V112, P598, DOI 10.7326/0003-4819-112-8-598; DONCHIN M, 1990, SPINE, V15, P1317, DOI 10.1097/00007632-199012000-00015; DWYER AP, 1987, CLIN ORTHOP RELAT R, V222, P35; FELDSTEIN A, 1993, J OCCUP ENVIRON MED, V35, P114, DOI 10.1097/00043764-199302000-00010; FIELDING JE, 1989, AM J PUBLIC HEALTH, V79, P16, DOI 10.2105/AJPH.79.1.16; FORSSELL MZ, 1981, SPINE, V6, P104, DOI 10.1097/00007632-198101000-00022; FOSTER DN, 1991, CLIN SPORT MED, V10, P197; FRYMOYER JW, 1983, J BONE JOINT SURG AM, V65, P213, DOI 10.2106/00004623-198365020-00010; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; FRYMOYER JW, 1980, SPINE, V5, P419, DOI 10.1097/00007632-198009000-00005; FRYMOYER JW, 1986, J BONE JOINT SURG AM, V68A, P469, DOI 10.2106/00004623-198668030-00028; FRYMOYER JW, 1992, BAILLIERE CLIN RHEUM, V6, P595, DOI 10.1016/S0950-3579(05)80129-3; FRYMOYER JW, 1985, CLIN ORTHOP RELAT R, P178; GRAVELING RA, 1991, ANN OCCUP HYG, V35, P427, DOI 10.1093/annhyg/35.4.427; GUNDEWALL B, 1993, SPINE, V18, P587, DOI 10.1097/00007632-199304000-00011; GYNTELBERG F, 1974, DAN MED BULL, V21, P30; HAAG AB, 1992, OCCUP MED, V7, P155; Hall H, 1980, Physiotherapy, V66, P115; Harvey B L, 1988, AAOHN J, V36, P211; HELIOVAARA M, 1991, SPINE, V16, P608, DOI 10.1097/00007632-199106000-00002; HELIOVAARA M, 1989, ANN MED, V21, P254, DOI 10.3109/07853898909149202; HELLIWELL PS, 1991, BRIT J RHEUMATOL, V30, P62; HEMBORG B, 1985, SCAND J REHABIL MED, V17, P15; HOLM S, 1988, UPSALA J MED SCI, V93, P91, DOI 10.1517/03009734000000042; HOLMSTROM EB, 1992, SPINE, V17, P663, DOI 10.1097/00007632-199206000-00005; HOYT WH, 1981, J AM OSTEOPATH ASSOC, V80, P474; ISERNHAGEN SJ, 1992, OCCUP MED, V7, P147; ISERNHAGEN SJ, 1992, OCCUP MED, V7, P139; KELLETT KM, 1991, PHYS THER, V71, P283, DOI 10.1093/ptj/71.4.283; KLEIN BP, 1984, J OCCUP ENVIRON MED, V26, P443, DOI 10.1097/00043764-198406000-00017; KRAUS H, 1977, NEW YORK STATE J MED, V77, P1335; KRAUS H, 1967, JOM-J OCCUP MED, V9, P555; LEINO P, 1987, J CHRON DIS, V40, P289, DOI 10.1016/0021-9681(87)90044-0; LEINO PI, 1993, SPINE, V18, P863, DOI 10.1097/00007632-199306000-00009; LIEBENSON CS, 1992, J MANIP PHYSIOL THER, V15, P299; LIEMOHN W, 1990, RHEUM DIS CLIN N AM, V16, P945; Liles D H, 1985, Occup Health Saf, V54, P57; LINTON SJ, 1987, PHYS THER, V67, P1375, DOI 10.1093/ptj/67.9.1375; LINTON SJ, 1989, PAIN, V36, P197, DOI 10.1016/0304-3959(89)90024-9; LINTON SJ, 1992, CLIN J PAIN, V8, P227, DOI 10.1097/00002508-199209000-00007; MANTLE MJ, 1981, RHEUMATOL REHABIL, V20, P227, DOI 10.1093/rheumatology/20.4.227; Mattmiller A W, 1980, Physiotherapy, V66, P118; MCCAULEY M, 1990, AM J OCCUP THER, V44, P402, DOI 10.5014/ajot.44.5.402; McElligott J, 1989, Conn Med, V53, P711; MCKENZIE RA, 1979, NEW ZEAL MED J, V89, P22; MCNEILL T, 1980, SPINE, V5, P529, DOI 10.1097/00007632-198011000-00008; MILLION R, 1981, ANN RHEUM DIS, V40, P449, DOI 10.1136/ard.40.5.449; MORRISON GEC, 1988, ARCH PHYS MED REHAB, V69, P605; NACHEMSON A, 1983, CLIN ORTHOP RELAT R, P77; NACHEMSON A, 1969, Scandinavian Journal of Rehabilitation Medicine, V1, P60; NACHEMSON A, 1964, J BONE JOINT SURG AM, V46, P1077, DOI 10.2106/00004623-196446050-00012; NACHEMSON AL, 1984, B HOSP JOINT DIS ORT, V44, P1; NORDIN M, 1992, BAILLIERE CLIN RHEUM, V6, P685, DOI 10.1016/S0950-3579(05)80133-5; NORDIN M, 1991, ADULT SPINE PRINCIPL, P1641; PIETRI F, 1992, SCAND J WORK ENV HEA, V18, P52, DOI 10.5271/sjweh.1614; POPE MH, 1985, SPINE, V10, P644, DOI 10.1097/00007632-198509000-00009; POPE MH, 1980, SPINE, V5, P173, DOI 10.1097/00007632-198003000-00012; REDDELL CR, 1992, APPL ERGON, V23, P319, DOI 10.1016/0003-6870(92)90293-5; RONCARATI A, 1988, J MANIP PHYSIOL THER, V11, P158; SCHLAPBACH P, 1991, RHEUMATOLOGY, V14, P25; SCHLAPBACH P, 1991, RHEUMATOLOGY, V14, P34; SNOOK SH, 1978, J OCCUP ENVIRON MED, V20, P478, DOI 10.1097/00043764-197807000-00009; SNOOK SH, 1984, OCCUPATIONAL LOW BAC, P233; SVENSSON HO, 1983, SPINE, V8, P272, DOI 10.1097/00007632-198304000-00007; TROUP JDG, 1987, SPINE, V12, P645, DOI 10.1097/00007632-198709000-00003; TURNER MS, 1986, PROSTHET ORTHOT INT, V10, P83; VENNING PJ, 1987, J OCCUP ENVIRON MED, V29, P820; VERSLOOT JM, 1992, SPINE, V17, P22, DOI 10.1097/00007632-199201000-00004; VIDEMAN T, 1984, SPINE, V9, P400, DOI 10.1097/00007632-198405000-00013; VIDEMAN T, 1989, SPINE, V14, P148, DOI 10.1097/00007632-198902000-00002; WALSH NE, 1990, AM J PHYS MED REHAB, V69, P245, DOI 10.1097/00002060-199010000-00004; WILLNER S, 1985, ACTA ORTHOP SCAND, V56, P40, DOI 10.3109/17453678508992977; WOOD DJ, 1987, SPINE, V12, P77, DOI 10.1097/00007632-198703000-00001; 1988, BACK INJURIES COST C	101	147	148	2	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1286	1291		10.1001/jama.272.16.1286	http://dx.doi.org/10.1001/jama.272.16.1286			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933374				2022-12-28	WOS:A1994PN06800036
J	HOUGHTON, LA; FOSTER, JM; WHORWELL, PJ; MORRIS, J; FOWLER, P				HOUGHTON, LA; FOSTER, JM; WHORWELL, PJ; MORRIS, J; FOWLER, P			IS CHEST PAIN AFTER SUMATRIPTAN ESOPHAGEAL IN ORIGIN	LANCET			English	Note								3-5% of patients taking the 5HT(1D) agonist sumatriptan for migraine have chest discomfort, suggesting a cardiac origin. We have investigated an alternative explanation of an oesophageal cause in 24 volunteers after the subcutaneous administration of a supratherapeutic dose of sumatriptan (16 mg) or placebo in a randomised, double-blind crossover study. Sumatriptan did not alter the electrocardiogram but increased the amplitude (p<0.001) and duration (p<0.001) of oesophageal contractions without affecting velocity of propagation. Clinically abnormal motility was also increased (p=0.001), and was more common in the 5 subjects with chest pain after sumatriptan. The effect of sumatriptan on oesophageal function provides an alternative explanation for the chest symptoms.	UNIV S MANCHESTER HOSP,DEPT MED STAT,MANCHESTER M20 2LR,LANCS,ENGLAND; GLAXO GRP RES LTD,RES & DEV,GREENFORD,MIDDX,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; GlaxoSmithKline	HOUGHTON, LA (corresponding author), UNIV S MANCHESTER HOSP,DEPT MED,MANCHESTER M20 2LR,LANCS,ENGLAND.			Whorwell, Peter/0000-0002-5220-8474; Houghton, Lesley/0000-0002-5351-0229				ADHAM N, 1992, MOL PHARMACOL, V41, P1; CATTANO C J, 1990, Practical Gastroenterology, V14, P57; HILLIS WS, 1993, LANCET, V341, P1564, DOI 10.1016/0140-6736(93)90700-Q; MELLOW MH, 1983, GASTROENTEROLOGY, V85, P306; Morrison LM, 1940, J AMER MED ASSOC, V114, P217; OTTERVANGER JP, 1993, LANCET, V341, P861, DOI 10.1016/0140-6736(93)93064-8; PATERSON WG, 1993, DIGEST DIS SCI, V38, P795, DOI 10.1007/BF01295903; ROMAN C, 1987, PHYSL GASTROINTESTIN; THOR KB, 1992, SYNAPSE, V10, P217, DOI 10.1002/syn.890100305	9	60	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					985	986		10.1016/S0140-6736(94)91642-X	http://dx.doi.org/10.1016/S0140-6736(94)91642-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934431				2022-12-28	WOS:A1994PK97800010
J	TULLY, T; PREAT, T; BOYNTON, SC; DELVECCHIO, M				TULLY, T; PREAT, T; BOYNTON, SC; DELVECCHIO, M			GENETIC DISSECTION OF CONSOLIDATED MEMORY IN DROSOPHILA	CELL			English	Article							APLYSIA SENSORY NEURONS; PROTEIN KINASE-A; INDUCED RETROGRADE-AMNESIA; LONG-TERM FACILITATION; WITHDRAWAL REFLEX; ADENYLATE-CYCLASE; MUTANT DROSOPHILA; OLFACTORY MEMORY; GILL-WITHDRAWAL; MUSHROOM BODIES	Behavioral and pharmacological experiments in many animal species have suggested that memory is consolidated from an initial, disruptable form into a longlasting, stable form within a few hours after training. We combined these traditional approaches with genetic analyses in Drosophila to show that consolidated memory of conditioned (learned) odor avoidance 1 day after extended training consisted of two genetically distinct, functionally independent memory components: anesthesia-resistant memory (ARM) and longterm memory (LTM). ARM decayed away within 4 days, was resistant to hypothermic disruption, was insensitive to the protein synthesis inhibitor cycloheximide (CXM), and was disrupted by the radish single-gene mutation. LTM showed no appreciable decay over 7 days, was sensitive to CXM, and was not disrupted by the radish mutation.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University	TULLY, T (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Preat, Thomas/0000-0001-9976-1763	NICHD NIH HHS [HD32245] Funding Source: Medline; NIGMS NIH HHS [P01-GM33205] Funding Source: Medline; NINDS NIH HHS [NS25621] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM033205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025621] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agranoff BW, 1981, BASIC NEUROCHEMISTRY, P801; AKAHANE R, 1983, J INSECT PHYSIOL, V29, P331, DOI 10.1016/0022-1910(83)90034-3; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ALLWEIS C, 1984, BEHAV BRAIN RES, V11, P117, DOI 10.1016/0166-4328(84)90134-7; ALLWEIS C, 1991, NEURAL BEHAV PLASTIC, P370; Andrew RJ, 1980, ADV STUD BEHAV, P337; ARMSTRONG RC, 1993, ANNU REV NEUROSCI, V16, P17, DOI 10.1146/annurev.ne.16.030193.000313; ASZODI A, 1991, P NATL ACAD SCI USA, V88, P5832, DOI 10.1073/pnas.88.13.5832; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BADDELEY A, 1976, PSYCHOL MEMORY; BAILEY CH, 1994, SEMIN NEUROSCI, V6, P35; BERGOLD PJ, 1992, NEURON, V8, P387, DOI 10.1016/0896-6273(92)90304-V; BERMAN RF, 1978, BRAIN RES, V158, P171, DOI 10.1016/0006-8993(78)90013-6; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYNTON S, 1992, GENETICS, V131, P655; BOYNTON S, 1990, BIOL MEMORY, P91; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; CAREW TJ, 1972, SCIENCE, V175, P451, DOI 10.1126/science.175.4020.451; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CROW T, 1993, J NEUROPHYSIOL, V69, P636, DOI 10.1152/jn.1993.69.2.636; DANIELS D, 1971, J COMP PHYSIOL PSYCH, V76, P110, DOI 10.1037/h0031044; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DUDAI Y, 1983, P NATL ACAD SCI-BIOL, V80, P5445, DOI 10.1073/pnas.80.17.5445; DUDAI Y, 1988, J COMP PHYSIOL A, V162, P101, DOI 10.1007/BF01342707; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; ERBER J, 1976, J COMP PHYSIOL PSYCH, V90, P41, DOI 10.1037/h0077258; FLOOD JF, 1977, BEHAV BIOL, V21, P307, DOI 10.1016/S0091-6773(77)90101-8; FOLKERS E, 1993, P NATL ACAD SCI USA, V90, P8123, DOI 10.1073/pnas.90.17.8123; FRECKLETON WC, 1968, PSYCHON SCI, V12, P179; FRIEDER B, 1978, BEHAV BIOL, V22, P178, DOI 10.1016/S0091-6773(78)92200-9; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GAILEY DA, 1991, J COMP PHYSIOL A, V169, P685; GALL CM, 1991, MEMORY ORG LOCUS CHA, P301; GELLER A, 1968, PSYCHON SCI, V12, P169; GLICKMAN SE, 1961, PSYCHOL BULL, V58, P218, DOI 10.1037/h0044212; GREENOUGH WT, 1984, TRENDS NEUROSCI, V7, P229, DOI 10.1016/S0166-2236(84)80211-8; Hintzman D. L., 1974, THEORIES COGNITIVE P, P77; HIRSCH J, 1956, PSYCHOL BULL, V53, P402, DOI 10.1037/h0040715; JAFFE K, 1980, PHYSIOL BEHAV, V25, P367, DOI 10.1016/0031-9384(80)90275-9; James W., 1890, PRINCIPLES PSYCHOL, P449, DOI [https://doi.org/10.1037/11059-009, DOI 10.1037/11059-009]; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KESNER RP, 1981, BRAIN RES, V209, P159, DOI 10.1016/0006-8993(81)91178-1; KNOWLTON BJ, 1993, SCIENCE, V262, P1747, DOI 10.1126/science.8259522; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MALDONADO H, 1980, J INSECT PHYSIOL, V26, P339, DOI 10.1016/0022-1910(80)90002-5; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351; MCGAUGH JL, 1972, MEMORY CONSOLIDATION; MENZEL R, 1993, NATURWISSENSCHAFTEN, V80, P380, DOI 10.1007/BF01138799; MENZEL R, 1990, BRAIN PERCEPTION COG, P111; MIZUMORI SJY, 1985, BEHAV NEUROSCI, V99, P220, DOI 10.1037/0735-7044.99.2.220; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NAGY ZM, 1993, B PSYCHONOMIC SOC, V31, P225, DOI 10.3758/BF03337330; NAZIF FA, 1991, BRAIN RES, V539, P324, DOI 10.1016/0006-8993(91)91638-H; PRUZAN A, 1977, PHARMACOL BIOCHEM BE, V6, P355, DOI 10.1016/0091-3057(77)90037-5; QUINN WG, 1976, NATURE, V262, P576, DOI 10.1038/262576a0; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; RIBOT TA, 1892, DICT PSYCHOL MED; Riccio D. C., 1981, INFORMATION PROCESSI, P291; RIEGE WH, 1974, BEHAV BIOL, V12, P477, DOI 10.1016/S0091-6773(74)92291-3; ROSE SPR, 1991, TRENDS NEUROSCI, V14, P390, DOI 10.1016/0166-2236(91)90027-R; ROSE SPR, 1987, BEHAV NEURAL BIOL, V48, P246, DOI 10.1016/S0163-1047(87)90808-9; ROSE SPR, 1984, BEHAV NEURAL BIOL, V42, P663; ROSENZWEIG MR, 1984, NEUROBIOLOGY LEARNIN, P263; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Sokal R. R, 1981, BIOMETRY; Squire L. R., 1987, MEMORY BRAIN; SQUIRE LR, 1980, SCIENCE, V209, P836, DOI 10.1126/science.7190729; STAUBLI U, 1985, BEHAV NEURAL BIOL, V43, P287, DOI 10.1016/S0163-1047(85)91632-2; STEWART MG, 1991, NEURAL BEHAVIOURAL P, P305; TEMPEL BL, 1983, P NATL ACAD SCI-BIOL, V80, P1482, DOI 10.1073/pnas.80.5.1482; TULLY T, 1986, J NEUROGENET, V3, P33, DOI 10.3109/01677068609106893; TULLY T, 1990, COLD SH Q B, V55, P203; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1993, J NEUROGENET, V9, P55, DOI 10.3109/01677069309167275; TULLY T, 1988, MODULATION SYNAPTIC, P401; Tully T., 1991, NEUROBIOLOGY LEARNIN, P29; WILLMUND R, 1979, NATURWISSENSCHAFTEN, V66, P318, DOI 10.1007/BF00441282; YAMADA A, 1992, J NEUROSCI, V12, P729; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	91	707	721	0	59	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					35	47		10.1016/0092-8674(94)90398-0	http://dx.doi.org/10.1016/0092-8674(94)90398-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923375				2022-12-28	WOS:A1994PK58500006
J	GREENBERGER, NJ; MINER, PB				GREENBERGER, NJ; MINER, PB			IS MAINTENANCE THERAPY EFFECTIVE IN CROHNS-DISEASE	LANCET			English	Editorial Material							PREDNISOLONE				GREENBERGER, NJ (corresponding author), UNIV KANSAS,MED CTR,DEPT MED,KANSAS CITY,KS 66103, USA.							EWE K, 1993, GASTROENTEROLOGY, V105, P367, DOI 10.1016/0016-5085(93)90709-L; GENDRE JP, 1993, GASTROENTEROLOGY, V104, P435, DOI 10.1016/0016-5085(93)90411-5; HANAUER SB, 1993, AM J GASTROENTEROL, V88, P1343; MESSORI A, 1994, AM J GASTROENTEROL, V89, P692; MODIGLIANI R, 1990, GASTROENTEROLOGY, V98, P811, DOI 10.1016/0016-5085(90)90002-I; SINGLETON JW, 1993, GASTROENTEROLOGY, V104, P1292; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; SUTHERLAND L, 1991, GUT, V32, P1071, DOI 10.1136/gut.32.9.1071	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					900	901		10.1016/S0140-6736(94)92261-6	http://dx.doi.org/10.1016/S0140-6736(94)92261-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934340				2022-12-28	WOS:A1994PJ28700002
J	MANZONI, OJ; MANABE, T; NICOLL, RA				MANZONI, OJ; MANABE, T; NICOLL, RA			RELEASE OF ADENOSINE BY ACTIVATION OF NMDA RECEPTORS IN THE HIPPOCAMPUS	SCIENCE			English	Article							GLUTAMATE-EVOKED RELEASE; EXCITATORY AMINO-ACIDS; RAT CORTICAL SLICES; SYNAPTIC TRANSMISSION; PRESYNAPTIC INHIBITION; ENDOGENOUS ADENOSINE; POSTTETANIC DEPRESSION; CEREBRAL-CORTEX; BRAIN-SLICES; AREA CA1	Adenosine is present in the mammalian brain in large amounts and has patent effects on neuronal activity, but its role in neural signaling is poorly understood. The glutamate receptor agonist N-methyl-D-aspartate (NMDA) caused a presynaptic depression of excitatory synaptic transmission in the CA1 region of guinea pig hippocampal slices. This depression was blocked by an adenosine A1 receptor antagonist, which suggests that activation of the NMDA subtype of glutamate receptor raises the concentration of extracellular adenosine, which acts on presynaptic inhibitory A1 receptors. Strong tetanic stimulation caused a heterosynaptic inhibition that was blocked by both NMDA and A1 receptor antagonists. Enkephalin, which selectively inhibits interneurons, antagonized the heterosynaptic inhibition. These findings suggest that synaptically released glutamate activates NMDA receptors, which in turn releases adenosine, at least in part from interneurons, that acts at a distance to inhibit presynaptically the release of glutamate from excitatory synapses. Thus, interneurons may mediate a widespread purinergic presynaptic inhibition.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV TOKYO, FAC MED, INST BRAIN RES, DEPT NEUROPHYSIOL, TOKYO 113, JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Tokyo			Manzoni, Olivier/M-7899-2016	Manzoni, Olivier/0000-0002-5579-6208				BASHIR ZI, 1992, EUR J NEUROSCI, V4, P485, DOI 10.1111/j.1460-9568.1992.tb00898.x; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BOUITON CL, 1993, J PHYSIOL-LONDON, V467, pP181; CAPOGNA M, 1993, J PHYSIOL-LONDON, V470, P539, DOI 10.1113/jphysiol.1993.sp019874; COHEN GA, 1992, NEURON, V9, P325, DOI 10.1016/0896-6273(92)90171-9; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CRAIG CG, 1993, J NEUROCHEM, V60, P1073, DOI 10.1111/j.1471-4159.1993.tb03256.x; CULLCANDY SG, 1991, ANN NY ACAD SCI, V633, P458; CUNHA RA, 1992, J NEUROCHEM, V59, P657, DOI 10.1111/j.1471-4159.1992.tb09420.x; DUNWIDDIE TV, 1985, J PHYSIOL-LONDON, V369, P365, DOI 10.1113/jphysiol.1985.sp015907; DUNWIDDIE TV, 1985, INT REV NEUROBIOL, V27, P63, DOI 10.1016/S0074-7742(08)60556-5; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; GROVER LM, 1993, SYNAPSE, V15, P149, DOI 10.1002/syn.890150207; GROVER LM, 1993, NEUROSCI LETT, V154, P39, DOI 10.1016/0304-3940(93)90166-I; HAAS HL, 1988, N-S ARCH PHARMACOL, V337, P561; HOEHN K, 1990, J NEUROCHEM, V54, P256, DOI 10.1111/j.1471-4159.1990.tb13309.x; HOEHN K, 1990, J NEUROCHEM, V54, P1716, DOI 10.1111/j.1471-4159.1990.tb01226.x; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; LUPICA CR, 1992, J NEUROSCI, V12, P3753; MADISON DV, 1988, J PHYSIOL-LONDON, V398, P123, DOI 10.1113/jphysiol.1988.sp017033; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MITCHELL JB, 1993, J NEUROSCI, V13, P3439; NICOLL RA, 1980, NATURE, V287, P22, DOI 10.1038/287022a0; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; PHILLIS JW, 1981, PROG NEUROBIOL, V16, P187, DOI 10.1016/0301-0082(81)90014-9; PONS F, 1980, J NEUROCHEM, V34, P1319, DOI 10.1111/j.1471-4159.1980.tb09977.x; PRINCE DA, 1992, P NATL ACAD SCI USA, V89, P8586, DOI 10.1073/pnas.89.18.8586; PULL I, 1973, BIOCHEM J, V136, P893, DOI 10.1042/bj1360893; SAH P, 1990, J PHYSIOL-LONDON, V430, P605, DOI 10.1113/jphysiol.1990.sp018310; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SEKINO Y, 1992, NEUROSCI LETT, V148, P109, DOI 10.1016/0304-3940(92)90816-P; SILINSKY EM, 1984, J PHYSIOL-LONDON, V346, P243, DOI 10.1113/jphysiol.1984.sp015019; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; ZETTERSTROM T, 1982, NEUROSCI LETT, V29, P111, DOI 10.1016/0304-3940(82)90338-X; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610	39	252	257	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	1994	265	5181					2098	2101		10.1126/science.7916485	http://dx.doi.org/10.1126/science.7916485			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	7916485				2022-12-28	WOS:A1994PJ91200032
J	AVNER, ED				AVNER, ED			GENE TIME FOR POLYCYSTIC KIDNEY-DISEASE	LANCET			English	Editorial Material											AVNER, ED (corresponding author), CHILDRENS HOSP & MED CTR,DIV PEDIAT NEPHROL,SEATTLE,WA 98105, USA.							AVNER ED, 1993, SEMIN NEPHROL, V13, P427; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; MCDONALD RA, 1991, SEMIN NEPHROL, V11, P632; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; WOO DDL, 1994, NATURE, V368, P750, DOI 10.1038/368750a0; ZERRES K, 1994, NAT GENET, V7, P429, DOI 10.1038/ng0794-429; 1994, CELL, V77, P1	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					833	834		10.1016/S0140-6736(94)92820-7	http://dx.doi.org/10.1016/S0140-6736(94)92820-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916394				2022-12-28	WOS:A1994PH25300004
J	ROUSE, J; COHEN, P; TRIGON, S; MORANGE, M; ALONSOLLAMAZARES, A; ZAMANILLO, D; HUNT, T; NEBREDA, AR				ROUSE, J; COHEN, P; TRIGON, S; MORANGE, M; ALONSOLLAMAZARES, A; ZAMANILLO, D; HUNT, T; NEBREDA, AR			A NOVEL KINASE CASCADE TRIGGERED BY STRESS AND HEAT-SHOCK THAT STIMULATES MAPKAP KINASE-2 AND PHOSPHORYLATION OF THE SMALL HEAT-SHOCK PROTEINS	CELL			English	Article							TUMOR-NECROSIS-FACTOR; NERVE GROWTH-FACTOR; SIGNAL-REGULATED KINASE; IMMEDIATE-EARLY GENE; TYROSINE PHOSPHORYLATION; RODENT CELLS; HUMAN HSP27; ACTIVATION; EXPRESSION; INTERLEUKIN-1	MAPK-activated protein kinase-2 (MAPKAP kinase-2) is activated in vitro by the p42 and p44 isoforms of MAPK (p42/p44(MAPK)). In several cell lines, however, MAPKAP kinase-2 is activated by sodium arsenite, heat shock, or osmotic stress and not by agonists that activate p42/p44(MAPK). We have identified a MAPK-like enzyme that acts as a MAPKAP kinase-a reactivating kinase (RK). RK is recognized by an antiserum raised against a Xenopus MAPK (Mpk2), which is most similar to HOG1 from S. cerevisiae. We also identified a RK kinase (RKK) on the basis of its ability to activate either RK or a GST-Mpk2 fusion protein. The RKK, RK, and MAPKAP kinase-2 constitute a new stress-activated signal transduction pathway in vertebrates that is distinct from the classical MAPK cascade.	ECOLE NORMALE SUPER, DEPT BIOL, MOLEC GENET UNIT, F-75230 PARIS 05, FRANCE; IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	ROUSE, J (corresponding author), UNIV DUNDEE, INST MED SCI, DEPT BIOCHEM, MRC, PROT PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND.		Nebreda, Angel Rodriguez/R-9594-2019					ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BIRD TA, 1994, FEBS LETT, V338, P31, DOI 10.1016/0014-5793(94)80111-8; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHARLES CH, 1992, ONCOGENE, V7, P187; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ENGEL K, 1993, FEBS LETT, V336, P143, DOI 10.1016/0014-5793(93)81628-D; ERSHLER MA, 1993, GENE, V124, P305, DOI 10.1016/0378-1119(93)90411-U; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HEPBURN A, 1988, FEBS LETT, V227, P175, DOI 10.1016/0014-5793(88)80892-5; JOHNSTON D, 1980, J BIOL CHEM, V255, P6975; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; KNAUF U, 1992, FEBS LETT, V309, P297, DOI 10.1016/0014-5793(92)80793-G; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LINT JV, 1992, J BIOL CHEM, V267, P25916; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MING Z, 1993, J BIOL CHEM, V268, P35; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; STAFSTROM JP, 1993, PLANT MOL BIOL, V22, P83, DOI 10.1007/BF00038997; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; TANGUAY RM, 1983, CAN J BIOCHEM CELL B, V61, P414, DOI 10.1139/o83-056; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TRAVERSE S, 1993, ONCOGENE, V8, P3175; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WHITEWAY M, 1992, P NATL ACAD SCI USA, V89, P9410, DOI 10.1073/pnas.89.20.9410; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566	62	1524	1587	0	55	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					1027	1037		10.1016/0092-8674(94)90277-1	http://dx.doi.org/10.1016/0092-8674(94)90277-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923353				2022-12-28	WOS:A1994PJ29400013
J	LU, Z; MACKINNON, R				LU, Z; MACKINNON, R			ELECTROSTATIC TUNING OF MG2+ AFFINITY IN AN INWARD-RECTIFIER K+ CHANNEL	NATURE			English	Article							GUINEA-PIG HEART; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; VENTRICULAR CELLS; MAGNESIUM BLOCK; INTERNAL MG-2+; RECTIFICATION; ACTIVATION; IONS	INWARD-RECTIFIER potassium channels conduct K+ across the cell membrane more efficiently in the inward than outward direction. This unusual conduction property is directly related to the biological action of these channels(1-6). One basis for inward rectification is voltage-dependent blockade by intracellular Mg2+ (refs 1, 7-9): strong inward-rectifier channels are so sensitive to intracellular Mg2+ that no outward K+ current is measurable under physiological conditions; weak inward rectifiers are less sensitive and allow some K+ to flow outwards. Background K1 channels and acetylcholine-regulated K+ channels from the heart are examples of strong inward rectifiers and ATP-sensitive K+ channels are weak rectifiers(1,7-10). Here we show that mutations at one position in the second transmembrane segment can alter the Mg2+ affinity and convert a weakly rectifying channel (ROMK1) into a strong rectifier. The amino acid at this position exposes its side chain to the aqueous pore and affects Mg2+ blockade as well as K+ conduction through an electrostatic mechanism.			LU, Z (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.							ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; Creighton T. E., 1993, PROTEINS STRUCTURES; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P1025; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; GRAHAME DC, 1947, CHEM REV, V41, P441, DOI 10.1021/cr60130a002; Hille B., 1991, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MATSUDA H, 1991, J PHYSIOL-LONDON, V435, P83, DOI 10.1113/jphysiol.1991.sp018499; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; NOMA A, 1983, PFLUGERS ARCH, V400, P424; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SEOJIMA M, 1984, PFLUGERS ARCH, V400, P424; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560	29	273	278	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					243	246		10.1038/371243a0	http://dx.doi.org/10.1038/371243a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	7915826				2022-12-28	WOS:A1994PG29000051
J	PHILIPP, T; DURAZZO, M; TRAUTWEIN, C; ALEX, B; STRAUB, P; LAMB, JG; JOHNSON, EF; TUKEY, RH; MANNS, MP				PHILIPP, T; DURAZZO, M; TRAUTWEIN, C; ALEX, B; STRAUB, P; LAMB, JG; JOHNSON, EF; TUKEY, RH; MANNS, MP			RECOGNITION OF URIDINE-DIPHOSPHATE GLUCURONOSYL TRANSFERASES BY LKM-3 ANTIBODIES IN CHRONIC HEPATITIS-D	LANCET			English	Article							BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE; CRIGLER-NAJJAR SYNDROME; DELTA-VIRUS-INFECTION; AUTOIMMUNE HEPATITIS; MICROSOMAL AUTOANTIBODIES; DEVELOPMENTAL EXPRESSION; RAT; CYTOCHROME-P-450; SEQUENCE; GENE	Patients with chronic hepatitis D often have liver-kidney microsoma I a nti bod ies type 3 (LKM-3). These a nti bod ies react with several microsomal antigens that have a molecular weight of 55 KDa and an isoelectric point of about 8. We studied the molecular nature of the antigen and, by immunoscreening a human liver cDNA expression library with KM-3 sera, found that uridine diphosphate glucuronosyl transferases (UGT) appeared as candidate antigens. We confirmed the identity of UGT as an antigen by reacting the sera with recombinant rabbit liver UGT proteins. Some sera reacted with rabbit UGT-2 proteins, but UGT-1 proteins were more sensitive and specific in detecting LKM-3 autoantibodies in patient sera. Anti-UGT-1 antibodies were detected in all LKM-3 positive sera from patients with hepatitis D and 1 out of 11 patients with autoimmune hepatitis type 2. Sera from patients who had hepatitis B only did not react with UGT proteins. The UGT proteins are part of the phase II enzymes of drug metabolism and a re the fi rst such enzymes to be identified as human autoantigens.	HANNOVER MED SCH, DEPT GASTROENTEROL & HEPATOL, HANNOVER, GERMANY; UNIV TURIN, IST MED INTERNA, TURIN, ITALY; UNIV CALIF SAN DIEGO, CTR CANC, DEPT PHARMACOL, SAN DIEGO, CA 92103 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92093 USA	Hannover Medical School; University of Turin; University of California System; University of California San Diego; Scripps Research Institute				DURAZZO, Marilena/0000-0003-2450-5911	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135, R01GM031001] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31001, GM49135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMENGUAL MJ, 1989, CLIN EXP IMMUNOL, V78, P80; BEAUNE P, 1987, P NATL ACAD SCI USA, V84, P551, DOI 10.1073/pnas.84.2.551; BOSMA PJ, 1993, GASTROENTEROLOGY, V105, P216, DOI 10.1016/0016-5085(93)90029-C; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; COUGHTRIE MWH, 1988, MOL PHARMACOL, V34, P729; CRIVELLI O, 1983, CLIN EXP IMMUNOL, V54, P232; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HAQUE SJ, 1991, DNA CELL BIOL, V10, P515, DOI 10.1089/dna.1991.10.515; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; KIRKPATRICK RB, 1988, HEPATOLOGY, V8, P353, DOI 10.1002/hep.1840080227; MACKENZIE PI, 1992, J STEROID BIOCHEM, V43, P1099, DOI 10.1016/0960-0760(92)90338-J; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; MANNS MP, 1990, ARCH BIOCHEM BIOPHYS, V280, P229, DOI 10.1016/0003-9861(90)90541-6; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; NORMAN RL, 1978, J BIOL CHEM, V253, P8640; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1992, J BIOL CHEM, V267, P3257; ROBERTSON KJ, 1991, J INHERIT METAB DIS, V14, P563, DOI 10.1007/BF01797927; Schwab GE., 1987, MAMMALIAN CYTOCHROME, VI, P55; STRAUB P, 1993, J BIOL CHEM, V268, P21997; SUTHERLAND L, 1992, FEBS LETT, V308, P161, DOI 10.1016/0014-5793(92)81266-O; TUKEY RH, 1993, J BIOL CHEM, V268, P15260; VERGANI D, 1993, GASTROENTEROLOGY, V104, P1870, DOI 10.1016/0016-5085(93)90673-Z; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WESIERSKAGADEK J, 1990, HEPATOLOGY, V12, P1129; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256; ZAULI D, 1986, J CLIN PATHOL, V39, P897, DOI 10.1136/jcp.39.8.897; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074	32	104	107	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					578	581		10.1016/S0140-6736(94)91966-6	http://dx.doi.org/10.1016/S0140-6736(94)91966-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914961				2022-12-28	WOS:A1994PD42400010
J	SMYTH, JF; MOSSMAN, J; HALL, R; HEPBURN, S; PINKERTON, R; RICHARDS, M; THATCHER, N; BOX, J				SMYTH, JF; MOSSMAN, J; HALL, R; HEPBURN, S; PINKERTON, R; RICHARDS, M; THATCHER, N; BOX, J			CONDUCTING CLINICAL RESEARCH IN THE NEW NHS - THE MODEL OF CANCER	BRITISH MEDICAL JOURNAL			English	Article								The United Kingdom Coordinating Committee on Cancer Research represents the major organisations funding cancer research in the United Kingdom. The deliberations of a working party convened by the committee to evaluate recently expressed concerns that the changes in the NHS threaten research, especially clinical trials to evaluate new treatments, are reported. A survey of contributors to trials coordinated by the committee showed that half are now experiencing difficulties in continuing to participate in clinical trials. The two major problems identified were lack of time and of staff, especially for NHS staff in non-teaching hospitals. Recent changes in junior doctors' hours and proposed reductions in the length of time for training will exacerbate this. It is possible to identify the direct and indirect excess costs of conducting research in the NHS, but currently the mechanism does not exist to designate funds specifically for this purpose. Consultation with the regional directors of research and development confirmed that the service increment for teaching and research is not the solution for this, Proposals are made to secure future clinical research in the NHS, including finance, indemnity, the licensing of new drugs, the greater use of nurse counsellors, and the value of cancer registries.	UNITED KINGDOM COORDINATING COMM CANC RES,LONDON WC2A 3PX,ENGLAND; FREEMAN RD HOSP,DEPT UROL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND; ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND; GUYS HOSP,IMPERIAL CANC RES FUND,BREAST CANC UNIT,LONDON SE1 9RT,ENGLAND; CHRISTIE HOSP,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND; MRC,LONDON W1N 4AL,ENGLAND	Newcastle Freeman Hospital; Royal Marsden NHS Foundation Trust; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Christie NHS Foundation Trust; Christie Hospital	SMYTH, JF (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		pinkerton, ross/I-4808-2014					1992, ASSESSING EFFECTS HL	1	41	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					457	461		10.1136/bmj.309.6952.457	http://dx.doi.org/10.1136/bmj.309.6952.457			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920132	Green Published			2022-12-28	WOS:A1994PC40400024
J	TILLOTSON, SL; FUGGLE, PW; SMITH, I; ADES, AE; GRANT, DB				TILLOTSON, SL; FUGGLE, PW; SMITH, I; ADES, AE; GRANT, DB			RELATION BETWEEN BIOCHEMICAL SEVERITY AND INTELLIGENCE IN EARLY TREATED CONGENITAL HYPOTHYROIDISM - A THRESHOLD EFFECT	BRITISH MEDICAL JOURNAL			English	Article							FETAL HYPOTHYROIDISM; MENTAL-DEVELOPMENT; THYROXINE; CHILDREN; PARAMETERS; INFANTS; TESTS; AGE	Objectives-To assess whether early treatment of congenital hypothyroidism fully prevents intellectual impairment. Design-A national register of children with congenital hypothyroidism who were compared with unaffected children from the same school classes and matched for age, sex, social class, and first language. Setting-First three years (1982-4) of a neonatal screening programme in England, Wales, and Northern Ireland. Subjects-361 children with congenital hypothyroidism given early treatment and 315 control children. Main outcome measures-Intelligence quotient (IQ) measured at school entry at 5 years of age with the Wechsler preschool and primary scale of intelligence. Results-There was a discontinuous relation between IQ and plasma thyroxine concentration at diagnosis, with a threshold at 42.8 nmol/l (95% confidence interval 35.2 to 47.1 nmol/l). Hypothyroid children with thyroxine values below 42.8 nmol/l had a mean IQ 10.3 points (6.9 to 13.7 points) lower than those with higher values and than controls. None of the measures of quality of treatment (age at start of treatment (range 1-173 days), average thyoxine dose (12-76 mu g in the first year), average thyroxine concentration during treatment (79-234 nmol/l in the first year), and thyroxine concentration 103 nmol/l less than at least once during the first year) influenced IQ at age 5. Conclusions-Despite early treatment in congenital hypothyroidism the disease severity has a threshold effect on brain development, probably determined prenatally. The 55% of infants with more severe disease continue to show clinically significant intellectual impairment; infants with milder disease show no such impairment. The findings predict that	INST CHILD HLTH, MRC, REGISTER CHILDREN HYPOTHYROIDISM, MED UNIT, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, DEPT EPIDEMIOL & BIOSTAT, LONDON WC1H 1EH, ENGLAND	University of London; University College London; University of London; University College London								DAVIDSON R, 1981, ECONOMETRICA, V49, P781, DOI 10.2307/1911522; DEONA CR, 1988, PEDIATR RES, V24, P588, DOI 10.1203/00006450-198811000-00010; FISHER DA, 1979, J PEDIATR-US, V94, P700, DOI 10.1016/S0022-3476(79)80133-X; FLYNN JR, 1987, PSYCHOL BULL, V101, P171, DOI 10.1037/0033-2909.101.2.171; FUGGLE PW, 1992, J CHILD PSYCHOL PSYC, V33, P1241, DOI 10.1111/j.1469-7610.1992.tb00942.x; FUGGLE PW, 1991, EUR J PEDIATR, V150, P570, DOI 10.1007/BF02072209; GLORIEUX J, 1983, J PEDIATR-US, V102, P19, DOI 10.1016/S0022-3476(83)80279-0; GLORIEUX J, 1988, PEDIATR RES, V24, P6, DOI 10.1203/00006450-198807000-00003; GRANT DB, 1993, ARCH DIS CHILD, V69, P555, DOI 10.1136/adc.69.5.555; GRANT DB, 1992, ARCH DIS CHILD, V67, P87, DOI 10.1136/adc.67.1.87; GRANT DB, 1988, BRIT MED J, V296, P1355, DOI 10.1136/bmj.296.6633.1355; HEYERDAHL S, 1991, J PEDIATR-US, V118, P850, DOI 10.1016/S0022-3476(05)82194-8; HULSE JA, 1984, ARCH DIS CHILD, V59, P23, DOI 10.1136/adc.59.1.23; ILICKI A, 1991, ACTA PAEDIATR SCAND, V80, P199, DOI 10.1111/j.1651-2227.1991.tb11834.x; ILLIG R, 1987, ARCH DIS CHILD, V62, P1050, DOI 10.1136/adc.62.10.1050; KLEIN AH, 1972, J PEDIATR-US, V81, P912, DOI 10.1016/S0022-3476(72)80542-0; KOMIANOU F, 1988, EUR J PEDIATR, V147, P275, DOI 10.1007/BF00442694; LARSEN PR, 1989, NEW ENGL J MED, V321, P44, DOI 10.1056/NEJM198907063210108; MATTHEWS DE, 1988, BIOMETRIKA, V75, P139; ROCHICCIOLI P, 1984, ARCH FR PEDIATR, V41, P329; ROVET J, 1987, J PEDIATR-US, V110, P700, DOI 10.1016/S0022-3476(87)80005-7; ROYSTON P, IN PRESS BIOMETRICS; TILLOTSON SL, 1992, J CLIN PATHOL, V45, P819, DOI 10.1136/jcp.45.9.819; VIRTANEN M, 1989, ACTA PAEDIATR SCAND, V78, P405, DOI 10.1111/j.1651-2227.1989.tb11100.x; VULSMA T, 1989, NEW ENGL J MED, V321, P13, DOI 10.1056/NEJM198907063210103; 1984, J PEDIATR, V104, P539; 1981, LANCET, V2, P1095; 1990, J PEDIATR, V116, P27; 1990, LABOUR FORCE SURVEY; 1982, 1981 CENSUS NATIONAL	30	144	148	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					440	445		10.1136/bmj.309.6952.440	http://dx.doi.org/10.1136/bmj.309.6952.440			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920127	Green Published			2022-12-28	WOS:A1994PC40400017
J	BELSHE, RB; GRAHAM, BS; KEEFER, MC; GORSE, GJ; WRIGHT, P; DOLIN, R; MATTHEWS, T; WEINHOLD, K; BOLOGNESI, DP; SPOSTO, R; STABLEIN, DM; TWADDELL, T; BERMAN, PW; GREGORY, T; IZU, AE; WALKER, MC; FAST, P				BELSHE, RB; GRAHAM, BS; KEEFER, MC; GORSE, GJ; WRIGHT, P; DOLIN, R; MATTHEWS, T; WEINHOLD, K; BOLOGNESI, DP; SPOSTO, R; STABLEIN, DM; TWADDELL, T; BERMAN, PW; GREGORY, T; IZU, AE; WALKER, MC; FAST, P			NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZED WITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GLYCOPROTEIN GP120; TYPE-1 HIV-1; GP160; CHIMPANZEES; VACCINE; PROTECTION; INFECTION; IMMUNOGENICITY; PREVENTION	Objective.-To evaluate the safety and immunogenicity of the MN strain of recombinant gp120 (MN rgpl20) as a vaccine prototype to prevent human immunodeficiency virus (HIV). Design.-Double-blind, randomized, placebo-controlled study with subjects vaccinated at 0, 4, 24, and 48 weeks and followed up through 64 weeks. Setting.-The AIDS Vaccine Evaluation Units in St Louis, Mo, Nashville, Tenn, and Rochester, NY, conducted the clinical study. Laboratory studies were conducted at Duke University, Raleigh, NC; data analysis was done by the Data Coordinating and Analysis Center at the EMMES Corporation, Potomac, Md: Participants.-Fifty-seven persons seronegative for HIV, at low risk for acquiring HIV infection, and 18 to 60 years of age. Interventions.-The MN rgpl20 vaccine was administered to 12 volunteers each in doses of 100 mu g, 300 mu g, or 600 mu g, and 12 volunteers received a combination of 300 mu g of MN rgp1 20 vaccine and 300 mu g of vaccine from rgpl20 of strain IIIB. Nine volunteers received alum adjuvant alone (control). Main Outcome Measures.-Safety was assessed by monitoring lymphocyte subsets, serum creatinine, and liver enzymes. Immunogenicity was measured by enzyme-linked immunosorbent assay using the immunogen and synthetic peptide corresponding to the variable region 3 domain of gp120. Functional antibody assays included CD4 binding blocking; antibody-dependent, cell-mediated cytotoxicity; and neutralization of homologous and heterologous HIV strains. Results.-No severe adverse reactions occurred. In 33 of 48 volunteers, two doses of vaccine induced antibodies that neutralized the homologous strain HIV1/MN. Three doses of vaccine induced antibodies that neutralized MN (in 46 of 48 volunteers), SF-2 (in 45 of 48 volunteers), or IIIB strains of HIV-1 (in 30 of 48 volunteers). Conclusion.-The vaccines were safe and immunogenic. Multiple injections of vaccine broadened and increased the neutralizing antibody response.	VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37212; VANDERBILT UNIV,SCH MED,DEPT PEDIAT,NASHVILLE,TN 37212; UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; DUKE UNIV,SCH MED,DEPT SURG,RALEIGH,NC; EMMES CORP,POTOMAC,MD; GENENTECH INC,S SAN FRANCISCO,CA 94080; NIAID,DIV AIDS,BETHESDA,MD 20892	Vanderbilt University; Vanderbilt University; University of Rochester; Duke University; Emmes Corporation; Roche Holding; Genentech; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	BELSHE, RB (corresponding author), ST LOUIS UNIV,SCH MED,DEPT MED,DIV INFECT DIS,1402 S GRAND BLVD,ST LOUIS,MO 63104, USA.		Graham, Barney S./AAC-5898-2019	Graham, Barney S./0000-0001-8112-0853	NIAID NIH HHS [AI-05062, AI-05063, AI-05064] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELSHE RB, 1993, J INFECT DIS, V168, P1387, DOI 10.1093/infdis/168.6.1387; BERMAN PW, 1992, J VIROL, V66, P4464, DOI 10.1128/JVI.66.7.4464-4469.1992; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; Brown A J, 1991, AIDS, V5 Suppl 2, pS35, DOI 10.1097/00002030-199101001-00005; DENORONHA F, 1978, VIROLOGY, V85, P617, DOI 10.1016/0042-6822(78)90467-1; DENORONHA F, 1977, NATURE, V267, P54, DOI 10.1038/267054a0; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; FAST PE, 1993, AIDS, V7, pS147, DOI 10.1097/00002030-199301001-00020; FULTZ PN, 1992, SCIENCE, V256, P1687, DOI 10.1126/science.256.5064.1687; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GORSE GJ, 1992, VACCINE, V10, P383, DOI 10.1016/0264-410X(92)90068-U; GRAHAM BS, 1993, J INFECT DIS, V167, P533, DOI 10.1093/infdis/167.3.533; KUSUMI K, 1992, J VIROL, V66, P875, DOI 10.1128/JVI.66.2.875-885.1992; LYERLY HK, 1987, P NATL ACAD SCI USA, V84, P4601, DOI 10.1073/pnas.84.13.4601; MANNHALTER JW, 1991, AIDS RES HUM RETROV, V7, P485, DOI 10.1089/aid.1991.7.485; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MYERS G, 1993, HUMAN RETROVIRUSES A; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; SCHWARZ H, 1979, VIROLOGY, V93, P159, DOI 10.1016/0042-6822(79)90284-8; WARD EC, 1982, JNCI-J NATL CANCER I, V69, P509; WEINHOLD KJ, 1990, TECHNIQUES HIV RES, P187; YOSHIYAMA H, 1994, J VIROL, V68, P974, DOI 10.1128/JVI.68.2.974-978.1994	23	121	125	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					475	480		10.1001/jama.272.6.475	http://dx.doi.org/10.1001/jama.272.6.475			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	7913731				2022-12-28	WOS:A1994PA27800030
J	HAN, J; LEE, JD; BIBBS, L; ULEVITCH, RJ				HAN, J; LEE, JD; BIBBS, L; ULEVITCH, RJ			A MAP KINASE TARGETED BY ENDOTOXIN AND HYPEROSMOLARITY IN MAMMALIAN-CELLS	SCIENCE			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAY; MACROPHAGES; FAMILY; YEAST; GENES; TAXOL; CD14	Mammalian cells respond to endotoxic lipopolysaccharide (LPS) by activation of protein kinase cascades that lead to new gene expression. A protein kinase, p38, that was tyrosine phosphorylated in response to LPS, was cloned. The p38 enzyme and the product of the Saccharomyces cerevisiae HOG 1 gene, which are both members of the mitogen-activated protein (MAP) kinase family, have sequences at and adjacent to critical phosphorylation sites that distinguish these proteins from most other MAP kinase family members. Both HOG1 and p38 are tyrosine phosphorylated after extracellular changes in osmolarity. These findings link a signaling pathway in mammalian cells with a pathway in yeast that is responsive to physiological stress.	SCRIPPS RES INST, MICROCHEM FACIL, LA JOLLA, CA 92037 USA	Scripps Research Institute	HAN, J (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Ulevitch, Richard J/Q-3393-2017; Han, J/G-4671-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028485, P01GM037696, R37GM028485] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM28485, GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CORRADIN SB, 1992, J LEUKOCYTE BIOL, V52, P363, DOI 10.1002/jlb.52.4.363; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUSTIN M, COMMUNICATION; Han J., UNPUB; HAN JH, 1993, J BIOL CHEM, V268, P25009; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Tracey K J, 1990, Adv Surg, V23, P21; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	26	2398	2539	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					808	811		10.1126/science.7914033	http://dx.doi.org/10.1126/science.7914033			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7914033				2022-12-28	WOS:A1994PA37200041
J	HEYM, B; HONORE, N; TRUFFOTPERNOT, C; BANERJEE, A; SCHURRA, C; JACOBS, WR; VANEMBDEN, JD; GROSSET, JH; COLE, ST				HEYM, B; HONORE, N; TRUFFOTPERNOT, C; BANERJEE, A; SCHURRA, C; JACOBS, WR; VANEMBDEN, JD; GROSSET, JH; COLE, ST			IMPLICATIONS OF MULTIDRUG-RESISTANCE FOR THE FUTURE OF SHORT-COURSE CHEMOTHERAPY OF TUBERCULOSIS - A MOLECULAR STUDY	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; STREPTOMYCIN RESISTANCE; PULMONARY TUBERCULOSIS; GENE; RIFAMPIN; SINGLE; MUTATIONS; LEPRAE	Tuberculosis-control programmes are compromised by the increased frequency of multidrug-resistant strains of Mycobacterium tuberculosis. We used the polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis techniques to establish the molecular basis of resistance in 37 drug-resistant isolates of M tuberculosis, and correlated these findings with clinical and antibiotic-sensitivity data. Resistance to isoniazid was found in 36 strains, 16 of which were also resistant to ethionamide. Of the 36 isoniazid-resistant strains, 23 had mutations in the katG gene, and 5 of these also had mutations in the inhA gene. A further 5 strains had alterations in the inhA locus without the katG gene being mutated. Rifampicin resistance was less frequent (13 strains) and usually associated with isoniazid resistance (11 of 13 strains). Mutations in the rpoB gene were detected for all these rifampicin-resistant isolates. Mutations in the rpsL and rrs genes, associated with streptomycin resistance, were found in 13 of 25 and 2 of 25 streptomycin-resistant strains, respectively. The same chromosomal mutations, or combinations of mutations, were found in strains displaying single or multidrug resistance, from cases of both primary and secondary resistance, and from patients infected with human immunodeficiency virus. Thus, multidrug resistance is not due to a novel mechanism and tuberculosis chemotherapy is not subject to a new threat.	INST PASTEUR,UNITE GENET MOLEC BACTERIENNE,F-75724 PARIS 15,FRANCE; UNIV PARIS 06,PARIS,FRANCE; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY; NATL INST PUBL HLTH & HYG,BILTHOVEN,NETHERLANDS	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Yeshiva University				Jacobs, William/0000-0003-3321-3080				BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; HONORE N, 1994, ANTIMICROB AGENTS CH, V38, P238, DOI 10.1128/AAC.38.2.238; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; Imboden Paul, 1993, P519; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; MARTIN C, 1990, MOL BIOL MYCOBACTERI, P121; MCCLATCHY JK, 1986, ANTIBIOTICS LABORATO, P181; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; NAIR J, 1993, MOL MICROBIOL, V10, P521, DOI 10.1111/j.1365-2958.1993.tb00924.x; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773, DOI 10.1128/AAC.38.4.773; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; TELENTI A, 1993, ANTIMICROB AGENTS CH, V37, P2054, DOI 10.1128/AAC.37.10.2054; WOODS SA, 1989, FEMS MICROBIOL LETT, V65, P305; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; 1992, MMWR-MORBID MORTAL W, V42, P5; 1991, MMWR-MORBID MORTAL W, V40, P585; 1993, MMWR-MORBID MORTAL W, V42, P1	29	240	261	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					293	298		10.1016/S0140-6736(94)91338-2	http://dx.doi.org/10.1016/S0140-6736(94)91338-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914261				2022-12-28	WOS:A1994NZ23300007
J	WEINER, JP				WEINER, JP			FORECASTING THE EFFECTS OF HEALTH REFORM ON US PHYSICIAN WORKFORCE REQUIREMENT - EVIDENCE FROM HMO STAFFING PATTERNS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED CARE; INSURANCE	This article provides an estimate of the effects of health reform on the US physician workforce requirement. Its basic methodology is to extrapolate current patterns of staffing within managed care plans to the reshaped health care system of the year 2000. In this analysis it is assumed that 40% to 65% of Americans will be receiving care from integrated managed care networks in the near future, and that all citizens will be covered by some type of health insurance. On the basis of these assumptions, this article forecasts that in the year 2000, (1) there will be an overall surplus of about 165 000 patient care physicians; (2) the requirement and supply of primary care physicians will be in relative balance; and (3) the supply of specialists will outstrip the requirement by more than 60%. In summation, it appears that national health reform-based largely on an expansion of managed care networks-will have significant impact on the US physician workforce. Concerns have been raised by others that health system reform's shift toward more primary and preventive care will be stymied by workforce availability. This study underscores this concern to some degree. However, the evidence presented herein suggests that the issue is not so much a primary care provider shortage as a specialty care surplus.			WEINER, JP (corresponding author), JOHNS HOPKINS UNIV,SCH PUBL HLTH,624 N BROADWAY,ROOM 605,BALTIMORE,MD 21205, USA.							CAWLEY JF, 1993, ROLE PHYSICIAN ASSIS, pCH3; FELL FC, 1993, JAMA-J AM MED ASSOC, V269, P2659; FRANKS P, 1993, AM J PUBLIC HEALTH, V83, P1295, DOI 10.2105/AJPH.83.9.1295; GAMLIEL S, 1993, SUPPLY REQUIREMENTS; HOOKER R, 1993, ROLE PHYSICIAN ASSIS, pCH5; HOY EW, 1991, HEALTH AFFAIR, V10, P18, DOI 10.1377/hlthaff.10.4.18; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; MULHAUSEN R, 1989, JAMA-J AM MED ASSOC, V261, P1930, DOI 10.1001/jama.261.13.1930; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; SCITOVSKY AA, 1981, MED CARE, V19, P1165, DOI 10.1097/00005650-198112000-00002; STEINWACHS DM, 1986, NEW ENGL J MED, V314, P217, DOI 10.1056/NEJM198601233140406; STRAUB W, 1993, REQUIREMENTS PRIMARY; Tarlov A R, 1986, Health Aff (Millwood), V5, P23, DOI 10.1377/hlthaff.5.1.23; Weiner J P, 1993, Med Care Rev, V50, P411, DOI 10.1177/002570879305000403; Weiner J P, 1991, J Rural Health, V7, P373, DOI 10.1111/j.1748-0361.1991.tb00382.x; WEINER JP, 1993, J HEALTH POLIT POLIC, V18, P75, DOI 10.1215/03616878-18-1-75; WEINER JP, 1986, AM J PUBLIC HEALTH, V76, P507, DOI 10.2105/AJPH.76.5.507; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; 1988, 1ST REPORT COUNCIL; 1993, PHYSICIAN CHARACTERI; 1992, DHHS HRSPOD921 BUR H; 1993, HMO IND PROFILE 1992; 1993, SURVEY HMOS STAFFING; 1993, OSTEOPATHIC PHYSICIA; 1993, HLTH SECURITY PRESID; 1993, PATTERNS HMO ENROLLM; 1993, SOCIOECONOMIC CHARAC; 1981, DHHS HRA81651 US DEP; 1992, NATIONAL 1990 POPULA; 1992, 3RD REPORT COUNCIL	32	395	395	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					222	230						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NW185	7912746				2022-12-28	WOS:A1994NW18500024
J	THOMSON, MA; STOREY, P; GREER, R; CLEGHORN, GJ				THOMSON, MA; STOREY, P; GREER, R; CLEGHORN, GJ			CANINE-HUMAN TRANSMISSION OF GASTROSPIRILLUM-HOMINIS	LANCET			English	Note							HELICOBACTER-PYLORI; SPIRAL BACTERIUM; ORGANISMS	We report electron microscopic evidence of transmission from a pet dog to a 12-year-girl of Gastrospirillum hominis which caused gastric disease in both that was eradicable with treatment.	ROYAL CHILDRENS HOSP,GASTROENTEROL UNIT,BRISBANE,QLD 4029,AUSTRALIA; ROYAL BRISBANE HOSP,DEPT PATHOL,BRISBANE,QLD,AUSTRALIA	Royal Children's Hospital Brisbane; Royal Brisbane & Women's Hospital			Greer, Ristan/ABB-9511-2021; Greer, Ristan Mary/N-6948-2015; Cleghorn, Geoffrey/B-9072-2009	Greer, Ristan Mary/0000-0002-1574-4729; Cleghorn, Geoffrey/0000-0003-3473-6991				BREED RS, 1948, BERGEYS MANUAL DETER, P217; DENT JC, 1987, LANCET, V2, P96; FISCHER R, 1992, DIGEST DIS, V10, P144, DOI 10.1159/000171352; FOX JG, 1989, LAB ANIM SCI, V39, P543; HEILMANN KL, 1991, GUT, V32, P137, DOI 10.1136/gut.32.2.137; LEE A, 1993, GASTROENTEROL CLIN N, V22, P21; MCNULTY CAM, 1989, J CLIN PATHOL, V42, P585, DOI 10.1136/jcp.42.6.585; RAPPIN JP, CITED INDIRECTLY; ROSH JR, 1992, AM J GASTROENTEROL, V87, P135; SOLNICK JV, 1993, J INFECT DIS, V168, P379, DOI 10.1093/infdis/168.2.379	10	59	62	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1605	1607		10.1016/S0140-6736(94)93060-0	http://dx.doi.org/10.1016/S0140-6736(94)93060-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911923				2022-12-28	WOS:A1994NU35400013
J	KUNST, CB; WARREN, ST				KUNST, CB; WARREN, ST			CRYPTIC AND POLAR VARIATION OF THE FRAGILE-X REPEAT COULD RESULT IN PREDISPOSING NORMAL ALLELES	CELL			English	Article							FMR-I LOCUS; MYOTONIC-DYSTROPHY; FOUNDER CHROMOSOMES; RNA-BINDING; CGG-REPEAT; CTG REPEAT; CAG REPEAT; GENE; DNA; INSTABILITY	Fragile X syndrome results from the expansion of a CGG repeat that is normally interrupted by occasional AGG triplets. Linkage disequilibrium suggests that certain normal haplotypes may contribute unequally to the pool of fragile X chromosomes. Sequence analysis of normal alleles demonstrates haplotype-specific variation of the cryptic nature of the repeat. Variation occurs principally at the 3' end of the repeat, suggesting stability differences between the leading and lagging strands of DNA replication. Normal alleles with greater than 24 perfect 3' CGG repeats appear more frequently on haplotypes overrepresented among fragile X chromosomes. Such alleles are found in 2% of normal chromosomes and could comprise the ancestral allelic pool from which fragile X chromosomes are derived. These data also may imply that equilibrium between certain predisposed alleles and fragile X expansions has not yet been attained, indicating ongoing evolutionary change at this locus.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Emory University; Emory University	KUNST, CB (corresponding author), EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322, USA.		Warren, Stephen T/A-2498-2012		NICHD NIH HHS [HD20521] Funding Source: Medline; OHS HRSA HHS [ST32 GM08367] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, R01HD020521] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); OHS HRSA HHS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMOUR JAL, 1993, HUM MOL GENET, V2, P1137, DOI 10.1093/hmg/2.8.1137; ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN WT, 1993, JAMA-J AM MED ASSOC, V270, P1569, DOI 10.1001/jama.270.13.1569; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CHAKRAVARTI A, 1992, NAT GENET, V1, P237, DOI 10.1038/ng0792-237; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DAVIES J, 1992, CELL, V68, P799; ECKHART M, 1993, AM J HUM GENET, V53, pA796; FAIRMAN R, 1988, BIOCHEMISTRY-US, V27, P560, DOI 10.1021/bi00402a009; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GLOVER TW, 1987, AM J HUM GENET, V41, P882; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MACDONALD ME, 1992, NAT GENET, V1, P99, DOI 10.1038/ng0592-99; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MCCONKIEROSELL A, 1993, AM J HUM GENET, V53, P800; MORTON NE, 1992, P NATL ACAD SCI USA, V89, P4215, DOI 10.1073/pnas.89.9.4215; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; OUDET C, 1993, AM J HUM GENET, V52, P297; PETES TD, 1991, GENOME DYNAMICS PROT, V1; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROUSSEAU F, 1993, AM J HUM GENET, V53, pA3; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SMITS APT, 1993, J MED GENET, V30, P94, DOI 10.1136/jmg.30.2.94; SNOW K, 1993, AM J HUM GENET, V53, P1217; STARR C, 1984, BIOL UNITY DIVERSITY; STIENBACH P, 1993, HUM GENET, V92, P491; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SZABO P, 1984, P NATL ACAD SCI-BIOL, V81, P7855, DOI 10.1073/pnas.81.24.7855; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; VAUTE X, 1993, SCIENCE, V261, P598; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WOHRLE D, 1992, HUM GENET, V89, P114, DOI 10.1007/BF00207057; WOHRLE D, 1993, NAT GENET, V4, P140, DOI 10.1038/ng0693-140; YU S, 1992, AM J HUM GENET, V50, P968; 1993, CELL, V72, P971	53	334	337	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					853	861		10.1016/0092-8674(94)90134-1	http://dx.doi.org/10.1016/0092-8674(94)90134-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	7911740				2022-12-28	WOS:A1994NT33100010
J	BOVBJERG, RR; PETRONIS, KR				BOVBJERG, RR; PETRONIS, KR			THE RELATIONSHIP BETWEEN PHYSICIANS MALPRACTICE CLAIMS HISTORY AND LATER CLAIMS - DOES THE PAST PREDICT THE FUTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY IMPROVEMENT ACT; INSURANCE; CARE; EXPERIENCE; SEVERITY	Objective.-To investigate whether an association exists between physicians' past and subsequent claims of medical malpractice, particularly whether a history of even unpaid claims ($0) or small claims (<$30 000) predicts subsequently higher rates of claims, especially large paid claims (greater than or equal to$30 000) (all in 1990 dollars). Data.-All medical malpractice claims closed in the state of Florida from January 1975 through August 1988 (N=20 016, 92% involving physicians), matched with the American Medical Association's Physician Masterfile on all practicing physicians in the state of Florida during that period. Claims history was automated into physician-year claims files, then partitioned into a baseline period (1975 through 1980) and a subsequent period (1981 through 1983). Inconsequential claims were excluded, ie, cases closed without a named claimant and without expense for investigation (30.4% of raw claims). Methods.-Descriptive analysis of all physician claims; odds ratio analysis of physicians in practice throughout both periods (N=8247), comparing claims experience in baseline vs subsequent period, adjusted for specialty of practice. Results.-For all consequential physician claims, 60% were unpaid claims, 17% were small paid claims, and 23% were large paid claims. The 8247 continuously practicing physicians had a total of 6614 claims, averaging 0.9 per year, but 59.2% of physicians had no claims in 9 years, only 13.4% had any paid claims, and 7.2% had multiple paid claims. Less than 8% of physicians had any large paid claims during the baseline period, and less than 7% had any in the subsequent period. Physicians with any baseline claims (whether paid or unpaid, small or large, single or multiple) had elevated odds of subsequent claims (whether defined as any claims, any paid claims, any large claims, or multiple claims) relative to physicians with no baseline claims. With a baseline of all small claims, the adjusted odds ratio for any subsequent claim was 2.84 (95% confidence interval [CI], 2.32 to 3.49), for any subsequent paid claim was 2.97 (95% CI, 2.34 to 3.77), for all large subsequent claims was 2.42 (95% CI, 1.76 to 3.33), and for subsequent multiple claims was 2.83 (95% CI, 2.08 to 3.86). Even having a single unpaid baseline claim approximately doubled the odds. Conclusions.-Claims history had predictive value, even with only unpaid claims. Small paid claims were better predictors than unpaid claims, large paid claims were better predictors than small paid claims, and multiple paid claims were better predictors than single paid claims. Claims history of all kinds is a reasonable statistical measure, eg, for the screening purposes of the National Practitioner Data Bank.			BOVBJERG, RR (corresponding author), URBAN INST,CTR HLTH POLICY,2100 M ST NW,WASHINGTON,DC 20037, USA.							Agresti A., 1990, CATEGORICAL DATA ANA, pXV; BOVBJERG RR, 1991, LAW CONTEMP PROBL, V54, P5, DOI 10.2307/1191855; CURRAN WJ, 1987, NEW ENGL J MED, V316, P597, DOI 10.1056/NEJM198703053161006; DANZON PM, 1986, LAW CONTEMP PROBL, V49, P57, DOI 10.2307/1191415; DOLIN LC, 1985, NEW ENGL J MED, V313, P1156, DOI 10.1056/NEJM198510313131810; Fleiss JL, 1981, STAT METHODS RATES P; HORNER SL, 1990, AM J LAW MED, V16, P455; IGLEHART J, 1987, NEW ENGL J MED, V316, P960; JOHNSON ID, 1991, JAMA-J AM MED ASSOC, V265, P407, DOI 10.1001/jama.265.3.407; MORLOCK LL, 1993, UTILIZATION MARYLAND; Nye BF, 1988, J RISK INSUR, V55, P150, DOI [10.2307/253287, DOI 10.2307/253287]; ROLPH JE, 1991, JAMA-J AM MED ASSOC, V266, P2093, DOI 10.1001/jama.266.15.2093; ROLPH JE, 1993, INQUIRY-J HEALTH CAR, V30, P441; ROLPH JE, 1981, J RISK INSUR, V48, P247, DOI 10.2307/252739; ROLPH JE, 1991, LAW CONTEMP PROBL, V54, P65; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SLOAN FA, 1990, J HEALTH ECON, V9, P289, DOI 10.1016/0167-6296(90)90048-8; SLOAN FA, 1990, AM ECON REV, V80, P128; SLOAN FA, 1989, JAMA-J AM MED ASSOC, V262, P3291, DOI 10.1001/jama.262.23.3291; SLOAN FA, 1991, INSURING MED MALPRAC; TARAGIN MI, 1992, ANN INTERN MED, V117, P780, DOI 10.7326/0003-4819-117-9-780; WEBER D, 1991, INSURANCE REV    SEP, P47; 1990, FED REGISTER, V55, P7035; 1992, NATIONAL PRACTITIONE; 1986, GAOHRD81112 US GEN A; 1988, OTAH386 PUBL; 1980, MALPRACTICE CLAIMS F, P2; 1987, GAOHRD8755 US GEN AC	28	69	69	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1421	1426		10.1001/jama.272.18.1421	http://dx.doi.org/10.1001/jama.272.18.1421			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP690	7933423				2022-12-28	WOS:A1994PP69000029
J	VONLICHTENBERG, F				VONLICHTENBERG, F			OMEGA-YES, ALPHA-NO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		JACKSON MF, 1966, B MED LIBR ASSOC, V54, P325; KENT A, 1966, J AMER MED ASSOC, V196, P927; LOUKAS A, 1994, AM J TROP MED HYG, V50, P69, DOI 10.4269/ajtmh.1994.50.69; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V270, P2495, DOI 10.1001/jama.1993.03510200101040; PROCIV P, 1990, LANCET, V335, P1299, DOI 10.1016/0140-6736(90)91186-E; ROGERS AM, 1946, AM J MED SCI, V211, P531, DOI 10.1097/00000441-194621150-00002; WERTZ RK, 1986, JAMA-J AM MED ASSOC, V256, P3375	7	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1412	1412						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP690	7933421				2022-12-28	WOS:A1994PP69000027
J	KAY, D; FLEISHER, JM; SALMON, RL; JONES, F; WYER, MD; GODFREE, AF; ZELENAUCHJACQUOTTE, Z; SHORE, R				KAY, D; FLEISHER, JM; SALMON, RL; JONES, F; WYER, MD; GODFREE, AF; ZELENAUCHJACQUOTTE, Z; SHORE, R			PREDICTING LIKELIHOOD OF GASTROENTERITIS FROM SEA BATHING - RESULTS FROM RANDOMIZED EXPOSURE	LANCET			English	Article							WATER-QUALITY; HEALTH; SEWAGE; STAPHYLOCOCCUS; RECOVERY; ILLNESS	The health effects of bathing in coastal waters is an area of scientific controversy. We conducted the first ever randomised ''trial'' of an environmental exposure to measure the health effects of this activity. The trial was spread over four summers in four UK resorts and 1216 adults took part. Detailed interviews were used to collect data on potential confounding factors and intensive water quality monitoring was used to provide more precise indices of exposure. 548 people were randomised to bathing, and the exposure included total immersion of the head. Crude rates of gastroenteritis were significantly higher in the exposed group (14.8 per 100) than the unexposed group (9.7 per 100; p=0.01). Linear trend and multiple logistic regression techniques were used to establish relations between gastroenteritis and microbiological water quality. Of a range of microbiological indicators assayed only faecal streptococci concentration, measured at chest depth, showed a significant dose-response relation with gastroenteritis. Adverse health effects were identified when faecal streptococci concentrations exceeded 32 per 100 mL. This relation was independent of non-water-related predictors of gastroenteritis. We do not suggest that faecal streptococci caused the excess of gastrointestinal symptoms in sea bathers but these microorganisms do seem to be a better indicator of water quality than the traditional coliform counts. Bathing water standards should be revised with these findings in mind.	SUNY HLTH SCI CTR, DEPT PREVENT MED, BROOKLYN, NY USA; PHLS, CTR COMMUNICABLE DIS SURVEILLANCE, WELSH UNIT, CARDIFF, S GLAM, WALES; ACER ENVIRONM, RUNCORN, CHESHIRE, ENGLAND; NYU, MED CTR, INST ENVIRONM MED, NEW YORK, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; New York University	KAY, D (corresponding author), UNIV LEEDS, LEEDS ENVIRONM CTR, CTR RES ENVIRONM & HLTH, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND.							ALEXANDER LM, 1992, J EPIDEMIOL COMMUN H, V46, P340, DOI 10.1136/jech.46.4.340; ALICO RK, 1986, APPL ENVIRON MICROB, V51, P699, DOI 10.1128/AEM.51.4.699-702.1986; BALARAJAN R, 1991, BRIT MED J, V303, P1444, DOI 10.1136/bmj.303.6815.1444; Breslow N, 1980, STATISTICAL METHODS, V32; CABELLI VJ, 1982, AM J EPIDEMIOL, V115, P606, DOI 10.1093/oxfordjournals.aje.a113342; CABELLI VJ, 1983, J WATER POLLUT CON F, V55, P1306; CAMPOSFILHO BSN, 1988, MULTLR MICROCOMPUTER; CHEUNG WHS, 1988, P I WATER ENV MANAGE, P378; DIXON WJ, 1988, BMDP STATISTICAL SOF, V2; El Sharkawi F, 1982, B HIGH I PUB HLTH AL, V12, P337; FATTAL B, 1987, CHEMOSPHERE, V16, P565, DOI 10.1016/0045-6535(87)90268-2; FLEISHER JM, 1993, INT J EPIDEMIOL, V22, P698, DOI 10.1093/ije/22.4.698; FLEISHER JM, 1991, RES J WATER POLLUT C, V63, P259; Foulon G, 1983, REV FR SCI EAUX, V2, P127; JONES F, 1990, J INST WATER ENV MAN, V4, P295; JONES F, 1991, J INST WATER ENV MAN, V5, P91; KAPLAN JE, 1982, AM J PUBLIC HEALTH, V72, P1329, DOI 10.2105/AJPH.72.12.1329; Kay D., 1992, RECREATIONAL WATER Q, P129; LAMBDEN PR, 1993, SCIENCE, V259, P516, DOI 10.1126/science.8380940; LIGHTFOOT NE, 1989, THESIS U TORONTO; MACLURE M, 1992, AM J EPIDEMIOL, V135, P92; SEYFRIED P L, 1985, American Journal of Public Health, V75, P1068, DOI 10.2105/AJPH.75.9.1068; SEYFRIED PL, 1985, AM J PUBLIC HEALTH, V75, P1071, DOI 10.2105/AJPH.75.9.1071; STENGREN SR, 1984, MICROBIOS, V41, P191; STEVENSON AH, 1953, AM J PUBLIC HEALTH, V43, P529; WALKER A, 1992, BRIT MED J, V304, P242, DOI 10.1136/bmj.304.6821.242; 1968, WATER QUALITY CRITER; 1980, BEACH HARBOR SAMPLIN; COM94940006SYN COMM; 1976, OFFIC J EUR COMMUN L, V31, P1; 1983, 71 PUBL HLTH MED SUB; 1986, EPA440584002 OFF WAT; 1959, 37 MED RES COUNC MED; 1985, USERS GUIDE STATISTI; 1976, QUALITY CRITERIA WAT; 1972, HLTH CRITERIA QUALIT	36	231	236	1	31	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					905	909		10.1016/S0140-6736(94)92267-5	http://dx.doi.org/10.1016/S0140-6736(94)92267-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934344	hybrid			2022-12-28	WOS:A1994PJ28700008
J	HORIE, S; HIGASHIHARA, E; NUTAHARA, K; MIKAMI, Y; OKUBO, A; KANO, M; KAWABE, K				HORIE, S; HIGASHIHARA, E; NUTAHARA, K; MIKAMI, Y; OKUBO, A; KANO, M; KAWABE, K			MEDIATION OF RENAL CYST FORMATION BY HEPATOCYTE GROWTH-FACTOR	LANCET			English	Note							CELLS	Hepatocyte growth factor (HGF) is a potent mitogen for renal tubular cells, and HGF and its receptor (c-met proto-oncogene product, Met) can induce lumen formation in epithelial cells. We measured the concentration of HGF in cyst fluids from patients with renal cystic diseases. The concentration of HGF was high in proximal cyst fluid (mean 2.45 vs 0.42 ng/mL in distal cysts). Cyclic AMP concentration was higher in distal than in proximal cysts (663 vs 6.0 pmol/L). mRNA of HGF and Met were cc-expressed in cyst walls from cases with polycystic kidney disease. These findings suggest that HGF is a growth factor that may mediate human renal cyst genesis.	UNIV TOKYO,FAC MED,DEPT LAB MED,TOKYO 113,JAPAN; KYORIN UNIV,FAC MED,DEPT UROL,TOKYO,JAPAN	University of Tokyo; Kyorin University	HORIE, S (corresponding author), UNIV TOKYO,FAC MED,DEPT UROL,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							GRANTHAM JJ, 1993, ADV INTERNAL MED, V38, P409; HUSEMAN R, 1980, KIDNEY INT, V18, P375, DOI 10.1038/ki.1980.148; Maniatis T., 1982, MOL CLONING; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MATSUNAGA T, 1994, EXP CELL RES, V210, P326, DOI 10.1006/excr.1994.1045; NEUFELD TK, 1992, KIDNEY INT, V41, P1222, DOI 10.1038/ki.1992.184; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; TSARFATY I, 1992, SCIENCE, V152, P802; TSUBOUCHI H, 1992, LANCET, V340, P307, DOI 10.1016/0140-6736(92)92396-W; WILSON SE, 1993, INVEST OPHTH VIS SCI, V34, P2544	10	48	49	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					789	791		10.1016/S0140-6736(94)92344-2	http://dx.doi.org/10.1016/S0140-6736(94)92344-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916076				2022-12-28	WOS:A1994PG17800013
J	ADAM, IJ; MOHAMDEE, MO; MARTIN, IG; SCOTT, N; FINAN, PJ; JOHNSTON, D; DIXON, MF; QUIRKE, P				ADAM, IJ; MOHAMDEE, MO; MARTIN, IG; SCOTT, N; FINAN, PJ; JOHNSTON, D; DIXON, MF; QUIRKE, P			ROLE OF CIRCUMFERENTIAL MARGIN INVOLVEMENT IN THE LOCAL RECURRENCE OF RECTAL-CANCER	LANCET			English	Article							MESORECTAL EXCISION; SURVIVAL; RESECTION; CLEARANCE; SURGERY; SPREAD	Local recurrence after resection for rectal cancer remains common despite growing acceptance that inadequate local excision may be implicated. In a prospective study of 190 patients with rectal cancer, we examined the circumferential margin of excision of resected specimens for tumour presence, to examine its frequency and its relation to subsequent local recurrence. Tumour involvement of the circumferential margin was seen in 25% (35/141) of specimens for which the surgeon thought the resection was potentially curative, and in 36% (69/190) of all cases. After a median 5 years' follow-up (range 3.0-7.7 years), the frequency of local recurrence after potentially curative resection was 25% (95% Cl 18-33%). The frequency of local recurrence was significantly higher for patients who had had tumour involvement of the circumferential margin than for those without such involvement (78 [95% Cl 62-94] vs 10 [4-16]%). By Cox's regression analysis tumour involvement of the circumferential margin independently influenced both local recurrence (hazard ratio=12.2 [4.4-34.6]) and survival (3.2 [1.6-6.53]). These results show the importance of wide local excision during resection for rectal cancer, and the need for routine assessment of the circumferential margin to assess significant influence on survival, whereas the other prognosis.	GEN INFIRM,CTR DIGEST DIS,ACAD UNIT PATHOL SCI,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; GEN INFIRM,CTR DIGEST DIS,ACAD SURG UNIT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds; Leeds General Infirmary; University of Leeds			Quirke, Philip/AAI-1362-2019	Quirke, Philip/0000-0002-3597-5444				ABULAFI AM, 1994, BRIT J SURG, V81, P7, DOI 10.1002/bjs.1800810106; CAWTHORN SJ, 1990, LANCET, V335, P1055, DOI 10.1016/0140-6736(90)92631-Q; CHAN KW, 1985, HISTOPATHOLOGY, V9, P1319, DOI 10.1111/j.1365-2559.1985.tb02813.x; COX DR, 1972, J R STAT SOC B, V34, P187; DUKES CE, 1932, J PATHOL BACTERIOL, V35, P330; FIELDING LP, 1978, LANCET, V2, P778; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; Gordon-Watson C, 1938, LANCET, V1, P239; HEALD RJ, 1986, LANCET, V1, P1479; JASS JR, 1987, LANCET, V1, P1303; MACFARLANE JK, 1993, LANCET, V341, P457, DOI 10.1016/0140-6736(93)90207-W; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MORSON BC, 1963, BMJ-BRIT MED J, P13, DOI 10.1136/bmj.2.5348.13; NG IOL, 1993, CANCER-AM CANCER SOC, V71, P1972, DOI 10.1002/1097-0142(19930315)71:6<1972::AID-CNCR2820710608>3.0.CO;2-V; PETO R, 1973, BIOMETRICS, V29, P579, DOI 10.2307/2529177; PHILLIPS RKS, 1984, BRIT J SURG, V71, P12, DOI 10.1002/bjs.1800710104; POWERS WE, 1964, NATURE, V201, P172; QUIRKE P, 1986, LANCET, V2, P996, DOI 10.1016/s0140-6736(86)92612-7; QUIRKE P, 1988, INT J COLORECTAL DIS, V3, P127, DOI 10.1007/BF01645318; WILLIAMSON RCN, 1982, GUT, V23, P316, DOI 10.1136/gut.23.4.316; 1987, AM J CLIN ONCOL-CANC, V10, P369; 1990, LANCET, V335, P1067	22	772	794	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					707	711		10.1016/S0140-6736(94)92206-3	http://dx.doi.org/10.1016/S0140-6736(94)92206-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915774				2022-12-28	WOS:A1994PF18700008
J	BOULTONJONES, M				BOULTONJONES, M			DIALYSIS MEMBRANES - CLINICAL EFFECTS	LANCET			English	Editorial Material							COMPLEMENT ACTIVATION; DIALYZER				BOULTONJONES, M (corresponding author), ROYAL INFIRM,RENAL UNIT,GLASGOW,SCOTLAND.							CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710; FINK MP, 1991, CRIT CARE MED, V19, P627, DOI 10.1097/00003246-199105000-00009; HAKIM RM, 1984, NEW ENGL J MED, V311, P878, DOI 10.1056/NEJM198410043111403; PARNES EL, 1991, KIDNEY INT, V40, P1148, DOI 10.1038/ki.1991.327; Simpson K., 1993, Nephrology Dialysis Transplantation, V8, P946	5	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					559	559		10.1016/S0140-6736(94)91958-5	http://dx.doi.org/10.1016/S0140-6736(94)91958-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914953				2022-12-28	WOS:A1994PD42400002
J	REVUELTA, JM; BERNAL, JM; RABASA, JM				REVUELTA, JM; BERNAL, JM; RABASA, JM			PARTIAL HOMOGRAFT REPLACEMENT OF MITRAL-VALVE	LANCET			English	Note								To date, treatment of mitral valve disease with mitral homograft implantation has been unsatisfactory, We describe two cases of mitral valve repair in man with a cryopreserved partial mitral homograft. Massive mitral insufficiency was surgically corrected by replacement of the severely affected posterior leaflet and the subvalvular apparatus with their corresponding mitral-valve homograft tissue. 22 and 4 months after surgery, the repaired valves remain competent with flexible and normal functioning leaflets and subvalvular apparatus, and the patients are symptom-free.			REVUELTA, JM (corresponding author), UNIV CANTABRIA,HOSP UNIV VALDECILLA,E-39008 SANTANDER,SPAIN.							BERNAL JM, 1993, CIRCULATION, V88, P1746, DOI 10.1161/01.CIR.88.4.1746; DALY RC, 1991, CIRCULATION, V84, P81; MATSUKI O, 1988, ANN THORAC SURG, V46, P187, DOI 10.1016/S0003-4975(10)65895-X; RASTELLI GC, 1965, J THORAC CARDIOV SUR, V49, P459, DOI 10.1016/S0022-5223(19)33282-9; REVUELTA JM, 1992, J THORAC CARDIOV SUR, V104, P1274; ROSS DN, 1962, LANCET, V2, P487	6	13	13	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					514	514		10.1016/S0140-6736(94)91901-1	http://dx.doi.org/10.1016/S0140-6736(94)91901-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914616				2022-12-28	WOS:A1994PC53500012
J	MARSHALL, H; STUDER, M; POPPERL, H; APARICIO, S; KUROIWA, A; BRENNER, S; KRUMLAUF, R				MARSHALL, H; STUDER, M; POPPERL, H; APARICIO, S; KUROIWA, A; BRENNER, S; KRUMLAUF, R			A CONSERVED RETINOIC ACID RESPONSE ELEMENT REQUIRED FOR EARLY EXPRESSION OF THE HOMEOBOX GENE HOXB-1	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; XENOPUS EMBRYOS; MOUSE HINDBRAIN; PATTERN; IDENTIFICATION; HOX-2.9; TRANSFORMATION; SEGMENTATION; RHOMBOMERES; RECEPTORS	WITHIN the Herb homeobox gene complex, Hoxb-1 is the earliest member expressed in the mesoderm and neuroectoderm of primitive streak and presomite embryos, preceding rhombomere-restricted expression in the hindbrain(1-7). Ectopic exposure of embryos to retinoic acid alters spatial aspects of Hox gene expression patterns(8-15). However, the role of retinoids in regulating these genes during normal development is unclear. We have now identified two enhancers, 3' of the mouse Hoxb-1 gene, which together reconstruct the early endogenous expression pattern and mediate the early ectopic response to retinoic acid. Furthermore, these regions are functionally conserved in both chicken and pufferfish (Fugu rubripes)(16) Hoxb-1 genes. The enhancer that controls the retinoic acid response, and regulates expression predominantly in neuroectoderm, contains a retinoic acid response element (RARE). Point mutations in the RARE abolish expression in neuroectoderm. Therefore, this RARE is not only involved in the ectopic response to retinoic acid, but is also essential for establishing aspects of the early Hoxb-1 expression pattern.	NATL INST MED RES,DEV NEUROBIOL LAB,LONDON NW7 1AA,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,MOLEC GENET UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN	MRC National Institute for Medical Research; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Nagoya University			Krumlauf, Robb/AAH-5012-2019; Studer, Michele/P-4580-2016	Krumlauf, Robb/0000-0001-9102-7927; Studer, Michele/0000-0001-7105-2957; Kuroiwa, Atsushi/0000-0001-7710-4041; Aparicio, Samuel/0000-0002-0487-9599				ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ALTABA ARI, 1991, DEVELOPMENT, V112, P945; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; CONLON RA, 1992, DEVELOPMENT, V116, P357; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HOLDER N, 1991, DEVELOPMENT, V113, P1159; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KESSEL M, 1993, NEURON, V10, P379, DOI 10.1016/0896-6273(93)90328-O; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; MADEN M, 1991, DEVELOPMENT, V111, P35; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; POPPERL H, 1993, MOL CELL BIOL, V13, P257; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUNDIN O, 1992, DEVELOPMENT, V114, P841; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	30	388	390	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					567	571		10.1038/370567a0	http://dx.doi.org/10.1038/370567a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	7914354				2022-12-28	WOS:A1994PC53700058
J	HUTTON, JL; COOKE, T; PHAROAH, POD				HUTTON, JL; COOKE, T; PHAROAH, POD			LIFE EXPECTANCY IN CHILDREN WITH CEREBRAL-PALSY	BRITISH MEDICAL JOURNAL			English	Article							MENTAL-RETARDATION; BIRTH-WEIGHT; TRENDS; SURVIVAL; HANDICAPS; FINLAND; PEOPLE; AGE	Objective-To determine life expectancy of children with cerebral palsy. Design-Cohort analysis, by means of register compiled from multiple sources of ascertainment, of all children with cerebral palsy born during 1966-84 to mothers resident in Mersey region. Status of children was determined by flagging through NHS central register. Subjects-1258 subjects with idiopathic cerebral palsy, of whom 1251 were traced and included in analysis. Main outcome measures-Effect of functional ability (ambulation, manual dexterity, and mental ability), sex, birth weight, and gestational age on survival. Results-20 year survival for whole cohort was 89.3% for females and 86.9% for males. For subjects with no severe functional disabilities 20 year survival was 99% (95% confidence interval 98% to 100%), while subjects severely disabled in all three functional groups had 20 year survival of 50% (42% to 58%). Subjects with birth weight less than or equal to 2500 g had 20 year survival of 92% (89% to 95%), while those with birth weight >2500 g had survival of 87% (84% to 89%). Subjects with gestational age of >37 weeks had 20 year survival of 93% (91% to 96%), white those with gestational age greater than or equal to 37 weeks had survival of 85% (83% to 88%). Birth weight and gestational age were less predictive of survival than functional disability. Best statistical model used gestational age and number of severe functional disabilities as predictors. Conclusions-Life expectancy of this cohort of children with cerebral palsy was greater than has been suggested in some previous studies. This has important implications for social, educational, and health services.	UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT STAT,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT COMPUTAT MATH,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool; University of Liverpool; University of Liverpool								BAIRD PA, 1987, J PEDIATR-US, V110, P849, DOI 10.1016/S0022-3476(87)80395-5; BALAKRISHNAN TR, 1976, AM J MENT DEF, V80, P650; COX DR, 1984, ANAL SURVIVAL DATA, P53; COX DR, 1982, THEORETICAL STATISTI, P92; Dayton NA, 1932, NEW ENGL J MED, V206, P555, DOI 10.1056/NEJM193203172061103; DOWDING VM, 1988, IRISH MED J, V81, P25; EVANS PM, 1990, ARCH DIS CHILD, V65, P1329, DOI 10.1136/adc.65.12.1329; EYMAN RK, 1993, AM J DIS CHILD, V147, P329, DOI 10.1001/archpedi.1993.02160270091029; EYMAN RK, 1990, NEW ENGL J MED, V323, P584, DOI 10.1056/NEJM199008303230906; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HAGBERG B, 1984, ACTA PAEDIATR SCAND, V73, P433, DOI 10.1111/j.1651-2227.1984.tb09951.x; KUDRJAVCEV T, 1985, NEUROLOGY, V35, P900, DOI 10.1212/WNL.35.6.900; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PHAROAH POD, 1987, ARCH DIS CHILD, V62, P379, DOI 10.1136/adc.62.4.379; RIIKONEN R, 1989, ACTA PAEDIATR SCAND, V78, P581, DOI 10.1111/j.1651-2227.1989.tb17940.x; SAHAMOTO Y, 1986, AKAIKE INFORMATION C; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; VONWENDT L, 1985, ANN CLIN RES, V17, P156; 1979, OPCS SERIES DS, V2; 1989, SAS STAT USERS GUIDE, V2, P997	20	119	125	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					431	435		10.1136/bmj.309.6952.431	http://dx.doi.org/10.1136/bmj.309.6952.431			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920125	Green Published			2022-12-28	WOS:A1994PC40400015
J	WINLAW, DS; SMYTHE, GA; KEOGH, AM; SCHYVENS, CG; SPRATT, PM; MACDONALD, PS				WINLAW, DS; SMYTHE, GA; KEOGH, AM; SCHYVENS, CG; SPRATT, PM; MACDONALD, PS			INCREASED NITRIC-OXIDE PRODUCTION IN HEART-FAILURE	LANCET			English	Note								The role of nitric oxide in heart failure is unknown. The high-capacity inducible isoform of nitric oxide synthase is present in the myocardium of patients with idiopathic dilated cardiomyopathy. Plasma nitrate, the stable end-product of nitric oxide production, was significantly increased in patients with heart failure compared with normal controls (means 51.3 and 24.6 mu mol/L). Vasodilation caused by increased nitric oxide may compensate for the vasoconstrictor effect of neurohumoral adaptions to heart failure. Alternatively, excess production may be detrimental to the heart by a direct negative inotropic effect.	ST VINCENTS HOSP,VICTOR CHANG CARDIAC RES INST,DEPT CARDIOPULM TRANSPLANTAT,SYDNEY,NSW 2010,AUSTRALIA; ST VINCENTS HOSP,VICTOR CHANG CARDIAC RES INST,DEPT CHEM PATHOL,SYDNEY,NSW 2010,AUSTRALIA	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute			Macdonald, Peter/Q-3188-2019; Winlaw, David S/F-8365-2016; Winlaw, David/B-9405-2019	Winlaw, David S/0000-0001-8005-3361; Winlaw, David/0000-0001-8005-3361				DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DREXLER H, 1992, AM J CARDIOL, V69, P1596, DOI 10.1016/0002-9149(92)90710-G; EVANS HG, 1993, CARDIOVASC RES, V27, P1486, DOI 10.1093/cvr/27.8.1486; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; LANGREHR JM, 1992, J CLIN INVEST, V90, P679, DOI 10.1172/JCI115911; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; TAKAHASHI H, 1992, J CARDIOVASC PHARM, V20, pS214, DOI 10.1097/00005344-199204002-00061	9	217	223	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					373	374		10.1016/S0140-6736(94)91403-6	http://dx.doi.org/10.1016/S0140-6736(94)91403-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914309				2022-12-28	WOS:A1994PA30300012
J	WHELTON, PK				WHELTON, PK			EPIDEMIOLOGY OF HYPERTENSION	LANCET			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; UNITED-STATES; RISK; POPULATIONS; MANAGEMENT; STROKE; LIFE				WHELTON, PK (corresponding author), JOHNS HOPKINS UNIV HOSP, WELCH CTR PREVENT EPIDEMIOL & CLIN RES, 600 N WOLFE ST, CARNEGIE 292, BALTIMORE, MD 21287 USA.							[Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; BAKER D, 1994, LANCET, V343, P496, DOI 10.1016/S0140-6736(94)91455-9; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; CARVALHO JJM, 1989, HYPERTENSION, V14, P238, DOI 10.1161/01.HYP.14.3.238; CLOHER TP, 1986, ARCH INTERN MED, V146, P529, DOI 10.1001/archinte.146.3.529; COLLINS R, 1990, LANCET, V336, P370, DOI 10.1016/0140-6736(90)91908-S; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GROSS TP, 1989, HYPERTENSION S1, V13, P113; HE J, 1991, AM J EPIDEMIOL, V134, P1085, DOI 10.1093/oxfordjournals.aje.a116012; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; JACKSON R, 1994, LANCET, V343, P496, DOI 10.1016/S0140-6736(94)91456-7; KANNEL WB, 1991, AM HEART J, V121, P951, DOI 10.1016/0002-8703(91)90225-7; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARMOT MG, 1985, HDB HYPERTENSION, V6, P89; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P1272, DOI 10.1001/jama.269.10.1272; REED D, 1989, INT J EPIDEMIOL, V18, pS82; ROBERTS J, 1977, VITAL HLTH STATSI 11, V203; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; STAMLER R, 1991, HYPERTENSION, V17, pI16, DOI 10.1161/01.HYP.17.1_Suppl.I16; THOM TJ, 1992, US DHHS PHS NIH92308; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WHELTON PK, 1993, CLIN EXP HYPERTENS, V15, P1147, DOI 10.3109/10641969309037101; WHELTON PK, 1992, J HYPERTENS, V10, pS77; WHELTON PK, IN PRESS TXB HYPERTE; WHELTON PK, 1985, HDB HYPERTENSION, V6, P51; WHELTON PK, IN PRESS PREVENTION; WHELTON PK, 1994, J HYPERTENS       S3, V12, P561; 1991, WORLD HLTH STATISTIC	35	396	413	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	1994	344	8915					101	106		10.1016/S0140-6736(94)91285-8	http://dx.doi.org/10.1016/S0140-6736(94)91285-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912348				2022-12-28	WOS:A1994NV73200013
J	ECHELARD, Y; EPSTEIN, DJ; STJACQUES, B; SHEN, L; MOHLER, J; MCMAHON, JA; MCMAHON, AP				ECHELARD, Y; EPSTEIN, DJ; STJACQUES, B; SHEN, L; MOHLER, J; MCMAHON, JA; MCMAHON, AP			SONIC-HEDGEHOG, A MEMBER OF A FAMILY OF PUTATIVE SIGNALING MOLECULES, IS IMPLICATED IN THE REGULATION OF CNS POLARITY	CELL			English	Article							DROSOPHILA PATCHED GENE; CENTRAL-NERVOUS-SYSTEM; NEURAL-TUBE FORMATION; FLOOR PLATE; INT-1 PROTOONCOGENE; ONCOGENE INT-1; SPINAL-CORD; EXPRESSION; PROTEIN; TRANSCRIPTION	We have identified three members of a mouse gene family related to the Drosophila segment polarity gene, hedgehog (hh). Like hh, they encode putative secreted proteins and are thus implicated in cell-cell interactions. One of these, Sonic hh (Shh), is expressed in the notochord, the floor plate, and the zone of polarizing activity, signaling centers that are thought to mediate central nervous system (CNS) and limb polarity. Ectopic expression of Shh in the mouse CNS leads to the activation of floor plate-expressed genes. These results suggest that Shh may play a role in the normal inductive interactions that pattern the ventral CNS.	ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA; COLUMBIA UNIV BARNARD COLL, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University	ECHELARD, Y (corresponding author), HARVARD UNIV, DEPT BIOCHEM MOLEC BIOL & CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA.		McMahon, Andrew P/ABE-7520-2020					ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1993, CURR OPIN GENET DEV, V3, P633, DOI 10.1016/0959-437X(93)90100-4; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FAHRNER K, 1987, EMBO J, V6, P1265, DOI 10.1002/j.1460-2075.1987.tb02363.x; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIRANO S, 1991, SCIENCE, V251, P310, DOI 10.1126/science.1987648; HOGAN B, 1986, MANIPULATING MOUSE E; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1993, IN PRESS NATURE; JESSELL TM, 1992, HARVEY LECT, V86, P87; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PARR BA, 1993, DEVELOPMENT, V119, P247; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SASAKI H, 1993, DEVELOPMENT, V118, P47; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TASHIRO S, 1993, GENE, V124, P183; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TICKLE C, 1976, NATURE, V259, P396, DOI 10.1038/259396a0; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	59	1793	1868	1	101	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1417	1430		10.1016/0092-8674(93)90627-3	http://dx.doi.org/10.1016/0092-8674(93)90627-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7916661				2022-12-28	WOS:A1993MP86900019
J	GRUMBACH, K; BODENHEIMER, T				GRUMBACH, K; BODENHEIMER, T			PAINFUL VS PAINLESS COST CONTROL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; CONTAINMENT; RESPONSIBILITIES; STRATEGIES; PHYSICIANS; POPULATION; QUALITY		UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	GRUMBACH, K (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,BOX 1364,SAN FRANCISCO,CA 94143, USA.		Grumbach, Kevin/L-9222-2016					AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; AARON HJ, 1984, PAINFUL PRESCRIPTION; BODENHEIMER TS, 1995, UNDERSTANDING HLTH P; BROOK RH, 1986, ISSUES SCI TECHNOL, V3, P68; Burner S T, 1992, Health Care Financ Rev, V14, P1; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; DONABEDIAN A, 1988, INQUIRY-J HEALTH CAR, V25, P90; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P2575, DOI 10.1001/jama.268.18.2575; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P1446, DOI 10.1001/jama.265.11.1446; EDDY DM, 1993, JAMA-J AM MED ASSOC, V269, P1849, DOI 10.1001/jama.269.14.1849; EISENBERG J, 1986, DOCTORS DECISIONS CO; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; EVANS RG, 1984, STRAINED MERCY EC CA; FUCHS VR, 1990, SCIENCE, V247, P534, DOI 10.1126/science.2300814; FUCHS VR, 1993, JAMA-J AM MED ASSOC, V269, P631; GINZBERG E, 1983, NEW ENGL J MED, V308, P1220, DOI 10.1056/NEJM198305193082010; GREENLICK MR, 1992, JAMA-J AM MED ASSOC, V267, P1645, DOI 10.1001/jama.267.12.1645; GREENSPAN AM, 1988, NEW ENGL J MED, V318, P158, DOI 10.1056/NEJM198801213180306; GRIMES DA, 1993, JAMA-J AM MED ASSOC, V269, P3030, DOI 10.1001/jama.269.23.3030; HIATT HH, 1975, NEW ENGL J MED, V293, P325; LEAPE LL, 1992, ANNU REV PUBL HEALTH, V13, P363, DOI 10.1146/annurev.pu.13.050192.002051; LEGORRETA AP, 1993, JAMA-J AM MED ASSOC, V270, P1429, DOI 10.1001/jama.270.12.1429; LOMAS J, 1989, HEALTH AFFAIR, V8, P80, DOI 10.1377/hlthaff.8.1.80; MENZEL PT, 1992, HASTINGS CENT REP, V22, P21, DOI 10.2307/3562943; PLATT R, 1983, NEW ENGL J MED, V309, P726, DOI 10.1056/NEJM198309223091211; REINHARDT UE, 1987, MILBANK Q, V65, P153, DOI 10.2307/3350018; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SCHIEBER GJ, 1993, HEALTH AFFAIR, V12, P120, DOI 10.1377/hlthaff.12.2.120; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; STAFFORD RS, 1990, JAMA-J AM MED ASSOC, V263, P683, DOI 10.1001/jama.263.5.683; STASON WB, 1987, J HYPERTENS, V5, pS55; SUSSER M, 1993, AM J PUBLIC HEALTH, V83, P418, DOI 10.2105/AJPH.83.3.418; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V258, P2568, DOI 10.1001/jama.258.18.2568; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1988, PRENATAL CARE REACHI	37	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1458	1464		10.1001/jama.272.18.1458	http://dx.doi.org/10.1001/jama.272.18.1458			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP690	7933431				2022-12-28	WOS:A1994PP69000039
J	GHOSH, A; TANG, MHY; LAM, YH; FUNG, E; CHAN, V				GHOSH, A; TANG, MHY; LAM, YH; FUNG, E; CHAN, V			ULTRASOUND MEASUREMENT OF PLACENTAL THICKNESS TO DETECT PREGNANCIES AFFECTED BY HOMOZYGOUS ALPHA-THALASSEMIA-1	LANCET			English	Note							ALPHA-THALASSEMIA; HYDROPS-FETALIS; DIAGNOSIS	Homozygous alpha-thalessaemia-1, a common cause of hydrops fetalis, is usually diagnosed invasively. We measured placental thickness by ultrasound at 10-21 weeks' gestation in 231 at-risk pregnancies. 60 were affected (by DNA analysis). The sensitivity and specificity in detecting affected pregnancies at cut-off of mean placental thickness plus 2 SD before 12 weeks' gestation were 0.72 (95% Cl 0.52-0.93) and 0.97 (0.9-1.0). After 12 weeks sensitivity increased to 0.95 (0.89-1.0) and by 18 weeks reached 1.0 (0.60-0.99) without change in specificity. Selection of pregnancies at risk by measurement of placental thickness will reduce the number of invasive diagnostic procedures.	QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG	University of Hong Kong	GHOSH, A (corresponding author), UNIV HONG KONG,TSAN YUK HOSP,DEPT OBSTET & GYNAECOL,HOSP RD,HONG KONG,HONG KONG.		Tang, Mary Hoi Yin/A-7638-2013; Chan, Vivian/C-4217-2009					CHAN V, 1984, BMJ-BRIT MED J, V288, P1327, DOI 10.1136/bmj.288.6427.1327; GHOSH A, 1987, PRENATAL DIAG, V7, P307, DOI 10.1002/pd.1970070503; HSIEH FJ, 1989, OBSTET GYNECOL, V74, P722; KANOKPONGSAKDI S, 1990, PRENATAL DIAG, V10, P809, DOI 10.1002/pd.1970101208; LEIINJO LE, 1962, BLOOD, V20, P581; LIANG ST, 1985, BRIT J OBSTET GYNAEC, V92, P680, DOI 10.1111/j.1471-0528.1985.tb01447.x; RUBIN EM, 1985, LANCET, V1, P75; THUMASATHIT B, 1986, J PEDIATR, V73, P132; TODD D, 1967, BRIT MED J, V3, P347, DOI 10.1136/bmj.3.5561.347; WEATHERALL DJ, 1970, BRIT J HAEMATOL, V18, P357, DOI 10.1111/j.1365-2141.1970.tb01449.x	10	53	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					988	989		10.1016/S0140-6736(94)91644-6	http://dx.doi.org/10.1016/S0140-6736(94)91644-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934433				2022-12-28	WOS:A1994PK97800012
J	JOHN, TJ				JOHN, TJ			LEARNING FROM PLAGUE IN INDIA	LANCET			English	Editorial Material											JOHN, TJ (corresponding author), CHRISTIAN MED COLL & HOSP,DEPT MICROBIOL & VIROL,VELLORE 632004,TAMIL NADU,INDIA.							1994, LANCET, V344, P941	1	13	13	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					972	972		10.1016/S0140-6736(94)91637-3	http://dx.doi.org/10.1016/S0140-6736(94)91637-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK978	7934426				2022-12-28	WOS:A1994PK97800005
J	HARRAP, SB				HARRAP, SB			GENETICS OF CORONARY-DISEASE - BEGINNING THE LONG JOURNEY	LANCET			English	Editorial Material							ANGIOTENSIN-CONVERTING ENZYME; RISK				HARRAP, SB (corresponding author), AUSTIN HOSP,DEPT MED,GENET PHYSIOL UNIT,HEIDELBERG,VIC,AUSTRALIA.							BOHN M, 1993, CLIN GENET, V44, P292; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; HARRAP SB, 1993, HYPERTENSION, V21, P455, DOI 10.1161/01.HYP.21.4.455; KREUTZ R, 1993, CIRCULATION, V88, P510	4	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					901	902		10.1016/S0140-6736(94)92262-4	http://dx.doi.org/10.1016/S0140-6736(94)92262-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934341				2022-12-28	WOS:A1994PJ28700003
J	SCULLY, C; MORTIMER, P				SCULLY, C; MORTIMER, P			GNASHINGS OF HIV	LANCET			English	Editorial Material							INFECTED DENTIST; DENTAL PRACTICE; TRANSMISSION		PUBL HLTH LAB SERV, LONDON, ENGLAND	Public Health England	SCULLY, C (corresponding author), UCL EASTMAN DENT INST ORAL HEALTHCARE SCI, LONDON, ENGLAND.							ARNOW PM, 1993, PUBLIC HEALTH REP, V108, P273; BLANK S, 1994, LANCET, V344, P512, DOI 10.1016/S0140-6736(94)91900-3; CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; DEBRY RW, 1993, NATURE, V361, P691, DOI 10.1038/361691a0; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; GORE SM, 1994, J INFECTION, V28, P209, DOI 10.1016/S0163-4453(94)95740-1; HILLIS DM, 1994, NATURE, V369, P24, DOI 10.1038/369024a0; NACCACHE H, 1993, AIDS PATIENT CARE, V7, P134, DOI 10.1089/apc.1993.7.134; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PORTER SR, 1993, BRIT DENT J, V175, P254, DOI 10.1038/sj.bdj.4808292; SCULLY C, 1993, BRIT DENT J, V175, P381, DOI 10.1038/sj.bdj.4808330; SCULLY C, 1993, BRIT MED J, V306, P1754, DOI 10.1136/bmj.306.6894.1754-a; SCULLY C, 1990, BRIT DENTAL J LONDON, P142; SCULLY C, 1994, HLTH TRENDS, V26, P15; YORK AK, 1993, J AM DENT ASSOC, V124, P74, DOI 10.14219/jada.archive.1993.0141	16	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					904	904		10.1016/S0140-6736(94)92265-9	http://dx.doi.org/10.1016/S0140-6736(94)92265-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934343				2022-12-28	WOS:A1994PJ28700006
J	BUEKENS, P; ALEXANDER, S; BOUTSEN, M; BLONDEL, B; KAMINSKI, M; REID, M; OLSEN, JS; BERBIK, I; MONAGHAN, J; PINTO, P; ARAUJO, MP; GONZALEZ, AG; DEMUYLDER, X; LEJEUNE, B; VANDERVELLEN, R; VEROUGSTRAETE, A; WESEL, S; BALDUR, B; HANSEN, T; RYAN, R; AMBROSINI, A; MANDRUZZATO, G; MERIALDI, A; MANGUINHAS, JMB; FEITINHA, F; CRUZ, JM; DOSSANTOS, LN; PIERONI, B; RAMONEDA, VCI; ALMENDRAL, JLC; EZCURDIA, M; NALDA, AH; CALPARSORO, MU; GRIPPA, J; SOUMENKOFF, G				BUEKENS, P; ALEXANDER, S; BOUTSEN, M; BLONDEL, B; KAMINSKI, M; REID, M; OLSEN, JS; BERBIK, I; MONAGHAN, J; PINTO, P; ARAUJO, MP; GONZALEZ, AG; DEMUYLDER, X; LEJEUNE, B; VANDERVELLEN, R; VEROUGSTRAETE, A; WESEL, S; BALDUR, B; HANSEN, T; RYAN, R; AMBROSINI, A; MANDRUZZATO, G; MERIALDI, A; MANGUINHAS, JMB; FEITINHA, F; CRUZ, JM; DOSSANTOS, LN; PIERONI, B; RAMONEDA, VCI; ALMENDRAL, JLC; EZCURDIA, M; NALDA, AH; CALPARSORO, MU; GRIPPA, J; SOUMENKOFF, G			RANDOMIZED CONTROLLED TRIAL OF ROUTINE CERVICAL EXAMINATIONS IN PREGNANCY	LANCET			English	Article							PRETERM BIRTH PREVENTION; PREMATURE RUPTURE; VAGINAL EXAMINATIONS; PREDICTION; MEMBRANES; LABOR; DELIVERY; RISKS	Preterm delivery is strongly associated with neonatal mortality and morbidity. In some European countries, cervical examinations are used routinely during pregnancy to identify women at risk of preterm delivery. We sought to evaluate the efficacy and secondary effects of these routine cervical examinations. We did a randomised controlled trial in seven European countries, comparing two policies-namely, an attempt to do a cervical examination at every prenatal visit (2803 women) and avoidance of cervical examination if possible (2799). The median number of cervical examinations was 6 in the experimental group and 1 in the controls. There were 6.7% preterm (<37 weeks) deliveries in the experimental group and 6.4% in the control group (risk ratio 1.05 [95% confidence interval 0.85-1.29]; non-significant). The low birthweight rate was 6.6% in the experimental group and 7.7% in the controls (non-significant), Premature rupture of membranes was not significantly more frequent in the experimental group (27.1% vs 26.5%). Our findings do not support the routine use of cervical examinations during pregnancy.	INSERM,EPIDEMIOL RES UNIT WOMEN & CHILD HLTH,PARIS,FRANCE; UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW,SCOTLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Glasgow	BUEKENS, P (corresponding author), FREE UNIV BRUSSELS,SCH PUBL HLTH,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.		Blondel, Beatrice/G-5011-2017; González Ríos, Andrea/HGU-7618-2022; Gonzalez, Andrea/HDM-9987-2022					ALEXANDER GR, 1991, BIRTH-ISS PERINAT C, V18, P160, DOI 10.1111/j.1523-536X.1991.tb00088.x; Altman DG, 1991, PRACTICAL STATISTICS; ANDERSON AB, 1969, AM J OBSTET GYNECOL, V105, P1207, DOI 10.1016/0002-9378(69)90291-9; BIVINS HA, 1993, AM J OBSTET GYNECOL, V169, P22, DOI 10.1016/0002-9378(93)90125-3; BLONDEL B, 1988, LANCET, V2, P846; BLONDEL B, 1990, AM J OBSTET GYNECOL, V162, P1042, DOI 10.1016/0002-9378(90)91312-Z; BOUYER J, 1986, OBSTET GYNECOL, V68, P209; COPPER RL, 1990, AM J OBSTET GYNECOL, V162, P748, DOI 10.1016/0002-9378(90)91000-3; HERINGA M, 1988, EUR J OBSTET GYN R B, V28, P7; HOLBROOK RH, 1987, AM J PERINAT, V4, P240, DOI 10.1055/s-2007-999782; JENNIGES K, 1990, J NURSE-MIDWIFERY, V35, P46, DOI 10.1016/0091-2182(90)90057-C; LENIHAN JP, 1984, OBSTET GYNECOL, V63, P33; LEVENO KJ, 1986, OBSTET GYNECOL, V68, P434, DOI 10.1097/00006250-198609000-00031; Lumley J., 1987, PREMATURITY, P43; MCDUFFIE RS, 1992, OBSTET GYNECOL, V79, P219; MITCHELL MD, 1977, BRIT MED J, V2, P1183, DOI 10.1136/bmj.2.6096.1183; MORTENSEN OA, 1987, ACTA OBSTET GYN SCAN, V66, P507, DOI 10.3109/00016348709015725; NEILSON JP, 1988, OBSTET GYNECOL, V72, P719; PAPIERNIK E, 1986, OBSTET GYNECOL, V67, P238, DOI 10.1097/00006250-198602000-00014; PIERRE F, 1986, MEMOIRE OBTENTION ME; Rothman K, 1986, MODERN EPIDEMIOLOGY; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; STUBBS TM, 1986, AM J OBSTET GYNECOL, V155, P829, DOI 10.1016/S0002-9378(86)80031-X; WOOD C, 1965, AM J OBSTET GYNECOL, V91, P396, DOI 10.1016/0002-9378(65)90255-3; 1992, LOW BIRTH WEIGHT TAB	25	61	62	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					841	844		10.1016/S0140-6736(94)92825-8	http://dx.doi.org/10.1016/S0140-6736(94)92825-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916399				2022-12-28	WOS:A1994PH25300009
J	STUDER, M; POPPERL, H; MARSHALL, H; KUROIWA, A; KRUMLAUF, R				STUDER, M; POPPERL, H; MARSHALL, H; KUROIWA, A; KRUMLAUF, R			ROLE OF A CONSERVED RETINOIC ACID RESPONSE ELEMENT IN RHOMBOMERE RESTRICTION OF HOXB-1	SCIENCE			English	Article							ZINC-FINGER GENE; SEGMENT-SPECIFIC EXPRESSION; HOMEOBOX-CONTAINING GENES; EMBRYONIC EXPRESSION; CHICK HINDBRAIN; MOUSE HINDBRAIN; VERTEBRATE HEAD; NERVOUS-SYSTEM; NEURAL CREST; HOX-1.6	After activation in mesoderm and neuroectoderm, expression of the Hoxb-1 gene is progressively restricted to rhombomere (r) 4 in the hindbrain. Analysis of the chick and mouse Hoxb-1 genes identified positive and negative regulatory regions that cooperate to mediate segment-restricted expression during rhombomere formation. An enhancer generates expression extending into r3 and r5, and a repressor limits this domain to r4. The repressor contains a conserved retinoic acid response element, point mutations in which allow expression to spread into adjacent rhombomeres. Retinoids and their nuclear receptors may therefore participate in sharpening segment-restricted expression of Hoxb-1 during rhombomere boundary formation.	NATL INST MED RES, DEV NEUROBIOL LAB, LONDON NW7 1AA, ENGLAND; NAGOYA UNIV, SCH SCI, DEPT MOLEC BIOL, NAGOYA 46401, JAPAN	MRC National Institute for Medical Research; Nagoya University			Krumlauf, Robb/AAH-5012-2019; Studer, Michele/P-4580-2016	Krumlauf, Robb/0000-0001-9102-7927; Studer, Michele/0000-0001-7105-2957; Kuroiwa, Atsushi/0000-0001-7710-4041				CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CONLON RA, 1992, DEVELOPMENT, V116, P357; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FJOSE A, 1993, EMBO J, V12, P1403, DOI 10.1002/j.1460-2075.1993.tb05784.x; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GEADA AMC, 1992, DEVELOPMENT, V116, P497; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1993, DEVELOPMENT, V118, P527; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HOGAN B, 1986, MANIPULATING MOUSE E; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; IP YT, 1992, J CELL SCI, P33; JACKLE H, 1992, J CELL SCI, P39; KESSEL M, 1993, NEURON, V10, P379, DOI 10.1016/0896-6273(93)90328-O; KIMMEL CB, 1988, DEVELOPMENT, V104, P197; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MADEN M, 1991, DEVELOPMENT, V111, P35; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MENDELSOHN C, 1994, MECH DEVELOP, V45, P227, DOI 10.1016/0925-4773(94)90010-8; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; POPPERL H, 1993, MOL CELL BIOL, V13, P257; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUNDIN O, 1992, DEVELOPMENT, V114, P841; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	46	247	248	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	1994	265	5179					1728	1732		10.1126/science.7916164	http://dx.doi.org/10.1126/science.7916164			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	7916164				2022-12-28	WOS:A1994PG28400037
J	MALMBERG, P				MALMBERG, P			COKING TO DEATH	LANCET			English	Editorial Material											MALMBERG, P (corresponding author), NATL INST OCCUPAT HLTH,S-17184 SOLNA,SWEDEN.							ANDERSSON K, 1993, HYGIEA, V102, P120; BHOPAL RS, 1994, J EPIDEMIOL COMMUN H, V48, P237, DOI 10.1136/jech.48.3.237; NORLEN U, 1993, INDOOR CLIMATE SWE D, V10; STENBERG B, 1993, JUL P INDOOR AIR HEL, P399	4	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					632	632		10.1016/S0140-6736(94)92081-8	http://dx.doi.org/10.1016/S0140-6736(94)92081-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915346				2022-12-28	WOS:A1994PE38600006
J	BARRIOZ, T; INGRAND, P; BESSON, I; DELEDINGHEN, V; SILVAIN, C; BEAUCHANT, M				BARRIOZ, T; INGRAND, P; BESSON, I; DELEDINGHEN, V; SILVAIN, C; BEAUCHANT, M			RANDOMIZED TRIAL OF PREVENTION OF BILIARY STENT OCCLUSION BY URSODEOXYCHOLIC ACID PLUS NORFLOXACIN	LANCET			English	Note							ENDOPROSTHESES	Biliary stents are liable to clog. We investigated whether a choleretic plus an antibiotic could delay clogging. 20 consecutive patients with a malignant biliary stricture were randomised after endoscopic insertion of a polyethylene stent to receive ursodeoxycholic acid plus norfloxacin (13-15 mg/kg and 400 mg, daily) or conservative treatment. The drug combination was associated with: a longer median patency of first (49 vs 6 weeks) and all stents (38 vs 7 weeks); a prolonged median survival (67 vs 18 weeks); and a shorter mean hospital stay (0.2 vs 1.0 days per week of survival). Thus ursodeoxycholic acid plus norfloxacin may prevent stent clogging.	UNIV HOSP POITIERS,HEPATOL UNIT,F-86021 POITIERS,FRANCE; UNIV POITIERS,FAC MED,DEPT BIOSTAT,POITIERS,FRANCE	CHU Poitiers; Universite de Poitiers; CHU Poitiers; Universite de Poitiers								COENE PPLO, 1990, GUT, V31, P913, DOI 10.1136/gut.31.8.913; DAVIDS PHP, 1992, LANCET, V340, P1488, DOI 10.1016/0140-6736(92)92752-2; GHOSH S, 1993, GASTROENTEROLOGY, V104, pA361; LIBBY ED, 1994, GASTROENTEROLOGY, V106, pA346; MOESCH C, 1991, HEPATOLOGY, V14, P1142, DOI 10.1016/0270-9139(91)90141-H; REICHEN J, 1993, SEMIN LIVER DIS, V13, P302, DOI 10.1055/s-2007-1007358; SMIT JM, 1989, GASTROINTEST ENDOSC, V35, P485, DOI 10.1016/S0016-5107(89)72895-9; SORIANO G, 1992, GASTROENTEROLOGY, V103, P1267, DOI 10.1016/0016-5085(92)91514-5; SUNG JY, 1991, HEPATOLOGY, V14, P313, DOI 10.1016/0270-9139(91)91421-V	9	69	71	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					581	582		10.1016/S0140-6736(94)91967-4	http://dx.doi.org/10.1016/S0140-6736(94)91967-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914962				2022-12-28	WOS:A1994PD42400011
J	BIESMA, DH; MARX, JJM; KRAAIJENHAGEN, RJ; FRANKE, W; MESSINGER, D; VANDEWIEL, A				BIESMA, DH; MARX, JJM; KRAAIJENHAGEN, RJ; FRANKE, W; MESSINGER, D; VANDEWIEL, A			LOWER HOMOLOGOUS BLOOD REQUIREMENT IN AUTOLOGOUS BLOOD-DONORS AFTER TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN	LANCET			English	Article							TRANSFUSION PRACTICES; ANEMIA; STRATEGIES; COLLECTION	The risk of blood-borne diseases has substantially increased the use of autologous blood transfusion. Many autologous donors, however, still need homologous transfusions. To find out whether recombinant erythropoietin (rhEPO) reduces requirements for homologous blood transfusion, we carried out a randomised, controlled trial, in which patients were stratified according to blood volume. We studied 95 autologous blood donors undergoing elective hip surgery. 50 patients were randomly assigned 500 U/kg rhEPO subcutaneously twice a week for 3 weeks, and 45 patients received no treatment (control group). The patients each donated two units of blood before surgery. Only 5 (10%) rhEPO-treated patients received homologous transfusions compared with 16 (36%) controls (p<0.01). rhEPO was most useful in patients with a blood volume below 4 L and an estimated blood loss below 2 L or with a blood volume of 4-5 L and blood loss of 1-2 L. Continued administration of rhEPO caused no further increase in reticulocyte counts after the fourth injection, which was accompanied by a pronounced depletion of storage iron. rhEPO treatment had no effect on renal function, platelet count, or blood pressure. Subcutaneous rhEPO is an effective and safe way to reduce exposure to homologous blood in autologous donors. Its use can be restricted to a subpopulation of autologous blood donors, which improves the cost-effectiveness of this expensive approach.	HOSP EEMLAND,DEPT INTERNAL MED,AMERSFOORT,NETHERLANDS; HOSP EEMLAND,DEPT CLIN CHEM,AMERSFOORT,NETHERLANDS; BOEHRINGER MANNHEIM GMBH,DEPT CLIN RES,W-6800 MANNHEIM,GERMANY		BIESMA, DH (corresponding author), UNIV UTRECHT HOSP,DEPT INTERNAL MED,ROOM F02126,POB 85500,3508 GA UTRECHT,NETHERLANDS.		Biesma, Douwe H./AAV-6343-2020; Marx, Joannes/AAS-9268-2020	Biesma, Douwe H./0000-0001-8334-3057; 				BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364; BIESMA DH, 1992, TRANSFUSION, V32, P162, DOI 10.1046/j.1537-2995.1992.32292180147.x; BIESMA DH, 1993, TRANSFUSION, V33, P825, DOI 10.1046/j.1537-2995.1993.331094054619.x; BRUGNARA C, 1993, BLOOD, V81, P956; GOODNOUGH LT, 1988, JAMA-J AM MED ASSOC, V259, P2405, DOI 10.1001/jama.1988.03720160026022; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; HACKMANN T, 1989, NEW ENGL J MED, V321, P1437, DOI 10.1056/NEJM198911233212104; HOLLAND PV, 1987, STANDARDS BLOOD BANK; HOWRD MR, 1992, BRIT MED J, V305, P1470; KICKLER TS, 1988, JAMA-J AM MED ASSOC, V260, P65, DOI 10.1001/jama.260.1.65; KOOISTRA MP, 1991, BRIT J HAEMATOL, V79, P634, DOI 10.1111/j.1365-2141.1991.tb08093.x; LENNON RL, 1987, MAYO CLIN PROC, V62, P1090, DOI 10.1016/S0025-6196(12)62501-4; LORENTZ A, 1991, TRANSFUSION, V31, P650, DOI 10.1046/j.1537-2995.1991.31791368345.x; MERCURIALI F, 1993, TRANSFUSION, V33, P55, DOI 10.1046/j.1537-2995.1993.33193142311.x; NADLER SB, 1962, SURGERY, V51, P224; PIOMELLI S, 1973, J LAB CLIN MED, V81, P932; SILBERSTEIN LE, 1989, JAMA-J AM MED ASSOC, V262, P1993, DOI 10.1001/jama.262.14.1993; STEHLING LC, 1987, VOX SANG, V52, P60, DOI 10.1111/j.1423-0410.1987.tb02990.x; VANWYCK DB, 1989, KIDNEY INT, V35, P712, DOI 10.1038/ki.1989.43; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; WILSON WJ, 1989, J BONE JOINT SURG AM, V71A, P8, DOI 10.2106/00004623-198971010-00003; 1988, JAMA-J AM MED ASSOC, V260, P2700; 1986, JAMA-J AM MED ASSOC, V256, P2378; 1987, NEW ENGL J MED, V316, P517	25	57	58	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					367	370		10.1016/S0140-6736(94)91401-X	http://dx.doi.org/10.1016/S0140-6736(94)91401-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914307				2022-12-28	WOS:A1994PA30300010
J	GUENDELMAN, S				GUENDELMAN, S			MEXICAN WOMEN IN THE UNITED-STATES	LANCET			English	Editorial Material							INFANT-MORTALITY; BIRTH				GUENDELMAN, S (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720, USA.							BALCAZAR H, 1994, AM J PUBLIC HEALTH, V84, P462, DOI 10.2105/AJPH.84.3.462; BECERRA JE, 1991, JAMA-J AM MED ASSOC, V265, P217, DOI 10.1001/jama.265.2.217; FRISBIE P, 1989, INT REV COMP PUBL PO, V1, P65; GUENDELMAN S, IN PRESS AM J PUBL H; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P259, DOI 10.1001/jama.267.2.259; HEDDERSON J, 1982, SOC SCI J, V199, P68; MENDOZA F, 1991, JAMA-J AM MED ASSOC, V265, P277; SCRIBNER R, 1989, AM J PUBLIC HEALTH, V79, P1263, DOI 10.2105/AJPH.79.9.1263; VEGA WA, 1990, J MARRIAGE FAM, V52, P1015, DOI 10.2307/353316; 1992, 1990 CPH L 90 1990 C; 1994, ADV DATA VITAL HLTH, V241	11	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					352	352		10.1016/S0140-6736(94)91397-8	http://dx.doi.org/10.1016/S0140-6736(94)91397-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA303	7914303				2022-12-28	WOS:A1994PA30300006
J	KUMAR, L				KUMAR, L			CAN MOLECULAR MONITORING IMPROVE OUTCOME IN LEUKEMIA	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; POLYMERASE CHAIN-REACTION; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; B-CELL LYMPHOMA; RELAPSE				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,NEW DELHI,INDIA.							BASH RO, 1993, BLOOD, V81, P2110; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; CRIST WM, 1990, BLOOD, V76, P117; CROSS NCP, 1993, BLOOD, V82, P1929; DROBYSKI WR, 1993, BLOOD, V81, P551; GRIBBEN JG, 1993, BLOOD, V81, P3449; GRIBBEN JG, 1991, NEW ENGL J MED, V325, P1525, DOI 10.1056/NEJM199111283252201; LION T, 1993, LANCET, V341, P275, DOI 10.1016/0140-6736(93)92619-5; MILLER WH, 1993, BLOOD, V82, P1689; NIZET Y, 1993, BLOOD, V82, P1618; ROTH MS, 1992, BLOOD, V79, P276; WEISDORF DJ, 1993, TRANSPLANTATION, V55, P61, DOI 10.1097/00007890-199301000-00012	13	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					348	349		10.1016/S0140-6736(94)91393-5	http://dx.doi.org/10.1016/S0140-6736(94)91393-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914299				2022-12-28	WOS:A1994PA30300002
J	COHEN, RJ; BROWN, KH; CANAHUATI, J; RIVERA, LL; DEWEY, KG				COHEN, RJ; BROWN, KH; CANAHUATI, J; RIVERA, LL; DEWEY, KG			EFFECTS OF AGE OF INTRODUCTION OF COMPLEMENTARY FOODS ON INFANT BREAST-MILK INTAKE, TOTAL-ENERGY INTAKE, AND GROWTH - A RANDOMIZED INTERVENTION STUDY IN HONDURAS	LANCET			English	Article							FORMULA-FED INFANTS; FEEDING PRACTICES; HUASCAR LIMA; DIARRHEAL; COUNTRIES; DISEASES; PERU	In developing countries, the age at which breastfed infants are first given complementary foods is of public health importance because of the risk of diarrhoeal disease from contaminated weaning foods, and the potential risk of growth faltering if foods are inappropriately delayed. To evaluate whether there are any advantage of complementary feeding prior to 6 months, low-income primiparous mothers who had exclusively breastfed for 4 months were randomly assigned to one of 3 groups: continued exclusive breastfeeding to 6 months (EBF) (n = 50); introduction of complementary foods at 4 months with ad libitum nursing from 4-6 months (SF) (n = 47); and introduction of complementary foods at 4 months, with maintenance of baseline nursing frequency from 4-6 months (SF-M) (n = 44). Baby foods in jars were provided to the SF and SF-M groups from 4 to 6 months. Subjects were visited weekly and provided with lactation guidance; at 4, 5, and 6 months measurements were made of infant intake and breast milk composition. At 4 months, breast milk intake averaged 797 (139) g per day (no difference among groups). Between 4 and 6 months, breast milk intake was unchanged in EBF infants (+ 6) but decreased in the SF (- 103), and SF-M (- 62) groups (p < 0.001). Change in total energy intake (including solid foods) and infant weight and length gain did not differ significantly between groups. Weight and length gain from 4-6 months were comparable to those of breastfed infants in an affluent USA population. The results indicate that breastfed infants self-regulate their total energy intake when other foods are introduced. As a result, there is no advantage in introducing complementary foods before 6 months in this population, whereas there may be disadvantages if there is increased exposure to contaminated weaning foods.	UNIV CALIF DAVIS, DEPT NUTR, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, PROGRAM INT NUTR, DAVIS, CA 95616 USA; LA LECHE LEAGUE HONDURAS, SAN PEDRO SULA, HONDURAS	University of California System; University of California Davis; University of California System; University of California Davis				Landa-Rivera, Leonardo/0000-0001-6705-700X				BROWN KH, 1989, PEDIATRICS, V83, P31; BROWN KH, 1986, PEDIATRICS, V78, P909; BUTTE NF, 1984, J PEDIATR-US, V104, P187, DOI 10.1016/S0022-3476(84)80990-7; BUTTE NF, 1992, AM J CLIN NUTR, V55, P1109, DOI 10.1093/ajcn/55.6.1109; DAHLQVIST A, 1964, ANAL BIOCHEM, V7, P18, DOI 10.1016/0003-2697(64)90115-0; DEKANASHIRO HC, 1990, AM J CLIN NUTR, V52, P995, DOI 10.1093/ajcn/52.6.995; DEWEY KG, 1992, PEDIATRICS, V89, P1035; DEWEY KG, 1991, PEDIATRICS, V87, P829; DEWEY KG, 1986, ACTA PAEDIATR SCAND, V75, P893, DOI 10.1111/j.1651-2227.1986.tb10313.x; DEWEY KG, 1993, FASEB J, V7, pA512; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; FOLCH J, 1957, J BIOL CHEM, V226, P497; Garza C., 1985, Human lactation. Milk components and methodologies, P121; HAMBRAEUS L, 1976, ANAL BIOCHEM, V72, P78, DOI 10.1016/0003-2697(76)90508-X; HEINIG MJ, 1993, ACTA PAEDIATR, V82, P999, DOI 10.1111/j.1651-2227.1993.tb12798.x; HEINIG MJ, 1993, AM J CLIN NUTR, V58, P152, DOI 10.1093/ajcn/58.2.152; POPKIN BM, 1990, PEDIATRICS, V86, P874; SACHDEV HPS, 1991, LANCET, V337, P929, DOI 10.1016/0140-6736(91)91568-F; STUFF JE, 1989, J PEDIATR-US, V115, P959, DOI 10.1016/S0022-3476(89)80750-4; UNDERWOOD BA, 1982, ACTA PAEDIATR SCAND, P1; WATERLOW JC, 1980, LANCET, V2, P1176; WATERLOW JC, 1979, LANCET, V2, P238; WHITEHEAD RG, 1984, EARLY HUM DEV, V9, P187, DOI 10.1016/0378-3782(84)90031-8; ZUMRAWI FY, 1987, HUM NUTR-CLIN NUTR, V41C, P383; 1977, NCHS GROWTH CURVES C; 1980, PEDIATRICS, V2, P1176; 1993, BREASTFEEDING TECHNI; 1989, RECOMMENDED DIETARY; 1979, CONT PATTERNS BREAST; 1990, QUESTIONS ANSWERS IN	30	176	190	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	1994	344	8918					288	293		10.1016/S0140-6736(94)91337-4	http://dx.doi.org/10.1016/S0140-6736(94)91337-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914260				2022-12-28	WOS:A1994NZ23300006
J	HUTCHINSON, CM; HOOK, EW; SHEPHERD, M; VERLEY, J; ROMPALO, AM				HUTCHINSON, CM; HOOK, EW; SHEPHERD, M; VERLEY, J; ROMPALO, AM			ALTERED CLINICAL PRESENTATION OF EARLY SYPHILIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article							TREPONEMA-PALLIDUM ANTIGENS; SECONDARY SYPHILIS; HIV-INFECTION; HOMOSEXUAL MEN; MANIFESTATIONS; ASSOCIATION; DIAGNOSIS; SARCOMA; RISK	Objectives: To compare clinical presentations of patients with early syphilis who did or did not have human immunodeficiency virus (HIV) infection. Design: Case-control study. Setting: The sexually transmitted diseases clinics of the Baltimore City Health Department. Patients: Patients with newly diagnosed primary, secondary, or early latent syphilis who had voluntary HIV testing from January 1990 to November 1991. Measurements: Data on sexual history, risk behaviors, and physical findings (before knowledge of HIV or syphilis serologic test results) were extracted from clinical records. Diagnoses of syphilis were confirmed by reactive syphilis serologic tests. Rapid plasma reagin titers reported to the disease registry of the Baltimore City Health Department were abstracted to determine therapeutic response. Patients positive for HIV who returned for follow-up had further counseling, staging, and CD4 lymphocyte testing. Results: Data were available on 309 of 527 patients with early syphilis: 108 patients with primary syphilis, 116 with secondary syphilis, and 85 with early latent syphilis. Seventy (23%) patients had concurrent HIV infection. Patients with HIV infection presented more often with secondary syphilis than did patients with syphilis who were HIV seronegative (53% [37 of 70] compared with 33% [79 of 239]; P = 0.01). The same was true for heterosexual men with HIV infection (46% [16 of 35]) compared with heterosexual men without infection (25% [35 of 142]; P < 0.03). Among those who denied intravenous drug use, 59% (22 of 37) of patients with HIV infection presented with secondary syphilis compared with 33% (65 of 198) of patients without infection (P < 0.01). Among patients with first episodes of syphilis, patients positive for HIV who had secondary syphilis were more likely to present with persistent chancres (43% [9 of 21] compared with 15% [11 of 72]; P = 0.01). The rate of decline in the rapid plasma reagin titers during a 12-month period after treatment did not differ between patients with and without HIV infection (P = 0.15). Conclusions.- The clinical presentation of syphilis in patients with HIV infection differs from that of patients without HIV infection in that patients with HIV infection present more often in the secondary stage and those with secondary syphilis are more likely to have chancres.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA; UNIV ALABAMA, BIRMINGHAM, AL USA	Johns Hopkins University; University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [R01-AI27727-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027727] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BLOUNT JH, 1978, BIOL PARSITIC SPIROC, P157; DARROW WW, 1987, AM J PUBLIC HEALTH, V77, P479, DOI 10.2105/AJPH.77.4.479; FIUMARA NJ, 1980, JAMA-J AM MED ASSOC, V243, P2500, DOI 10.1001/jama.243.24.2500; GOUREVITCH MN, 1993, ANN INTERN MED, V118, P350, DOI 10.7326/0003-4819-118-5-199303010-00005; HAAS JS, 1990, J INFECT DIS, V162, P862, DOI 10.1093/infdis/162.4.862; HICKS CB, 1987, ANN INTERN MED, V107, P492, DOI 10.7326/0003-4819-107-4-492; HUTCHINSON CM, 1991, JAMA-J AM MED ASSOC, V266, P253, DOI 10.1001/jama.266.2.253; HUTCHINSON CM, 1991, ARCH INTERN MED, V151, P511, DOI 10.1001/archinte.151.3.511; JAFFE HW, 1975, ANN INTERN MED, V83, P846, DOI 10.7326/0003-4819-83-6-846; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; LUKEHART SA, 1980, J IMMUNOL, V124, P454; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MAGNUSON HJ, 1956, MEDICINE, V35, P33, DOI 10.1097/00005792-195602000-00002; MARRA CM, 1992, J INFECT DIS, V165, P1020, DOI 10.1093/infdis/165.6.1020; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; QUINN TC, 1990, ARCH INTERN MED, V150, P1297, DOI 10.1001/archinte.150.6.1297; RADOLF JD, 1988, J AM ACAD DERMATOL, V18, P423, DOI 10.1016/S0190-9622(88)70062-6; ROMPALO AM, 1992, J INFECT DIS, V165, P1124, DOI 10.1093/infdis/165.6.1124; ROSENBERG ZF, 1992, SEXUALLY TRANSMITTED, P165; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; STOKES JH, 1944, MODERN CLIN SYPHILOL; STOUMBOS VD, 1987, AM J OPHTHALMOL, V103, P103, DOI 10.1016/S0002-9394(14)74179-0; 1989, MMWR MORB MORTAL WKL, V38; 1988, MMWR-MORBID MORTAL W, V37, P755; 1988, MMWR-MORBID MORTAL W, V37, P35; 1988, MMWR-MORBID MORTAL W, V37, P486	30	111	118	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					94	99		10.7326/0003-4819-121-2-199407150-00003	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	7912483				2022-12-28	WOS:A1994NW18600003
J	HARRISON, P; DEGEN, SJF; WILLIAMS, R; FARZANEH, F				HARRISON, P; DEGEN, SJF; WILLIAMS, R; FARZANEH, F			HEPATIC EXPRESSION OF HEPATOCYTE-GROWTH-FACTOR-LIKE MACROPHAGE-STIMULATING PROTEIN MESSENGER-RNA IN FULMINANT HEPATIC-FAILURE	LANCET			English	Note							GENE	We investigated whether impaired Kupffer cell phagocytosis in fulminant hepatic failure could be due to reduced synthesis of hepatocyte-growth-factor-like/macrophage-stimulating protein (HGFL/MSP), a serum protein synthesised predominantly in hepatocytes and required by tissue macrophages for phagocytosis. Hepatic expression of the 3.0 kb HGFL/MSP mRNA, assessed by northern hybridisation, was lower in nine patients with fulminant hepatic failure undergoing liver transplantation than in three liver grafts as controls (median absorbance units 97 [range 15-1200] versus 1114 [1100-1120], respectively; p < 0.05). Decreased hepatic HGFL/MSP production might cause impaired Kupffer cell phagocytosis in fulminant hepatic failure.	UNIV LONDON KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 9PJ,ENGLAND; CHILDRENS HOSP RES FDN,DIV BASIC SCI RES,CINCINNATI,OH 45229	University of London; King's College London; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	HARRISON, P (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MOLEC MED,BESSEMER RD,LONDON SE5 9PJ,ENGLAND.		Farzaneh, Farzin/B-4902-2009; Harrison, Phillip M/D-5374-2009	Farzaneh, Farzin/0000-0002-9275-2415; opoku, anita/0000-0001-7243-8157				BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; CANALESE J, 1982, GUT, V23, P265, DOI 10.1136/gut.23.4.265; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HUGHES RD, 1986, EUR J CLIN INVEST, V16, P352, DOI 10.1111/j.1365-2362.1986.tb01008.x; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; ROLANDO N, 1990, HEPATOLOGY, V11, P49, DOI 10.1002/hep.1840110110; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	8	13	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					27	28		10.1016/S0140-6736(94)91050-2	http://dx.doi.org/10.1016/S0140-6736(94)91050-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912298				2022-12-28	WOS:A1994NU91700013
J	OTSUKI, Y; MISAKI, O; SUGIMOTO, O; ITO, Y; TSUJIMOTO, Y; AKAO, Y				OTSUKI, Y; MISAKI, O; SUGIMOTO, O; ITO, Y; TSUJIMOTO, Y; AKAO, Y			CYCLIC BCL-2 GENE-EXPRESSION IN HUMAN UTERINE ENDOMETRIUM DURING MENSTRUAL-CYCLE	LANCET			English	Note							TISSUES	To investigate an apoptotic role for bcl-2 in menses, we studied bcl-2 protein production throughout the cycle. Bcl-2 protein was observed in endometrial glandular, stromal and myometrial smooth-muscle cells. Glandular cells expressed bcl-2 at proliferative through early secretory phases but not at late secretory through menstrual phases. This cyclic expression of bcl-2 gene was similar to that of oestrogen and progesterone receptors. Thus bcl-2 expression in glandular cells may be regulated by ovarian hormones. The disappearance of bcl-2 expression in glandular cells at late secretory phase was consistent with the appearance of apoptotic cells in the same phase.	OSAKA MED COLL,DEPT OBSTET & GYNAECOL,TAKATSUKI,OSAKA,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA 553,JAPAN	Osaka Medical College; Osaka University	OTSUKI, Y (corresponding author), OSAKA MED COLL,DEPT ANAT & BIOL,2-7 DIAGAKU MACHI,TAKATSUKI,OSAKA 569,JAPAN.							ADACHI M, 1990, ONCOGENE, V5, P1653; AKAO Y, 1994, CANCER RES, V84, P2468; GARCIA I, 1992, SCIENCE, V258, P303; HOPWOOD D, 1976, J PATHOL, V119, P159; LEBRUN DP, 1993, AM J PATHOL, V142, P743; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; SATYASWAROOP PG, 1979, J CLIN ENDOCR METAB, V48, P639, DOI 10.1210/jcem-48-4-639; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331	9	177	184	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					28	29						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912299				2022-12-28	WOS:A1994NU91700014
J	PEDRINELLI, R; GIAMPIETRO, O; CARMASSI, F; MELILLO, E; DELLOMO, G; CATAPANO, G; MATTEUCCI, E; TALARICO, L; MORALE, M; DENEGRI, F; DIBELLO, V				PEDRINELLI, R; GIAMPIETRO, O; CARMASSI, F; MELILLO, E; DELLOMO, G; CATAPANO, G; MATTEUCCI, E; TALARICO, L; MORALE, M; DENEGRI, F; DIBELLO, V			MICROALBUMINURIA AND ENDOTHELIAL DYSFUNCTION IN ESSENTIAL-HYPERTENSION	LANCET			English	Article							LEFT-VENTRICULAR HYPERTROPHY; VONWILLEBRAND-FACTOR; CARDIOVASCULAR-DISEASE; RISK-FACTORS; ATHEROSCLEROSIS; LIPOPROTEIN; MECHANISMS; INHIBITION; FIBRINOGEN; PRESSURE	Microalbuminuria (urinary albumin excretion between 20 and 200 mu g/min) and endothelial dysfunction coexist in patients with essential hypertension. To evaluate whether the two phenomena are related and the determinants of that association, we recruited 10 untreated males with essential hypertension and microalbuminuria without diabetes to be compared with an equal number of matched patients with essential hypertension excreting albumin in normal amounts and 10 normal controls. The status of endothelial function was inferred from circulating von Willebrand Factor antigen (vWF), a glycoprotein secreted in greater amounts when the vascular endothelium is damaged. vWF concentrations were higher in hypertensive patients with microalbuminuria than in hypertensive patients without and controls. Individual vWF and urine albumin-excretion values were correlated (r = 0.55, p < 0.002). Blood pressure correlated with both urinary albumin excretion and vWF. Left ventricular mass index and minimal forearm vascular resistances were comparable in patients with hypertension and higher than in controls; total and low-density lipoprotein cholesterol, triglycerides, lipoprotein-a, Factor VII, and plasminogen activator inhibitor-1 did not differ. Fibrinogen was higher and creatinine clearance lower in microalbuminurics. Albuminuria in essential hypertension may reflect systemic dysfunction of the vascular endothelium, a structure intimately involved in permeability, haemostasis, fibrinolysis, and blood pressure control. This abnormality may have important physiopathological implications and expose these patients to increased cardiovascular risk.	UNIV PISA,MED CLIN 2,I-56100 PISA,ITALY; UNIV PISA,REPARTO MED INTERNA,I-56100 PISA,ITALY	University of Pisa; University of Pisa	PEDRINELLI, R (corresponding author), UNIV PISA,MED CLIN 1,USL 12,I-56100 PISA,ITALY.			Carmassi, Franco/0000-0003-2244-4430				BIGAZZI R, 1992, NEPHRON, V61, P94, DOI 10.1159/000186842; BLANN A D, 1991, Medical Science Research, V19, P535; BLANN AD, 1993, J HUM HYPERTENS, V7, P107; CARMASSI F, 1992, THROMB RES, V67, P643, DOI 10.1016/0049-3848(92)90068-L; CERASOLA G, 1992, REV LAT CARDIOL, V13, P3; Christensen C K, 1983, J Hypertens, V1, P45; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CORRADI L, 1993, J HYPERTENS, V11, pS190; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; GIAMPIETRO O, 1992, ACTA DIABETOL, V28, P239, DOI 10.1007/BF00779006; JANSSON JH, 1991, BRIT HEART J, V66, P351; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; METTINGER KL, 1982, THROMB RES, V26, P183, DOI 10.1016/0049-3848(82)90139-6; MITROPOULOS KA, 1989, ATHEROSCLEROSIS, V76, P203, DOI 10.1016/0021-9150(89)90104-4; NICHOLS TC, 1990, ARTERIOSCLEROSIS, V10, P449, DOI 10.1161/01.ATV.10.3.449; NITENBERG A, 1993, AM J MED, V95, P71, DOI 10.1016/0002-9343(93)90234-G; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PARVING HH, 1973, CIRC RES, V32, P643, DOI 10.1161/01.RES.32.5.643; PEDRINELLI R, 1990, J HYPERTENS, V8, P467, DOI 10.1097/00004872-199005000-00012; PEDRINELLI R, 1993, ARTERIOSCLER THROMB, V13, P900, DOI 10.1161/01.ATV.13.6.900; PHILLIPS GB, 1993, J HYPERTENS, V11, P699, DOI 10.1097/00004872-199307000-00003; PICKERING TG, 1990, HYPERTENSION PATHOPH, P1397; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SALAZAR FJ, 1992, HYPERTENSION, V20, P113, DOI 10.1161/01.HYP.20.1.113; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; VANE JR, 1990, NEW ENGL J MED, V323, P27; VIBERTI GC, 1990, ACTA DIABETOL LAT, V27, P267, DOI 10.1007/BF02581339; WILLIAMS RR, 1990, HYPERTENSION PATHOPH, V9, P127; YUDKIN JS, 1988, LANCET, V2, P531	32	353	369	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					14	18		10.1016/S0140-6736(94)91047-2	http://dx.doi.org/10.1016/S0140-6736(94)91047-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912295				2022-12-28	WOS:A1994NU91700010
J	KUSS, BJ; DEELEY, RG; COLE, SPC; WILLMAN, CL; KOPECKY, KJ; WOLMAN, SR; EYRE, HJ; LANE, SA; NANCARROW, JK; WHITMORE, SA; CALLEN, DF				KUSS, BJ; DEELEY, RG; COLE, SPC; WILLMAN, CL; KOPECKY, KJ; WOLMAN, SR; EYRE, HJ; LANE, SA; NANCARROW, JK; WHITMORE, SA; CALLEN, DF			DELETION OF GENE FOR MULTIDRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA WITH INVERSION IN CHROMOSOME-16 - PROGNOSTIC IMPLICATIONS	LANCET			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; CANCER CELL-LINE; P-GLYCOPROTEIN; ACCUMULATION; ASSOCIATION; TRANSPORTER; MECHANISMS	Acute myeloid leukaemia (AML) associated with an inversion in chromosome 16 has a relatively favourable prognosis. The AML subclass most commonly associated with this chromosomal abnormality is acute myelomonocytic leukaemia with abnormal eosinophils. In some AML patients with inversion 16 the chromosomal lesion results in deletion of MRP, the gene for multidrug resistance associated protein. This gene is proximal to the primary breakpoint and loss of its function may play a key role in determining the favourable outcome in inversion 16 AML. We have demonstrated deletion of MRP by in situ hybridisation, by gene dosage studies and by studying loss of heterogeneity of a flanking microsatellite marker. Among 13 AML patients with inversion 16 MRP deletion was detected in 5 while 7 had no deletion. Deletion of MRP gene was associated with longer time from diagnosis until death or relapse from complete remission (p=0.007). These findings provide important insight into the biology of inversion 16 leukaemia and suggest that MRP deletion, as detected by molecular analysis, may,have a key role in determining outcome in patients with inversion 16 AML.	QUEENS UNIV,CANC RES LABS,KINGSTON,ON,CANADA; CTR MOLEC & CELLULAR DIAGNOST,CTR CANC,ALBUQUERQUE,NM; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA; MICHIGAN CANC FDN,DETROIT,MI; ONCOR,GAITHERSBURG,MD; SW ONCOL GRP,LEUKAEMIA BIOL PROGRAM,SAN ANTONIO,TX	Queens University - Canada; Fred Hutchinson Cancer Center; Southwest Oncology Group	KUSS, BJ (corresponding author), WOMENS & CHILDRENS HOSP,CTR MED GENET,DEPT CYTOGENET & MOLEC GENET,KING WILLIAM RD,ADELAIDE,SA 5006,AUSTRALIA.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017; Callen, David F/G-1975-2012	Cole, Susan P.C./0000-0001-6571-6884; Callen, David/0000-0002-6189-9991	NCI NIH HHS [CA32102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA032102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTHUR DC, 1983, BLOOD, V61, P994; BAE SC, 1993, ONCOGENE, V8, P809; BARRAND MA, 1993, BR J CANCER S20, V67, P77; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CAMPBELL LJ, 1991, GENE CHROMOSOME CANC, V3, P55, DOI 10.1002/gcc.2870030110; CAMPOS L, 1992, EUR J HAEMATOL, V48, P254; COLE SPC, 1989, BRIT J CANCER, V59, P42, DOI 10.1038/bjc.1989.9; COLE SPC, 1991, CANCER RES, V51, P3345; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cole Susan P. C., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P579; DACHARY D, 1986, CANCER GENET CYTOGEN, V20, P241, DOI 10.1016/0165-4608(86)90079-8; DAUWERSE JG, 1993, HUM MOL GENET, V2, P1527, DOI 10.1093/hmg/2.10.1527; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, IN PRESS CANCER RES; HART SM, 1993, BLOOD S, pA258; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LARSON RA, 1986, BLOOD, V68, P1242; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARQUARDT D, 1992, CANCER RES, V52, P3157; MARQUARDT D, 1990, CANCER RES, V50, P1426; OHYASHIKI K, 1988, LEUKEMIA, V2, P398; RAIMONDI SC, 1989, CANCER GENET CYTOGEN, V40, P13, DOI 10.1016/0165-4608(89)90141-6; ROSS DD, 1993, BLOOD, V82, P1288; SLOVAK ML, 1993, CANCER RES, V53, P3221; ZHAO S, 1993, BLOOD S, pA258	27	108	113	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1531	1534		10.1016/S0140-6736(94)92938-6	http://dx.doi.org/10.1016/S0140-6736(94)92938-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911871				2022-12-28	WOS:A1994NR32900008
J	EBENS, AJ; GARREN, H; CHEYETTE, BNR; ZIPURSKY, SL				EBENS, AJ; GARREN, H; CHEYETTE, BNR; ZIPURSKY, SL			THE DROSOPHILA ANACHRONISM LOCUS - A GLYCOPROTEIN SECRETED BY GLIA INHIBITS NEUROBLAST PROLIFERATION	CELL			English	Article							POSTEMBRYONIC NEUROBLASTS; DEVELOPMENTAL SWITCH; 44-45 REGION; MELANOGASTER; GENE; NEUROGENESIS; MUTAGENESIS; PROTEIN; PATTERN; BRIDE	The Drosophila anachronism (ana) locus controls the proliferation of neuroblasts, neuronal stem cells that give rise to the central nervous system. In ana mutants, quiescent postembryonic central brain and optic lobe neuroblasts enter S phase precociously. ana encodes a novel secreted protein of 474 amino acids that is expressed not in the affected neuroblasts, but rather in a subclass of neighboring glial cells. These studies argue for an important role for glia in negatively regulating proliferation of neuronal precursor cells, thereby controlling the timing of postembryonic neurogenesis.	UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	EBENS, AJ (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT COORDINATED SCI, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA.		Cheyette, Benjamin/K-5535-2014	Cheyette, Benjamin/0000-0001-9934-7941; Zipursky, Stephen/0000-0001-5630-7181	NIGMS NIH HHS [GM-07104] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Bauer V, 1904, ZOOL JB ABT ANAT ONT, V20, P123; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GREEN P, 1993, IN PRESS CELL TISSUE; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P473, DOI 10.1007/BF00399871; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HEISENBERG M, 1979, Z NATURFORSCH C, V34, P143; HOFBAUER A, 1990, ROUX ARCH DEV BIOL, V198, P264, DOI 10.1007/BF00377393; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; KONEV AY, 1991, GENETIKA+, V27, P77; KONEV AY, 1991, GENETIKA+, V27, P667; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maniatis T., 1982, MOL CLONING; MEINERTZHAGEN IA, 1973, DEV NEUROBIOLOGY ART, P51; MOSER MH, 1991, TRENDS PHARMACOL SCI, V12, P304, DOI 10.1016/0165-6147(91)90582-D; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PROKOP A, 1991, DEVELOPMENT, V111, P79; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOLBERT LP, 1989, TRENDS NEUROSCI, V12, P70, DOI 10.1016/0166-2236(89)90139-2; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; VERNADAKIS A, 1988, INT REV NEUROBIOL, V30, P149	38	173	174	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					15	27		10.1016/0092-8674(93)90291-W	http://dx.doi.org/10.1016/0092-8674(93)90291-W			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7916657				2022-12-28	WOS:A1993LN62500004
J	AARON, AD				AARON, AD			THE MANAGEMENT OF CANCER METASTATIC TO BONE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; CARCINOMA; ETIDRONATE; PALLIATION; INVASION; PROSTATE; GROWTH		NIAMS,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	AARON, AD (corresponding author), GEORGETOWN UNIV HOSP,DEPT ORTHOPED SURG,3800 RESERVOIR RD NW,PHC-G,WASHINGTON,DC 20007, USA.							[Anonymous], 1989, CLIN ORTHOP; BASSANI D, 1990, ONCOLOGY, V47, P160; Batson OV, 1942, ANN INTERN MED, V16, P38, DOI 10.7326/0003-4819-16-1-38; BONARIGO BC, 1967, RADIOLOGY, V88, P889, DOI 10.1148/88.5.889; CHACKALROY M, 1989, J CLIN INVEST, V84, P43, DOI 10.1172/JCI114167; ELOMAA I, 1983, LANCET, V1, P146; Ewing J., 1928, NEOPLASTICS, P77; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; Frassica F J, 1992, Instr Course Lect, V41, P293; GAINOR BJ, 1983, CLIN ORTHOP RELAT R, V178, P297; GLEAVE M, 1991, CANCER RES, V51, P3753; GUAITANI A, 1985, CANCER RES, V45, P2206; HABERMANN ET, 1982, CLIN ORTHOP RELAT R, V169, P70; HARRINGTON KD, 1986, J BONE JOINT SURG AM, V68A, P1110, DOI 10.2106/00004623-198668070-00025; Harrington KD, 1988, ORTHOPAEDIC MANAGEME, P7; KEENE JS, 1986, CLIN ORTHOP RELAT R, V203, P282; KOENDERS PG, 1992, BREAST CANCER RES TR, V21, P173, DOI 10.1007/BF01975000; LAING AH, 1991, BRIT J RADIOL, V64, P816, DOI 10.1259/0007-1285-64-765-816; MAGRO C, 1985, J NATL CANCER I, V74, P829; MURRAY JA, 1974, J BONE JOINT SURG AM, VA 56, P311, DOI 10.2106/00004623-197456020-00009; NIELSEN OS, 1991, J CLIN ONCOL, V9, P509, DOI 10.1200/JCO.1991.9.3.509; ORR FW, 1993, BREAST CANCER RES TR, V25, P151, DOI 10.1007/BF00662140; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; PARRISH FF, 1970, J BONE JOINT SURG AM, VA 52, P665, DOI 10.2106/00004623-197052040-00002; POWELL N, 1983, BRIT J RADIOL, V56, P582, DOI 10.1259/0007-1285-56-668-582; ROUGRAFF BT, 1993, J BONE JOINT SURG AM, V75A, P1276, DOI 10.2106/00004623-199309000-00003; SMITH JA, 1989, J UROLOGY, V141, P85, DOI 10.1016/S0022-5347(17)40597-0; VANHOLTENVERZANTVOORT AT, 1987, LANCET, V2, P983; [No title captured]	29	94	96	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1206	1209		10.1001/jama.272.15.1206	http://dx.doi.org/10.1001/jama.272.15.1206			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933350				2022-12-28	WOS:A1994PL21200036
J	SACHSENMAIER, C; RADLERPOHL, A; ZINCK, R; NORDHEIM, A; HERRLICH, P; RAHMSDORF, HJ				SACHSENMAIER, C; RADLERPOHL, A; ZINCK, R; NORDHEIM, A; HERRLICH, P; RAHMSDORF, HJ			INVOLVEMENT OF GROWTH-FACTOR RECEPTORS IN THE MAMMALIAN UVC RESPONSE	CELL			English	Article							C-FOS PROMOTER; TYROSINE KINASES; PROTEIN-KINASE; TERNARY COMPLEX; TRANSCRIPTIONAL ACTIVATION; AUTOCRINE TRANSFORMATION; ENHANCER ELEMENT; PHORBOL ESTER; FACTOR P62TCF; JUN ACTIVITY	Irradiation of HeLa cells with short-wavelength ultraviolet light (UVC) induces the modification and activation of the preexisting transcription factors c-fos-c-Jun (AP-1) and TCF/Elk-1, as well as the protein synthesis independent transcriptional activation of the c-fos and c-jun genes. This response to UVC is mediated via obligatory cytoplasmic signal transduction, involving Pas and Raf, Src, and MAP kinases. The UVC response is inhibited by prior down-modulation of growth factor receptor signaling upon growth factor prestimulation, by suramin (an inhibitor of receptor activation) or by expression of a dominant negative epidermal growth factor (EGF) receptor mutant. These data suggest the involvement of several growth factor receptors in the UVC response. Indeed, UVC induces the suramin-inhibitable immediate tyrosine phosphorylation of the EGF receptor.	HANNOVER MED SCH,INST MOLEK BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School	SACHSENMAIER, C (corresponding author), KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET,D-76021 KARLSRUHE,GERMANY.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCHER M, 1988, ONCOGENE, V3, P301; COCHET C, 1984, J BIOL CHEM, V259, P2553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELLEM KAO, 1988, CARCINOGENESIS, V9, P797, DOI 10.1093/carcin/9.5.797; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HUANG SS, 1988, J BIOL CHEM, V263, P12608; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAMER M, 1993, J BIOL CHEM, V268, P6734; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PINGOUD V, 1994, IN PRESS J BIOL CHEM; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rahmsdorf H., 1992, INDUCED EFFECTS GENO, P141; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	53	414	422	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					963	972		10.1016/0092-8674(94)90272-0	http://dx.doi.org/10.1016/0092-8674(94)90272-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923365				2022-12-28	WOS:A1994PJ29400008
J	SOGAARD, M; TANI, K; YE, RR; GEROMANOS, S; TEMPST, P; KIRCHHAUSEN, T; ROTHMAN, JE; SOLLNER, T				SOGAARD, M; TANI, K; YE, RR; GEROMANOS, S; TEMPST, P; KIRCHHAUSEN, T; ROTHMAN, JE; SOLLNER, T			A RAB PROTEIN IS REQUIRED FOR THE ASSEMBLY OF SNARE COMPLEXES IN THE DOCKING OF TRANSPORT VESICLES	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; BINDING YPT1 PROTEIN; VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; GOLGI-COMPLEX; SYNAPTIC VESICLES; NEUROTRANSMITTER RELEASE; SACCHAROMYCES-CEREVISIAE; FUSION PROTEIN	Rab proteins are generally required for transport vesicle docking. We have exploited yeast secretion mutants to demonstrate that a rab protein is required for v-SNAREs and t-SNAREs to assemble. The absence of the rab protein in the docking complex suggests that, in a broad sense, rab proteins participate in a reaction catalyzing SNARE complex assembly. In so doing, mb proteins could help impart an additional layer of specificity to vesicle docking. This mechanism likely involves the Sec1 homolog Sly1, which we identified in isolated docking complexes. We also report the identification of a novel v-SNARE (Ykt6p) component of the yeast ER-Golgi docking complex that has a CAAX box and is predicted to be lipid anchored. The surprising finding that docking complexes can contain many distinct species of SNAREs (Sed5p, Bos1p, Sec22p, Ykt6p, and likely Bet1p, p28, and p14) suggests that multimeric interactions are features of the fusion machinery, and may also improve the fidelity of vesicle targeting.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	Memorial Sloan Kettering Cancer Center; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	SOGAARD, M (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BANFIELD D, 1994, IN PRESS J CELL BIOL; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARLOW E, 1988, ANTIBODIES LABORATOR; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KNUDSEN KA, 1985, ANAL BIOCHEM, V147, P285, DOI 10.1016/0003-2697(85)90273-8; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	62	465	470	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					937	948		10.1016/0092-8674(94)90270-4	http://dx.doi.org/10.1016/0092-8674(94)90270-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923363				2022-12-28	WOS:A1994PJ29400006
J	WOLF, AR				WOLF, AR			NEONATAL SEDATION - MORE ART THAN SCIENCE	LANCET			English	Editorial Material							PHARMACOKINETICS; MIDAZOLAM; INFUSION; FENTANYL; CHILDREN; MORPHINE; UNIT				WOLF, AR (corresponding author), ROYAL HOSP SICK CHILDREN,DIRECTORATE ANAESTHESIA,GLASGOW G3 8SJ,SCOTLAND.							COLLINS C, 1985, ANESTH ANALG, V64, P1078; HARTWIG S, 1991, EUR J PEDIATR, V150, P784, DOI 10.1007/BF02026712; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; JACQZAIGRAIN E, 1994, LANCET, V344, P646, DOI 10.1016/S0140-6736(94)92085-0; JACQZAIGRAIN E, 1992, EUR J CLIN PHARMACOL, V42, P329; MAYERS DJ, 1991, DEV PHARMACOL THERAP, V16, P71, DOI 10.1159/000480561; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; TUBARO E, 1983, J INFECT DIS, V148, P656, DOI 10.1093/infdis/148.4.656; WATT I, 1984, ANAESTHESIA, V39, P973, DOI 10.1111/j.1365-2044.1984.tb08885.x; WOLF AR, 1993, LANCET, V342, P319, DOI 10.1016/0140-6736(93)91468-2; YEAGER MP, 1992, CLIN IMMUNOL IMMUNOP, V62, P336, DOI 10.1016/0090-1229(92)90112-2	11	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					628	629		10.1016/S0140-6736(94)92077-X	http://dx.doi.org/10.1016/S0140-6736(94)92077-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915342				2022-12-28	WOS:A1994PE38600002
J	TAKAHAMA, Y; SUZUKI, H; KATZ, KS; GRUSBY, MJ; SINGER, A				TAKAHAMA, Y; SUZUKI, H; KATZ, KS; GRUSBY, MJ; SINGER, A			POSITIVE SELECTION OF CD4+ T-CELLS BY TCR LIGATION WITHOUT AGGREGATION EVEN IN THE ABSENCE OF MHC	NATURE			English	Article							CD3/T-CELL RECEPTOR COMPLEX; CLASS-II MOLECULES; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; IMMATURE THYMOCYTES; NEGATIVE SELECTION; TRANSGENIC MICE; CROSS-LINKING; THYMUS; BETA	THE developmental fate of immature thymocytes is determined by the specificity of their T-cell antigen receptors (TCRs). Immature CD4(+)8(+) thymocytes are positively selected to differentiate into mature T cells by recognition of peptides associated with major histocompatibility complex (MHC) encoded molecules(7-10) on But neither the identity of molecules transducing positive selection signals nor the nature of the signals themselves is fully known. Here we report that direct ligation of TCR molecules by monoclonal antibodies specific for either clonotypic or CD3 chains can signal immature thymocytes to differentiate into mature CD4(+)8(-) T cells, even in the absence of MHC expression and MHC-dependent CD4 co-receptor signalling. Moreover, we show that TCR engagement induces positive selection signals only in the absence of TCR aggregation and that TCR aggregation is inhibitory for positive selection. Thus, low valency of TCR crosslinking is a critical parameter(15), distinguishing positive selection from other TCR-mediated signalling events.	NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA; SYNTEX INST IMMUNOL, NIIHARI 30041, JAPAN; HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT RHEUMATOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School			Takahama, Yousuke/A-5863-2010; Suzuki, Harumi/L-1271-2013	Takahama, Yousuke/0000-0002-4992-9174; Suzuki, Harumi/0000-0003-3616-9361				ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BORN W, 1987, J IMMUNOL, V138, P999; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; COULIE PG, 1991, EUR J IMMUNOL, V21, P1703, DOI 10.1002/eji.1830210718; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HUGO P, 1992, NATURE, V360, P679, DOI 10.1038/360679a0; HUNIG T, 1988, EUR J IMMUNOL, V18, P2089, DOI 10.1002/eji.1830181234; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KOURILSKY P, 1989, CELL, V56, P327, DOI 10.1016/0092-8674(89)90233-X; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; MANDEL TE, 1978, IMMUNOLOGY, V35, P317; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCDUFFIE M, 1986, P NATL ACAD SCI USA, V83, P8728, DOI 10.1073/pnas.83.22.8728; MULLER KP, 1993, EUR J IMMUNOL, V23, P1661, DOI 10.1002/eji.1830230740; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAKAYAMA T, 1991, P NATL ACAD SCI USA, V88, P9949, DOI 10.1073/pnas.88.22.9949; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PUNT JA, 1993, J IMMUNOL, V151, P1290; PUNT JA, 1994, J EXP MED, V180, P587, DOI 10.1084/jem.180.2.587; ROBINSON JH, 1976, CLIN EXP IMMUNOL, V23, P347; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SINGER A, 1987, TRANSPLANT P, V19, P107; Singer A., 1986, PROG IMMUNOL, V6, P60; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VUKMANOVIC S, 1992, NATURE, V359, P729, DOI 10.1038/359729a0; YACHELINI P, 1990, J IMMUNOL, V145, P1382	46	77	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 1	1994	371	6492					67	70		10.1038/371067a0	http://dx.doi.org/10.1038/371067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	7915400				2022-12-28	WOS:A1994PE38100052
J	SCHIFFL, H; LANG, SM; KONIG, A; STRASSER, T; HAIDER, MC; HELD, E				SCHIFFL, H; LANG, SM; KONIG, A; STRASSER, T; HAIDER, MC; HELD, E			BIOCOMPATIBLE MEMBRANES IN ACUTE-RENAL-FAILURE - PROSPECTIVE CASE-CONTROLLED STUDY	LANCET			English	Article							INTENSIVE-CARE UNIT; LEUKOTRIENE-B4; ACTIVATION; COMPLEMENT; DIALYSIS	The mortality of critically ill patients with acute renal failure has been halved through intervention by haemodialysis. However, several reports suggest that the course df the disorder may be prolonged by this procedure. Our prospective randomised study was done to see whether the generation of inflammatory mediators by bio-incompatible membranes has an adverse effect on the outcome of acute renal failure. 52 patients, similar in age, severity of acute renal failure, general disease status (APACHE II),and management of acute renal failure or its related conditions, were divided into two groups. Haemodialysis was done with cuprophane or polyacrylonitrile membranes. Cuprophane membranes induced intense activation of the complement system (as judged by measurement of C3a) and lipooxygenase pathway (leukotriene 84) resulting in alterations of neutrophil kinetics and function. The cuprophane group had a lower survival rate (38 vs 65%), a higher proportion of patients dying from sepsis (71 vs 40%), required more haemodialysis sessions (12 vs 9), and demonstrated delayed resolution and recovery from acute renal failure than the polyacrylonitrile group. The difference in mortality regarding lethal sepsis as cause of death was statistically significant. Our observations indicate that the outcome of critically ill patients with acute renal failure may be influenced by bio-incompatibility reactions to the dialysis membrane. These results have direct implications for such patients on haemodialysis.			SCHIFFL, H (corresponding author), UNIV MUNICH, KLINIKUM INNENSTADT, MED KLIN, ZIEMSSENSTR 1, D-80336 MUNICH, GERMANY.							ASAD SN, 1987, BLOOD PURIFICATION P, P54; BADR K, 1992, KIDNEY INT       S38, V421, pS101; BLAGG CR, 1983, REPLACEMENT RENAL FU, P611; CAMERON JS, 1986, INTENS CARE MED, V12, P64; CHENOWETH D E, 1986, Complement, V3, P152; CONGER JD, 1990, SEMIN DIALYSIS, V3, P146, DOI 10.1111/j.1525-139X.1990.tb00031.x; CORWIN HL, 1988, INTENS CARE MED, V14, P86; Dinarello C A, 1988, Kidney Int Suppl, V24, pS21; HIMMELFARB J, 1991, AM J KIDNEY DIS, V17, P271, DOI 10.1016/S0272-6386(12)80473-2; IVANOVICH P, 1983, KIDNEY INT, V24, P758, DOI 10.1038/ki.1983.224; Johnson K J, 1993, Curr Opin Nephrol Hypertens, V2, P625, DOI 10.1097/00041552-199307000-00014; KENNEDY AC, 1973, Q J MED, V42, P73; KJELLSTRAND CM, 1981, T AM SOC ART INT ORG, V27, P45; KLAUSNER JM, 1989, AM J PHYSIOL, V256, pF794, DOI 10.1152/ajprenal.1989.256.5.F794; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEVIN N W, 1991, Journal of the American Society of Nephrology, V2, P335; MYERS BD, 1986, NEW ENGL J MED, V314, P97; NATH KA, 1992, KIDNEY INT, V42, pS109; SCHULMAN G, 1991, KIDNEY INT, V40, P1069, DOI 10.1038/ki.1991.316; SOLEZ K, 1979, MEDICINE, V58, P362, DOI 10.1097/00005792-197909000-00003; STRASSER T, 1991, KLIN WOCHENSCHR, V69, P808, DOI 10.1007/BF01744274; STRASSER T, 1990, BIOCHIM BIOPHYS ACTA, V1046, P326, DOI 10.1016/0005-2760(90)90249-W; TURNEY JH, 1992, ADV RENAL MED, P314; VANHOLDER R, 1993, NEPHRON, V63, P409, DOI 10.1159/000187244	24	278	283	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	1994	344	8922					570	572		10.1016/S0140-6736(94)91964-X	http://dx.doi.org/10.1016/S0140-6736(94)91964-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914959				2022-12-28	WOS:A1994PD42400008
J	BLANK, S; SIMONDS, RJ; WEISFUSE, I; RUDNICK, J; CHIASSON, MA; THOMAS, P				BLANK, S; SIMONDS, RJ; WEISFUSE, I; RUDNICK, J; CHIASSON, MA; THOMAS, P			POSSIBLE NOSOCOMIAL TRANSMISSION OF HIV	LANCET			English	Note								We report an infant with AIDS whose source of HIV is unknown; investigation supported the possibility of patient-to-patient transmission of HIV during medical care.	CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV STD HIV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	BLANK, S (corresponding author), NEW YORK CITY DEPT HLTH,BUR STD CONTROL,DIV DIS INTERVENT,BOX 73,ROOM 207,125 WORTH ST,NEW YORK,NY 10013, USA.							CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; POLISH LB, 1992, NEW ENGL J MED, V326, P721, DOI 10.1056/NEJM199203123261101; 1988, MMWR-MORBID MORTAL W, V37, P377; 1992, MMWR-MORBID MORTAL W, V41, P228; 1993, MMWR-MORBID MORTAL W, V42, P969; 1987, MMWR-MORBID M    S2S, V36, pS1; 1988, MMWR-MORBID MORTAL W, V37, P387; 1992, MMWR-MORBID MORTAL W, V41, P575	10	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					512	514		10.1016/S0140-6736(94)91900-3	http://dx.doi.org/10.1016/S0140-6736(94)91900-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914615				2022-12-28	WOS:A1994PC53500011
J	ALDERMAN, MH				ALDERMAN, MH			NONPHARMACOLOGICAL TREATMENT OF HYPERTENSION	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; ALL-CAUSE MORTALITY; BLOOD-PRESSURE; ALCOHOL-CONSUMPTION; SODIUM RESTRICTION; PHYSICAL-ACTIVITY; WEIGHT-LOSS; REDUCTION; SALT				ALDERMAN, MH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, BRONX, NY 10461 USA.							ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; [Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; [Anonymous], 1989, Clin Exp Hypertens A, V11, P1011; BLAIR SN, 1993, ANN INTERN MED, V119, P749, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00024; BLUMENTHAL JA, 1991, JAMA-J AM MED ASSOC, V266, P2098, DOI 10.1001/jama.266.15.2098; Bock, 1960, ESSENTIAL HYPERTENSI, P53; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CUTLER JA, 1993, CLIN EXP HYPERTENS, V15, P1193, DOI 10.3109/10641969309037105; CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; DAVIS BR, 1993, ARCH INTERN MED, V153, P1773, DOI 10.1001/archinte.153.15.1773; DENKER PS, 1992, ARCH INTERN MED, V152, P1649, DOI 10.1001/archinte.152.8.1649; DOLE VP, 1950, J CLIN INVEST, V29, P1189, DOI 10.1172/JCI102357; EISENBERG DM, 1993, ANN INTERN MED, V118, P964, DOI 10.7326/0003-4819-118-12-199306150-00009; ELLIOTT P, 1988, BRIT MED J, V297, P319; Fagard R, 1985, HDB HYPERTENSION, V6, P104; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FOLKOW B, 1992, CLIN EXP HYPERTENS A, V14, P1, DOI 10.3109/10641969209036167; FRIEDMAN GD, 1982, HYPERTENSION, V4, P143; GRIMM RH, 1992, CIRCULATION, V86, P145; Hambrecht R, 1993, J AM COLL CARDIOL, V22, P468, DOI 10.1016/0735-1097(93)90051-2; JOHNSON OD, 1962, NEW ENGL J MED, V267, P336, DOI 10.1056/NEJM196208162670705; KAPLAN NM, 1991, HYPERTENSION, V18, P153; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KNAPP HR, 1989, NEW ENGL J MED, V320, P1037, DOI 10.1056/NEJM198904203201603; LANGFORD HG, 1985, JAMA-J AM MED ASSOC, V253, P657, DOI 10.1001/jama.253.5.657; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LONGWORTH DL, 1980, CLIN PHARMACOL THER, V27, P544, DOI 10.1038/clpt.1980.76; LUFT FC, 1990, AM J HYPERTENS, V3, pS156, DOI 10.1093/ajh/3.8.156; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAHESWARAN R, 1992, HYPERTENSION, V19, P79, DOI 10.1161/01.HYP.19.1.79; MCCARRON DA, 1984, SCIENCE, V224, P1392, DOI 10.1126/science.6729459; NICHOLSON JP, 1987, ANN INTERN MED, V107, P329, DOI 10.7326/0003-4819-107-2-329; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PALATINI P, 1988, SPORTS MED, V5, P353, DOI 10.2165/00007256-198805060-00002; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; POULTER NR, 1985, J HYPERTENS, V3, pS375; PUDDEY IB, 1985, HYPERTENSION, V7, P707, DOI 10.1161/01.HYP.7.5.707; PUDDEY IB, 1987, LANCET, V1, P647; REISIN E, 1978, NEW ENGL J MED, V298, P1, DOI 10.1056/NEJM197801052980101; REISIN E, 1990, HYPERTENSION PATHOPH, V2, P2025; RESNICK LM, 1992, AM J MED, V93, P115; SMITH SJ, 1985, BMJ-BRIT MED J, V290, P110, DOI 10.1136/bmj.290.6462.110; SMITH WCS, 1988, BRIT MED J, V297, P329, DOI 10.1136/bmj.297.6644.329; STAESSEN J, 1988, J HYPERTENS, V6, P965, DOI 10.1097/00004872-198812000-00003; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; SULLIVAN JM, 1991, HYPERTENSION, V17, pI61, DOI 10.1161/01.HYP.17.1_Suppl.I61; SWALES JD, 1991, J HYPERTENS       S6, V8, P342; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613; WASSERTHEILSMOLLER S, 1992, AM J HYPERTENS, V5, P37, DOI 10.1093/ajh/5.1.37; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302	53	39	39	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	1994	344	8918					307	311		10.1016/S0140-6736(94)91343-9	http://dx.doi.org/10.1016/S0140-6736(94)91343-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914266				2022-12-28	WOS:A1994NZ23300012
J	CAO, XY; JIANG, XM; KAREEM, A; DOU, ZH; RAKEMAN, MA; ZHANG, ML; MA, T; ODONNELL, K; DELONG, N; DELONG, GR				CAO, XY; JIANG, XM; KAREEM, A; DOU, ZH; RAKEMAN, MA; ZHANG, ML; MA, T; ODONNELL, K; DELONG, N; DELONG, GR			IODINATION OF IRRIGATION WATER AS A METHOD OF SUPPLYING IODINE TO A SEVERELY IODINE-DEFICIENT POPULATION IN XINJIANG, CHINA	LANCET			English	Article								Severe iodine deficiency still occurs in many countries, and causes cretinism and mental impairment. In southern Xinjiang province, China, after usual methods of iodine supplementation had failed, we iodinated irrigation water to increase iodine in soil, crops, animals, and human beings. 5% potassium iodate solution, dripped into an irrigation canal for 12 or 24 days, increased soil iodine 3-fold, and crop and animal iodine 2-fold. Median urinary iodine excretion in children increased from 18 to 49 mu g/L (two groups of similar age). The cost for iodine was US $0.05 per person per year. Soil iodine remained stable over one winter, and dripping of iodine during the second year (US $0.12 per person per year) resulted in a further 4-fold increase in soil iodine and a 1.8-fold increase in iodine in crops. We conclude that iodination of irrigation water is an advantageous and cost-effective method of supplying iodine in southern Xinjiang, and may be useful in other areas dependent on irrigation.	DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; XINJIANG HLTH & ANTIEPIDEM STN, XINJIANG, PEOPLES R CHINA; INST ENDEM DIS CONTROL & RES, XINJIANG, PEOPLES R CHINA; TIANJIN MED COLL, TIANJIN, PEOPLES R CHINA	Duke University; Tianjin Medical University								ANKE M, 1991, ELIMINATION IODINE D, P1; DELANGE F, 1990, ACTA CLIN BELG, V45, P394, DOI 10.1080/17843286.1990.11718117; DELANGE FM, 1981, FETAL BRAIN DISORDER, P285; Delong G. Robeert, 1993, American Journal of Clinical Nutrition, V57, p286S, DOI 10.1093/ajcn/57.2.286S; DELONG GR, 1989, IODINE BRAIN; Delong R., 1986, PREVENTION CONTROL I, P49; Dunn JT., 1987, PREVENTION CONTROL I, P135; FISHER KD, 1974, PB233599; HALPERN JP, 1991, BRAIN, V114, P825, DOI 10.1093/brain/114.2.825; HEMKEN RW, 1972, J DAIRY SCI, V55, P931, DOI 10.3168/jds.S0022-0302(72)85599-1; Hetzel B.S., 1986, TRACE ELEMENTS HUMAN, P139; 1980, MINERAL TOLERANCE DO, P227	12	69	74	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	1994	344	8915					107	110		10.1016/S0140-6736(94)91286-6	http://dx.doi.org/10.1016/S0140-6736(94)91286-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912349				2022-12-28	WOS:A1994NV73200014
J	HO, DSW; ZECCHIN, RP; RICHARDS, DAB; UTHER, JB; ROSS, DL				HO, DSW; ZECCHIN, RP; RICHARDS, DAB; UTHER, JB; ROSS, DL			DOUBLE-BLIND TRIAL OF LIGNOCAINE VERSUS SOTALOL FOR ACUTE TERMINATION OF SPONTANEOUS SUSTAINED VENTRICULAR-TACHYCARDIA	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; WIDE QRS COMPLEX; PROPHYLACTIC LIDOCAINE; CARDIAC-ARREST; ARRHYTHMIAS; EFFICACY; SAFETY; DRUG; TACHYARRHYTHMIAS; FIBRILLATION	The efficacy of antiarrhythmic drugs for terminating sustained ventricular tachycardia (VT) has been disappointing. Lignocaine is the traditional drug but it is not very effective. Sotalol, one of the most effective drugs in suppressing spontaneous or induced VT, should theoretically be useful in this setting. We have compared lignocaine with sotalol for the acute termination of spontaneous sustained VT not causing cardiac arrest in 33 patients (26 males, 7 females, aged 21-90) whose underlying heart disease was old myocardial infarction (28), acute myocardial infarction (2), dilated cardiomyopathy (1), or idiopathic cardiomyopathy (2). Left-ventricular ejection fraction was 35% (range 18-76%). Patients were randomly allocated in a double-blind fashion to lignocaine 100 mg (n = 17) or sotalol 100 mg (n = 16) given intravenously over 5 min. Those with persistent VT 15 min after onset of administration of the first drug were crossed over to the other drug. Sotalol was significantly more effective than lignocaine whether analysed on an intention-to-treat basis (69% vs 18%; 95% confidence interval for absolute difference of 51% 22-80%, p = 0.003) or by analysis limited to the 31 patients with subsequent electrophysiologically proven VT (69% vs 20%). 1 patient in each group required cardioversion after the first drug. Tachycardia persisted in 14 patients in the lignocaine group and 4 in the sotalol group after 15 min. Tachycardia ceased in 7 (50%) patients who crossed over to sotalol, and in 1 patient who crossed over to lignocaine. There was 1 death in each group after the first drug and 1 death after both drugs. We conclude that sotalol was superior to lignocaine for the acute termination of sustained VT, The incidence of adverse effects was similar for the two drugs.	WESTMEAD HOSP, DEPT CARDIOL, SYDNEY, NSW 2145, AUSTRALIA	University of Sydney			Zecchin, Robert/L-5735-2019	Zecchin, Robert/0000-0001-7288-0906				ADHAR GC, 1988, J AM COLL CARDIOL, V12, P159, DOI 10.1016/0735-1097(88)90369-5; ARMENGOL RE, 1989, ANN EMERG MED, V18, P254, DOI 10.1016/S0196-0644(89)80409-3; BRACHMANN J, 1985, EUR HEART J, V6, P171, DOI 10.1093/eurheartj/6.suppl_D.171; BRUGADA P, 1991, CIRCULATION, V83, P1649, DOI 10.1161/01.CIR.83.5.1649; CAMPBELL RWF, 1981, BRIT HEART J, V46, P351; CARRUTH JE, 1982, AM HEART J, V104, P545, DOI 10.1016/0002-8703(82)90225-3; COLATSKY TJ, 1982, CIRC RES, V50, P17, DOI 10.1161/01.RES.50.1.17; DEBAKKER JMT, 1988, CIRCULATION, V77, P589, DOI 10.1161/01.CIR.77.3.589; DUNN HM, 1985, AM HEART J, V110, P353, DOI 10.1016/0002-8703(85)90156-5; FENOGLIO JJ, 1983, CIRCULATION, V68, P518, DOI 10.1161/01.CIR.68.3.518; GORGELS AP, 1989, CIRCULATION S2, V80, P652; GRIFFITH MJ, 1990, LANCET, V336, P670, DOI 10.1016/0140-6736(90)92158-E; HARGARTEN K, 1990, ANN EMERG MED, V19, P1274, DOI 10.1016/S0196-0644(05)82287-5; HILL BC, 1990, J CARDIOVASC PHARM, V16, P871, DOI 10.1097/00005344-199012000-00003; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HO DS, 1993, AUST NZ J MED, V23, P68; HOROWITZ LN, 1978, CIRCULATION, V58, P986, DOI 10.1161/01.CIR.58.6.986; KEHOE RF, 1990, AM J CARDIOL, V65, pA58; KERTES P, 1984, BRIT HEART J, V52, P241; KLEIN H, 1982, CIRCULATION, V66, P847, DOI 10.1161/01.CIR.66.4.847; KOSTER RW, 1985, NEW ENGL J MED, V313, P1105, DOI 10.1056/NEJM198510313131801; LIE KI, 1974, NEW ENGL J MED, V291, P1324, DOI 10.1056/NEJM197412192912504; LOWN B, 1967, J AMER MED ASSOC, V199, P188, DOI 10.1001/jama.199.3.188; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; NADEMANEE K, 1985, CIRCULATION, V72, P555, DOI 10.1161/01.CIR.72.3.555; ROSS DL, 1982, CIRCULATION, V66, P1205, DOI 10.1161/01.CIR.66.6.1205; ROSS DL, 1990, MED J AUSTRALIA, V153, P37, DOI 10.5694/j.1326-5377.1990.tb125462.x; SENGES J, 1984, CIRCULATION, V69, P577, DOI 10.1161/01.CIR.69.3.577; SINGH BN, 1970, BRIT J PHARMACOL, V39, P657, DOI 10.1111/j.1476-5381.1970.tb09891.x; SINGH SN, 1988, AM J CARDIOL, V62, P399, DOI 10.1016/0002-9149(88)90966-6; SOMANI P, 1968, J PHARMACOL EXP THER, V164, P317; SOUTHWORTH JL, 1950, JAMA-J AM MED ASSOC, V143, P717, DOI 10.1001/jama.1950.02910430009003; SOYKA LF, 1990, AM J CARDIOL, V65, pA74; STEVENSON WG, 1985, CIRCULATION, V71, P1146, DOI 10.1161/01.CIR.71.6.1146; VALENTINE PA, 1974, NEW ENGL J MED, V291, P1327, DOI 10.1056/NEJM197412192912505; WANG M, 1989, PACE, V12, P1522, DOI 10.1111/j.1540-8159.1989.tb06157.x; WELLENS HJJ, 1976, CIRCULATION, V54, P237, DOI 10.1161/01.CIR.54.2.237; ZIPES DP, 1991, HEART DISEASE TXB CA, P696	38	69	70	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	1994	344	8914					18	23		10.1016/S0140-6736(94)91048-0	http://dx.doi.org/10.1016/S0140-6736(94)91048-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912296				2022-12-28	WOS:A1994NU91700011
J	WEDEGAERTNER, PB; BOURNE, HR				WEDEGAERTNER, PB; BOURNE, HR			ACTIVATION AND DEPALMITOYLATION OF G(S-ALPHA)	CELL			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA-ADRENERGIC RECEPTORS; G-PROTEIN; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; PLASMA-MEMBRANE; PALMITOYLATION; STIMULATION; MUTATION; BINDING	[H-3]palmitate attached to mutationally activated alpha(s) (alpha(s)-R201C) turns over rapidly, compared with palmitate linked to normal alpha(s) (t(1/2) approximate to 2 min versus 90 min); although alpha(s)-R201C (unlike normal alpha(s)) is predominantly found in the cytosol, [3H]palmitate is linked only to the membrane-bound pool of alpha(s), normal or mutant. Similarly, activation of wild-type alpha(s) by isoproterenol, a beta-adrenoceptor agonist that also induces membrane-to-cytosol translocation of alpha(s), dramatically accelerates depalmitoylation of alpha(s). Thus, activation-induced removal of palmitate provides an explanation for activation-induced shifts of alpha(s) to the cytosol. Regulated palmitoylation cycles provide a potential general mechanism for controlling reversible changes in the cellular location and activity of a protein.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	WEDEGAERTNER, PB (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOURNE HR, 1981, MOL PHARMACOL, V20, P435; CAMP LA, 1993, J BIOL CHEM, V268, P22566; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; Grassie Morag A., 1993, Biochemical Society Transactions, V21, p499S; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOCHEN A, 1991, BIOCHEM BIOPH RES CO, V177, P797, DOI 10.1016/0006-291X(91)91859-B; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE E, 1992, J BIOL CHEM, V267, P1212; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NEGISHI M, 1992, J BIOL CHEM, V267, P2367; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PIMLIKAR SW, 1993, NATURE, V362, P456; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; SALOMON MR, 1981, MOL PHARMACOL, V19, P109; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	35	321	321	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1063	1070		10.1016/0092-8674(94)90445-6	http://dx.doi.org/10.1016/0092-8674(94)90445-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	7912657				2022-12-28	WOS:A1994NV42500014
J	GUINEE, VF; OLSSON, H; MOLLER, T; HESS, KR; TAYLOR, SH; FAHEY, T; GLADIKOV, JV; VANDENBLINK, JW; BONICHON, F; DISCHE, S; YATES, JW; CLETON, FJ				GUINEE, VF; OLSSON, H; MOLLER, T; HESS, KR; TAYLOR, SH; FAHEY, T; GLADIKOV, JV; VANDENBLINK, JW; BONICHON, F; DISCHE, S; YATES, JW; CLETON, FJ			EFFECT OF PREGNANCY ON PROGNOSIS FOR YOUNG-WOMEN WITH BREAST-CANCER	LANCET			English	Article							AGE; SURVIVAL; CARCINOMA	Breast cancer in women under 30 years old carries a poor prognosis, for reasons that have not been identified. This study aimed to identify prognostic factors in this age group. Special attention was paid to the history of pregnancy. The clinical presentation and course of breast cancer was documented for 407 women, aged 20-29 years, who registered between 1978 and 1988 at one of nine cancer centres. Eligible patients had histologically confirmed local or regional invasive breast carcinoma, and received part or all of their initial therapy at the participating hospital. For patients whose breast cancers were diagnosed during pregnancy, the risk of dying from breast cancer was significantly greater than that of women who had never been pregnant (relative risk 3.26 [95% Cl 1.81-5.87], p = 0.0004). Adjustment for number of axillary nodes affected and tumour diameter reduced the relative risk only slightly (2.83 [1.24-6.45], p = 0.023). For each 1-year increment in the time between the latest previous pregnancy and breast cancer diagnosis, the risk of dying decreased by 15% (relative risk 0.85, p = 0.011). Thus concurrent or recent previous pregnancy adversely affects survival of breast cancer in young women. The size of the effect is such that it probably contributes substantially to the poor prognosis of breast cancer in this age group as a whole.	UNIV LUND HOSP,S-22185 LUND,SWEDEN; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; RUSSIAN ACAD MED SCI,CANC RES CTR,MOSCOW,RUSSIA; DR DANIEL DEN HOED CANC CTR,3008 AE ROTTERDAM,NETHERLANDS; FDN BERGONIE,F-33076 BORDEAUX,FRANCE; MT VERNON HOSP,REG CTR RADIOTHERAPY & ONCOL,NORTHWOOD,MIDDX,ENGLAND; ROSWELL PK CANC INST,BUFFALO,NY; LEIDEN UNIV HOSP,LEIDEN,NETHERLANDS	Lund University; Skane University Hospital; Memorial Sloan Kettering Cancer Center; Russian Academy of Medical Sciences; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; UNICANCER; Institut Bergonie; Roswell Park Cancer Institute; Leiden University; Leiden University Medical Center (LUMC)	GUINEE, VF (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATIENT STUDIES,1515 HOLCOMBE BLVD,BOX 214,HOUSTON,TX 77030, USA.		Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070; Olsson, Hakan/0000-0002-8794-9635				ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; Clark R M, 1989, Clin Oncol (R Coll Radiol), V1, P11, DOI 10.1016/S0936-6555(89)80004-4; DELAROCHEFORDIERE A, 1993, LANCET, V341, P1039, DOI 10.1016/0140-6736(93)92407-K; FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3; HOLLEB AI, 1962, SURG GYNECOL OBSTET, V115, P65; HOST H, 1986, CANCER-AM CANCER SOC, V57, P2217, DOI 10.1002/1097-0142(19860601)57:11<2217::AID-CNCR2820571124>3.0.CO;2-T; MOHLEBOETANI J, 1986, NEW ENGL J MED, V315, P587; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; NOYES RD, 1982, CANCER, V49, P1302, DOI 10.1002/1097-0142(19820315)49:6<1302::AID-CNCR2820490638>3.0.CO;2-0; NUGENT P, 1985, ARCH SURG-CHICAGO, V120, P1221; PETERS MV, 1965, PROG CLIN CANCER, V1, P471; PETREK JA, 1991, CANCER-AM CANCER SOC, V67, P869, DOI 10.1002/1097-0142(19910215)67:4<869::AID-CNCR2820670402>3.0.CO;2-Q; RIBEIRO G, 1986, BRIT J SURG, V73, P607, DOI 10.1002/bjs.1800730805; TRETLI S, 1988, BRIT J CANCER, V58, P382, DOI 10.1038/bjc.1988.224; ZEMLICKIS D, 1992, AM J OBSTET GYNECOL, V166, P781, DOI 10.1016/0002-9378(92)91334-7; 1990, DHHS PHS90100 PUB; 1988, VITAL STATISTICS US, V1, P7	17	147	150	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1587	1589						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911917				2022-12-28	WOS:A1994NU35400007
J	MAKITA, Z; BUCALA, R; RAYFIELD, EJ; FRIEDMAN, EA; KAUFMAN, AM; KORBET, SM; BARTH, RH; WINSTON, JA; FUH, H; MANOGUE, KR; CERAMI, A; VLASSARA, H				MAKITA, Z; BUCALA, R; RAYFIELD, EJ; FRIEDMAN, EA; KAUFMAN, AM; KORBET, SM; BARTH, RH; WINSTON, JA; FUH, H; MANOGUE, KR; CERAMI, A; VLASSARA, H			REACTIVE GLYCOSYLATION ENDPRODUCTS IN DIABETIC UREMIA AND TREATMENT OF RENAL-FAILURE	LANCET			English	Article							END-PRODUCTS; GROWTH-FACTOR; MODIFIED PROTEINS; COMPLICATIONS; COLLAGEN; DISEASE; TISSUE	In diabetes and ageing, glucose-derived advanced glycosylation endproducts (AGEs) cross-link proteins and cause vascular tissue damage. Elimination of circulating low-molecular weight AGE-modified molecules (LMW-AGEs) by the kidney is impaired in diabetic patients with end-stage renal disease, a group subject to accelerated atherosclerosis. We determined the effectiveness of current renal replacement treatments on elimination of serum LMW-AGEs in diabetic and non-diabetic patients with end-stage renal disease. Although diabetic patients receiving high-flux haemodialysis achieved 33% lower steady-state serum LMW-AGE than did those in conventional haemodialysis (p<0.005), LMW-AGE concentrations remained 3.5-6 fold above normal, whether high-flux dialysis, conventional haemodialysis, or chronic ambulatory peritoneal dialysis were used. High-flux haemodialysis markedly reduced AGE during each treatment session (47.9% in the diabetic, p<0.001 and 60.6% in the non-diabetic group, p<0.001) but concentrations returned to pre-treatment range within 3 hours. In contrast, normal LMW-AGE concentrations were maintained in patients with functioning renal transplants. We found that LMW-AGEs with an apparent molecular weight of 2000-6000 circulate and retain strong inherent chemical reactivity-when exposed to collagen in vitro, up to 77% attached covalently to form AGE-collagen, and the AGE-crosslink inhibitor aminoguanidine completely inhibited this reaction. The results suggest that LMW-AGEs comprise a set of chemically-reactive molecules that are refractory to removal by current dialysis treatments. Through covalent reattachment onto vascular matrix or serum components, LMW-AGEs may exacerbate vascular pathology associated with end-stage renal disease.	PICOWER INST MED RES, MANHASSET, NY 11030 USA; SUNY HOSP, DOWNSTATE MED CTR, DEPT MED, DIV RENAL DIS, NEW YORK, NY USA; BETH ISRAEL HOSP, MED CTR, NEW YORK, NY USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL 60612 USA; SUNY, DEPT VET AFFAIRS MED CTR, NEW YORK, NY USA; MT SINAI MED CTR, NEW YORK, NY USA	Northwell Health; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Rush University; State University of New York (SUNY) System; SUNY Community College; SUNY Maritime College; SUNY Optometry; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE ON AGING [R01AG009453] Funding Source: NIH RePORTER; NIA NIH HHS [AG-9453] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; BUCALA R, 1993, DIABETES, V42, pA119; BUCALA R, 1992, ADV GLYCOSYLATION EN, V2, P53; BUCALA R, 1993, AGE MODIFIED LDL AGE, P16; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FRIEDMAN EA, 1992, DIABETES SPECTRUM, V5, P6; FUH H, 1992, DIABETES, V41, pA9; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; LEVIN NW, 1991, J AM SOC NEPHROL, V1, P1055; LOWRIE EG, 1983, KIDNEY INT, pS113; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; RADOFF S, 1991, DIABETES, V40, P1731, DOI 10.2337/diabetes.40.12.1731; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; VLASSARA H, 1994, J LAB INVEST, V70, P138; 1992, USRDS1992 NAT I DIAB; 1985, WHO TECHNICAL REPORT, P727	24	349	354	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	1994	343	8912					1519	1522		10.1016/S0140-6736(94)92935-1	http://dx.doi.org/10.1016/S0140-6736(94)92935-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911868				2022-12-28	WOS:A1994NR32900005
J	AYLETT, MJ; CREIGHTON, P; JACHUCK, S; NEWRICK, D; EVANS, A				AYLETT, MJ; CREIGHTON, P; JACHUCK, S; NEWRICK, D; EVANS, A			WITHDRAWING ANTIHYPERTENSIVE DRUGS	LANCET			English	Letter							BRITISH-HYPERTENSION-SOCIETY; WORKING PARTY				AYLETT, MJ (corresponding author), GLENDALE SURG, STOSH PROJECT, WOOLER NE71 6DN, NORTHD, ENGLAND.							[Anonymous], 1991, Arch Intern Med, V151, P1413; AYLETT M, 1991, BRIT MED J, V303, P345, DOI 10.1136/bmj.303.6798.345; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SWALES JD, 1989, BMJ-BRIT MED J, V298, P694; VANDENBOSCH WJHM, 1994, LANCET, V343, P1157, DOI 10.1016/S0140-6736(94)90260-7	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	1994	343	8911					1512	1512		10.1016/S0140-6736(94)92625-5	http://dx.doi.org/10.1016/S0140-6736(94)92625-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911219				2022-12-28	WOS:A1994NQ41500059
J	SMARR, LE				SMARR, LE			MALPRACTICE CLAIMS - DOES THE PAST PREDICT THE FUTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SMARR, LE (corresponding author), PHYSICIAN INSURERS ASSOC AMER,1130 CONNECTICUT AVE NW,SUITE 800,WASHINGTON,DC 20036, USA.							BOVBJERG RR, 1994, JAMA-J AM MED ASSOC, V272, P1421, DOI 10.1001/jama.272.18.1421; KUEHN R, 1992, REV SELECTED RES PAP, P15; 1992, GAOIMTEC9256 US GEN, P1; 1992, NATIONAL PRACTITIONE; 1993, 11 PHYS INS ASS AM R, P1; 1993, 1314 PHYS INS ASS AM; 1993, NATIONAL PRACTITIONE	7	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1453	1454						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP690	7933429				2022-12-28	WOS:A1994PP69000035
J	AUBUCHON, JP; BIRKMEYER, JD				AUBUCHON, JP; BIRKMEYER, JD			SAFETY AND COST-EFFECTIVENESS OF SOLVENT-DETERGENT-TREATED PLASMA - IN SEARCH OF A ZERO-RISK BLOOD-SUPPLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FRESH-FROZEN PLASMA; ARTERY BYPASS-SURGERY; TRANSFUSION; HEPATITIS; INACTIVATION; INFECTION; DERIVATIVES; COMPONENTS; HIV	Objective.-To determine the public health and economic implications of Solvent-detergent-treated frozen plasma (SD FP). While this processing technique nearly eliminates the risk of transmitting lipid-enveloped viruses (hepatitis B and C and human immunodeficiency virus), it has associated costs and, because it requires pooling many plasma units, may increase risks of nonenveloped virus transmission. Design.-A previously published Markov decision analysis model was modified to assess transfusion-related outcomes in hypothetical cohorts of plasma recipients. In-hospital mortality and other characteristics were determined in 61 patients receiving plasma transfusions at a medium-sized tertiary care center to provide data for the model. Other parameters were obtained from the medical literature. Main Outcome Measures.-Expected SD FP costs, benefits, and cost-effectiveness, assessed as cost per quality-adjusted life-year saved. Results.-Compared with untreated plasma, a unit of SD FP produces a net benefit of 35 minutes in quality-adjusted life expectancy at a cost of about $19. Extrapolated to the 2.2 million plasma units transfused annually in the United States, SD FP would save 147 quality-adjusted life-years at a cost of $42.5 million. The marginal cost-effectiveness, $289 300 per quality-adjusted life-year saved in the baseline analysis, was most sensitive to estimates of SD treatment cost and the clinical setting of plasma use. In sensitivity analysis, the net benefit of SD FP was negated by the existence of even a minute risk of nonenveloped virus infection. Conclusions.-From a public health perspective, the relatively high costs and small benefits of reducing enveloped virus infection risks with SD FP (and the additional risks of nonenveloped virus transmission) do not appear to justify widespread implementation of this new technology.	DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT SURG,LEBANON,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,CTR EVALUAT CLIN SCI,LEBANON,NH 03756	Dartmouth College; Dartmouth College	AUBUCHON, JP (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT PATHOL,1 MED CTR DR,LEBANON,NH 03756, USA.							ANDERSON LJ, 1991, CURR CLIN TOP INFECT, V11, P261; ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; AUBUCHON JP, 1992, CLIN LAB MED, V12, P787, DOI 10.1016/S0272-2712(18)30488-8; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BOWDEN RA, 1991, BLOOD, V78, P246; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; COHEN BJ, 1990, J VIROL METHODS, V30, P233, DOI 10.1016/0166-0934(90)90065-N; CONTRERAS M, 1991, LANCET, V337, P753, DOI 10.1016/0140-6736(91)91370-A; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DODD RY, 1990, TRANSFUSION MEDICINE IN THE 1990S, P223; DONAHUE JG, 1992, NEW ENGL J MED, V327, P869; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EDWARDS CA, 1987, VOX SANG, V52, P53, DOI 10.1111/j.1423-0410.1987.tb02989.x; EVANS RW, 1986, SURG CLIN N AM, V66, P603; GERITZEN A, 1992, LANCET, V340, P1231; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HELLSTERN P, 1992, VOX SANG, V63, P178, DOI 10.1111/j.1423-0410.1992.tb05097.x; HOROWITZ B, 1990, YALE J BIOL MED, V63, P361; HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x; HOROWITZ B, 1992, BLOOD, V79, P826; HOROWITZ B, 1985, TRANSFUSION, V25, P523, DOI 10.1046/j.1537-2995.1985.25686071423.x; HOROWITZ B, 1994, MAR FDA WORKSH ROL V; LEFRERE JJ, 1994, LANCET, V343, P211, DOI 10.1016/S0140-6736(94)90993-8; LEUSCHNER J, 1994, MAR FDA WORKSH ROL V; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MENITOVE JE, 1990, ARCH PATHOL LAB MED, V114, P330; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; PIET MPJ, 1990, TRANSFUSION, V30, P591, DOI 10.1046/j.1537-2995.1990.30790385516.x; PIQUET Y, 1992, VOX SANG, V63, P251, DOI 10.1111/j.1423-0410.1992.tb01230.x; SHANBERGE JN, 1992, TRANSFUSION MED, V2, P189, DOI 10.1111/j.1365-3148.1992.tb00154.x; SIMON TL, 1992, CLIN LAB MED, V12, P655, DOI 10.1016/S0272-2712(18)30479-7; SONNENBERG FA, 1988, 11TH P ANN S COMP AP; STANGE PV, 1978, NEW ENGL J MED, V298, P372, DOI 10.1056/NEJM197802162980705; SURGENOR D, 1994, MAR FDA WORKSH ROL V; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; Weinstein MC, 1980, CLIN DECISION ANAL; WIEDING JU, 1993, ANN HEMATOL, V67, P259, DOI 10.1007/BF01696345; ZUCK TF, 1987, TRANSFUSION, V27, P447, DOI 10.1046/j.1537-2995.1987.27688071691.x; 1989, MMWR-MORBID MORTAL W, V38, P91; 1987, VITAL STATISTICS U A, V2, P8; 1991, MMWR-MORBID MORTAL W, V40, P1	51	64	64	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1210	1214		10.1001/jama.272.15.1210	http://dx.doi.org/10.1001/jama.272.15.1210			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933351				2022-12-28	WOS:A1994PL21200037
J	BESSER, RE; FEIKIN, DR; EBERHARTPHILLIPS, JE; MASCOLA, L; GRIFFIN, PM				BESSER, RE; FEIKIN, DR; EBERHARTPHILLIPS, JE; MASCOLA, L; GRIFFIN, PM			DIAGNOSIS AND TREATMENT OF CHOLERA IN THE UNITED-STATES - ARE WE PREPARED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To assess cholera recognition and treatment by US health care workers in the largest cholera outbreak in the United States this century. Design.-We reviewed the medical records of passengers from a flight on which a cholera outbreak occurred. To determine the availability of oral rehydration solutions, we surveyed treatment facilities and referral pharmacies. Setting.-On February 14, 1992, more than 100 passengers on a flight from South America to Los Angeles, Calif, were infected with toxigenic Vibrio cholerae 01. Subjects.-Fifty-four of 67 passengers who sought care in California and Nevada. Results.-We reviewed the records of 54 passengers, including 39 with diarrhea and 15 without symptoms. All 17 persons who sought treatment before the outbreak was widely reported by the media had diarrhea. For 12 of these persons, recent travel to South America was noted, but only those four whose records listed cholera as a possible diagnosis were immediately hospitalized. Seven sought cars again within 3 days; three were dehydrated, two of these three were hospitalized, and one of these two died. None of the 26 patients suspected to have cholera received appropriate fluids; severely dehydrated patients did not receive Ringer's lactate solution and those not severely dehydrated did not receive an oral rehydration solution. None of the facilities and pharmacies involved stocked World Health Organization oral rehydration salts solution, the preferred solution for treating cho!era and other diarrheal diseases. Conclusions.-Treatment of cholera in the United States was suboptimal. Oral fluids appropriate for the treatment of cholera and other diarrheal diseases were generally unavailable. Widespread cholera in the developing world means that US physicians should be prepared to treat ''imported'' cases. Physicians evaluating patients with diarrhea should obtain a travel history, should consider cholera in patients returning from countries with endemic or epidemic cholera, and should instruct patients in appropriate use of World Health Organization oral rehydration salts solution or other oral rehydration solutions containing 75 to 90 mmol/L of sodium. Pharmacies and medical facilities should stock these solutions.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30341; CTY LOS ANGELES DEPT HLTH SERV,LOS ANGELES,CA; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								MAHALANABIS D, 1992, CHOLERA, P266; SWERDLOW DL, 1992, JAMA-J AM MED ASSOC, V267, P1495, DOI 10.1001/jama.267.11.1495; 1991, WHOSER9115 PROGR CON, P1; 1993, MMWR MORN MORTAL WKL, V42, P89; 1991, MMWR-MORBID MORTAL W, V40, P562; 1990, WHOSER802 PROGR CONT; 1992, MMWR-MORBID MORTAL W, V41, P1	7	22	23	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1203	1205		10.1001/jama.272.15.1203	http://dx.doi.org/10.1001/jama.272.15.1203			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933349				2022-12-28	WOS:A1994PL21200035
J	SUGAYA, N; NEROME, K; ISHIDA, M; MATSUMOTO, M; MITAMURA, K; NIRASAWA, M				SUGAYA, N; NEROME, K; ISHIDA, M; MATSUMOTO, M; MITAMURA, K; NIRASAWA, M			EFFICACY OF INACTIVATED VACCINE IN PREVENTING ANTIGENICALLY DRIFTED INFLUENZA TYPE-A AND WELL-MATCHED TYPE-B	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN; VIRUS; ADULTS	Objective.-To evaluate the efficacy of currently used inactivated influenza vaccine during a severe epidemic caused by antigenically drifted influenza type A(H3N2) and well-matched type B viruses during the 1992-1993 season. Design.-Prospective nonrandomized controlled trial. Setting.-An urban general hospital pediatric asthma clinic in Japan. Participants.-A total of 137 children with moderate to severe asthma (mean age, 7.0 years; range, 2 to 14 years). Interventions.-Eighty-five children received trivalent split-antigen vaccine containing A/Beijing/352/89 (H3N2) and B/Bangkok/163/90 (B/Panama/45/90-like strain). Fifty-two were unvaccinated. Main Outcome Measures.-Protection against infection was determined using hemagglutination inhibition test and virus isolation. Clinical efficacy was estimated based on febrile episodes with antibody rise or virus isolation. Results.-Although marked antigenic drift in hemagglutinin was demonstrated in the epidemic virus (A/Beijing/32/92-like strain), the protection against influenza type A(H3N2) infection was 67.5% (P<.01). The protection against influenza type B infection was 43.7% (P<.01), although the epidemic influenza type B viruses were antigenically almost identical to the vaccine strain. Inactivated vaccine was not effective for protection against influenza type B infection in children younger than 7 years. High clinical effectiveness was demonstrated in children at least 7 years of age during the epidemic. Conclusions.-Our data suggest that current inactivated vaccine is highly effective for protection against influenza type A(H3N2) virus infection regardless of antigenic drift. In contrast, the protective efficacy obtained by vaccination may not be sufficient against influenza type B virus infection, and especially in young children, it does not offer protection.	NATL INST HLTH,DEPT VIROL & RICKETTSIOL,TOKYO 141,JAPAN	National Institute of Health Sciences - Japan	SUGAYA, N (corresponding author), NIPPON KOKAN LTD CO HOSP,DEPT PEDIAT,KAWASAKI KU,1-2-1 KOKANDORI,KAWASAKI,KANAGAWA 210,JAPAN.							DOWDLE WR, 1980, J INFECT DIS, V141, P288; FEERY BJ, 1978, J HYG-CAMBRIDGE, V81, P331, DOI 10.1017/S0022172400025201; FOX JP, 1982, AM J EPIDEMIOL, V116, P28; FOY HM, 1981, J INFECT DIS, V143, P700, DOI 10.1093/infdis/143.5.700; GROSS PA, 1977, J INFECT DIS, V136, P623, DOI 10.1093/infdis/136.5.623; GRUBER WC, 1993, J INFECT DIS, V168, P53, DOI 10.1093/infdis/168.1.53; HEILMAN C, 1990, PEDIATR CLIN N AM, V37, P669; KANEGAE Y, 1990, J VIROL, V64, P2860, DOI 10.1128/JVI.64.6.2860-2865.1990; MEIKLEJOHN, 1978, J INFECT DIS, V138, P618; MONTO AS, 1970, J INFECT DIS, V122, P16, DOI 10.1093/infdis/122.1-2.16; OYA A, 1986, OPTIONS CONTROL INFL, P183; RUDENKO LG, 1993, J INFECT DIS, V168, P881, DOI 10.1093/infdis/168.4.881; STIVER HG, 1973, NEW ENGL J MED, V289, P1267, DOI 10.1056/NEJM197312132892402; SUGAYA N, 1992, J INFECT DIS, V165, P373, DOI 10.1093/infdis/165.2.373; WRIGHT PF, 1980, J INFECT DIS, V141, P430, DOI 10.1093/infdis/141.4.430; WRIGHT PF, 1993, OPTIONS CONTROL INFL, P71; 1993, MMWR-MORBID MORTAL W, V42, P385	17	103	112	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1122	1126		10.1001/jama.272.14.1122	http://dx.doi.org/10.1001/jama.272.14.1122			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK124	7933325				2022-12-28	WOS:A1994PK12400032
J	ALTOMARE, DF; REGINA, G; LOVREGLIO, R; MEMEO, V				ALTOMARE, DF; REGINA, G; LOVREGLIO, R; MEMEO, V			ACETYLCHOLINE SWEAT TEST - AN EFFECTIVE WAY TO SELECT PATIENTS FOR LUMBAR SYMPATHECTOMY	LANCET			English	Article								Although lumbar sympathectomy can benefit patients with critical limb ischaemia, many derive no benefit from the procedure. The poor prediction of outcome may be related to pre-existing damage to the sympathetic fibres. We assessed sympathetic nerve function with the acetylcholine sweatspot test before and after lumber sympathectomy in 31 patients with critical limb ischaemia. Of 9 patients with normal sympathetic function or minor denervation preoperatively (sweatspot score greater than or equal to 8), 8 showed improvement in pain and/or healing of ischaemic lesions after sympathectomy. The procedure did not achieve denervation in the patient without improvement, as shown by persisting sympathetic activity postoperatively. By contrast, among the 22 patients with lower sweatspot scores, indicating severe or complete sympathetic denervation, only 1 showed improvement (partial) after lumbar sympathectomy. 9 patients underwent oximetry before and after the operation; in this subgroup there was a positive correlation between preoperative sweatspot score and the change in tissue partial pressure of oxygen (r(2)=0.35). Preoperative assessment of sympathetic nerve function by means of a sensitive, quantitative test of autonomic integrity can predict the outcome of the procedure with high sensitivity and specificity. A postoperative test allows verification of sympathetic denervation. We recommend use of this simple test in selecting patients for lumbar sympathectomy.	UNIV BARI,CATTEDRA CHIRURG VASC,I-70124 BARI,ITALY; UNIV BARI,DERMATOL CLIN,I-70124 BARI,ITALY	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	ALTOMARE, DF (corresponding author), UNIV BARI,IST CLIN CHIRURG,CATTEDRA METODOL CLIN,PIAZZA G CESARE 11,I-70124 BARI,ITALY.			Altomare, Donato Francesco/0000-0001-8980-2752				ALTOMARE D, 1992, GUT, V33, P1539, DOI 10.1136/gut.33.11.1539; BAKER DM, 1993, BR J SURG S, V80, pA666; BROTHERS TE, 1993, SURGERY, V113, P433; COTTON LT, 1985, BRIT J SURG, V72, P678, DOI 10.1002/bjs.1800720903; IMPARATO AM, 1979, SURG CLIN N AM, V59, P719; KIM GE, 1976, ANN SURG, V183, P157, DOI 10.1097/00000658-197602000-00012; LINDENAUER SM, 1982, BRIT J SURG S, V69, P32; MORGAN RH, 1989, BRIT J SURG, V76, pA1340; PERSSON AV, 1985, SURG CLIN N AM, V65, P393; PLECHA FR, 1980, SURGERY, V88, P375; RYDER REJ, 1988, LANCET, V1, P1303, DOI 10.1016/S0140-6736(88)92120-4; SEEGER JM, 1977, AM J SURG, V134, P749, DOI 10.1016/0002-9610(77)90316-6; SMITHWICK RH, 1957, SURGERY, V42, P415; SZILAGYI DE, 1967, ARCH SURG-CHICAGO, V95, P753; WALKER PM, 1980, SURGERY, V87, P216; YAO JST, 1973, ARCH SURG-CHICAGO, V107, P676	16	6	6	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					976	978		10.1016/S0140-6736(94)91639-X	http://dx.doi.org/10.1016/S0140-6736(94)91639-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934428				2022-12-28	WOS:A1994PK97800007
J	TIRET, L; BONNARDEAUX, A; POIRIER, O; RICARD, S; MARQUESVIDAL, P; EVANS, A; ARVEILER, D; LUC, G; KEE, F; DUCIMETIERE, P; SOUBRIER, F; CAMBIEN, F				TIRET, L; BONNARDEAUX, A; POIRIER, O; RICARD, S; MARQUESVIDAL, P; EVANS, A; ARVEILER, D; LUC, G; KEE, F; DUCIMETIERE, P; SOUBRIER, F; CAMBIEN, F			SYNERGISTIC EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME AND ANGIOTENSIN-II TYPE-1 RECEPTOR GENE POLYMORPHISMS ON RISK OF MYOCARDIAL-INFARCTION	LANCET			English	Article							INSERTION DELETION POLYMORPHISM; CORONARY HEART-DISEASE; EXPRESSION; CARDIOMYOPATHY; GENOTYPE; HISTORY; CELLS	We reported from our previous multicentre case-control study that the deletion (D) polymorphism of the gene encoding angiotensin-converting enzyme (ACE) was associated with increased risk of myocardial infarction. The main function of ACE is to convert angiotensin I into angiotensin II, which exerts its known cellular actions through the angiotensin II AT(1) receptor subtype (AGT(1)R). We have now investigated the role of a common polymorphism of the AT(1) receptor gene (an A-->C transversion at position 1166 of AGT(1)R) and looked for an interaction between ACE and AGT(7)R gene polymorphisms on the risk of myocardial infarction. We analysed DNA from 613 patients with myocardial infarction and 723 age-matched population controls. We found a significant interaction between ACE and AGT(1)R gene polymorphisms; the odds ratio for myocardial infarction associated with the ACE DD genotype was 1.05 (95% Cl 0.75-1.49) for subjects without the AGT(1)R C allele, 1.52 (1.06-2.18) in AC heterozygotes, and 3.95 (1.26-12.4) in CC homozygotes (test for trend, p<0.02). Among patients defined as low risk by traditional risk factors (serum apolipoprotein B <1.25 g/L, body-mass index <26 kg/m(2)) the interaction was even stronger (odds ratios 1.64 [0.68-3.92], 7.03 [2.61-19.0], and 13.3 [p=0.05], respectively). These findings, if confirmed, could have clinical implications for the prevention and treatment of coronary heart disease.	INSERM,SC7,F-75005 PARIS,FRANCE; INSERM,U258,PARIS,FRANCE; INSERM,U36,PARIS,FRANCE; MONICA PROJECT,HAUTE GARONNE,FRANCE; MONICA PROJECT,BELFAST,ANTRIM,NORTH IRELAND; MONICA PROJECT,BAS RHIN,FRANCE; MONICA PROJECT,LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Marques-Vidal, Pedro M/C-9449-2009	Marques-Vidal, Pedro M/0000-0002-4548-8500				BOHN M, 1993, CLIN GENET, V44, P298; BOHN M, 1993, CLIN GENET, V44, P292; BONITHONKOPP C, 1994, CIRCULATION, V89, P952, DOI 10.1161/01.CIR.89.3.952; BONNARDEAUX A, 1994, HYPERTENSION, V24, P63, DOI 10.1161/01.HYP.24.1.63; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DANSER AHJ, 1992, AM J PHYSIOL, V263, pH418, DOI 10.1152/ajpheart.1992.263.2.H418; EVANS AE, 1994, Q J MED, V87, P211; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; KEE F, 1993, BRIT MED J, V307, P1528, DOI 10.1136/bmj.307.6918.1528; KREUTZ R, 1993, CIRCULATION, V88, P510; LUDWIG EH, 1993, CIRCULATION, V88, P364; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; OHISHI M, 1993, NAT GENET, V5, P324, DOI 10.1038/ng1293-324; PARRA HJ, 1992, ARTERIOSCLER THROMB, V12, P701, DOI 10.1161/01.ATV.12.6.701; PAXTON WG, 1993, AM J PHYSIOL, V264, pF989, DOI 10.1152/ajprenal.1993.264.6.F989; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; RUIZ J, 1994, P NATL ACAD SCI USA, V91, P3662, DOI 10.1073/pnas.91.9.3662; SCHEIFFER B, 1994, CIRCULATION, V89, P2273; SHUNKERT H, 1994, NEW ENGL J MED, V330, P1634; TAKAYANAGI R, 1992, BIOCHEM BIOPH RES CO, V183, P910, DOI 10.1016/0006-291X(92)90570-B; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TIRET L, 1992, AM J HUM GENET, V51, P197; TIRET L, 1993, LANCET, V341, P991, DOI 10.1016/0140-6736(93)91075-W; Zhao Y, 1994, HYPERTENS RES, V17, P55	30	400	425	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					910	913		10.1016/S0140-6736(94)92268-3	http://dx.doi.org/10.1016/S0140-6736(94)92268-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934345	Green Submitted			2022-12-28	WOS:A1994PJ28700009
J	ASHTON, LJ; LEARMONT, J; LUO, K; WYLIE, B; STEWART, G; KALDOR, JM				ASHTON, LJ; LEARMONT, J; LUO, K; WYLIE, B; STEWART, G; KALDOR, JM			HIV-INFECTION IN RECIPIENTS OF BLOOD PRODUCTS FROM DONORS WITH KNOWN DURATION OF INFECTION	LANCET			English	Note							TRANSFUSION; AIDS; AUSTRALIA; PEOPLE	From a registry of people with transfusion-acquired HIV infection, 25 recipients were identified for whom the dates of HIV infection in the 8 corresponding donors could be established. Longer times to AIDS and to death in recipients were independently associated (p<0.01) with the receipt of blood from donors who developed AIDS more than 10 years after HIV infection, as well as with older age and fewer transfusions. Sex, zidovudine treatment, and severity of illness at transfusion were not significantly associated with survival.	UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW 2010,AUSTRALIA; NEW S WALES RED CROSS,BLOOD TRANSFUS SERV,SYDNEY,NSW,AUSTRALIA; WESTMEAD HOSP,DEPT IMMUNOPATHOL,WESTMEAD,NSW 2145,AUSTRALIA	University of New South Wales Sydney; Kirby Institute; Australian Red Cross Blood Service; University of Sydney			Wylie, Bruce/H-3182-2014; Kaldor, John M/D-4545-2011	Wylie, Bruce/0000-0002-7374-1083; 				BLAXHULT A, 1990, AIDS, V4, P125, DOI 10.1097/00002030-199002000-00005; KALDOR J, 1993, MED J AUSTRALIA, V158, P10, DOI 10.5694/j.1326-5377.1993.tb121640.x; KOPECSCHRADER E, 1993, AIDS, V7, P1009, DOI 10.1097/00002030-199307000-00016; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; SWANSON CE, 1990, AIDS, V4, P749, DOI 10.1097/00002030-199008000-00006; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406	6	25	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					718	720		10.1016/S0140-6736(94)92210-1	http://dx.doi.org/10.1016/S0140-6736(94)92210-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915778				2022-12-28	WOS:A1994PF18700012
J	WILKINSON, P; LAJI, K; RANJADAYALAN, K; PARSONS, L; TIMMIS, AD				WILKINSON, P; LAJI, K; RANJADAYALAN, K; PARSONS, L; TIMMIS, AD			ACUTE MYOCARDIAL-INFARCTION IN WOMEN - SURVIVAL ANALYSIS IN FIRST 6 MONTHS	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; DISEASE; MEN	Objective-To examine the influence that being female has on the outcome of acu Design-Observational follow up study. Setting-London district general hospital. Patients-216 women and 607 men with acute myocardial infarction admitted to a coronary care unit from 1 January 1988 to 31 December 1992. Main outcome measures-All cause mortality and recurrent ischaemic events in the first six months. Results-Event free survival (95% confidence interval) at six months was 63.3% (56.3% to 69.4%) in women and 76.1% (72.4% to 79.4%) in men, P < 0.001. The difference was confined to the first 30 days but thereafter the hazard plots for women and men converged, with reduction of the hazard ratio from 2.36 (1.70 to 3.27) to 0.81 (0.44 to 1.48). Women were older, but their excess risk persisted after adjustment for age, other baseline variables, and indices of severity of infarction (hazard ratio 1.53 (1.09 to 2.15), P = 0.015). Women tended to be treated with thrombolysis less commonly than men but the difference was small. Substantially fewer women than men, however, were discharged taking beta blockers (23.3% v 41.4%, P < 0.001), and although additional adjustment for discharge treatment did not further reduce the point estimate of the hazard ratio (1.84 (0.89-3.83)), the 95% confidence interval was wide and statistical significance was lost. Conclusions-Women with acute myocardial infarction have a worse prognosis than men but the excess risk is confined to the first 30 days and is only partly explained by age and other baseline variables. The tendency for women to receive less vigorous treatment than men must be remedied before gender can be considered to be an independent determinant of risk.	LONDON CHEST HOSP, DEPT CARDIOL, LONDON E2 9JX, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT ENVIRONM EPIDEMIOL, LONDON WC1E 7HT, ENGLAND; NEWHAM DIST GEN HOSP, DEPT CARDIOL, LONDON E13 8SL, ENGLAND; CITY HLTH AUTHOR, LONDON E3 2AN, ENGLAND; DEPT PUBL HLTH MED, LONDON, ENGLAND	University of London; Queen Mary University London; University of London; London School of Hygiene & Tropical Medicine				Wilkinson, Paul/0000-0001-7456-259X				AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; COX DR, 1972, J R STAT SOC B, V34, P187; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; KAHN SS, 1990, ANN INTERN MED, V112, P561; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; KEE F, 1993, BRIT MED J, V307, P1305, DOI 10.1136/bmj.307.6915.1305; LINCOFF AM, 1993, J AM COLL CARDIOL, V22, P1780, DOI 10.1016/0735-1097(93)90757-R; MAYNARD C, 1991, AM J CARDIOL, V68, P529, DOI 10.1016/0002-9149(91)90791-I; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; MURABITO JM, 1993, CIRCULATION, V88, P2548, DOI 10.1161/01.CIR.88.6.2548; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; TUNSTALLPEDOE H, 1975, LANCET, V2, P833; VARMA V K, 1992, Journal of the American College of Cardiology, V19, p20A; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1993, STATA REFERNECE MANU, V2, P100	20	68	69	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					566	569		10.1136/bmj.309.6954.566	http://dx.doi.org/10.1136/bmj.309.6954.566			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	7916229	Green Published			2022-12-28	WOS:A1994PF33000015
J	WULFF, HR				WULFF, HR			QUALITY-OF-LIFE AND TREATMENT FOR PROXIMAL DEEP-VEIN THROMBOSIS	LANCET			English	Editorial Material											WULFF, HR (corresponding author), HERLEV HOSP,DEPT MED C,HERLEV,DENMARK.							HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; NAYLOR CD, 1994, J CLIN EPIDEMIOL, V47, P987; OMEARA JJ, 1994, NEW ENGL J MED, V330, P117; RAWLES J, 1989, J MED ETHICS, V15, P143, DOI 10.1136/jme.15.3.143; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P199	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					420	421		10.1016/S0140-6736(94)91764-7	http://dx.doi.org/10.1016/S0140-6736(94)91764-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB761	7914561				2022-12-28	WOS:A1994PB76100004
J	FASSATI, A; TEDESCHI, S; BORDONI, A; AMBONI, P; CURCIO, C; BRESOLIN, N; SCARLATO, G				FASSATI, A; TEDESCHI, S; BORDONI, A; AMBONI, P; CURCIO, C; BRESOLIN, N; SCARLATO, G			RAPID DIRECT DIAGNOSIS OF DELETIONS CARRIERS OF DUCHENNE AND BECKER MUSCULAR-DYSTROPHIES	LANCET			English	Note							POLYMERASE CHAIN-REACTION; INTRAGENIC RECOMBINATION; GENE	13 families and 34 women at risk of being carriers of Duchenne and Becker muscular dystrophies were analysed blind by restriction fragment length polymorphisms (RFLPs) and a new, non-radioactive direct test based on competitive polymerase-chain-reaction (PCR) amplification. All obligate carriers were correctly diagnosed by RFLPs and competitive PCR, and 7 women with a 99% risk of being carriers were also diagnosed carriers by competitive PCR. There were no false positives or false negatives. Only 1 PCR result was non-informative. Our test allows rapid, precise, and direct carrier diagnosis of women whose relatives have a known deletion of the dystrophin gene.	UNIV MILAN,IST CLIN NEUROL,I-20122 MILAN,ITALY; IST CLIN PERFEZIONAMENTO,MILAN,ITALY	University of Milan	FASSATI, A (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT EXPTL PATHOL,LONDON BRIDGE,LONDON SE1 9RT,ENGLAND.		CURCIO, CRISTINA/D-3898-2011; CURCIO, CRISTINA/AAO-1488-2020	CURCIO, CRISTINA/0000-0001-9275-3242; Bresolin, Nereo/0000-0001-6694-3595				ABBS S, 1990, GENOMICS, V7, P602, DOI 10.1016/0888-7543(90)90205-9; ABBS S, 1992, J MED GENET, V29, P191, DOI 10.1136/jmg.29.3.191; BEGGS AH, 1990, HUM GENET, V86, P45; BEGGS AH, 1990, NUCLEIC ACIDS RES, V18, P1931, DOI 10.1093/nar/18.7.1931; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; LATHROP GM, 1984, AM J HUM GENET, V36, P460; OUDET C, 1991, AM J HUM GENET, V49, P311; ROBERTS RG, 1989, NUCLEIC ACIDS RES, V17, P811, DOI 10.1093/nar/17.2.811	10	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					302	303		10.1016/S0140-6736(94)91340-4	http://dx.doi.org/10.1016/S0140-6736(94)91340-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914263				2022-12-28	WOS:A1994NZ23300009
J	WEIGEL, D; MEYEROWITZ, EM				WEIGEL, D; MEYEROWITZ, EM			THE ABCS OF FLORAL HOMEOTIC GENES	CELL			English	Review							FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; MADS-BOX; TRANSCRIPTION FACTORS; ARABIDOPSIS-THALIANA; EXPRESSION; DEFICIENS; TRANSPOSON; DROSOPHILA; INITIATION		CALTECH, DIV BIOL 156-29, PASADENA, CA 91125 USA	California Institute of Technology	WEIGEL, D (corresponding author), SALK INST BIOL STUDIES, PLANT BIOL LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/C-1418-2008; Meyerowitz, Elliot M/A-7118-2009; Weigel, Detlef/AAR-3312-2021	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; 				ANGENENT GC, 1993, PLANT J, V4, P101, DOI 10.1046/j.1365-313X.1993.04010101.x; ANGENENT GC, 1994, PLANT J, V5, P33, DOI 10.1046/j.1365-313X.1994.5010033.x; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; CULLEN PF, 1990, J A ARBORETUM, V71, P179; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; GOTO K, 1994, IN PRESS GENES DEV; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JOFUKU KD, 1994, IN PRESS PLANT CELL; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MAHONEY PA, 1987, DEV BIOL, V122, P464, DOI 10.1016/0012-1606(87)90310-1; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; Masters MT., 1869, VEGETABLE TERATOLOGY; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1991, DEVELOPMENT, P157; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; MODRUSAN Z, 1994, PLANT CELL, V6, P333, DOI 10.1105/tpc.6.3.333; PNUELI L, 1994, PLANT CELL, V6, P175, DOI 10.1105/tpc.6.2.175; RAY A, 1994, P NATL ACAD SCI USA, V91, P5761, DOI 10.1073/pnas.91.13.5761; REINITZ J, 1990, DEV BIOL, V140, P57, DOI 10.1016/0012-1606(90)90053-L; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; VANDERKROL AR, 1993, GENE DEV, V7, P1214, DOI 10.1101/gad.7.7a.1214; von Goethe J. W., 1790, VERSUCH METAMORPHOSE; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	46	807	928	6	147	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					203	209		10.1016/0092-8674(94)90291-7	http://dx.doi.org/10.1016/0092-8674(94)90291-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	7913881				2022-12-28	WOS:A1994NZ24200005
J	BARRETO, ML; SANTOS, LMP; ASSIS, AMO; ARAUJO, MPN; FARENZENA, GG; SANTOS, PAB; FIACCONE, RL				BARRETO, ML; SANTOS, LMP; ASSIS, AMO; ARAUJO, MPN; FARENZENA, GG; SANTOS, PAB; FIACCONE, RL			EFFECT OF VITAMIN-A SUPPLEMENTATION ON DIARRHEA AND ACUTE LOWER-RESPIRATORY-TRACT INFECTIONS IN YOUNG-CHILDREN IN BRAZIL	LANCET			English	Article							A SUPPLEMENTATION; CHILDHOOD MORTALITY; SOUTHERN INDIA; XEROPHTHALMIA; MORBIDITY; NORTHEAST; EPISODES; PARAIBA; IMPACT; STATE	A beneficial effect of periodic Vitamin A supplementation on childhood mortality has been demonstrated, but the effect on morbidity is less clear. We investigated the effect of vitamin A supplementation on diarrhoea and acute lower-respiratoty-tract infections (ALRI) in children from northeastern Brazil in a randomised, double-blind, placebo-controlled community trial. 1240 children aged 6-48 months were assigned vitamin A or placebo every 4 months for 1 year. They were followed up at home three times a week, and data about the occurrence and severity of diarrhoea and ALRI were collected. Any child with cough and respiratory rate above 40 breaths per min was visited by a paediatrician. The overall incidence of diarrhoea episodes was significantly lower in the vitamin-A-supplemented group than in the placebo group (18.42 vs 19.58 x 10(-3) child-days; rate ratio 0.94 [95% Cl 0.90-0.9 8]). The benefit of supplementation was greater as regards severe episodes of diarrhoea; the incidence was 20% lower in the vitamin A group than in the placebo group (rate ratio 0.80 [0.65-0.98]). With the standard definition of diarrhoea (greater than or equal to 3 liquid or semi-liquid stools in 24 h) the effect of vitamin A on mean daily prevalence did not reach significance, but as the definition of diarrhoea was made more stringent (increasing number of stools per day), a significant benefit became apparent, reaching for diarrhoea with 6 or more liquid or semi-liquid stools in 24 h a 23% lower prevalence. We found no effect of vitamin A supplementation on the incidence of ALRI. The reduction in severity of diarrhoea may be the most important factor in the lowering of mortality by vitamin A supplementation.	UNIV FED BAHIA,DEPT NUTR SCI,SALVADOR,BA,BRAZIL; UNIV FED BAHIA,DEPT SURG,SALVADOR,BA,BRAZIL	Universidade Federal da Bahia; Universidade Federal da Bahia	BARRETO, ML (corresponding author), UNIV FED BAHIA,DEPT PREVENT MED,RUA PADRE FEIJO 29,4 ANDAR,CANELA,BR-40110170 SALVADOR,BA,BRAZIL.		Barreto, Mauricio L/B-1752-2008	Barreto, Mauricio L/0000-0002-0215-4930; santos, leonor maria pacheco/0000-0002-6739-6260				ARTHUR P, 1992, LANCET, V339, P361, DOI 10.1016/0140-6736(92)91677-Z; BAQUI AH, 1991, INT J EPIDEMIOL, V20, P1057, DOI 10.1093/ije/20.4.1057; Beaton G., 1993, EFFECTIVENESS VITAMI; DANS CD, 1988, ECOL FOOD NUTR, V22, P131, DOI 10.1080/03670244.1988.9991063; DAULAIRE NMP, 1992, BMJ-BRIT MED J, V304, P207, DOI 10.1136/bmj.304.6821.207; DIBLEY MJ, 1992, FASEB J, V6, pA1787; FAWIZ WW, 1993, JAMA-J AM MED ASSOC, V269, P898; GLAZIOU PP, 1993, BRIT MED J, V306, P366; GRIFFIN PM, 1988, AM J EPIDEMIOL, V128, P1322, DOI 10.1093/oxfordjournals.aje.a115085; HERRERA MG, 1992, LANCET, V340, P267, DOI 10.1016/0140-6736(92)92357-L; LATHAM MC, 1993, LANCET, V342, P549, DOI 10.1016/0140-6736(93)91671-8; LULSEGED S, 1992, ETHIOPIAN MED J, V30, P69; MUHILAL PD, 1988, AM J CLIN NUTR, V48, P1271; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; RAHMATHULLAH L, 1991, AM J CLIN NUTR, V54, P568, DOI 10.1093/ajcn/54.3.568; SANTOS LMP, 1983, AM J CLIN NUTR, V38, P139, DOI 10.1093/ajcn/38.1.139; SCHORLING JB, 1990, AM J EPIDEMIOL, V132, P144, DOI 10.1093/oxfordjournals.aje.a115626; SOMMER A, 1986, LANCET, V1, P1169; STANSFIELD SK, 1993, LANCET, V341, P578; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6; 1982, WHO TECH REP SER, P672; 1983, MED CAMBIO ESTADO NU; 1993, LANCET, V342, P7	24	205	218	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					228	231		10.1016/S0140-6736(94)92998-X	http://dx.doi.org/10.1016/S0140-6736(94)92998-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913157	Green Published			2022-12-28	WOS:A1994NY06000010
J	FOSTER, S; NORMAND, C; SHEAFF, R				FOSTER, S; NORMAND, C; SHEAFF, R			HEALTH-CARE REFORM - THE ISSUES AND THE ROLE OF DONORS	LANCET			English	Editorial Material									UNIV MANCHESTER,HLTH SERV MANAGEMENT UNIT,MANCHESTER M13,LANCS,ENGLAND	University of Manchester	FOSTER, S (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Sheaff, Rod/I-5187-2013; Sheaff, Rod/N-2404-2019	Sheaff, Rod/0000-0002-7984-2627; Sheaff, Rod/0000-0002-7984-2627; Normand, Charles/0000-0002-0885-5754				BENNETT S, 1991, DEP PUBLIC HLTH POLI, V4; BOWLING A, 1993, SOC SCI MED, V37, P851, DOI 10.1016/0277-9536(93)90138-T; Enthoven A.C., 1985, REFLECTIONS MANAGEME; FEACHEM R, 1994, NATURE, V367, P313, DOI 10.1038/367313a0; Foster S. D., 1990, Tropical Diseases Bulletin, V87, pR1; FOSTER SD, 1993, ROY SOC TROP MED JUL; Newhouse JP, 1993, FREE ALL LESSONS RAN; 1993, INVESTING HLTH	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					175	177		10.1016/S0140-6736(94)92765-0	http://dx.doi.org/10.1016/S0140-6736(94)92765-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NW810	7912773				2022-12-28	WOS:A1994NW81000017
J	MAEDA, N; WATANABE, K; NEGORO, T; ASO, K; OHKI, T; ITO, K; KATO, T				MAEDA, N; WATANABE, K; NEGORO, T; ASO, K; OHKI, T; ITO, K; KATO, T			EVOLUTIONAL CHANGES OF CORTICAL HYPOMETABOLISM IN WESTS SYNDROME	LANCET			English	Article							INFANTILE SPASMS; SURGICAL-TREATMENT	The pathophysiological basis of the epileptic encephalopathy West's syndrome remains unknown. We have done serial positron emission tomography (PET) with fluorine-18-labelled 2-deoxy-3-fluoro-D-glucose (FDG) in twelve patients with newly diagnosed West's syndrome. Throughout follow-up, PET revealed diffuse or focal cortical hypometabolism in eleven patients, whereas magnetic resonance imaging (MRI) showed morphological abnormalities in only five. At disease onset, PET showed cortical hypometabolism in eight patients (diffuse in three, focal in five). The second PET showed normal metabolism in six of these patients but focal abnormalities in three of the four with normal results on first PET. In all seven patients with normal findings on the second PET, tonic spasms ceased after initial treatment and no epileptic seizure occurred thereafter. In the five patients with cortical hypometabolism on the second PET, tonic spasms persisted or recurred, or partial seizures appeared. However, in two patients PET abnormalities disappeared in accordance with the later resolution of epileptic seizures. All patients with normal MRI and second PET results had normal psychomotor development. Diffuse or focal cortical hypometabolism that cannot be detected by MRI or computed tomography is common in patients with West's syndrome. However, this anomaly is not permanent and changes with clinical symptoms. These functional abnormalities in the cerebral cortex may be associated with the development of West's syndrome.	NAGOYA UNIV,SCH MED,DEPT RADIOL,NAGOYA 461,JAPAN	Nagoya University	MAEDA, N (corresponding author), NAGOYA UNIV,SCH MED,DEPT PEDIAT,SHOWA KU,65 TSURUMA CHO,NAGOYA,AICHI 466,JAPAN.							CHUGANI HT, 1990, ANN NEUROL, V27, P406, DOI 10.1002/ana.410270408; CHUGANI HT, 1992, ANN NEUROL, V31, P212, DOI 10.1002/ana.410310212; ENGEL J, 1993, NEUROLOGY, V43, P1612, DOI 10.1212/WNL.43.8.1612; MAEDA N, 1993, PEDIATR NEUROL, V9, P430, DOI 10.1016/0887-8994(93)90021-4; YAMAMOTO N, 1988, EPILEPSIA, V29, P34, DOI 10.1111/j.1528-1157.1988.tb05095.x; 1992, EPILEPSIA, V33, P195	6	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1620	1623		10.1016/S0140-6736(94)93065-1	http://dx.doi.org/10.1016/S0140-6736(94)93065-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911927				2022-12-28	WOS:A1994NU35400018
J	BASLER, K; EDLUND, T; JESSELL, TM; YAMADA, T				BASLER, K; EDLUND, T; JESSELL, TM; YAMADA, T			CONTROL OF CELL PATTERN IN THE NEURAL-TUBE - REGULATION OF CELL-DIFFERENTIATION BY DORSALIN-1, A NOVEL TGF-BETA FAMILY MEMBER	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FLOOR PLATE; CREST CELLS; MONOCLONAL-ANTIBODIES; CHICK-EMBRYO; DROSOPHILA EMBRYO; VENTRAL AXIS; NOTOCHORD; BONE; IDENTIFICATION	Distinct cell types differentiate along the dorsoventral axis of the neural tube. We have cloned and characterized a novel member of the TGFbeta gene family, dorsalin-1 (dsl-1), that appears to regulate cell differentiation within the neural tube. dsl-1 is expressed selectively in the dorsal neural tube, and its pattern of expression appears to be restricted by early signals from the notochord. Exposure of neural plate cells to dsl-1 promotes the differentiation of cells with neural crest-like properties and inhibits the induction of motor neurons by signals from the notochord and floor plate. These findings suggest that dsl-1 regulates the differentiation of cell types along the dorsoventral axis of the neural tube, acting in conjunction with distinct ventralizing signals from the notochord and floor plate.	UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Umea University	BASLER, K (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, DEPT BIOCHEM & MOLEC BIOPHYS, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.			Basler, Konrad/0000-0003-3534-1529				ABO T, 1981, J IMMUNOL, V127, P1024; ALTABA AR, 1989, NATURE, V341, P33; ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BERND P, 1985, DEV BIOL, V112, P145, DOI 10.1016/0012-1606(85)90128-9; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DARNELL DK, 1992, DEV DYNAM, V193, P389, DOI 10.1002/aja.1001930411; DELANNET M, 1992, DEVELOPMENT, V116, P275; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GRABOWSKI CT, 1956, J EXP ZOOL, V133, P301, DOI 10.1002/jez.1401330207; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREVE JM, 1982, J CELL BIOCHEM, V18, P221, DOI 10.1002/jcb.1982.240180209; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HIRANO S, 1991, SCIENCE, V251, P310, DOI 10.1126/science.1987648; Hoffmann FM, 1991, CURR OPIN CELL BIOL, V3, P947, DOI 10.1016/0955-0674(91)90112-C; JONES CM, 1991, DEVELOPMENT, V111, P531; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MAXWELL GD, 1988, NEURON, V1, P557, DOI 10.1016/0896-6273(88)90105-5; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; RAY RP, 1991, DEVELOPMENT, V113, P35; ROGERS SL, 1992, DEV BIOL, V151, P192, DOI 10.1016/0012-1606(92)90226-7; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STOCKER KM, 1991, DEVELOPMENT, V111, P635; TAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P10237, DOI 10.1073/pnas.89.21.10237; TANAKA H, 1989, DEV BIOL, V132, P419, DOI 10.1016/0012-1606(89)90238-8; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	61	320	356	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					687	702		10.1016/0092-8674(93)90249-P	http://dx.doi.org/10.1016/0092-8674(93)90249-P			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	7916656	hybrid, Green Accepted			2022-12-28	WOS:A1993LD83000008
J	BROWNING, JL; NGAMEK, A; LAWTON, P; DEMARINIS, J; TIZARD, R; CHOW, EPC; HESSION, C; OBRINEGRECO, B; FOLEY, SF; WARE, CF				BROWNING, JL; NGAMEK, A; LAWTON, P; DEMARINIS, J; TIZARD, R; CHOW, EPC; HESSION, C; OBRINEGRECO, B; FOLEY, SF; WARE, CF			LYMPHOTOXIN-BETA, A NOVEL MEMBER OF THE TNF FAMILY THAT FORMS A HETEROMERIC COMPLEX WITH LYMPHOTOXIN ON THE CELL-SURFACE	CELL			English	Article							TUMOR-NECROSIS-FACTOR; MAJOR HISTOCOMPATIBILITY COMPLEX; FACTOR-ALPHA; MOLECULAR-CLONING; RECEPTOR-BINDING; FACTOR CACHECTIN; LYMPHOCYTES-T; AMINO-ACID; EXPRESSION; GENES	The lymphokine tumor necrosis factor (TNF) has a well-defined role as an inducer of inflammatory responses; however, the function of the structurally related molecule lymphotoxin (LTalpha) is unknown. LTalpha is present on the surface of activated T, B, and LAK cells as a complex with a 33 kd glycoprotein, and cloning of the cDNA encoding the associated protein, called lymphotoxin beta (LTbeta), revealed it to be a type II membrane protein with significant homology to TNF, LTalpha, and the ligand for the CD40 receptor. The gene for LTbeta was found next to the TNF-LT locus in the major histocompatibility complex (MHC), a region of the MHC with possible linkage to autoimmune disease. These observations raise the possibility that a surface LTalpha-LTbeta complex may have a specific role in immune regulation distinct from the functions ascribed to TNF.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521	University of California System; University of California Riverside	BROWNING, JL (corresponding author), BIOGEN INC,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.			Browning, Jeffrey/0000-0001-9168-5233				ABE Y, 1991, JPN J CANCER RES, V82, P23, DOI 10.1111/j.1349-7006.1991.tb01740.x; ABE Y, 1992, LYMPHOKINE CYTOK RES, V11, P115; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AMEISEN JC, 1992, IMMUNOL TODAY, V13, P288; ANDREWS JS, 1990, J IMMUNOL, V144, P2582; ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BADENHOOP K, 1990, J IMMUNOGENET, V16, P455; BEUTLER B, 1990, PEPTIDE GROWTH FACTO, V2, P39; BROWNING J, 1989, J IMMUNOL, V143, P1859; BROWNING JL, 1991, J IMMUNOL, V147, P1230; DAWKINS RL, 1989, HUM IMMUNOL, V26, P91, DOI 10.1016/0198-8859(89)90094-3; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FARRAH T, 1992, NATURE, V358, P26, DOI 10.1038/358026b0; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUGGER L, 1989, SCAND J IMMUNOL, V30, P185, DOI 10.1111/j.1365-3083.1989.tb01200.x; GARDNER SM, 1987, J IMMUNOL, V139, P476; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P968, DOI 10.1073/pnas.87.3.968; JACOB CO, 1988, NATURE, V331, P356, DOI 10.1038/331356a0; JEVNIKAR AM, 1991, KIDNEY INT, V40, P203, DOI 10.1038/ki.1991.201; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONGENEEL CV, 1990, J EXP MED, V171, P2141, DOI 10.1084/jem.171.6.2141; KINKHABWALA M, 1990, J EXP MED, V171, P941, DOI 10.1084/jem.171.3.941; Kossodo S., 1992, J EXP MED, V176, P1259; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; MIYAKE M, 1992, EUR J IMMUNOL, V22, P2147, DOI 10.1002/eji.1830220828; MUELLER U, 1987, Nature (London), V325, P265; NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611, DOI 10.1101/SQB.1986.051.01.073; NEDOSPASOV SA, 1991, J IMMUNOL, V147, P1053; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PORCIOT F, 1991, SCAND J IMMUNOL, V33, P37; RAINES EW, 1990, PEPTIDE GROWTH FACTO, V2, P173; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; RUDDLE NH, 1988, PROG ALLERGY, V40, P162; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SPIES T, 1986, P NATL ACAD SCI USA, V83, P8699, DOI 10.1073/pnas.83.22.8699; SPIES T, 1989, SCIENCE, V243, P214, DOI 10.1126/science.2911734; SPRIGGS DR, 1988, J CLIN INVEST, V81, P455, DOI 10.1172/JCI113341; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TAVERNIER J, 1989, FEBS LETT, V257, P315, DOI 10.1016/0014-5793(89)81560-1; TSUGE I, 1987, IMMUNOGENETICS, V26, P378, DOI 10.1007/BF00343709; VALE W, 1990, PEPTIDE GROWTH FACTO, V2, P211; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WANTANABEFUKUNA.R, 1992, NATURE, V356, P314; WARE CF, 1992, J IMMUNOL, V149, P3881; WEBB GC, 1990, J IMMUNOL, V145, P1278; WINGFIELD P, 1987, FEBS LETT, V211, P179, DOI 10.1016/0014-5793(87)81432-1; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	67	450	498	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					847	856		10.1016/0092-8674(93)90574-A	http://dx.doi.org/10.1016/0092-8674(93)90574-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	7916655				2022-12-28	WOS:A1993KU17500006
J	DESAINTONGE, DMC; HERXHEIMER, A				DESAINTONGE, DMC; HERXHEIMER, A			HARNESSING PLACEBO-EFFECTS IN HEALTH-CARE	LANCET			English	Article									UK COCHRANE CTR, OXFORD OX2 7LG, ENGLAND; LONDON HOSP, COLL MED, LONDON E1 1BB, ENGLAND	Cochrane Centre; University of London; Queen Mary University London								BECKER MH, 1972, J PEDIATR-US, V81, P843, DOI 10.1016/S0022-3476(72)80118-5; BLACKWELL B, 1972, LANCET, V1, P1279; BOURNE HR, 1978, CLIN PHARM BASIC PRI, P1052; BUCKALEW LW, 1982, J CLIN PSYCHOPHARM, V2, P245; DOWNER SM, 1994, BRIT MED J, V309, P86, DOI 10.1136/bmj.309.6947.86; DYMOND EC, 1960, AM J CARDIOL, V5, P483; EGBERT LD, 1964, NEW ENGL J MED, V270, P825, DOI 10.1056/NEJM196404162701606; EVANS FJ, 1985, PLACEBO THEORY RES M; Hahn R.A., 1985, PLACEBO THEORY RES M, P167; HONIGFELD G, 1964, DIS NERV SYST, V25, P145; KLUGER MT, 1991, ANAESTH INTENS CARE, V19, P412, DOI 10.1177/0310057X9101900319; LUPARELLO TJ, 1970, PSYCHOSOM MED, V32, P509, DOI 10.1097/00006842-197009000-00009; MORGAN AD, 1983, BRIT MED J, V286, P171, DOI 10.1136/bmj.286.6360.171; OH VMS, 1994, BRIT MED J, V309, P69, DOI 10.1136/bmj.309.6947.69; POGGE RC, 1963, MED TIMES, V91, P1; Shapiro A, 1984, BEHAV HLTH HDB HLTH, P371; Shapiro AK., 1964, AM J PSYCHOTHER, V18, P73, DOI [10.1176/appi.psychotherapy.1964.18.s1.73, DOI 10.1176/APPI.PSYCHOTHERAPY.1964.18.S1.73]; Spiro HM, 1986, DOCTORS PATIENTS PLA; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; White L, 1985, PLACEBO THEORY RES M; WICKREMASEKERA IA, 1985, PLACEBO THEORY RES M; WIED G L, 1953, Arztl Wochensch, V8, P623; WOLF S, 1954, JAMA-J AM MED ASSOC, V155, P339, DOI 10.1001/jama.1954.03690220013004; 1978, DRUG THERAPEUTICS B, V16, P53; 1980, NEW ENGL J MED, V303, P1038	26	94	94	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	1994	344	8928					995	998		10.1016/S0140-6736(94)91647-0	http://dx.doi.org/10.1016/S0140-6736(94)91647-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934436				2022-12-28	WOS:A1994PK97800015
J	DEGROOT, RP; BALLOU, LM; SASSONECORSI, P				DEGROOT, RP; BALLOU, LM; SASSONECORSI, P			POSITIVE REGULATION OF THE CAMP-RESPONSIVE ACTIVATOR CREM BY THE P70 S6 KINASE - AN ALTERNATIVE ROUTE TO MITOGEN-INDUCED GENE-EXPRESSION	CELL			English	Article							PROTEIN-KINASE; SIGNALING PATHWAYS; 70K-S6 KINASE; MAP KINASE; RAT-LIVER; T-CELLS; PHOSPHORYLATION; TRANSCRIPTION; BINDING; PROMOTER	Activation of the adenylyl cyclase signaling pathway elicits the induction of genes via activators binding to cAMP-responsive elements (CREs). Nuclear factor CRE modulator (CREM) is activated by PKA-mediated phosphorylation on a serine at position 117. We show that Ser-117 is also phosphorylated by the mitogen-activated p70 S6 kinase (p70(S6K)) in vitro. Activation of cellular p70(S6K) by serum factors enhances Ser-117 phosphorylation and CREM transactivation. Coexpression of p70(S6K) significantly increases transactivation by a GAL4-CREM fusion. The macrolide rapamycin, a potent and specific inhibitor of p70(S6K) in vivo, completely blocks CREM activation induced by serum and by p70(S6K). Thus, CREM constitutes a target for mitogenic signaling through p70(S6K) and may acts as a nuclear effector in which transduction pathways may converge and cross-talk.	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHEN RH, 1992, MOL CELL BIOL, V12, P925; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DEGROOT RP, 1994, ONCOGENE, V9, P463; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P1495, DOI 10.1210/me.7.11.1495; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; FRANCO R, 1990, J BIOL CHEM, V265, P4321; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LALLI E, 1994, J BIOL CHEM, V269, P17359; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MACNICOL M, 1992, FEBS LETT, V304, P237, DOI 10.1016/0014-5793(92)80627-S; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKAHASHI JS, 1993, NATURE, V365, P299, DOI 10.1038/365299a0; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	54	210	213	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					81	91		10.1016/0092-8674(94)90402-2	http://dx.doi.org/10.1016/0092-8674(94)90402-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923380				2022-12-28	WOS:A1994PK58500010
J	HALLIWELL, B				HALLIWELL, B			FREE-RADICALS, ANTIOXIDANTS, AND HUMAN-DISEASE - CURIOSITY, CAUSE, OR CONSEQUENCE	LANCET			English	Article							CORONARY HEART-DISEASE; GLUTATHIONE; MECHANISMS; FLAVONOIDS; OXIDATION; DAMAGE; ACID; IRON				HALLIWELL, B (corresponding author), UNIV LONDON KINGS COLL,NEURODEGENERAT DIS RES GRP,LONDON SW3 6LX,ENGLAND.		Halliwell, Barry/C-8318-2009					AUST SD, 1993, TOXICOL APPL PHARM, V120, P168, DOI 10.1006/taap.1993.1100; BABIOR BM, 1990, SEMIN HEMATOL, V27, P247; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BREIMER LH, 1991, FREE RADICAL RES COM, V14, P159, DOI 10.3109/10715769109088945; BURT MJ, 1993, BRIT MED J, V307, P575, DOI 10.1136/bmj.307.6904.575; BYERS T, 1993, NUTR REV, V51, P333, DOI 10.1111/j.1753-4887.1993.tb03759.x; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Dizdaroglu M., 1993, DNA FREE RADICALS, P19; GUTTERIDGE JMC, 1981, CRC CR REV CL LAB SC, V14, P257, DOI 10.3109/10408368109105866; GUTTERIDGE JMC, 1993, FREE RADICAL RES COM, V19, P141, DOI 10.3109/10715769309111598; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HALLIWELL B, 1984, LANCET, V1, P1396; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HOFSTRA AH, 1993, TOXICOLOGY, V82, P221, DOI 10.1016/0300-483X(93)90066-2; KAUR H, 1990, CHEM-BIOL INTERACT, V73, P235, DOI 10.1016/0009-2797(90)90006-9; KEIZER HG, 1990, PHARMACOL THERAPEUT, V47, P219, DOI 10.1016/0163-7258(90)90088-J; KRINSKY NI, 1991, AM J CLIN NUTR, V53, pS238, DOI 10.1093/ajcn/53.1.238S; LAUGHTON MJ, 1991, BIOCHEM PHARMACOL, V42, P1673, DOI 10.1016/0006-2952(91)90501-U; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; MAIORINO M, 1991, J BIOL CHEM, V266, P7728; MEISTER A, 1992, BIOCHEM PHARMACOL, V44, P1905, DOI 10.1016/0006-2952(92)90091-V; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MULLER DPR, 1990, CRIT REV NEUROBIOL, V5, P239; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; SARAFIAN TA, 1994, FREE RADICAL RES, V20, P1; SIES H, 1991, OXIDATIVE STRESS, V2; SLADE R, 1993, EXP LUNG RES, V19, P469, DOI 10.3109/01902149309064358; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STILLWELL WG, 1989, CHEM RES TOXICOL, V2, P94, DOI 10.1021/tx00008a004	32	2163	2262	5	145	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					721	724		10.1016/S0140-6736(94)92211-X	http://dx.doi.org/10.1016/S0140-6736(94)92211-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915779				2022-12-28	WOS:A1994PF18700013
J	KOCISKO, DA; COME, JH; PRIOLA, SA; CHESEBRO, B; RAYMOND, GJ; LANSBURY, PT; CAUGHEY, B				KOCISKO, DA; COME, JH; PRIOLA, SA; CHESEBRO, B; RAYMOND, GJ; LANSBURY, PT; CAUGHEY, B			CELL-FREE FORMATION OF PROTEASE-RESISTANT PRION PROTEIN	NATURE			English	Article							SCRAPIE-ASSOCIATED FORM; CULTURED-CELLS; PRP; CONVERSION; DISEASES; FIBRILS; BIOLOGY; ACID	THE infectious agent (or 'prion') of the transmissible spongiform encephalopathies (TSEs) such as scrapie resembles a virus in that it replicates in vivo and has distinct strains(1), but it was postulated long ago to contain only protein(2-3). More recently, PrPSc, a pathogenic, scrapie-associated form of the host-encoded prion protein (PrP), was identified as a possible primary TSE agent protein(4-6). PrPSc is defined biochemically by its insolubility and resistance to proteases(7) and is derived post-translationally from normal, protease-sensitive PrP (PrPc)(8,9). The conversion seems to involve conformational change rather than covalent modification(10-13) However, the conversion mechanism and the relationship of PrPSc formation to TSE agent replication remain unclear. Here we report the conversion of PrPc to protease-resistant forms similar to PrPSc in a cell-free system composed of substantially purified constituents. This conversion was selective and required the presence of preexisting PrPSc, providing direct evidence that PrPSc derives from specific PrPc-PrPSc interactions.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; NIAID,ROCKY MT LABS,PERSISTENT VIRAL DIS LAB,HAMILTON,MT 59840	Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								AIKEN JM, 1990, MICROBIOL REV, V54, P242, DOI 10.1128/MMBR.54.3.242-246.1990; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1988, NOVEL INFECTIOUS AGE, V1, P164; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; FRASER H, 1993, BRIT MED BULL, V49, P792, DOI 10.1093/oxfordjournals.bmb.a072647; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1967, VET REC, V80, P2, DOI 10.1136/vr.80.1.2; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; Riesner D., 1991, SEMIN VIROL, V2, P215; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SNOW AD, 1990, LAB INVEST, V63, P601; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	30	766	802	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					471	474		10.1038/370471a0	http://dx.doi.org/10.1038/370471a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	7913989	Green Published			2022-12-28	WOS:A1994PB40700059
J	GOLDSTEIN, KP; DAUM, RS				GOLDSTEIN, KP; DAUM, RS			COUNTING IMMUNIZATIONS	LANCET			English	Editorial Material											GOLDSTEIN, KP (corresponding author), UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637, USA.							GOLDSTEIN KP, 1993, JAMA-J AM MED ASSOC, V270, P2190, DOI 10.1001/jama.270.18.2190; GOLDSTEIN KP, 1994, PEDIATR RES, V35, pA114; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833; 1994, MMWR-MORBID MORTAL W, V42, P985; 1991, MMWR-MORBID MORTAL W, V40, P369	6	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					144	145						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912760				2022-12-28	WOS:A1994NW81000004
J	CLARK, DA				CLARK, DA			STRESS WITHOUT DISTRESS - THE INTRAUTERINE PERSPECTIVE	LANCET			English	Editorial Material											CLARK, DA (corresponding author), MCMASTER UNIV,MED CTR,HAMILTON,ON,CANADA.							GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; IRWIN M, 1993, ANN NY ACAD SCI, V697, P203, DOI 10.1111/j.1749-6632.1993.tb49933.x; ROGERS MC, 1992, NEW ENGL J MED, V326, P55, DOI 10.1056/NEJM199201023260109; WOLF AR, 1993, LANCET, V342, P319, DOI 10.1016/0140-6736(93)91468-2	4	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					73	74		10.1016/S0140-6736(94)91275-0	http://dx.doi.org/10.1016/S0140-6736(94)91275-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912387				2022-12-28	WOS:A1994NV73200003
J	CLEARY, MA; WALTER, JH; WRAITH, JE; JENKINS, JPR; ALANI, SM; TYLER, K; WHITTLE, D				CLEARY, MA; WALTER, JH; WRAITH, JE; JENKINS, JPR; ALANI, SM; TYLER, K; WHITTLE, D			MAGNETIC-RESONANCE-IMAGING OF THE BRAIN IN PHENYLKETONURIA	LANCET			English	Article							MULTIPLE-SCLEROSIS; EXPERIMENTAL HYPERPHENYLALANINEMIA; NEUROLOGICAL DETERIORATION; DIETARY-TREATMENT; ADOLESCENTS; STIMULATION; MR; INTELLIGENCE; MYELIN	Abnormalities of magnetic resonance imaging (MRI) of the brain occur in some patients with phenylketonuria but the clinical importance of this finding is not clear. In order to determine the frequency and functional significance of changes on MRI we investigated 77 adolescent and adult patients with phenylketonuria. Patients aged 14-49 years and taking a restricted diet of 1 g/kg protein underwent clinical examination, IQ testing, neurophysiological investigation, and MRI of the brain. Patients aged between 10-14 years taking a low phenylalanine diet with aminoacid supplements had MRI of the brain only. Biochemical control was assessed from: the lifetime blood phenylalanine determined from the mean blood concentration throughout life; the accumulated time for each patient that phenylalanine was < 120 mu mol/L; the accumulated time for each patient that phenylalanine was > 1200 mu mol/L); mean blood concentration in the first 4 years of life; and the mean blood phe concentration in the 5 years prior to imaging. MRI changes, compatible with a disturbance in the water content of white matter, were present in all but 1 patient. The severity of abnormality was most strongly associated with the blood phenylalanine concentration at the time of imaging. Clinical and neurophysiological abnormalities were less common and usually mild. 3 patients had prolonged central motor conduction time, 7 had prolonged visual evoked potentials, and 5 had impaired peripheral sensory nerve conduction. There was no significant association between the extent of MRI abnormalities and IQ, and the presence of neurophysiological, or clinical abnormalities. An abnormal brain scan in PKU may reflect present biochemical control rather than indicate significant neurological damage. As yet there is little evidence that in most patients with PKU these MRI changes are of clinical importance.	ROYAL MANCHESTER CHILDRENS HOSP,WILLINK BIOCHEM GENET UNIT,MANCHESTER M27 4HA,LANCS,ENGLAND; HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND; MANCHESTER ROYAL INFIRM,DEPT CLIN RADIOL,MANCHESTER,ENGLAND	Royal Manchester Children's Hospital; University of Manchester								BICK U, 1991, EUR J PEDIATR, V150, P185, DOI 10.1007/BF01963563; BICK U, 1993, EUR J PEDIATR, V152, P1012, DOI 10.1007/BF01957228; BRANTZAWADZKI M, 1988, RADIOLOGY, V166, P1; DOBSON JC, 1977, PEDIATRICS, V60, P822; EISEN A, 1990, MUSCLE NERVE, V13, P146, DOI 10.1002/mus.880130211; HALLIDAY AM, 1973, BRIT MED J, V4, P661, DOI 10.1136/bmj.4.5893.661; HOMMES FA, 1982, J INHERIT METAB DIS, V5, P21, DOI 10.1007/BF01799750; INGRAM DA, 1988, J NEUROL NEUROSUR PS, V51, P487, DOI 10.1136/jnnp.51.4.487; KAMMAN RL, 1988, MAGNET RESON MED, V6, P265, DOI 10.1002/mrm.1910060304; KORINTHENBERG R, 1988, NEUROPEDIATRICS, V19, P175, DOI 10.1055/s-2008-1052440; LOU HC, 1992, J INHERIT METAB DIS, V15, P687, DOI 10.1007/BF01800008; LUDOLPH AC, 1992, ACTA NEUROL SCAND, V85, P243; MALAMUD N, 1966, J NEUROPATH EXP NEUR, V25, P254, DOI 10.1097/00005072-196604000-00006; MAYR N, 1991, NEUROLOGY, V41, P566, DOI 10.1212/WNL.41.4.566; MCDONALD WI, 1988, CLIN NEUROL NEUROSUR, V90, P3; PEARSEN KD, 1990, RADIOLOGY, V177, P437, DOI 10.1148/radiology.177.2.2217781; REYNOLDS R, 1992, EXP NEUROL, V115, P347, DOI 10.1016/0014-4886(92)90200-A; SAUDUBRAY JM, 1987, EUR J PEDIATR, V146, P20; SHAW DWW, 1990, J COMPUT ASSIST TOMO, V14, P458, DOI 10.1097/00004728-199005000-00026; SMITH I, 1990, ARCH DIS CHILD, V65, P472, DOI 10.1136/adc.65.5.472; SMITH I, 1985, GENETIC METABOLIC DI, P166; TAYLOR EH, 1983, INT J NEUROSCI, V20, P217, DOI 10.3109/00207458308986575; THOMPSON AJ, 1993, BRAIN, V116, P811, DOI 10.1093/brain/116.4.811; THOMPSON AJ, 1990, LANCET, V336, P602, DOI 10.1016/0140-6736(90)93401-A; TOMA P, 1991, NEUROPEDIATRICS, V22, P174; Valk J., 1989, MAGNETIC RESONANCE M; VILLASANA D, 1989, J INHERIT METAB DIS, V12, P451, DOI 10.1007/BF01802042; Waisbren S E, 1980, J Inherit Metab Dis, V3, P149, DOI 10.1007/BF02312549; WAISBREN SE, 1987, PEDIATRICS, V79, P351; WALTER JH, 1993, EUR J PEDIATR, V152, P822, DOI 10.1007/BF02073379	30	121	125	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					87	90		10.1016/S0140-6736(94)91281-5	http://dx.doi.org/10.1016/S0140-6736(94)91281-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912392				2022-12-28	WOS:A1994NV73200009
J	SACCHETTI, E; CONTE, G; GUARNERI, L				SACCHETTI, E; CONTE, G; GUARNERI, L			ARE SSRI ANTIDEPRESSANTS A CLINICALLY HOMOGENEOUS CLASS OF COMPOUNDS	LANCET			English	Letter									UNIV MILAN,OSPED SAN PAOLO,DEPT MENTAL HLTH,USSL 75 IV,I-20142 MILAN,ITALY	San Paolo-Polo Universitaria Hospital; University of Milan	SACCHETTI, E (corresponding author), UNIV MILAN,SCH MED,SAN PAOLO BIOMED SCI INST,I-20142 MILAN,ITALY.							LECRUBIER J, 1993, NEW PHARM APPROACHES, P83; Leonard B E, 1992, Drugs, V43 Suppl 2, P3; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199400910-00008	3	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					126	127		10.1016/S0140-6736(94)91310-2	http://dx.doi.org/10.1016/S0140-6736(94)91310-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NV732	7912358				2022-12-28	WOS:A1994NV73200038
J	VINCENT, C; YOUNG, M; PHILLIPS, A				VINCENT, C; YOUNG, M; PHILLIPS, A			WHY DO PEOPLE SUE DOCTORS - A STUDY OF PATIENTS AND RELATIVES TAKING LEGAL ACTION	LANCET			English	Article								To examine the reasons patients and their relatives take legal action, we surveyed 227 patients and relatives who were taking legal action through five firms of plaintiff medical negligence solicitors. Over 70% of respondents were seriously affected by incidents that gave rise to litigation with long-term effects on work, social life, and family relationships. Intense emotions were aroused and continued to be felt for a long time. The decision to take legal action was determined not only by the original injury, but also by insensitive handling and poor communication after the original incident. Where explanations were given, less than 15% were considered satisfactory. Four main themes emerged from the analysis of reasons for litigation: concern with standards of care-both patients and relatives wanted to prevent similar incidents in the future; the need for an explanation-to know how the injury happened and why; compensation-for actual losses, pain and suffering or to provide care in the future for an injured person; and accountability-a belief that the staff or organisation should have to account for their actions. Patients taking legal action wanted greater honesty, an appreciation of the severity of the trauma they had suffered, and assurances that lessons had been learnt from their experiences. A no-fault compensation system, however well intended, would not address all patients' concerns. If litigation is viewed solely as a legal and financial problem, many fundamental issues will not be addressed or resolved.			VINCENT, C (corresponding author), ST MARYS HOSP,ACAD DEPT PSYCHIAT,PRAED ST,LONDON W2 1NY,ENGLAND.		Vincent, Charles A/D-1134-2010	Vincent, Charles A/0000-0003-0270-0222				BRAHAMS D, 1987, LANCET, V1, P698; CAPSTICK B, 1991, BRIT MED J, V302, P230, DOI 10.1136/bmj.302.6770.230; CHARLES SC, 1985, AM J PSYCHIAT, V192, P437; Donaldson L J, 1992, Qual Health Care, V1, P21, DOI 10.1136/qshc.1.1.21; ENNIS M, 1993, MED ACCIDENTS; Fenn P., 1993, MED ACCIDENTS; Firth-Cozens J, 1993, MED ACCIDENTS; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LEAPE LL, 1991, IATROGENICS, V1, P17; SIMANOWITZ A, 1985, LANCET, V2, P546; Tabachnick B.G., 2019, USING MULTIVARIATE S, V7th; Vincent C A, 1993, Qual Health Care, V2, P77, DOI 10.1136/qshc.2.2.77	13	432	436	0	24	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1609	1613		10.1016/S0140-6736(94)93062-7	http://dx.doi.org/10.1016/S0140-6736(94)93062-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NU354	7911925				2022-12-28	WOS:A1994NU35400015
J	KIM, DE; BERLOWITZ, DR				KIM, DE; BERLOWITZ, DR			THE LIMITED VALUE OF ROUTINE LABORATORY ASSESSMENTS IN SEVERELY IMPAIRED NURSING-HOME RESIDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY PATIENTS; BACTERIURIA; POPULATION; YIELD; CARE	Objective.-To determine the usefulness of a routine, comprehensive battery of laboratory tests in a severely impaired elderly nursing home population. Design.-Prospective observational survey. Setting.-Skilled nursing facility wards of a geriatric and extended care veterans hospital. Patients.-Consecutive sample of 108 veterans with severe cognitive and functional impairments, who had been hospitalized at least 6 months. Main Outcome Measures.-Proportions of tests categorized as screening, monitoring, follow-up, or diagnostic; frequency of abnormal test results, interventions warranted and performed on the basis of these abnormalities, and beneficial or adverse effects. Results.-Of 6771 individual nondiagnostic tests performed, 17.2% yielded abnormal results; of these, 33.3% were new. However, only 0.2% of tests resulted in patient benefit. Of 989 panels performed, 31.0% contained at least one abnormality, but only 1.0% of panels (10 patients) yielded any benefit. Overall usefulness was related to the purpose of the testing, with 31.5% of screening tests yielding abnormalities, compared with 45.5%, 78.2%, and 68.7% of monitoring, follow-up, and diagnostic panels, respectively (P<.05 for each compared with screening panels). None of the screening panels detected an abnormality that led to patient benefit, compared with 1.0%, 1.4%, and 3.0% of monitoring, follow-up, and diagnostic panels. Conclusions.-Routine comprehensive laboratory panels may not be warranted in the most severely impaired elderly patients in long-term care settings. Discontinuing true screening tests and limiting testing strictly to monitoring, followup, or diagnostic purposes could minimize the costs of laboratory assessment without losing its potential benefits.	EDITH NOURSE ROGERS MEM VET ADM HOSP,HSR&D FIELD PROGRAM,BEDFORD,MA 01730; EDITH NOURSE ROGERS MEM VET ADM HOSP,GERIATR SERV,BEDFORD,MA 01730; BOSTON UNIV,SCH MED,BOSTON,MA 02118	Boston University				Berlowitz, Dan/0000-0002-8783-5611				BOSCIA JA, 1986, AM J MED, V80, P208, DOI 10.1016/0002-9343(86)90011-2; Colton T., 1974, STAT MED, V1; DOMOTO K, 1985, AM J PUBLIC HEALTH, V75, P243, DOI 10.2105/AJPH.75.3.243; GAMBERT SR, 1982, J CHRON DIS, V35, P65, DOI 10.1016/0021-9681(82)90031-5; GOLODETZ A, 1985, AM J PUBLIC HEALTH, V75, P227, DOI 10.2105/AJPH.75.3.227; HODKINSON HM, 1973, BMJ-BRIT MED J, V4, P94, DOI 10.1136/bmj.4.5884.94; IRVINE PW, 1984, J AM GERIATR SOC, V32, P540, DOI 10.1111/j.1532-5415.1984.tb02243.x; JOSEPH C, 1992, J AM GERIATR SOC, V40, P98, DOI 10.1111/j.1532-5415.1992.tb01837.x; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KOMAROFF AL, 1987, JAMA-J AM MED ASSOC, V258, P1941; LEVINSTEIN MR, 1987, JAMA-J AM MED ASSOC, V258, P1909, DOI 10.1001/jama.258.14.1909; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; NICOLLE LE, 1983, NEW ENGL J MED, V309, P1420, DOI 10.1056/NEJM198312083092304; NORDENSTAM GR, 1986, NEW ENGL J MED, V314, P1152, DOI 10.1056/NEJM198605013141804; OUSLANDER JG, 1994, ANN INTERN MED, V120, P584, DOI 10.7326/0003-4819-120-7-199404010-00010; PELLOCK JM, 1991, NEUROLOGY, V41, P961, DOI 10.1212/WNL.41.7.961; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; WERTMAN BG, 1983, CLIN LAB MED, P235; WOLFKLEIN GP, 1985, J AM GERIATR SOC, V33, P325, DOI 10.1111/j.1532-5415.1985.tb07131.x	19	10	11	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1447	1452		10.1001/jama.272.18.1447	http://dx.doi.org/10.1001/jama.272.18.1447			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP690	7933428				2022-12-28	WOS:A1994PP69000034
J	BELL, BP; GOLDOFT, M; GRIFFIN, PM; DAVIS, MA; GORDON, DC; TARR, PI; BARTLESON, CA; LEWIS, JH; BARRETT, TJ; WELLS, JG; BARON, R; KOBAYASHI, J				BELL, BP; GOLDOFT, M; GRIFFIN, PM; DAVIS, MA; GORDON, DC; TARR, PI; BARTLESON, CA; LEWIS, JH; BARRETT, TJ; WELLS, JG; BARON, R; KOBAYASHI, J			A MULTISTATE OUTBREAK OF ESCHERICHIA-COLI-O157-H7 ASSOCIATED BLOODY DIARRHEA AND HEMOLYTIC-UREMIC-SYNDROME FROM HAMBURGERS - THE WASHINGTON EXPERIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; HEMORRHAGIC COLITIS; O157-H7 STRAINS; NURSING-HOME; EPIDEMIOLOGY; 0157-H7; INFECTION; CHILDREN; DISEASE	Objective.-To determine the source of and describe a large outbreak of Escherichia coli O157:H7 infections in Washington State. Design.-Case-control study; environmental investigation; provider-based surveillance for E coli O157:H7 infections. Setting.-Chain of fast-food restaurants, hospitals, physician offices, local laboratories, and local health departments. Participants.-Patients with diarrhea and neighborhood controls. A case was defined as diarrhea with culture-confirmed E coli O157:H7 infection or postdiarrheal hemolytic uremic syndrome (HUS) occurring from December 1, 1992, through February 28, 1993, in a Washington State resident. Controls were age- and neighborhood-matched friends of the first 16 case patients. Interventions.-Announcement to the public; recall of implicated hamburger lots. Main Outcome Measure.-Abatement of outbreak due to E coli O157:H7. Results.-Infection was associated with eating at a fast-food chain (chain A) in the 10 days before symptoms began. Twelve (75%) of 16 case patients but no controls had eaten at chain A (matched odds ratio undefined; lower 95% confidence interval, 3.5; P<.001). In total, 501 cases were reported, including 151 hospitalizations (31%), 45 cases of HUS (9%), and three deaths. Forty-eight patients (10%) had secondary infections. Of the remaining 453 patients (90%), 398 (86%) reported eating at a Washington chain A restaurant; 92% of them reported eating a regular hamburger. The pulsed-field gel electrophoresis pattern of the E coli O157:H7 strains isolated from all regular hamburger lots of a single production date shipped to Washington was identical to that of the strains isolated from patients. Ten (63%) of 16 regular hamburgers cooked according to chain A policy had internal temperatures below 60 degrees C. Public health action removed more than 250 000 potentially contaminated hamburgers, preventing an estimated 800 cases. Conclusions.-This E coli O157:H7 outbreak, the largest reported, resulted from errors in meat processing and cooking. Public health surveillance through state-mandated reporting of E coli O157:H7 infection as is carried out in Washington State was critical for prompt outbreak recognition and control. Measures should be developed to reduce meat contamination. Consumers and food service workers should be educated about cooking hamburger meat thoroughly.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,FOODBORNE & DIARRHEAL DIS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV FIELD EPIDEMIOL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; WASHINGTON STATE DEPT HLTH,SEATTLE,WA; WASHINGTON STATE DEPT HLTH,OLYMPIA,WA; SEATTLE KING CTY DEPT PUBL HLTH,SEATTLE,WA; SNOHOMISH HLTH DIST,EVERETT,WA; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,DIV GASTROENTEROL,SEATTLE,WA 98195; CHILDRENS HOSP & MED CTR,SEATTLE,WA 98105	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; Seattle Children's Hospital								BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BOHM H, 1992, J CLIN MICROBIOL, V30, P2169; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; DOYLE MP, 1984, APPL ENVIRON MICROB, V48, P855, DOI 10.1128/AEM.48.4.855-856.1984; DOYLE MP, 1987, APPL ENVIRON MICROB, V53, P2394, DOI 10.1128/AEM.53.10.2394-2396.1987; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; MACDONALD KL, 1988, JAMA-J AM MED ASSOC, V259, P3567, DOI 10.1001/jama.259.24.3567; MACDONALD KL, 1993, JAMA-J AM MED ASSOC, V269, P2264, DOI 10.1001/jama.269.17.2264; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; OSTROFF SM, 1989, JAMA-J AM MED ASSOC, V262, P355, DOI 10.1001/jama.262.3.355; REMIS RS, 1984, ANN INTERN MED, V101, P624, DOI 10.7326/0003-4819-101-5-624; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROWE PC, 1991, J PEDIATR-US, V119, P218, DOI 10.1016/S0022-3476(05)80730-9; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SAMADPOUR M, 1993, J CLIN MICROBIOL, V31, P3179, DOI 10.1128/JCM.31.12.3179-3183.1993; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; STROCKBINE NA, 1992, MOL CELL PROBE, V6, P93, DOI 10.1016/0890-8508(92)90052-Y; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; WEISSMAN JB, 1974, J PEDIATR-US, V84, P797, DOI 10.1016/S0022-3476(74)80750-X; WELLS JG, 1991, J CLIN MICROBIOL, V29, P985, DOI 10.1128/JCM.29.5.985-989.1991; WILSON R, 1981, J INFECT DIS, V143, P130, DOI 10.1093/infdis/143.1.130; 1976, US DHEW782081 US FOO, P28; 1993, MMWR-MORBID MORTAL W, V42, P258	25	513	536	0	72	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1349	1353		10.1001/jama.272.17.1349	http://dx.doi.org/10.1001/jama.272.17.1349			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933395				2022-12-28	WOS:A1994PP02000029
J	JACQ, X; BROU, C; LUTZ, Y; DAVIDSON, I; CHAMBON, P; TORA, L				JACQ, X; BROU, C; LUTZ, Y; DAVIDSON, I; CHAMBON, P; TORA, L			HUMAN TAF(II)30 IS PRESENT IN A DISTINCT TFIID COMPLEX AND IS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION BY THE ESTROGEN-RECEPTOR	CELL			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; CLONING; DOMAINS; PURIFICATION; STIMULATION; INITIATION; EXPRESSION; SEQUENCE; GAL-VP16	We showed previously that coactivators mediating stimulation by different activators were associated with the TATA-binding protein (TBP) in distinct TFIID complexes. We have characterized a human TBP-associated factor (TAF), hTAF(II)30, associated with a subset of TFIID complexes. hTAF(II)30 interacts with the AF-2-containing region E of the human estrogen receptor (ER), but not with ER AF-1 or VP16. An antibody against hTAF(II)30 inhibited transcriptional stimulation by the ER AF-2 without affecting basal or VP16-activated transcription and allowed the separation of TFIID complex(es) containing hTAF(II)30 from complexes mediating the activity of VP16. These results directly demonstrate the existence of functionally dis tinct TFIID populations that share common TAF(II)s but differ in specific TAF(II)s.			JACQ, X (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.		Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250; Davidson, Irwin/0000-0001-5533-1171				BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, IN PRESS EMBO J; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRUNDY FJ, 1989, VIROLOGY, V172, P223, DOI 10.1016/0042-6822(89)90124-4; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ING NH, 1992, J BIOL CHEM, V267, P17617; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIERRAT P, 1994, GENE, V143, P193; PUGH BF, 1992, J BIOL CHEM, V267, P679; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	47	359	365	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					107	117		10.1016/0092-8674(94)90404-9	http://dx.doi.org/10.1016/0092-8674(94)90404-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923369				2022-12-28	WOS:A1994PK58500012
J	WEST, MJ; COLEMAN, PD; FLOOD, DG; TRONCOSO, JC				WEST, MJ; COLEMAN, PD; FLOOD, DG; TRONCOSO, JC			DIFFERENCES IN THE PATTERN OF HIPPOCAMPAL NEURONAL LOSS IN NORMAL AGING AND ALZHEIMERS-DISEASE	LANCET			English	Article							POPULATION; DIAGNOSIS; DEMENTIA; PLAQUES	The distinction between the neurodegenerative changes that accompany normal ageing and those that characterise Alzheimer's disease is not clear. The resolution of this issue has important implications for the design of therapeutic and investigative strategies. To this end we have used modern stereological techniques to compare the regional pattern of neuronal cell loss in the hippocampus related to normal ageing to that associated with Alzheimer's disease. The loss related to normal ageing was evaluated from estimates of the total number of neurons in each of the major hippocampal subdivisions of 45 normal ageing subjects who ranged in age from 13 to 101 years. The Alzheimer's disease related losses were evaluated from similar data obtained from 7 cases of Alzheimer's disease and 14 age matched controls. Qualitative differences were observed in the regional patterns of neuronal loss related to normal ageing and Alzheimer's disease. The most distinctive Alzheimer's disease related neuron loss was seen in the CA1 region of the hippocampus. In the normal ageing group there was almost no neuron loss in this region (final neuron count in the CA1 region: 4.40 x 10(6) neurons for the Alzheimer's disease group vs 14.08 x 10(6) neurons in the normal ageing group). It is concluded that the neurodegenerative processes associated with normal ageing and with Alzheimer's disease are qualitatively different and that Alzheimer's disease is not accelerated by ageing but is a distinct pathological process.	AARHUS UNIV,INST NEUROBIOL,DK-8000 AARHUS C,DENMARK; UNIV ROCHESTER,MED CTR,DEPT NEUROBIOL & ANAT,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT NEUROL,ROCHESTER,NY 14642; JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,BALTIMORE,MD 21205	Aarhus University; University of Rochester; University of Rochester; Johns Hopkins University	WEST, MJ (corresponding author), AARHUS UNIV,STEREOL RES LAB,DK-8000 AARHUS C,DENMARK.							ARRIAGADA PV, 1992, NEUROLOGY, V42, P1681, DOI 10.1212/WNL.42.9.1681; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; BALL MJ, 1988, INTERDISCIP TOP GERO, V25, P16; BERG L, 1985, ARCH NEUROL-CHICAGO, V42, P737, DOI 10.1001/archneur.1985.04210090001001; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; CANDY JM, 1986, LANCET, V1, P350; COLEMAN PD, 1987, NEUROBIOL AGING, V8, P531; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DICKSON DW, 1991, NEUROBIOL AGING, V13, P179; ESIRI MM, 1988, INTERDISCIPLINARY TO, V25, P119; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; HARDY J, 1991, LANCET, V337, P1342; HARDY JA, 1986, NEUROBIOL AGING, V7, P489, DOI 10.1016/0197-4580(86)90086-2; HYMAN BT, 1990, NEUROLOGY, V40, P1721, DOI 10.1212/WNL.40.11.1721; HYMAN BT, 1989, ANNU REV PUBL HEALTH, V10, P115; JELLINGER K, 1990, ALZHEIMERS DIS EPIDE, P61; JOBST KA, 1994, LANCET, V343, P829, DOI 10.1016/S0140-6736(94)92028-1; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; MANN DMA, 1984, ACTA NEUROPATHOL, V63, P72, DOI 10.1007/BF00688473; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1991, NEUROLOGY, V41, P469, DOI 10.1212/WNL.41.4.469; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; PRICE JL, 1991, NEUROBIOL AGING, V12, P295, DOI 10.1016/0197-4580(91)90006-6; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P	29	947	974	0	52	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					769	772		10.1016/S0140-6736(94)92338-8	http://dx.doi.org/10.1016/S0140-6736(94)92338-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916070	hybrid			2022-12-28	WOS:A1994PG17800007
J	HARRIS, GC; ASTONJONES, G				HARRIS, GC; ASTONJONES, G			INVOLVEMENT OF D2 DOPAMINE-RECEPTORS IN THE NUCLEUS-ACCUMBENS IN THE OPIATE WITHDRAWAL SYNDROME	NATURE			English	Article							LOCUS-COERULEUS NEURONS; CYCLIC-AMP FORMATION; RAT; MORPHINE; CLONIDINE; REWARD; SPECIFICITY; PROJECTIONS; ABSTINENCE; INHIBITION	THE nucleus accumbens is prominently implicated in the reinforcing effects of abused drugs(1-4), and is an important site for mediating aversive stimulus properties of opiate withdrawal(5). It is generally thought, however, that the role of the accumbens is negligible in the somatic signs of opiate withdrawal(5-7). Contrary to this assumption, we now report that D2 dopaminergic receptor activity in the accumbens area potently regulates somatic symptoms of opiate withdrawal. We find that activation of D2 receptors within the accumbens prevents somatic signs of naloxone-induced opiate withdrawal and, conversely, that blockade of accumbal D2 receptors in opiate-dependent animals elicits somatic withdrawal symptoms. These data indicate that dopamine in the accumbens not only is important in the rewarding effects of abused drugs, but also (via D2 receptors) plays a pivotal role in opiate withdrawal.	HAHNEMANN UNIV,DEPT MENTAL HLTH SCI,DIV BEHAV NEUROBIOL,PHILADELPHIA,PA 19102	Drexel University								AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; AKAOKA H, 1991, J NEUROSCI, V11, P3830; BOZARTH MA, 1984, SCIENCE, V224, P516, DOI 10.1126/science.6324347; DEOLMOS J, 1985, RAT NERVOUS SYSTEM, V1, P223; DWORKIN SI, 1988, PHARMACOL BIOCHEM BE, V29, P175, DOI 10.1016/0091-3057(88)90292-4; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GOLD MS, 1978, LANCET, V2, P599; HEIJNA MH, 1992, EUR J PHARMACOL, V229, P197, DOI 10.1016/0014-2999(92)90555-I; HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y; HENSELMANS JML, 1993, NEUROSCI LETT, V158, P79, DOI 10.1016/0304-3940(93)90617-T; KELLY E, 1987, N-S ARCH PHARMACOL, V335, P508; KOOB GF, 1989, PSYCHOPHARMACOLOGY, V98, P530, DOI 10.1007/BF00441954; KOOB GF, 1988, SCIENCE, V242, P615; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F; RASMUSSEN K, 1990, J NEUROSCI, V10, P2308; ROSSETTI ZL, 1992, EUR J PHARMACOL, V221, P227, DOI 10.1016/0014-2999(92)90706-A; STINUS L, 1990, NEUROSCIENCE, V37, P767, DOI 10.1016/0306-4522(90)90106-E; Stoof JC, 1981, NATURE, V294, P366, DOI 10.1038/294366a0; STOOF JC, 1986, EUR J PHARMACOL, V129, P205, DOI 10.1016/0014-2999(86)90358-4; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; TUCKER DC, 1985, BRAIN RES, V360, P159, DOI 10.1016/0006-8993(85)91231-4; VACCARINO FJ, 1985, PSYCHOPHARMACOLOGY, V86, P37, DOI 10.1007/BF00431681; VANDERKOOY D, 1984, J COMP NEUROL, V224, P1, DOI 10.1002/cne.902240102; WEI E, 1973, J PHARMACOL EXP THER, V184, P398; WISE RA, 1989, NEUROSCI BIOBEHAV R, V13, P129, DOI 10.1016/S0149-7634(89)80021-1; ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D	30	181	185	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					155	157		10.1038/371155a0	http://dx.doi.org/10.1038/371155a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	7915401				2022-12-28	WOS:A1994PF19100063
J	YUSUF, SW; BAKER, DM; CHUTER, TAM; WHITAKER, SC; WENHAM, PW; HOPKINSON, BR				YUSUF, SW; BAKER, DM; CHUTER, TAM; WHITAKER, SC; WENHAM, PW; HOPKINSON, BR			TRANSFEMORAL ENDOLUMINAL REPAIR OF ABDOMINAL AORTIC-ANEURYSM WITH BIFURCATED GRAFT	LANCET			English	Note								Traditional open repair of abdominal aortic aneurysm has disadvantages. We present our experience of transfemoral endoluminal repair with a bifurcated graft system. 29 patients with aortic aneurysm over 5.5 cm in diameter and 1 with a 3.2 cm aneurysm and bilateral iliac stenosis were assessed; 5 were suitable for the procedure. The operation was successful in all the patients, without haemodynamic compromise or major complications. This technique has the potential to reduce morbidity and mortality from abdominal aortic aneurysm. Further modifications are required to make it applicable to most aneurysms.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG,NEW YORK,NY	Columbia University	YUSUF, SW (corresponding author), UNIV NOTTINGHAM HOSP,NOTTINGHAM NG7 2UH,ENGLAND.			Yusuf, Salim/0000-0003-4776-5601; Baker, Daryll/0000-0002-0098-405X				CHUTER TAM, 1994, THESIS U NOTTINGHAM; Clark NJ, 1994, ANESTHESIA, P1851; COLLIN J, 1988, LANCET, V2, P613; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; GREENHALGH RM, 1990, BRIT MED J, V301, P136, DOI 10.1136/bmj.301.6744.136; Hertzer N R, 1987, Ann Vasc Surg, V1, P616, DOI 10.1016/S0890-5096(06)61452-0; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; SCOTT RAP, 1994, LANCET, V343, P413, DOI 10.1016/S0140-6736(94)91247-5	9	88	100	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					650	651		10.1016/S0140-6736(94)92086-9	http://dx.doi.org/10.1016/S0140-6736(94)92086-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915349				2022-12-28	WOS:A1994PE38600011
J	BOOY, R; HODGSON, S; CARPENTER, L; MAYONWHITE, RT; SLACK, MPE; MACFARLANE, JA; HAWORTH, EA; KIDDLE, M; SHRIBMAN, S; ROBERTS, JSC; MOXON, ER				BOOY, R; HODGSON, S; CARPENTER, L; MAYONWHITE, RT; SLACK, MPE; MACFARLANE, JA; HAWORTH, EA; KIDDLE, M; SHRIBMAN, S; ROBERTS, JSC; MOXON, ER			EFFICACY OF HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINE PRP-T	LANCET			English	Article							POLYSACCHARIDE; EPIDEMIOLOGY; CHILDREN; DISEASE; INFANTS; SAFETY	Efficacy of the Haemophilus influenzae type b (Hib) conjugate vaccine PRP-T (Pasteur-Merieux) was evaluated in a controlled community intervention study in the Oxford region, UK. PRP-T was offered to infants from May 1, 1991 in three of the region's eight districts and from July 1, 1991, in a fourth district. It was given by separate injection in addition to the standard diphtheria, tetanus, and pertussis vaccine according to an accelerated 2, 3, and 4 month schedule without a booster dose in the second year of life. By October 1, 1992, more than 90% of infants in vaccine districts had received at least one dose of PRP-T. None of the infants given three doses had developed Hib infection, whereas 11 infections occurred in the control population (vaccine efficacy 100%, 95% Cl 80-100%). Intention-to-treat analysis also showed a high estimate of efficacy for the vaccine (90%, 50-99%). Follow-up of study children until November 1, 1993, has shown only 1 vaccine failure in an infant, and no invasive infections in those older than 1 year (average age 22 months). PRP-T vaccine had high protective efficacy with an accelerated immunisation schedule. Furthermore, the vaccine appears to remain protective through the second year of life without a booster dose. These findings provide encouragement for use of PRP-T in the Expanded Programme of Immunisation.	OXFORD RADCLIFE HOSP,DEPT PAEDIAT,OXFORD,ENGLAND; OXFORD RADCLIFFE HOSP,DEPT PUBL HLTH MED,OXFORD,ENGLAND; OXFORD RADCLIFFE HOSP,DEPT BACTERIOL,OXFORD,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND; RADCLIFFE INFIRM,DEPT COMMUNITY HLTH,OXFORD OX2 6HE,ENGLAND; BUCKINGHAMSHIRE HLTH AUTHOR,HIGH WYCOMBE,BUCKS,ENGLAND; KETTERING HLTH AUTHOR,DEPT COMMUNITY CHILD HLTH,KETTERING,NORTHANTS,ENGLAND; NORTHAMPTON GEN HOSP,CTR CHILD DEV,NORTHAMPTON,ENGLAND; MERLEUX UK,MALDENHEAD,ENGLAND	University of Oxford; University of Oxford; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary								BIJLMER HA, 1991, VACCINE, V9, pS5, DOI 10.1016/0264-410X(91)90172-3; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BOOY R, 1992, ARCH DIS CHILD, V67, P475, DOI 10.1136/adc.67.4.475; BOOY R, 1993, ARCH DIS CHILD, V68, P440, DOI 10.1136/adc.68.4.440; BOOY R, 1993, ARCH DIS CHILD, V69, P25; CLAYTON D, 1993, STATISTICAL MODELS E; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; FALLA TJ, 1993, 93RD AM SOC MICR GEN; FRITZELL B, 1992, J PEDIATR-US, V121, P355, DOI 10.1016/S0022-3476(05)81786-X; HOWARD AJ, 1991, BRIT MED J, V303, P441, DOI 10.1136/bmj.303.6800.441; ISTRE GR, 1985, J PEDIATR-US, V106, P190, DOI 10.1016/S0022-3476(85)80285-7; KAYHTY H, 1991, AM J DIS CHILD, V145, P223; KROLL JS, 1988, CELL, V53, P347, DOI 10.1016/0092-8674(88)90155-9; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; WENGER JD, 1991, LANCET, V338, P395; 1992, OFFICE POPULATION CE	19	104	106	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					362	366		10.1016/S0140-6736(94)91400-1	http://dx.doi.org/10.1016/S0140-6736(94)91400-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914306				2022-12-28	WOS:A1994PA30300009
J	POWSNER, SM; TUFTE, ER				POWSNER, SM; TUFTE, ER			GRAPHICAL SUMMARY OF PATIENT STATUS	LANCET			English	Article							MEDICAL-RECORD; INFORMATION; QUALITY; SYSTEM		YALE UNIV,DEPT PSYCHIAT,NEW HAVEN,CT 06520; YALE UNIV,CTR MED INFORMAT,NEW HAVEN,CT; YALE UNIV,DEPT COMP SCI,NEW HAVEN,CT 06520; YALE UNIV,DEPT GRAPH DESIGN,NEW HAVEN,CT; YALE UNIV,DEPT POLIT SCI,NEW HAVEN,CT; YALE UNIV,DEPT STAT,NEW HAVEN,CT	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University			Ross, Shane D/B-7237-2009	Ross, Shane D/0000-0001-5523-2376				BARNETT GO, 1978, MED CARE, V16, P962, DOI 10.1097/00005650-197811000-00007; BARNETT GO, 1993, ANN INTERN MED, V119, P1046, DOI 10.7326/0003-4819-119-10-199311150-00014; BORZO G, 1993, AM MED NEWS     1101, P9; BRINGHURST R, 1992, ELEMENTS TYPOGRAPHIC; CARTER M, 1982, BELL CENTENNIAL TYPE; DENISON DM, 1983, BR J DIS, V77, P36; DICK RS, 1991, COMPUTER BASED PATIE, P34; DONNELLY WJ, 1988, JAMA-J AM MED ASSOC, V260, P823, DOI 10.1001/jama.260.6.823; FEINSTEI.AR, 1973, ANN INTERN MED, V78, P751, DOI 10.7326/0003-4819-78-5-751; GORDON J, 1992, MED J AUSTRALIA, V156, P701, DOI 10.5694/j.1326-5377.1992.tb121511.x; HAYT E, 1964, LEGAL ASPECTS MED RE, P1; HAYT E, 1964, LEGAL ASPECTS MED RE, P3; HUFFMAN EK, 1955, MANUAL MED RECORD LI; Johnson J. A., 1993, Communications of the ACM, V36, P40, DOI 10.1145/255950.153576; MACDONALDROSS M, 1977, AV COMMUN REV, V25, P359; MASSARO TA, 1993, ACAD MED, V68, P20, DOI 10.1097/00001888-199301000-00003; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; ROBERT LL, 1989, COMPREHENSIVE TXB PS, P544; RODGERS JL, 1979, MED CARE, V17, P618; TUFTE ER, IN PRESS VISUAL EXPL; TUFTE ER, 1983, VISUAL DISPLAY QUANT, P160; Tufte ER., 1990, ENVISIONING INFORMAT, P67; VANDERLEI J, 1993, ANN INTERN MED, V119, P1036, DOI 10.7326/0003-4819-119-10-199311150-00011; WEED L L, 1964, Ir J Med Sci, V462, P271; WEED LL, 1968, NEW ENGL J MED, V278, P652, DOI 10.1056/NEJM196803212781204; WEED LL, 1968, NEW ENGL J MED, V278, P593, DOI 10.1056/NEJM196803142781105; WHITINGOKEEFE QE, 1985, JAMA-J AM MED ASSOC, V254, P1185, DOI 10.1001/jama.254.9.1185; WYATT JC, 1993, 17TH P AN S COMP APP, P834	28	124	130	0	22	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					386	389		10.1016/S0140-6736(94)91406-0	http://dx.doi.org/10.1016/S0140-6736(94)91406-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914312				2022-12-28	WOS:A1994PA30300015
J	JORGENSEN, HS; NAKAYAMA, H; RAASCHOU, HO; OLSEN, TS				JORGENSEN, HS; NAKAYAMA, H; RAASCHOU, HO; OLSEN, TS			EFFECT OF BLOOD-PRESSURE AND DIABETES ON STROKE IN PROGRESSION	LANCET			English	Article							SYSTEM CEREBRAL INFARCTION; PROFILE CLINICAL COURSE; ISCHEMIC STROKE	Progression of acute stroke after arrival at hospital is frequent and the prognosis severe. However, risk factors and mechanisms behind progression are largely unknown. A prospective, community-based study of 868 patients with acute stroke was undertaken to discover factors of importance in the development of stroke in progression. Diagnosis of progression was based on the Scandinavian Neurological Stroke Scale, Patients were divided according to whether progression occurred early (within 36 hours from stroke onset) or late (with in the first week from onset). Results were analysed by comparing patients with and without progression. Marked progression developed in 32%. Risk factors for early progression were identified as systolic blood pressure on admission (decreased the relative risk by 0.66 per 20 mm Hg increase, 95% Cl 0.55-0.83) and diabetes (increased the relative risk by 1.9, 95% Cl 1.1-3.3). Stroke severity was the only risk factor found in late progression (OR 1.4 per 20-point increase in stroke severity, 95% Cl 1.1-1.7).These relations were independent of age, sex, blood glucose, heart disease, and other stroke risk factors. Early progression is related to systolic blood pressure and diabetes. Late progression is related to initial stroke severity. Although this study does not prove that a causal relationship exists between systolic blood pressure and the development of early progression, such a relationship would, however, explain our findings.	BISPEBJERG HOSP, DEPT RADIOL, DK-2400 COPENHAGEN NV, DENMARK	University of Copenhagen; Bispebjerg Hospital	JORGENSEN, HS (corresponding author), BISPEBJERG HOSP, DEPT NEUROL, DK-2400 COPENHAGEN NV, DENMARK.							[Anonymous], 1989, Stroke, V20, P1407; ASPLUND K, 1985, STROKE, V16, P885; ASPLUND K, 1992, CEREBROVASC DIS, V2, P317, DOI 10.1159/000109037; ASPLUND K, 1993, THROMBOLYTIC THERAPY, V2, P119; BENTSEN N, 1975, STROKE, V6, P497, DOI 10.1161/01.STR.6.5.497; BRITTON M, 1986, STROKE, V17, P861, DOI 10.1161/01.STR.17.5.861; BRITTON M, 1985, STROKE, V16, P629, DOI 10.1161/01.STR.16.4.629; DAVALOS A, 1990, NEUROLOGY, V40, P1865, DOI 10.1212/WNL.40.12.1865; GAUTIER JC, 1985, STROKE, V16, P729, DOI 10.1161/01.STR.16.4.729; HACHINSKI V, 1985, ACUTE STROKE, P123; JONES HR, 1976, STROKE, V7, P64, DOI 10.1161/01.STR.7.1.64; JONES HR, 1980, STROKE, V11, P173, DOI 10.1161/01.STR.11.2.173; JORGENSEN HS, 1994, STROKE, V25, P97, DOI 10.1161/01.STR.25.1.97; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; MAHONEY F I, 1965, Md State Med J, V14, P61; MARCHAL G, 1993, LANCET, V341, P925, DOI 10.1016/0140-6736(93)91214-7; MILLIKAN CH, 1981, STROKE, V12, P397, DOI 10.1161/01.STR.12.4.397; Millikan CH, 1975, STROKE, V6, P564; OBRIEN MD, 1974, ARCH NEUROL-CHICAGO, V30, P461, DOI 10.1001/archneur.1974.00490360037008; OLSEN TS, 1983, STROKE, V14, P332, DOI 10.1161/01.STR.14.3.332; SHIMA T, 1983, J CEREB BLOOD FLO S1, V3, P620	21	252	258	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	1994	344	8916					156	159						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912765				2022-12-28	WOS:A1994NW81000009
J	THOMPSON, BT; COCKRILL, BA				THOMPSON, BT; COCKRILL, BA			RENAL-DOSE DOPAMINE - A SIREN SONG	LANCET			English	Editorial Material							BLOOD-FLOW; SHOCK				THOMPSON, BT (corresponding author), MASSACHUSETTS GEN HOSP,PULM & CRIT CARE UNIT,BOSTON,MA, USA.							BALDWIN L, 1994, ANN INTERN MED, V120, P744, DOI 10.7326/0003-4819-120-9-199405010-00004; BRESLOW MJ, 1987, AM J PHYSIOL, V252, pH291, DOI 10.1152/ajpheart.1987.252.2.H291; DASTA JF, 1986, PHARMACOTHERAPY, V6, P304; GIRAUD GD, 1984, J PHARMACOL EXP THER, V230, P214; GOLDBERG LI, 1972, PHARMACOL REV, V24, P1; GREENE SI, 1976, NEW ENGL J MED, V294, P114; ORME MLE, 1973, EUR J CLIN PHARMACOL, V6, P150, DOI 10.1007/BF00558278; PASS LJ, 1988, J THORAC CARDIOV SUR, V95, P608; PAWLIK W, 1976, AM HEART J, V75, P325; SCANNELL G, 1994, CRIT CARE MED, V22, pA187; SEGAL JM, 1992, J APPL PHYSIOL, V73, P1159, DOI 10.1152/jappl.1992.73.3.1159; SWYGERT TH, 1991, ANESTHESIOLOGY, V75, P571, DOI 10.1097/00000542-199110000-00005	12	78	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					7	8		10.1016/S0140-6736(94)91044-8	http://dx.doi.org/10.1016/S0140-6736(94)91044-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912346				2022-12-28	WOS:A1994NU91700007
J	ROEP, BO; HEIDENTHAL, E; DEVRIES, RRP; KOLB, H; MARTIN, S				ROEP, BO; HEIDENTHAL, E; DEVRIES, RRP; KOLB, H; MARTIN, S			SOLUBLE FORMS OF INTERCELLULAR-ADHESION MOLECULE-1 IN INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							CARDIAC ALLOGRAFT; ICAM-1; ANTIBODIES; LFA-1; PROTEIN; INVIVO; INJURY; CELLS	Soluble adhesion molecules are detectable at low levels in healthy people but are increased in various disorders. However, their physiological role is unknown. Circulating intercellular adhesion molecule-1 (clCAM-1) may modulate inflammation or a rise as a consequence of inflammation. We have described elevated concentrations of clCAM-1 in subjects at risk of developing insulin-dependent diabetes mellitus (IDDM), compared with recent-onset IDDM patients and healthy controls. Here we tested the ability of a monomeric soluble recombinant form of ICAM-1 (rlCAM-1), to prevent the proliferation of T cells to islet-cell and other antigens. We also tested the ability of two multivalent ICAM-1-immunoglobulin (ICAM-1-Ig) fusion proteins to stop proliferation of T cells in vitro. Autoreactive T-cell proliferation was suppressed by monoclonal antibodies directed against ICAM-1 or lymphocyte-function antigen-1 (LFA-1). Furthermore, 100 mu mol rlCAM-1 blocked T-cell proliferation in response to an islet-cell autoantigen, and multivalent ICAM-1-Ig fusion proteins were approximately 1000-fold more effective. The usual interleukin-2-induced proliferation of T cells was unaffected by ICAM or ICAM-Ig. In addition, rlCAM-1 blocked primary T-cell responses from peripheral blood mononuclear cells of newly diagnosed IDDM patients in concentrations similar to elevated clCAM-1 concentrations in individuals at risk for the disease. Thus, naturally circulating ICAM-1 may downregulate inflammation in subjects at risk of developing IDDM. Ig-ICAM-1 fusion proteins may thus provide novel means to intervene in the pathogenesis of autoimmune diseases.	UNIV DUSSELDORF,DIABET RES INST,DEPT CLIN,D-40225 DUSSELDORF,GERMANY; UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,BLOOD BANK,2300 RC LEIDEN,NETHERLANDS	Heinrich Heine University Dusseldorf; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)			Roep, Bart/AAD-7609-2021					ALTMANN DM, 1989, NATURE, V338, P512, DOI 10.1038/338512a0; [Anonymous], 1988, DIABETES, V37, P1574, DOI 10.2337/diabetes.37.11.15742903105; ARGENBRIGHT LW, 1992, J CLIN INVEST, V89, P259, DOI 10.1172/JCI115570; ASSAN R, 1985, LANCET, V2, P119; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BARTON RW, 1989, J IMMUNOL, V143, P1278; BECKER JC, 1991, J IMMUNOL, V147, P4398; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DOUGHERTY GJ, 1988, EUR J IMMUNOL, V18, P35, DOI 10.1002/eji.1830180107; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FLAVIN T, 1991, TRANSPLANT P, V23, P533; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; IIGO Y, 1991, J IMMUNOL, V147, P4167; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KAKIMOTO K, 1992, CELL IMMUNOL, V142, P326, DOI 10.1016/0008-8749(92)90294-Y; LAMPETER ER, 1992, DIABETES, V41, P1668, DOI 10.2337/diabetes.41.12.1668; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MIYAZAKI A, 1992, CLIN EXP IMMUNOL, V89, P52; NISHIKAWA K, 1993, J EXP MED, V177, P667, DOI 10.1084/jem.177.3.667; PATARROYO M, 1991, CLIN IMMUNOL IMMUNOP, V60, P333, DOI 10.1016/0090-1229(91)90091-N; ROEP BO, 1990, NATURE, V345, P632, DOI 10.1038/345632a0; ROEP BO, 1991, LANCET, V337, P1439, DOI 10.1016/0140-6736(91)93127-U; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579	24	96	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1590	1593		10.1016/S0140-6736(94)93055-4	http://dx.doi.org/10.1016/S0140-6736(94)93055-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911918				2022-12-28	WOS:A1994NU35400008
J	WEG, JG; BALK, RA; THARRATT, RS; JENKINSON, SG; SHAH, JB; ZACCARDELLI, D; HORTON, J; PATTISHALL, EN				WEG, JG; BALK, RA; THARRATT, RS; JENKINSON, SG; SHAH, JB; ZACCARDELLI, D; HORTON, J; PATTISHALL, EN			SAFETY AND POTENTIAL EFFICACY OF AN AEROSOLIZED SURFACTANT IN HUMAN SEPSIS-INDUCED ADULT-RESPIRATORY-DISTRESS-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SYNTHETIC SURFACTANT; PULMONARY SURFACTANT; EXOGENOUS SURFACTANT; LUNG INJURY; MORTALITY; FAILURE; DELIVERY; SYSTEM	Objective.-To evaluate the safety and potential efficacy of aerosolized surfactant in intubated patients with adult respiratory distress syndrome (ARDS). Design.-A prospective, double-blind, placebo-controlled, randomized, parallel, mutlicenter pilot clinical trial. Patients.-A total of 51 patients with sepsis-induced ARDS were entered into the study within 18 hours of developing sepsis or sepsis syndrome. Intervention.-Patients were randomized into four treatment groups in a 2:1:2:1 ratio, as follows: 12 hours of surfactant per day, 12 hours of 0.6% saline per day, 24 hours of surfactant per day, and 24 hours of 0.6% saline per day. Surfactant or saline was aerosolized continuously for up to 5 days using an in-line nebulizer that aerosolized only during inspiration. Main Outcome Measures.-Ventilatory data, arterial blood gases, and hemodynamic parameters were measured at baseline, every 4 or 8 hours during the 5 days of treatment, 24 hours after treatment, and 30 days after treatment, at which time mortality was also assessed. Safety was evaluated throughout the 30 days of the study. Results.-Surfactant was administered safely in ventilated patients when given continuously throughout the 5 days using the nebulizer system. Although there were no differences in any physiological parameter between the treatment groups, there was a dose-dependent trend in reduction of mortality from 47% in the combined placebo group to 41% and 35% in the groups treated with 12 hours and 24 hours of surfactant per day, respectively. Conclusions-Aerosolized surfactant was well tolerated when administered on a continuous basis for up to 5 days; however, at the doses given, it did not result in significant improvements in patients with sepsis-induced ARDS.	RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PULM & CRIT CARE MED,CHICAGO,IL 60612; UNIV CALIF DAVIS,CTR MED,DIV PULM & CRIT CARE MED,SACRAMENTO,CA; AUDIE L MURPHY VET AFFAIRS HOSP,PULM DIS SECT,SAN ANTONIO,TX; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANESTHESIOL,RICHMOND,VA 23298; BURROUGHS WELLCOME CO,DIV CLIMATE RES,RES TRIANGLE PK,NC 27709	Rush University; University of California System; University of California Davis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Virginia Commonwealth University; Burroughs Wellcome Fund	WEG, JG (corresponding author), UNIV MICHIGAN,CTR MED,DEPT INTERNAL MED,DIV PULM & CRIT CARE MED,ROOM B1H245-0026,ANN ARBOR,MI 48109, USA.							ASHBAUGH DG, 1967, LANCET, V2, P319; BARTMANN P, 1992, J PERINAT MED, V20, P189, DOI 10.1515/jpme.1992.20.3.189; BERNARD GR, 1986, HEART LUNG, V15, P250; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CHAN CYJ, 1992, CLIN PHARMACY, V11, P880; DANTZKER DR, 1979, AM REV RESPIR DIS, V120, P1039; DURAND DJ, 1985, J PEDIATR-US, V107, P775, DOI 10.1016/S0022-3476(85)80416-9; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; FUCHIMUKAI T, 1987, J APPL PHYSIOL, V62, P429, DOI 10.1152/jappl.1987.62.2.429; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; HAAS CF, 1993, CRIT CARE MED, V21, P125, DOI 10.1097/00003246-199301000-00023; HALLMAN M, 1991, ACTA ANAESTH SCAND, V35, P15, DOI 10.1111/j.1399-6576.1991.tb03395.x; HOLLANDER M, 1973, NONPARAMETRIC STATIS; HOLM B A, 1989, P273; HOLM BA, 1989, ANESTH ANALG, V69, P805; HOLM BA, 1987, J APPL PHYSIOL, V62, P2230, DOI 10.1152/jappl.1987.62.6.2230; HORBAR JD, 1993, PEDIATRICS, V92, P191; HYERS TM, 1986, FASEB J, V45, P25; LACHMANN B, 1987, EXP LUNG RES, V12, P163, DOI 10.3109/01902148709062839; LACHMANN B, 1989, EUR RESPIR J S3, V2, pS98; LEWIS J, 1991, J APPL PHYSIOL, V71, P1270, DOI 10.1152/jappl.1991.71.4.1270; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; LONG W, 1991, NEW ENGL J MED, V325, P1696, DOI 10.1056/NEJM199112123252404; MACINTYRE NR, 1985, CRIT CARE MED, V13, P81, DOI 10.1097/00003246-198502000-00005; MERRITT TA, 1989, DRUGS, V38, P591, DOI 10.2165/00003495-198938040-00006; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MORRIS AH, 1992, AM REV RESPIR DIS, V145, pA60; PATTISHALL E, 1992, American Review of Respiratory Disease, V145, pA79; PISON U, 1990, J TRAUMA, V30, P19, DOI 10.1097/00005373-199001000-00003; RAABE OG, 1989, J AEROSOL MED, V2, P201; RICHMAN PS, 1989, EUR RESPIR J S3, V2, pS109; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; THOMASSEN MJ, 1992, AM J RESP CELL MOL, V7, P257, DOI 10.1165/ajrcmb/7.3.257; WEG JG, 1991, CRIT CARE MED, V19, P650, DOI 10.1097/00003246-199105000-00011; 1979, EXTRACORPOREAL SUPPO, P243	37	113	118	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1433	1438		10.1001/jama.272.18.1433	http://dx.doi.org/10.1001/jama.272.18.1433			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP690	7933425				2022-12-28	WOS:A1994PP69000031
J	MOORE, S; WOLFE, SM; LINDES, D; DOUGLAS, CE				MOORE, S; WOLFE, SM; LINDES, D; DOUGLAS, CE			EPIDEMIOLOGY OF FAILED TOBACCO CONTROL LEGISLATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate the influence of tobacco industry campaign donations, district location, and political party affiliation on tobacco control legislation among members of the US Congress. Design.-Data were obtained from the Federal Election Commission on money contributed by the 10 leading tobacco political action committees and by tobacco industry-aligned individuals to members of the US House of Representatives (1991-1992) and Senate (1987-1992). Logistic regression analyses were performed using recorded votes and cosponsorship activities concerning tobacco control legislation during the 102nd and 103rd Congresses and membership on the House Congressional Task Force on Tobacco and Health as the dependent variables and tobacco money received, party, district location, and caucus or committee membership as the independent variables. Setting.-United States Congress in 1991 and 1992. Interventions.-None. Main Outcome Measure.-Support for federal tobacco control legislation. Results.-The tobacco industry donated approximately $2.4 million to members of Congress from January 1991 through December 1992. House members received an average of $2943 (1991-1992) and senators received an average of $11593 (1937-1992). The more tobacco money a member received, the less likely the member was to support tobacco control legislation. In the Senate, on a vote to end the taxpayer subsidy of tobacco products in military stores, the odds ratio that senators in the top quartile of tobacco money recipients did not support the measure vs senators in the lowest quartile of tobacco money recipients was 42.2 (95% confidence interval, 4.1 to 430.0; P<.001). In the House, on a vote to end a $3.5 million subsidy to promote American tobacco abroad, the odds that House members in the top third of tobacco money recipients would oppose the legislation were 14.4 times greater (95% confidence interval, 5.5 to 39.0; P<.001) than for House members in the lowest third of tobacco money recipients. Receiving more tobacco money, being a member of the Republican party, and representing a tobacco producing state were all associated with decreased support for tobacco control issues. The amount of tobacco money received was the variable most strongly and consistently associated with a lack of support for tobacco control legislation, even when we controlled for additional factors such as district location and party. Conclusion.-Tobacco industry contributions to members of the US Congress strongly influence the federal tobacco policy process. Unless this influence is diminished through a combination of members refusing tobacco money and campaign finance reform, this process of contributing to death by thwarting tobacco control will continue to claim hundreds of thousands of lives a year.	PUBL CITIZENS HLTH RES GRP,WASHINGTON,DC 20036; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,PREVENT MED RESIDENCY PROGRAM,BALTIMORE,MD; WASHINGTON UNIV,ST LOUIS,MO; AMER CANC SOC,WASHINGTON,DC	Johns Hopkins University; Washington University (WUSTL); American Cancer Society								BEGAY ME, 1993, AM J PUBLIC HEALTH, V83, P1214, DOI 10.2105/AJPH.83.9.1214; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MOORE S, 1993, CONTRIBUTING DEATH I; WOLFE SM, 1993, PUBLIC CITIZEN HLTH, V9, P1; 1992, STATISTICAL ABSTRACT, P733; 1993, SAVING LIVES RAISING	6	55	55	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1171	1175		10.1001/jama.272.15.1171	http://dx.doi.org/10.1001/jama.272.15.1171			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL212	7933346				2022-12-28	WOS:A1994PL21200030
J	PRITCHARD, J; HICKMAN, JA				PRITCHARD, J; HICKMAN, JA			WHY DOES STAGE 4S NEUROBLASTOMA REGRESS SPONTANEOUSLY	LANCET			English	Note							CELL-DEATH; IV-S; APOPTOSIS; BCL-2; DNA; INDUCTION; RECEPTOR; PROTEIN		INST CHILD HLTH,LONDON WC1N 3JH,ENGLAND; UNIV MANCHESTER,CRC,MOLEC & CELLULAR PHARMACOL RES GRP,MANCHESTER,ENGLAND	University of London; University College London; University of Manchester	PRITCHARD, J (corresponding author), GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT HAEMATOL & ONCOL,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.							ALLEN RC, 1992, AM J HUM GENET, V51, P1229; ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; BOURHIS J, 1991, J CLIN ONCOL, V9, P1371, DOI 10.1200/JCO.1991.9.8.1371; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; CASTLE VP, 1993, AM J PATHOL, V143, P1543; CHALLIS GB, 1990, ACTA ONCOL, V29, P545, DOI 10.3109/02841869009090048; DANGIO GJ, 1971, LANCET, V1, P1046; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; HANADA M, 1993, CANCER RES, V53, P4978; HELLSTROM IE, 1968, P NATL ACAD SCI USA, V60, P1231, DOI 10.1073/pnas.60.4.1231; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; JAFFE N, 1976, CANCER TREAT REV, V3, P61, DOI 10.1016/S0305-7372(76)80005-9; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; KORSMEYER SJ, 1992, BLOOD, V80, P879; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NINANE J, 1982, ARCH DIS CHILD, V57, P438, DOI 10.1136/adc.57.6.438; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OLIVER RTD, 1992, CANCER SURV, V13, P173; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RANGEGROFT L, 1977, ARCH DIS CHILD, V53, P815; WILSON PCG, 1991, MED PEDIATR ONCOL, V19, P467, DOI 10.1002/mpo.2950190604; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057	24	96	96	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					869	870		10.1016/S0140-6736(94)92834-7	http://dx.doi.org/10.1016/S0140-6736(94)92834-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916408				2022-12-28	WOS:A1994PH25300018
J	MANABE, T; NICOLL, RA				MANABE, T; NICOLL, RA			LONG-TERM POTENTIATION - EVIDENCE AGAINST AN INCREASE IN TRANSMITTER RELEASE PROBABILITY IN THE CA1 REGION OF THE HIPPOCAMPUS	SCIENCE			English	Article							PAIRED-PULSE; FACILITATION; TRANSMISSION; ENHANCEMENT; MECHANISMS; CURRENTS; INVITRO; NEURONS; SYNAPSE; SLICES	It is widely accepted that N-methyl-D-aspartate (NMDA)-receptor-dependent long-term potentiation (LTP) in the CA1 region of the hippocampus is triggered postsynaptically, but there is considerable debate as to the site at which the increase in synaptic strength is expressed. The irreversible open-channel blocking action of the NMDA receptor antagonist MK-801 has been used to test whether the probability of transmitter release (P-r) is increased during LTP. Although the rate of decline of the amplitude of the NMDA receptor-mediated excitatory postsynaptic current (EPSC) in the presence of MK-801 strongly depends on P-r, the rate of decline of the EPSC evoked at synapses expressing LTP is identical to that observed at synapses not expressing LTP. These findings are difficult to reconcile with models in which the expression of LTP is due to an increase in P-r.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,TOKYO 113,JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Tokyo								BAUDRY M, 1991, LONG TERM POTENTIATI; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GUSTAFSSON B, 1988, NEUROSCI LETT, V85, P77, DOI 10.1016/0304-3940(88)90432-6; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MULLER D, 1989, BRAIN RES, V479, P290, DOI 10.1016/0006-8993(89)91631-4; NICOLL RA, 1994, CELLULAR MOL MECHANI, P189; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; VORONIN LL, 1990, NEUROSCI RES COMMUN, V6, P149; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	24	117	118	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1888	1892		10.1126/science.7916483	http://dx.doi.org/10.1126/science.7916483			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7916483				2022-12-28	WOS:A1994PH25800040
J	OOSTVOGEL, PM; VANWIJNGAARDEN, JK; VANDERAVOORT, HGAM; MULDERS, MN; CONYNVANSPAENDONCK, MAE; RUMKE, HC; VANSTEENIS, G; VANLOON, AM				OOSTVOGEL, PM; VANWIJNGAARDEN, JK; VANDERAVOORT, HGAM; MULDERS, MN; CONYNVANSPAENDONCK, MAE; RUMKE, HC; VANSTEENIS, G; VANLOON, AM			POLIOMYELITIS OUTBREAK IN AN UNVACCINATED COMMUNITY IN THE NETHERLANDS, 1992-93	LANCET			English	Article							PARALYTIC POLIOMYELITIS; WILD POLIOVIRUS; EPIDEMIC; VACCINE	An outbreak of poliomyelitis occurred in the Netherlands between September, 1992, and February, 1993, after 14 years without endemic cases. The outbreak was due to pollovirus type 3 and involved 71 patients, of whom 2 died and 59 had paralysis. The patients were aged between 10 days and 61 years (median 18 years). None of the patients had been vaccinated, and all but 1 belonged to a socially and geographically clustered group of people who refuse vaccination for religious reasons. Control measures were taken within 5 days of notification of the first patient and included a wide offer of vaccination with the trivalent oral poliovirus vaccine to the population at risk. Sequence analysis of the viral genome showed closest similarity (96.7%) with a strain isolated in India in 1992, indicating that the virus probably originates from the Indian subcontinent. The difference, however, is still too large to assume direct import. Extensive outbreak investigation at schools, in the environment, at virus diagnostic laboratories, and in the general population showed no evidence of widespread circulation of the epidemic virus outside the groups at risk and area where these groups live. As in the previous outbreak in 1978, the general population, including the majority of unvaccinated people who live dispersed in the population, seemed to be well-protected against poliomyelitis.	NATL INST PUBL HLTH & ENVIRONM PROTECT,VIROL LAB,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,WHO,COLLABORATING CTR REFERENCE & RES POLIOMYELITIS,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT INFECT DIS EPIDEMIOL,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,CLIN VACCINE RES LAB,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,CONTROL BIOL PROD LAB,3720 BA BILTHOVEN,NETHERLANDS; MED INSPECTORATE HLTH,RIJSWIJK,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; World Health Organization; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment								BIJKERK H, 1984, REV INFECT DIS, V6, pS451; BIJKERK H, 1981, DEV BIOL STAND, V47, P233; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; Expanded programme on immunization, 1993, WKLY EPIDEMIOL REC, V68, P297; HOVI T, 1986, LANCET, V1, P1427; KIMFARLEY RJ, 1984, LANCET, V2, P1322; Nibbeling R, 1994, Clin Diagn Virol, V2, P113, DOI 10.1016/0928-0197(94)90044-2; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; Rumke H C, 1993, Ned Tijdschr Geneeskd, V137, P1380; SCHAAP GJP, 1984, PROG MED VIROL, V29, P124; SLATER PE, 1990, LANCET, V335, P1192, DOI 10.1016/0140-6736(90)92705-M; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; VANDENKERKHOF H, 1993, B INFECT, V4, P203; VANLOON AM, 1993, MEASLES POLIOMYELITI, P359; VANWEZEL AL, 1979, INTERVIROLOGY, V11, P1; VERBRUGGE HP, 1990, PEDIATRICS, V86, P1060; WHITE FMM, 1981, CANJ PUBL HLTH, V72, P119; WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504; YANG CF, 1991, VIRUS RES, V20, P159; 1979, MMWR-MORBID MORTAL W, V28, P345; 1993, CCDR, V19, P96; 1992, WKLY EPIDEMIOL REC, V67, P336	22	169	172	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					665	670		10.1016/S0140-6736(94)92091-5	http://dx.doi.org/10.1016/S0140-6736(94)92091-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915354				2022-12-28	WOS:A1994PE38600016
J	HALL, CB				HALL, CB			PROSPECTS FOR A RESPIRATORY SYNCYTIAL VIRUS-VACCINE	SCIENCE			English	Editorial Material							BALB/C MICE; IMMUNIZATION				HALL, CB (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT & MED,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.							ALWAN WH, 1994, J EXP MED, V179, P81, DOI 10.1084/jem.179.1.81; CHANOCK RM, 1992, PEDIATRICS, V90, P137; CONNORS M, 1992, J VIROL, V66, P7444, DOI 10.1128/JVI.66.12.7444-7451.1992; CROWE JE, 1994, P NATL ACAD SCI USA, V91, P1386, DOI 10.1073/pnas.91.4.1386; FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956; GOSSELIN EJ, 1992, J IMMUNOL, V149, P3477; GRAHAM BS, 1993, J IMMUNOL, V151, P2032; Hall C.B., 1992, TXB PEDIAT INFECT DI, P1633; HEILMAN CA, 1990, J INFECT DIS, V161, P402, DOI 10.1093/infdis/161.3.402; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; MURPHY BR, 1988, J CLIN MICROBIOL, V26, P1595, DOI 10.1128/JCM.26.8.1595-1597.1988; PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3; TRUDEL M, 1992, VACCINE, V10, P107, DOI 10.1016/0264-410X(92)90026-G; Wertz G W, 1992, Biotechnology, V20, P151	16	75	88	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1393	1394		10.1126/science.7915433	http://dx.doi.org/10.1126/science.7915433			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	7915433				2022-12-28	WOS:A1994PE73300034
J	HOUBIERS, JGA; BRAND, A; VANDEWATERING, LMG; HERMANS, J; VERWEY, PJM; BIJNEN, AB; PAHLPLATZ, P; SCHATTENKERK, ME; WOBBES, T; DEVRIES, JE; KLEMENTSCHITSCH, P; VANDEMAAS, AHM; VANDEVELDE, CJH				HOUBIERS, JGA; BRAND, A; VANDEWATERING, LMG; HERMANS, J; VERWEY, PJM; BIJNEN, AB; PAHLPLATZ, P; SCHATTENKERK, ME; WOBBES, T; DEVRIES, JE; KLEMENTSCHITSCH, P; VANDEMAAS, AHM; VANDEVELDE, CJH			RANDOMIZED CONTROLLED TRIAL COMPARING TRANSFUSION OF LEUKOCYTE-DEPLETED OR BUFFY-COAT-DEPLETED BLOOD IN SURGERY FOR COLORECTAL-CANCER	LANCET			English	Article							POSTOPERATIVE SEPTIC COMPLICATIONS; LARGE BOWEL-CANCER; INFECTIOUS COMPLICATIONS; MULTIVARIATE-ANALYSIS; SURVIVAL; CARCINOMA; ASSOCIATION; RECURRENCE; PROGNOSIS; RESECTION	In retrospective studies, perioperative blood transfusions were associated with poor prognosis after surgery for cancer and were a major independent risk factor for postoperative bacterial infection. Leucocyte-depleted, in contrast to buffy-coat-depleted, blood has no immunosuppressive effects in transplantation and so might lack detrimental effects on cancer prognosis and postoperative infections. We studied this hypothesis in a controlled trial by randomly allocating patients to receive either leucocyte-depleted red cells or packed cells without buffy coat when blood was needed. Between 1987 and 1990, 871 eligible patients with colorectal cancer, including 697 patients operated upon with curative intent, were randomised in the 16 participating hospitals. Neither the eligible group nor the curative group showed significant differences between the two trial transfusions in survival, disease-free survival, cancer recurrence rates, or overall infection rates after an average follow-up of 36 months. Patients who had a curative resection and who received blood of a ny sort had a lower 3-year survival than non-transfused patients (69% vs 81%, p=0.001) and a higher infection rate (39% vs 24%, p<0.001). Colorectal cancer recurrence rates, however, were not influenced by blood transfusion (30% vs 26%, p=0.22). These combined observations confirm the association between blood transfusion and poor patient survival but indicate that the relation is not due to promotion of cancer.	UNIV LEIDEN HOSP,DEPT SURG,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT IMMUNOHAEMATOL,2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,BLOOD BANK,2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT MED STAT,2300 RA LEIDEN,NETHERLANDS; MED CENTRUM ALKMAAR,ALKMAAR,NETHERLANDS; LEYENBURG ZIEKENHUIS,THE HAGUE,NETHERLANDS; STICHTING DEVENTER ZIEKENHUIS,DEVENTER,NETHERLANDS; UNIV NIJMEGEN HOSP,NIJMEGEN,NETHERLANDS; SOPHIA HOSP,ZWOLLE,NETHERLANDS; ZIEKENHUIS WEEZENLANDEN,ZWOLLE,NETHERLANDS; RIJNSTATE ZIEKENHUIZEN,ARNHEM,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC; Medical Center Of Alkmaar; Deventer Hospital; Radboud University Nijmegen; Rijnstate Hospital								ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015; BRAGA M, 1992, EUR J SURG, V158, P531; BURROWS L, 1982, LANCET, V2, P662; BUSCH ORC, 1993, NEW ENGL J MED, V328, P1372, DOI 10.1056/NEJM199305133281902; CHAPUIS PH, 1985, BRIT J SURG, V72, P698, DOI 10.1002/bjs.1800720909; CHUNG M, 1993, BRIT J SURG, V80, P427, DOI 10.1002/bjs.1800800407; DAWES LG, 1986, SURGERY, V100, P796; FRANCIS DMA, 1991, BRIT J SURG, V78, P1420, DOI 10.1002/bjs.1800781205; GANTT CL, 1981, LANCET, V2, P363; HEISS MM, 1993, LANCET, V342, P1328, DOI 10.1016/0140-6736(93)92247-Q; HEISS MM, 1992, P AN M AM SOC CLIN, V11, P172; HOUBIERS JGA, 1994, LANCET, V343, P668; JAHNSON S, 1992, EUR J SURG, V158, P419; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; JENSEN LS, 1990, BRIT J SURG, V77, P513, DOI 10.1002/bjs.1800770514; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LEARDI S, 1989, Annali Italiani di Chirurgia, V60, P537; LIEWALD F, 1990, EUR J CANCER, V26, P327, DOI 10.1016/0277-5379(90)90230-Q; MASSE M, 1991, TRANSFUSION, V31, P792, DOI 10.1046/j.1537-2995.1991.31992094664.x; PERSIJN GG, 1979, TRANSPLANTATION, V28, P396, DOI 10.1097/00007890-197911000-00010; PIETERSZ RNI, 1992, VOX SANG, V62, P76, DOI 10.1111/j.1423-0410.1992.tb01174.x; PINTO V, 1991, TRANSFUSION, V31, P114, DOI 10.1046/j.1537-2995.1991.31291142940.x; RAPAPORT FT, 1983, TRANSPLANT P, V15, P952; TANG RP, 1993, CANCER, V72, P341, DOI 10.1002/1097-0142(19930715)72:2<341::AID-CNCR2820720206>3.0.CO;2-E; TARTTER PI, 1988, BRIT J SURG, V75, P789, DOI 10.1002/bjs.1800750822; TARTTER PI, 1992, ANN SURG, V216, P633, DOI 10.1097/00000658-199212000-00004; TARTTER PI, 1988, AM J SURG, V155, P43, DOI 10.1016/S0002-9610(88)80256-3; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; VANPABST WPV, 1988, EUR J CANCER CLIN ON, V24, P741, DOI 10.1016/0277-5379(88)90309-4; VANTWUYVER E, 1991, NEW ENGL J MED, V325, P1210, DOI 10.1056/NEJM199110243251704; VOOGT PJ, 1987, CANCER, V59, P836, DOI 10.1002/1097-0142(19870215)59:4<836::AID-CNCR2820590430>3.0.CO;2-S; WIGGERS T, 1988, CANCER, V61, P386, DOI 10.1002/1097-0142(19880115)61:2<386::AID-CNCR2820610231>3.0.CO;2-J; WOBBES T, 1990, SURG GYNECOL OBSTET, V171, P59; WOBBES T, 1989, DIS COLON RECTUM, V32, P743, DOI 10.1007/BF02562121	34	313	317	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					573	578		10.1016/S0140-6736(94)91965-8	http://dx.doi.org/10.1016/S0140-6736(94)91965-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914960				2022-12-28	WOS:A1994PD42400009
J	RAYMOND, EG; TAFARI, N; TROENDLE, JF; CLEMENS, JD				RAYMOND, EG; TAFARI, N; TROENDLE, JF; CLEMENS, JD			DEVELOPMENT OF A PRACTICAL SCREENING TOOL TO IDENTIFY PRETERM, LOW-BIRTH-WEIGHT NEONATES IN ETHIOPIA	LANCET			English	Article							LOW-BIRTH-WEIGHT; INTRAUTERINE GROWTH-RETARDATION; DEVELOPING-COUNTRIES; MORTALITY; CIRCUMFERENCE; INFANTS; ARM; PREMATURITY; MORBIDITY; HEAD	Preterm, low-birthweight (LBW) newborn infants are at high risk of neonatal mortality and morbidity and need early referral for special paediatric care. In developing countries, birthweight and gestational age often cannot be measured and a practical screening tool based on surrogate neonatal body measurements to identify high-risk infants would be very useful. We studied a consecutive series of 843 singleton infants born at a referral hospital in Addis Ababa, Ethiopia. Gestational age, birthweight, and four body measurements (chest, head, and mid-arm circumferences and length) were accurately recorded. We randomly divided the series into equal-sized training and validation groups. In the training group, we used a recursive partitioning technique to develop a simple predictive algorithm-infants were classified as high risk if head circumference was 31 cm or less or if chest circumference was 30 cm or less, and were classified as low risk otherwise. When tested in the validation group, this algorithm had sensitivity, specificity, and negative predictive value for prediction of preterm and LBW births above 90%. Thus, neonatal body measurements can be combined into a pragmatic, accurate screening tool suitable for clinical use in developing countries.	NICHHD,DIV EPIDEMIOL STAT & PREVENT RES,ROCKVILLE,MD 20852; UNIV ADDIS ABABA,FAC MED,DEPT PEDIAT,ADDIS ABABA,ETHIOPIA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Addis Ababa University								Alves J G, 1991, Bull Pan Am Health Organ, V25, P207; ARIAS F, 1982, OBSTET GYNECOL, V60, P277; BHARGAVA SK, 1985, BMJ-BRIT MED J, V291, P1617, DOI 10.1136/bmj.291.6509.1617; Breiman L., 1984, CLASSIFICATION REGRE; DIAMOND ID, 1991, J TROP PEDIATRICS, V37, P323, DOI 10.1093/tropej/37.6.323; DUSITSIN N, 1991, AM J PUBLIC HEALTH, V81, P1201, DOI 10.2105/AJPH.81.9.1201; EREGIE CO, 1991, J TROP PEDIATRICS, V37, P182, DOI 10.1093/tropej/37.4.182; GEBREMEDHIN M, 1978, ACTA PAEDIATR SCAND, V67, P781, DOI 10.1111/j.1651-2227.1978.tb16261.x; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOZAL D, 1991, J PEDIATR-US, V118, P800, DOI 10.1016/S0022-3476(05)80049-6; GRAY RH, 1991, INT J EPIDEMIOL, V20, P467, DOI 10.1093/ije/20.2.467; HUQUE F, 1991, Indian Journal of Pediatrics, V58, P223, DOI 10.1007/BF02751125; KRAMER MS, 1989, PEDIATRICS, V84, P717; LANDICHO B, 1985, J TROP PEDIATRICS, V31, P301, DOI 10.1093/tropej/31.6.301; MOHAN M, 1991, Indian Pediatrics, V28, P1299; NEELAJ, 1991, INDIAN PEDIATR, V28, P881; SAUERBORN R, 1990, TROP MED PARASITOL, V41, P65; SHARMA J N, 1989, Indian Pediatrics, V26, P348; STARFIELD B, 1982, J PEDIATR-US, V101, P978, DOI 10.1016/S0022-3476(82)80025-5; VICTORA CG, 1987, INT J EPIDEMIOL, V16, P239, DOI 10.1093/ije/16.2.239; VILLAR J, 1986, EARLY HUM DEV, V14, P307, DOI 10.1016/0378-3782(86)90193-3; VILLAR J, 1982, AM J OBSTET GYNECOL, V143, P793, DOI 10.1016/0002-9378(82)90012-6; VILLAR J, 1986, B WORLD HEALTH ORGAN, V64, P847; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; 1993, B WORLD HEALTH ORGAN, V71, P157	25	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					524	527		10.1016/S0140-6736(94)91905-4	http://dx.doi.org/10.1016/S0140-6736(94)91905-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914620				2022-12-28	WOS:A1994PC53500016
J	SKINGLE, SJ; CRISP, AJ				SKINGLE, SJ; CRISP, AJ			INCREASED BONE-DENSITY IN PATIENTS ON STEROIDS WITH ETIDRONATE	LANCET			English	Letter							POSTMENOPAUSAL OSTEOPOROSIS				SKINGLE, SJ (corresponding author), ADDENBROOKES HOSP,DEPT RHEUMATOL,BOX 204,CAMBRIDGE CB2 2QQ,ENGLAND.							MULDER H, 1994, BRIT J RHEUMATOL, V33, P348; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	3	27	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					543	544		10.1016/S0140-6736(94)91932-1	http://dx.doi.org/10.1016/S0140-6736(94)91932-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914635				2022-12-28	WOS:A1994PC53500047
J	VALLANCE, P; COLLIER, J				VALLANCE, P; COLLIER, J			FORTNIGHTLY REVIEW - BIOLOGY AND CLINICAL RELEVANCE OF NITRIC-OXIDE	BRITISH MEDICAL JOURNAL			English	Article							L-ARGININE; ULCERATIVE-COLITIS; 7-NITRO INDAZOLE; SYNTHASE; INHIBITOR; PHARMACOLOGY; DISEASE; PATHWAY; RATS				VALLANCE, P (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,CLIN PHARMACOL UNIT,LONDON SW17 0RE,ENGLAND.							BAGETTA G, 1993, BRIT J PHARMACOL, V108, P858, DOI 10.1111/j.1476-5381.1993.tb13477.x; BARBUL A, 1986, JPEN-PARENTER ENTER, V10, P227, DOI 10.1177/0148607186010002227; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BOUGHTONSMITH NK, 1993, LANCET, V342, P338, DOI 10.1016/0140-6736(93)91476-3; BREDT D, 1993, ENDOTHELIUM S, V1, pS6; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; CALVER A, 1993, EXP PHYSIOL, V78, P303, DOI 10.1113/expphysiol.1993.sp003687; CONRAD KP, 1993, FASEB J, V7, P566, DOI 10.1096/fasebj.7.6.7682524; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DEBELDER AJ, 1994, CARDIOVASC RES, V28, P591; DREXLERH, 1991, LANCET, V338, P1546; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HENDERSON AH, 1992, CARDIOVASC RES, V26, P305, DOI 10.1093/cvr/26.4.305; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; KURTZMAN J, 1993, ENDOTHELIUM S, V1, pS75; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE PK, 1993, BRIT J PHARMACOL, V108, P296, DOI 10.1111/j.1476-5381.1993.tb12798.x; MOORE PK, 1993, BRIT J PHARMACOL, V110, P219, DOI 10.1111/j.1476-5381.1993.tb13795.x; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; RIEGEL F, 1876, CYCLOPAEDIA PRACTICE, V4, P275; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SNYDER SH, 1993, NATURE, V364, P577, DOI 10.1038/364577a0; Vallance P, 1993, New Horiz, V1, P77; VALLANCE P, 1992, LANCET, V339, P572	30	119	123	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					453	457		10.1136/bmj.309.6952.453	http://dx.doi.org/10.1136/bmj.309.6952.453			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920131	Green Published			2022-12-28	WOS:A1994PC40400023
J	ROZE, JC; STORME, L; ZUPAN, V; MORVILLE, P; DINHXUAN, AT; MERCIER, JC				ROZE, JC; STORME, L; ZUPAN, V; MORVILLE, P; DINHXUAN, AT; MERCIER, JC			ECHOCARDIOGRAPHIC INVESTIGATION OF INHALED NITRIC-OXIDE IN NEWBORN BABIES WITH SEVERE HYPOXEMIA	LANCET			English	Note							PERSISTENT PULMONARY-HYPERTENSION; RESPIRATORY-DISTRESS SYNDROME	Nitric oxide inhalation can benefit newborn babies with right-to-left extrapulmonary shunt (EPS). Using doppler ultrasound, we compared the effects of nitric oxide on systemic oxygenation and mean pulmonary-blood-flow velocity (MPBFV) in severely hypoxic babies with or without EPS. With a median (interquartile range) dose of 20 (32) parts per million, oxygenation index decreased significantly in both groups (EPS, 49 [19] vs 11 [9]; non-EPS, 40 [11] vs 20 [13]). The decrease was significantly greater in the EPS group. MPBFV increased significantly in the EPS group (18 [4] vs 29 [8] m/s) only. Nitric oxide may improve systemic oxygenation in neonates with severe hypoxaemia secondary to EPS by increasing pulmonary blood flow, and in those without EPS by improving ventilation-perfusion matching.	HOP UNIV NANTES,DEPT NEONATOL,NANTES,FRANCE; HOP UNIV LILLE,DEPT NEONATOL,LILLE,FRANCE; HOP ANTOINE BECLERE,DEPT NEONATOL,CLAMART,FRANCE; AMER MEM HOSP,DEPT NEONATOL,REIMS,FRANCE; HOP COCHIN,DEPT PHYSIOL,F-75674 PARIS,FRANCE; HOP ROBERT DEBRE,DEPT PEDIAT,F-75019 PARIS,FRANCE	Nantes Universite; CHU de Nantes; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; CHU de Reims; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite			DINH-XUAN, Anh Tuan/A-9691-2008; Rozé, Jean-Christophe/AAS-1314-2021	DINH-XUAN, Anh Tuan/0000-0001-8651-5176; 				CHU J, 1967, PEDIATRICS, V40, P709; CORBET AJS, 1974, J APPL PHYSIOL, V36, P74, DOI 10.1152/jappl.1974.36.1.74; EVANS N, 1993, PEDIATRICS, V92, P737; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; MERCIER JC, 1993, LANCET, V342, P431, DOI 10.1016/0140-6736(93)92843-I; MUSEWE NN, 1990, J AM COLL CARDIOL, V15, P446, DOI 10.1016/S0735-1097(10)80076-2; PISON U, 1993, J APPL PHYSIOL, V74, P1287, DOI 10.1152/jappl.1993.74.3.1287; ROBERTS JD, 1992, LANCET, V340, P818, DOI 10.1016/0140-6736(92)92686-A; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; WALTHER FJ, 1992, PEDIATRICS, V90, P899	10	56	56	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					303	305		10.1016/S0140-6736(94)91341-2	http://dx.doi.org/10.1016/S0140-6736(94)91341-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914264				2022-12-28	WOS:A1994NZ23300010
J	SCHIPPER, H				SCHIPPER, H			WHITHER CANCER CENTERS	LANCET			English	Editorial Material									MANITOBA CANC TREATMENT & RES FDN,WINNIPEG R3E 0V9,MB,CANADA		SCHIPPER, H (corresponding author), WHO,COLLABORATING CTR QUAL LIFE CANC CARE,WINNIPEG,MB,CANADA.							KALUZNY AD, 1991, CAN MED ASSOC J, V144, P1427; SCHIPPER H, DELIVERING CANCER CA; 1993, NATIONAL CANCER CONT; 1994, POLICY FRAMEWORK COM	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					281	282		10.1016/S0140-6736(94)91334-X	http://dx.doi.org/10.1016/S0140-6736(94)91334-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914257				2022-12-28	WOS:A1994NZ23300003
J	KURTZ, TW				KURTZ, TW			GENETIC MODELS OF HYPERTENSION	LANCET			English	Article							BLOOD-PRESSURE; ANIMAL-MODELS; LINKAGE; MOUSE; RENIN; RATS				KURTZ, TW (corresponding author), UNIV CALIF SAN FRANCISCO, LONG HOSP,MED CTR,DEPT LAB MED,ROOM 518, BOX 0134, SAN FRANCISCO, CA 94143 USA.							CICILA GT, 1993, NAT GENET, V3, P346, DOI 10.1038/ng0493-346; DENG YL, 1992, NAT GENET, V1, P267, DOI 10.1038/ng0792-267; GANTEN D, 1987, HYPERTENSION, V9, pI2; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; KURTZ TW, 1993, J CLIN INVEST, V91, P741, DOI 10.1172/JCI116291; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; OKAMOTO KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282; PRAVENEC M, 1989, J HYPERTENS, V7, P217; RAPP JP, 1987, HYPERTENSION, V10, P7, DOI 10.1161/01.HYP.10.1.7; SMITHIES O, 1993, TRENDS GENET, V9, P112, DOI 10.1016/0168-9525(93)90204-U; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; STLEZIN E, 1993, HYPERTENSION, V22, P421; STLEZIN EM, 1993, TRENDS CARDIOVAS MED, V3, P119, DOI 10.1016/1050-1738(93)90011-T; TURNER ME, 1991, HYPERTENSION, V17, P1097, DOI 10.1161/01.HYP.17.6.1097; YAMADA J, 1994, MAMM GENOME, V5, P63, DOI 10.1007/BF00292332	17	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	1994	344	8916					167	168		10.1016/S0140-6736(94)92761-8	http://dx.doi.org/10.1016/S0140-6736(94)92761-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912769				2022-12-28	WOS:A1994NW81000013
J	MAGUIRE, J; SANTORO, T; JENSEN, P; SIEBENLIST, U; YEWDELL, J; KELLY, K				MAGUIRE, J; SANTORO, T; JENSEN, P; SIEBENLIST, U; YEWDELL, J; KELLY, K			GEM - AN INDUCED, IMMEDIATE-EARLY PROTEIN BELONGING TO THE RAS FAMILY	SCIENCE			English	Article							MECHANISM; GROWTH; ACTIVATION; CLONES; CELLS	A gene encoding a 35-kilodalton guanosine triphosphate (GTP)-binding protein, Gem, was cloned from mitogen-induced human peripheral blood T cells. Gem and Rad, the product of a gene overexpressed in skeletal muscle in individuals with Type II diabetes, constitute a new family of Ras-related GTP-binding proteins. The distinct structural features of this family include the G3 GTP-binding motif, extensive amino- and carboxyl-terminal extensions beyond the Ras-related domain, and a motif that determines membrane association. Gem was transiently expressed in human peripheral blood T cells in response to mitogenic stimulation; the protein was phosphorylated on tyrosine residues and localized to the cytosolic face of the plasma membrane. Deregulated Gem expression prevented proliferation of normal and transformed 3T3 cells. These results suggest that Gem is a regulatory protein, possibly participating in receptor-mediated signal transduction at the plasma membrane.	NCI,PATHOL LAB,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			yewdell, jyewdell@nih.gov jonathan/A-1702-2012					ANDREWS PW, 1984, LAB INVEST, V50, P147; BARBACID M, 1981, J VIROL, V37, P518, DOI 10.1128/JVI.37.1.518-523.1981; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GERRARD TL, 1983, CELL IMMUNOL, V82, P394, DOI 10.1016/0008-8749(83)90172-7; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORGAN K, 1991, CURRENT PROTOCOLS IM, V1; HWANG YW, 1989, GUANINE NUCLEOTIDE B, P77; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MAGUIRE JM, UNPUB; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Sambrook J, 1989, MOL CLONING LABORATO; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	20	165	172	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					241	244		10.1126/science.7912851	http://dx.doi.org/10.1126/science.7912851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7912851	Green Submitted			2022-12-28	WOS:A1994NV95700039
J	MOFFATT, F; HILL, MR; CORNELIS, F; SCHOU, C; FAUX, JA; YOUNG, RP; JAMES, AL; RYAN, G; LESOUEF, P; MUSK, AW; HOPKIN, JM; COOKSON, WOCM				MOFFATT, F; HILL, MR; CORNELIS, F; SCHOU, C; FAUX, JA; YOUNG, RP; JAMES, AL; RYAN, G; LESOUEF, P; MUSK, AW; HOPKIN, JM; COOKSON, WOCM			GENETIC-LINKAGE OF T-CELL RECEPTOR ALPHA/DELTA COMPLEX TO SPECIFIC IGE RESPONSES	LANCET			English	Article							ALLELIC VARIATIONS; IMMUNOGLOBULIN-E; RELATIVE RISKS; REPERTOIRE; ADULTS	IgE responses to inhaled proteins underlie the clinical syndrome of allergic (atopic) asthma and rhinitis. We have investigated genetic linkage between specific IgE reactions to highly purified major allergens and the T-cell receptor (TCR) alpha: and beta gene complexes on chromosome 14 and 7, respectively. Antigens tested included highly purified proteins from the housedust mite Dermatophagoides pteronyssinus, the domestic cat and dog, grass pollen, and the mould Alternaria alternata. Affected sibling-pair methods were used in two independent sets of families, one in the UK and one in Australia, No linkage of IgE serotypes to TCR-beta was detected, but significant linkage to TCR-alpha was seen in both family groups, For several of the IgE phenotypes investigated (positive responses to whole allergen sources or purified antigens or serum IgE above the 70th percentile in the population) the affected sibling-pairs showed significant sharing of TCR-alpha microsatellite alleles from both parents. The results show that a gene (or genes) in the TCR-alpha region modifies specific IgE responses.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD,ENGLAND; ALK LABS,HORSHOLM,DENMARK; SIR CHARLES GAIRDINER HOSP,DEPT RESP MED,PERTH,WA 6000,AUSTRALIA; UNIV WESTERN AUSTRALIA,PRINCESS MARGARET HOSP,DEPT PAEDIAT,PERTH,WA 6009,AUSTRALIA; CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND	University of Oxford; University of Oxford; University of Western Australia; University of Oxford			Hill, Michael/C-4861-2008; Le Souef, Peter N/H-5256-2014; Cookson, William/HHC-1790-2022	Le Souef, Peter/0000-0003-0930-1654	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; COOKSON WOCM, 1991, CLIN EXP ALLERGY, V21, P473, DOI 10.1111/j.1365-2222.1991.tb01688.x; CORNELIS F, 1993, EUR J IMMUNOL, V23, P1277, DOI 10.1002/eji.1830230613; CORNELIS F, 1992, GENOMICS, V13, P820, DOI 10.1016/0888-7543(92)90159-P; DIZIER MH, 1993, GENET EPIDEMIOL, V10, P333; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; Holt P G, 1991, Clin Exp Allergy, V21 Suppl 1, P148, DOI 10.1111/j.1365-2222.1991.tb01719.x; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; LI YX, 1990, J EXP MED, V171, P221, DOI 10.1084/jem.171.1.221; LOVERIDGE JA, 1991, IMMUNOLOGY, V74, P246; MOHAPATRA SS, 1994, IMMUNOLOGY, V81, P15; MOSS PAH, 1993, EUR J IMMUNOL, V23, P1153, DOI 10.1002/eji.1830230526; ROBINSON MA, 1987, P NATL ACAD SCI USA, V84, P9089, DOI 10.1073/pnas.84.24.9089; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x	20	177	181	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1597	1600		10.1016/S0140-6736(94)93057-0	http://dx.doi.org/10.1016/S0140-6736(94)93057-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911920				2022-12-28	WOS:A1994NU35400010
J	NILSEN, TW				NILSEN, TW			UNUSUAL STRATEGIES OF GENE-EXPRESSION AND CONTROL IN PARASITES	SCIENCE			English	Editorial Material							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; SPLICED LEADER SEQUENCE; TRYPANOSOMA-BRUCEI; MESSENGER-RNAS; C-ELEGANS; CHLORAMPHENICOL ACETYLTRANSFERASE; DEVELOPMENTAL REGULATION; U6 SNRNA; TRANSFECTION; LEISHMANIA				NILSEN, TW (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,CTR MOLEC PARASITOL,DEPT MOLEC BIOL & MICROBIOL,CLEVELAND,OH 44106, USA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BELLOFATTO V, 1989, SCIENCE, V244, P1167, DOI 10.1126/science.2499047; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; GOONEWARDENE R, 1993, P NATL ACAD SCI USA, V90, P5234, DOI 10.1073/pnas.90.11.5234; HANNON GJ, 1992, SCIENCE, V258, P1775, DOI 10.1126/science.1465612; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; JEFFERIES D, 1991, MOL CELL BIOL, V11, P338, DOI 10.1128/MCB.11.1.338; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LABAN A, 1989, P NATL ACAD SCI USA, V86, P9119, DOI 10.1073/pnas.86.23.9119; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; SALDATI D, 1993, SCIENCE, V260, P349; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; VANDOREN K, 1988, NATURE, V335, P556; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WATKINS KP, 1994, CELL, V76, P171, DOI 10.1016/0092-8674(94)90181-3; WATKINS KP, 1991, GENE DEV, V5, P1859, DOI 10.1101/gad.5.10.1859; YU YT, 1993, CELL, V75, P1049, DOI 10.1016/0092-8674(93)90315-H	31	20	20	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1868	1869		10.1126/science.7912006	http://dx.doi.org/10.1126/science.7912006			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7912006				2022-12-28	WOS:A1994NT84700027
J	PETERSON, DB; FISHER, K; CARTER, RD; MANN, J				PETERSON, DB; FISHER, K; CARTER, RD; MANN, J			FATTY-ACID COMPOSITION OF ERYTHROCYTES AND PLASMA TRIGLYCERIDE AND CARDIOVASCULAR RISK IN ASIAN DIABETIC-PATIENTS	LANCET			English	Article							CORONARY HEART-DISEASE; LIPOPROTEINS; SERUM; DIET	The excess of coronary heart disease in Indian Asians compared with Europeans is unexplained by conventional risk factors, although the high prevalence of diabetes may play a part. To explore the contribution of diet we compared the fatty acid composition of erythrocyte membrane phospholipid and plasma triglyceride in 36 Gujarati Asians and 24 Europeans with non-insulin-dependent diabetes. Erythrocytes from Asian subjects contained higher proportions of linoleic, dihomogammalinolenic, and arachidonic acids, and lower proportions of oleic and n-3 series fatty acids; triglycerides contained higher linoleic and lower oleic acid levels. For example, mean percentage (SE) of oleic acid (18:1n-9) in erythrocytes was 16.7 (0.2) in Asians and 20.5 (0.6) in Europeans (p=0.0001), and total n-6:n-3 ratio was, respectively, 12.8 (0.7) and 6.7 (0.7) (p=0.0001). A high dietary intake of linoleic acid may not be cardioprotective unless balanced by significant intakes of oleic and n-3 series fatty acids, at least in diabetic Indian Asians, By itself, the conventional recommendation to substitute polyunsaturated for saturated fat in the diet may be inadequate to reduce thrombogenesis, and the overall balance of fatty acids, including monounsaturates, should be considered.	RADCLIFFE INFIRM,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford								BECKLES GLA, 1986, LANCET, V1, P1298; BOBERG M, 1985, CLIN SCI, V68, P581, DOI 10.1042/cs0680581; BONANOME A, 1992, ARTERIOSCLER THROMB, V12, P529, DOI 10.1161/01.ATV.12.4.529; BURSTEIN M, 1970, J LIPID RES, V11, P583; DODGE JT, 1967, J LIPID RES, V8, P667; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; HALL PM, 1983, ANN CLIN BIOCHEM, V20, P129, DOI 10.1177/000456328302000301; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MCKEIGUE PM, 1985, LANCET, V2, P1086; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PETERSON DB, 1986, BRIT MED J, V292, P170, DOI 10.1136/bmj.292.6514.170; TAN S, 1985, IMMIGRANT FOODS S; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M	14	25	25	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1528	1530		10.1016/S0140-6736(94)92937-8	http://dx.doi.org/10.1016/S0140-6736(94)92937-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911870				2022-12-28	WOS:A1994NR32900007
J	HAUPT, R; FEARS, TR; ROBISON, LL; MILLS, JL; NICHOLSON, HS; ZELTZER, LK; MEADOWS, AT; BYRNE, J				HAUPT, R; FEARS, TR; ROBISON, LL; MILLS, JL; NICHOLSON, HS; ZELTZER, LK; MEADOWS, AT; BYRNE, J			EDUCATIONAL-ATTAINMENT IN LONG-TERM SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; CENTRAL NERVOUS-SYSTEM; CRANIAL IRRADIATION; IQ SCORES; CHILDREN; SEQUELAE; CANCER; PROPHYLAXIS; THERAPY; AGE	Objective.-To determine the impact of treatment on scholastic performance in the first cohort of survivors of childhood acute lymphoblastic leukemia who are old enough to have completed their educational experience. Design.-Retrospective cohort study. Setting.-Twenty-three institutions in the Childrens Cancer Group. Subjects.-A total of 593 adult survivors of childhood acute lymphoblastic leukemia and 409 sibling controls. Outcome Measures.-Enrollment in special programs, grades during high school, graduation from high school, college admission, and college graduation. Results.-After diagnosis, survivors were more likely than their sibling controls to enter a special education (relative risk [RR] =3.4; P<.01) or a learning disabled (RR=3.6; P<.01) program, while just as likely to enter gifted and talented programs (RR=1.0). The risk associated with special education and learning disabled programs increased with increasing dose of cranial radiotherapy. Despite these problems, survivors generally had the same probability as their siblings of finishing high school, entering college, and earning a bachelor's degree. However, survivors treated with 24 Gy and those diagnosed before 6 years of age were less likely to enter college (RR=0.67 and 0.6, respectively; P<.01). Conclusions.-This large study demonstrates that childhood acute lymphoblastic leukemia survivors have a greater likelihood of being placed in special education or learning disabled programs than their siblings, but that most are able to overcome these problems. Dose of cranial radiotherapy and age at diagnosis are the most important education-related risk factors.	NCI,CLIN EPIDEMIOL BRANCH,BETHESDA,MD 20892; NCI,BIOSTAT BRANCH,BETHESDA,MD 20892; NICHHD,EPIDEMIOL BRANCH,BETHESDA,MD 20892; CHILDRENS NATL MED CTR,DEPT HEMATOL ONCOL,WASHINGTON,DC 20010; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104; UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV CALIF LOS ANGELES,MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90024	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Children's National Health System; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center			Robison, Leslie/N-8122-2018; Haupt, Riccardo/AAA-7437-2020	Haupt, Riccardo/0000-0003-0571-8460; Mills, James/0000-0003-4496-332X	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP061012] Funding Source: NIH RePORTER; NCI NIH HHS [N0I-CP-61012, CPO-5625, CPI-5602] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLEYER WA, 1990, PEDIATR HEMATOL ONCO, V7, P3298; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BROUWERS P, 1985, J PEDIATR-US, V106, P723, DOI 10.1016/S0022-3476(85)80343-7; CHARLTON A, 1991, ARCH DIS CHILD, V66, P1217, DOI 10.1136/adc.66.10.1217; COPELAND DR, 1985, PEDIATRICS, V75, P745; COX DR, 1972, J R STAT SOC B, V34, P187; DAITER S, 1988, J CLIN ONCOL, V6, P613, DOI 10.1200/JCO.1988.6.4.613; JANKOVIC M, 1994, LANCET, V344, P224, DOI 10.1016/S0140-6736(94)92997-1; JANNOUN L, 1983, ARCH DIS CHILD, V58, P953, DOI 10.1136/adc.58.12.953; JANNOUN L, 1987, PEDIATR HEMAT ONCOL, V4, P293, DOI 10.3109/08880018709141282; MEADOWS AT, 1981, LANCET, V2, P1015; MOORE IMK, 1991, CANCER, V68, P1913; MULHERN RK, 1992, J CLIN ONCOL, V10, P1095, DOI 10.1200/JCO.1992.10.7.1095; MULHERN RK, 1991, J CLIN ONCOL, V9, P1348, DOI 10.1200/JCO.1991.9.8.1348; PAAKKO E, 1992, CANCER, V70, P2728, DOI 10.1002/1097-0142(19921201)70:11<2728::AID-CNCR2820701126>3.0.CO;2-7; PACKER RJ, 1987, MED PEDIATR ONCOL, V15, P241, DOI 10.1002/mpo.2950150505; PECKHAM VC, 1988, PEDIATRICS, V81, P127; PINKEL D, 1992, LEUKEMIA, V6, P127; PRESTON DL, 1990, EPICURE RISK REGRESS; ROBISON LL, 1984, AM J PEDIAT HEMATOL, V6, P115; ROWLAND JH, 1984, J CLIN ONCOL, V2, P1327, DOI 10.1200/JCO.1984.2.12.1327; SILBER JH, 1992, J CLIN ONCOL, V10, P1390, DOI 10.1200/JCO.1992.10.9.1390; TWADDLE V, 1983, ARCH DIS CHILD, V58, P949, DOI 10.1136/adc.58.12.949; TWADDLE V, 1986, ARCH DIS CHILD, V61, P700, DOI 10.1136/adc.61.7.700; WABER DP, 1990, J PEDIATR PSYCHOL, V15, P105, DOI 10.1093/jpepsy/15.1.105; 1985, SAS VERSION 5	27	123	123	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1427	1432		10.1001/jama.272.18.1427	http://dx.doi.org/10.1001/jama.272.18.1427			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP690	7933424				2022-12-28	WOS:A1994PP69000030
J	FISHER, LA				FISHER, LA			THE LAST OF AUGUST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1310	1310		10.1001/jama.272.17.1310	http://dx.doi.org/10.1001/jama.272.17.1310			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933377				2022-12-28	WOS:A1994PP02000002
J	WILSON, MM; CHELALA, C				WILSON, MM; CHELALA, C			CHOLERA IS WALKING SOUTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									MINIST HLTH & SOCIAL ACT,NATL COMMISS AGAINST CHOLERA,BUENOS AIRES,DF,ARGENTINA									TAUXE R, 1994, VIBRIO CHOLERAE CHOL; TAUXE RV, 1992, JAMA-J AM MED ASSOC, V267, P1388, DOI 10.1001/jama.267.10.1388; 1993, CHOLERA SITUATION AM; 1993, MMWR-MORBID MORTAL W, V42, P89; 1994, INFORME          JUN; 1994, EPIDEMIOL B, V15, P13	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1226	1227		10.1001/jama.272.15.1226	http://dx.doi.org/10.1001/jama.272.15.1226			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933354				2022-12-28	WOS:A1994PL21200040
J	DONALDSON, LJ; RANKIN, J; PROCTOR, S				DONALDSON, LJ; RANKIN, J; PROCTOR, S			IS IT POSSIBLE TO CATCH LEUKEMIA FROM A CAT	LANCET			English	Editorial Material							VIRUS; INFECTION				DONALDSON, LJ (corresponding author), UNIV NEWCASTLE UPON TYNE, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND.							BROSS IDJ, 1972, AM J PUBLIC HEALTH N, V62, P1520, DOI 10.2105/AJPH.62.11.1520; BROSS IDJ, 1970, J MED, V1, P180; HOSIE MJ, 1989, VET REC, V125, P293, DOI 10.1136/vr.125.11.293; JARRETT O, 1991, J AM VET MED ASSOC, V199, P1279; JARRETT O, 1994, SYMP SOC GEN MICROBI, V51, P235; MORGAN RA, 1993, VIROLOGY, V193, P439, DOI 10.1006/viro.1993.1141; PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650; PILET C, 1989, B ACAD NAT MED PARIS, V173, P617; SORDILLO PP, 1982, JNCI-J NATL CANCER I, V69, P333; VIOLA MV, 1968, JAMA-J AM MED ASSOC, V205, P95; YAMAMOTO JK, 1989, J AM VET MED ASSOC, V194, P213	11	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					971	972		10.1016/S0140-6736(94)91636-5	http://dx.doi.org/10.1016/S0140-6736(94)91636-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934425				2022-12-28	WOS:A1994PK97800004
J	HENG, MK; HENG, MCY				HENG, MK; HENG, MCY			HEAT-SHOCK PROTEIN-65 AND ACTIVATED GAMMA/DELTA T-CELLS IN INJURED ARTERIES	LANCET			English	Note							ATHEROSCLEROTIC LESIONS; HUMANS	Because immune mechanisms are implicated in atherogenesis, we investigated the T-lymphocyte subset and factors related to its activation after acute arterial ligation (22 ligated and 13 non-ligated specimens). Ligated arteries produced heat-shock protein 65 (hsp65) acid were infiltrated with activated T cells (mostly dendritic, CD3+, CD4-, CD8-, and gamma/delta T-cell-receptor bearing). The protein was found with dendritic T cells, with immunogold-labelled hsp65 beside the dendritic processes. Thus, the immune reaction after acute arterial injury may be associated with binding and recognition of in-situ hsp65 by dendritic gamma/delta T-cells.			HENG, MK (corresponding author), UNIV CALIF LOS ANGELES,SEPULVEDA VA MED CTR,DEPT MED,DIV CARDIOL,SEPULVEDA,CA 91343, USA.							BERBERIAN PA, 1990, AM J PATHOL, V136, P71; BERGSTRESSER PR, 1993, J INVEST DERMATOL, V100, pS80, DOI 10.1111/1523-1747.ep12356076; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; KLEINDIENST R, 1993, AM J PATHOL, V142, P1927; OBRIEN RL, 1989, CELL, V57, P668; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STEMME S, 1992, ARTERIOSCLER THROMB, V12, P206, DOI 10.1161/01.ATV.12.2.206; VANDERWAL AC, 1989, LAB INVEST, V61, P166; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X; XU QB, 1992, ARTERIOSCLER THROMB, V12, P789, DOI 10.1161/01.ATV.12.7.789	10	13	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					921	923		10.1016/S0140-6736(94)92271-3	http://dx.doi.org/10.1016/S0140-6736(94)92271-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934348				2022-12-28	WOS:A1994PJ28700012
J	WHITHAM, S; DINESHKUMAR, SP; CHOI, D; HEHL, R; CORR, C; BAKER, B				WHITHAM, S; DINESHKUMAR, SP; CHOI, D; HEHL, R; CORR, C; BAKER, B			THE PRODUCT OF THE TOBACCO MOSAIC-VIRUS RESISTANCE GENE-N - SIMILARITY TO TOLL AND THE INTERLEUKIN-1 RECEPTOR	CELL			English	Article							TRANSPOSABLE ELEMENT ACTIVATOR; LEUCINE-RICH REPEATS; DISEASE-RESISTANCE; TRANSMEMBRANE PROTEIN; ARABIDOPSIS-THALIANA; ADENYLATE-CYCLASE; DROSOPHILA EMBRYO; DNA-SEQUENCE; MAIZE; KINASE	The products of plant disease resistance genes are postulated to recognize invading pathogens and rapidly trigger host defense responses. Here we describe isolation of the resistance gene N of tobacco that mediates resistance to the viral pathogen tobacco mosaic virus (TMV). The N gene was isolated by transposon tagging using the maize Activator transposon. A genomic DNA fragment containing the N gene conferred TMV resistance to TMV susceptible tobacco. Sequence analysis of the N gene shows that it encodes a protein of 131.4 kDa with an amino-terminal domain similar to that of the cytoplasmic domain of the Drosophila Toll protein and the interleukin-1 receptor (IL-1R) in mammals, a nucleotide-binding site (NBS), and 4 imperfect leucine-rich repeats (LRR). The sequence similarity of N, Toll, and IL-1 R suggests that N mediates rapid gene induction and TMV resistance through a Toll-IL-1-like pathway.	UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720; UNIV CALIF ALBANY,CTR PLANT GENE EXPRESS,ALBANY,CA 94710; USDA ARS,ALBANY,CA 94710	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	WHITHAM, S (corresponding author), UNIV CALIF BERKELEY,DEPT PLANT PATHOL,BERKELEY,CA 94720, USA.		Dinesh-Kumar, Savithramma/E-1153-2011; Choi, Doil/F-5002-2011; Baker, Barbara/Z-1108-2019; Baker, Barbara/L-7198-2016; Hehl, Reinhard/AAF-2970-2020	Baker, Barbara/0000-0002-1276-971X; Baker, Barbara/0000-0002-1276-971X; Hehl, Reinhard/0000-0002-1550-3394				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAKER B, 1986, P NATL ACAD SCI USA, V83, P4844, DOI 10.1073/pnas.83.13.4844; BAKER B, 1987, EMBO J, V6, P1547, DOI 10.1002/j.1460-2075.1987.tb02399.x; BENNETZEN JL, 1988, NATURE, V332, P369, DOI 10.1038/332369a0; BERNATZKY R, 1986, GENETICS, V112, P887; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CHUCK G, 1993, PLANT CELL, V5, P371, DOI 10.1105/tpc.5.4.371; CULVER JN, 1991, MOL PLANT MICROBE IN, V4, P458, DOI 10.1094/MPMI-4-458; DAWSON WO, 1992, VIROLOGY, V186, P359, DOI 10.1016/0042-6822(92)90001-6; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; FEDOROFF NV, 1989, MOBILE DNA, P375; Flor H. H., 1947, JOUR AGRIC RES, V74, P241; FULTON RW, 1979, NICOTIANA PROCEDURES, P79; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HEHL R, 1990, PLANT CELL, V2, P709, DOI 10.1105/tpc.2.8.709; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Holmes FO, 1938, PHYTOPATHOLOGY, V28, P553; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HULBERT SH, 1991, MOL GEN GENET, V226, P377, DOI 10.1007/BF00260649; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; Keen N. T., 1993, Biotechnology in plant disease control., P65; KEEN NT, 1992, PLANT MOL BIOL, V19, P109, DOI 10.1007/BF00015609; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; Klement Z., 1990, METHODS PHYTOBACTERI, P101; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LEE FS, 1990, P NATL ACAD SCI USA, V87, P1879, DOI 10.1073/pnas.87.5.1879; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MATTHIEU HAJ, 1994, NATURE, V367, P384; MCCLINTOCK B, 1948, CARNEGIE I WASH, V47, P155; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MINDRINOS M, 1994, CELL, V78, P1101; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; PADGETT HS, 1993, PLANT CELL, V5, P577, DOI 10.1105/tpc.5.5.577; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHAW JG, 1986, VIROLOGY, V148, P326, DOI 10.1016/0042-6822(86)90329-6; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; STJOHNSTON D, 1992, CELL, V68, P201; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TAKAHASHI WN, 1956, PHYTOPATHOLOGY, V46, P654; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; VALON C, 1993, PLANT MOL BIOL, V23, P415, DOI 10.1007/BF00029017; VANDENACKERVEKEN GFJM, 1993, PLANT PHYSIOL, V103, P91, DOI 10.1104/pp.103.1.91; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; YUCEL I, 1994, MOL PLANT MICROBE IN, V7, P148, DOI 10.1094/MPMI-7-0148	64	1010	1118	10	141	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					1101	1115		10.1016/0092-8674(94)90283-6	http://dx.doi.org/10.1016/0092-8674(94)90283-6			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923359				2022-12-28	WOS:A1994PJ29400019
J	MANCINI, GBJ				MANCINI, GBJ			MORE BAD-NEWS FOR COUCH POTATOES AND SMOKERS WHO ATONE THROUGH EXERCISE	LANCET			English	Editorial Material							PHYSICAL-ACTIVITY		VANCOUVER HOSP & HLTH SCI CTR,VANCOUVER,BC,CANADA	University of British Columbia	MANCINI, GBJ (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC,CANADA.							ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; Fletcher G F, 1993, Heart Dis Stroke, V2, P183; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; RODRIGUEZ BL, 1994, CIRCULATION, V89, P2540, DOI 10.1161/01.CIR.89.6.2540	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					629	630		10.1016/S0140-6736(94)92078-8	http://dx.doi.org/10.1016/S0140-6736(94)92078-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915343				2022-12-28	WOS:A1994PE38600003
J	MARSHALL, S; MEREDITH, PA; ELLIOTT, HL				MARSHALL, S; MEREDITH, PA; ELLIOTT, HL			EFFICACY OF LOW-DENSITY-LIPOPROTEIN LOWERING WITH STATINS	LANCET			English	Letter											MARSHALL, S (corresponding author), UNIV GLASGOW,WESTERN INFIRM,GARDINER INST,DEPT MED & THERAPEUT,GLASGOW G11 6NT,SCOTLAND.							GOTO Y, 1989, RINSHO IYAKU, V5, P2011; KUHN P, 1989, CURR THER RES CLIN E, V46, P381; NAKAYA N, 1989, 8TH INT S ATH ROM; SHEINER LB, 1991, STAT MED, V10, P303, DOI 10.1002/sim.4780100303; WALKER JF, 1990, DRUG INVEST        S, V2, P53	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					684	684						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915369				2022-12-28	WOS:A1994PE38600044
J	MULCAHY, HE; DUFFY, MJ; GIBBONS, D; MCCARTHY, P; PARFREY, NA; ODONOGHUE, DP; SHEAHAN, K				MULCAHY, HE; DUFFY, MJ; GIBBONS, D; MCCARTHY, P; PARFREY, NA; ODONOGHUE, DP; SHEAHAN, K			UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND OUTCOME IN DUKES B-COLORECTAL-CANCER	LANCET			English	Note							BREAST-CANCER; STROMAL CELLS; ADENOCARCINOMAS; RECEPTOR; COLON	Urokinase-type plasminogen activator (u-PA) is a serine protease involved in cancer metastasis. Using immunohistochemical methods, we examined the relation between u-PA and long-term survival in 70 patients with Dukes' B colorectal cancer. 8-year survival was 81% in patients whose tumours demonstrated low-grade epithelial u-PA staining and 43% in those with high-grade staining (log-rank test, p=0.01). Survival was unrelated to stromal u-PA staining. These results suggest that u-PA may be useful in the identification of patients with non-metastatic colorectal cancer at risk of tumour recurrence.	ST VINCENTS HOSP,DEPT PATHOL,DUBLIN 4,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DUBLIN 4,IRELAND; ST VINCENTS HOSP,DEPT NUCL MED,DUBLIN 4,IRELAND; ST VINCENTS HOSP,GASTROENTEROL & LIVER UNIT,DUBLIN 4,IRELAND	University College Dublin; University College Dublin; University College Dublin; University College Dublin				mulcahy, hugh/0000-0002-7087-6177				DUFFY MJ, 1990, CANCER RES, V50, P6827; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P144; GELISTER JSK, 1986, BRIT MED J, V293, P728, DOI 10.1136/bmj.293.6549.728; GRONDAHLHANSEN J, 1991, AM J PATHOL, V138, P111; JANICKE F, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90001-Z; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; MURNANE MJ, 1991, CANCER RES, V51, P1137; PYKE C, 1991, AM J PATHOL, V138, P1059; SIER CFM, 1991, HISTOPATHOLOGY, V19, P231, DOI 10.1111/j.1365-2559.1991.tb00027.x; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0	10	125	128	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					583	584		10.1016/S0140-6736(94)91968-2	http://dx.doi.org/10.1016/S0140-6736(94)91968-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914963				2022-12-28	WOS:A1994PD42400012
J	[Anonymous]				[Anonymous]			CAIRO - A MATTER OF CHOICE	LANCET			English	Editorial Material																		FREEDMAN MA, 1986, AM J PUBLIC HEALTH, V76, P550, DOI 10.2105/AJPH.76.5.550; MUMFORD SD, 1984, AM J OBSTET GYNECOL, V149, P640; NAVARROVALLS J, 1994, SEP INT C POP DEV; POOLE J, 1993, HARM WE DO; POTTS M, 1994, AM J PUBLIC HEALTH, V84, P890, DOI 10.2105/AJPH.84.6.890; SADIK N, 1994, PRIVATE DECISIONS PU; SAMUELS SE, 1994, PILL PRESCRIPTION CO; SNOW R, 1994, LANCET, V344, P459, DOI 10.1016/S0140-6736(94)91777-9; 1994, ICPD C CAIRO NEW YOR	9	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					557	558						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PD424	7914952				2022-12-28	WOS:A1994PD42400001
J	GARCIAFERNANDEZ, J; HOLLAND, PWH				GARCIAFERNANDEZ, J; HOLLAND, PWH			ARCHETYPAL ORGANIZATION OF THE AMPHIOXUS HOX GENE-CLUSTER	NATURE			English	Article							HOMEOBOX-CONTAINING GENES; CAENORHABDITIS-ELEGANS; VERTEBRATE EVOLUTION; EXPRESSION; METAZOAN; FAMILY; MOUSE	ORGANIZATION into gene clusters is an essential and diagnostic feature of Hox genes(1). Insect and nematode genomes possess single Hox gene clusters (split in Dvosophila); in mammals, there are 38 Hox genes in four clusters on different chromosomes(2,3). A collinear relationship between chromosomal position, activation time and anterior expression limit of vertebrate Hox genes suggests that clustering may be important for precise spatiotemporal gene regulation and hence embryonic patterning(2,4). Hox genes have a wide phylogenetic distribution within the metazoa, and are implicated in the control of regionalization along the anteroposterior body axis(2,5). It has been suggested that changes in Hox gene number and genomic organization played a role in metazoan body-plan evolution(6-8), but identifying significant changes is difficult because Hox gene organization is known from only very few and widely divergent taxa (principally insects, nematodes and vertebrates)(3). Here we analyse the complexity and organization of Hox genes in a cephalochordate, amphioxus, the taxon thought to be the sister group of the vertebrates(9). We find that the amphioxus genome has only one Hox gene cluster. It has similar genomic organization to the four mammalian Hox clusters, and contains homologues of at least the first ten paralogous groups of vertebrate Hox genes in a collinear array. Remarkably, this organization is compatible with that inferred for a direct ancestor of the vertebrates; we conclude; that amphioxus is a living representative of a critical intermediate stage in Hox cluster evolution.	UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND	University of Oxford			Garcia-Fernandez, Jordi/B-3839-2013	Garcia-Fernandez, Jordi/0000-0001-5677-5970; Holland, Peter/0000-0003-1533-9376				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1988, DEVELOPMENT, V104, P123; BELLEVILLE S, 1992, GENE, V114, P179, DOI 10.1016/0378-1119(92)90572-7; Burglin Thomas R., 1994, P25; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; BURGLIN TR, 1993, CURR OPIN GENET DEV, V3, P615, DOI 10.1016/0959-437X(93)90097-9; DEKKER EJ, 1992, MECH DEVELOP, V40, P3; HOLLAND P, 1992, BIOESSAYS, V14, P267, DOI 10.1002/bies.950140412; HOLLAND PWH, 1994, J MAR BIOL ASSOC UK, V74, P49, DOI 10.1017/S0025315400035657; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; HOLLAND PWH, 1993, ESSENTIAL DEV BIOL P, P243; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KAPPEN C, 1993, CURR OPIN GENET DEV, V3, P931, DOI 10.1016/0959-437X(93)90016-I; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOLVEN A, 1993, BIOCHIM BIOPHYS ACTA, V1173, P102, DOI 10.1016/0167-4781(93)90253-A; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SANSOM IJ, 1992, SCIENCE, V256, P1308, DOI 10.1126/science.1598573; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SCHUGHART K, 1988, P NATL ACAD SCI USA, V85, P5582, DOI 10.1073/pnas.85.15.5582; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; TABIN CJ, 1992, DEVELOPMENT, V116, P289; WEBSTER PJ, 1992, MECH DEVELOP, V38, P25, DOI 10.1016/0925-4773(92)90035-I; Willey A., 1894, AMPHIOXUS ANCESTRY V	29	471	483	4	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					563	566		10.1038/370563a0	http://dx.doi.org/10.1038/370563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	7914353				2022-12-28	WOS:A1994PC53700057
J	BRAUN, MM; CAPORASO, NE; PAGE, WF; HOOVER, RN				BRAUN, MM; CAPORASO, NE; PAGE, WF; HOOVER, RN			GENETIC COMPONENT OF LUNG-CANCER - COHORT STUDY OF TWINS	LANCET			English	Article							RISK; SUSCEPTIBILITY; ASSOCIATION; STATISTICS; MUTATIONS; MORTALITY; REGISTRY; SMOKING; LOCUS	Epidemiological and molecular epidemiological findings suggest that inherited predisposition may be a component of lung cancer risk and an important modulator of the carcinogenic effects of cigarette smoke. We have carried out a genetic analysis of lung cancer mortality on the National Academy of Sciences/National Research Council Twin Registry. The registry is composed of 15 924 male twin pairs who were born in the USA between 1917 and 1927 and who served in the armed forces during World War II. As evidence for a genetic effect on lung cancer, we required concordance for lung cancer death to be greater among monozygotic than among dizygotic twin pairs. No genetic effect on lung cancer mortality was observed. The ratio of observed to expected concordance among monozygotic twins did not exceed that among dizygotic twins (overall rate ratio 0.75 [95% CI 0.35-1.6]), even though monozygotic twin pairs are more likely to be concordant for smoking than dizygotic twin pairs in this population. A cohort analysis (accounting for age, sex, race, and smoking intensity) of lung cancer mortality found no lung cancer deaths during 300 person-years of follow-up (observed to expected ratio 0 [0-4.09]) among 47 monozygotic twin smokers whose smoking twins had died of lung cancer, even though smoking histories were very similar within twin pairs. In our study, there is little if any effect of inherited predisposition on development of lung cancer. Genetic factors are not likely to be strongly predictive of lung cancer risk in most male smokers older than 50, the age group in which the vast majority of cases occur.	NATL ACAD SCI, INST MED, MED FOLLOW UP AGCY, WASHINGTON, DC 20418 USA	National Academies of Sciences, Engineering & Medicine	BRAUN, MM (corresponding author), NCI, EPIDEMIOL & BIOSTAT PROGRAM, EPN 443, 6130 EXECUT BLVD, ROCKVILLE, MD 20852 USA.							[Anonymous], 1986, IARC MONOGRAPHS EVAL, V38; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; CAPORASO N, 1989, CANCER RES, V49, P3675; CARMELLI D, 1992, NEW ENGL J MED, V327, P829, DOI 10.1056/NEJM199209173271201; CARMELLI D, 1990, ACTA GENET MED GEMEL, V39, P91, DOI 10.1017/S0001566000005602; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; DORN HF, 1959, PUBLIC HEALTH REP, V74, P581, DOI 10.2307/4590516; HALPERN MT, 1993, JNCI-J NATL CANCER I, V85, P457, DOI 10.1093/jnci/85.6.457; HARRIS CC, 1980, ANN INTERN MED, V92, P809, DOI 10.7326/0003-4819-92-6-809; HRUBEC Z, 1982, AM J HUM GENET, V34, P658; HRUBEC Z, 1977, TWIN RES, P153; JABLON S, 1967, AM J HUM GENET, V19, P133; KAHN HAROLD A., 1966, NAT CANCER INST MONOGR, V19, P1; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1551; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; MATTSON ME, 1987, AM J PUBLIC HEALTH, V77, P425, DOI 10.2105/AJPH.77.4.425; NAKACHI K, 1993, CANCER RES, V53, P2994; NICHOLS RC, 1966, ACTA GENET STAT MED, V16, P265; OOI WL, 1986, J NATL CANCER I, V76, P217; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; PETO R, 1984, LUNG CANCER CAUSES P, P1; RIES LAG, 1991, NCI NIH912789 PUB; SAMET JM, 1986, AM REV RESPIR DIS, V134, P466; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SHAW GL, 1991, J CLIN EPIDEMIOL, V44, P429, DOI 10.1016/0895-4356(91)90082-K; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SUGIMURA H, 1990, CANCER RES, V50, P1857; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2	30	53	54	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					440	443		10.1016/S0140-6736(94)91770-1	http://dx.doi.org/10.1016/S0140-6736(94)91770-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914565				2022-12-28	WOS:A1994PB76100010
J	NICOLAIDES, K; BRIZOT, MD; PATEL, F; SNIJDERS, R				NICOLAIDES, K; BRIZOT, MD; PATEL, F; SNIJDERS, R			COMPARISON OF CHORIONIC VILLUS SAMPLING AND AMNIOCENTESIS FOR FETAL KARYOTYPING AT 10-13 WEEKS GESTATION	LANCET			English	Article							ABNORMALITIES; PREGNANCY	We did a prospective study of women with singleton viable pregnancies at 10-13 weeks' gestation who requested first-trimester fetal karyotyping because of advanced maternal age, parental anxiety, or family history of chromosomal abnormality. Women were counselled as to the available options of non-invasive screening or invasive testing by mid-trimester amniocentesis, early amniocentesis (EA), or chorionic villus sampling (CVS), or randomisation to EA or CVS at 10-13 weeks. EA was done in 731. patients (493 by choice and 238 by randomisation) and CVS in 570 (320 by choice and 250 by randomisation). Both procedures were done by transabdominal ultrasound-guided insertion of a 20-gauge needle. The rate of successful sampling was the same for both procedures (97.5%). Spontaneous loss (intrauterine or neonatal death) was significantly higher after EA (total group mean = 5.3%, 95% CI 3.8-7.2; randomised subgroup mean = 5.9%, 3.3-9.7) than after CVS (total group: mean = 2.3%, 1.2-3.9; randomised subgroup: mean = 1.294, 0.3-3.5), The gestation at delivery and birthweight of the infants after EA and CVS were similar. In the EA group the incidence of talipes equinovarus (1.63%), was higher than in the CVS group (0.56%), but this difference was not significant.			NICOLAIDES, K (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED,HARRIS BIRTHWEIGHT RES CTR FETAL MED,DENMARK HILL,LONDON SE5 8RX,ENGLAND.		de Lourdes Brizot, Maria/C-5706-2013	de Lourdes Brizot, Maria/0000-0002-6135-4844; Nicolaides, Kypros/0000-0003-1266-0711; Snijders, Rosalinde/0000-0003-1809-7886				[Anonymous], 1991, LANCET, V337, P1491; BYRNE D, 1991, ULTRASOUND OBST GYN, V1, P235, DOI 10.1046/j.1469-0705.1991.01040235.x; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; HANSON FW, 1992, AM J OBSTET GYNECOL, V166, P1707, DOI 10.1016/0002-9378(92)91560-W; NEVIN J, 1990, PRENATAL DIAG, V10, P79, DOI 10.1002/pd.1970100203; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; NICOLAIDES KH, 1992, LANCET, V340, P704, DOI 10.1016/0140-6736(92)92240-G; PENSO CA, 1990, OBSTET GYNECOL, V76, P1032; SMIDTJENSEN S, 1992, LANCET, V340, P1237, DOI 10.1016/0140-6736(92)92946-D; SNIJDERS RJM, IN PRESS PREN DIAGN; STRIPPARO L, 1990, PRENAT DIAGN, V10, P3359; TABOR A, 1986, LANCET, V1, P1287; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5	15	144	147	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					435	439		10.1016/S0140-6736(94)91769-8	http://dx.doi.org/10.1016/S0140-6736(94)91769-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914564				2022-12-28	WOS:A1994PB76100009
J	CHEYNIER, R; HENRICHWARK, S; HADIDA, F; PELLETIER, E; OKSENHENDLER, E; AUTRAN, B; WAINHOBSON, S				CHEYNIER, R; HENRICHWARK, S; HADIDA, F; PELLETIER, E; OKSENHENDLER, E; AUTRAN, B; WAINHOBSON, S			HIV AND T-CELL EXPANSION IN SPLENIC WHITE PULPS IS ACCOMPANIED BY INFILTRATION OF HIV-SPECIFIC CYTOTOXIC T-LYMPHOCYTES	CELL			English	Article							RECEPTOR-V-BETA; PERIPHERAL-BLOOD LYMPHOCYTES; AIDS-RELATED LYMPHADENOPATHY; FOLLICULAR DENDRITIC CELLS; POLYMERASE CHAIN-REACTION; VIRUS-LIKE PARTICLES; GERMINAL-CENTERS; HYPERVARIABLE REGIONS; INFECTED PATIENTS; IMMUNE-RESPONSE	Human immunodeficiency virus (HIV) replication and T cell proliferation were investigated in situ by a PCR-based analysis of individual microdissected splenic white pulps. Founder effects, revealed by an exquisite compartmentalization of HIV genotypes and T cells, indicated the recruitment of latently infected CD4(+) T cells through highly localized antigen presentation rather than the infection of CD4(+) T lymphoblasts by blood-borne virus or immune complexes. HIV-infected white pulps could be Infiltrated by HIV-specific cytotoxic T lymphocytes, thereby implicating them in CD4(+) T cell destruction in vivo. Together these data describe an iterative and deleterious mechanism of antigen-driven T cell recruitment and activation, as well as HIV replication and spread, with consequent destruction of the newly infected cells.	HOP LA PITIE SALPETRIERE, IMMUNOL CELLULAIRE & TISSULAIRE LAB, F-75651 PARIS, FRANCE; HOP ST LOUIS, SERV IMMUNOPATHOL & HEMATOL, F-75010 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	CHEYNIER, R (corresponding author), INST PASTEUR, UNITE RETROVIROL MOLEC, F-75724 PARIS, FRANCE.		Cheynier, Remi/E-9921-2010	Cheynier, Remi/0000-0003-1146-660X; Pelletier, Eric/0000-0003-4228-1712				AKOLKAR PN, 1993, J IMMUNOL, V150, P2761; ANDERSON P, 1990, J IMMUNOL, V144, P574; ARMSTRONG JA, 1984, LANCET, V2, P370; BIBERFELD P, 1986, AM J PATHOL, V133, P516; BRINCHMANN JE, 1992, J VIROL, V66, P5924, DOI 10.1128/JVI.66.10.5924-5928.1992; BUTCHER EC, 1982, J IMMUNOL, V129, P2698; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025; DELASSUS S, 1992, J VIROL, V66, P5642, DOI 10.1128/JVI.66.9.5642-5645.1992; DEVERGNE O, 1991, AIDS, V5, P1071, DOI 10.1097/00002030-199109000-00002; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EPSTEIN LG, 1991, VIROLOGY, V180, P583, DOI 10.1016/0042-6822(91)90072-J; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FULLER KA, 1993, J IMMUNOL, V151, P4505; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; HADIDA F, 1992, J CLIN INVEST, V89, P53, DOI 10.1172/JCI115585; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; JANOFF EN, 1993, J INFECT DIS, V167, P49, DOI 10.1093/infdis/167.1.49; KIMURA N, 1986, J EXP MED, V164, P739, DOI 10.1084/jem.164.3.739; LAMAN JD, 1992, AIDS, V6, P333, DOI 10.1097/00002030-199203000-00014; LETOURNEAU A, 1986, HUM PATHOL, V17, P1047, DOI 10.1016/S0046-8177(86)80089-2; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; LU W, 1993, LANCET, V342, P298, DOI 10.1016/0140-6736(93)91839-E; MALHOTRA U, 1992, J IMMUNOL, V149, P1802; MARTINS LP, 1992, VIROLOGY, V191, P837, DOI 10.1016/0042-6822(92)90259-R; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; MIEDEMA F, 1990, IMMUNOL TODAY, V11, P293, DOI 10.1016/0167-5699(90)90116-Q; Myers G., 1993, HUMAN RETROVIRUSES A; OKSENHENDLER E, 1992, LANCET, V340, P207, DOI 10.1016/0140-6736(92)90471-E; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PELUSO R, 1985, VIROLOGY, V147, P231, DOI 10.1016/0042-6822(85)90246-6; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; RACZ P, 1986, PROG ALLERGY, V37, P81; RIEUXLAUCAT F, 1993, EUR J IMMUNOL, V23, P928, DOI 10.1002/eji.1830230425; ROSENBERG WMC, 1992, EUR J IMMUNOL, V22, P541, DOI 10.1002/eji.1830220237; SALA M, 1994, IN PRESS J VIROL, V68; SONIGO P, 1985, CELL, V42, P369, DOI 10.1016/S0092-8674(85)80132-X; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; TENNERRACZ K, 1985, LANCET, V1, P105; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; VANDENEERTWEGH AJM, 1992, EUR J IMMUNOL, V22, P719, DOI 10.1002/eji.1830220315; WAINHOBSON S, 1993, NATURE, V366, P22, DOI 10.1038/366022b0; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WEINSTEIN PD, 1991, INT IMMUNOL, V3, P1253, DOI 10.1093/intimm/3.12.1253; WOLFS TFW, 1991, VIROLOGY, V185, P195, DOI 10.1016/0042-6822(91)90767-6; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	53	184	184	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 12	1994	78	3					373	387		10.1016/0092-8674(94)90417-0	http://dx.doi.org/10.1016/0092-8674(94)90417-0			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	7914835				2022-12-28	WOS:A1994PC40500005
J	SCHUPF, N; KAPELL, D; LEE, JH; OTTMAN, R; MAYEUX, R				SCHUPF, N; KAPELL, D; LEE, JH; OTTMAN, R; MAYEUX, R			INCREASED RISK OF ALZHEIMERS-DISEASE IN MOTHERS OF ADULTS WITH DOWNS-SYNDROME	LANCET			English	Article							DEMENTIA; ASSOCIATION; AGE	Most adults with Down's syndrome (DS) develop neuropathology characteristic of Alzheimer's disease (AD) by the age of 40. Most of the non-dysjunction events in DS are of maternal origin. We postulated therefore that a shared genetic susceptibility to DS and AD would be associated with an increased frequency of AD among mothers, but not fathers, of individuals with DS. We further hypothesised that the shared susceptibility could involve an accelerated ageing process, leading to the birth of a child with DS to a relatively young mother and to an increased risk of dementia in the mother and her relatives. Families of 96 adults with DS and of 80 adults with other forms of mental retardation were ascertained through the New York State Developmental Disabilities services network. A semi-structured interview was used to obtain information on the presence or absence of non-stroke-related dementia and other disorders in parents. There was an increase in risk of dementia among mothers of DS probands compared with control mothers (risk ratio 2.6 [95% Cl 0.9-7.3]). The risk of dementia among mothers who were 35 or younger when their DS children were born was 5 times that of control mothers (4.9 [1.6-15.4]). There was no increase in risk of dementia among mothers who were older ( > 35 years) at the proband's birth (0.8 [0.2-3.4]). There was no difference in risk of dementia between fathers of DS cases and fathers of controls (1.2 [0.4-3.9]) and no discernible influence of age on this risk. Familial aggregation of dementia among mothers of adults with DS supports the hypothesis of a shared genetic susceptibility to DS and AD.	COLUMBIA UNIV, FAC MED, GERTRUDE H SERGIEVSKY CTR, NEW YORK, NY USA; COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY USA; NEW YORK STATE PSYCHIAT INST & HOSP, EPIDEMIOL BRAIN DISORDERS RES DEPT, NEW YORK, NY USA; COLUMBIA UNIV, DEPT NEUROL, NEW YORK, NY USA; COLUMBIA UNIV, DEPT PSYCHIAT, NEW YORK, NY USA; COLUMBIA UNIV, DEPT PHYS & SURG, NEW YORK, NY USA	Columbia University; Columbia University; New York State Psychiatry Institute; Columbia University; Columbia University; Columbia University	SCHUPF, N (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABIL, EPIDEMIOL LAB, 1050 FOREST HILL RD, STATEN ISL, NY 10314 USA.		Ottman, Ruth/O-2371-2013; Lee, Joseph H/D-2441-2012	Ottman, Ruth/0000-0001-7074-242X; Lee, Joseph H/0000-0002-2000-4821	NIA NIH HHS [AG10963, AG09400, AG08702] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R35AG010963, R01AG009400, P50AG008702] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; BERR C, 1989, AM J MED GENET, V33, P545, DOI 10.1002/ajmg.1320330427; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; FITCH N, 1988, ANN NEUROL, V23, P14, DOI 10.1002/ana.410230104; HASSOLD T, 1993, CURR OPIN GENET DEV, V3, P398, DOI 10.1016/0959-437X(93)90111-2; HASSOLD T, 1984, ANN HUM GENET, V48, P129, DOI 10.1111/j.1469-1809.1984.tb01008.x; HESTON LL, 1981, ARCH GEN PSYCHIAT, V38, P1085; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HOOK EB, 1982, DOWN SYNDROME ADV BI, P11; HUFF FJ, 1988, NEUROLOGY, V38, P786, DOI 10.1212/WNL.38.5.786; KLINE J, 1989, MONOGRAPHS EPIDEMIOL, V14, P102; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LI G, 1989, ACTA PSYCHIAT SCAND, V79, P557, DOI 10.1111/j.1600-0447.1989.tb10303.x; LI G, 1992, NEUROLOGY, V42, P1481, DOI 10.1212/WNL.42.8.1481; Malamud N., 1972, NEUROPATHOLOGY ORGAN, P63; MARTIN RL, 1988, ARCH GEN PSYCHIAT, V45, P894; MENDEZ MF, 1992, NEUROLOGY, V42, P770, DOI 10.1212/WNL.42.4.770; STOLL C, 1990, AM J MED GENET, P79; SUSSER E, 1989, AM J EPIDEMIOL, V129, P23, DOI 10.1093/oxfordjournals.aje.a115119; THOMPSON JS, 1986, GENET MED, P119; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS13, DOI 10.1093/ije/20.Supplement_2.S13; WHALLEY LJ, 1982, BRIT J PSYCHIAT, V140, P249, DOI 10.1192/bjp.140.3.249; WISNIEWSKI KE, 1985, NEUROLOGY, V35, P957, DOI 10.1212/WNL.35.7.957; YATHAM LN, 1988, ACTA PSYCHIAT SCAND, V77, P38, DOI 10.1111/j.1600-0447.1988.tb05074.x	26	80	83	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	1994	344	8919					353	356		10.1016/S0140-6736(94)91398-6	http://dx.doi.org/10.1016/S0140-6736(94)91398-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914304	hybrid			2022-12-28	WOS:A1994PA30300007
J	PIPPARD, MJ				PIPPARD, MJ			MEGALOBLASTIC-ANEMIA - GEOGRAPHY AND DIAGNOSIS	LANCET			English	Editorial Material							COBALAMIN DEFICIENCY; ANEMIA				PIPPARD, MJ (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT HAEMATOL,DUNDEE DD1 9SY,SCOTLAND.							ALLEN RH, 1990, AM J HEMATOL, V34, P90, DOI 10.1002/ajh.2830340204; CARMEL R, 1978, NEW ENGL J MED, V298, P647, DOI 10.1056/NEJM197803232981203; CHANARIN I, 1985, LANCET, V2, P1168; Chanarin I, 1990, MEGALOBLASTIC ANAEMI; METZ J, 1968, BRIT J HAEMATOL, V14, P575, DOI 10.1111/j.1365-2141.1968.tb00364.x; SAVAGE D, 1994, BRIT J HAEMATOL, V86, P844, DOI 10.1111/j.1365-2141.1994.tb04840.x; STABLER SP, 1990, BLOOD, V76, P871	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					6	7		10.1016/S0140-6736(94)91043-X	http://dx.doi.org/10.1016/S0140-6736(94)91043-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912325				2022-12-28	WOS:A1994NU91700006
J	MORRIS, DL; KRITCHEVSKY, SB; DAVIS, CE				MORRIS, DL; KRITCHEVSKY, SB; DAVIS, CE			SERUM CAROTENOIDS AND CORONARY HEART-DISEASE - THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL AND FOLLOW-UP-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							FOOD-FREQUENCY QUESTIONNAIRE; VITAMIN-E; BETA-CAROTENE; RISK; MORTALITY	Objective.-To examine the relationship between total serum carotenoid levels and the risk of subsequent coronary heart disease (CHD) events. Design.--New analysis of a cohort from the Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study (LRC-CPPT). The LRC-CPPT was a multicenter placebo-controlled trial of cholestyramine resin and CHD with a follow-up period of 13 years. Serum carotenoids were measured at baseline. Participants.-The placebo group of the LRC-CPPT, which consisted of 1899 men aged 40 to 59 years with type II-a hyperlipidemia and without known preexisting CHD, cancer, or other major illnesses. Main Outcome Measures.-Nonfatal myocardial infarctions and deaths attributable to CHD ascertained from hospital records, autopsy reports, and death certificates and reviewed by a panel of cardiologists. Results.-After adjustment for known CHD risk factors including smoking, serum carotenoids were inversely related to CHD events. Men in the highest quartile of serum carotenoids had an adjusted relative risk (RR) of 0.64 (95% confidence interval [CI], 0.44 to 0.92) compared with the lowest quartile. For men who never smoked, this RR was 0.28 (95% CI, 0.11 to 0.73). Conclusions.-The LRC-CPPT participants with higher serum carotenoid levels had a decreased risk of incident CHD. This finding was stronger among men who never smoked.	UNIV N CAROLINA, SCH PUBL HLTH, DEPT BIOSTAT, CHAPEL HILL, NC USA; UNIV TENNESSEE, COLL MED, DEPT PREVENT MED, MEMPHIS, TN USA	University of North Carolina; University of North Carolina Chapel Hill; University of Tennessee System; University of Tennessee Health Science Center	MORRIS, DL (corresponding author), UNIV N CAROLINA, SCH MED, DEPT EMERGENCY MED, CAMPUS BOX 7594, CHAPEL HILL, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL050391] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50391-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1992, Arch Intern Med, V152, P1399; BOLTONSMITH C, 1991, BRIT J NUTR, V65, P337, DOI 10.1079/BJN19910094; COATES RJ, 1991, AM J EPIDEMIOL, V134, P658, DOI 10.1093/oxfordjournals.aje.a116138; COX DR, 1972, J R STAT SOC, V34, P220; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; FORMAN MR, 1993, AM J CLIN NUTR, V58, P519, DOI 10.1093/ajcn/58.4.519; GAZIANO JM, 1990, CIRCULATION, V82, P201; GAZIANO JM, 1993, ANN NY ACAD SCI, V691, P148, DOI 10.1111/j.1749-6632.1993.tb26166.x; GEY KF, 1989, ANN NY ACAD SCI, V570, P268; GOODMAN DS, 1984, J NATL CANCER I, V73, P1375; HALEVY O, 1987, BIOCHIM BIOPHYS ACTA, V918, P304, DOI 10.1016/0005-2760(87)90235-9; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HENRY RJ, 1974, CLIN CHEM PRINCIPLES, P1375; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; KRINSKY NI, 1993, ANNU REV NUTR, V13, P561, DOI 10.1146/annurev.nutr.13.1.561; MANSON JE, 1991, AM J PREV MED, V7, P150, DOI 10.1016/S0749-3797(18)30931-0; PANDEY D, 1993, CIRCULATION, V87, P678; PARKER RS, 1989, J NUTR, V119, P101, DOI 10.1093/jn/119.1.101; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIFKIND BM, 1983, J CHRON DIS, V36, P467; RIFKIND BM, 1979, J CHRON DIS, V32, P609; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALONEN JT, 1993, CIRCULATION, V87, P678; 1986, SAS STAT USERS GUIDE	29	199	208	2	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1439	1441		10.1001/jama.272.18.1439	http://dx.doi.org/10.1001/jama.272.18.1439			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP690	7933426				2022-12-28	WOS:A1994PP69000032
J	BAUGHMAN, AL; WILLIAMS, WW; ATKINSON, WL; COOK, LG; COLLINS, M				BAUGHMAN, AL; WILLIAMS, WW; ATKINSON, WL; COOK, LG; COLLINS, M			THE IMPACT OF COLLEGE PREMATRICULATION IMMUNIZATION REQUIREMENTS ON RISK FOR MEASLES OUTBREAKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; ADULTS	Objective.-To assess whether prematriculation immunization requirements (PIRs) affect the number of measles cases on college campuses. Design.-We surveyed a stratified random sample of 880 colleges and universities to determine their immunization policies and practices and occurrence of measles outbreaks from 1988 through 1991. We merged national measles surveillance data with survey data by county to determine the risk for measles introduction on college campuses. We used logistic regression methods to estimate the effect of PIRs and assess risk factors for college measles outbreaks. Setting.-A total of 3205 US colleges and universities listed in standard guides. Results.-Of selected schools, 91 (11%) of the 796 responding schools reported one or more measles cases occurring from 1988 through 1991. Schools with a state-mandated PIR were significantly less likely to report measles outbreaks of two or more cases than other institutions (adjusted relative risk [RR]=0.30; 95% confidence interval [CI], 0.11 to 0.84). None of the 14 schools that reported outbreaks of 10 or more cases was subject to state regulation or had a PIR specifying two doses of measles vaccine in place. Of schools with introduction of measles, residential colleges were more likely to report extensive spread of measles (five or more cases) than nonresidential colleges (RR=35.8; 95% CI, 2.08 to 617.0). Of public schools, 4-year programs had a higher risk of a large outbreak (five or more cases) than 2-year programs. Conclusions.-These results strongly support current recommendations for requiring proof of vaccination of college students to decrease the risk for measles outbreaks on college campuses. State regulations mandating PIRs ensure the best protection against widespread measles transmission.	UNIV PENN,STUDENT HLTH SERV,PHILADELPHIA,PA 19104; AMER COLL HLTH ASSOC,BALTIMORE,MD	University of Pennsylvania	BAUGHMAN, AL (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,1600 CLIFTON RD NE,MAILSTOP E-52,ATLANTA,GA 30333, USA.							ABBOTT RD, 1985, AM J EPIDEMIOL, V121, P465, DOI 10.1093/oxfordjournals.aje.a114019; ALLEN LJ, 1993, STAT MED, V12, P229, DOI 10.1002/sim.4780120307; BIRKHEAD GS, 1991, PUBLIC HEALTH REP, V106, P338; COLLINS M, 1987, Journal of American College Health, V35, P247; Cook L G, 1993, J Am Coll Health, V42, P91; DAVIS RM, 1987, AM J EPIDEMIOL, V126, P438, DOI 10.1093/oxfordjournals.aje.a114675; DAVIS SF, 1993, AM J PUBLIC HEALTH, V83, P1011, DOI 10.2105/AJPH.83.7.1011; DILTS SW, 1990, PETERSONS GUIDE 2 YE; Fleiss JL, 1981, STAT METHODS RATES P; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; HERSH BS, 1992, JAMA-J AM MED ASSOC, V267, P1936, DOI 10.1001/jama.267.14.1936; Hosmer DW, 1989, APPL LOGISTIC REGRES, P238; NARAIN JP, 1985, AM J PUBLIC HEALTH, V75, P397, DOI 10.2105/AJPH.75.4.397; NKOWANE BM, 1987, AM J PUBLIC HLHT, V77, P424; ROBBINS KB, 1981, AM J PUBLIC HEALTH, V71, P270, DOI 10.2105/AJPH.71.3.270; SHAH BV, 1991, CROSSTAB PROCEDURE S; STRUEWING JP, 1993, AM J PUBLIC HEALTH, V83, P1717, DOI 10.2105/AJPH.83.12.1717; Williams W W, 1989, J Am Coll Health, V37, P197; WILLIAMS W W, 1987, Journal of American College Health, V35, P252; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1983, J AM COLL HLTH, V32, P7; 1987, MMWR-MORBID MORTAL W, V36, P209; 1992, MODEL LEGISLATION AC; 1989, ACTION, V28, P5; 1979, MMWR MORBID MORTAL S, V27, P41; 1989, MMWR-MORBID MORTAL W, V38, P11; 1989, LOGISTIC PROCEDURE S, P1071; 1978, MMWR MORBID MORTAL S, V26, P23	29	42	42	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1127	1132		10.1001/jama.272.14.1127	http://dx.doi.org/10.1001/jama.272.14.1127			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK124	7933326				2022-12-28	WOS:A1994PK12400033
J	MUSTIN, HD; HOLT, VL; CONNELL, FA				MUSTIN, HD; HOLT, VL; CONNELL, FA			ADEQUACY OF WELL-CHILD CARE AND IMMUNIZATIONS IN US INFANTS BORN IN 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERTUSSIS-VACCINE; UNITED-STATES; BENEFITS; RISKS; COSTS	Objective.-To determine adequacy of preventive care for US infants, including both well-child care visits and immunizations, and to identify risk factors for inadequate receipt of care. Design.-Analysis of the 1988 National Maternal and Infant Health Survey of the National Center for Health Statistics. Sample.-Nationally representative sample of all US children born in 1988. Participants.-A total of 7035 infants from a live-birth subsample who were at least 8 months of age and living with their mothers at the time of the survey. Main Outcome Measures.-Percentage of children receiving both adequate well-child visits and adequate immunizations by 8 months of age. Results.-Adequate visits were received by 82% of white infants and 75% of black infants; adequate immunizations were received by 46% and 34%, respectively. Forty-two percent of white infants and 29% of black infants received both. Sixty percent of infants who did not have adequate immunizations by 8 months of age had at least three well-baby visits. With adjustment for maternal education level, poor white children had a relative risk of 1.5 of receiving inadequate care compared with infants in families with income greater than 185% of the federal poverty level. Infants with Medicaid or other government assistance had significantly lower levels of adequate care than did infants with private insurance. Conclusions.-This study demonstrates a wide gap between actual immunization coverage levels and recommended levels among US infants born in 1988. Public health agencies, Medicaid programs, and primary care providers should explore ways to take better advantage of well-child visits that are already occurring to achieve appropriate levels of immunization coverage.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA	University of Washington; University of Washington Seattle	MUSTIN, HD (corresponding author), UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SC-37,SEATTLE,WA 98195, USA.				AHRQ HHS [5 T 123 HS00034] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BOBO JK, 1993, PEDIATRICS, V91, P308; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; CUTTS FT, 1992, ANNU REV PUBL HEALTH, V13, P385, DOI 10.1146/annurev.publhealth.13.1.385; HINMAN AR, 1984, JAMA-J AM MED ASSOC, V251, P3109, DOI 10.1001/jama.251.23.3109; KESSNER DM, 1973, INFANT DEATH ANAL MA; KOPLAN JP, 1982, AM J DIS CHILD, V136, P362, DOI 10.1001/archpedi.1982.03970400080021; KOPLAN JP, 1979, NEW ENGL J MED, V301, P906, DOI 10.1056/NEJM197910253011703; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SHORT PF, 1992, MED CARE, V30, P766, DOI 10.1097/00005650-199209000-00002; WAGNER JL, 1989, HEALTH AFFAIR, V8, P147, DOI 10.1377/hlthaff.8.3.147; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833; 1992, MMWR-MORBID MORTAL W, V40, P888; 1990, PHS9150212 US DEP HL; 1988, REPORT COMMITTEES IN; 1991, PUBLIC USE DATA TAPE; 1994, MMWR-MORBID MORTAL W, V42, P985; 1990, PHS901100 US DEP HLT; 1989, MMWR-MORBID MORTAL W, V38, P205; 1988, GUIDELINES HLTH SUPE, V2; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1992, MMWR-MORBID MORTAL W, V41, P103; 1989, P60 CURR POP REP SER; 1992, MMWR-MORBID MORTAL W, V41, P11; 1989, PHS891232 PUBL	24	69	69	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1111	1115		10.1001/jama.272.14.1111	http://dx.doi.org/10.1001/jama.272.14.1111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK124	7933323				2022-12-28	WOS:A1994PK12400030
J	COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; GOODRIDGE, DMG; SHORVON, SD				COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; GOODRIDGE, DMG; SHORVON, SD			MORTALITY FROM EPILEPSY - RESULTS FROM A PROSPECTIVE POPULATION-BASED STUDY	LANCET			English	Article							NATIONAL GENERAL-PRACTICE; ISCHEMIC HEART-DISEASE; COHORT; DRUGS	Patients with epilepsy may be subject to an increased risk of premature death from the underlying cause, or from the epilepsy intself. The extent and nature of this risk has been insufficiently investigated. Standard mortality ratios (SMRs) of patients with newly diagnosed epilepsy were determined in a prospective national population-based study. 1091 patients with newly diagnosed pr suspected epilepsy were ascertained who were attending one of 275 UK general practices from 1984-1987. 1091 patients were classified after 6 months as definite epilepsy (564), possible epilepsy (228), febrile seizures (220), or riot epilepsy (79). Over a median follow up of 6.9 years the SMR for patients with definite or possible epilepsy was 2.5 (95% Cl 2.1-2.9), and 3.0 (2.5-3.7) for definite epilepsy. The SMR was highest during the first year after diagnosis 5.1 (3.8-6.5), declined to 2.5 (1.5-3.9) at 3 years, and 1.3 (0.7-2.0) at 5 years. The commonest causes of death were pneumonia (SMR 7.2), cancer (3.5), and stroke (3.7). The SMR for patients with idiopathic epilepsy was 1.6 (1.0-2.4), remote symptomatic epilepsy 4.3 (3.3-5.5), and acute symptomatic epilepsy 2.9 (1.7-4.5). Mortality in patients with newly-diagnosed epilepsy was high, mainly due to the underlying cause. The SMR for idiopathic epilepsy was also raised, suggesting that epilepsy per se may carry a small risk of death.	INST NEUROL, LONDON, ENGLAND; CHALFONT CTR EPILEPSY, CHALFONT ST PETER SL9 0RJ, BUCKS, ENGLAND; INST PUBL HLTH, MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND	University of London; University College London; MRC Biostatistics Unit; University of Cambridge	COCKERELL, OC (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, EPILEPSY RES GRP, LONDON, ENGLAND.		Shorvon, Simon D/A-2019-2009; Sander, Josemir W/C-1576-2008	Sander, Josemir W/0000-0001-6041-9661; Shorvon, Simon/0000-0003-0313-2001				ANNEGERS JF, 1984, EPILEPSIA, V25, P699, DOI 10.1111/j.1528-1157.1984.tb03480.x; ANNEGERS JF, 1976, EPILEPSIA, V17, P11, DOI 10.1111/j.1528-1157.1976.tb03376.x; BARRACLOUGH BM, 1987, ACTA PSYCHIAT SCAND, V76, P339, DOI 10.1111/j.1600-0447.1987.tb05616.x; BRADFORDHILL A, 1984, SHORT TXB MED STATIS, P259; COLEMAN MP, 1989, PERSON YEARS PYRS FU; Gowers WR., 1885, EPILEPSY OTHER CHRON; HART YM, 1989, NEUROEPIDEMIOLOGY, V8, P221; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; JANCAR J, 1980, LANCET, V1, P484; JICK SS, 1992, PHARMACOEPIDEM DR S, V1, P59, DOI DOI 10.1002/PDS.2630010203; KLENERMAN P, 1993, J NEUROL NEUROSUR PS, V56, P149, DOI 10.1136/jnnp.56.2.149; Livingston Samuel, 1963, LIVING EPILEPTIC SEI; MASSEY E W, 1985, Neuroepidemiology, V4, P65; MOORE MT, 1959, JAMA-J AM MED ASSOC, V171, P1328, DOI 10.1001/jama.1959.03010280052013; Munson JF., 2010, MED REC, V77, P58; MUURONEN A, 1985, BRIT MED J, V291, P1481, DOI 10.1136/bmj.291.6507.1481; Rodin E, 1968, PROGNOSIS PATIENTS E, P156; SCHWADE ED, 1954, JAMA-J AM MED ASSOC, V156, P1526; WHITE SJ, 1979, LANCET, V2, P458; ZIELINSKI JJ, 1974, EPILEPSIA, V15, P191, DOI 10.1111/j.1528-1157.1974.tb04941.x	21	322	329	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					918	921		10.1016/S0140-6736(94)92270-5	http://dx.doi.org/10.1016/S0140-6736(94)92270-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934347				2022-12-28	WOS:A1994PJ28700011
J	SCHMIDT, HHHW; WALTER, U				SCHMIDT, HHHW; WALTER, U			NO AT WORK	CELL			English	Review							NITRIC-OXIDE SYNTHASE; LONG-TERM POTENTIATION; INTERCELLULAR MESSENGER; SUPEROXIDE-DISMUTASE; SYNAPTIC PLASTICITY; SIGNAL-TRANSDUCTION; INSULIN-SECRETION; SMOOTH-MUSCLE; L-ARGININE; CELLS				SCHMIDT, HHHW (corresponding author), UNIV WURZBURG,MED KLIN,BIOCHEM & PATHOBIOCHEM KLIN,VERSBACHER STR 5,D-97078 WURZBURG,GERMANY.		Walter, ulrich/W-2478-2017; Schmidt, Harald HHW/B-1549-2008	Walter, ulrich/0000-0001-6784-2307; Schmidt, Harald HHW/0000-0003-0419-5549				BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BOHME GA, 1993, P NATL ACAD SCI USA, V90, P9191, DOI 10.1073/pnas.90.19.9191; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BREER H, 1993, TRENDS NEUROSCI, V16, P5, DOI 10.1016/0166-2236(93)90040-S; BROWN JF, 1993, AM J PHYSIOL, V265, pG418, DOI 10.1152/ajpgi.1993.265.3.G418; BUSSE R, 1993, CURR OPIN CARDIOL, V8, P719, DOI 10.1097/00001573-199309000-00002; DANIEL H, 1993, EUR J NEUROSCI, V5, P1079, DOI 10.1111/j.1460-9568.1993.tb00961.x; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GARBERS DL, 1992, CELL, V74, P1; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; GEIGER J, 1994, AM J PHYSIOL, V267, pC236, DOI 10.1152/ajpcell.1994.267.1.C236; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; GREEN IC, 1994, BIOCHEM SOC T, V22, P30, DOI 10.1042/bst0220030; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HEISS LN, 1994, P NATL ACAD SCI USA, V91, P267, DOI 10.1073/pnas.91.1.267; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; HORSTRUP K, 1994, IN PRESS EUR J BIOCH; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; INAGAKI S, 1991, BRAIN RES, V549, P174, DOI 10.1016/0006-8993(91)90618-6; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KOCH KW, 1994, EMBO J, V13, P3312, DOI 10.1002/j.1460-2075.1994.tb06633.x; KOLESNIKOV YA, 1993, P NATL ACAD SCI USA, V90, P5162, DOI 10.1073/pnas.90.11.5162; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MEFFERT MK, 1994, NEURON, V12, P1235, DOI 10.1016/0896-6273(94)90440-5; MELLER ST, 1993, PAIN, V52, P127, DOI 10.1016/0304-3959(93)90124-8; Mitchell HH, 1916, J BIOL CHEM, V24, P461; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PUBLICOVER NG, 1993, P NATL ACAD SCI USA, V90, P2087, DOI 10.1073/pnas.90.5.2087; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCHMIDT HHHW, 1992, SCIENCE, V258, P1376, DOI 10.1126/science.258.5086.1376-a; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; VALTSCHANOFF JG, 1993, J COMP NEUROL, V331, P111, DOI 10.1002/cne.903310107; WEINBERG JB, 1994, J EXP MED, V179, P651, DOI 10.1084/jem.179.2.651; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; WILLIAMS CV, 1994, J NEUROSCI, V14, P1746, DOI 10.1523/JNEUROSCI.14-03-01746.1994; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WORL J, 1994, IN PRESS J AUTONOMIC; YALLAMPALLI C, 1993, ENDOCRINOLOGY, V133, P1899, DOI 10.1210/en.133.4.1899; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481	58	1395	1453	1	42	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					919	925		10.1016/0092-8674(94)90267-4	http://dx.doi.org/10.1016/0092-8674(94)90267-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923361				2022-12-28	WOS:A1994PJ29400003
J	STAMLER, JS				STAMLER, JS			REDOX SIGNALING - NITROSYLATION AND RELATED TARGET INTERACTIONS OF NITRIC-OXIDE	CELL			English	Review							S-NITROSYLATION; ACTIVATION; NO; MACROPHAGES; SUPEROXIDE; OXIDATION; PROTEINS; BINDING; CELLS		DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOVASC MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University	STAMLER, JS (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV RESP,DURHAM,NC 27710, USA.			Stamler, Jonathan/0000-0002-6866-1572	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052529, K08HL002582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02582, HL52529] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGELSON S, 1994, CANCER RES, V54, P36; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRUNE B, 1994, LIFE SCI, V54, P61, DOI 10.1016/0024-3205(94)00775-6; CLANCY RM, 1993, BIOCHEM BIOPH RES CO, V191, P847, DOI 10.1006/bbrc.1993.1294; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CONSENTINO F, 1994, HYPERTENSION, V23, P229, DOI DOI 10.1161/01.HYP.23.2.229; CORRALIZA IM, 1993, BIOCHEM BIOPH RES CO, V196, P342, DOI 10.1006/bbrc.1993.2254; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GUPTA JB, 1992, AM J PHYSIOL, V263, P1714; HAUSLADEN A, 1994, IN PRESS J BIOL CHEM; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; KHATSENKO OG, 1993, P NATL ACAD SCI USA, V90, P11147, DOI 10.1073/pnas.90.23.11147; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LANDER HM, 1993, J IMMUNOL, V151, P7182; LAVAL F, 1994, CARCINOGENESIS, V15, P443, DOI 10.1093/carcin/15.3.443; LEWISMOLOCK Y, 1994, AM J RESP CELL MOL, V10, P133, DOI 10.1165/ajrcmb.10.2.8110468; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MAKINGS LR, 1994, J BIOL CHEM, V269, P6282; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MYERS LC, 1993, SCIENCE, V261, P1164, DOI 10.1126/science.8395079; NIROOMAND F, 1989, BIOCHEM BIOPH RES CO, V161, P75, DOI 10.1016/0006-291X(89)91562-3; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; RADI R, 1991, J BIOL CHEM, V266, P4244; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, IN PRESS CURR TOPICS; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; THOMAS SR, 1994, J BIOL CHEM, V269, P14457; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	44	1565	1619	3	62	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					931	936		10.1016/0092-8674(94)90269-0	http://dx.doi.org/10.1016/0092-8674(94)90269-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923362				2022-12-28	WOS:A1994PJ29400005
J	GOEDERT, JJ; COHEN, AR; KESSLER, CM; EICHINGER, S; SEREMETIS, SV; RABKIN, CS; YELLIN, FJ; ROSENBERG, PS; ALEDORT, LM				GOEDERT, JJ; COHEN, AR; KESSLER, CM; EICHINGER, S; SEREMETIS, SV; RABKIN, CS; YELLIN, FJ; ROSENBERG, PS; ALEDORT, LM			RISKS OF IMMUNODEFICIENCY, AIDS, AND DEATH RELATED TO PURITY OF FACTOR-VIII CONCENTRATE	LANCET			English	Note							INFECTED HEMOPHILIACS	In HIV-infected subjects with haemophilia, CD4 counts seem to fall more slowly in those on high-purity factor VIII (FVIII) than on intermediate-purity product. We evaluated whether risks for AIDS or death were associated with either product among 411 HIV-infected individuals. The relative hazard of AIDS was slightly elevated for both current (1.34 per month) and cumulative (1.01 per month) use of high-purity products (neither significant). The corresponding hazards for death were 1.49 and 1.03 (neither significant). Thus we found no evidence that high-purity FVIII concentrates retard the development of AIDS.	NCI,VIRAL EPIDEMIOL BRANCH,AIDS & CANC SECT,ROCKVILLE,MD; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104; GEORGE WASHINGTON UNIV HOSP,WASHINGTON,DC; UNIV VIENNA,VIENNA,AUSTRIA; MT SINAI MED CTR,NEW YORK,NY 10029; COMP SCI CORP,PROFESS SERV GRP,ROCKVILLE,MD; NCI,EPIDEMIOL METHODS SECT,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; George Washington University; University of Vienna; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; DEBIASI R, 1991, BLOOD, V78, P1919; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOLDSMITH JM, 1991, THROMB HAEMOSTASIS, V66, P415; HILGARTNER MW, 1993, LANCET, V341, P1373, DOI 10.1016/0140-6736(93)90943-B; PRESTON DL, 1990, EPICURE RISK REGRESS; SEREMETIS SV, 1993, LANCET, V342, P700, DOI 10.1016/0140-6736(93)91706-R; THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4; 1994, LANCET, V343, P871	9	46	46	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					791	792		10.1016/S0140-6736(94)92345-0	http://dx.doi.org/10.1016/S0140-6736(94)92345-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916077				2022-12-28	WOS:A1994PG17800014
J	DAVIS, MB; BATEMAN, D; QUINN, NP; MARSDEN, CD; HARDING, AE				DAVIS, MB; BATEMAN, D; QUINN, NP; MARSDEN, CD; HARDING, AE			MUTATION ANALYSIS IN PATIENTS WITH POSSIBLE BUT APPARENTLY SPORADIC HUNTINGTONS-DISEASE	LANCET			English	Article							TRINUCLEOTIDE REPEAT; MOLECULAR ANALYSIS; ONSET; LENGTH; AGE; INSTABILITY; EXPANSION; SIZE	Until the advent of mutation analysis it was impossible to make a certain diagnosis of Huntington's disease (HD) in the absence of a positive family history, and sporadic cases of possible HD presented a substantial diagnostic dilemma. We have looked for the characteristic expanded trinucleotide (CAG) repeat sequence in the HD gene in 44 patients with probable or possible HD who did not have similarly affected relatives. We used two methods, the traditional widely used method, which estimates both the CAG repeat and the flanking CCG repeat and gives the CAG length by subtraction, and the more precise CAG method, which estimates the repeat length directly. With the CAG method, the HD mutation was detected in 25 (89%) of 28 patients with the typical clinical features of HD and 5 (31%) of 16 in whom the diagnosis was more doubtful. The CAG-CCG method gave results in the borderline abnormal range of repeats for 13 of the 33 patients eventually shown to have an unequivocal repeat expansion by the CAG method. Most of these patients had late onset of symptoms. There was evidence of expansion of an intermediate-length paternal allele in 1 patient and of non-paternity in another. The identification of the mutation causing HD means that it is now possible to confirm or exclude the diagnosis with confidence, even in the absence of a family history, by analysis of DNA from a blood sample. The precise method of measuring the CAG repeat, which is technically more difficult than the traditional method, may be needed to clarify results in a substantial proportion of such patients.	UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,LONDON WC1N 3BG,ENGLAND	University of London; University College London								ANDREW SE, 1994, HUM MOL GENET, V3, P65, DOI 10.1093/hmg/3.1.65; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; BARRON LH, 1993, J MED GENET, V30, P1003, DOI 10.1136/jmg.30.12.1003; BATEMAN D, 1992, ANN NEUROL, V31, P293, DOI 10.1002/ana.410310311; CRAUFURD D, 1993, J MED GENET, V30, P1008, DOI 10.1136/jmg.30.12.1008; DEROOIJ KE, 1993, J MED GENET, V30, P996, DOI 10.1136/jmg.30.12.996; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; GIBB WRG, 1989, NEUROLOGY, V39, P999, DOI 10.1212/WNL.39.7.999; GOLDBERG YP, 1993, HUM MOL GENET, V2, P635, DOI 10.1093/hmg/2.6.635; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; KREMER B, 1993, J MED GENET, V30, P991, DOI 10.1136/jmg.30.12.991; MACMILLAN JC, 1993, LANCET, V342, P954, DOI 10.1016/0140-6736(93)92002-B; MYERS RH, 1993, NAT GENET, V5, P168, DOI 10.1038/ng1093-168; QUARRELL OWJ, 1986, CLIN GENET, V30, P433; RUBINSZTEIN DC, 1993, HUM MOL GENET, V2, P1713, DOI 10.1093/hmg/2.10.1713; SIMPSON SA, 1993, J MED GENET, V30, P1036, DOI 10.1136/jmg.30.12.1036; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; WARNER JP, 1993, MOL CELL PROBE, V7, P235, DOI 10.1006/mcpr.1993.1034; 1993, CELL, V72, P971	20	45	47	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					714	717		10.1016/S0140-6736(94)92208-X	http://dx.doi.org/10.1016/S0140-6736(94)92208-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915776				2022-12-28	WOS:A1994PF18700010
J	JAMES, I				JAMES, I			WHEN THE MUSIC HAS TO STOP	LANCET			English	Editorial Material							MEDICAL PROBLEMS				JAMES, I (corresponding author), UNIV LONDON ROYAL FREE HOSP,DEPT MED,LONDON NW3 2QG,ENGLAND.							FISHBEIN M, 1988, MED PROBL PERFORM AR, V3, P1; Fry H. J. H., 1986, MED PROBL PERFORM AR, V1, P1; JAMES IM, 1992, BRIT J RHEUMATOL, V31, P795; LAMBERT CM, 1992, BRIT J RHEUMATOL, V31, P265; LOCKWOOD AH, 1989, NEW ENGL J MED, V320, P221, DOI 10.1056/NEJM198901263200405; MOULTON B, 1992, BEHAV RES THER, V30, P375, DOI 10.1016/0005-7967(92)90049-M; PALIN SL, 1994, OCCUP MED-OXFORD, V44, P130, DOI 10.1093/occmed/44.3.130; SPEAKS C, 1970, JOM-J OCCUP MED, V12, P216, DOI 10.1097/00043764-197006000-00004	8	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					631	632		10.1016/S0140-6736(94)92080-X	http://dx.doi.org/10.1016/S0140-6736(94)92080-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915345				2022-12-28	WOS:A1994PE38600005
J	SERAFINI, M; GHISELLI, A; FERROLUZZI, A				SERAFINI, M; GHISELLI, A; FERROLUZZI, A			RED WINE, TEA, AND ANTIOXIDANTS	LANCET			English	Letter											SERAFINI, M (corresponding author), NATL INST NUTR,HUMAN NUTR UNIT,I-00178 ROME,ITALY.		Serafini, Mauro/K-6498-2018	Serafini, Mauro/0000-0003-0913-936X; GHISELLI, ANDREA/0000-0001-9808-2304				FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; GHISELLI A, IN PRESS FREE RAD BI; MAXWELL, 1994, LANCET 0716, P193; VENDEMIALE G, 1989, J HEPATOL, V9, P359, DOI 10.1016/0168-8278(89)90146-3; 1990, INT TEA COMMITTEE LT	5	98	103	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					626	626		10.1016/S0140-6736(94)92017-6	http://dx.doi.org/10.1016/S0140-6736(94)92017-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7915001				2022-12-28	WOS:A1994PD42400073
J	CHARITE, J; DEGRAAFF, W; SHEN, SB; DESCHAMPS, J				CHARITE, J; DEGRAAFF, W; SHEN, SB; DESCHAMPS, J			ECTOPIC EXPRESSION OF HOXB-8 CAUSES DUPLICATION OF THE ZPA IN THE FORELIMB AND HOMEOTIC TRANSFORMATION OF AXIAL STRUCTURES	CELL			English	Article							HOX-2.4 HOMEOBOX GENE; CHICK WING BUD; LIMB-BUD; TARGETED DISRUPTION; TRANSGENIC MICE; RETINOIC ACID; DEVELOPMENTAL DEFECTS; ANTEROPOSTERIOR AXIS; POLARIZING ACTIVITY; MYELOID-LEUKEMIA	Transgenic embryos were generated carrying a Hoxb-8 transgene under control of the mouse RAR beta 2 promoter, which extends the normal expression domain to more anterior regions of the embryo. These embryos showed mirror-image duplications in the forelimb, analogous to the duplications observed in chick in response to transplantation of a ZPA to the anterior margin of the limb bud. Examination of Sonic hedgehog, Fgf-4, and Hoxd-11 gene expression confirmed that a second ZPA had been generated at the anterior side of the limb bud. Besides other alterations, posterior homeotic transformations of axial structures were observed, involving the first spinal (Froriep's) ganglion and several cervical vertebrae.			CHARITE, J (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Shen, Sanbing/E-3750-2015	Shen, Sanbing/0000-0002-8217-9811				ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V42, P275; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CONDIE BG, 1993, DEVELOPMENT, V119, P579; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; DESCHAMPS J, 1993, DEV BIOL, V156, P473, DOI 10.1006/dbio.1993.1093; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; Hamburger V, 1938, J EXP ZOOL, V77, P379, DOI 10.1002/jez.1400770304; Harrison RG, 1918, J EXP ZOOL, V25, P413, DOI 10.1002/jez.1400250204; HINCHCLIFFE JR, 1983, DEV EVOLUTION; HONIG LS, 1985, J EMBRYOL EXP MORPH, V87, P163; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIMMEL CA, 1981, STAIN TECHNOL, V56, P271, DOI 10.3109/10520298109067325; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KRESS C, 1990, DEVELOPMENT, V109, P775; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LIM TM, 1987, DEVELOPMENT, V100, P525; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RUGH R, 1990, MOUSE ITS REPRODUCTI; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAUNDERS JW, 1977, VERTEBRATE LIMB SOMI, P1; SCHUGHART K, 1989, P NATL ACAD SCI USA, V86, P7067, DOI 10.1073/pnas.86.18.7067; Shen S, 1991, DNA Seq, V2, P111, DOI 10.3109/10425179109039679; SMITH JC, 1981, J EMBRYOL EXP MORPH, V63, P127; SMITH JC, 1980, J EMBRYOL EXP MORPH, V60, P321; SUMMERBELL D, 1981, J EMBRYOL EXP MORPH, V63, P161; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199; VOGELS R, 1993, DEVELOPMENT, V118, P71; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZWILLING E, 1956, J EXP ZOOL, V132, P157, DOI 10.1002/jez.1401320110	55	219	226	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					589	601		10.1016/0092-8674(94)90524-X	http://dx.doi.org/10.1016/0092-8674(94)90524-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915198				2022-12-28	WOS:A1994PD69300008
J	VOLBERDING, PA; LAGAKOS, SW; GRIMES, JM; STEIN, DS; BALFOUR, HH; REICHMAN, RC; BARTLETT, JA; HIRSCH, MS; PHAIR, JP; MITSUYASU, RT; FISCHL, MA; SOEIRO, R				VOLBERDING, PA; LAGAKOS, SW; GRIMES, JM; STEIN, DS; BALFOUR, HH; REICHMAN, RC; BARTLETT, JA; HIRSCH, MS; PHAIR, JP; MITSUYASU, RT; FISCHL, MA; SOEIRO, R			THE DURATION OF ZIDOVUDINE BENEFIT IN PERSONS WITH ASYMPTOMATIC HIV-INFECTION - PROLONGED EVALUATION OF PROTOCOL-019 OF THE AIDS-CLINICAL-TRIALS-GROUP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLACEBO-CONTROLLED TRIAL; CD4+ CELL COUNTS; CUBIC MILLIMETER; DOUBLE-BLIND; EFFICACY; COMPLEX; AZT	Objective.-To determine the durability of zidovudine-induced delay in clinical progression of asymptomatic human immunodeficiency virus (HIV) disease and to assess the relationship between this effect and the entry CD4(+) cell count. Design and Interventions.-Extended follow-up data from subjects participating in protocol 019 of the AIDS [acquired immunodeficiency syndrome] Clinical Trials Group were examined. Subjects were offered a total daily dose of 500 mg of open-label zidovudine after the unblinding of the original randomized trial in 1989. Original treatment groups included placebo, 500 mg of zidovudine, or 1500 mg of zidovudine daily in divided doses. Three distinct analyses were conducted to assess the duration of zidovudine's effect on progression to AIDS or death: (1) analysis of all follow-up information from all subjects, (2) analysis of all subjects but with follow-up of original placebo-assigned subjects censored at the time open-label zidovudine was initiated, and (3) analysis of the effect of initiating zidovudine in subjects initially assigned to receive placebo. Setting.-University-based and university-affiliate AIDS research clinics participating in AIDS Clinical Trials Group protocol 019. Patients.-A total of 1565 asymptomatic HIV-infected subjects with entry CD4(+) cell counts less than 0.50x10(9)/L (500/mu L). Main Outcome Measure.-Time to progression to AIDS or death. Results.-During follow-up of up to 4.5 years (mean, 2.6 years), 232 subjects progressed to AIDS or died. In each of the three analyses described herein, zidovudine was associated with a significant (P=.008, .004, .007) decrease in the risk of such progression. However, each of these analyses also indicated a decreasing placebo:zidovudine relative risk with duration of use (P=.002, .08, .04), suggesting a nonpermanent effect. The duration of benefit appeared to be related to entry CD4(+) cell count, with greater benefit in those with higher counts at entry. No significant differences in survival were found between those originally randomized to zidovudine or placebo. Conclusions.-Zidovudine at 500 mg/d caused a significant delay in progression to AIDS or death, but its earlier use in asymptomatic disease was not associated with an additional prolongation of survival compared with delayed initiation. The delay in progression diminished overtime especially in subjects with entry CD4(+) cell counts less than 0.30x10(9)/L (300/mu L). Treatment strategies that alter drug regimens before the loss of zidovudine benefit should be explored.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; NIAID,BETHESDA,MD; UNIV MINNESOTA,MINNEAPOLIS,MN 55455; UNIV ROCHESTER,SCH MED & DENT,ROCHESTER,NY; DUKE UNIV,MED CTR,DURHAM,NC; HARVARD UNIV,SCH MED,BOSTON,MA; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; NORTHWESTERN UNIV,CHICAGO,IL 60611; UNIV CALIF LOS ANGELES,LOS ANGELES,CA; UNIV MIAMI,SCH MED,MIAMI,FL; ALBERT EINSTEIN MONTEFIORE MED CTR,NEW YORK,NY	University of California System; University of California San Francisco; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities; University of Rochester; Duke University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Northwestern University; University of California System; University of California Los Angeles; University of Miami; Montefiore Medical Center; Yeshiva University	VOLBERDING, PA (corresponding author), SAN FRANCISCO GEN HOSP,AIDS PROGRAM,WARD 84,995 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.							ABRAMS DI, 1994, NEW ENGL J MED, V330, P657, DOI 10.1056/NEJM199403103301001; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; COX DR, 1972, J R STAT SOC B, V34, P187; DOLIN R, 1993, 9 INT C AIDS BERL; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FISCHL MA, 1993, 9TH INT C AIDS BERL; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOCH MA, 1992, ARCH INTERN MED, V152, P2286, DOI 10.1001/archinte.152.11.2286; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MERIGAN TC, 1991, BLOOD, V78, P900; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1994, LANCET, V343, P871	21	129	129	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					437	442		10.1001/jama.272.6.437	http://dx.doi.org/10.1001/jama.272.6.437			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	7913730				2022-12-28	WOS:A1994PA27800024
J	FONTES, P; RAO, AS; DEMETRIS, AJ; ZEEVI, A; TRUCCO, M; CARROLL, P; RYBKA, W; RUDERT, WA; RICORDI, C; DODSON, F; SHAPIRO, R; TZAKIS, A; TODO, S; ABUELMAGD, K; JORDAN, M; FUNG, JJ; STARZL, TE				FONTES, P; RAO, AS; DEMETRIS, AJ; ZEEVI, A; TRUCCO, M; CARROLL, P; RYBKA, W; RUDERT, WA; RICORDI, C; DODSON, F; SHAPIRO, R; TZAKIS, A; TODO, S; ABUELMAGD, K; JORDAN, M; FUNG, JJ; STARZL, TE			BONE-MARROW AUGMENTATION OF DONOR-CELL CHIMERISM IN KIDNEY, LIVER, HEART, AND PANCREAS ISLET TRANSPLANTATION	LANCET			English	Article							TOTAL LYMPHOID IRRADIATION; ORGAN-TRANSPLANTATION; GRAFT ACCEPTANCE; RENAL-ALLOGRAFT; RECIPIENTS; MIGRATION	We have previously postulated that donor cell chimerism in organ transplantation is needed to attain a tolerant state. Here we show that donor cell chimerism can be augmented in organ recipients if they are infused perioperatively with 3 x 10(8) per kg of unmodified donor bone marrow cells and are kept on a conventional immunosuppressive regimen of tacrolimus (FK506) and prednisolone. 36 patients took part, of whom the first 18 patients have good transplanted kidney (n=10), liver (n=7), and heart (n=7) function when followed up between 4 and 16 months. All patients are well. We found persistent multilineage leucocyte chimerism in blood of 17 recipients by flow cytometry and PCR techniques to detect donor alleles or Y chromosomes in female recipients of male organs. The use of the 5-antigen HLA matched same sex donor precluded detection of chimerism in one patient.	UNIV PITTSBURGH, MED CTR, PITTSBURGH TRANSPLANT INST, DEPT SURG, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PAEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA 15260 USA; DIABET RES INST, MIAMI, FL USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			RICORDI, CAMILLO/AAA-4740-2019; FUNG, John Julian/A-2679-2012; Rao, Abdul Sohail/E-1453-2011	FUNG, John Julian/0000-0002-3038-0441; Ricordi, Camillo/0000-0001-8092-7153	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961, R37DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK029961-19, DK 29961] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER WH, 1991, TRANSPLANTATION, V51, P70, DOI 10.1097/00007890-199101000-00011; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; KAHN DR, 1984, ANN THORAC SURG, V38, P169, DOI 10.1016/S0003-4975(10)62227-8; KOCOVA M, 1993, LANCET, V342, P140, DOI 10.1016/0140-6736(93)91345-M; MONACO AP, 1976, SURGERY, V79, P384; MYBURGH JA, 1989, TRANSPLANT P, V21, P826; NAJARIAN JS, 1982, ANN SURG, V196, P442, DOI 10.1097/00000658-198210000-00007; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; ROLLES K, 1994, LANCET, V343, P263, DOI 10.1016/S0140-6736(94)91113-4; SALVATIERRA O, 1985, TRANSPLANTATION, V40, P654, DOI 10.1097/00007890-198512000-00016; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P385; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; STARZL TE, 1991, TRANSPLANT P, V23, P914; STARZL TE, IN PRESS TRANSPLANT	19	282	285	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	1994	344	8916					151	155		10.1016/S0140-6736(94)92756-1	http://dx.doi.org/10.1016/S0140-6736(94)92756-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912764	Green Accepted			2022-12-28	WOS:A1994NW81000008
J	FIELDING, J; HALFON, N				FIELDING, J; HALFON, N			WHERE IS THE HEALTH IN HEALTH SYSTEM REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTION PROGRAM; COST-EFFECTIVENESS; UNITED-STATES; CHILDREN; DISEASE		UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT COMMUNITY HLTH SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT HLTH SERV,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BLENDON RJ, 1989, HLTH AFF MILLWOOD, V8, P148; Chaloupka F. J., 1993, ALCOHOL HEALTH RES W, V17, P46; CHRISTOFFEL KK, 1990, AM J DIS CHILD, V144, P697, DOI 10.1001/archpedi.1990.02150300095025; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; DAVIDSON LL, 1994, AM J PUBLIC HEALTH, V84, P580, DOI 10.2105/AJPH.84.4.580; FELDMAN MA, 1993, RES DEV DISABIL, V14, P387, DOI 10.1016/0891-4222(93)90010-H; HALFON N, 1993, VISIONS ENTITLEMENT, P175; HERMANSON B, 1988, NEW ENGL J MED, V319, P1365, DOI 10.1056/NEJM198811243192101; KIPKE MD, 1993, J ADOLESCENT HEALTH, V14, P533, DOI 10.1016/1054-139X(93)90136-D; LAU RR, 1990, J HEALTH SOC BEHAV, V31, P240, DOI 10.2307/2136890; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; LOOSE C, 1994, WASHINGTON POST 0102, P19; LOOSE C, 1994, WASHINGTON POST 0102, P1; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Mechanic D, 1994, INESCAPABLE DECISION; OLDS DL, 1993, MED CARE, V31, P155, DOI 10.1097/00005650-199302000-00006; OSTROWSKY JT, 1985, AM J PUBLIC HEALTH, V75, P732, DOI 10.2105/AJPH.75.7.732; PARKIN PC, 1993, PEDIATRICS, V91, P772; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; SCHAFER HJ, 1994, P 2 INT S EL SYNTH K, P1; SCHAUFFLER HH, 1994, AM J PREV MED, V10, P1; Sisk J E, 1993, JAMA, V269, P1715, DOI 10.1001/jama.269.13.1710; SISK JE, 1993, JAMA-J AM MED ASSOC, V269, P1715; SMITH MD, 1992, HEALTH AFFAIR, V11, P125, DOI 10.1377/hlthaff.11.2.125; STARRP, 1991, AM PROSPECT, V6, P7; STPIERRE TL, 1992, AM J COMMUN PSYCHOL, V20, P673; TOLSMA DD, 1992, PUBLIC HLTH PREVENTI, P701; WHITE E, 1993, ANNU REV PUBL HEALTH, V14, P605; 1989, GUIDE CLIN PREVENTIO; 1992, 1992 NATIONAL SURVEY; 1991, STATEMENT LEAD EXPOS; [No title captured]	32	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1292	1296		10.1001/jama.272.16.1292	http://dx.doi.org/10.1001/jama.272.16.1292			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN068	7933375				2022-12-28	WOS:A1994PN06800037
J	BOHMANN, D; ELLIS, MC; STASZEWSKI, LM; MLODZIK, M				BOHMANN, D; ELLIS, MC; STASZEWSKI, LM; MLODZIK, M			DROSOPHILA JUN MEDIATES RAS-DEPENDENT PHOTORECEPTOR DETERMINATION	CELL			English	Article							RECEPTOR TYROSINE KINASE; GUANINE-NUCLEOTIDE EXCHANGE; TRANSCRIPTION FACTOR AP-1; C-JUN; SEVENLESS PROTEIN; CELL FATE; SIGNAL-TRANSDUCTION; FUNCTIONS DOWNSTREAM; ECTOPIC EXPRESSION; NEGATIVE REGULATOR	The expression of the D. melanogaster transcription factor Jun in the eye imaginal disc correlates temporally and spatially with the determination of neuronal photoreceptor fate. Expression of dominant negative forms of Jun in photoreceptor precursor cells results in dose-dependent loss of photoreceptors in the adult fly. Conversely, localized overexpression of Jun in the eye imaginal disc can induce the differentiation of additional photoreceptor cells. Furthermore, the transformation of nonneuronal cone cells into R7 neurons elicited by constitutively active forms of sevenless, Ras1, Raf, and MAP kinase is relieved in the presence of Jun mutants. These results demonstrate a requirement of Jun downstream of the sevenless/ras signaling pathway for neuronal development in the Drosophila eye.			BOHMANN, D (corresponding author), EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1988, COLD SPRING HARB SYM, V53, P695, DOI 10.1101/SQB.1988.053.01.079; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BROWN PH, 1993, ONCOGENE, V8, P877; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FISCHERVIZE JA, 1992, DEVELOPMENT, V115, P89; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAFEN E, 1993, PHILOS T R SOC B, V340, P273, DOI 10.1098/rstb.1993.0068; HARLOW E, 1988, ANTIBODIES LABORATOR; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIROMI Y, 1993, DEVELOPMENT, V118, P1123; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; MULLINS MC, 1991, P NATL ACAD SCI USA, V88, P9387, DOI 10.1073/pnas.88.21.9387; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281	73	84	84	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					973	986		10.1016/0092-8674(94)90273-9	http://dx.doi.org/10.1016/0092-8674(94)90273-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923366				2022-12-28	WOS:A1994PJ29400009
J	HASTBACKA, J; DELACHAPELLE, A; MAHTANI, MM; CLINES, G; REEVEDALY, MP; DALY, M; HAMILTON, BA; KUSUMI, K; TRIVEDI, B; WEAVER, A; COLOMA, A; LOVETT, M; BUCKLER, A; KAITILA, I; LANDER, ES				HASTBACKA, J; DELACHAPELLE, A; MAHTANI, MM; CLINES, G; REEVEDALY, MP; DALY, M; HAMILTON, BA; KUSUMI, K; TRIVEDI, B; WEAVER, A; COLOMA, A; LOVETT, M; BUCKLER, A; KAITILA, I; LANDER, ES			THE DIASTROPHIC DYSPLASIA GENE ENCODES A NOVEL SULFATE TRANSPORTER - POSITIONAL CLONING BY FINE-STRUCTURE LINKAGE DISEQUILIBRIUM MAPPING	CELL			English	Article							3'-PHOSPHOADENOSINE 5'-PHOSPHOSULFATE SYNTHESIS; INTACT ARTICULAR-CARTILAGE; BORDER MEMBRANE-VESICLES; CYSTIC-FIBROSIS GENE; BRACHYMORPHIC MICE; INORGANIC SULFATE; NUCLEOTIDE-SEQUENCE; HAPLOTYPE ANALYSIS; HEPARAN-SULFATE; RAT INVIVO	Diastrophic dysplasia (DTD) is a well-characterized autosomal recessive osteochondrodysplasia with clinical features including dwarfism, spinal deformation, and specific joint abnormalities. The disease occurs in most populations, but is particularly prevalent in Finland owing to an apparent founder effect. DTD maps to distal chromosome 5q and, based on linkage disequilibrium studies in the Finnish population, we had previously predicted that the DTD gene should lie about 64 kb away from the CSF1R locus. Here, we report the positional cloning of the DTD gene by finestructure linkage disequilibrium mapping. The gene lies in the predicted location, approximately 70 kb proximal to CSF1R, and encodes a novel sulfate transporter. Impaired function of its product is likely to lead to undersulfation of proteoglycans in cartilage matrix and thereby to cause the clinical phenotype of the disease. These results demonstrate the power of linkage disequilibrium mapping in isolated populations for positional cloning.	UNIV HELSINKI, DEPT MED GENET, SF-00014 HELSINKI, FINLAND; FOLKHALSAN INST GENET, SF-00014 HELSINKI, FINLAND; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, MCDERMOTT CTR, DALLAS, TX 75235 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MASSACHUSETTS GEN HOSP, DEPT NEUROGENET, BOSTON, MA 02129 USA; UNIV HELSINKI, CENT HOSP, DEPT MED GENET, SF-00290 HELSINKI, FINLAND	University of Helsinki; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; University of Helsinki; Helsinki University Central Hospital	HASTBACKA, J (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Kusumi, Kenro/J-2626-2012	Kusumi, Kenro/0000-0002-1458-4540; Hamilton, Bruce/0000-0001-5599-9139	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041970] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00098, HG00882] Funding Source: Medline; NIAMS NIH HHS [AR41970] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKSENTIJEVICH I, 1993, AM J HUM GENET, V53, P644; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BISSIG M, 1994, J BIOL CHEM, V269, P3017; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; Cavalcanti F, 1992, Acta Neurol (Napoli), V14, P519; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; DEVRIES BJ, 1986, J RHEUMATOL, V13, P686; DIAB M, 1994, AM J MED GENET, V49, P402, DOI 10.1002/ajmg.1320490411; DUANCE VC, 1990, ANN NY ACAD SCI, V580, P480; ELGAVISH A, 1985, J CELL PHYSIOL, V125, P243, DOI 10.1002/jcp.1041250211; ELGAVISH A, 1991, AM PHYS SOC, pL450; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESTEP JA, 1981, J APPL PHYSIOL, V50, P383, DOI 10.1152/jappl.1981.50.2.383; EYRE DR, 1991, SEMIN ARTHRITIS RHEU, V21, P2, DOI 10.1016/0049-0172(91)90035-X; FESCHENKO SP, 1989, VOP MED KHIM, V35, P24; FRANSSON LA, 1981, J BIOL CHEM, V256, P3044; GARDINER RM, 1993, J INHERIT METAB DIS, V16, P787, DOI 10.1007/BF00711910; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HAMILTON BA, 1991, NUCLEIC ACIDS RES, V19, P1951, DOI 10.1093/nar/19.8.1951; HAMPE A, 1989, ONCOGENE RES, V4, P9; HART GW, 1978, J BIOL CHEM, V253, P347; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HELLSTEN E, 1993, GENOMICS, V16, P720, DOI 10.1006/geno.1993.1253; HORTON WA, 1987, PEDIATR RES, V22, P324, DOI 10.1203/00006450-198709000-00017; HORTON WA, 1979, PEDIATR RES, V13, P904, DOI 10.1203/00006450-197908000-00007; HUMPHRIES DE, 1986, J BIOL CHEM, V261, P9122; ITO K, 1982, J BIOL CHEM, V257, P917; KAITILA I, 1983, PRENATAL DIAG, V3, P237, DOI 10.1002/pd.1970030309; KELLER JM, 1987, BIOCHIM BIOPHYS ACTA, V926, P139, DOI 10.1016/0304-4165(87)90230-3; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KETTER JS, 1991, BIOCHEMISTRY-US, V30, P1780, DOI 10.1021/bi00221a008; KOUCHI H, 1993, MOL GEN GENET, V238, P106, DOI 10.1007/BF00279537; KRAWCZAK M, 1992, HUM GENET, V90, P41; KRIJGSHELD KR, 1982, BIOCHEM PHARMACOL, V31, P3997, DOI 10.1016/0006-2952(82)90646-3; KRIJGSHELD KR, 1981, BIOCHEM PHARMACOL, V30, P1973, DOI 10.1016/0006-2952(81)90208-2; KUPKE KG, 1992, AM J HUM GENET, V50, P808; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMY M, 1960, PRESSE MED, V68, P1977; LANDER ES, 1986, COLD SPRING HARB SYM, V51, P49, DOI 10.1101/SQB.1986.051.01.007; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; LI X, 1994, GENOMICS, V19, P470, DOI 10.1006/geno.1994.1096; LOFTUS SK, 1993, HUM MOL GENET, V2, P1785, DOI 10.1093/hmg/2.11.1785; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKE H, 1979, BIOCHEM J, V182, P223; Luria SE, 1943, GENETICS, V28, P491; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MULDER GJ, 1978, BIOCHEM J, V176, P959, DOI 10.1042/bj1760959; OEHLMANN R, 1993, AM J HUM GENET, V53, P1250; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENNYPACKER JP, 1981, DEV BIOL, V81, P280, DOI 10.1016/0012-1606(81)90291-8; RAMSAY M, 1993, HUM MOL GENET, V2, P1007, DOI 10.1093/hmg/2.7.1007; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; Sambrook J, 1989, MOL CLONING LABORATO; SCHECK M, 1978, VIRCHOWS ARCH A, V378, P347, DOI 10.1007/BF00465601; SCHNEIDER EG, 1984, J BIOL CHEM, V259, P4591; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHWARZ LR, 1982, SULFATE METABOLISM S; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SHAPIRO F, 1992, CALCIFIED TISSUE INT, V51, P324, DOI 10.1007/BF00334495; SHENK AK, 1910, THESIS MILITARY MED; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SIRUGO G, 1992, AM J HUM GENET, V50, P559; SMITH PL, 1981, J MEMBRANE BIOL, V63, P199, DOI 10.1007/BF01870981; SOBUE M, 1978, J BIOL CHEM, V253, P6190; SPRANGER J, 1992, EUR J PEDIATR, V151, P407; SPRANGER J, 1988, PATHOL IMMUNOPATH R, V7, P76, DOI 10.1159/000157098; STANESCU V, 1994, AM J MED GENET, V51, P22, DOI 10.1002/ajmg.1320510106; STANESCU V, 1984, J BONE JOINT SURG AM, V66A, P817, DOI 10.2106/00004623-198466060-00002; STEWART FM, 1994, GENETICS, V137, P1139; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P589, DOI 10.1016/0003-9861(82)90064-9; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P602, DOI 10.1016/0003-9861(82)90065-0; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; SULISALO T, 1993, NAT GENET, V3, P338, DOI 10.1038/ng0493-338; TEMPLETON DM, 1992, CAN J PHYSIOL PHARM, V70, P843, DOI 10.1139/y92-113; VANDERKRAAN PM, 1989, J ORTHOPAED RES, V7, P645, DOI 10.1002/jor.1100070504; VONDIPPE P, 1982, J BIOL CHEM, V257, P4381; WALKER BA, 1972, MEDICINE, V51, P41, DOI 10.1097/00005792-197201000-00003	83	599	613	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					1073	1087		10.1016/0092-8674(94)90281-X	http://dx.doi.org/10.1016/0092-8674(94)90281-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923357				2022-12-28	WOS:A1994PJ29400017
J	GROSS, R; SCHULTINK, W; JULIAWATI				GROSS, R; SCHULTINK, W; JULIAWATI			TREATMENT OF ANEMIA WITH WEEKLY IRON SUPPLEMENTATION	LANCET			English	Letter									DEUTSCH GESELLSCH TECH ZUSAMMENARBEIT GMBH,ESCHBORN,GERMANY		GROSS, R (corresponding author), UNIV INDONESIA,CTR COMMUNITY NUTR,REG SE ASIAN MINIST EDUC ORG,POB 3852,JAKARTA 10038,INDONESIA.			Untoro, Juliawati/0000-0003-1287-0217				BONNAR J, 1969, LANCET, V1, P457; DeMaeyer EM., 1989, PREVENTING CONTROLLI; SCHULTINK W, 1993, AM J CLIN NUTR, V57, P135, DOI 10.1093/ajcn/57.2.135; WRIGHT AJA, 1990, BRIT J NUTR, V63, P579, DOI 10.1079/BJN19900144; 1991, ACC SCN STATE ART SE	5	35	38	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					821	821		10.1016/S0140-6736(94)92378-7	http://dx.doi.org/10.1016/S0140-6736(94)92378-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916099				2022-12-28	WOS:A1994PG17800048
J	KOIZUMI, A				KOIZUMI, A			FIGHTING MYTHS	LANCET			English	Editorial Material											KOIZUMI, A (corresponding author), AKITA UNIV,SCH MED,DEPT HYG,AKITA 010,JAPAN.							BALLANTYNE B, 1987, CLIN EXPT TOXICOLOGY, P473; KOIZUMI A, 1994, LANCET, V343, P1411, DOI 10.1016/S0140-6736(94)92530-5; NICHOLSON PJ, 1994, OCCUP MED-OXFORD, V44, P125, DOI 10.1093/occmed/44.3.125	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					559	560		10.1016/S0140-6736(94)91959-3	http://dx.doi.org/10.1016/S0140-6736(94)91959-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914954				2022-12-28	WOS:A1994PD42400003
J	RITTER, JK				RITTER, JK			AUTOANTIBODIES IN HEPATITIS-DELTA	LANCET			English	Editorial Material							AUTOIMMUNE HEPATITIS; MICROSOMAL AUTOANTIBODIES; C VIRUS; CYTOCHROME-P-450; INFECTION; BILIRUBIN; CLONING; PHENOL; CELLS				RITTER, JK (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA.							BEAUNE P, 1987, P NATL ACAD SCI USA, V84, P551, DOI 10.1073/pnas.84.2.551; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; CRIVELLI O, 1983, CLIN EXP IMMUNOL, V54, P232; Dutton G.F., 1980, GLUCURONIDATION DRUG; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; IYANAGI T, 1993, 7TH INT GLUC WORKSH; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RIZZETTO M, 1991, INT CONGR SER, V895, P327; VERGANI D, 1993, GASTROENTEROLOGY, V104, P1870, DOI 10.1016/0016-5085(93)90673-Z; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256	14	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					560	561		10.1016/S0140-6736(94)91960-7	http://dx.doi.org/10.1016/S0140-6736(94)91960-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914955				2022-12-28	WOS:A1994PD42400004
J	SINGER, PA				SINGER, PA			DISEASE-SPECIFIC ADVANCE DIRECTIVES	LANCET			English	Editorial Material											SINGER, PA (corresponding author), UNIV TORONTO,CTR BIOETH,88 COLL ST,TORONTO M5G 1L4,ON,CANADA.								0	40	43	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					594	596		10.1016/S0140-6736(94)91971-2	http://dx.doi.org/10.1016/S0140-6736(94)91971-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914966				2022-12-28	WOS:A1994PD42400015
J	BUSTURIA, A; LAWRENCE, PA				BUSTURIA, A; LAWRENCE, PA			REGULATION OF CELL NUMBER IN DROSOPHILA	NATURE			English	Article							IMAGINAL WING DISK; PATTERN-FORMATION; FUSHI-TARAZU; FATE MAP; MELANOGASTER; EMBRYO; LARVAL; LOCALIZATION; PARASEGMENTS; REGENERATION	DURING animal development, different parts grow independently (such as the left and right hands) but they stop growing when they reach the correct size. In most insects, growth of the epidermis is so controlled that, at each moult, there is a precise and proportionate increase in cell number(1). The mechanisms responsible for this size regulation are not known(2), but rigid programming of the number of cell divisions is not a requirement as even sister cells in an epithelial sheet divide variably(3-5). In the abdomen of dipterans, such as Drosophila, the opportunity for regulation is limited, because mitoses occur only in the embryo and during metamorphosis and not during larval growth. Here we used embryos with a reduced number of cells in the abdominal primordia to determine,whether they can regulate towards the normal during subsequent growth. In contrast to expectations(6-8), we find no evidence for regulation of cell number.			BUSTURIA, A (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.			Lawrence, Peter/0000-0002-9554-8268				BECKER HJ, 1957, Z INDUKT ABSTAMM VER, V88, P333, DOI 10.1007/BF00309128; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DRIEVER W, 1994, DEV DROSOPHILA MELAN, V1; GARCIABELLIDO A, 1971, DEV BIOL, V26, P264, DOI 10.1016/0012-1606(71)90126-6; HARTENSTEIN V, 1992, ROUX ARCH DEV BIOL, V194, P308; HAYNIE JL, 1977, ROUX ARCH DEV BIOL, V183, P85, DOI 10.1007/BF00848779; Lawrence P., 1973, DEVELOPMENTAL SYSTEM, P157; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MADHAVAN MM, 1980, J EMBRYOL EXP MORPH, V60, P1; MADHAVAN MM, 1984, J EMBRYOL EXP MORPH, V82, P1; MEISE M, 1993, DEVELOPMENT, V118, P1107; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORTEGA JAC, 1985, EMBRYONIC DEV DROSOP; ROSELAND CR, 1979, ROUX ARCH DEV BIOL, V186, P235, DOI 10.1007/BF00848591; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SANTAMARIA P, 1972, J EMBRYOL EXP MORPH, V28, P397; SCHWEIZER P, 1972, BIOPHYSIK, V8, P158, DOI 10.1007/BF01188566; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WIGGLESWORTH VB, 1965, PRINCIPLES INSECT PH, P61; WRIGHT DA, 1981, DEV BIOL, V85, P317, DOI 10.1016/0012-1606(81)90263-3; YASUDA GK, 1991, GENE DEV, V5, P1800, DOI 10.1101/gad.5.10.1800	30	24	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	1994	370	6490					561	563		10.1038/370561a0	http://dx.doi.org/10.1038/370561a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	7914352				2022-12-28	WOS:A1994PC53700056
J	BRITTON, J; PAVORD, I; RICHARDS, K; WISNIEWSKI, A; KNOX, A; LEWIS, S; TATTERSFIELD, A; WEISS, S				BRITTON, J; PAVORD, I; RICHARDS, K; WISNIEWSKI, A; KNOX, A; LEWIS, S; TATTERSFIELD, A; WEISS, S			DIETARY MAGNESIUM, LUNG-FUNCTION, WHEEZING, AND AIRWAY HYPERREACTIVITY IN A RANDOM ADULT-POPULATION SAMPLE	LANCET			English	Article							BRONCHIAL RESPONSIVENESS; SMOOTH-MUSCLE; EXCRETION; SODIUM; QUESTIONNAIRE; HISTAMINE; POTASSIUM; SYMPTOMS; CALCIUM; SULFATE	Magnesium is involved in a wide range of biological activities, including some that may protect against the development of asthma and chronic airflow obstruction. We tested the hypothesis that high dietary magnesium intake is associated with better lung function, and a reduced risk of airway hyper-reactivity and wheezing in a random sample of adults. In 2633 adults aged 18-70 sampled from the electoral register of an administrative area of Nottingham, UK, we measured dietary magnesium intake by semiquantitative food-frequency questionnaire, lung function as the 1-sec forced expiratory volume (FEV(1)), and atopy as the mean shin-prick test response to three common environmental allergens. We measured airway reactivity to methacholine in 2415 individuals, defining hyper-reactivity as a 20% fall in FEV(1) after a cumulative dose of 12.25 mu mol or less. Mean (SD) daily intake of magnesium was 380 (114) mg/day. After adjusting for age, sex, and height, and for the effects of atopy and smoking, a 100 mg/day higher magnesium intake Was associated with a 27.7 (95% Cl, 11.9-43.5) mL higher FEV(1), and a reduction in the relative odds of hyper-reactivity by a ratio of 0.82 (0.72-0.93). The same incremental difference in magnesium intake was also associated with a reduction in the odds of self-reported wheeze within the past 12 months, adjusted for age, sex, smoking, atopy, and kilojoule intake, by a ratio of 0.85 (0.76-0.95). Dietary magnesium intake is independently related to lung function and the occurrence of airway hyper-reactivity and self-reported wheezing in the general population. Low magnesium intake may therefore be involved in the aetiology of asthma and chronic obstructive airways disease.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	BRITTON, J (corresponding author), UNIV NOTTINGHAM,CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND.		Britton, John R/G-9705-2011	Knox, Alan/0000-0002-5906-4143; Pavord, Ian/0000-0002-4288-5973				BOIS P, 1963, BRIT J EXP PATHOL, V44, P151; BRITTON J, 1994, EUR RESPIR J, V7, P881; BRITTON J, 1993, AM REV RESPIR DIS, V147, P377; BRITTON J, 1993, AM REV RESPIR DIS, V147, P369; BURNEY PGJ, 1986, BRIT MED J, V292, P1483, DOI 10.1136/bmj.292.6534.1483; BURNEY PGJ, 1989, THORAX, V44, P36, DOI 10.1136/thx.44.1.36; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; DANGELO EKG, 1992, J CLIN INVEST, V89, P1988, DOI 10.1172/JCI115807; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P370, DOI 10.1113/jphysiol.1954.sp005114; DUNNETT J, 1978, J MOL CELL CARDIOL, V10, P487, DOI 10.1016/0022-2828(78)90369-3; DURLACH J, 1975, REV FR ALLERGOL, V15, P133, DOI 10.1016/S0335-7457(75)80025-6; DYCKNER T, 1984, DRUGS, V28, P161, DOI 10.2165/00003495-198400281-00016; Gregory F., 1990, DIETARY NUTR SURVEY; HAURY VG, 1938, J PHARMACOL EXP THER, V64, P4; KEMP PA, 1994, BRIT J PHARMACOL, V111, P325, DOI 10.1111/j.1476-5381.1994.tb14063.x; LEVINE BS, 1984, NEW ENGL J MED, V310, P1253, DOI 10.1056/NEJM198405103101910; LEWIS J, 1988, BRIT J NUTR, V60, P413, DOI 10.1079/BJN19880113; NADLER JL, 1987, HYPERTENSION, V9, P379, DOI 10.1161/01.HYP.9.4.379; NOPPEN M, 1990, CHEST, V97, P373, DOI 10.1378/chest.97.2.373; Paul A.A., 1988, MCCANCE WIDDOWSONS C; PISTELLI R, 1993, EUR RESPIR J, V6, P517; SCHROEDER HA, 1969, J CHRON DIS, V21, P815, DOI 10.1016/0021-9681(69)90027-7; SKOBELOFF EM, 1989, JAMA-J AM MED ASSOC, V262, P1210; SPARROW D, 1991, AM REV RESPIR DIS, V144, P722, DOI 10.1164/ajrccm/144.3_Pt_1.722; SPIVEY WH, 1990, ANN EMERG MED, V19, P1107, DOI 10.1016/S0196-0644(05)81513-6; WACKER WEC, 1958, NEW ENGL J MED, V259, P475, DOI 10.1056/NEJM195809042591005; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103; 1991, SMOKING EPIDEMIC COU, V3; 1991, DIETARY REFERENCE VA, P146	30	199	205	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					357	362		10.1016/S0140-6736(94)91399-4	http://dx.doi.org/10.1016/S0140-6736(94)91399-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914305				2022-12-28	WOS:A1994PA30300008
J	GREENING, AP; IND, PW; NORTHFIELD, M; SHAW, G				GREENING, AP; IND, PW; NORTHFIELD, M; SHAW, G			ADDED SALMETEROL VERSUS HIGHER-DOSE CORTICOSTEROID IN ASTHMA PATIENTS WITH SYMPTOMS ON EXISTING INHALED CORTICOSTEROID	LANCET			English	Article							BECLOMETHASONE DIPROPIONATE; ADRENOCEPTOR AGONIST; BRONCHIAL-ASTHMA; AIRWAYS DISEASE; MODERATE ASTHMA; SALBUTAMOL; BUDESONIDE; MANAGEMENT; EFFICACY; AEROSOL	Guidelines on asthma management recommend that in patients who still have symptoms on treatment with low-dose inhaled corticosteroids the first step should be an increase in inhaled corticosteroid dose. The addition of long-acting inhaled beta(2)-adrenoceptor agonists is another option. We have compared these two strategies in a randomised, double-blind, parallel-group trial. We studied 429 adult asthmatic patients who still had symptoms despite maintenance treatment with 200 mu g twice daily inhaled beclomethasone dipropionate (BDP). 3 did not provide verifiable data. Of the others, 220 were assigned salmeterol xinafoate (50 mu g twice daily) plus BDP and 206 were assigned higher-dose BDP (500 mu g twice daily) for 6 months. The mean morning peak expiratory flow increased from baseline in both groups, but the increase was greater in the salmeterol/BDP group than in the higher-dose BDP group at all time points (differences 16-21 L/min, p < 0.05), Mean evening PEF also increased with salmeterol/BDP but not with higher-dose BDP. There were significant differences in favour of salmeterol/BDP in diurnal variation of PEF (all time points) and in use of rescue bronchodilator (salbutamol) and daytime and night-time symptoms (some time points). There was no significant difference between the groups in adverse effects or exacerbations of asthma, indicating that in this group of patients regular beta(2)-agonist therapy was not associated with any risk of deteriorating asthma control over 6 months. This study suggests a need for a flexible approach to asthma management.	HAMMERSMITH HOSP,DEPT RESP MED,LONDON,ENGLAND; EALLING HOSP,LONDON,ENGLAND; ST GEORGES DR SURG,MOSTON,ENGLAND; THE SURGERY,FLEETWOOD,LANCS,ENGLAND	Imperial College London	GREENING, AP (corresponding author), WESTERN GEN HOSP,RESP MED UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							[Anonymous], 1990, BMJ, V301, P797; BOE J, 1989, ALLERGY, V44, P349, DOI 10.1111/j.1398-9995.1989.tb00457.x; British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; BUCKNALL CE, 1988, LANCET, V1, P748; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; DAHL R, 1991, EUR RESPIR J, V4, P1178; EASON J, 1987, BRIT MED J, V294, P1255, DOI 10.1136/bmj.294.6582.1255; GADDIE J, 1973, LANCET, V2, P280; GIBBONS JD, 1985, NONPARAMETRIC STATIS; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; JOHANSSON SA, 1988, ALLERGY, V43, P173; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; PALMER JBD, 1992, RESP MED, V86, P409, DOI 10.1016/S0954-6111(06)80008-9; PALMER JBD, 1991, EUR RESPIR REV, V4, P297; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; QUADE D, 1967, J AM STAT ASSOC, V62, P1187, DOI 10.2307/2283769; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; 1992, CLIN EXPT ALLERGY S, V22, P1; [No title captured]; 1990, BRIT MED J, V301, P651	26	773	792	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					219	224		10.1016/S0140-6736(94)92996-3	http://dx.doi.org/10.1016/S0140-6736(94)92996-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913155				2022-12-28	WOS:A1994NY06000008
J	VANDENVELDE, C; DUYS, M; VANBEERS, D				VANDENVELDE, C; DUYS, M; VANBEERS, D			TESTING FOR INTRAUTERINE INFECTION	LANCET			English	Letter											VANDENVELDE, C (corresponding author), FREE UNIV BRUSSELS,HOP UNIV BRUGMANN,DEPT VIROL,PL VAN GEHUCHTEN,B-1020 BRUSSELS,BELGIUM.							MICHIE, 1994, LANCET, V343, P1259; REIMER CB, 1975, ANN NY ACAD SCI, V254, P77, DOI 10.1111/j.1749-6632.1975.tb29159.x	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					135	135		10.1016/S0140-6736(94)91324-2	http://dx.doi.org/10.1016/S0140-6736(94)91324-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912375				2022-12-28	WOS:A1994NV73200056
J	SAMBROOK, PN				SAMBROOK, PN			OSTEOPOROSIS IN RHEUMATOID-ARTHRITIS - WHAT IS THE ROLE OF ANTIRHEUMATIC THERAPY	LANCET			English	Editorial Material							AXIAL BONE LOSS				SAMBROOK, PN (corresponding author), GARVAN INST MED RES,SYDNEY,NSW,AUSTRALIA.							BYRON MA, 1985, BRIT J RHEUMATOL, V24, P164; CASH JM, 1994, NEW ENGL J MED, V330, P1368; DUNCAN H, 1965, ARTHRITIS RHEUM-US, V8, P943, DOI 10.1002/art.1780080504; FRIES JF, 1990, J RHEUMATOL, V17, P12; HALL GM, 1994, ANN RHEUM DIS, V53, P112, DOI 10.1136/ard.53.2.112; LAAN RFJM, 1993, ANN INTERN MED, V119, P963, DOI 10.7326/0003-4819-119-10-199311150-00001; RALSTON SH, 1989, ANN RHEUM DIS, V48, P396, DOI 10.1136/ard.48.5.396; SAMBROOK PN, 1987, ARTHRITIS RHEUM, V30, P721, DOI 10.1002/art.1780300701; WILSKE KR, 1989, J RHEUMATOL, V16, P565	9	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					3	4		10.1016/S0140-6736(94)91040-5	http://dx.doi.org/10.1016/S0140-6736(94)91040-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912301				2022-12-28	WOS:A1994NU91700003
J	SAILER, A; BUELER, H; FISCHER, M; AGUZZI, A; WEISSMANN, C				SAILER, A; BUELER, H; FISCHER, M; AGUZZI, A; WEISSMANN, C			NO PROPAGATION OF PRIONS IN MICE DEVOID OF PRP	CELL			English	Note							SCRAPIE		UNIV ZURICH,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich	SAILER, A (corresponding author), UNIV ZURICH,INST MOLEK BIOL 1,CH-8093 ZURICH,SWITZERLAND.		Büeler, Hansruedi/J-6965-2017; Aguzzi, Adriano/A-3351-2008; Sailer, Andreas/M-9913-2016	Büeler, Hansruedi/0000-0002-4892-7177; Aguzzi, Adriano/0000-0002-0344-6708; Sailer, Andreas/0000-0002-9015-7946				BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CHESEBRO B, 1993, CURR BIOL, V3, P696, DOI 10.1016/0960-9822(93)90072-V; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608	4	235	241	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					967	968		10.1016/0092-8674(94)90436-7	http://dx.doi.org/10.1016/0092-8674(94)90436-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	7912659				2022-12-28	WOS:A1994NV42500005
J	WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B				WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B			THE P21 INHIBITOR OF CYCLIN-DEPENDENT KINASES CONTROLS DNA-REPLICATION BY INTERACTION WITH PCNA	NATURE			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-DELTA; STRAND SYNTHESIS; PROTEIN; INVITRO; P53; INITIATION; SUBUNIT; REPAIR; ORIGIN	THE p53 tumour-suppressor protein controls the expression of a gene encoding the p21 cyclin-dependent protein kinase (CDK) regulator(1-6). Levels of p21 protein are increased in senescent cells and p21 overexpression blocks the growth of tumour cells(1,3,7). In normal human cells, but not in many tumour cells, p21 exists in a guaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (PCNA)(5,8). p21 controls CDK activity, thereby affecting cell-cycle control(2-4,6), whereas PCNA functions in both DNA replication(9-12) and repair(13). Here we use simian virus 40 DNA replication in vitro to show that p21 directly inhibits PCNA-dependent DNA replication in the absence of a cyclin/CDK. Furthermore, p21 blocks the ability of PCNA to activate DNA polymerase delta, the principal replicative DNA polymerase. This regulation results from a direct interaction between p21 and PCNA. Thus, during p53-mediated suppression of cell proliferation, p21 and PCNA mag be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.	HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	Howard Hughes Medical Institute	WAGA, S (corresponding author), COLD SPRING HARBOR LAB, POB 100, BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.		Hannon, Gregory/AAB-3568-2019	Stillman, Bruce/0000-0002-9453-4091; Waga, Shou/0000-0003-4986-8735				BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KONG XP, 1992, J CELL, V69, P425; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	29	1634	1691	34	345	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	1994	369	6481					574	578		10.1038/369574a0	http://dx.doi.org/10.1038/369574a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	7911228				2022-12-28	WOS:A1994NR29400054
J	POLLAK, MR; BROWN, EM; CHOU, YHW; HEBERT, SC; MARX, SJ; STEINMANN, B; LEVI, T; SEIDMAN, CE; SEIDMAN, JG				POLLAK, MR; BROWN, EM; CHOU, YHW; HEBERT, SC; MARX, SJ; STEINMANN, B; LEVI, T; SEIDMAN, CE; SEIDMAN, JG			MUTATIONS IN THE HUMAN CA2+-SENSING RECEPTOR GENE CAUSE FAMILIAL HYPOCALCIURIC HYPERCALCEMIA AND NEONATAL SEVERE HYPERPARATHYROIDISM	CELL			English	Article							KINDREDS	We demonstrate that mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT), two inherited conditions characterized by altered calcium homeostasis. The Ca2+-sensing receptor belongs to the superfamily of seven membrane-spanning G protein-coupled receptors. Three nonconservative missense mutations are reported: two occur in the extracellular N-terminal domain of the receptor; the third occurs in the final intracellular loop. One mutated receptor identified in FHH individuals was expressed in X. laevis oocytes. The expressed wild-type receptor elicted large inward currents in response to perfused polyvalent cations; a markedly attenuated response was observed with the mutated protein. We conclude that the mammalian Ca2+-sensing receptor ''sets'' the extracellular Ca2+ level and is defective in individuals with FHH and NSHPT.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; NIDDKD,METAB DIS BRANCH,BETHESDA,MD 20892; UNIV ZURICH,DEPT PEDIAT,CH-8032 ZURICH,SWITZERLAND	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Zurich	POLLAK, MR (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115, USA.		Lima, Thaísa/AAG-6483-2021		NIDDK NIH HHS [DK46422, DK02138, DK44588] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002138, R01DK046422, R01DK044588] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTIE MF, 1983, J CLIN INVEST, V72, P667, DOI 10.1172/JCI111016; Ausubel FM, 1988, MOL REPROD DEV; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CHOU YHW, 1992, NAT GENET, V1, P295, DOI 10.1038/ng0792-295; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; HOLCOMBE R F, 1987, Genomics, V1, P287, DOI 10.1016/0888-7543(87)90058-9; KHOSLA S, 1993, J CLIN ENDOCR METAB, V76, P715, DOI 10.1210/jc.76.3.715; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LAW WM, 1985, ANN INTERN MED, V102, P511, DOI 10.7326/0003-4819-102-4-511; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MARX SJ, 1977, AM J MED, V62, P698, DOI 10.1016/0002-9343(77)90873-7; MARX SJ, 1982, NEW ENGL J MED, V306, P257, DOI 10.1056/NEJM198202043060502; MARX SJ, 1981, MEDICINE, V60, P397, DOI 10.1097/00005792-198111000-00002; MARX SJ, 1986, J CLIN ENDOCR METAB, V62, P445, DOI 10.1210/jcem-62-2-445; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OTT J, 1983, ANAL HUMAN GENETIC L; POLLAK MR, 1994, IN PRESS J CLIN INVE; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINMANN B, 1984, HELV PAEDIATR ACTA, V39, P171	24	808	830	1	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1297	1303		10.1016/0092-8674(93)90617-Y	http://dx.doi.org/10.1016/0092-8674(93)90617-Y			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7916660				2022-12-28	WOS:A1993MP86900009
J	REID, MM				REID, MM			SPLENECTOMY, SEPSIS, IMMUNIZATION, AND GUIDELINES	LANCET			English	Editorial Material							MANAGEMENT; CHILDHOOD				REID, MM (corresponding author), ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							EDEN OB, 1992, ARCH DIS CHILD, V67, P1056, DOI 10.1136/adc.67.8.1056; ERAKLIS AJ, 1972, J PEDIATR SURG, V7, P382, DOI 10.1016/0022-3468(72)90006-1; GRAHAM RCA, 1994, BRIT MED J, V308, P133, DOI 10.1136/bmj.308.6921.133b; MCMULLIN M, 1993, BRIT MED J, V307, P1372, DOI 10.1136/bmj.307.6916.1372; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; WALKER W, 1976, BRIT J SURG, V63, P36, DOI 10.1002/bjs.1800630109; 1990, DRUG THER B, V28, P31; 1989, MMWR-MORBID MORTAL W, V38, P64; 1994, CMOS UPDATE, V1, P3; 1992, GUIDELINES ETHICAL C; 1992, IMMUNISATION INFECTI	11	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					970	971						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934424				2022-12-28	WOS:A1994PK97800003
J	CHEN, JL; ATTARDI, LD; VERRIJZER, CP; YOKOMORI, K; TJIAN, R				CHEN, JL; ATTARDI, LD; VERRIJZER, CP; YOKOMORI, K; TJIAN, R			ASSEMBLY OF RECOMBINANT TFIID REVEALS DIFFERENTIAL COACTIVATOR REQUIREMENTS FOR DISTINCT TRANSCRIPTIONAL ACTIVATORS	CELL			English	Article							TATA-BINDING PROTEIN; RNA POLYMERASE-II; GENE-TRANSCRIPTION; MOLECULAR-CLONING; DNA-BINDING; SUBUNIT; COMPLEX; EXPRESSION; TBP; INTERACTS	We previously reported that transcriptional regulators can bind selected TAF subunits of the TFIID complex. However, the specificity and function of individual TAFs in mediating transcriptional activation remained unknown. Here we report the in vitro assembly and transcriptional properties of TBP-TAF complexes reconstituted from the nine recombinant subunits of Drosophila TFIID. A minimal complex containing TBP and TAF(II)250 directs basal but not activator-responsive transcription. By contrast, reconstituted hole TFIID supports activation by an assortment of activators. The activator NTF-1, which binds TAF(II)150, stimulates transcription with a complex containing only TBP, TAF(II)250, and TAF(II)150, whereas Sp1 binds and additionally requires TAF(II)110 for activation. Interestingly, TAF(II)150 enhances Spl activation even though this subunit does not bind directly to Sp1. These results establish that specific subcomplexes of TFIID can mediate activation by different classes of activators and suggest that TAFs perform multiple functions during activation.			CHEN, JL (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CURR OPIN CELL BIOL, V6, P403; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLUG A, 1993, NATURE, V365, P486, DOI 10.1038/365486a0; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIJAN R, 1994, CELL, V77, P5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	37	350	354	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					93	105		10.1016/0092-8674(94)90403-0	http://dx.doi.org/10.1016/0092-8674(94)90403-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923382				2022-12-28	WOS:A1994PK58500011
J	VOGELSTEIN, B; KINZLER, KW				VOGELSTEIN, B; KINZLER, KW			HAS THE BREAST-CANCER GENE BEEN FOUND	CELL			English	Review							FAMILIAL BREAST; OVARIAN-CANCER; CHROMOSOME-17Q; LINKAGE; TUMORS; REGION; WT1				VOGELSTEIN, B (corresponding author), JOHNS HOPKINS UNIV,CTR ONCOL,BALTIMORE,MD 21231, USA.							CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; CROPP CS, 1994, CANCER RES, V54, P2548; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EASTON DF, 1993, AM J HUM GENET, V52, P678; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTREAL PA, 1994, IN PRESS SCIENCE; GLEBOV OK, 1994, CANCER RES, V54, P3703; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JACOBS IJ, 1993, CANCER RES, V53, P1218; KNUDSON AG, 1985, CANCER RES, V45, P1437; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MIKI Y, 1994, IN PRESS SCIENCE; NAGAI MA, 1994, GENE CHROMOSOME CANC, V11, P58, DOI 10.1002/gcc.2870110109; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; SAITO H, 1993, CANCER RES, V53, P3382; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; WOOSTER R, 1994, IN PRESS SCIENCE	21	56	57	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					1	3		10.1016/0092-8674(94)90393-X	http://dx.doi.org/10.1016/0092-8674(94)90393-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923368				2022-12-28	WOS:A1994PK58500001
J	SCHIPPER, H; DICK, JAM				SCHIPPER, H; DICK, JAM			DOES CONSENSUS HELP IN BREAST-CANCER	LANCET			English	Editorial Material									MANITOBA BREAST CANC COUNCIL,WINNIPEG,MB,CANADA		SCHIPPER, H (corresponding author), UNIV MANITOBA,WINNIPEG,MB,CANADA.							CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FERRARO S, 1993, NY TIMES MAGAZI 0815; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; ROSEN PP, 1991, J CLIN ONCOL, V9, P1650, DOI 10.1200/JCO.1991.9.9.1650; 1991, JAMA-J AM MED ASSOC, V265, P391; 1993, BREAST CANCER B NCI; 1992, LANCET, V339, P71; 1994, 1ST AUSTR NAT BREAST	9	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					836	836		10.1016/S0140-6736(94)92823-1	http://dx.doi.org/10.1016/S0140-6736(94)92823-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916397				2022-12-28	WOS:A1994PH25300007
J	VANDIJK, MA; MURRE, C				VANDIJK, MA; MURRE, C			EXTRADENTICLE RAISES THE DNA-BINDING SPECIFICITY OF HOMEOTIC SELECTOR GENE-PRODUCTS	CELL			English	Article							HUMAN PROTOONCOGENE PBX1; DROSOPHILA EMBRYOS; PRE-B; ULTRABITHORAX HOMEODOMAIN; DEVELOPMENTAL DEFECTS; TRANSLOCATION PROTEIN; TARGETED DISRUPTION; SEGMENTAL IDENTITY; CRYSTAL-STRUCTURE; HOMEOBOX GENES	Recently, a Drosophila gene has been identified, extradenticle, whose product modulates the morphological consequences of homeotic selector genes. We shaw here that extradenticle protein raises the DNA binding specificity of Ultrabithorax and abdominal-A but not that of Abdominal-B. We further show that extradenticle modulates the DNA binding activity of engrailed to a different target site. While a region N-terminal of the extradenticle homeodomain is required far Ultrabithorax and abdominal-A cooperativity, engrailed requires a domain C-terminal of the extradenticle homeobox. These studies show directly how the DNA binding specificity of selector gene products can be raised by extradenticle and provides a mechanism, cooperative DMA binding, that allows selector gene products to achieve some of their biological specificity.	UNIV CALIF SAN DIEGO,DEPT BIOL 0116,LA JOLLA,CA 92093	University of California System; University of California San Diego					NCI NIH HHS [CA54198-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA054198, R01CA054198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JOHNSON A, 1992, TRANSCRIPTIONAL REGU, V2, P975; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	36	237	238	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					617	624		10.1016/0092-8674(94)90526-6	http://dx.doi.org/10.1016/0092-8674(94)90526-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915200				2022-12-28	WOS:A1994PD69300010
J	WILLIAMS, B				WILLIAMS, B			INSULIN-RESISTANCE - THE SHAPE OF THINGS TO COME	LANCET			English	Article							CARDIOVASCULAR RISK-FACTORS; BLOOD-PRESSURE; BODY-FAT; HYPERTENSION; HYPERINSULINEMIA; DISEASE; OBESITY; LEVEL				WILLIAMS, B (corresponding author), LEICESTER ROYAL INFIRM,DEPT MED & THERAPEUT,CLIN SCI BLDG,POB 65,LEICESTER LE2 7LX,ENGLAND.			Williams, Bryan/0000-0002-8094-1841				BLACK HR, 1990, J CARDIOVASC PHARM, V15, pS26; CARRETTA R, 1989, J HYPERTENS, V7, pS196, DOI 10.1097/00004872-198900076-00094; COOPER ME, 1992, 9TH P INT C END; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DONAHUE RP, 1990, AM J EPIDEMIOL, V132, P827, DOI 10.1093/oxfordjournals.aje.a115725; FAGARD RH, 1993, J HYPERTENS, V11, pS47; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; GOLAY A, 1988, DIABETES METAB REV, V4, P727, DOI 10.1002/dmr.5610040803; HAFFNER SM, 1988, METABOLISM, V37, P338, DOI 10.1016/0026-0495(88)90133-3; HALL JE, 1991, FASEB J, V5, pA737; HARTMANN J, 1989, LIFE SCI, V45, P267, DOI 10.1016/0024-3205(89)90260-9; Himsworth HP, 1936, LANCET, V1, P127; HUANG HJS, 1992, HYPERTENSION S1, V19, P101; KANAI H, 1990, HYPERTENSION, V16, P484, DOI 10.1161/01.HYP.16.5.484; KISSEBAH AH, 1989, DIABETES METAB REV, V5, P83, DOI 10.1002/dmr.5610050202; LANDIN K, 1991, J INTERN MED, V229, P181, DOI 10.1111/j.1365-2796.1991.tb00328.x; LESLIE RDG, 1987, DIABETES ANN, V3, P39; LILLIOJA S, 1987, J CLIN INVEST, V80, P415, DOI 10.1172/JCI113088; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; NAGI DK, 1990, DIABETOLOGIA, V33, P532, DOI 10.1007/BF00404140; REAVEN GM, 1987, LANCET, V2, P435; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SAWICKIPT, 1992, DIABETOLOGIA, V35, P649; STRIDSBERG M, 1993, DIABETOLOGIA, V36, P843, DOI 10.1007/BF00400360; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; WEINSIER RL, 1985, HYPERTENSION, V7, P578, DOI 10.1161/01.HYP.7.4.578; WELBORN TA, 1966, LANCET, V1, P1336; Zavaroni I, 1989, NEW ENGL J MED, V320, P502	29	89	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					521	524		10.1016/S0140-6736(94)91904-6	http://dx.doi.org/10.1016/S0140-6736(94)91904-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914619				2022-12-28	WOS:A1994PC53500015
J	SUMMERFIELD, D				SUMMERFIELD, D			TURKEY AND THE KURDS - A GRAVE HUMAN-RIGHTS PICTURE	LANCET			English	Editorial Material											SUMMERFIELD, D (corresponding author), MED FDN CARE VICTIMS TORTURE,LONDON,ENGLAND.							TURNER SW, 1989, LANCET, V1, P1319; 1994, DISAPPEARANCES POLIT, P55; 1994, EUR441394 AMN INT	3	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					350	351		10.1016/S0140-6736(94)91395-1	http://dx.doi.org/10.1016/S0140-6736(94)91395-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	PA303	7914301				2022-12-28	WOS:A1994PA30300004
J	WEISS, M; YELLIN, A; HUSZAR, M; EISENSTEIN, Z; BARZIV, J; KRAUSZ, Y				WEISS, M; YELLIN, A; HUSZAR, M; EISENSTEIN, Z; BARZIV, J; KRAUSZ, Y			LOCALIZATION OF ADRENOCORTICOTROPIC HORMONE-SECRETING BRONCHIAL CARCINOID-TUMOR BY SOMATOSTATIN-RECEPTOR SCINTIGRAPHY	ANNALS OF INTERNAL MEDICINE			English	Note							CUSHINGS-SYNDROME; ACTH; DIAGNOSIS; ANALOGS		CHAIM SHEBA MED CTR, IL-52621 TEL HASHOMER, ISRAEL; TEL AVIV UNIV, SACKLER SCH MED, IL-69978 TEL AVIV, ISRAEL; HADASSAH UNIV HOSP, IL-91120 JERUSALEM, ISRAEL	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem	WEISS, M (corresponding author), E WOLFSON MED CTR, POB 5, IL-58100 HOLON, ISRAEL.							CHEUNG NW, 1992, CLIN ENDOCRINOL, V36, P361, DOI 10.1111/j.1365-2265.1992.tb01461.x; COLOMBO P, 1993, J ENDOCRINOL INVE S1, V16, pS5; DOPPMAN JL, 1989, RADIOLOGY, V172, P115, DOI 10.1148/radiology.172.1.2544919; FINDLING JW, 1990, MAYO CLIN PROC, V65, P1377, DOI 10.1016/S0025-6196(12)62150-8; HEARN PR, 1988, CLIN ENDOCRINOL, V28, P181, DOI 10.1111/j.1365-2265.1988.tb03654.x; JEX RK, 1985, AM J SURG, V149, P276; LAMBERTS SWJ, 1988, ENDOCR REV, V9, P417, DOI 10.1210/edrv-9-4-417; LAMBERTS SWJ, 1993, FRONT NEUROENDOCRIN, V14, P27, DOI 10.1006/frne.1993.1002; LEINUNG MC, 1990, MAYO CLIN PROC, V65, P1314, DOI 10.1016/S0025-6196(12)62142-9; PHLIPPONNEAU M, 1994, J CLIN ENDOCR METAB, V78, P20, DOI 10.1210/jc.78.1.20; VANNOORDEN S, 1987, EXPERIENTIA, V43, P724	11	30	32	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					198	199		10.7326/0003-4819-121-3-199408010-00007	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	7912484				2022-12-28	WOS:A1994NY33800007
J	MOREAU, T; THORPE, J; MILLER, D; MOSELEY, I; HALE, G; WALDMANN, H; CLAYTON, D; WING, M; SCOLDING, N; COMPSTON, A				MOREAU, T; THORPE, J; MILLER, D; MOSELEY, I; HALE, G; WALDMANN, H; CLAYTON, D; WING, M; SCOLDING, N; COMPSTON, A			PRELIMINARY EVIDENCE FROM MAGNETIC-RESONANCE-IMAGING FOR REDUCTION IN DISEASE-ACTIVITY AFTER LYMPHOCYTE DEPLETION IN MULTIPLE-SCLEROSIS	LANCET			English	Article							MONOCLONAL-ANTIBODY THERAPY; LESION DEVELOPMENT; GUIDELINES; TRIAL	The central nervous system lesions of multiple sclerosis (MS) can be detected by magnetic resonance imaging (MRI) and the initial perivascular inflammatory component is distinguished by the presence of gadolinium enhancement. To assess the effect of systemic lymphocyte depletion on disease activity, seven patients with MS received a 10-day intravenous course of the humanised monoclonal antibody CAMPATH-1H (anti-CDw52). With some variations in the protocol, enhanced cerebral MR images were obtained monthly for 3-4 months before and at least 6 months after treatment. 28 enhancing areas were detected on the first series of 7 scans; 51 additional active lesions were identified on 18 scans before treatment; 15 were detected on 20 scans done over the next 3 months, but only 2 active lesions were seen on 23 scans during follow-up beyond 3 months. The difference in lesion incidence rate before and after treatment varied and the rate ratio was significantly reduced in only three patients. Collectively, in a ''meta-analysis'', the rate ratios were 0.58 (95% Cl 0.09-0.24) for all seven patients and 0.24 (0.14-0.42; p < 0.001) with exclusion of the patient whose scanning schedule differed. The effect of CAMPATH-1H on disease activity provides direct, but preliminary, evidence that disease activity in MS depends on the availability of circulating lymphocytes and can be prevented by lymphocyte depletion. It is too early to say anything about the clinical results of treatment with this agent.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,NEUROL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; INST NEUROL,NMR RES UNIT,LONDON WC1,ENGLAND; NATL HOSP,LONDON WC1,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,DIV IMMUNOL,CAMBRIDGE CB2 1QP,ENGLAND; INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE,CAMBS,ENGLAND; ADDENBROOKES HOSP,CTR MRC,MOLEC IMMUNOPATHOL UNIT,CAMBRIDGE,ENGLAND; MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Cambridge; MRC Biostatistics Unit; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge			waldmann, herman/W-8051-2019	Hale, Geoff/0000-0001-9473-423X; Waldmann, Herman/0000-0001-7519-6720				CLAYTON D, 1993, STAT MODELS EPIDEMIO, P110; EBERS GC, 1994, LANCET, V343, P275, DOI 10.1016/S0140-6736(94)91119-3; FFRENCHCONSTANT C, 1994, LANCET, V343, P271, DOI 10.1016/S0140-6736(94)91118-5; FILIIPPI M, IN PRESS NEUROLOGY; FILIPPI M, 1994, NEUROLOGY, V44, pA339; HAFLER DA, 1988, J IMMUNOL, V141, P131; HALE G, 1990, TISSUE ANTIGENS, V35, P1; ISAACS JD, 1992, LANCET, V340, P748, DOI 10.1016/0140-6736(92)92294-P; KATZ D, 1993, ANN NEUROL, V34, P661, DOI 10.1002/ana.410340507; KERMODE AG, 1990, BRAIN, V113, P1477, DOI 10.1093/brain/113.5.1477; LINDSEY JW, 1994, NEUROLOGY, V44, P413, DOI 10.1212/WNL.44.3_Part_1.413; LOCKWOOD CM, 1993, LANCET, V341, P1620, DOI 10.1016/0140-6736(93)90759-A; MILLER DH, 1991, J NEUROL NEUROSUR PS, V54, P683, DOI 10.1136/jnnp.54.8.683; NAUTA JJP, 1994, J NEUROL SCI, V122, P6, DOI 10.1016/0022-510X(94)90045-0; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAINE CS, 1991, NEUROPATH APPL NEURO, V17, P265, DOI 10.1111/j.1365-2990.1991.tb00724.x; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; WEINSHENKER BG, 1991, NEUROLOGY, V41, P1047, DOI 10.1212/WNL.41.7.1047; YOUL BD, 1991, BRAIN, V114, P2437, DOI 10.1093/brain/114.6.2437	21	161	168	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					298	301		10.1016/S0140-6736(94)91339-0	http://dx.doi.org/10.1016/S0140-6736(94)91339-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914262				2022-12-28	WOS:A1994NZ23300008
J	SCHMIDT, M; RUTKAT, K; RACHEL, R; PFEIFER, G; JAENICKE, R; VIITANEN, P; LORIMER, G; BUCHNER, J				SCHMIDT, M; RUTKAT, K; RACHEL, R; PFEIFER, G; JAENICKE, R; VIITANEN, P; LORIMER, G; BUCHNER, J			SYMMETRICAL COMPLEXES OF GROE CHAPERONINS AS PART OF THE FUNCTIONAL CYCLE	SCIENCE			English	Article							ESCHERICHIA-COLI; ELECTRON-MICROSCOPY; ATP HYDROLYSIS; CENTRAL CAVITY; PROTEIN; COOPERATIVITY; PURIFICATION; INTERACTS; SURFACE	The particular structural arrangement of chaperonins probably contributes to their ability to assist in the folding of proteins. The interaction of the oligomeric bacterial chaperonin GroEL and its cochaperonin, GroES, in the presence of adenosine diphosphate (ADP) forms an asymmetric complex. However, in the presence of adenosine triphosphate (ATP) or its nonhydrolyzable analogs, symmetric complexes were found by electron microscopy and image analysis. The existence of symmetric chaperonin complexes is not predicted by current models of the functional cycle for GroE-mediated protein folding. Because complete folding of a nonnative substrate protein in the presence of GroEL and GroES only occurs in the presence of ATP, but not with ADP, the symmetric chaperonin complexes formed during the GroE cycle are proposed to be functionally significant.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY; UNIV REGENSBURG,INST MIKROBIOL,D-93040 REGENSBURG,GERMANY; MAX PLANCK INST BIOCHEM,D-82153 MARTINSRIED,GERMANY; DUPONT CO INC,DEPT CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	University of Regensburg; University of Regensburg; Max Planck Society; DuPont			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEGERL R, 1982, ULTRAMICROSCOPY, V9, P109, DOI 10.1016/0304-3991(82)90233-9; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SAXTON WO, 1979, ULTRAMICROSCOPY, V9, P109; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; Schmidt M. K., UNPUB; SVENSSON LA, 1994, J MOL BIOL, V235, P47; TAGOUCHI H, 1991, J BIOL CHEM, V266, P22411; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZWICKL P, 1990, J STRUCT BIOL, V103, P197, DOI 10.1016/1047-8477(90)90037-D	33	186	187	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					656	659		10.1126/science.7913554	http://dx.doi.org/10.1126/science.7913554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	7913554				2022-12-28	WOS:A1994NZ53800032
J	BATESON, M				BATESON, M			2ND OPINIONS IN LAPAROSCOPIC CHOLECYSTECTOMY	LANCET			English	Editorial Material											BATESON, M (corresponding author), BISHOP AUCKLAND GEN HOSP,DURHAM,ENGLAND.							BATES T, 1991, BRIT J SURG, V78, P964, DOI 10.1002/bjs.1800780823; BATESON MC, 1984, LANCET, V2, P621; BAXTER JN, 1992, BMJ-BRIT MED J, V304, P559, DOI 10.1136/bmj.304.6826.559; DEZIEL DJ, 1993, AM J SURG, V165, P9, DOI 10.1016/S0002-9610(05)80397-6; DIEHL AK, 1987, LANCET, V2, P683; LEGORRETA AP, 1993, JAMA-J AM MED ASSOC, V270, P1429, DOI 10.1001/jama.270.12.1429; NORRBY S, 1986, SCAND J GASTROENTERO, V21, P158, DOI 10.3109/00365528609034641; RUSSELL RCG, 1993, BRIT MED J, V307, P1266, DOI 10.1136/bmj.307.6914.1266; SALTZSTEIN EC, 1992, SURG GYNECOL OBSTET, V174, P173; STEINER CA, 1994, NEW ENGL J MED, V330, P403, DOI 10.1056/NEJM199402103300607	10	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					76	76		10.1016/S0140-6736(94)91278-5	http://dx.doi.org/10.1016/S0140-6736(94)91278-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912390				2022-12-28	WOS:A1994NV73200006
J	LOHMANN, T; LESLIE, RDG; HAWA, M; GEYSEN, M; RODDA, S; LONDEI, M				LOHMANN, T; LESLIE, RDG; HAWA, M; GEYSEN, M; RODDA, S; LONDEI, M			IMMUNODOMINANT EPITOPES OF GLUTAMIC-ACID DECARBOXYLASE-65 AND DECARBOXYLASE-67 IN INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note							GAD	To find the dominant epitopes of a major autoantigen in insulin-dependent diabetes mellitus (IDDM), glutamic acid decarboxylase (GAD), we studied the reactivity of peripheral blood T lymphocytes with peptides covering both major isoforms. A significant response to GAD 65 or GAD 67 peptides was detected in 13 of 15 IDDM patients and in 9 of 10 normal controls. Controls most frequently recognised the central region of GAD 65 (residues 161-243). IDDM patients preferentially recognised residues 473-555 (p < 0.03). T-cell responses to GAD 67 peptides were similar in IDDM patients and controls. T lymphocytes from IDDM patients recognise a distinct dominant epitope of GAD, which may be an important target for the disease process.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT DIABET & METAB,LONDON EC1A 7BE,ENGLAND; KENNEDY INST,LONDON W6,ENGLAND; CHIRON MIMOTOPES,CLAYTON,VIC,AUSTRALIA	University of London; Queen Mary University London			Leslie, Richard/AAF-6977-2020; Rodda, Simone/S-9766-2018	Leslie, Richard/0000-0002-1786-1531; Rodda, Simone/0000-0002-7973-1003				ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; CHRISTIE MR, 1992, DIABETES, V41, P782, DOI 10.2337/diabetes.41.7.782; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; REECE JC, 1993, J IMMUNOL, V151, P6175; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Zhang J, 1992, Int Rev Immunol, V9, P183, DOI 10.3109/08830189209061790	9	100	102	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1607	1608		10.1016/S0140-6736(94)93061-9	http://dx.doi.org/10.1016/S0140-6736(94)93061-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911924				2022-12-28	WOS:A1994NU35400014
J	IZPISUABELMONTE, JC; DEROBERTIS, EM; STOREY, KG; STERN, CD				IZPISUABELMONTE, JC; DEROBERTIS, EM; STOREY, KG; STERN, CD			THE HOMEOBOX GENE GOOSECOID AND THE ORIGIN OF ORGANIZER CELLS IN THE EARLY CHICK BLASTODERM	CELL			English	Article							PRIMITIVE STREAK FORMATION; MARGINAL ZONE; HENSEN NODE; NEURAL INDUCTION; XENOPUS EMBRYOS; HYPOBLAST; MESODERM; INVOLVEMENT; EXPRESSION; POTENCIES	The chick homeobox gene goosecoid (gsc) is first expressed in a barely noticeable cell population near the posterior margin (Koller's sickle) of the unincubated egg. Then it is detected in Hensen's node, traditionally considered the chick organizer. Later, gsc-expressing cells leave the node with the prechordal plate. Fate mapping indicates that these three regions are related by cell lineage, and transplantation experiments suggest that they all have inducing activity. Quail posterior margin and anterior primitive streak grafts (gsc expressing) induce gsc transcription in neighboring chick host cells. We propose that development of the chick organizer starts earlier than previously thought and that gsc marks this changing cell population.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV OXFORD, DEPT HUMAN ANAT, OXFORD OX1 3QX, ENGLAND	University of California System; University of California Los Angeles; University of Oxford	IZPISUABELMONTE, JC (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.		Stern, Claudio/AAZ-7381-2021; Stern, Claudio D/C-6265-2008	Stern, Claudio/0000-0002-9907-889X; Stern, Claudio D/0000-0002-9907-889X; Storey, Kate/0000-0003-3506-1287				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AZAR Y, 1979, J EMBRYOL EXP MORPH, V52, P79; AZAR Y, 1981, J EMBRYOL EXP MORPH, V61, P133; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; COOKE J, 1972, J EMBRYOL EXP MORPH, V28, P47; DIAS MS, 1990, ANAT RECORD, V228, P437, DOI 10.1002/ar.1092280410; DRURY RAB, 1967, CARLETONS HISTOLOGIC; EYALGILADI H, 1992, DEVELOPMENT, V116, P819; EYALGILADI H, 1976, DEV BIOL, V49, P321, DOI 10.1016/0012-1606(76)90178-0; EYALGILADI H, 1989, DEV BIOL, V134, P215, DOI 10.1016/0012-1606(89)90091-2; Gallera J., 1971, Adv Morphogen, V9, P149; GALLERA J, 1966, ACTA ANAT, V63, P388; GAUNT SJ, 1993, DEVELOPMENT, V117, P769; GERHART J, 1989, DEVELOPMENT, V107, P37; GERHART J, 1991, BOD MAR LAB, P57; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARA K, 1961, THESIS U UTRECHT UTR; HARA K, 1978, ORG MILESTONE HALF C; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; HUTSON JM, 1984, STAIN TECHNOL, V59, P105, DOI 10.3109/10520298409113839; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KELLER R, 1991, BOD MAR LAB, P101; KHANER O, 1986, DEV BIOL, V115, P275, DOI 10.1016/0012-1606(86)90248-4; KHANER O, 1989, DEV BIOL, V134, P206, DOI 10.1016/0012-1606(89)90090-0; KHANER O, 1985, J EMBRYOL EXP MORPH, V89, P235; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEIKOLA A, 1976, EXPERIENTIA, V32, P269, DOI 10.1007/BF01940787; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Pannett C.A., 1924, LANCET, V206, P381; ROBERTS C, 1991, DEVELOPMENT, V112, P959; ROSENQUIST GC, 1983, ANAT REC, V207, P349, DOI 10.1002/ar.1092070214; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SELLECK MAJ, 1992, DEVELOPMENT, V114, P403; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPRATT NT, 1955, J EXP ZOOL, V128, P121, DOI 10.1002/jez.1401280106; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; STERN CD, 1990, DEVELOPMENT, V109, P667; STERN CD, 1992, DEVELOPMENT, P151; STERN CD, 1981, ANAT EMBRYOL, V163, P245, DOI 10.1007/BF00315703; STOREY KG, 1992, DEVELOPMENT, V114, P729; VAKAET L, 1973, B ASSOC ANAT, V57, P157; Waddington CH, 1933, J EXP BIOL, V10, P38; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	56	267	270	1	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 27	1993	74	4					645	659		10.1016/0092-8674(93)90512-O	http://dx.doi.org/10.1016/0092-8674(93)90512-O			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	7916659				2022-12-28	WOS:A1993LU59200008
J	OXMAN, AD; COOK, DJ; GUYATT, GH				OXMAN, AD; COOK, DJ; GUYATT, GH			USERS GUIDES TO THE MEDICAL LITERATURE .6. HOW TO USE AN OVERVIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHOLESTEROL-LOWERING TRIALS; CLINICAL-TRIALS; MYOCARDIAL-INFARCTION; RANDOMIZED TRIALS; PUBLICATION BIAS; META-ANALYSIS; METAANALYSIS; PREVENTION; MORTALITY; RISK		MCMASTER UNIV, HLTH SCI CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8N 3Z5, ON, CANADA; MCMASTER UNIV, DEPT MED, HAMILTON, ON, CANADA; MCMASTER UNIV, DEPT FAMILY MED, HAMILTON L8S 4L8, ON, CANADA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University			Oxman, Andrew/Y-3004-2019	Oxman, Andrew/0000-0002-5608-5061; Gerstein, Hertzel/0000-0001-8072-2836; Bass, Eric/0000-0001-9106-527X				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; Cochrane A. L., 1979, MED YEAR 2000, P2; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; COOPER HM, 1980, PSYCHOL BULL, V87, P442, DOI 10.1037/0033-2909.87.3.442; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DICKERSIN K, 1993, ONLINE J CURR CLIN T, P50; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; ENKIN MW, 1993, COCHRANE PREGNANCY C; GLASS GV, 1981, META ANAL SOCIAL RES, P18; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; Horwitz R I, 1987, Am J Med, V82, P498, DOI 10.1016/0002-9343(87)90450-5; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; Rosenthal R., 1991, METAANALYTIC PROCEDU, DOI [10.2307/1175262, DOI 10.2307/1175262]; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SILBERBERG JS, 1991, MED J AUSTRALIA, V155, P665, DOI 10.5694/j.1326-5377.1991.tb93956.x; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SMITH K, 1992, AM REV RESPIR DIS, V145, P533, DOI 10.1164/ajrccm/145.3.533; WILLIAMSON JW, 1986, MED USE STATISTICS, P370; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; 1994, COCHRANE COLLABORATI	39	630	653	2	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1367	1371		10.1001/jama.272.17.1367	http://dx.doi.org/10.1001/jama.272.17.1367			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933399				2022-12-28	WOS:A1994PP02000033
J	ALPERS, DH				ALPERS, DH			ZINC AND DEFICIENCIES OF TASTE AND SMELL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DOUBLE-BLIND; DYSFUNCTION				ALPERS, DH (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO, USA.							BALES CW, 1986, AM J CLIN NUTR, V44, P664, DOI 10.1093/ajcn/44.5.664; HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006; HENKIN RI, 1975, ARCH NEUROL-CHICAGO, V32, P745, DOI 10.1001/archneur.1975.00490530067006; MAHAJAN SK, 1980, AM J CLIN NUTR, V33, P1517, DOI 10.1093/ajcn/33.7.1517; WEIFFENBACH JM, 1982, J GERONTOL, V37, P372, DOI 10.1093/geronj/37.3.372; WOLMAN SL, 1979, GASTROENTEROLOGY, V76, P458	6	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1233	1234						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933356				2022-12-28	WOS:A1994PN06800003
J	LIPS, CJM; LANDSVATER, RM; HOPPENER, JWM; GEERDINK, RA; BLIJHAM, G; VANVEEN, JMJS; VANGILS, APG; DEWIT, MJ; ZEWALD, RA; BERENDS, MJH; BEEMER, FA; BROUWERSSMALBRAAK, J; JANSEN, RPM; VANAMSTEL, HKP; VANVROONHOVEN, TJM; VROOM, TM				LIPS, CJM; LANDSVATER, RM; HOPPENER, JWM; GEERDINK, RA; BLIJHAM, G; VANVEEN, JMJS; VANGILS, APG; DEWIT, MJ; ZEWALD, RA; BERENDS, MJH; BEEMER, FA; BROUWERSSMALBRAAK, J; JANSEN, RPM; VANAMSTEL, HKP; VANVROONHOVEN, TJM; VROOM, TM			CLINICAL SCREENING AS COMPARED WITH DNA ANALYSIS IN FAMILIES WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C-CELL HYPERPLASIA; MEDULLARY-THYROID-CARCINOMA; RET PROTOONCOGENE; CENTRAL REGISTRATION; CHROMOSOME-10; CALCITONIN; LINKAGE; NETHERLANDS; MUTATIONS; LOCUS	Background. Multiple endocrine neoplasia type 2A (MEN-2A) is characterized by medullary thyroid carcinoma in combination with pheochromocytoma and sometimes parathyroid adenoma. Missense mutations in the RET proto-oncogene are associated with MEN-2A. Their detection by DNA analysis allows the identification of carriers of the gene, in whom the risk of medullary thyroid carcinoma is 100 percent. We compared the reliability of biochemical tests with that of DNA analysis in identifying carriers of the MEN2A gene. Methods. Starting in 1975, we screened 300 subjects in four large families with MEN-2A for expression of the disease, using measurements of plasma calcitonin after stimulation with pentagastrin or calcium and urinary excretion of catecholamines and catecholamine metabolites. We tested for carrier status by DNA analysis, including linkage analysis, and more recently by analysis of mutations in the RET gene. Results. Of 80 MEN2A gene carriers (in 61 of whom carrier status was proved by DNA analysis), 66 had abnormal plasma calcitonin values and medullary thyroid carcinoma. Fourteen young carriers had normal results of plasma calcitonin tests. In 8 of these 14, thyroidectomy revealed small foci of medullary thyroid carcinoma; the remaining 6 have not yet been operated on. Of the other 220 family members, 68 were found by DNA analysis not to carry the MEN2A gene. None of these 68 subjects had medullary thyroid carcinoma or pheochromocytoma; 6 had elevated plasma calcitonin concentrations and underwent thyroidectomy but had only C-cell hyperplasia. Conclusions. Unlike biochemical tests, DNA analysis permits the unambiguous identification of MEN2A gene carriers.	UNIV UTRECHT HOSP,DEPT RADIOL,UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,DEPT SURG,UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,DEPT PATHOL,3508 GA UTRECHT,NETHERLANDS; WESTEINDE ZIEKENHUIS,DEPT PATHOL,THE HAGUE,NETHERLANDS; CLIN GENET CTR,3501 CA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	LIPS, CJM (corresponding author), UNIV UTRECHT HOSP,DEPT INTERNAL MED,HEIDELBERGLAAN 100,3584 CX UTRECHT,NETHERLANDS.							CARNEY JA, 1976, ORAL SURG ORAL MED O, V41, P739, DOI 10.1016/0030-4220(76)90187-0; DEGROOT LJ, 1975, MED CLIN N AM, V59, P1233, DOI 10.1016/S0025-7125(16)31971-X; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; GAGEL RF, 1988, NEW ENGL J MED, V318, P478, DOI 10.1056/NEJM198802253180804; GIBSON WCH, 1981, AM J CLIN PATHOL, V75, P347; GIBSON WGH, 1982, AM J PATHOL, V106, P388; HENNESSY JF, 1974, J CLIN ENDOCR METAB, V39, P487, DOI 10.1210/jcem-39-3-487; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOWE JR, 1992, AM J HUM GENET, V51, P1430; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jackson C E, 1989, Henry Ford Hosp Med J, V37, P116; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LAIRMORE TC, 1991, GENOMICS, V9, P181, DOI 10.1016/0888-7543(91)90237-9; LAIRMORE TC, 1991, GENOMICS, V10, P514; LANDSVATER RM, 1993, AM J HUM GENET, V52, P335; LIOU GI, 1987, NUCLEIC ACIDS RES, V15, P3196, DOI 10.1093/nar/15.7.3196; Lips C J, 1987, Henry Ford Hosp Med J, V35, P133; LIPS CJM, 1978, AM J MED, V64, P569, DOI 10.1016/0002-9343(78)90575-2; LIPS KJM, 1982, AM J MED, V73, P305, DOI 10.1016/0002-9343(82)90710-0; LOVE DR, 1993, HUM MOL GENET, V2, P491, DOI 10.1093/hmg/2.4.491-a; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MELVIN KEW, 1971, NEW ENGL J MED, V285, P1115, DOI 10.1056/NEJM197111112852004; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P374, DOI 10.1093/nar/16.1.374; NAKAMURA Y, 1988, GENOMICS, V3, P389, DOI 10.1016/0888-7543(88)90133-4; OTOOLE K, 1985, HUM PATHOL, V16, P991, DOI 10.1016/S0046-8177(85)80276-8; PONDER BAJ, 1989, H FORD HOSP MED J, V37, P205; SCHIMKE RN, 1968, NEW ENGL J MED, V279, P1, DOI 10.1056/NEJM196807042790101; SCOPSI L, 1991, MODERN PATHOL, V4, P297; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SIPPLE JH, 1961, AM J MED, V31, P163, DOI 10.1016/0002-9343(61)90234-0; STEINER AL, 1968, MEDICINE, V47, P371, DOI 10.1097/00005792-196809000-00001; VANGILS APG, 1991, RADIOGRAPHICS, V11, P37, DOI 10.1148/radiographics.11.1.1671719; VASEN HFA, 1987, AM J MED, V83, P847, DOI 10.1016/0002-9343(87)90641-3; WOLFE HJ, 1973, NEW ENGL J MED, V289, P437, DOI 10.1056/NEJM197308302890901; WOLFE HJ, 1981, CLIN ENDOCRINOL META, V10, P351, DOI 10.1016/S0300-595X(81)80027-8; WU JS, 1989, HUM GENET, V83, P383, DOI 10.1007/BF00291386	39	339	352	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	1994	331	13					828	835		10.1056/NEJM199409293311302	http://dx.doi.org/10.1056/NEJM199409293311302			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH530	7915822				2022-12-28	WOS:A1994PH53000002
J	ARIYOSHI, M; VASSYLYEV, DG; IWASAKI, H; NAKAMURA, H; SHINAGAWA, H; MORIKAWA, K				ARIYOSHI, M; VASSYLYEV, DG; IWASAKI, H; NAKAMURA, H; SHINAGAWA, H; MORIKAWA, K			ATOMIC-STRUCTURE OF THE RUVC RESOLVASE - A HOLLIDAY JUNCTION-SPECIFIC ENDONUCLEASE FROM ESCHERICHIA-COLI	CELL			English	Article							SOLVENT-FLATTENED PHASES; DATA-COLLECTION SYSTEM; 4-WAY DNA JUNCTION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; DIFFRACTION DATA; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN CRYSTALLOGRAPHY; WEISSENBERG CAMERA; BRANCH MIGRATION	The crystal structure of the RuvC protein, a Holliday junction resolvase from E. coli, has been determined at 2.5 Angstrom resolution. The enzyme forms a dimer of 19 kDa subunits related by a dyad axis. Together with results from extensive mutational analyses, the refined structure reveals that the catalytic center, comprising four acidic residues, lies at the bottom of a cleft that nicely fits a DNA duplex. The structural features of the dimer, with a 30 Angstrom spacing between the two catalytic centers, provide a substantially defined image of the Holliday junction architecture. The folding topology in the vicinity of the catalytic site exhibits a striking similarity to that of RNAase H1 from E. coli.	OSAKA UNIV, MICROBIAL DIS RES INST, DEPT MOLEC MICROBIOL, SUITA, OSAKA 565, JAPAN	Osaka University	ARIYOSHI, M (corresponding author), PROT ENGN RES INST, 6-2-3 FURUEDAI, SUITA, OSAKA 565, JAPAN.		Vassylyev, Dmitry/A-9005-2008; Nakamura, Haruki/O-4028-2014; Iwasaki, Hiroshi/Y-7946-2018	Iwasaki, Hiroshi/0000-0002-0153-6873; Ariyoshi, Mariko/0000-0002-1361-2642				ARIYOSHI M, 1994, J MOL BIOL, V241, P281, DOI 10.1006/jmbi.1994.1500; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1993, X PLOR VERSION 3 1; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; CURA V, 1992, ACTA CRYSTALLOGR A, V48, P756, DOI 10.1107/S0108767392003416; DEMASSY B, 1984, COLD SPRING HARB SYM, V49, P715, DOI 10.1101/SQB.1984.049.01.081; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HYDE H, 1994, J BIOL CHEM, V269, P5202; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; MAIN P, 1980, MULTAN SYSTEM COMPUT; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; NAKAMURA H, 1987, J PHYS SOC JPN, V56, P1609, DOI 10.1143/JPSJ.56.1609; NAVIA MA, 1974, ACTA CRYSTALLOGR A, VA 30, P706, DOI 10.1107/S0567739474001768; NISHIKAWA K, 1993, PROTEIN ENG, V6, P811, DOI 10.1093/protein/6.8.811; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHERRATT D, 1989, MOBILE DNA, P163; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STEIGEMANN W, 1974, THESIS TU MUNICH; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; TAKAHAGI M, 1994, J BIOL CHEM, V269, P15132; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TANAKA I, 1990, J APPL CRYSTALLOGR, V23, P334, DOI 10.1107/S0021889890004009; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WILSON KS, 1978, ACTA CRYSTALLOGR B, V34, P1599, DOI 10.1107/S0567740878006135; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	58	267	274	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					1063	1072		10.1016/0092-8674(94)90280-1	http://dx.doi.org/10.1016/0092-8674(94)90280-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923356				2022-12-28	WOS:A1994PJ29400016
J	KOENIG, W; SUND, M; LOWE, GDO; LEE, AJ; RESCH, KL; TUNSTALLPEDOE, H; KEIL, U; ERNST, E				KOENIG, W; SUND, M; LOWE, GDO; LEE, AJ; RESCH, KL; TUNSTALLPEDOE, H; KEIL, U; ERNST, E			GEOGRAPHICAL VARIATIONS IN PLASMA VISCOSITY AND RELATION TO CORONARY EVENT RATES	LANCET			English	Article							CARDIOVASCULAR RISK FACTOR; BLOOD-VISCOSITY; MONICA PROJECT; FIBRINOGEN; POPULATION; RHEOLOGY; DISEASE	Plasma viscosity is reported to be predictive of coronary heart disease (CHD) and stroke. To find out whether regional differences in CHD event rates correlate with differences in plasma viscosity, we compared plasma viscosity in a high-risk area for CHD (Glasgow Multinational Monitoring of Trends and Determinants in Cardiovascular Disease [MONICA] and Scottish Heart Health Study population surveys, 1985/86; n=1166) and in a lower-risk area (MONICA Augsburg survey, 1984/85; n=3258) in men and women aged 25-64 years. Mean plasma viscosity (37 degrees C) was 1.261 (SD 0.067) mPa s in Augsburg and 1.327 (0.093) mPa s in the west of Scotland for men, and 1.248 (0.066) mPa s and 1.318 (0.087) mPa s, respectively, for women. The unadjusted difference of the means between the west of Scotland and Augsburg was 0.066 (95% Cl from weighted regression 0.058-0.073) mPa s for men and 0.070 (0.062-0.078) mPa s for women. Adjustment for age, smoking behaviour, total and high-density-lipoprotein cholesterol, systolic and diastolic blood pressure, and body-mass index had no effect on these differences. Age-standardised coronary event rates in 1985-87 were at least two times higher among men, and four times higher among women, in MONICA Glasgow than in MONICA Augsburg. This large geographical difference in plasma viscosity might partly explain the differences in CHD event rates between these populations. Further studies are needed on the determinants of plasma viscosity, and on its potential roles in atherosclerosis, thrombosis, and ischaemia.	GESELL STRAHLEN & UMWELTFORSCH MBH,ENVIRONM RES CTR,W-8042 NEUHERBERG,GERMANY; HLTH MEDIS INST,NEUHERBERG,GERMANY; UNIV GLASGOW,ROYAL INFIRM,DEPT MED,GLASGOW G31 2ER,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND; UNIV VIENNA,DEPT PHYS MED & REHABIL,VIENNA,AUSTRIA; UNIV MUNSTER,INST EPIDEMIOL & SOCIAL MED,W-4400 MUNSTER,GERMANY; UNIV EXETER,POSTGRAD MED SCH,EXETER,ENGLAND	Royal Infirmary of Edinburgh; University of Glasgow; University of Dundee; University of Vienna; University of Munster; University of Exeter	KOENIG, W (corresponding author), UNIV ULM,MED CTR,DEPT INTERNAL MED 2,ROBERT KOCH STR 8,D-89081 ULM,GERMANY.							[Anonymous], 1982, CLIN LAB HAEMATOL, V4, P83; [Anonymous], 1990, WHO MONICA PROJECT M; BOETHIG S, 1989, INT J EPIDEMIOL S1, V18, P29; BRAY GA, 1978, INT J OBESITY, V2, P99; CHAMBLESS L, 1987, GSF3186 GES STRAHL U; DESIMONE G, 1990, CIRCULATION, V81, P107, DOI 10.1161/01.CIR.81.1.107; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; ERNST E, 1988, ARTERIOSCLEROSIS, V8, P385, DOI 10.1161/01.ATV.8.4.385; HARKNESS J, 1963, LANCET, V2, P280; KEIL U, 1988, ACTA MED SCAND S, V728, P119; KEIL U, 1985, GSF2085 GES STRAHL U; KOENIG W, 1992, CIRCULATION, V86, P1045, DOI 10.1161/01.CIR.86.3.1045; KOENIG W, 1992, CIRCULATION, V85, P2197, DOI 10.1161/01.CIR.85.6.2197; LOWE GDO, 1988, CLIN HEMORHEOL, V8, P517; LOWE GDO, 1993, CIRCULATION, V87, P1915, DOI 10.1161/01.CIR.87.6.1915; RESCH KL, 1992, ANN INTERN MED, V117, P371, DOI 10.7326/0003-4819-117-5-371; SMITH W C S, 1987, Health Bulletin (Edinburgh), V45, P211; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; SMITH WCS, 1992, J HYPERTENS, V10, P467, DOI 10.1097/00004872-199205000-00010; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1984, J CLIN PATHOL, V37, P1147; 1988, J CLIN EPIDEMIOL, V34, P105	23	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					711	714		10.1016/S0140-6736(94)92207-1	http://dx.doi.org/10.1016/S0140-6736(94)92207-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915775				2022-12-28	WOS:A1994PF18700009
J	POLO, O; BERTHONJONES, M; DOUGLAS, NJ; SULLIVAN, CE				POLO, O; BERTHONJONES, M; DOUGLAS, NJ; SULLIVAN, CE			MANAGEMENT OF OBSTRUCTIVE SLEEP APNOEA/HYPOPNOEA SYNDROME	LANCET			English	Article							POSITIVE AIRWAY PRESSURE; APNEA SYNDROME; NASAL CPAP; FOLLOW-UP; UVULOPALATOPHARYNGOPLASTY; SURGERY; THERAPY; MASK		UNIV SYDNEY,DEPT MED,DAVID READ LAB,SYDNEY,NSW 2006,AUSTRALIA; ROYAL PRINCE ALFRED HOSP,CTR RESP FAILURE & SLEEP DISORDERS,SYDNEY,AUSTRALIA; CITY HOSP EDINBURGH,RESP MED UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND	University of Sydney; University of Sydney			Douglas, Neil/B-1491-2013					ALIHANKA J, 1981, AM J PHYSIOL, V240, P384; AUBERTTULKENS G, 1987, AM REV RESPIR DIS, V136, P851, DOI 10.1164/ajrccm/136.4.851; BARTHONJONES M, 1993, SLEEP, V16, pS120; CONWAY W, 1985, CHEST, V88, P385, DOI 10.1378/chest.88.3.385; DOUGLAS NJ, 1992, LANCET, V339, P347, DOI 10.1016/0140-6736(92)91660-Z; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; FARNEY RJ, 1992, CHEST, V101, P1228, DOI 10.1378/chest.101.5.1228; FUJITA S, 1981, OTOLARYNG HEAD NECK, V89, P923, DOI 10.1177/019459988108900609; GISLASON T, 1988, ARCH OTOLARYNGOL, V114, P45; GUGGER M, 1992, THORAX, V47, P809, DOI 10.1136/thx.47.10.809; GUILLEMINAULT C, 1993, CHEST, V104, P781, DOI 10.1378/chest.104.3.781; GUILLEMINAULT C, 1989, EUR RESPIR J, V2, P604; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; KEENAN SP, 1994, CHEST, V105, P155, DOI 10.1378/chest.105.1.155; LARSSON H, 1991, ACTA OTO-LARYNGOL, V111, P582, DOI 10.3109/00016489109138387; MIKI H, 1989, AM REV RESPIR DIS, V140, P1285, DOI 10.1164/ajrccm/140.5.1285; PIPER AJ, 1994, CHEST, V105, P434, DOI 10.1378/chest.105.2.434; POLO O, 1989, ARCH OTOLARYNGOL, V115, P1350; POLO O, IN PRESS 1994 P WORL; POLO O, 1992, ACTA PHYSL SCAN S606, V145, P1; POLO OJ, 1991, AM REV RESPIR DIS, V143, P1288, DOI 10.1164/ajrccm/143.6.1288; RILEY RW, 1990, CHEST, V98, P1421, DOI 10.1378/chest.98.6.1421; ROLFE I, 1991, AM REV RESPIR DIS, V144, P1130, DOI 10.1164/ajrccm/144.5.1130; Sadeh A., 1989, J AMBUL MONITOR, V2, P209; SANDERS MH, 1993, AM REV RESPIR DIS, V147, P1169, DOI 10.1164/ajrccm/147.5.1169; SANDERS MH, 1990, CHEST, V98, P317, DOI 10.1378/chest.98.2.317; SCHMIDTNOWARA WW, 1991, CHEST, V99, P1378, DOI 10.1378/chest.99.6.1378; SHEPARD JW, 1991, SLEEP, V14, P361, DOI 10.1093/sleep/14.4.361; SJOHOLM T, IN PRESS J ORAL REHA; Stradling, 1992, J Sleep Res, V1, P265; SULLIVAN CE, 1981, LANCET, V1, P862; WALDHORN RE, 1990, CHEST, V97, P33, DOI 10.1378/chest.97.1.33; WHYTE KF, 1988, SLEEP, V11, P463, DOI 10.1093/sleep/11.5.463	33	66	66	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					656	660		10.1016/S0140-6736(94)92089-3	http://dx.doi.org/10.1016/S0140-6736(94)92089-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915352				2022-12-28	WOS:A1994PE38600014
J	STOLLER, JL				STOLLER, JL			WAITING FOR THE LOCKSMITH	LANCET			English	Editorial Material											STOLLER, JL (corresponding author), LAUREL MED CTR,VANCOUVER,BC,CANADA.							DAVIDSON JD, 1991, GREAT RECKONING; STOLLER JL, 1994, LANCET, V343, P857, DOI 10.1016/S0140-6736(94)92059-1	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					562	562		10.1016/S0140-6736(94)91962-3	http://dx.doi.org/10.1016/S0140-6736(94)91962-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914957				2022-12-28	WOS:A1994PD42400006
J	KAPLAN, NM				KAPLAN, NM			ETHNIC ASPECTS OF HYPERTENSION	LANCET			English	Article							BLOOD-PRESSURE; UNITED-STATES; BLACK; RISK; MORTALITY; DISEASE; IMPACT; WHITES; AGENTS; RACE				KAPLAN, NM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							BARLEY J, 1991, J HYPERTENS, V9, P993, DOI 10.1097/00004872-199111000-00003; BIANCHI S, 1994, AM J HYPERTENS, V7, P23, DOI 10.1093/ajh/7.1.23; CAMPESE VM, 1991, HYPERTENSION, V18, P805, DOI 10.1161/01.HYP.18.6.805; CHATURVEDI N, 1993, HYPERTENSION, V22, P90, DOI 10.1161/01.HYP.22.1.90; COOPER RS, 1992, CIRCULATION, V85, P12; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CRUICKSHANK JK, 1985, J HYPERTENS, V3, P365, DOI 10.1097/00004872-198508000-00009; DYSART JN, 1994, AM J HYPERTENS, V7, P15, DOI 10.1093/ajh/7.1.15; FALKNER B, 1990, HYPERTENSION, V15, P681, DOI 10.1161/01.HYP.15.6.681; FISHER NDL, 1994, HYPERTENSION, V23, P179, DOI 10.1161/01.HYP.23.2.179; GRETLER DD, 1994, AM J HYPERTENS, V7, P7, DOI 10.1093/ajh/7.1.7; JAMERSON KA, 1993, CLIN EXP HYPERTENS, V15, P979, DOI 10.3109/10641969309037086; KAPLAN NM, 1994, HYPERTENSION POPULAT, P1; KOREN MJ, 1993, AM J HYPERTENS, V6, P815, DOI 10.1093/ajh/6.10.815; LOPES AAS, 1993, J AM SOC NEPHROL, V3, P1961; MANTUNGA AK, 1993, HYPERTENSION, V22, P84; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; OOI WL, 1989, HYPERTENSION, V14, P227, DOI 10.1161/01.HYP.14.3.227; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; ROWLAND M, 1982, NCHS ADV DATA, V84; SEEDAT YK, 1989, J HYPERTENS, V7, P515, DOI 10.1097/00004872-198907000-00001; SORLIE P, 1992, LANCET, V340, P346, DOI 10.1016/0140-6736(92)91413-3; VERDECCHIA P, 1993, CIRCULATION, V88, P986, DOI 10.1161/01.CIR.88.3.986; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; 1993, ARCH INTERN MED, V153, P154	26	71	71	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					450	452		10.1016/S0140-6736(94)91774-4	http://dx.doi.org/10.1016/S0140-6736(94)91774-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914569				2022-12-28	WOS:A1994PB76100014
J	HABIB, F; DUTKA, D; CROSSMAN, D; OAKLEY, CM; CLELAND, JGF				HABIB, F; DUTKA, D; CROSSMAN, D; OAKLEY, CM; CLELAND, JGF			ENHANCED BASAL NITRIC-OXIDE PRODUCTION IN HEART-FAILURE - ANOTHER FAILED COUNTER-REGULATORY VASODILATOR MECHANISM	LANCET			English	Note							SYNTHASE	Endothelial dysfunction in heart failure could impair nitric oxide production and lead to increased vascular resistance. If endogenous production of nitric oxide is reduced, N-G-monomethyl-L-arginine (L-NMMA), an inhibitor of such production, should have a diminished vasoconstrictor effect. We administered L-NMMA to 12 patients being investigated for heart failure. L-NMMA increased median pulmonary and systemic vascular resistances by 61 (range - 3 to 240) and 430 (63 to 1609)dynes s cm(-5), respectively (p<0.03 and p<0.005). Arterial pressures also increased. Median cardiac output fell by 0.6 (0 to -2.3) L per min (p<0.005). These data suggest that vascular nitric oxide may be another example of a failed counter-regulatory vasodilator system in heart failure.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED CARDIOL,LONDON W12,ENGLAND	Imperial College London			Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016; Crossman, David/0000-0003-4762-8623				CABANES L, 1992, NEW ENGL J MED, V326, P1661, DOI 10.1056/NEJM199206183262503; CLELAND JGF, 1991, BRIT HEART J, V66, P264; COHN JN, 1990, AM J CARDIOL, V66, P1507, DOI 10.1016/0002-9149(90)90544-B; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DREXLER H, 1992, AM J CARDIOL, V69, P1596, DOI 10.1016/0002-9149(92)90710-G; LOH E, 1993, CIRCULATION, V88, P25; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; ONTKEAN M, 1991, CIRC RES, V69, P1088, DOI 10.1161/01.RES.69.4.1088; PACKER M, 1992, LANCET, V340, P88, DOI 10.1016/0140-6736(92)90405-R; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WIESHAMMER S, 1993, BRIT HEART J, V70, P17	11	132	136	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					371	373		10.1016/S0140-6736(94)91402-8	http://dx.doi.org/10.1016/S0140-6736(94)91402-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914308				2022-12-28	WOS:A1994PA30300011
J	GOH, HS; CHAN, CS; KHINE, K; SMITH, DR				GOH, HS; CHAN, CS; KHINE, K; SMITH, DR			P53 AND BEHAVIOR OF COLORECTAL-CANCER	LANCET			English	Note							TUMOR SUPPRESSOR GENE; CARCINOMAS	The tumour suppressor gene p53 is altered in most colorectal tumours. We found that lymphatic dissemination was driven by the presence of mutated p53 whether or not the cell contained wild-type p53. In a total sample of 187 specimens, point mutation of the p53 gene occurred in 70% and 43% of cases with and without lymph-node involvement, respectively. By contrast, haematogenous dissemination was apparently the result of absent functional wild-type p53 (whether or not the cell contained mutated p53). These results are of potential importance in the prediction of the clinical behaviour of a tumour.			GOH, HS (corresponding author), SINGAPORE GEN HOSP,DEPT COLORECTAL SURG,OUTRAM RD,SINGAPORE 0316,SINGAPORE.		Smith, Duncan R/C-6891-2011	Smith, Duncan R/0000-0002-6592-9852				BARLOGIE B, 1983, CANCER RES, V43, P3982; CHANG FJ, 1993, AM J GASTROENTEROL, V88, P174; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; KHINE K, 1994, CANCER, V73, P28, DOI 10.1002/1097-0142(19940101)73:1<28::AID-CNCR2820730107>3.0.CO;2-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MELING GI, 1993, BRIT J CANCER, V67, P93, DOI 10.1038/bjc.1993.15; SAKAI E, 1992, ONCOGENE, V7, P927; TURNBULL RB, 1967, ANN SURG, V166, P420	9	72	73	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					233	234		10.1016/S0140-6736(94)93000-7	http://dx.doi.org/10.1016/S0140-6736(94)93000-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913159				2022-12-28	WOS:A1994NY06000012
J	GORDON, RD				GORDON, RD			MINERALOCORTICOID HYPERTENSION	LANCET			English	Article							GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; HYPERALDOSTERONISM; ADENOMA; VARIETY				GORDON, RD (corresponding author), GREENSLOPES HOSP,HYPERTENS UNIT,BRISBANE,QLD 4120,AUSTRALIA.		Gordon, Richard D/K-2555-2012					BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; Gordon R D, 1987, J Hypertens Suppl, V5, pS103; GORDON RD, 1991, CLIN EXP PHARMACOL P, V18, P283, DOI 10.1111/j.1440-1681.1991.tb01446.x; GORDON RD, 1992, LANCET, V340, P159, DOI 10.1016/0140-6736(92)93225-C; GORDON RD, 1993, J HYPERTENS, V11, pS310; Gordon RD., 1994, TXB HYPERTENSION, P865; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; IRONY I, 1987, J CLIN ENDOCR METAB, V65, P836, DOI 10.1210/jcem-65-5-836; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LONDON N, 1992, POSTGRAD MED J, V68, P976, DOI 10.1136/pgmj.68.806.976; RICH GM, 1992, ANN INTERN MED, V116, P813, DOI 10.7326/0003-4819-116-10-813; SOMA R, 1989, J ENDOCRINOL INVEST, V12, P183, DOI 10.1007/BF03349956; STEWART PM, 1988, J CLIN INVEST, V82, P340, DOI 10.1172/JCI113592; STOWASSER M, 1992, CLIN EXP PHARMACOL P, V19, P319, DOI 10.1111/j.1440-1681.1992.tb00462.x; STOWASSER M, 1993, J CLIN ENDOCR METAB, V77, P800, DOI 10.1210/jc.77.3.800	15	102	106	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					240	243		10.1016/S0140-6736(94)93003-1	http://dx.doi.org/10.1016/S0140-6736(94)93003-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913162				2022-12-28	WOS:A1994NY06000015
J	KWOK, RPS; LUNDBLAD, JR; CHRIVIA, JC; RICHARDS, JP; BACHINGER, HP; BRENNAN, RG; ROBERTS, SGE; GREEN, MR; GOODMAN, RH				KWOK, RPS; LUNDBLAD, JR; CHRIVIA, JC; RICHARDS, JP; BACHINGER, HP; BRENNAN, RG; ROBERTS, SGE; GREEN, MR; GOODMAN, RH			NUCLEAR-PROTEIN CBP IS A COACTIVATOR FOR THE TRANSCRIPTION FACTOR CREB	NATURE			English	Article							CYCLIC-AMP; SOMATOSTATIN GENE; ESCHERICHIA-COLI; FACTOR-TFIIB; ACTIVATION; ELEMENT; BINDING; DNA; PHOSPHORYLATION; IDENTIFICATION	THE transcription factor CREB binds to a DNA element known as the cAMP-regulated enhancer (CRE)(1-5). CREB is activated through phosphorylation by protein kinase A (PKA)(6), but precisely how phosphorylation stimulates CREB function is unknown. One model is that phosphorylation may allow the recruitment of coactivators which then interact with basal transcription factors. We have previously identified a nuclear protein of M(r) 265K, CBP, that binds specifically to the PKA-phosphorylated form of CREB(7). We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB:CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus. The activation,domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA-1 (ref. 8). Consistent with its role as a coactivator, CBP augments the activity of phosphorylated CREB to activate transcription of cAM-responsive genes.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201; ST LOUIS UNIV,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63014; SHRINERS HOSP CRIPPLED CHILDRENS,PORTLAND,OR 97201; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605	Oregon Health & Science University; Oregon Health & Science University; Saint Louis University; University of Massachusetts System; University of Massachusetts Worcester			Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365; Brennan, Richard/0000-0001-7647-485X				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HOEFFLER JP, 1988, SCIENCE, V242, P1428; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SHORT JM, 1986, J BIOL CHEM, V261, P9721; WILLIAMS JS, 1993, DNA CELL BIOL, V12, P183, DOI 10.1089/dna.1993.12.183	19	1282	1311	1	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					223	226		10.1038/370223a0	http://dx.doi.org/10.1038/370223a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	7913207				2022-12-28	WOS:A1994NX97100055
J	HARRAP, SB				HARRAP, SB			HYPERTENSION - GENES VERSUS ENVIRONMENT	LANCET			English	Article							BLOOD-PRESSURE; MIGRATION; MARKERS; DISEASE; RISK				HARRAP, SB (corresponding author), ALFRED HOSP,MONASH MED SCH,DEPT SOCIAL & PREVENT MED,COMMERCIAL RD,PRAHRAN,VIC 3181,AUSTRALIA.			Harrap, Stephen/0000-0003-2907-6714				BEAGLEHOLE R, 1990, EPIDEMIOL REV, V12, P1; BENNETT CL, 1993, BIOCHEM BIOPH RES CO, V197, P833, DOI 10.1006/bbrc.1993.2554; DEUTSCHER S, 1966, CIRCULATION, V33, P911, DOI 10.1161/01.CIR.33.6.911; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HOWE JR, 1992, SURGERY, V112, P219; HUNT SC, 1989, AM J EPIDEMIOL, V129, P625, DOI 10.1093/oxfordjournals.aje.a115175; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LONGINI IM, 1984, AM J EPIDEMIOL, V120, P131, DOI 10.1093/oxfordjournals.aje.a113862; MOLL PP, 1979, GENETIC ANAL COMMON, P307; MONGEAU JG, 1989, SEMIN NEPHROL, V9, P208; MONGEAU JG, 1986, CLIN EXP HYPERTENS A, V8, P653, DOI 10.3109/10641968609046581; MURPHY EA, 1964, J CHRON DIS, V17, P301, DOI 10.1016/0021-9681(64)90073-6; PICKERING GW, 1959, LANCET, V2, P1027; PLATT R, 1947, Q J MED, V16, P111; REEDERS ST, 1986, BRIT MED J, V292, P851, DOI 10.1136/bmj.292.6524.851; Rose G, 1987, Ciba Found Symp, V130, P247; SALMOND CE, 1989, AM J EPIDEMIOL, V130, P37, DOI 10.1093/oxfordjournals.aje.a115321; SUZUKI DT, 1989, INTRO GENETIC ANAL, P641; WARD R, 1990, HYPERTENSION PATHOPH, P81; WATT GCM, 1992, J HYPERTENS, V10, P474	22	78	82	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					169	171		10.1016/S0140-6736(94)92762-6	http://dx.doi.org/10.1016/S0140-6736(94)92762-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912770				2022-12-28	WOS:A1994NW81000014
J	CIANFARANI, S; VACCARO, F; BOSCHERINI, B				CIANFARANI, S; VACCARO, F; BOSCHERINI, B			WHAT IS THE RATIONALE FOR GROWTH-HORMONE THERAPY IN TURNERS-SYNDROME	LANCET			English	Editorial Material							OXANDROLONE; SECRETION; OBESITY; GH				CIANFARANI, S (corresponding author), UNIV ROMA TOR VERGATA, DEPT PAEDIAT, VIA O RAIMONDO, I-00173 ROME, ITALY.		Geremia, Caterina/AAA-9380-2020; cianfarani, stefano/K-2079-2016	cianfarani, stefano/0000-0002-2580-8781				CAPRIO S, 1992, J PEDIATR-US, V120, P238, DOI 10.1016/S0022-3476(05)80434-2; CIANFARANI S, 1994, HORM RES, V41, P27, DOI 10.1159/000183873; KOPELMAN PG, 1988, CLIN ENDOCRINOL, V28, P675; LANES R, 1990, J CLIN ENDOCR METAB, V71, P770, DOI 10.1210/jcem-71-3-770; LU PW, 1991, ARCH DIS CHILD, V66, P1184, DOI 10.1136/adc.66.10.1184; PASQUINO AM, 1992, HORM RES, V38, P120, DOI 10.1159/000182526; RANKE MB, 1993, ACTA PAEDIATR, V82, P82, DOI 10.1111/j.1651-2227.1993.tb12936.x; RANKE MB, 1987, ACTA ENDOCRINOL-COP, V116, P305, DOI 10.1530/acta.0.1160305; RAPPAPORT R, 1989, ACTA PAEDIATR SCAND, P82; ROSENFELD RG, 1992, J PEDIATR-US, V121, P49, DOI 10.1016/S0022-3476(05)82540-5; ROSS JL, 1985, J PEDIATR-US, V106, P202, DOI 10.1016/S0022-3476(85)80287-0; VANVLIET G, 1986, HUMAN GROWTH HORMONE, P115; WALKER JM, 1990, LANCET, V336, P1331, DOI 10.1016/0140-6736(90)92891-K; WEISE M, 1993, HORM RES, V39, P25, DOI 10.1159/000182763; WILSON DM, 1988, J PEDIATR-US, V112, P210, DOI 10.1016/S0022-3476(88)80057-X; ZADIK Z, 1992, J CLIN ENDOCR METAB, V75, P412, DOI 10.1210/jc.75.2.412	16	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	1994	344	8915					114	115		10.1016/S0140-6736(94)91288-2	http://dx.doi.org/10.1016/S0140-6736(94)91288-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912351				2022-12-28	WOS:A1994NV73200016
J	PARPURA, V; BASARSKY, TA; LIU, F; JEFTINIJA, K; JEFTINIJA, S; HAYDON, PG				PARPURA, V; BASARSKY, TA; LIU, F; JEFTINIJA, K; JEFTINIJA, S; HAYDON, PG			GLUTAMATE-MEDIATED ASTROCYTE NEURON SIGNALING	NATURE			English	Article							CALCIUM WAVES; HIPPOCAMPAL-NEURONS; SYNAPTIC CURRENTS; ASPARTATE; RESPONSES; RECEPTORS; CULTURES	NEUROTRANSMITTER released from neurons is known to signal to neighbouring neurons and glia(1-3). Here we demonstrate an additional signalling pathway in which glutamate is released from astrocytes and causes an NMDA (N-methyl-D-aspartate) receptor-mediated increase in neuronal calcium. Internal calcium was elevated and glutamate release stimulated by application of the neuroligand bradykinin to cultured astrocytes. Elevation of astrocyte internal calcium was also sufficient to induce glutamate release. To determine whether this released glutamate signals to neurons, we studied astrocyte-neuron co-cultures. Bradykinin significantly increased calcium levels in neurons co-cultured with astrocytes, but not in solitary neurons. The glutamate receptor antagonists D-2-amino-5-phosphonopentanoic acid and D-glutamylglycine prevented bradykinin-induced neuronal calcium elevation. When single astrocytes were directly stimulated to increase internal calcium and release glutamate, calcium levels of adjacent neurons were increased; this increase could be blocked by D-glutamyl-glycine. Thus, astrocytes regulate neuronal calcium levels through the calcium-dependent release of glutamate. -	IOWA STATE UNIV SCI & TECHNOL, DEPT ZOOL & GENET, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, DEPT VET ANAT, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, NEUROSCI PROGRAM, AMES, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University			Parpura, Vladimir/A-1242-2010	Parpura, Vladimir/0000-0002-4643-2197				BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BASARSKY TA, IN PRESS J NEUROSCI; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORNELLBELL AH, 1991, CELL CALCIUM, V12, P185, DOI 10.1016/0143-4160(91)90020-F; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; GLAUM SR, 1990, P NATL ACAD SCI USA, V87, P3454, DOI 10.1073/pnas.87.9.3454; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; INAGAKI N, 1991, NEUROSCI LETT, V128, P257, DOI 10.1016/0304-3940(91)90274-W; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; JENSEN AM, 1991, J NEUROSCI, V11, P1674; JONES AW, 1984, NEUROSCIENCE, V13, P573, DOI 10.1016/0306-4522(84)90250-1; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; LEVISON SW, 1991, CULTURING NERVE CELL, P309; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MCCARTHY KD, 1991, NEUROSCIENCE, V41, P325, DOI 10.1016/0306-4522(91)90330-Q; MCLARNON JG, 1991, CAN J PHYSIOL PHARM, V69, P1422, DOI 10.1139/y91-213; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; PARPURA V, 1993, J CELL SCI, V104, P427; REISER G, 1989, J CELL SCI, V93, P545; SCHEFFE H, 1953, BIOMETRIKA, V40, P87, DOI 10.1093/biomet/40.1-2.87; Sokal R. R., 1981, BIOMETRY PRINCIPLES, P400; TRIGGLE DJ, 1991, ANN NY ACAD SCI, V635, P123, DOI 10.1111/j.1749-6632.1991.tb36487.x	29	1336	1368	3	84	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	1994	369	6483					744	747		10.1038/369744a0	http://dx.doi.org/10.1038/369744a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	7911978				2022-12-28	WOS:A1994NU58100060
J	VOORBERG, J; ROELSE, J; KOOPMAN, R; BULLER, H; BERENDS, F; TENCATE, JW; MERTENS, K; VANMOURIK, JA				VOORBERG, J; ROELSE, J; KOOPMAN, R; BULLER, H; BERENDS, F; TENCATE, JW; MERTENS, K; VANMOURIK, JA			ASSOCIATION OF IDIOPATHIC VENOUS THROMBOEMBOLISM WITH SINGLE POINT-MUTATION AT ARG(506) OF FACTOR-V	LANCET			English	Note							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; THROMBOPHILIA; THROMBOSIS	Abnormal coagulation factor V may underlie the thrombotic events associated with resistance to activated protein C (APC). We analysed 27 consecutive patients with documented idiopathic (recurrent) thromboembolism for the occurrence of point mutations within the APC sensitive regions of blood coagulation factor V. In 10 patients we observed a single basepair mutation resulting in a substitution of Arg(506) to Gln. This mutation was significantly linked to in-vitro resistance to APC in these subjects. This mutation at Arg(506) of factor V may form the molecular basis for the thrombotic events associated with APC resistance.	UNIV AMSTERDAM,ACAD MED CTR,CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	VOORBERG, J (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT BLOOD COAGULAT,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.			Voorberg, Jan/0000-0003-4585-2621				BAUER KA, 1994, NEW ENGL J MED, V330, P566, DOI 10.1056/NEJM199402243300810; CUYPERS HTM, 1992, J CLIN MICROBIOL, V30, P3220, DOI 10.1128/JCM.30.12.3220-3224.1992; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; GRIFFIN JH, 1993, BLOOD, V82, P1989; HEYBOER H, 1990, NEW ENGL J MED, V323, P1512; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801	10	445	458	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1535	1536		10.1016/S0140-6736(94)92939-4	http://dx.doi.org/10.1016/S0140-6736(94)92939-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911872				2022-12-28	WOS:A1994NR32900009
J	CALIGIURI, M; BEACH, D				CALIGIURI, M; BEACH, D			SCT1 FUNCTIONS IN PARTNERSHIP WITH CDC10 IN A TRANSCRIPTION COMPLEX THAT ACTIVATES CELL-CYCLE START AND INHIBITS DIFFERENTIATION	CELL			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; ADENYLYL CYCLASE; BINDING-PROTEIN; BUDDING YEAST; REL ONCOGENE; DNA-SEQUENCE; C-ELEGANS; KAPPA-B	A fission yeast cell cycle START gene has been identified, sct1. Loss of sct1 function results in cell cycle arrest at START and simultaneously in derepression of the mating pathway. sct1 therefore functions both as an essential activator of the mitotic cell cycle and as a repressor of differentiation. p72sct1 shares 36% sequence similarity with p85cdc10. p72sct1 is shown to act in partnership with p85cdc10 in a cell cycle regulatory transcription complex. A single dominant mutation within the putative DNA-binding domain of p72sct1 renders the cell independent of cdc10 function for the execution of START.			CALIGIURI, M (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA.				NIGMS NIH HHS [GM34517-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034517] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; EGEL R, 1977, NATURE, V266, P172, DOI 10.1038/266172a0; FERNANDEZSARABI.MJ, 1993, IN PRESS MOL GEN GEN; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GORDON CB, 1986, EMBO J, V5, P2981, DOI 10.1002/j.1460-2075.1986.tb04595.x; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; Gutz H., 1974, HDB GENETICS, V1, P395; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MAEDA T, 1990, P NATL ACAD SCI USA, V87, P7814, DOI 10.1073/pnas.87.20.7814; MARKS J, 1992, J CELL SCI, V101, P517; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; REYMOND A, 1992, MOL GEN GENET, V234, P449, DOI 10.1007/BF00538705; Sambrook J, 1989, MOL CLONING LABORATO; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VERMA R, 1992, P NATL ACAD SCI USA, V89, P9479, DOI 10.1073/pnas.89.20.9479; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	49	110	112	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					607	619		10.1016/0092-8674(93)90079-6	http://dx.doi.org/10.1016/0092-8674(93)90079-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7916653				2022-12-28	WOS:A1993KP16500015
J	PATHMAN, DE; KONRAD, TR; RICKETTS, TC				PATHMAN, DE; KONRAD, TR; RICKETTS, TC			THE NATIONAL-HEALTH-SERVICE CORPS EXPERIENCE FOR RURAL PHYSICIANS IN THE LATE 1980S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To learn from physicians in the National Health Service Corps (referred to as NHSC or the Corps) scholarship program about their experiences in ru mi health professional shortage areas (HPSAs), to contrast their experiences with those of other physicians working in rural HPSAs, and to learn how NHSC physicians' retention is associated with the quality of their experiences. Design.-Cohort study. Participants.-Two groups of primary care physicians who moved to rural HPSAs nationwide from 1987 through 1990 were surveyed in 1991: group 1 consisted of ail 675 physicians in the NHSC scholarship program, and group 2 consisted of a stratified random sample of 1000 non-Corps physicians. Response rates were 73.7% and 69.1%, respectively. Analyses used comparable subsets of 417 NHSC and 206 non-NHSC respondents. Results.-Among NHSC physicians, 51% initially anticipated working in underserved areas longer than 10 years, although only 14% expected to remain more than 5 years in their assigned practices. Three quarters of the Corps group felt there were few acceptable practice sites available to them, one third likely would have preferred urban sites, and two thirds were matched in states where they had not lived or trained earlier. Corps physicians felt their spouses' and children's needs were less well satisfied in their communities than non-Corps physicians. Corps physicians reported lower satisfaction in their work and personal lives and demonstrated poorer retention. Group differences in satisfaction and retention remained after controlling for various features of physicians and sites where they worked. Among NHSC physicians, retention was dramatically lower for those less well matched to their communities and those less satisfied. Conclusions.-The needs and preferences of NHSC physicians andfamilies are not well accommodated. Low morale and poor retention are endemic among NHSC physicians. The NHSC is challenged by twin goals of meeting the immediate needs of underserved communities and providing personally and professionally satisfying environments where physicians can pursue long-term careers.	UNIV N CAROLINA, DEPT FAMILY MED, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, DEPT SOCIAL MED, CHAPEL HILL, NC USA; UNIV N CAROLINA, DEPT HLTH POLICY & ADM, CHAPEL HILL, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	PATHMAN, DE (corresponding author), UNIV N CAROLINA, CECIL G SHEPS CTR HLTH SERV RES, 725 AIRPORT RD, CAMPUS BOX 7590, CHAPEL HILL, NC 27599 USA.		Konrad, Thomas R./AAT-9276-2020	Pathman, Donald/0000-0002-6708-3707; Konrad, Thomas R/0000-0002-5269-0440	AHRQ HHS [1-RO1-HS06544-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON JM, 1993, FAM PRACT NEWS  0115, V2, P33; ANDERSON RJ, 1990, 101ST C; APPLEBOME P, 1990, NY TIMES        0212, pB11; Applebome Peter, 1990, N Y Times Web, pA21; BARBANEL J, 1990, NY TIMES        0624, P17; BARBANEL J, 1990, NY TIMES        0624, P1; Carmines E. G., 1979, RELIABILITY VALIDITY, V17; Conte S J, 1992, J Rural Health, V8, P185, DOI 10.1111/j.1748-0361.1992.tb00351.x; Cooper J K, 1975, Inquiry, V12, P18; CRUZ HA, 1962, AM MED NEWS     1123, P30; DICKSON P, 1979, PUBLIC HEALTH REP, P56; FINE M, 1990, NY TIMES        0728, P20; GEYMAN JP, 1979, J FAM PRACTICE, V9, P381; GRAY PP, 1972, HEALTH SERV REP, V87, P479, DOI 10.2307/4594572; HADLEY J, 1980, MED ED FINANCING POL, P260; Haglund K, 1979, New Physician, V28, P23; HARMON RG, 1992, ACAD MED, V67, P758, DOI 10.1097/00001888-199211000-00008; HELMS LB, 1991, ACAD MED, V66, P71, DOI 10.1097/00001888-199102000-00003; IMMERMAN B, 1977, NEW YORK STATE J MED, V77, P788; JOHNS MME, 1993, JAMA-J AM MED ASSOC, V269, P3156, DOI 10.1001/jama.269.24.3156; KONRAD TR, 1992, UNPUB LOOKING NEXT 2; LEWIS CE, 1976, RIGHT HLTH PROBLEM A, P127; MAYER ME, 1993, JAMA-J AM MED ASSOC, V269, P1112, DOI 10.1001/jama.269.9.1112; MCCORMICK K, 1989, CAN VOLUNTEERS SAVE; MICHELSEN E, 1979, PUBLIC HEALTH REP, V94, P11; MULLAN F, 1984, REFORMING MED LESSON, P176; OBRIEN EM, 1989, BLACK ISSUES HIGHER, V6, P12; PARKER RC, 1967, J MED EDUC, V42, P327; PATHMAN DE, 1992, JAMA-J AM MED ASSOC, V268, P1552; ROSENBLATT RA, 1980, MILBANK FUND Q, V58, P283, DOI 10.2307/3349715; ROSENBLATT RA, 1979, J FAM PRACTICE, V9, P507; Samuels M E, 1978, Ann N Y Acad Sci, V310, P163, DOI 10.1111/j.1749-6632.1978.tb22069.x; Silver P, 1980, J Miss State Med Assoc, V21, P29; SKELLEY BD, 1980, THESIS U GEORGIA; STONE VE, 1991, J HEALTH CARE POOR U, V2, P1; TOWNSEND P, 1992, AM MED NEWS     0921, P20; WHEELER L, 1992, WASHINGTON POST 0507, pC1; WHEELER L, 1992, WASHINGTON POST 0507, pC5; WOLFE L, 1991, JAMA-J AM MED ASSOC, V266, P2808, DOI 10.1001/jama.266.20.2808; ZICCONI J, 1992, UNIQUE OPPORTUNI NOV, P18; 1989, UNPUB PROPOSED STRAT; 1991, HPDP COMMUNICATO SUM, P2; 1990, UNPUB NATIONAL HLTH; 1986, NHSC NOTES, V9, P1; 1987, PHYSICIANS COMMUNITY; 1977, RETENTION NATIONAL H; 1978, HRD77135 US C GEN AC; 1990, OTAH434 US OFF TECHN	48	55	55	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1341	1348		10.1001/jama.272.17.1341	http://dx.doi.org/10.1001/jama.272.17.1341			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933394				2022-12-28	WOS:A1994PP02000028
J	NIKOSKELAINEN, EK; SAVONTAUS, ML; HUOPONEN, K; ANTILA, K; HARTIALA, J				NIKOSKELAINEN, EK; SAVONTAUS, ML; HUOPONEN, K; ANTILA, K; HARTIALA, J			PREEXCITATION SYNDROME IN LEBERS HEREDITARY OPTIC NEUROPATHY	LANCET			English	Note							ELECTROCARDIOGRAPHIC ABNORMALITIES; NEURORETINOPATHY; ATROPHY	Pre-excitation syndrome is common in families with Leber's hereditary optic neuropathy (LHON). 24 Finnish families with LHON were screened for the 11778 and the 3460 mitochondrial DNA mutations. 5 of 30 individuals with LHON and the 11778 mutation had the Wolff-Parhinson-White pre-excitation syndrome. None of 10 with the 3460 mutation or of 11 with ''other'' mutations had this syndrome. Overall, 5 of 51 LHON patients and 9 of 112 symptom-free maternal relatives had Wolff-Parhinson-White syndrome (9%). In paternal relatives, the frequency was 1.6%. Mitochondrial DNA causal for LHON may contribute to pre-excitation syndrome.	UNIV TURKU,DEPT MED GENET,SF-20520 TURKU,FINLAND; UNIV TURKU,DEPT CLIN PHYSIOL,SF-20520 TURKU,FINLAND	University of Turku; University of Turku	NIKOSKELAINEN, EK (corresponding author), UNIV TURKU,DEPT OPHTHALMOL,SF-20520 TURKU,FINLAND.				NEI NIH HHS [I-RO EY 409040-01] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIGGER JT, 1980, HEART DIS TXB CARDIO, V1, P682; BOWER SPC, 1992, LANCET, V339, P1427, DOI 10.1016/0140-6736(92)91257-9; FEDERICO A, 1987, J INHERIT METAB DIS, V10, P256, DOI 10.1007/BF01811419; HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8; HUOPONEN K, 1993, HUM GENET, V92, P379, DOI 10.1007/BF01247339; NIKOSKELAINEN E, 1985, LANCET, V1, P696; NIKOSKELAINEN EK, 1987, ARCH OPHTHALMOL-CHIC, V105, P665, DOI 10.1001/archopht.1987.01060050083043; ORTIZ RG, 1992, AM J OPHTHALMOL, V113, P561, DOI 10.1016/S0002-9394(14)74730-0; ROSE FC, 1970, BRIT J OPHTHALMOL, V54, P388, DOI 10.1136/bjo.54.6.388; VIDAILLET HJ, 1987, NEW ENGL J MED, V317, P65, DOI 10.1056/NEJM198707093170201	10	60	62	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					857	858		10.1016/S0140-6736(94)92830-4	http://dx.doi.org/10.1016/S0140-6736(94)92830-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916404				2022-12-28	WOS:A1994PH25300014
J	PORTER, A				PORTER, A			GODS FOOLS	LANCET			English	Editorial Material														Porter, Alan MW/0000-0001-5622-7288				BENDA J, 1928, TRAHISON CLERCS; CHESNAIS JC, 1994, NEW SCI, V143, P32; Festinger L., 1957, THEORY COGNITIVE DIS, V2; KING M, 1993, LANCET, V341, P669, DOI 10.1016/0140-6736(93)90431-F; PORTER AMW, 1993, J HUM EVOL, V25, P417, DOI 10.1006/jhev.1993.1059; RUSSELL C, 1979, J MED ETHICS, V5, P108, DOI 10.1136/jme.5.3.108; WHEELER PE, 1993, J HUM EVOL, V24, P13, DOI 10.1006/jhev.1993.1003	7	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					835	836		10.1016/S0140-6736(94)92822-3	http://dx.doi.org/10.1016/S0140-6736(94)92822-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH253	7916396				2022-12-28	WOS:A1994PH25300006
J	JENNER, P				JENNER, P			OXIDATIVE DAMAGE IN NEURODEGENERATIVE DISEASE	LANCET			English	Article							PARKINSONS-DISEASE; SUBSTANTIA NIGRA; IRON; RADICALS; FERRITIN; INCREASE; BRAINS				JENNER, P (corresponding author), UNIV LONDON,UNIV LONDON KINGS COLL,NEURODEGENERAT DIS RES CTR,DIV BIOMED SCI,LONDON SW3 6LX,ENGLAND.		Jenner, Peter G/M-3288-2013					BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; DEXTER DT, 1994, ANN NEUROL, V35, P38, DOI 10.1002/ana.410350107; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; IKEDA H, 1992, BRAIN RES, V575, P285, DOI 10.1016/0006-8993(92)90092-N; MARKLUND SL, 1985, J NEUROL SCI, V67, P319, DOI 10.1016/0022-510X(85)90156-X; MARTTILA RJ, 1988, J NEUROL SCI, V86, P321, DOI 10.1016/0022-510X(88)90108-6; MARX J, 1994, SCIENCE, V264, P1663, DOI 10.1126/science.8209242; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SAGGU H, 1989, J NEUROCHEM, V53, P692, DOI 10.1111/j.1471-4159.1989.tb11759.x; SANCHEZRAMOS JR, IN PRESS NEURODEGENE; SCHAPIRA AHV, 1994, MOVEMENT DISORD, V9, P125, DOI 10.1002/mds.870090202; SIAN J, IN PRESS ANN NEUROL; SPINA MB, 1989, P NATL ACAD SCI USA, V86, P1398, DOI 10.1073/pnas.86.4.1398; VANDERVLIET A, 1994, BIOCHEM J, V303, P295, DOI 10.1042/bj3030295	21	343	360	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					796	798		10.1016/S0140-6736(94)92347-7	http://dx.doi.org/10.1016/S0140-6736(94)92347-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916079				2022-12-28	WOS:A1994PG17800016
J	SLOAN, NL; CAMACHO, LWL; ROJAS, EP; STERN, C; ROMAN, FV; CASTRO, CN; ARIAS, A; ESTRELLA, L; PIZARRO, J; ESPIN, V; ACOSTA, M; ALTAMIRANO, M; BONILLA, M; CAIZALUISA, N; CEVALLOZ, S; CRUZ, X; LOPEZ, M; PONCE, M; SUPE, Y; TAPIA, M; TELLO, J; VINUEZA, Y; ZAPATA, J; DEMURGUEITIO, H; DEVITERI, G; ARIAS, A; LARREA, M				SLOAN, NL; CAMACHO, LWL; ROJAS, EP; STERN, C; ROMAN, FV; CASTRO, CN; ARIAS, A; ESTRELLA, L; PIZARRO, J; ESPIN, V; ACOSTA, M; ALTAMIRANO, M; BONILLA, M; CAIZALUISA, N; CEVALLOZ, S; CRUZ, X; LOPEZ, M; PONCE, M; SUPE, Y; TAPIA, M; TELLO, J; VINUEZA, Y; ZAPATA, J; DEMURGUEITIO, H; DEVITERI, G; ARIAS, A; LARREA, M			KANGAROO MOTHER METHOD - RANDOMIZED CONTROLLED TRIAL OF AN ALTERNATIVE METHOD OF CARE FOR STABILIZED LOW-BIRTH-WEIGHT INFANTS	LANCET			English	Article								Because resources for care of low-birthweight (LBW) infants in developing countries are scarce, the Kangaroo mother method (KMM) was developed. The infant is kept upright in skin-to-skin contact with the mother's breast. Previous studies reported several benefits with the KMM but interpretation of their findings is limited by small size and design weaknesses. We have done a longitudinal, randomised, controlled trial at the Isidro Ayora Maternity Hospital in Quite, Ecuador. Infants with LBW (< 2000 g) who satisfied out-of-risk criteria of tolerance of food and weight stabilisation were randomly assigned to KMM and control (standard incubator care) groups (n = 128 and 147, respectively). During 6 months of follow-up the KMM group had a significantly lower rate than the control group of serious illness (lower-respiratory-tract disorders, apnoea, aspiration, pneumonia, septicaemia, general infections; 7 [5%] vs 27 [18%], p < 0.002), although differences between the groups in less severe morbidity were not significant. There was no significant difference in growth or in the proportion of women breastfeeding, perhaps because the proportion breastfeeding was high in both groups owing to strong promotion. Mortality was the same in both groups; most deaths occurred during the stabilisation period before randomisation. KMM mothers made more unscheduled clinic visits than control mothers but their infants had fewer re-admissions and so the cost of care was lower with the KMM. Since the eligibility criteria excluded nearly 50% of LBW infants from the study, the KMM is not universally applicable to these infants. The benefits might be greater in populations where breastfeeding is not so common.	MATERN ISIDRO AYORA,QUITO,ECUADOR		SLOAN, NL (corresponding author), POPULAT COUNCIL,1 DAG HAMMARSKJOLD PLAZA,NEW YORK,NY 10017, USA.							ACOLET D, 1988, ACTA PAEDIATR SCAND, V79, P189; AFFONSO D, 1988, INFANT BEHAV DEV, V11, P4; Anderson G C, 1989, Image J Nurs Sch, V21, P196; ANDERSON GC, 1986, AM J NURS, V86, P807, DOI 10.2307/3425389; ANDERSON GC, 1989, AM J NURS, V89, P661; ARMSTRONG HC, 1987, J HUM LACT, V3, P34; BOSQUE E M, 1988, Pediatric Research, V23, p402A; DELEEUW R, 1986, VRAAGBAAK, V14, P50; MOELLERJENSEN H, 1987, SYGEPLEJERSKEN, V12, P11; ODENT M, 1984, BIRTH REBORN, P86; REY ES, 1983, MANEJO RACIONAL NINO, P137; WHITELAW A, 1988, ARCH DIS CHILD, V63, P1377, DOI 10.1136/adc.63.11.1377; WHITELAW A, 1986, MATERN CHILD HLTH J, V7, P242	13	125	135	1	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					782	785		10.1016/S0140-6736(94)92341-8	http://dx.doi.org/10.1016/S0140-6736(94)92341-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG178	7916073				2022-12-28	WOS:A1994PG17800010
J	BLANCHETTE, V; IMBACH, P; ANDREW, M; ADAMS, M; MCMILLAN, J; WANG, E; MILNER, R; ALI, K; BARNARD, D; BERNSTEIN, M; CHAN, KW; ESSELTINE, D; DEVEBER, B; ISRAELS, S; KOBRINSKY, N; LUKE, B				BLANCHETTE, V; IMBACH, P; ANDREW, M; ADAMS, M; MCMILLAN, J; WANG, E; MILNER, R; ALI, K; BARNARD, D; BERNSTEIN, M; CHAN, KW; ESSELTINE, D; DEVEBER, B; ISRAELS, S; KOBRINSKY, N; LUKE, B			RANDOMIZED TRIAL OF INTRAVENOUS IMMUNOGLOBULIN-G, INTRAVENOUS ANTI-D, AND ORAL PREDNISONE IN CHILDHOOD ACUTE IMMUNE THROMBOCYTOPENIC PURPURA	LANCET			English	Article							GAMMA-GLOBULIN; METHYLPREDNISOLONE; CHILDREN; THERAPY	The most serious complication of childhood acute immune thrombocytopenic purpura (ITP), intracranial haemorrhage, occurs in about 1% of children with platelet counts below 20 x 10(9)/L. We conducted a randomised study to explore three treatment options in this high-risk group. 146 children (> 6 months and < 18 years old) with typical acute ITP and platelet counts of 20 x 10(9)/L or lower were randomised to receive high-dose intravenous immunoglobulin G (IVIgG) 1 g/kg on 2 consecutive days (n=34), 0.8 g/kg once (n=35), intravenous anti-D 25 mu g/kg on 2 consecutive days (n=38), or oral prednisone 4 mg/kg per day with tapering and discontinuation of prednisone by day 21 (n=39). The rate of response as reflected by the number of days with platelet counts at 20 x 10(9)/L or lower and the time taken to achieve a platelet count 50 x 10(9)/L or more was significantly faster for both IVIgG groups than for the anti-D group (p<0.05); the difference between prednisone and IVIgG was significant (p< 0.05) only for the IVIgG 0.8 g/kg group, and responses to the two IgG groups were similar. These differences in response rates were reflected in the percentages of children with platelet counts of 20 x 10(9)/L or lower at 72 hours following the start of treatment: 3% (IVIgG 0.8 g/kg x 1), 6% (IVIgG 1 g/kg x 2), 18% (anti-D), and 21% (oral prednisone 4 mg/kg/day). Treatment-associated toxicities included a fall in haemoglobin with anti-D (to less than 100 g/L in 24% of cases); weight gain with oral prednisone; and fever, nausea, vomiting, and headache with IVIgG.On the basis of these results, intravenous anti-D cannot be recommended as initial therapy for children with acute ITP and platelet counts of 20 x 10(9)/L or lower. A single dose of 0.8 g/kg IVIgG offers the fastest recovery for the least treatment; additional IgG or oral prednisone can be reserved for the one-third of children who continue to have platelet counts of 20 x 10(9)/L or less at 48-72 hours after the start of treatment.	HOSP SICK CHILDREN,CLIN EPIDEMIOL UNIT,TORONTO M5G 1X8,ON,CANADA; UNIV BASEL,CHILDRENS HOSP,BASEL,SWITZERLAND; MCMASTER UNIV,CHILDRENS HOSP CHEDOKE,MED CTR,DEPT PEDIAT,HAMILTON,ON,CANADA; BRITISH COLUMBIA CHILDRENS HOSP,RES CONSULTING UNIT,VANCOUVER V6H 3V4,BC,CANADA; SASKATOON CANC CTR,DIV PEDIAT ONCOL,SASKATOON,SK,CANADA; IZAAK WALTON KILLAM HOSP CHILDREN,DIV HEMATOL,HALIFAX B3J 3G9,NS,CANADA; MONTREAL CHILDRENS HOSP,SERV HEMATOL,MONTREAL H3H 1P3,PQ,CANADA; MD ANDERSON CANC CTR,DIV PEDIAT,HOUSTON,TX; CHILDRENS HOSP WESTERN ONTARIO,LONDON,ON,CANADA; MANITOBA CANC TREATMENT & RES FDN,WINNIPEG R3E 0V9,MB,CANADA; ROGER MARIS CANC CTR,DEPT PEDIAT ONCOL,FARGO,ND; CHILDRENS HOSP EASTERN ONTARIO,DIV HEMATOL ONCOL,OTTAWA K1H 8L1,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Basel; McMaster University; BC Childrens Hospital; University of British Columbia; University of Saskatchewan; Dalhousie University; McGill University; University of Texas System; UTMD Anderson Cancer Center; Western University (University of Western Ontario); University of Ottawa; Children's Hospital of Eastern Ontario	BLANCHETTE, V (corresponding author), HOSP SICK CHILDREN,DEPT PEDIAT,DIV HAEMATOL ONCOL,555 UNIV AVE,TORONTO M5G 1X8,ON,CANADA.		Israels, Sara/ABC-3684-2021	Israels, Sara/0000-0002-1849-4825				ANDREW M, 1991, J PEDIATR, V120, P522; BEARDSLEY DS, 1993, HEMATOLOGY INFANCY C, V2, P1561; BLANCHETTE VS, 1993, J PEDIATR-US, V123, P989, DOI 10.1016/S0022-3476(05)80400-7; BLANCHETTE VS, 1985, J PEDIATR, V108, P326; BLANCHETTE VS, 1992, SEMIN HEMATOL, V29, P77; BUCHANAN GR, 1984, AM J PEDIAT HEMATOL, V6, P355; BUSSEL JB, 1987, VOX SANG, V52, P206, DOI 10.1111/j.1423-0410.1987.tb03029.x; COX DR, 1972, J R STAT SOC B, V34, P187; IMBACH P, 1981, LANCET, V1, P1228; IMBACH P, 1985, LANCET, V2, P464; JAYABOSE S, 1987, AM J PEDIAT HEMATOL, V9, P133; OZSOYLU S, 1989, EUR J HAEMATOL, V42, P431; SALAMA A, 1984, BLUT, V49, P29, DOI 10.1007/BF00320381; SARTORIUS JA, 1984, AM J PEDIAT HEMATOL, V6, P165; SAUREZ ER, 1986, AM J PEDIAT HEMATOL, V8, P111; VANHOFF J, 1988, J PEDIATR-US, V113, P563, DOI 10.1016/S0022-3476(88)80654-1; WOERNER SJ, 1981, PEDIATRICS, V67, P453	17	257	266	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					703	707		10.1016/S0140-6736(94)92205-5	http://dx.doi.org/10.1016/S0140-6736(94)92205-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915773				2022-12-28	WOS:A1994PF18700007
J	MARLINK, R; KANKI, P; THIOR, I; TRAVERS, K; EISEN, G; SIBY, T; TRAORE, I; HSIEH, CC; DIA, MC; GUEYE, E; HELLINGER, J; GUEYENDIAYE, A; SANKALE, JL; NDOYE, I; MBOUP, S; ESSEX, M				MARLINK, R; KANKI, P; THIOR, I; TRAVERS, K; EISEN, G; SIBY, T; TRAORE, I; HSIEH, CC; DIA, MC; GUEYE, E; HELLINGER, J; GUEYENDIAYE, A; SANKALE, JL; NDOYE, I; MBOUP, S; ESSEX, M			REDUCED RATE OF DISEASE DEVELOPMENT AFTER HIV-2 INFECTION AS COMPARED TO HIV-1	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; WEST-AFRICA; VERTICAL TRANSMISSION; GUINEA-BISSAU; IVORY-COAST; NATURAL-HISTORY; TYPE-2 HIV-2; AIDS; PREVALENCE; PROSTITUTES	Human immunodeficiency virus type-2 (HIV-2) is a close relative of the prototype acquired immunodeficiency syndrome (AIDS) virus, HIV-1. HIV-2 is biologically similar to HIV-1, but information is lacking concerning clinical outcomes of HIV-2-infected individuals. From 1985 to 1993, a prospective clinical study was conducted in women with HIV-2 and HIV-1 infection to determine and compare rates of disease development. HIV-1-infected women had a 67% probability of AIDS-free survival 5 years after seroconversion in contrast with 100% for HIV-2-infected women. In addition to having significantly less HIV-related disease outcome in HIV-2 enrollees compared to HIV-1 enrollees, the rate of developing abnormal CD4(+) lymphocyte counts with HIV-2 infection was also significantly reduced. This natural history study demonstrates that HIV-2 has a reduced virulence compared to HIV-1.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; UNIV CHEIKH ANTA DIOP,VIROL & BACTERIOL LAB,DAKAR,SENEGAL; INST SOCIAL HYG,DAKAR,SENEGAL; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; University Cheikh Anta Diop Dakar; Harvard University; Harvard T.H. Chan School of Public Health				Travers, Karin/0000-0002-9097-1710	NATIONAL CANCER INSTITUTE [R35CA039805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39805] Funding Source: Medline; NIAID NIH HHS [AI 30795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; BARIN F, 1985, LANCET, V2, P1387; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BRUNVEZINET F, 1987, LANCET, V1, P128; Bryceson A, 1988, Lancet, V2, P221; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DECOCK KM, 1989, LANCET, V2, P408; DENIS F, 1987, LANCET, V1, P408; DIEM K, 1970, SCI TABLES, P107; DONNELLY C, 1992, B MATH BIOL, V55, P731; KAHN HA, 1989, STATISTICAL METHODS, P206; KANKI P, 1992, AM J EPIDEMIOL, V136, P895, DOI 10.1093/aje/136.7.895; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAWAMURA M, 1989, LANCET, V1, P385; KORBER B, 1989, 4TH INT C AIDS ASS C; LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421; LIFSON AR, 1988, J INFECT DIS, V158, P1360, DOI 10.1093/infdis/158.6.1360; LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013; MABEY DCW, 1988, BRIT MED J, V296, P83, DOI 10.1136/bmj.296.6615.83; MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137; Marlink Richard, 1994, P47; MATHERON S, 1990, LANCET, V335, P1103, DOI 10.1016/0140-6736(90)92682-8; MORGAN G, 1990, AIDS, V4, P879, DOI 10.1097/00002030-199009000-00008; MOSS AR, 1989, AIDS, V3, P55, DOI 10.1097/00002030-198902000-00001; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; NAUCLER A, 1992, SCAND J INFECT DIS, V24, P725, DOI 10.3109/00365549209062457; NAUCLER A, 1991, AIDS, V5, P301, DOI 10.1097/00002030-199103000-00009; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220; ROMIEU I, 1992, WKLY EPIDEMIOL REC, V67, P9; SAMUEL KP, 1988, GENE, V64, P121, DOI 10.1016/0378-1119(88)90486-6; SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002; WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011; WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015; ZUBER M, 1990, AIDS RES HUM RETROV, V6, P525, DOI 10.1089/aid.1990.6.525; 1987, MORBID MORTAL WKL S1, V36, pS1; 1986, MMWR-MORBID MORTAL W, V35, P334; 1990, WKLY EPIDEMIOL REC, V65, P281	42	458	475	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1587	1590		10.1126/science.7915856	http://dx.doi.org/10.1126/science.7915856			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	7915856				2022-12-28	WOS:A1994PF33600038
J	LINN, FHH; WIJDICKS, EFM; VANDERGRAAF, Y; WEERDESTEYNVANVLIET, FAC; BARTELDS, AIM; VANGIJN, J				LINN, FHH; WIJDICKS, EFM; VANDERGRAAF, Y; WEERDESTEYNVANVLIET, FAC; BARTELDS, AIM; VANGIJN, J			PROSPECTIVE-STUDY OF SENTINEL HEADACHE IN ANEURYSMAL SUBARACHNOID HEMORRHAGE	LANCET			English	Article							INTRACRANIAL ANEURYSM; STROKE INCIDENCE; CASE FATALITY; WARNING LEAK; FOLLOW-UP; HEMORRHAGE; RUPTURE; POPULATION; EPIDEMIOLOGY; MANAGEMENT	Retrospective surveys of patients with subarachnoid haemorrhage suggest that minor episodes with sudden headache (warning leaks) may precede rupture of an aneurysm, and that early recognition and surgery might lead to improved outcome. We studied 148 patients with sudden and severe headache (possible sentinel headache) seen by 252 general practitioners in a 5-year period in the Netherlands. Subarachnoid haemorrhage was the cause in 37 patients (25%) (proven aneurysm in 21, negative angiogram in 6, no angiogram done in 6, sudden headache followed by death in 4). 103 patients had headache as the only symptom, 12 of whom proved to have subarachnoid haemorrhage (6 with a ruptured aneurysm). Previous bouts of sudden headache had occurred in only 2. Other serious neurological conditions were diagnosed in 18. In the remaining 93, no underlying cause of headache was found; follow-up over 1 year showed no subsequent subarachnoid haemorrhage or sudden death. In this cohort, acute, severe headache in general practice indicated a serious neurological disorder in 37% (95% CI 29-45%), and subarachnoid haemorrhage in 25% (18-32%). 12% (5-18%) of those with headache as the only symptom. The notion of warning leaks as a less serious variant of subarachnoid haemorrhage is not supported by this study. Early recognition of subarachnoid haemorrhage is important but will probably have only limited impact on the outcome in the general population.	UNIV UTRECHT,DEPT EPIDEMIOL,UTRECHT,NETHERLANDS; NETHERLANDS INST PRIMARY HLTH CARE,UTRECHT,NETHERLANDS	Utrecht University	LINN, FHH (corresponding author), UNIV UTRECHT,DEPT NEUROL,HEIDELBERGLAAN 100,3584 CX UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008					BALL MJ, 1975, CAN MED ASSOC J, V112, P78; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; BROUWERS PJAM, 1993, STROKE, V24, P809, DOI 10.1161/01.STR.24.6.809; COLLETTE HJA, 1982, ENV EPIDEMIOLOGY, P149; DUFFY GP, 1983, MED J AUSTRALIA, V1, P514, DOI 10.5694/j.1326-5377.1983.tb136193.x; GIROUD M, 1991, INT J EPIDEMIOL, V20, P892, DOI 10.1093/ije/20.4.892; HAUERBERG J, 1991, ACTA NEUROL SCAND, V83, P61; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; HIJDRA A, 1987, STROKE, V18, P1061, DOI 10.1161/01.STR.18.6.1061; INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; JENNETT B, 1975, LANCET, V1, P480; JUVELA S, 1992, NEUROSURGERY, V30, P7, DOI 10.1227/00006123-199201000-00002; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KISSEL JT, 1983, ANN NEUROL, V13, P149, DOI 10.1002/ana.410130207; LEBLANC R, 1985, CAN MED ASSOC J, V131, P1235; MARKUS HS, 1991, J NEUROL NEUROSUR PS, V54, P1117, DOI 10.1136/jnnp.54.12.1117; OKAWARA SH, 1973, J NEUROSURG, V38, P575, DOI 10.3171/jns.1973.38.5.0575; Pakarinen S, 1967, ACTA NEUROL SCAN S29, V43, P1; RAJA IA, 1972, J NEUROSURG, V36, P548, DOI 10.3171/jns.1972.36.5.0548; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; RICCI S, 1991, J NEUROL NEUROSUR PS, V54, P695, DOI 10.1136/jnnp.54.8.695; RINKEL GJE, 1991, AM J NEURORADIOL, V12, P829; TEASDALE G, 1974, LANCET, V2, P81; VERMEULEN M, 1990, J NEUROL NEUROSUR PS, V53, P365, DOI 10.1136/jnnp.53.5.365; VERWEIJ RD, 1988, ARCH NEUROL-CHICAGO, V45, P1019, DOI 10.1001/archneur.1988.00520330109018; WIJDICKS EFM, 1988, LANCET, V2, P68; 1989, CBS ANN PUBLICATI A1	29	172	174	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					590	593		10.1016/S0140-6736(94)91970-4	http://dx.doi.org/10.1016/S0140-6736(94)91970-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914965	Green Submitted			2022-12-28	WOS:A1994PD42400014
J	MANI, SK; ALLEN, JMC; CLARK, JH; BLAUSTEIN, JD; OMALLEY, BW				MANI, SK; ALLEN, JMC; CLARK, JH; BLAUSTEIN, JD; OMALLEY, BW			CONVERGENT PATHWAYS FOR STEROID HORMONE-INDUCED AND NEUROTRANSMITTER-INDUCED RAT SEXUAL-BEHAVIOR	SCIENCE			English	Article							MESSENGER RIBONUCLEIC-ACID; LIGAND-INDEPENDENT ACTIVATION; CENTRAL NERVOUS-SYSTEM; FEMALE GUINEA-PIGS; GROWTH FACTOR-I; PROGESTIN RECEPTORS; ESTROGEN-RECEPTOR; LORDOSIS BEHAVIOR; CONCENTRATING CELLS; OVARIECTOMIZED RATS	Estrogen and progesterone modulate gene expression in rodents by activation of intracellular receptors in the hypothalamus, which regulate neuronal networks that control female sexual behavior. However, the neurotransmitter dopamine has been shown to activate certain steroid receptors in a ligand-independent manner. A dopamine receptor stimulant and a D-1 receptor agonist, but not a D-2 receptor agonist, mimicked the effects of progesterone in facilitating sexual behavior in female rats. The facilitatory effect of the neurotransmitter was blocked by progesterone receptor antagonists, a D-1 receptor antagonist, or antisense oligonucleotides to the progesterone receptor. The results suggest that in rodents neurotransmitters may regulate in vivo gene expression and behavior by means of cross-talk with steroid receptors in the brain.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV MASSACHUSETTS,DEPT PSYCHOL,AMHERST,MA 01003; UNIV MASSACHUSETTS,NEUROSCI BEHAV PROGRAM,AMHERST,MA 01003	Baylor College of Medicine; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst					NIMH NIH HHS [MH-00885] Funding Source: Medline; NINDS NIH HHS [NS 19327] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019327] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLENIUS S, 1993, NEUROSCI BIOBEHAV R, V17, P43, DOI 10.1016/S0149-7634(05)80229-5; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ANTUNESR.J, 1970, P SOC EXP BIOL MED, V133, P1464; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Blaustein J. D., 1989, Advances in Comparative and Environmental Physiology, V3, P31; BLAUSTEIN JD, 1987, BRAIN RES, V436, P253, DOI 10.1016/0006-8993(87)91669-6; BLAUSTEIN JD, 1982, BRAIN RES, V243, P287, DOI 10.1016/0006-8993(82)90252-9; BLAUSTEIN JD, 1980, ENDOCRINOLOGY, V106, P1061, DOI 10.1210/endo-106-4-1061; BLAUSTEIN JD, 1989, J NEUROENDOCRINOL, V1, P333, DOI 10.1111/j.1365-2826.1989.tb00125.x; BLAUSTEIN JD, 1986, NEUROENDOCRINOLOGY, V43, P143, DOI 10.1159/000124521; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN T J, 1990, Molecular and Cellular Neuroscience, V1, P58, DOI 10.1016/1044-7431(90)90042-3; BROWN TJ, 1986, BRAIN RES, V373, P103, DOI 10.1016/0006-8993(86)90320-3; BROWN TJ, 1987, ENDOCRINOLOGY, V121, P298, DOI 10.1210/endo-121-1-298; BROWN TJ, 1984, BRAIN RES, V301, P343, DOI 10.1016/0006-8993(84)91103-X; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; DLUZEN DE, 1989, BRAIN RES, V494, P122, DOI 10.1016/0006-8993(89)90150-9; EVERITT BJ, 1974, EUR J PHARMACOL, V29, P187, DOI 10.1016/0014-2999(74)90190-3; FEDER HH, 1977, ANN NY ACAD SCI, V286, P331, DOI 10.1111/j.1749-6632.1977.tb29428.x; FOREMAN MM, 1979, PHYSIOL BEHAV, V22, P283, DOI 10.1016/0031-9384(79)90088-X; FOREMAN MM, 1987, PSYCHOPHARMACOLOGY, V91, P96, DOI 10.1007/BF00690934; FUXE K, 1976, SUBCELLULAR MECHANIS, P193; HAMBURGERBAR R, 1975, EUR J PHARMACOL, V32, P357, DOI 10.1016/0014-2999(75)90304-0; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; MACLUSKY NJ, 1980, ENDOCRINOLOGY, V106, P192, DOI 10.1210/endo-106-1-192; MANI S, UNPUB; MCEWEN BS, 1982, RECENT PROG HORM RES, V38, P41; MCEWEN BS, 1988, J STEROID BIOCHEM, V30, P179, DOI 10.1016/0022-4731(88)90091-X; MORISSETTE M, 1993, J NEUROCHEM, V60, P1876, DOI 10.1111/j.1471-4159.1993.tb13415.x; MORRELL JI, 1978, AM ZOOL, V18, P447; MORRIN LP, 1977, PHYSIOL BEHAV, V18, P701; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; NOCK B, 1981, BRAIN RES, V20, P371; OGAWA S, 1994, J NEUROSCI, V14, P1766, DOI 10.1523/JNEUROSCI.14-03-01766.1994; PARSONS B, 1980, ENDOCRINOLOGY, V107, P774, DOI 10.1210/endo-107-3-774; PFAFF D, 1973, J COMP NEUROL, V151, P121, DOI 10.1002/cne.901510204; PFAFF DW, 1983, SCIENCE, V219, P808, DOI 10.1126/science.6297008; PFAFF DW, 1988, PHYSL REPRODUCTION, V1, P1487; POLLIO G, 1993, MOL BRAIN RES, V19, P135, DOI 10.1016/0169-328X(93)90158-L; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; POWERS JB, 1976, PHYSIOL BEHAV, V117, P493; ROMANO GJ, 1988, MOL ENDOCRINOL, V2, P1320, DOI 10.1210/mend-2-12-1320; ROMANO GJ, 1989, MOL ENDOCRINOL, V3, P1295, DOI 10.1210/mend-3-8-1295; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; STANCEL GM, 1990, PROG CLIN BIOL RES, V322, P213; THORTON JE, 1986, BRAIN RES, V377, P1155; TITUS RD, 1983, J MED CHEM, V26, P1112, DOI 10.1021/jm00362a005; VATHY IU, 1989, HORM BEHAV, V23, P43, DOI 10.1016/0018-506X(89)90073-1; WILCOX JN, 1985, ENDOCRINOLOGY, V117, P2392, DOI 10.1210/endo-117-6-2392	51	287	288	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1246	1249		10.1126/science.7915049	http://dx.doi.org/10.1126/science.7915049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7915049				2022-12-28	WOS:A1994PD42200042
J	MCDONALD, GA; DUBOSE, TD; MOLONY, DA; VERANI, R				MCDONALD, GA; DUBOSE, TD; MOLONY, DA; VERANI, R			NEPHROTOXICITY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS	LANCET			English	Discussion							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RENAL PAPILLARY NECROSIS; INTERSTITIAL NEPHRITIS; FAILURE; HYPERTROPHY; DISEASE; PROGRESSION; DETERMINANT; MECHANISMS; PHENACETIN		UNIV TEXAS,HLTH SCI CTR,SCH MED,DIV NEPHROL,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT PATHOL & LAB MED,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT INTERNAL MED,HOUSTON,TX; HERMANN HOSP,HOUSTON,TX	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas System								ADAMS DH, 1986, LANCET, V1, P57; BANKIR L, 1991, AM J KIDNEY DIS, V17, P661, DOI 10.1016/S0272-6386(12)80346-5; Bennett WM, 1991, KIDNEY, P1430; BREZIN JH, 1979, NEW ENGL J MED, V301, P1271, DOI 10.1056/NEJM197912063012306; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; BURRY AF, 1967, NEPHRON, V5, P185; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; COGAN MC, 1978, AM J MED, V64, P500, DOI 10.1016/0002-9343(78)90237-1; DUBACH UC, 1983, NEW ENGL J MED, V308, P357, DOI 10.1056/NEJM198302173080703; DUBACH UC, 1991, NEW ENGL J MED, V324, P155, DOI 10.1056/NEJM199101173240304; FINKELSTEIN A, 1982, AM J MED, V72, P81, DOI 10.1016/0002-9343(82)90591-5; HENRICH WL, 1983, AM J KIDNEY DIS, V2, P478, DOI 10.1016/S0272-6386(83)80083-3; JCKSON B, 1978, N Z J MED, V8, P165; Kincaid-Smith P, 1968, Med J Aust, V1, P203; KUNCIO GS, 1991, KIDNEY INT, V39, P550, DOI 10.1038/ki.1991.63; KURTZ I, 1991, AM J KIDNEY DIS, V17, P650, DOI 10.1016/S0272-6386(12)80343-X; Lonnemann G., 1993, Journal of the American Society of Nephrology, V4, P616; LOURIE SH, 1977, ARTHRITIS RHEUM, V20, P917, DOI 10.1002/art.1780200403; MOLLAND EA, 1978, KIDNEY INT, V13, P5, DOI 10.1038/ki.1978.2; NATH KA, 1991, AM J KIDNEY DIS, V17, P654, DOI 10.1016/S0272-6386(12)80344-1; NATH KA, 1992, AM J KIDNEY DIS, V20, P1; PALLER MS, 1990, MED CLIN N AM, V74, P909, DOI 10.1016/S0025-7125(16)30525-9; POMMER W, 1989, AM J NEPHROL, V9, P403, DOI 10.1159/000168002; RODEMANN HP, 1991, AM J KIDNEY DIS, V17, P684, DOI 10.1016/S0272-6386(12)80352-0; SABATINI S, 1988, SEMIN NEPHROL, V8, P41; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SANDLER DP, 1991, ANN INTERN MED, V115, P165, DOI 10.7326/0003-4819-115-3-165; Segasothy M., 1993, Journal of the American Society of Nephrology, V4, P759; Sharma A., 1993, Journal of the American Society of Nephrology, V4, P633; TOTO RD, 1990, AM J MED SCI, V299, P392, DOI 10.1097/00000441-199006000-00007; WOLF G, 1991, KIDNEY INT, V39, P401, DOI 10.1038/ki.1991.52	31	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					515	518						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914617				2022-12-28	WOS:A1994PC53500013
J	PRESTON, NW				PRESTON, NW			PERTUSSIS VACCINATION - NEITHER PANIC NOR COMPLACENCY	LANCET			English	Editorial Material											PRESTON, NW (corresponding author), UNIV MANCHESTER,SCH MED,DEPT MED MICROBIOL,PERTUSSIS REFERENCE LAB,MANCHESTER,ENGLAND.							BARAFF LJ, 1984, PEDIATRICS, V73, P37; BOOY R, 1992, LANCET, V339, P507, DOI 10.1016/0140-6736(92)90336-2; CHRISTIE CDC, 1994, NEW ENGL J MED, V331, P16, DOI 10.1056/NEJM199407073310104; KHATTAK MN, 1993, J INFECTION, V27, P119, DOI 10.1016/0163-4453(93)94566-T; KNOWLES K, 1993, 33RD INT C ANT AG CH; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; Miller E, 1992, Commun Dis Rep CDR Rev, V2, pR152; Preston N. W., 1994, Tropical Diseases Bulletin, V91, pR151; Preston N W, 1992, Commun Dis Rep CDR Rev, V2, pR155; Preston N W, 1970, Lab Pract, V19, P482; PRESTON NW, 1988, PATHOGENESIS IMMUNIT, P1; STOTT NCH, 1981, BRIT MED J, V282, P1871, DOI 10.1136/bmj.282.6279.1871-a; WARDLAW AC, 1992, VACCINE, V10, P643, DOI 10.1016/0264-410X(92)90083-V	13	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					491	492		10.1016/S0140-6736(94)91894-5	http://dx.doi.org/10.1016/S0140-6736(94)91894-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914610				2022-12-28	WOS:A1994PC53500005
J	MILLER, HI				MILLER, HI			GENE-THERAPY FOR ENHANCEMENT	LANCET			English	Editorial Material											MILLER, HI (corresponding author), STANFORD UNIV,INST INT STUDIES,STANFORD,CA 94305, USA.							ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; ANDERSON WF, 1980, NEW ENGL J MED, V303, P1293, DOI 10.1056/NEJM198011273032210; ANDERSON WF, 1989, J MED PHILOS, V14, P681, DOI 10.1093/jmp/14.6.681; MILLER HI, 1990, HUM GENE THER, V1, P3, DOI 10.1089/hum.1990.1.1-3; 1993, SCRIP           0716, P27; 1992, ECONOMIST       0425, P11	6	7	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					316	317		10.1016/S0140-6736(94)91345-5	http://dx.doi.org/10.1016/S0140-6736(94)91345-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NZ233	7914268				2022-12-28	WOS:A1994NZ23300014
J	LAWRENCE, PA; MORATA, G				LAWRENCE, PA; MORATA, G			HOMEOBOX GENES - THEIR FUNCTION IN DROSOPHILA SEGMENTATION AND PATTERN-FORMATION	CELL			English	Review							BITHORAX COMPLEX; HOMEOTIC GENES; HOMOEOTIC GENES; ECTOPIC EXPRESSION; CLONAL ANALYSIS; GERM LAYERS; COMPARTMENTS; ANTENNAPEDIA; SEQUENCE; PROTEINS		UNIV AUTONOMA MADRID, FAC MED C-X, CSIC, CTR BIOL MOLEC, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	LAWRENCE, PA (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.			Morata, Gines/0000-0003-3274-5173; Lawrence, Peter/0000-0002-9554-8268				AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BACHILLER D, 1994, EMBO J, V13, P1930, DOI 10.1002/j.1460-2075.1994.tb06462.x; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1993, DEVELOPMENT, V119, P339; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; BREEN TR, 1993, DEVELOPMENT, V117, P119; BROOKMAN JJ, 1992, DEVELOPMENT, V116, P1185; BUSTURIA A, 1988, DEVELOPMENT, V104, P713; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; COHEN S, 1991, TRENDS GENET, V7, P267; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; CRICK FHC, 1975, SCIENCE, V189, P340, DOI 10.1126/science.806966; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; DUNCAN I, 1987, ANNU REV GENET, V102, P49; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1979, SCI AM, V241, P102, DOI 10.1038/scientificamerican0779-102; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1966, DEV BIOL, V14, P278, DOI 10.1016/0012-1606(66)90017-0; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; HAFEN E, 1984, NATURE, V307, P287, DOI 10.1038/307287a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HOPPLER S, 1994, CELL, V76, P689, DOI 10.1016/0092-8674(94)90508-8; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; INGHAM PW, 1985, J EMBRYOL EXP MORPH, V89, P349; JONES B, 1993, GENE DEV, V7, P229, DOI 10.1101/gad.7.2.229; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; Kaufman T C, 1990, Adv Genet, V27, P309; KAUFMAN TC, 1983, TIME SPACE PATTERN E, P365; LAWRENCE PA, 1973, J EMBRYOL EXP MORPH, V30, P681; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1993, DEVELOPMENT, V119, P971; LAWRENCE PA, 1983, CELL, V35, P27, DOI 10.1016/0092-8674(83)90204-0; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1963, AM ZOOL, V3, P33; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MARTINEZARIAS A, 1985, NATURE, V313, P639, DOI 10.1038/313639a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MEISE M, 1993, DEVELOPMENT, V118, P1107; MORATA G, 1977, NATURE, V265, P211, DOI 10.1038/265211a0; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; PELEGRI F, 1994, GENETICS, V136, P1341; REUTER R, 1994, DEVELOPMENT, V120, P1123; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RODER L, 1992, DEVELOPMENT, V115, P1017; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; STRUHL G, 1984, NATURE, V308, P454, DOI 10.1038/308454a0; STRUHL G, 1983, J EMBRYOL EXP MORPH, V76, P297; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1985, CELL, V43, P507, DOI 10.1016/0092-8674(85)90180-1; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THALI M, 1988, NATURE, V336, P598, DOI 10.1038/336598a0; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WAGNERBERNHOLZ JT, 1991, GENE DEV, V5, P2467, DOI 10.1101/gad.5.12b.2467; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571	72	254	261	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					181	189		10.1016/0092-8674(94)90289-5	http://dx.doi.org/10.1016/0092-8674(94)90289-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	7913879				2022-12-28	WOS:A1994NZ24200003
J	OXMAN, TE				OXMAN, TE			DELAYED RECALL - DEMENTED, DEPRESSED, OR TREATED	LANCET			English	Editorial Material							ALZHEIMERS		DARTMOUTH COLL,SCH MED,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03755	Dartmouth College	OXMAN, TE (corresponding author), DARTMOUTH COLL,SCH MED,DEPT PSYCHIAT,HANOVER,NH 03755, USA.							ALBERT MS, 1991, COMPREHENSIVE REV GE, P223; EMERY VO, 1992, AM J PSYCHIAT, V149, P305; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HINDMARCH I, 1992, PSYCHOPHARMACOLOGY S, V105, pS49; LACHNER G, 1994, J NERV MENT DIS, V181, P34; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; NIEDEREHE G, 1994, DEMENTIA PRESENTATIO, P19; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; RABINS PV, 1984, BRIT J PSYCHIAT, V144, P488, DOI 10.1192/bjp.144.5.488; REIFLER BV, 1989, AM J PSYCHIAT, V146, P45; TERI L, 1991, GERONTOLOGIST, V31, P413, DOI 10.1093/geront/31.3.413	11	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					213	214		10.1016/S0140-6736(94)92994-7	http://dx.doi.org/10.1016/S0140-6736(94)92994-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NY060	7913154				2022-12-28	WOS:A1994NY06000006
J	CLERICI, M; BEVILACQUA, M; VAGO, T; VILLA, ML; SHEARER, GM; NORBIATO, G				CLERICI, M; BEVILACQUA, M; VAGO, T; VILLA, ML; SHEARER, GM; NORBIATO, G			AN IMMUNOENDOCRINOLOGICAL HYPOTHESIS OF HIV-INFECTION	LANCET			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HUMAN MEDULLARY THYMOCYTES; GLUCOCORTICOID RECEPTOR; T-CELLS; IMMUNE-RESPONSES; IMMUNOGLOBULIN-E; GENE-EXPRESSION; INTERLEUKIN-2; DEHYDROEPIANDROSTERONE; SYSTEM		OSPED L SACCO,SERV ENDOCRINOL,MILAN,ITALY; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	University of Milan; Luigi Sacco Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	CLERICI, M (corresponding author), UNIV MILAN,CATTEDRA IMMUNOL,VIA VENEZIA 1,I-20133 MILAN,ITALY.			Clerici, Mario/0000-0001-5920-6191				BROWNE ES, 1993, J STEROID BIOCHEM, V45, P517, DOI 10.1016/0960-0760(93)90168-V; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; CHRISTEFF N, 1992, J ACQ IMMUN DEF SYND, V5, P841; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, IN PRESS P NATL ACAD; DAYNES RA, 1989, EUR J IMMUNOL, V19, P2319, DOI 10.1002/eji.1830191221; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GRINSPOON SK, 1992, NEW ENGL J MED, V327, P1360, DOI 10.1056/NEJM199211053271906; GROUX H, 1993, EUR J IMMUNOL, V23, P1623, DOI 10.1002/eji.1830230734; HELMBERG A, 1990, J IMMUNOL, V145, P4332; HERRSCHER RF, 1992, J CLIN INVEST, V90, P596, DOI 10.1172/JCI115898; KAM JC, 1993, J IMMUNOL, V151, P3460; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MEEYARD L, 1993, INNUMOL TODAY, V14, P161; MULDER JW, 1992, J INFECT DIS, V165, P413, DOI 10.1093/infdis/165.3.413; NIETO MA, 1990, J IMMUNOL, V145, P1364; NORBIATO G, 1992, J CLIN ENDOCR METAB, V74, P608, DOI 10.1210/jc.74.3.608; POLI G, 1993, CLIN RES, V41, pA211; RISDON G, 1990, AM J PATHOL, V136, P759; SALKOWSKI CA, 1992, J IMMUNOL, V148, P2770; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; TANG WW, 1993, AM J MED, V94, P169, DOI 10.1016/0002-9343(93)90179-S; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092	27	55	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1552	1553		10.1016/S0140-6736(94)92944-0	http://dx.doi.org/10.1016/S0140-6736(94)92944-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911876				2022-12-28	WOS:A1994NR32900014
J	THOMAS, JH				THOMAS, JH			THE MIND OF A WORM	SCIENCE			English	Editorial Material							NEMATODE CAENORHABDITIS-ELEGANS; KINESIN HEAVY-CHAIN; C-ELEGANS; NERVOUS-SYSTEM; GENETIC-ANALYSIS; NEURONS; ENCODES; PROTEIN				THOMAS, JH (corresponding author), UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195, USA.							ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; AVERY L, IN PRESS METHODS CEL; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; DESAI C, 1989, GENETICS, V121, P703; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; LIU DWC, 1994, J NEUROSCI, V14, P1953; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; RAIZEN DM, 1994, NEURON, V12, P483, DOI 10.1016/0896-6273(94)90207-0; RANKIN CH, 1990, BEHAV BRAIN RES, V37, P89, DOI 10.1016/0166-4328(90)90074-O; STARICH TA, 1993, GENETICS, V133, P527; THOMAS JH, 1993, GENETICS, V134, P1105; THOMAS JH, 1990, GENETICS, V124, P855; VOWELS JJ, IN PRESS GENETICS; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	28	15	22	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 17	1994	264	5166					1698	1699		10.1126/science.7911601	http://dx.doi.org/10.1126/science.7911601			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR600	7911601				2022-12-28	WOS:A1994NR60000030
J	MENDELSOHN, KD; NIEMAN, LZ; ISAACS, K; LEE, S; LEVISON, SP				MENDELSOHN, KD; NIEMAN, LZ; ISAACS, K; LEE, S; LEVISON, SP			SEX AND GENDER BIAS IN ANATOMY AND PHYSICAL DIAGNOSIS TEXT ILLUSTRATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN; HEALTH	Objective.-To examine the sex and gender distribution of illustrations in two atlases, five anatomy texts, and five physical diagnosis texts. Design.-Of 4060 illustrations that were identifiable by sex and gender in 12 commonly used anatomy and physical diagnosis textbooks, 3827 were categorized by two reviewers as female, male, or neutral. Results.-Females were represented, on average, in 21.2% of the anatomy text illustrations; males were represented, on average, in 44.3%; 34.4% of the illustrations were neutral. Of the nonreproductive anatomy illustrations, a mean of 11.1% (range, 4.6% to 23.8%) depicted women and 43.1% (range, 35.4% to 56.2%) depicted men. Of nonreproductive anatomy illustrations, a mean of 45.8% (range, 27.2% to 59.9%) were neutral. Overall, the physical diagnosis text illustrations demonstrated a more equal sex and gender distribution (21.5% female and 24.8% male). However, in the reproductive chapters of the physical diagnosis texts, females were depicted in a mean of 71.1% (range, 63.2% to 79.0%) of the illustrations, while in the nonreproductive chapters, females were depicted in 8.8% of total illustrations. Conclusions.-In anatomy and physical diagnosis texts, women are underrepresented in illustrations of nonreproductive anatomy. The finding that males are depicted in a majority of nonreproductive anatomy illustrations may perpetuate the image of the male body as the normal or standard model for medical education.	MED COLL PENN,DEPT MED,WOMENS HLTH EDUC PROGRAM,PHILADELPHIA,PA 19129; MED COLL PENN,OFF MED EDUC,PHILADELPHIA,PA	Drexel University; Drexel University								Agur A.M., 2013, GRANTS ATLAS ANATOMY; AGUR AMR, 1983, GRANTS ATLAS ANATOMY; ANGELL M, 1993, NEW ENGL J MED, V329, P271, DOI 10.1056/NEJM199307223290409; BATES B, 1991, POCKET GUIDE PHYSICA; BATES B, 1991, GUIDE PHYSICAL EXAMI; BENNETT JC, 1993, NEW ENGL J MED, V329, P288, DOI 10.1056/NEJM199307223290428; CLEMENTE CD, 1987, ANATOMY REGIONAL ATL; GIACOMINI M, 1986, PSYCHOL WOMEN QUART, V10, P413, DOI 10.1111/j.1471-6402.1986.tb00765.x; GUTTENTAG M, 1976, UNDOING SEX STEREOTY, P98; HORTON J, 1992, WOMENS HLTH DATA BOO; JUDGE RD, 1989, CLIN DIAGNOSIS PHYSL; LINDNER HH, 1989, CLIN ANATOMY; LIPMANBLUMEN J, 1984, GENDER ROLES POWER, P2; LURIE N, 1993, NEW ENGL J MED, V329, P478, DOI 10.1056/NEJM199308123290707; Moore K.L., 2017, CLIN ORIENTED ANATOM, V8th ed.; Moore KL., 1980, CLIN ORIENTED ANATOM; MORABIA A, 1992, J CLIN EPIDEMIOL, V45, P111, DOI 10.1016/0895-4356(92)90003-6; Nechas E., 1994, UNEQUAL TREATMENT WH; Netter F.H., 1989, ATLAS HUMAN ANATOMY; PINN VW, 1992, AM J PREV MED, V8, P324, DOI 10.1016/S0749-3797(18)30800-6; ROSE C, 1975, NEW DIRECTIONS HIGHE, P5; ROY JM, 1990, WOMEN HLTH MED AM HI, P419; SCOTT KP, 1985, HDB ACHIEVING SEX EQ, P218; SCULLY D, 1973, AM J SOCIOL, V78, P1045, DOI 10.1086/225420; SEIDEL HM, 1991, MOSBYS GUIDE PHYSICA; Snell R. S., 1981, CLIN ANATOMY MED STU; Snell RS, 1992, CLIN ANATOMY MED STU, P764; SWARTZ MH, 1989, TXB PHYSICAL DIAGNOS; USSHER J, 1991, WOMENS MADNESS MISOG, P63; Williams PL, 1989, GRAYS ANATOMY; 1992, AM HERITAGE DICT ENG, P1653; 1991, JAMA-J AM MED ASSOC, V266, P559; 1994, 103501 HOUS REPR REP, P31; 1985, WOMENS HLTH REPORT P, P2	34	51	51	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1267	1270		10.1001/jama.272.16.1267	http://dx.doi.org/10.1001/jama.272.16.1267			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933371				2022-12-28	WOS:A1994PN06800032
J	VANDENBUSSCHE, FPHA; KANHAI, HHH; KEIRSE, MJNC				VANDENBUSSCHE, FPHA; KANHAI, HHH; KEIRSE, MJNC			SAFETY OF EARLY AMNIOCENTESIS	LANCET			English	Letter											VANDENBUSSCHE, FPHA (corresponding author), LEIDEN UNIV HOSP,DEPT OBSTET,POB 9600,2300 LEIDEN,NETHERLANDS.		Vandenbussche, F.P.H.A./H-8100-2014					BYRNE D, 1991, ULTRASOUND OBST GYN, V1, P235, DOI 10.1046/j.1469-0705.1991.01040235.x; NICOLAIDES, 1994, LANCET, V344, P435; 1994, LANCET, V344, P825	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					1032	1032		10.1016/S0140-6736(94)91698-5	http://dx.doi.org/10.1016/S0140-6736(94)91698-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934420				2022-12-28	WOS:A1994PK97800073
J	BOURTCHULADZE, R; FRENGUELLI, B; BLENDY, J; CIOFFI, D; SCHUTZ, G; SILVA, AJ				BOURTCHULADZE, R; FRENGUELLI, B; BLENDY, J; CIOFFI, D; SCHUTZ, G; SILVA, AJ			DEFICIENT LONG-TERM-MEMORY IN MICE WITH A TARGETED MUTATION OF THE CAMP-RESPONSIVE ELEMENT-BINDING PROTEIN	CELL			English	Article							APLYSIA SENSORY NEURONS; HIPPOCAMPAL; POTENTIATION; RAT; FACILITATION; SHOCK; FEAR; LTP; MECHANISMS; NALOXONE	The cAMP-responsive element-binding protein (CREB) has been implicated in the activation of protein synthesis required for long-term facilitation, a cellular model of memory in Aplysia. Our studies with fear conditioning and with the water maze show that mice with a targeted disruption of the alpha and delta isoforms of CREB are profoundly deficient in long-term memory. In contrast, short-term memory, lasting between 30 and 60 min, is normal. Consistent with models claiming a role for long-term potentiation (LTP) in memory, LTP in hippocampal slices from CREB mutants decayed to baseline 90 min after tetanic stimulation. However, paired-pulse facilitation and posttetanic potentiation are normal. These results implicate CREB-dependent transcription in mammalian long-term memory.	UNIV HEIDELBERG, GERMAN CANC RES CTR, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	BOURTCHULADZE, R (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.		Frenguelli, Bruno/C-5007-2015; Silva, Alcino/ABD-7684-2021	Frenguelli, Bruno/0000-0001-7214-3172; Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494				ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DICKINSON A, 1978, ANNU REV PSYCHOL, V29, P587, DOI 10.1146/annurev.ps.29.020178.003103; EICHENBAUM H, 1993, TRENDS NEUROSCI, V16, P163, DOI 10.1016/0166-2236(93)90140-H; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; FANSELOW MS, 1979, B PSYCHONOMIC SOC, V14, P88; FANSELOW MS, 1986, LEARN MOTIV, V17, P16, DOI 10.1016/0023-9690(86)90018-4; FANSELOW MS, 1979, J COMP PHYSIOL PSYCH, V93, P736, DOI 10.1037/h0077609; FLOOD JF, 1975, PHYSIOL BEHAV, V15, P97, DOI 10.1016/0031-9384(75)90285-1; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; Huang Y Y, 1994, Learn Mem, V1, P74; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KIM JJ, 1992, BEHAV NEUROSCI, V106, P591, DOI 10.1037/0735-7044.106.4.591; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MATTHIES H, 1989, PROG NEUROBIOL, V32, P277, DOI 10.1016/0301-0082(89)90024-5; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MULLER D, 1989, BRAIN RES, V479, P290, DOI 10.1016/0006-8993(89)91631-4; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; REYMANN KG, 1993, FUNCT NEUROL S, V5, P7; RUDY JW, 1994, BEHAV NEUROSCI, V108, P227, DOI 10.1037/0735-7044.108.2.227; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STANTON PK, 1984, J NEUROSCI, V4, P3080; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TULLY T, 1991, NEUROBIOLOGY LEARNIN, P30; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; [No title captured]	38	1496	1543	3	82	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	1994	79	1					59	68		10.1016/0092-8674(94)90400-6	http://dx.doi.org/10.1016/0092-8674(94)90400-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923378				2022-12-28	WOS:A1994PK58500008
J	WEISSKOPF, MG; CASTILLO, PE; ZALUTSKY, RA; NICOLL, RA				WEISSKOPF, MG; CASTILLO, PE; ZALUTSKY, RA; NICOLL, RA			MEDIATION OF HIPPOCAMPAL MOSSY FIBER LONG-TERM POTENTIATION BY CYCLIC-AMP	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; CRAYFISH NEUROMUSCULAR-JUNCTION; ADENYLATE-CYCLASE; SYNAPTIC PLASTICITY; GLUTAMATE RECEPTORS; TRANSMITTER RELEASE; SYMPATHETIC-GANGLIA; SYNAPSES; NEURONS; FACILITATION	Repetitive activation of hippocampal messy fibers evokes a long-term potentiation (LTP) of synaptic responses in pyramidal cells in the CA3 region that is independent of N-methyl-D-aspartate receptor activation. Previous results suggest that the site for both the induction and expression of this form of LTP is presynaptic. Experimental elevation of cyclic adenosine 3',5'-monophosphate(cAMP) both mimics and interferes with tetanus-induced mossy fiber LTP, and blockers of the cAMP cascade block messy fiber LTP. It is proposed that calcium entry into the presynaptic terminal may activate Ca2+-calmodulin-sensitive adenylyl cyclase I which, through protein kinase A, causes a persistent enhancement of evoked glutamate release.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Castillo, Pablo/0000-0002-9834-1801				BAXTER DA, 1985, P NATL ACAD SCI USA, V82, P5978, DOI 10.1073/pnas.82.17.5978; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRIDGES AJ, 1988, J MED CHEM, V31, P1282, DOI 10.1021/jm00402a004; BRIGGS CA, 1985, J PHYSIOL-LONDON, V359, P503, DOI 10.1113/jphysiol.1985.sp015599; BRIGGS CA, 1988, J PHYSIOL-LONDON, V404, P129, DOI 10.1113/jphysiol.1988.sp017282; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CABELL L, 1993, INT J DEV NEUROSCI, V11, P357, DOI 10.1016/0736-5748(93)90007-Z; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DIXON D, 1989, J NEUROSCI, V9, P4246; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; HAAS HL, 1987, NEUROSCI LETT, V78, P171, DOI 10.1016/0304-3940(87)90628-8; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; Huang Y Y, 1994, Learn Mem, V1, P74; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KUBA K, 1986, J PHYSIOL-LONDON, V374, P515, DOI 10.1113/jphysiol.1986.sp016095; Langdon Ronald B., 1993, Society for Neuroscience Abstracts, V19, P433; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P245, DOI 10.1113/jphysiol.1986.sp016007; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; MINOTA S, 1991, J PHYSIOL-LONDON, V435, P421, DOI 10.1113/jphysiol.1991.sp018517; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; PARSONS ME, 1977, AGENTS ACTIONS, V7, P31, DOI 10.1007/BF01964878; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; REGEHR WG, 1991, NEURON, V7, P451, DOI 10.1016/0896-6273(91)90297-D; REGEHR WG, 1994, J NEUROSCI, V14, P523; SARVEY J M, 1988, P329; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; WEISSKOPF MG, 1993, SOC NEUR ABSTR, V19, P1708; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; WOJTOWICZ JM, 1988, J NEUROSCI, V8, P4667; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4053, DOI 10.1073/pnas.83.11.4053; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	61	458	466	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1878	1882		10.1126/science.7916482	http://dx.doi.org/10.1126/science.7916482			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7916482				2022-12-28	WOS:A1994PH25800037
J	HENDERSON, AH				HENDERSON, AH			AMIODARONE FOR CHRONIC HEART-FAILURE	LANCET			English	Editorial Material											HENDERSON, AH (corresponding author), UNIV WALES COLL MED,DEPT CARDIOL,CARDIFF,S GLAM,WALES.							CHATTERJEE K, 1989, J AM COLL CARDIOL, V14, P1775, DOI 10.1016/0735-1097(89)90031-4; CHELIMSKYFALLICK C, 1992, J AM COLL CARDIOL, V20, P1556, DOI 10.1016/0735-1097(92)90450-2; DARGIE HJ, 1987, CIRCULATION, V75, P98; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; WILSON JS, 1991, AM HEART J, V121, P158, DOI 10.1016/0002-8703(91)90969-O	5	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					489	490		10.1016/S0140-6736(94)91892-9	http://dx.doi.org/10.1016/S0140-6736(94)91892-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914608				2022-12-28	WOS:A1994PC53500003
J	POYNARD, T; BARTHELEMY, P; FRATTE, S; BOUDJEMA, K; DOFFOEL, M; VANLEMMENS, C; MIGUET, JP; MANTION, G; MESSNER, M; LAUNOIS, B; NAVEAU, S; CHAPUT, JC				POYNARD, T; BARTHELEMY, P; FRATTE, S; BOUDJEMA, K; DOFFOEL, M; VANLEMMENS, C; MIGUET, JP; MANTION, G; MESSNER, M; LAUNOIS, B; NAVEAU, S; CHAPUT, JC			EVALUATION OF EFFICACY OF LIVER-TRANSPLANTATION IN ALCOHOLIC CIRRHOSIS BY A CASE-CONTROL STUDY AND SIMULATED CONTROLS	LANCET			English	Article							PRIMARY BILIARY-CIRRHOSIS; PROGNOSTIC VALUE; DRINKERS; DISEASE; MODEL	To assess the efficacy of liver transplantation in patients with alcoholic cirrhosis, we compared 2-year survival of 169 liver transplantation patients in 12 French centres with survival of two control groups treated conservatively. The matched group was 169 patients of similar age, cirrhosis severity, and bleeding history; the simulated group was 169 patients whose theoretical survival was determined in a cohort of 797 patients with alcoholic cirrhosis. The probability of survival to 2 years in transplanted patients was 73 (95% confidence interval 67-79%) versus 67% (59-75) in the matched and 67% (63-71) in simulated controls. When prognostic factors were taken into account, transplantation was associated with survival (r = 0.527; p = 0.069). Patients with severe liver disease (high-risk group) benefited most for 2-year survival: 64% (42-86) vs 41% (23-59) in the matched and 23% (19-27) in the simulated control groups(p < 0.01). There was no difference for patients at low and at medium risk. Liver transplantation increases the 2-year survival of patients with severe alcoholic cirrhosis, In patients with less severe disease, further studies should be done by non-randomised controlled studies with longer follow-up or by randomised trials.			POYNARD, T (corresponding author), GRP HOSP PITIE SALPETRIERE,SERV HEPATOGASTROENTEROL,57-83 BLVD HOP,F-75651 PARIS,FRANCE.		Poynard, Thierry/C-1355-2010	Poynard, Thierry/0000-0002-3726-7230; Boudjema, Karim/0000-0002-3894-8767; Poynard, Thierry/0000-0002-2050-640X				DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; DOFFOEL M, 1991, GASTROENTEROL CLIN B, V15, P4; KUMAR S, 1990, HEPATOLOGY, V11, P159, DOI 10.1002/hep.1840110202; MACHIN D, 1989, STATISTICS CONFIDENC, P64; MARKUS BH, 1989, NEW ENGL J MED, V320, P1709, DOI 10.1056/NEJM198906293202602; NAVEAU S, 1985, HEPATOLOGY, V5, P819, DOI 10.1002/hep.1840050518; PIGNON JP, 1986, GASTROEN CLIN BIOL, V10, P461; POL S, 1990, ALCOHOL CLIN EXP RES, V14, P250, DOI 10.1111/j.1530-0277.1990.tb00481.x; POYNARD T, 1991, HEPATOLOGY, V13, P896, DOI 10.1016/0270-9139(91)90260-3; POYNARD T, 1984, HEPATOLOGY, V4, P324, DOI 10.1002/hep.1840040224; POYNARD T, 1991, NEW ENGL J MED, V324, P1532, DOI 10.1056/NEJM199105303242202; POYNARD T, 1991, GASTROENTEROLOGY, V100, P1397; POYNARD T, 1991, OXFORD TXB CLIN HEPA, P363; RAMOND MJ, 1992, NEW ENGL J MED, V326, P507, DOI 10.1056/NEJM199202203260802; SHENKER S, 1990, HEPATOLOGY, V11, P314; SORRELL MF, 1992, GASTROENTEROLOGY, V102, P1806, DOI 10.1016/0016-5085(92)91748-S	16	82	83	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					502	507		10.1016/S0140-6736(94)91897-X	http://dx.doi.org/10.1016/S0140-6736(94)91897-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914613				2022-12-28	WOS:A1994PC53500008
J	KINGMAN, S				KINGMAN, S			NHS UPDATE - FREEMAN-HOSPITAL - THE WILL TO SURVIVE .2.	BRITISH MEDICAL JOURNAL			English	Article								The future looks uncertain for the Freeman Hospital trust in Newcastle upon Tyne. There are plans to rationalise the health service in Newcastle by shifting resources from secondary to primary care, and by providing more services locally for people who live in the region but outside Newcastle. These could reduce the level of contracts that purchasers place with the trust in the future. Staff at the trust say the service they provide is good value for money, but purchasers do not seem to take this into account. Instead of choosing from a ''shopping list'' of priced procedures, purchasers are forcing the trust to dovetail its prices to meet their budgets. There is also concern at the potential impact on the trust's financial situation of reduced working hours for junior doctors and the Calman proposals on training.											0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					461	464		10.1136/bmj.309.6952.461	http://dx.doi.org/10.1136/bmj.309.6952.461			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920133	Green Published			2022-12-28	WOS:A1994PC40400025
J	PHILLIPS, AN; SABIN, CA; ELFORD, J; BOFILL, M; JANOSSY, G; LEE, CA				PHILLIPS, AN; SABIN, CA; ELFORD, J; BOFILL, M; JANOSSY, G; LEE, CA			USE OF CD4 LYMPHOCYTE COUNT TO PREDICT LONG-TERM SURVIVAL FREE OF AIDS AFTER HIV-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; HEMOPHILIC COHORT; NATURAL-HISTORY; HOMOSEXUAL MEN; PROGRESSION; MARKERS; DISEASE; SEROCONVERTERS; INCUBATION; FOLLOW	Objective-To estimate the probability remaining free of AIDS for up to 25 years after infection with HIV by extrapolation of changes in CD4 lymphocyte count. Design-Cohort study of subjects followed from time of HIV seroconversion until 1 January 1993. Creation of model by using extrapolated linear regression slopes of CD4 count to predict development of AIDS after 1993. Setting-Regional haemophilia centre in teaching hospital. Subjects-111 men with haemophilia infected with HIV during 1979-85. Median length of follow up 10.1 years, median number of CD4 counts 17. The model was not fitted for three men because only one CD4 measurement was available. Main outcome measures-Development of AIDS. Interventions-From 1989 prophylaxis against candida and Pneumocystis carinii pneumonia and antiretroviral drugs when CD4 count fell below 200 x 10(6)/1. Results-44 men developed AIDS up to 1 January 1993. When AIDS was defined as a CD4 count of 50 x 10(6)/1 the model predicted that 25% (95% confidence interval 16% to 34%) would survive for 20 years after seroconversion and 18% (11% to 25%) for 25 years. Changing the CD4 count at which AIDS was assumed to occur did not alter the results. Younger patients had a higher chance of 20 year survival than older patients (32% (12% to 52%) for those aged < 15, 26% (14% to 38%) for those aged 15-29, and 15% (0% to 31%) for those aged greater than or equal to 30). Conclusions-These results suggest that even with currently available treatment up to a quarter of patients with HIV infection will survive for 20 years after seroconversion without developing AIDS.	ROYAL FREE HOSP,SCH MED,DEPT CLIN IMMUNOL,LONDON NW3 2PF,ENGLAND; ROYAL FREE HOSP,SCH MED,CTR HAEMOPHILIA,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	PHILLIPS, AN (corresponding author), UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008; Sabin, Caroline/C-2464-2008	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760				ALCABES P, 1993, EPIDEMIOL REV, V15, P303, DOI 10.1093/oxfordjournals.epirev.a036122; [Anonymous], MMWR; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; Cox D. R., 1984, ANAL SURVIVAL DATA; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; DEGRUTTOLA V, 1991, J AM STAT ASSOC, V86, P569, DOI 10.2307/2290384; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GALAI N, 1993, STAT MED, V12, P2133, DOI 10.1002/sim.4780122207; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HUGHES MD, 1994, J INFECT DIS, V169, P28, DOI 10.1093/infdis/169.1.28; KRAMER A, 1992, AM J EPIDEMIOL, V136, P71; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PHILLIPS A, 1989, AIDS, V3, P737, DOI 10.1097/00002030-198911000-00008; PHILLIPS AN, 1991, LANCET, V337, P389; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SABIN C, 1993, BRIT J HAEMATOL, V83, P330, DOI 10.1111/j.1365-2141.1993.tb08290.x; SABIN C, IN PRESS THROMBOSIS; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; SCHWARTLANDER B, 1992, AIDS, V6, P413, DOI 10.1097/00002030-199204000-00009; SEREMETIS SV, 1993, LANCET, V342, P700, DOI 10.1016/0140-6736(93)91706-R; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; VANLEEUWEN R, 1992, IMMUNODEFICIENCY HIV, P32; 1993, COMMUNICABLE DISE S1, V3, pS1; 1993, STAT MED, V12, P2061; 1992, AIDS, V6, P421; 1994, LANCET, V343, P871; 1987, MMWR S1S, V36, pS3; 1992, MMWR-MORBID MORTAL W, V41, P1	40	61	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					309	313		10.1136/bmj.309.6950.309	http://dx.doi.org/10.1136/bmj.309.6950.309			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	7916226	Green Published			2022-12-28	WOS:A1994PA37300019
J	CONDIE, BG; CAPECCHI, MR				CONDIE, BG; CAPECCHI, MR			MICE WITH TARGETED DISRUPTIONS IN THE PARALOGOUS GENES HOXA-3 AND HORD-3 REVEAL SYNERGISTIC INTERACTIONS	NATURE			English	Article							HOMEOBOX GENE; HOMEOTIC TRANSFORMATIONS; DEVELOPMENTAL DEFECTS; MUTANT MICE; MOUSE; HOX-1.6; HINDBRAIN; EXPRESSION; VERTEBRAE; REGION	THE Hox genes encode transcription factors which mediate the formation of the mammalian body plan along the anteroposterior and appendicular axes(1-15). Paralogous Hox genes within the separate linkage groups are closely related with respect to DNA sequence and expression(16,17), suggesting that they could have at least partially redundant functions. We showed previously that mice homozygous for independent targeted disruptions in the paralogous genes hoxa-3 and hoxd-3 had no defects in common(1,8). But our current analysis of double mutants has revealed strong, dosage-dependent interactions between these genes. We report here that in hoxd-3(-) homozygotes the first cervical vertebra, the atlas, is homeotically transformed to the adjacent anterior structure. Unexpectedly, in double mutants, rather than observing a more extensive homeotic transformation, the entire atlas is deleted. These observations are interpreted in terms of a model in which these Hox genes differentially regulate the proliferation rates of the appropriate sets of precursor cells.	UNIV UTAH, SCH MED, HOWARD HUGHES MED INST, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah								ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CONDIE BG, 1993, DEVELOPMENT, V119, P579; DAVIS AP, IN PRESS DEVELOPMENT; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KOSTIC D, IN PRESS MECH DEV; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MARK M, 1993, DEVELOPMENT, V119, P319; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318	22	223	224	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 28	1994	370	6487					304	307		10.1038/370304a0	http://dx.doi.org/10.1038/370304a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	7913519				2022-12-28	WOS:A1994NZ22900067
J	PICKERING, TG				PICKERING, TG			BLOOD-PRESSURE MEASUREMENT AND DETECTION OF HYPERTENSION	LANCET			English	Article							WHITE COAT HYPERTENSION; PROGNOSTIC VALUE; HEART; POPULATION				PICKERING, TG (corresponding author), NEW YORK HOSP,CORNELL MED CTR,CTR HYPERTENS,525 E 68TH ST,NEW YORK,NY 10021, USA.							DUNNE FP, 1991, J AMBUL MONIT, V4, P275; FRATTOLA A, 1993, J HYPERTENS, V11, P1133, DOI 10.1097/00004872-199310000-00019; FREESTONE S, 1982, AM J MED, V73, P348, DOI 10.1016/0002-9343(82)90725-2; FRIEDMANN E, 1982, PSYCHOSOM MED, V44, P545, DOI 10.1097/00006842-198212000-00006; GOSSE P, 1993, HYPERTENSION, V22, P766, DOI 10.1161/01.HYP.22.5.766; HARSHFIELD GA, 1990, BLOOD PRESSURE MEASU, P241; HOEGHOLM A, 1993, AM J HYPERTENS, V6, P282, DOI 10.1093/ajh/6.4.282; IMAI Y, 1993, HYPERTENSION, V22, P900, DOI 10.1161/01.HYP.22.6.900; KENNEY MJ, 1993, HYPERTENSION, V22, P653, DOI 10.1161/01.HYP.22.5.653; LACOURCIERE Y, 1990, AM J CARDIOL, V65, P467, DOI 10.1016/0002-9149(90)90812-F; LIPSITZ LA, 1983, NEW ENGL J MED, V309, P81, DOI 10.1056/NEJM198307143090205; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANCIA G, 1983, CIRC RES, V53, P96, DOI 10.1161/01.RES.53.1.96; MANN SJ, 1991, JAMA-J AM MED ASSOC, V265, P2226, DOI 10.1001/jama.265.17.2226; MCKAY DW, 1990, J HUM HYPERTENS, V4, P639; MENARD J, 1988, HYPERTENSION, V11, P153, DOI 10.1161/01.HYP.11.2.153; MILLARCRAIG MW, 1978, LANCET, V1, P795; PEARCE KA, 1992, ARCH INTERN MED, V152, P750, DOI 10.1001/archinte.152.4.750; PERLOFF D, 1989, J HYPERTENS, V7, pS3; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PICKERING G, 1968, HIGH BLOOD PRESSURE; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1992, J HYPERTENS, V10, P401, DOI 10.1097/00004872-199205000-00001; PICKERING TG, 1989, J HYPERTENS, V7, pS65; Pickering TG., 1991, AMBULATORY MONITORIN; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; STAESSEN J, 1992, AM J HYPERTENS, V5, P386, DOI 10.1093/ajh/5.6.386; VANMONTFRANS GA, 1987, BRIT MED J, V295, P354, DOI 10.1136/bmj.295.6594.354; VEERMAN DP, 1993, J HYPERTENS, V11, P287, DOI 10.1097/00004872-199303000-00009; VERDECCHIA P, 1993, CIRCULATION, V88, P986, DOI 10.1161/01.CIR.88.3.986; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; WHITE WB, 1990, AM J CARDIOL, V65, P60, DOI 10.1016/0002-9149(90)90026-W; YELDERMAN M, 1979, ANESTHESIOLOGY, V50, P253, DOI 10.1097/00000542-197903000-00022; 1993, NIH931088 PUBL; 1993, ANN INTERN MED, V118, P889	35	114	116	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					31	35						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912303				2022-12-28	WOS:A1994NU91700016
J	ZOLLER, B; DAHLBACK, B				ZOLLER, B; DAHLBACK, B			LINKAGE BETWEEN INHERITED RESISTANCE TO ACTIVATED PROTEIN-C AND FACTOR-V GENE MUTATION IN VENOUS THROMBOSIS	LANCET			English	Note							POOR ANTICOAGULANT RESPONSE; THROMBOPHILIA; COFACTOR	Resistance to activated protein C (APC) is a major cause of familial thrombophilia, and can be corrected by an anticoagulant activity expressed by purified factor V. We investigated linkage between APC resistance and the factor V gene in a large kindred with familial thrombophilia. Restriction fragment length polymorphisms in exon 13 of the factor V gene were informative in 14 family members. The 100% linkage between factor V gene polymorphism and APC resistance strongly suggested a factor V gene mutation as a cause of APC resistance. A point mutation changing Arg(506) in the APC cleavage site to a Gin was found in APC resistant individuals. These results suggest factor V gene mutation to be the most common genetic cause of thrombophilia.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN	Lund University			Zöller, Bengt/H-8856-2012; Zöller, Bengt/M-3217-2019	Zöller, Bengt/0000-0002-8250-5613; Zöller, Bengt/0000-0002-8250-5613; Dahlback, Bjorn/0000-0003-1546-0328				DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; EWART AK, 1993, P NATL ACAD SCI USA, V90, P3226, DOI 10.1073/pnas.90.8.3226; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; GRIFFIN JH, 1993, BLOOD, V82, P1989; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; SHEN NLL, 1993, J IMMUNOL, V150, P2992; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; WANG H, 1988, GENOMICS, V2, P234	10	411	420	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1536	1538		10.1016/S0140-6736(94)92940-8	http://dx.doi.org/10.1016/S0140-6736(94)92940-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911873				2022-12-28	WOS:A1994NR32900010
J	KELLY, TJ; MARTIN, GS; FORSBURG, SL; STEPHEN, RJ; RUSSO, A; NURSE, P				KELLY, TJ; MARTIN, GS; FORSBURG, SL; STEPHEN, RJ; RUSSO, A; NURSE, P			THE FISSION YEAST CDC18+ GENE-PRODUCT COUPLES S-PHASE TO START AND MITOSIS	CELL			English	Article							CELL-DIVISION CYCLE; DNA-SYNTHESIS GENES; SCHIZOSACCHAROMYCES-POMBE ENCODES; CEREVISIAE CDC6 GENE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; DEPENDENT TRANSCRIPTION; REPLICATION GENES; NUCLEAR DIVISION; HO GENE	Commitment to the cell cycle in fission yeast requires the function of the cdc10+ transcriptional activator at START. The product of the cdc18+ gene is a major downstream target of cdc10+ and transcription of cdc18+ is activated by cdc10+ during passage through START. The cdc18+ function is required for entry into S phase. In addition, the product of the cdc18+ gene is part of the checkpoint control that prevents mitosis from occurring until S phase is completed. Thus, cdc18+ plays a key role in coupling S phase to START and mitosis.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	Johns Hopkins University; University of California System; University of California Berkeley	KELLY, TJ (corresponding author), UNIV OXFORD, DEPT BIOCHEM, IMPERIAL CANC RES FUND, CELL CYCLE GRP, OXFORD OX1 3QU, ENGLAND.			Forsburg, Susan L/0000-0002-4895-8598	NCI NIH HHS [CA17542, CA16519] Funding Source: Medline; NIGMS NIH HHS [GM44173] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519, R01CA017542, R37CA017542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GORDON CB, 1986, EMBO J, V5, P2981, DOI 10.1002/j.1460-2075.1986.tb04595.x; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; LISZIEWICZ J, 1988, NUCLEIC ACIDS RES, V16, P11507, DOI 10.1093/nar/16.24.11507; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MARKS J, 1992, J CELL SCI, V101, P517; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PALMER RE, 1990, GENETICS, V125, P763; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SAZER S, 1990, J CELL SCI, V97, P509; SIMANIS V, 1989, J CELL SCI, V92, P51; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; VERMA R, 1991, P NATL ACAD SCI USA, V88, P7155, DOI 10.1073/pnas.88.16.7155; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITE JHM, 1986, EMBO J, V5, P1705, DOI 10.1002/j.1460-2075.1986.tb04414.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZHOU C, 1989, J BIOL CHEM, V264, P9022	56	416	420	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 30	1993	74	2					371	382		10.1016/0092-8674(93)90427-R	http://dx.doi.org/10.1016/0092-8674(93)90427-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	7916658				2022-12-28	WOS:A1993LP72600017
J	SEDDON, JM; AJANI, UA; SPERDUTO, RD; HILLER, R; BLAIR, N; BURTON, TC; FARBER, MD; GRAGOUDAS, ES; HALLER, J; MILLER, DT; YANNUZZI, LA; WILLETT, W				SEDDON, JM; AJANI, UA; SPERDUTO, RD; HILLER, R; BLAIR, N; BURTON, TC; FARBER, MD; GRAGOUDAS, ES; HALLER, J; MILLER, DT; YANNUZZI, LA; WILLETT, W			DIETARY CAROTENOIDS, VITAMIN-A, VITAMIN-C, AND VITAMIN-E, AND ADVANCED AGE-RELATED MACULAR DEGENERATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE SMOKERS; RETINA; PLASMA; ASCORBATE; LIGHT; RATS	Objective.-To evaluate the relationships between dietary intake of carotenoids and vitamins A, C, and E and the risk of neovascular age-related macular degeneration (AMD), the leading cause of irreversible blindness among adults. Design.-The multicenter Eye Disease Case-Control Study. Setting.-Five ophthalmology centers in the United States. Patients.-A total of 356 case subjects who were diagnosed with the advanced stage of AMD within 1 year prior to their enrollment, aged 55 to 80 years, and residing near a participating clinical center. The 520 control subjects were from the same geographic areas as case subjects, had other ocular diseases, and were frequency-matched to cases according to age and sex. Main Outcome Measures.-The relative risk for AMD was estimated according to dietary indicators of antioxidant status, controlling for smoking and other risk factors, by using multiple logistic-regression analyses. Results.-A higher dietary intake of carotenoids was associated with a lower risk for AMD. Adjusting for other risk factors for AMD, we found that those in the highest quintile of carotenoid intake had a 43% lower risk for AMD compared with those in the lowest quintile (odds ratio, 0.57; 95% confidence interval, 0.35 to 0.92; P for trend=.02). Among the specific carotenoids, lutein and zeaxanthin, which are primarily obtained from dark green, leafy vegetables, were most strongly associated with a reduced risk for AMD (P for trend=.001). Several food items rich in carotenoids were inversely associated with AMD. In particular, a higher frequency of intake of spinach or collard greens was associated with a substantially lower risk for AMD (P for trend<.001). The intake of preformed vitamin A (retinol) was not appreciably related to AMD. Neither vitamin E nor total vitamin C consumption was associated with a statistically significant reduced risk for AMD, although a possibly lower risk for AMD was suggested among those with higher intake of vitamin C, particularly from foods. Conclusion.-Increasing the consumption of foods rich in certain carotenoids, in particular dark green, leafy vegetables, may decrease the risk of developing advanced or exudative AMD, the most visually disabling form of macular degeneration among older people. These findings support the need for further studies of this relationship.	MASSACHUSETTS EYE & EAR INFIRM,RETINA SERV,BOSTON,MA 02114; MASSACHUSETTS EYE & EAR INFIRM,DEPT OPHTHALMOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; NEI,BETHESDA,MD 20892; UNIV ILLINOIS,DEPT OPHTHALMOL,CHICAGO,IL 60680; MED COLL WISCONSIN,DEPT OPHTHALMOL,MILWAUKEE,WI 53226; WILMER EYE INST,BALTIMORE,MD; CTR DIS CONTROL & PREVENT,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30341; MANHATTAN EYE EAR & THROAT HOSP,NEW YORK,NY 10021; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical College of Wisconsin; Johns Hopkins University; Johns Hopkins Medicine; Centers for Disease Control & Prevention - USA; Manhattan Eye Ear & Throat Hospital; Harvard University; Brigham & Women's Hospital	SEDDON, JM (corresponding author), MASSACHUSETTS EYE & EAR INFIRM,EPIDEMIOL UNIT,243 CHARLES ST,BOSTON,MA 02114, USA.				NEI NIH HHS [EY09972] Funding Source: Medline; NATIONAL EYE INSTITUTE [R03EY009972] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AJANI UA, 1994, INVEST OPHTH VIS SCI, V35, P2725; BLACKMAN BC, 1984, ANN NY ACAD SCI, V435, P385, DOI 10.1111/j.1749-6632.1984.tb13828.x; BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V96, P552; CHOW CK, 1986, J AM COLL NUTR, V5, P305; Foote C.S, 1976, FREE RADICALS BIOL, P85, DOI DOI 10.1016/B978-0-12-566502-5.50010-X; GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023; HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198; Handelman Garry J., 1992, V213, P220; HAYES KC, 1974, INVEST OPHTH VISUAL, V13, P499; KATZ ML, 1982, EXP EYE RES, V34, P339, DOI 10.1016/0014-4835(82)90082-3; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3; MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3; NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192; ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580; SCHALCH W, 1992, FREE RADICALS AGING, P280; SEDDON JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P176, DOI 10.1001/archopht.1994.01090140052021; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; TSO MOM, 1984, CURR EYE RES, V3, P181, DOI 10.3109/02713688408997200; WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031; WILL, 1992, UII, V110, P1701; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9; 1984, NIH832471 US DEP HLT; 1993, ARCH OPHTHALMOL-CHIC, V111, P104	27	1094	1178	2	142	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	1994	272	18					1413	1420		10.1001/jama.272.18.1413	http://dx.doi.org/10.1001/jama.272.18.1413			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP690	7933422				2022-12-28	WOS:A1994PP69000028
J	MARIK, PE; MOHEDIN, M				MARIK, PE; MOHEDIN, M			THE CONTRASTING EFFECTS OF DOPAMINE AND NOREPINEPHRINE ON SYSTEMIC AND SPLANCHNIC OXYGEN UTILIZATION IN HYPERDYNAMIC SEPSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN SEPTIC SHOCK; SURGICAL PATIENTS; INTRAMURAL PH; HEMODYNAMICS; CONSUMPTION; VOLUNTEERS; VALIDATION; TRANSPORT; THERAPY; LACTATE	Objective.-To compare the effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in patients with hyperdynamic sepsis. Design.-A randomized short-term, interventional study. Setting.-An intensive care unit of a university hospital. Patients.-Twenty septic patients with a cardiac index greater than 3.2 L.min(-1).m(-2) and either a mean arterial pressure (MAP) less than 60 mm Hg or a systemic vascular resistance index less than 1200 dyne.s.cm(-5).m(-2). Methods and Interventions.-Patients were randomized to receive an infusion of either dopamine or norepinephrine titrated to increase the MAP to greater than 75 mm Hg. The hemodynamic profile, oxygen delivery, oxygen consumption (determined by indirect calorimetry), and gastric intramucosal pH (pHi) (determined by gastric tonometry) were determined at baseline and after 3 hours of achieving the target MAP. Results.-Dopamine increased the MAP largely by increasing the cardiac index whereas norepinephrine increased the MAP by increasing the systemic vascular resistance index while maintaining the cardiac index. Although oxygen delivery and oxygen consumption increased in both groups of patients, the pHi increased significantly in those patients treated with norepinephrine whereas the pHi decreased significantly in those patients receiving dopamine (P<.001, for corrected 3-hour value). Conclusions.-This study suggests that dopamine may cause an uncompensated increase in splanchnic oxygen requirements in septic patients. Norepinephrine, however, may have a more favorable hemodynamic profile and improve splanchnic tissue oxygen utilization in sepsis.	DETROIT RECEIVING HOSP & UNIV HLTH CTR,DIV CRIT CARE MED,DETROIT,MI; WAYNE STATE UNIV,DETROIT,MI 48202	Detroit Receiving Hospital & University Health Center; Wayne State University			Marik, Paul E/U-9733-2019					ANTONSSON JB, 1990, AM J PHYSIOL, V259, pG519, DOI 10.1152/ajpgi.1990.259.4.G519; BARTLETT RH, 1990, J CRIT CARE, V5, P77, DOI 10.1016/0883-9441(90)90051-A; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; COWAN BN, 1984, ANAESTHESIA, V39, P750, DOI 10.1111/j.1365-2044.1984.tb06516.x; DESJARS P, 1987, CRIT CARE MED, V15, P134, DOI 10.1097/00003246-198702000-00011; DESJARS P, 1989, CRIT CARE MED, V17, P426, DOI 10.1097/00003246-198905000-00010; ENSINGER H, 1993, CRIT CARE MED, V21, P1502, DOI 10.1097/00003246-199310000-00018; GIRAUD GD, 1984, J PHARMACOL EXP THER, V30, P214; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUCAS CE, 1994, CHEST, V105, P7, DOI 10.1378/chest.105.1.7; MARSHALL JC, 1988, ARCH SURG-CHICAGO, V123, P309; MARTIN C, 1993, CHEST, V103, P1826, DOI 10.1378/chest.103.6.1826; MIZOCK BA, 1992, CRIT CARE MED, V20, P80, DOI 10.1097/00003246-199201000-00020; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; PARILLO J E, 1990, Annals of Internal Medicine, V113, P227; PARKER MM, 1983, JAMA-J AM MED ASSOC, V250, P3324, DOI 10.1001/jama.250.24.3324; RONCO JJ, 1991, J CRIT CARE, V6, P36, DOI 10.1016/0883-9441(91)90031-N; ROSENBERG JC, 1968, SURG GYNECOL OBSTETR, V126, P1247; RUOKONEN E, 1993, CRIT CARE MED, V21, P1296; SCHREUDER WO, 1989, CHEST, V95, P1282, DOI 10.1378/chest.95.6.1282; SEGAL JM, 1992, J APPL PHYSIOL, V73, P1159, DOI 10.1152/jappl.1992.73.3.1159; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1989, CHEST, V96, P120, DOI 10.1378/chest.96.1.120; SIBBALD WJ, 1991, CHEST, V100, pS155, DOI 10.1378/chest.100.3.155S; THIJS LG, 1988, INTENSIVE CRIT CARE, V7, P9; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; UUSARO A, 1994, CRIT CARE MED, V22, pA70; VITEK V, 1971, ANN SURG, V173, P308, DOI 10.1097/00000658-197102000-00021; 1990, MMWR-MORBID MORTAL W, V39, P31	30	255	275	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1354	1357		10.1001/jama.272.17.1354	http://dx.doi.org/10.1001/jama.272.17.1354			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933396				2022-12-28	WOS:A1994PP02000030
J	STURDEE, DW; BARLOW, DH; ULRICH, LG; WELLS, M; GYDESEN, H; CAMPBELL, M; OBRIEN, K; VESSEY, M				STURDEE, DW; BARLOW, DH; ULRICH, LG; WELLS, M; GYDESEN, H; CAMPBELL, M; OBRIEN, K; VESSEY, M			IS THE TIMING OF WITHDRAWAL BLEEDING A GUIDE TO ENDOMETRIAL SAFETY DURING SEQUENTIAL ESTROGEN-PROGESTAGEN REPLACEMENT THERAPY	LANCET			English	Article							POST-MENOPAUSAL ENDOMETRIUM; POSTMENOPAUSAL WOMEN; LONG-TERM; ESTROGENS; PROGESTOGENS; HYPERPLASIA; MORPHOLOGY; DISEASE; CANCER; RISK	Current regimens of sequential hormone replacement therapy are based on data that show a protective effect on the endometrium of at least 10 days of progestagen. In clinical practice, onset of bleeding on or after day 11 of the progestagen phase is taken as reassurance of a normal endometrium. 413 postmenopausal women taking oestrogen-progestagen hormone replacement thera py with 10 or 12 days of progestagen per cycle completed bleeding diaries for 3 months before endometrial biopsy. For most women, bleeding started around the 13th day after starting progestagen. There was no correlation between endometrial histology and timing of onset of bleeding. 11 (2.7%) women had complex endometrial hyperplasia. The presence of hyperplasia was 2.4% with onset of bleeding after 10 days of progestagen and 2.8% after 12 days. The timing of onset of withdrawal bleeding during oestrogen-progestagen HRT does not predict endometrial hyperplasia.	UNIV OXFORD,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD,ENGLAND; NOVO NORDISK AS,DIV PHARMACEUT,BAGSVAERD,DENMARK; ST JAMESS UNIV HOSP,DEPT PATHOL,LEEDS,W YORKSHIRE,ENGLAND; UNIV SOUTHAMPTON,DEPT MED STAT,SOUTHAMPTON,HANTS,ENGLAND; NOVO NORDISK PHARMACEUT LTD,CRAWLEY,W SUSSEX,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND	University of Oxford; Novo Nordisk; Saint James's University Hospital; University of Leeds; University of Southampton; Novo Nordisk; University of Oxford	STURDEE, DW (corresponding author), SOLIHULL HOSP,LODE LANE,SOLIHULL B91 2JL,W MIDLANDS,ENGLAND.		Sturdee, David/ABF-9792-2020; Barlow, David/F-8738-2011; Campbell, Michael J/I-4253-2014	Campbell, Michael J/0000-0003-3529-2739				ARCHER DF, 1991, AM J OBSTET GYNECOL, V165, P317, DOI 10.1016/0002-9378(91)90084-5; FERENCZY A, 1989, AM J OBSTET GYNECOL, V160, P126, DOI 10.1016/0002-9378(89)90103-8; GAMBRELL RD, 1974, J AM GERIATR SOC, V22, P337, DOI 10.1111/j.1532-5415.1974.tb04838.x; GAMBRELL RD, 1988, MENOPAUSE, P247; GREENBLATT RB, 1965, NEW ENGL J MED, V272, P305, DOI 10.1056/NEJM196502112720608; KOSS LG, 1984, OBSTET GYNECOL, V64, P1; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; NORRIS HJ, 1986, CLIN OBSTET GYNAECOL, V13, P725; PADWICK ML, 1986, NEW ENGL J MED, V315, P930, DOI 10.1056/NEJM198610093151504; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; SCHIFF I, 1982, FERTIL STERIL, V37, P79; STURDEE DW, 1978, BRIT MED J, V1, P1575, DOI 10.1136/bmj.1.6127.1575; THOM MH, 1979, LANCET, V2, P455; TREVOUX R, 1986, MATURITAS, V8, P309, DOI 10.1016/0378-5122(86)90039-3; VARMA TR, 1985, ACTA OBSTET GYN SCAN, V64, P41, DOI 10.3109/00016348509154686; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WHITEHEAD MI, 1978, MATURITAS, V1, P87, DOI 10.1016/0378-5122(78)90015-4; WILSON RA, 1962, JAMA-J AM MED ASSOC, V182, P327, DOI 10.1001/jama.1962.03050430001001	20	69	71	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					979	982		10.1016/S0140-6736(94)91640-3	http://dx.doi.org/10.1016/S0140-6736(94)91640-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934429				2022-12-28	WOS:A1994PK97800008
J	HUANG, YY; LI, XC; KANDEL, ER				HUANG, YY; LI, XC; KANDEL, ER			CAMP CONTRIBUTES TO MESSY FIBER LTP BY INITIATING BOTH A COVALENTLY MEDIATED EARLY PHASE AND MACROMOLECULAR SYNTHESIS-DEPENDENT LATE-PHASE	CELL			English	Article							LONG-TERM POTENTIATION; APLYSIA SENSORY NEURONS; PROTEIN-KINASE; BEHAVIORAL SENSITIZATION; TRANSMITTER RELEASE; WITHDRAWAL REFLEX; GILL-WITHDRAWAL; MUTANT MICE; MEMORY; FACILITATION	Memory storage has a short-term phase that depends on preexisting proteins and a long-term phase that requires new protein and RNA synthesis. Hippocampal long-term potentiation (LTP) is thought to contribute to memory storage. Consistent with this idea, a cellular representation of these phases has been demonstrated in NMDA receptor-dependent LTP. By contrast, little is known a bout the NMDA receptor-independent LTP of the messy fiber pathway. We find that messy fiber LTP also has phases. Only late phase is blocked by protein and RNA synthesis inhibitors, but both phases are blocked by inhibitors of cAMP-dependent protein kinase, and both are stimulated by forskolin and Sp-cAMPS. During early phase, paired-pulse facilitation is occluded. This occlusion decays with the onset of late phase, consistent with its using a different mechanism. Thus, although Schaffer collateral and mossy fiber pathways use very different mechanisms for early phase, both use a cAMP-mediated mechanism far late phase.			HUANG, YY (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.				NIGMS NIH HHS [GM32099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; Amaral D G, 1993, Curr Opin Neurobiol, V3, P225, DOI 10.1016/0959-4388(93)90214-J; ANDERSEN P, 1971, EXP BRAIN RES, V13, P222; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; BYRNE JH, 1987, PHYSIOL REV, V67, P329, DOI 10.1152/physrev.1987.67.2.329; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; CASTELLUCCI V, 1976, SCIENCE, V194, P1176, DOI 10.1126/science.11560; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CROW T, 1990, P NATL ACAD SCI USA, V87, P4490, DOI 10.1073/pnas.87.12.4490; DALE N, 1987, J NEUROSCI, V7, P2232; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Hawkins RD, 1987, HDB PHYSL 1, VV, P25; Huang Y Y, 1994, Learn Mem, V1, P74; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; LATHORN TH, 1984, BRAIN RES, V290, P174; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; MILNER B, 1985, WE KNOW; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; NAZIF FA, 1991, BRAIN RES, V539, P324, DOI 10.1016/0006-8993(91)91638-H; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; OTANI S, 1992, NEUROSCIENCE, V47, P265, DOI 10.1016/0306-4522(92)90242-T; POLSTER MR, 1991, J COGNITIVE NEUROSCI, V3, P95, DOI 10.1162/jocn.1991.3.2.95; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SMELLIE FW, 1979, LIFE SCI, V24, P2475, DOI 10.1016/0024-3205(79)90458-2; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TULLY T, 1994, CELL, V7, P35; YIN JC, 1994, CELL, V7, P49; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950; ZUCKER RS, 1973, J PHYSIOL-LONDON, V229, P787, DOI 10.1113/jphysiol.1973.sp010167	52	432	438	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					69	79		10.1016/0092-8674(94)90401-4	http://dx.doi.org/10.1016/0092-8674(94)90401-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923379				2022-12-28	WOS:A1994PK58500009
J	OLSON, EN; ROSENTHAL, N				OLSON, EN; ROSENTHAL, N			HOMEOBOX GENES AND MUSCLE PATTERNING	CELL			English	Review							MYOGENIC LINEAGES; DIFFERENTIATION; EXPRESSION; MOUSE; NOTOCHORD; LIMB		MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital	OLSON, EN (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030, USA.			Rosenthal, Nadia/0000-0002-7599-7365				BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; BOBER E, 1994, DEVELOPMENT, V120, P603; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; GOULDING M, 1994, DEVELOPMENT, V120, P957; GREIG S, 1993, NATURE, V362, P630, DOI 10.1038/362630a0; GRIESHAMMER U, 1992, CELL, V69, P79, DOI 10.1016/0092-8674(92)90120-2; LEVI G, 1993, MECH DEVELOP, V43, P111, DOI 10.1016/0925-4773(93)90029-W; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MICHELSON AM, 1994, DEVELOPMENT, V120, P755; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; RONG PM, 1992, DEVELOPMENT, V115, P657; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	22	37	37	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					9	12		10.1016/0092-8674(94)90395-6	http://dx.doi.org/10.1016/0092-8674(94)90395-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923381				2022-12-28	WOS:A1994PK58500003
J	SCULPHER, MJ; SEED, P; HENDERSON, RA; BUXTON, MJ; POCOCK, SJ; PARKER, J; JOY, MD; SOWTON, E; HAMPTON, JR				SCULPHER, MJ; SEED, P; HENDERSON, RA; BUXTON, MJ; POCOCK, SJ; PARKER, J; JOY, MD; SOWTON, E; HAMPTON, JR			HEALTH-SERVICE COSTS OF CORONARY ANGIOPLASTY AND CORONARY-ARTERY BYPASS-SURGERY - THE RANDOMIZED INTERVENTION TREATMENT OF ANGINA (RITA) TRIAL	LANCET			English	Article							DISEASE	For some patients with coronary artery disease, percutaneous transluminal coronary angioplasty (PTCA) is an alternative to coronary artery bypass grafting (CABG). We report comparative health service costs of these interventions within the Randomised intervention Treatment of Angina (RITA) trial. Medications were costed at published UK prices; other resource use was costed with a set of unit costs estimated at two recruiting centres to the RITA trial, one in London and one outside. Over 2-year follow-up of 1011 patients, the estimated mean additional cost for those randomised to CABG compared with PTCA was pound 1050 (95% Cl pound 621-pound 1479),with unit costs from the non-London centre, and pound 1823 (pound 1202-pound 2444), with unit costs from the London centre. The initial average cost of treating a patient randomised to PTCA is about 52% of that of CABG, but after 2 years this increased to about 80% because of the greater need for subsequent interventions. The balance of advantage between PTCA and CABG may change after several years: funding has been obtained to continue RITA follow-up for 10 years. However, on the basis of patients' status at 2 years, the cost advantages of PTCA cannot be ignored. Further research is necessary to assess whether the advantage of PTCA in terms of cost is translated into one of cost-effectiveness.	BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND; LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON,ENGLAND; WYTHENSHAWE HOSP,DEPT CARDIOL,MANCHESTER M23 9LT,LANCS,ENGLAND; ST GEORGE HOSP,DEPT CARDIOTHORAC SURG,LONDON,ENGLAND; ST PETERS HOSP,DEPT CARDIOL,CHERTSEY,SURREY,ENGLAND; GUYS HOSP,DEPT CARDIOL,LONDON SE1 9RT,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT CARDIOVASC MED,NOTTINGHAM,ENGLAND	Brunel University; University of London; London School of Hygiene & Tropical Medicine; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; St Georges University London; Guy's & St Thomas' NHS Foundation Trust; University of Nottingham			Seed, Paul T/C-4435-2008	Seed, Paul T/0000-0001-7904-7933; Sculpher, Mark/0000-0003-3746-9913				BERREKLOUW E, 1989, EUR HEART J, V10, P61, DOI 10.1093/eurheartj/10.suppl_H.61; BLACK AJR, 1988, AM J CARDIOL, V62, P809, DOI 10.1016/0002-9149(88)91228-3; COHEN DJ, 1993, J AM COLL CARDIOL, V22, P1052, DOI 10.1016/0735-1097(93)90415-W; Drummond M, 1993, Int J Technol Assess Health Care, V9, P26; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HAMM CW, 1992, CIRCULATION S1, V82, P373; HENDERSON RA, 1989, BRIT HEART J, V62, P411; HUBNER PJ, 1992, BRIT HEART J, V68, P436; JANG C, 1984, AM J CARDIOL, V52, P52; KELLY ME, 1985, J AM COLL CARDIOL, V5, P16, DOI 10.1016/S0735-1097(85)80079-6; REEDER GS, 1984, NEW ENGL J MED, V311, P1157, DOI 10.1056/NEJM198411013111805; Torrance GW, 1987, METHODS EC EVALUATIO; VANDENBRAND M, 1990, EUR HEART J, V11, P765; WEINTRAUB WS, 1990, AM J CARDIOL, V65, P183, DOI 10.1016/0002-9149(90)90082-C; WITTELS EH, 1990, AM J CARDIOL, V65, P432, DOI 10.1016/0002-9149(90)90806-C; 1991, EC APPRAISAL CENTRAL; 1993, BRIT NATIONAL FORMUL; 1993, LANCET, V341, P573; 1992, ASSESSING EFFECTS HL	19	75	75	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					927	930		10.1016/S0140-6736(94)92274-8	http://dx.doi.org/10.1016/S0140-6736(94)92274-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934351				2022-12-28	WOS:A1994PJ28700015
J	FENWICK, JC; CAMERON, M; NAIMAN, SC; HALEY, LP; RONCO, JJ; WIGGS, BR; TWEEDDALE, MG				FENWICK, JC; CAMERON, M; NAIMAN, SC; HALEY, LP; RONCO, JJ; WIGGS, BR; TWEEDDALE, MG			BLOOD-TRANSFUSION AS A CAUSE OF LEUKOCYTOSIS IN CRITICALLY ILL PATIENTS	LANCET			English	Note								The diagnosis of infection in the intensive care unit is confounded by the presence of non-infectious causes of leucocytosis. Unless such causes are recognised, time and effort will be spent on unnecessary investigations and treatments. In a prospective study we have shown that the transfusion of blood frequently (45/50 patients) causes an acute leucocytosis in such patients. This effect was not seen in 8 patients who received plasma. Blood transfusion should be added to the list of non-infectious causes of leucocytosis in the critically ill.	UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DIV HEMATOPATHOL,VANCOUVER V5Z 1M9,BC,CANADA; UNIV BRITISH COLUMBIA,ST PAULS HOSP,VANCOUVER,BC,CANADA	University of British Columbia; St. Paul's Hospital; University of British Columbia; University of Saskatchewan	FENWICK, JC (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,INTENS CARE UNIT,PROGRAM CRIT CARE MED,ROOM 2438,VANCOUVER V5Z 1M9,BC,CANADA.							Crowder M.J., 1990, ANAL REPEATED MEASUR; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE RG, 1993, WINTROBES CLIN HEMAT; MAYNE E E, 1970, Acta Haematologica (Basel), V44, P155; MUIR AL, 1984, J APPL PHYSIOL, V57, P711, DOI 10.1152/jappl.1984.57.3.711; 1992, CHEST, V101, P1644	6	26	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					855	856		10.1016/S0140-6736(94)92828-2	http://dx.doi.org/10.1016/S0140-6736(94)92828-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916402				2022-12-28	WOS:A1994PH25300012
J	MCNAMEE, D				MCNAMEE, D			FREE-RADICALS - TRICK OR TREAT	LANCET			English	Editorial Material																		HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X	1	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					702	702		10.1016/S0140-6736(94)92204-7	http://dx.doi.org/10.1016/S0140-6736(94)92204-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915772				2022-12-28	WOS:A1994PF18700006
J	COLLINS, CD; GREEN, AT; HUNTER, DJ				COLLINS, CD; GREEN, AT; HUNTER, DJ			INTERNATIONAL TRANSFERS OF NATIONAL-HEALTH-SERVICE REFORMS - PROBLEMS AND ISSUES	LANCET			English	Editorial Material								Recent market-style reforms in the UK National Health Service (NHS) have attracted the attention of health care professionals, managers, and policy-makers from many developing and central and eastern European countries. This article asks how NHS managers and health professionals should react to such international interest. Six key issues have to be considered when introducing market-style reforms into developing and eastern European countries. First, health sector reform should be formulated on the basis of sound research and evidence. We should also take particular care in understanding how efficiency contributes to health policy objectives and the extent to which private management practices are appropriate to the public sector. We should also question the value of international technology transfer and evaluate the experiences of health sector reform in other countries. Last we should look at the way in which health sector reform is formulated and implemented. Here we highlight important questions about the suitability of replicating the UK experience in other countries.			COLLINS, CD (corresponding author), UNIV LEEDS,NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND.							[Anonymous], 1993, WORLD BANK DEV REPOR; Collins C, 1994, J Manag Med, V8, P42, DOI 10.1108/02689239410059633; GREEN A, 1992, INTRO HLTH PLANNING; HUNTER DJ, 1994, GUARDIAN        0309; MILLS A, 1990, HLTH SYSTEMS DECENTR; RIFKIN SB, 1986, SOC SCI MED, V23, P559, DOI 10.1016/0277-9536(86)90149-8; STEWART J, 1992, PUBLIC ADMIN, V70, P499, DOI 10.1111/j.1467-9299.1992.tb00952.x	7	10	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					248	250		10.1016/S0140-6736(94)93006-6	http://dx.doi.org/10.1016/S0140-6736(94)93006-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NY060	7913165				2022-12-28	WOS:A1994NY06000018
J	MCCLURE, N; HEALY, DL; ROGERS, PAW; SULLIVAN, J; BEATON, L; HANING, RV; CONNOLLY, DT; ROBERTSON, DM				MCCLURE, N; HEALY, DL; ROGERS, PAW; SULLIVAN, J; BEATON, L; HANING, RV; CONNOLLY, DT; ROBERTSON, DM			VASCULAR ENDOTHELIAL GROWTH-FACTOR AS CAPILLARY-PERMEABILITY AGENT IN OVARIAN HYPERSTIMULATION SYNDROME	LANCET			English	Note								We investigated the role of vascular endothelial growth factor (VEGF) in ovarian hyperstimulation syndrome (OHSS). Two similar peaks of permeability activity were seen in OHSS ascites and liver ascites spiked with recombinant human VEGF (rhVEGF); no activity was seen in control liver ascites. Incubation with rhVEGF antiserum decreased activity in the two OHSS peaks by 79% and 65% and the two spiked liver peaks by 49% and 50%. Control serum produced 24% and 27%, and 17% and 0% reductions, respectively, This is evidence that the major capillary permeability agent in OHSS ascites fluid is VEGF.	MONASH UNIV,DEPT OBSTET & GYNAECOL,CLAYTON,VIC 3168,AUSTRALIA; MONASH MED CTR,PRINCE HENRYS INST MED RES,CLAYTON,VIC 3168,AUSTRALIA; BROWN UNIV,WOMEN & INFANTS HOSP,DEPT OBSTET & GYNECOL,PROVIDENCE,RI; MONSANTO CO,HLTH SCI,ST LOUIS,MO	Monash University; Monash University; Prince Henry's Institute of Medical Research; Brown University; Women & Infants Hospital Rhode Island; Monsanto			Rogers, Peter AW/C-2651-2008	Rogers, Peter AW/0000-0002-7399-8997				Basset DL, 1943, AM J ANAT, V73, P251, DOI 10.1002/aja.1000730206; CAVENDER JL, 1988, BIOL REPROD, V39, P989, DOI 10.1095/biolreprod39.4.989; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; MCCLURE N, 1992, HUM REPROD, V7, P758, DOI 10.1093/oxfordjournals.humrep.a137733; MCCLURE N, IN PRESS J PHARM TOX; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; RAVINDRANATH N, 1992, ENDOCRINOLOGY, V131, P254, DOI 10.1210/en.131.1.254; 1991, LANCET, V338, P1111	8	305	318	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					235	236		10.1016/S0140-6736(94)93001-5	http://dx.doi.org/10.1016/S0140-6736(94)93001-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913160				2022-12-28	WOS:A1994NY06000013
J	ILLINGWORTH, DR; ERKELENS, DW; KELLER, U; THOMPSON, GR; TIKKANEN, MJ				ILLINGWORTH, DR; ERKELENS, DW; KELLER, U; THOMPSON, GR; TIKKANEN, MJ			DEFINED DAILY DOSES IN RELATION TO HYPOLIPEMIC EFFICACY OF LOVASTATIN, PRAVASTATIN, AND SIMVASTATIN	LANCET			English	Editorial Material							HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; SHORT-TERM EFFICACY; CHOLESTYRAMINE; TOLERABILITY; MANAGEMENT; MEVINOLIN		UNIV UTRECHT HOSP, DEPT ENDOCRINOL, UTRECHT, NETHERLANDS; KANTONSSPITAL, DEPT INTERNAL MED, CH-4031 BASEL, SWITZERLAND; HAMMERSMITH HOSP, MRC, LIPOPROT TEAM, LONDON W12 0HS, ENGLAND; UNIV HELSINKI HOSP, DEPT INTERNAL MED, HELSINKI, FINLAND	Utrecht University; Utrecht University Medical Center; Kantonsspital Aarau AG (KSA); University of Basel; Imperial College London; University of Helsinki; Helsinki University Central Hospital	ILLINGWORTH, DR (corresponding author), OREGON HLTH SCI UNIV, DEPT MED L465, DIV ENDOCRINOL DIABET CLIN NUTR, PORTLAND, OR 97201 USA.							BETTERIDGE DJ, 1992, BRIT MED J, V304, P1335, DOI 10.1136/bmj.304.6838.1335; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; DOUSTEBLAZY P, 1993, DRUG INVEST, V6, P353, DOI 10.1007/BF03259612; FARMER JA, 1992, CLIN THER, V14, P708; FROHLICH J, 1993, CAN J CARDIOL, V9, P405; HAVEL RJ, 1987, ANN INTERN MED, V107, P609, DOI 10.7326/0003-4819-107-5-609; ILLINGWORTH DR, 1992, ATHEROSCLEROSIS, V96, P53, DOI 10.1016/0021-9150(92)90037-H; ILLINGWORTH DR, 1984, J CLIN INVEST, V74, P1972, DOI 10.1172/JCI111618; LAMBRECHT LJ, 1993, ACTA CARDIOL, V48, P541; MCPHERSON R, 1992, CLIN THER, V14, P276; MITCHEL YB, 1993, AM J CARDIOL, V71, P810; MOL MJTM, 1986, LANCET, V2, P936; PAN HY, 1991, CLIN THER, V13, P368; SWEANY AE, 1993, AM J CARDIOL, V71, P1408; WIKLUND O, 1990, J INTERN MED, V228, P241, DOI 10.1111/j.1365-2796.1990.tb00225.x; IN PRESS CARDIOLOGY; 1994, ANATOMICAL THERAPEUT, P14	17	83	83	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	1994	343	8912					1554	1555		10.1016/S0140-6736(94)92945-9	http://dx.doi.org/10.1016/S0140-6736(94)92945-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911877				2022-12-28	WOS:A1994NR32900015
J	BROOKSGUNN, J; MCCARTON, CM; CASEY, PH; MCCORMICK, MC; BAUER, CR; BERNBAUM, JC; TYSON, J; SWANSON, M; BENNETT, FC; SCOTT, DT; TONASCIA, J; MEINERT, CL				BROOKSGUNN, J; MCCARTON, CM; CASEY, PH; MCCORMICK, MC; BAUER, CR; BERNBAUM, JC; TYSON, J; SWANSON, M; BENNETT, FC; SCOTT, DT; TONASCIA, J; MEINERT, CL			EARLY INTERVENTION IN LOW-BIRTH-WEIGHT PREMATURE-INFANTS - RESULTS THROUGH AGE 5 YEARS FROM THE INFANT HEALTH AND DEVELOPMENT PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY-CHILDHOOD INTERVENTION; PRESCHOOL PROGRAMS; PRETERM INFANTS; CHILDREN; TRIAL; RISK; CARE	Objective.-To evaluate the persistence of effects on health and development at age 5 years of the Infant Health and Development Program, an early childhood intervention that was provided to low-birth-weight (LBW) premature infants from neonatal discharge through age 3 years. Design.-Randomized, controlled, multicenter trial, stratified by two LBW groups: lighter (less than or equal to 2000 g) and heavier (2001 to 2500 g). Setting.-Eight socioeconomically heterogeneous clinical sites. Participants.-Of 985 eligible infants weighing 2500 g or less and at 37 weeks' or less gestational age, 377 infants were randomly assigned to the intervention group and 608 to the follow-up only group. About two thirds of the infants in each group were in the lighter LBW stratum, and one third were in the heavier LBW stratum. Intervention.-The intervention group received home visits (from neonatal discharge through age 3 years) as well as center-based schooling (from 1 to 3 years of age). Children in both groups received pediatric surveillance. Main Outcome Measures.-Cognitive development, behavioral competence, and health status. Results.-At age 5 years, the intervention group had full-scale IQ scores similar to children in the follow-up only group. However, in the heavier LBW stratum, children in the intervention group had higher full-scale IQ scores (3.7 points higher; P=.03) and higher verbal IQ scores (4.2 points higher; P=.02). No significant differences between intervention and follow-up only groups in cognitive measures at age 5 years were noted in the lighter LBW infants. The intervention and follow-up groups were similar in behavior and health measures regardless of LBW stratum. Conclusion.-The early childhood intervention provided in the first 3 years of life had effects on heavier LBW premature infants' IQ and verbal performance at age 5 years that were not observed for lighter LBW premature infants. The intervention did not affect health or behavior at age 5 years in either LBW stratum.	ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10467; UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT,LITTLE ROCK,AR 72205; HARVARD UNIV,SCH PUBL HLTH,DEPT MATERNAL & CHILD HLTH,BOSTON,MA 02115; UNIV MIAMI,SCH MED,DEPT PEDIAT,MIAMI,FL; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104; UNIV TEXAS,HLTH SCI CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; YALE UNIV,DEPT PEDIAT,NEW HAVEN,CT 06520; JOHNS HOPKINS UNIV,DEPT PEDIAT,BALTIMORE,MD 21218	Yeshiva University; Albert Einstein College of Medicine; University of Arkansas System; University of Arkansas Medical Sciences; Harvard University; Harvard T.H. Chan School of Public Health; University of Miami; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Texas System; University of Texas Dallas; University of Washington; University of Washington Seattle; Yale University; Johns Hopkins University	BROOKSGUNN, J (corresponding author), COLUMBIA UNIV,TEACHERS COLL,CTR CHILDREN & FAMILIES,NEW YORK,NY 10027, USA.			McCormmick, Marie/0000-0002-3938-1707	PHS HHS [MCJ-360593-01-02-0] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHENBACH TM, 1987, J ABNORM CHILD PSYCH, V15, P629, DOI 10.1007/BF00917246; ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Baker P. C., 1989, NLSY CHILD HDB 1989; BAYDAR N, 1993, CHILD DEV, V64, P815; Benasich A. A., 1992, J APPL DEV PSYCHOL, V13, P311, DOI 10.1016/0193-3973(92)90035-G; BENNETT FC, 1987, EFFECTIVENESS EARLY, P79; Bloom B. S., 1964, STABILITY CHANGE HUM; Broman S. H., 1975, PRESCHOOL IQ PRENATA; BROOKSGUNN J, 1990, IMPROVING THE LIFE CHANCES OF CHILDREN AT RISK, P125; BROOKSGUNN J, 1993, CHILD DEV, V64, P736, DOI 10.2307/1131215; BROOKSGUNN J, 1992, J PEDIATR-US, V120, P350, DOI 10.1016/S0022-3476(05)80896-0; CLARKESTEWART KA, 1983, HDB CHILD PSYCHOL, V4, P918; COHEN J, 1977, STATISTICAL POWER AN; CONSTANTINE NA, 1987, J PEDIATR-US, V110, P921, DOI 10.1016/S0022-3476(87)80416-X; CONSTANTINE WL, 1993, J DEV BEHAV PEDIATR, V14, P1; DARLINGTON RB, 1980, SCIENCE, V208, P202, DOI 10.1126/science.208.4440.202; Dunn L.M., 2007, PEABODY PICTURE VOCA; Hayes C, 1990, WHO CARES AM CHILDRE; HUNT JM, 1961, ENV EXPERIENCES; KLEIN NK, 1989, J DEV BEHAV PEDIATR, V10, P32; KOPP CB, 1989, AM PSYCHOL, V44, P224, DOI 10.1037/0003-066X.44.2.224; KRAEMER HC, 1990, J CLIN EPIDEMIOL, V43, P1157, DOI 10.1016/0895-4356(90)90017-J; LEE VE, 1990, CHILD DEV, V61, P495, DOI 10.1111/j.1467-8624.1990.tb02795.x; MCCARTON C, IN PRESS INFANT HLTH; MCCONAUGHAY SH, 1988, PRACTICAL GUIDE CHIL; MCCORMICK MC, 1992, JAMA-J AM MED ASSOC, V267, P2204, DOI 10.1001/jama.267.16.2204; MCCORMICK MC, 1991, JAMA-J AM MED ASSOC, V265, P2212, DOI 10.1001/jama.265.17.2212; MCCORMICK MC, 1980, PEDIATRICS, V66, P991; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P24; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; Meisels SJ, 1990, HDB EARLY INTERVENTI; RAMEY CT, 1991, CHILDREN POVERTY; RAMEY CT, 1992, PEDIATRICS, V3, P454; RICHMOND J, 1990, JAMA-J AM MED ASSOC, V263, P3069, DOI 10.1001/jama.263.22.3069; SCOTT DT, 1989, PEDIATR RES, V25, pA263; SCOTT DT, 1987, SEMIN PERINATOL, V11, P191; SEARLE SR, 1980, AM STAT, V34, P216, DOI 10.2307/2684063; SPALLING J, 1988, EARLY PARTNERS CURRI; Terman L. M., 1973, STANFORD BINET INTEL; WASIK BH, 1990, CHILD DEV, V61, P1682; Wechsler D., 2014, WECHSLER PRESCHOOL P; WOODHEAD M, 1988, AM PSYCHOL, V43, P443, DOI 10.1037/0003-066X.43.6.443; ZIGLER E, 1992, AM PSYCHOL, V47, P997, DOI 10.1037/0003-066X.47.8.997; 1982, VITAL HLTH STAT 10, V141; 1990, JAMA-J AM MED ASSOC, V263, P3035; [No title captured]	46	207	211	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1257	1262		10.1001/jama.272.16.1257	http://dx.doi.org/10.1001/jama.272.16.1257			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN068	7933370				2022-12-28	WOS:A1994PN06800030
J	COPE, H; DAVID, A; PELOSI, A; MANN, A				COPE, H; DAVID, A; PELOSI, A; MANN, A			PREDICTORS OF CHRONIC POSTVIRAL FATIGUE	LANCET			English	Article							GENERAL-PRACTICE; MUSCLE	We set out to determine the relation between a general practitioner (GP) diagnosis of viral illness and development of chronic fatigue 6 months later. 618 subjects who attended GPs clinics in London, south, and southwest England and who received a diagnosis of viral illness were followed prospectively and fatigue was assessed by questionnaire after 6 months. At presentation, GPs recorded fatigue in 62.6% of subjects, usually since the onset of symptoms. 502 (81.2%) subjects completed the 6-month questionnaire, of whom 88 (17.5%) met criteria for chronic fatigue and 65 (12.9%) had no reported fatigue before the viral illness. Compared with a similar group of non-postviral GP attenders, the risk ratio for chronic fatigue in the present cohort was 1.45 (95% CI 1.14-2.04). Infective symptoms did not predict fatigue 6 months later. Psychiatric morbidity, belief in vulnerability to viruses, and attributional style at initial presentation were all associated with self-designated postviral fatigue. Logistic regression showed that somatic attributional style, less definite diagnosis by the GP, and sick certification were the only significant predictors of chronic fatigue after viral infection when other factors were controlled for. Chronic severe fatigue 6 months after GP-diagnosed viral illness is related to symptom-attributional style and doctor behaviour, rather than to features of the viral illness. Some subjects with apparent postviral fatigue had complained of tiredness before their presentation with a viral illness.	INST PSYCHIAT,DEPT PSYCHOL MED,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,EPIDEMIOL & GEN PRACTICE SECT,LONDON SE5 8AF,ENGLAND; HALRMYRES HOSP,GLASGOW,LANARK,SCOTLAND	University of London; King's College London; University of London; King's College London			David, Anthony S/C-1315-2011; David, Anthony/O-1750-2019	David, Anthony S/0000-0003-0967-774X; David, Anthony/0000-0003-0967-774X; Pelosi, Anthony/0000-0002-5501-2661				BARTLETT FC, 1932, REMEMBERING, P20; BRUCEJONES WDA, 1994, PSYCHOL MED, V24, P651, DOI 10.1017/S003329170002780X; COHEN S, 1993, J PERS SOC PSYCHOL, V64, P131, DOI 10.1037/0022-3514.64.1.131; COPE H, 1994, J PSYCHOSOM RES, V38, P89, DOI 10.1016/0022-3999(94)90082-5; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; DAVID AS, 1991, BRIT J HOSP MED, V45, P158; DAVID AS, 1991, BRIT MED BULL, V47, P966, DOI 10.1093/oxfordjournals.bmb.a072524; Goldthorpe J. H., 1974, SOCIAL GRADING OCCUP; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GOW JW, 1992, J CLIN PATHOL, V45, P1058, DOI 10.1136/jcp.45.12.1058; GOW JW, 1994, IN PRESS CLIN INFECT; HANSEN V, 1989, BRIT MED J, V299, P85, DOI 10.1136/bmj.299.6691.85; IMBODEN J, 1961, ARCH INTERN MED, V108, P115; KATON WJ, 1991, J GENERAL INT MED, V6, P227; KLEINMANN A, 1993, CIBA F S, V173; MCDONALD E, 1993, PSYCHOL MED, V23, P987, DOI 10.1017/S0033291700026453; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Ramsay M, 1986, POSTVIRAL FATIGUE SY; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; ROBBINS JM, 1991, PSYCHOL MED, V21, P1029, DOI 10.1017/S0033291700030026; RUTHERFORD OM, 1991, J NEUROL NEUROSUR PS, V54, P961, DOI 10.1136/jnnp.54.11.961; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WOOD GC, 1991, PSYCHOL MED, V21, P619, DOI 10.1017/S003329170002225X	28	102	104	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					864	868		10.1016/S0140-6736(94)92833-9	http://dx.doi.org/10.1016/S0140-6736(94)92833-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH253	7916407				2022-12-28	WOS:A1994PH25300017
J	HEBERT, JM; ROSENQUIST, T; GOTZ, J; MARTIN, GR				HEBERT, JM; ROSENQUIST, T; GOTZ, J; MARTIN, GR			FGF5 AS A REGULATOR OF THE HAIR-GROWTH CYCLE - EVIDENCE FROM TARGETED AND SPONTANEOUS MUTATIONS	CELL			English	Article							PROTO-ONCOGENE INT-2; EMBRYONIC STEM-CELLS; MOUSE EMBRYO; SKELETAL-MUSCLE; HOMOLOGOUS RECOMBINATION; TRANSGENIC MICE; FACTOR-5 GENE; FACTOR FAMILY; EXPRESSION; PROTOONCOGENE	Fibroblast growth factor 5 (FGF5) is a secreted signaling protein. Mice homozygous for a predicted null allele of the Fgf5 gene, fgf5(neo), produced by gene targeting in embryonic stem cells, have abnormally long hair. This phenotype appears identical to that of mice homozygous far the spontaneous mutation angora (go). The fgf5(neo) and go mutations fail to complement one another, and exon 1 of Fgf5 is deleted in DNA from go homozygotes, demonstrating that go is a mutant allele of Fgf5. Expression of Fgf5 is detected in hair follicles from wild-type mice and is localized to the outer root sheath during the anagen VI phase of the hair growth cycle. These findings provide evidence that FGF5 functions as an inhibitor of hair elongation, thus identifying a molecule whose normal function is apparently to regulate one step in the progression of the follicle through the hair growth cycle.	UNIV CALIF SAN FRANCISCO, SCH MED, GENET PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEV BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	HEBERT, JM (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.		Götz, Jürgen/C-2448-2014	Götz, Jürgen/0000-0001-8501-7896	NCI NIH HHS [CA 09043] Funding Source: Medline; NHLBI NIH HHS [P01 HL 43821] Funding Source: Medline; NICHD NIH HHS [R01 HD22731] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022731] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Burns M., 1966, GENETICS DOG BASIS S; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; CRARY DD, 1953, J EXP ZOOL, V124, P31, DOI 10.1002/jez.1401240103; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DICKIE MN, 1963, MOUSE NEWS LETT, V29, P39; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUCROS DL, 1993, DEV BIOL, V156, P444, DOI 10.1006/dbio.1993.1091; FRASER AS, 1953, J GENET, V51, P237, DOI 10.1007/BF03023295; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GREEN MR, 1984, J INVEST DERMATOL, V83, P118, DOI 10.1111/1523-1747.ep12263298; GREN MC, 1990, GENETIC VARIANTS STR, P12; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HAN JK, 1993, DEV BIOL, V158, P549, DOI 10.1006/dbio.1993.1212; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HAUB O, 1991, DEVELOPMENT, V112, P397; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HEBERT JM, 1991, DEVELOPMENT, V112, P407; HUGHES RA, 1993, NEURON, V10, P369, DOI 10.1016/0896-6273(93)90327-N; JOHNSON P, 1990, GENE, V88, P207, DOI 10.1016/0378-1119(90)90033-N; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; KOBAYASHI K, 1993, P NATL ACAD SCI USA, V90, P7391, DOI 10.1073/pnas.90.15.7391; KOLLER BH, 1992, ANNU REV IMMUNOL, V10, P705, DOI 10.1146/annurev.iy.10.040192.003421; Konyukhov B. V., 1990, MOUSE GENOME, V87, P94; LAVKER RM, 1993, J INVEST DERMATOL, V101, pS16, DOI 10.1111/1523-1747.ep12362556; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; LYONS KM, 1990, DEVELOPMENT, V109, P833; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN GR, 1987, DEV BIOL, V121, P20, DOI 10.1016/0012-1606(87)90134-5; MATTEI MG, 1992, MAMM GENOME, V2, P135, DOI 10.1007/BF00353862; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MESSENGER AG, 1993, J INVEST DERMATOL, V101, pS4, DOI 10.1111/1523-1747.ep12362437; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Parakkal P. F., 1972, KERATINIZATION SURVE; PENNYCUIK PR, 1984, GENET RES, V44, P283, DOI 10.1017/S0016672300026525; ROBINSON R, 1977, GENETICS CAT BREEDER; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Rook A., 1982, DISEASES HAIR SCALP; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; STRAILE WE, 1961, J EXP ZOOL, V148, P205, DOI 10.1002/jez.1401480304; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TAYLOR BA, 1990, GENETIC VARIANTS STR, P773; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAGNER JA, 1991, CURR TOP MICROBIOL, V165, P95; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	63	448	489	1	49	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					1017	1025		10.1016/0092-8674(94)90276-3	http://dx.doi.org/10.1016/0092-8674(94)90276-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923352				2022-12-28	WOS:A1994PJ29400012
J	ASHTON, JR				ASHTON, JR			PREVENTING EPIDEMIC SUICIDE IN YOUNG-PEOPLE	LANCET			English	Editorial Material							INQUESTS				ASHTON, JR (corresponding author), NW REG HLTH AUTHOR,WARRINGTON,CHESHIRE,ENGLAND.							ASHTON J, 1980, NEW SOC         1009, P57; ASHTON J, 1979, BRIT MED J, V11, P769; ASHTON JR, 1981, PSYCHOL MED, V11, P735, DOI 10.1017/S0033291700041234; BARRACLOUGH B, 1977, BRIT J PSYCHIAT, V131, P528, DOI 10.1192/bjp.131.5.528; BRENT DA, 1989, J AM ACAD CHILD PSY, V28, P918, DOI 10.1097/00004583-198911000-00017; DAVIDSON LE, 1989, JAMA-J AM MED ASSOC, V262, P2687, DOI 10.1001/jama.262.19.2687; DURKHEIM E, 1975, SUICIDE; 1994, MMWR-MORBID MORTAL W, V44, pRR6	8	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					768	768		10.1016/S0140-6736(94)92337-X	http://dx.doi.org/10.1016/S0140-6736(94)92337-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG178	7916069				2022-12-28	WOS:A1994PG17800006
J	SAURA, R; ROUX, D; TAINE, L; MAUGEY, B; LAULON, D; LAPLACE, JP; HOROVITZ, J				SAURA, R; ROUX, D; TAINE, L; MAUGEY, B; LAULON, D; LAPLACE, JP; HOROVITZ, J			EARLY AMNIOCENTESIS VERSUS CHORIONIC VILLUS SAMPLING FOR FETAL KARYOTYPING	LANCET			English	Letter											SAURA, R (corresponding author), CHU BORDEAUX,CTR PRENATAL DIAG,F-33076 BORDEAUX,FRANCE.							SAURA R, 1990, PRENATAL DIAG, V10, P461, DOI 10.1002/pd.1970100708; SAURA R, 1994, PRENATAL DIAG, V14, P70, DOI 10.1002/pd.1970140115; SAURA R, 1991, LANCET, V338, P449, DOI 10.1016/0140-6736(91)91074-5; SAURA R, IN PRESS PRENAT DIAG; SAURA R, 1992, AM J OBSTET GYNECOL, V167, P1983; 1994, LANCET, V344, P435	6	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					825	826		10.1016/S0140-6736(94)92384-1	http://dx.doi.org/10.1016/S0140-6736(94)92384-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916106				2022-12-28	WOS:A1994PG17800056
J	MORIN, PA; MOORE, JJ; CHAKRABORTY, R; JIN, L; GOODALL, J; WOODRUFF, DS				MORIN, PA; MOORE, JJ; CHAKRABORTY, R; JIN, L; GOODALL, J; WOODRUFF, DS			KIN SELECTION, SOCIAL-STRUCTURE, GENE FLOW, AND THE EVOLUTION OF CHIMPANZEES	SCIENCE			English	Article							HUMAN MITOCHONDRIAL-DNA; DINUCLEOTIDE REPEAT POLYMORPHISMS; CYTOCHROME-B SEQUENCE; D-LOOP REGION; PHYLOGENETIC-RELATIONSHIPS; NATURAL-POPULATIONS; COMMON ANCESTOR; LOCI; AMPLIFICATION; NUMBER	Hypotheses about chimpanzee social behavior, phylogeography, and evolution were evaluated by noninvasive genotyping of free-ranging individuals from 20 African sites. Degrees of relatedness among individuals in one community were inferred from allele-sharing at eight nuclear simple sequence repeat (SSR) loci. Males are related on the order of half-siblings, and homozygosity is significantly increased at several SSR loci compared to Hardy-Weinberg expectations. These data support the kin-selection hypothesis for the evolution of cooperation among males. Sequence variation patterns at two mitochondrial loci indicate historically high long-distance gene flow and clarify the relationships among three allopatric subspecies. The unexpectedly large genetic distance between the western subspecies, Pan troglodytes verus, and the other two subspecies suggests a divergence time of about 1.58 million years. This result, if confirmed at nuclear loci and supported by eco-behavioral data, implies that P. t. verus should be elevated to full species rank.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT ANTHROPOL, LA JOLLA, CA 92093 USA; UNIV TEXAS, GRAD SCH BIOMED SCI, CTR DEMOG & POPULAT GENET, HOUSTON, TX 77225 USA; JANE GOODALL INST USA, RIDGEFIELD, CT 06877 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System			Klein, Richard G/B-5910-2009; Morin, Phillip A/E-9515-2010; Jin, Li/C-1468-2009; Jin, Li/M-5063-2019	Jin, Li/0000-0002-4546-2415; Morin, Phillip/0000-0002-3279-1519	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000005] Funding Source: NIH RePORTER; NHGRI NIH HHS [1T32 HG00005-02] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BROWN AHD, 1980, GENETICS, V96, P523; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; CHAKRABORTY R, 1994, HUM HERED, V44, P1, DOI 10.1159/000154181; CHAKRABORTY R, 1984, GENETICS, V108, P719; COPPENS Y, 1994, SCI AM, V270, P88, DOI 10.1038/scientificamerican0594-88; DEKA R, 1991, GENOMICS, V11, P83, DOI 10.1016/0888-7543(91)90104-M; DIRIENZO A, 1991, P NATL ACAD SCI USA, V88, P1597, DOI 10.1073/pnas.88.5.1597; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EDWARDS A, 1991, AM J HUM GENET, V49, P746; EPPLEN JT, 1991, EXPER SUPPL, V58, P50; FERRIS SD, 1981, P NATL ACAD SCI-BIOL, V78, P6319, DOI 10.1073/pnas.78.10.6319; FORAN DR, 1988, NUCLEIC ACIDS RES, V16, P5841, DOI 10.1093/nar/16.13.5841; Garza JC, 1992, MOL PHYLOGENET EVOL, V1, P202, DOI 10.1016/1055-7903(92)90016-A; GEFFEN E, 1992, J ZOOL, V228, P27, DOI 10.1111/j.1469-7998.1992.tb04430.x; GOODALL J, 1990, UNDERSTANDING CHIMPA, P360; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; Groves C., 1989, THEORY HUMAN PRIMATE; GROVES CP, 1992, J HUM EVOL, V22, P327, DOI 10.1016/0047-2484(92)90063-F; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Hamilton A.C., 1988, P13; HASEGAWA M, 1990, J MOL EVOL, V31, P113, DOI 10.1007/BF02109480; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; Hill W. C. O., 1969, P22; HOELZEL AR, 1991, MOL BIOL EVOL, V8, P475; HORAI S, 1992, J MOL EVOL, V35, P32, DOI 10.1007/BF00160258; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KOCHER TD, 1991, EVOLUTION OF LIFE, P391; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; LI CC, 1976, 1ST COURSE POPULATIO; LITT M, 1989, AM J HUM GENET, V44, P397; LYNCH M, 1990, EVOLUTION, V44, P1725, DOI 10.1111/j.1558-5646.1990.tb05244.x; LYNCH M, 1992, P INT CO CONSERVATIO, P258; MERCURE A, 1993, EVOLUTION, V47, P1313, DOI 10.1111/j.1558-5646.1993.tb02157.x; MOON MA, 1993, NIH RES RESOURCES RE, V17, P7; MORIN PA, 1992, PATERNITY IN PRIMATES : GENETIC TESTS AND THEORIES, P63; MORIN PA, 1993, PRIMATES, V34, P347, DOI 10.1007/BF02382630; MORIN PA, 1992, P ROY SOC B-BIOL SCI, V249, P293, DOI 10.1098/rspb.1992.0117; MORIN PA, 1993, YEARB PHYS ANTHROPOL, V36, P179; MORIN PA, 1992, THESIS U CALIFORNIA; MORIN PA, IN PRESS MOL ECOL; MORIN PA, 1979, GREAT APES, P73; MORTON NE, 1992, P NATL ACAD SCI USA, V89, P2556, DOI 10.1073/pnas.89.7.2556; Musser G G, 1993, MAMMAL SPECIES WORLD; NEI M, 1992, MOL BIOL EVOL, V9, P1176; NEI M, 1978, GENETICS, V89, P583; NEI M, 1987, MOL EVOLUTIONARY GEN, P276; Nishida T., 1979, GREAT APES, P73; Nishida T., 1990, CHIMPANZEES MAHALE M; NORMARK BB, 1991, MOL BIOL EVOL, V8, P819; NOWAK RM, 1991, WALKERS MAMMALS WORL, V1; PESOLE G, 1992, MOL BIOL EVOL, V9, P587; Pusey A, 1979, GREAT APES, P465; PUSEY AE, 1980, ANIM BEHAV, V28, P543, DOI 10.1016/S0003-3472(80)80063-7; RIER KB, 1992, FACES FOREST; ROGERS J, 1993, J HUM EVOL, V25, P201, DOI 10.1006/jhev.1993.1044; RUANO G, 1992, MOL BIOL EVOL, V9, P575; RUVOLO M, 1993, MOL BIOL EVOL, V10, P1115; RUVOLO M, 1994, AM J PHYS ANTHROPOL, V94, P89, DOI 10.1002/ajpa.1330940108; RUVOLO M, 1993, SCIENCE, V260, P892; RUVOLO M, COMMUNICATION; RYDER OA, 1986, TRENDS ECOL EVOL, V1, P9, DOI 10.1016/0169-5347(86)90059-5; SAITOU N, 1991, AM J PHYS ANTHROPOL, V84, P75, DOI 10.1002/ajpa.1330840107; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SARICH VM, 1967, SCIENCE, V158, P1200, DOI 10.1126/science.158.3805.1200; SEAL US, 1986, PRIMATES ROAD SELF S, P47; Shea Brian T., 1993, P265; SHEA BT, 1988, J HUM EVOL, V17, P671, DOI 10.1016/0047-2484(88)90024-3; SMITH MF, 1991, MOL BIOL EVOL, V8, P85; Sokal Robert R., 1969, BIOMETRY; Spiess EB, 1989, GENES POPULATIONS; Stanley S. M., 1979, MACROEVOLUTION; STAUB KC, 1990, AM MALACOL BULL, V7, P93; STONEKING M, 1991, AM J HUM GENET, V48, P370; STRIER KB, 1993, J ZOO WILDLIFE MED, V24, P229; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; VANDENBUSSCHE RA, 1993, MOL BIOL EVOL, V10, P944; VANDENBUSSCHE RA, 1993, J MAMMAL, V74, P793, DOI 10.2307/1382304; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; Vineberg EO, 1991, LAST APE PYGMY CHIMP; WAKELEY J, 1994, MOL BIOL EVOL, V11, P436; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P6465, DOI 10.1093/nar/18.21.6465-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4034, DOI 10.1093/nar/18.13.4034; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WILLS C, IN PRESS EVOLUTION; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; WILSON AC, 1985, BIOL J LINN SOC, V26, P375, DOI 10.1111/j.1095-8312.1985.tb02048.x; Woodford M. H., 1994, P178; WOODRUFF DS, 1993, PRIMATES, V34, P333, DOI 10.1007/BF02382629; WOODRUFF DS, 1990, J SCI SOC THAILAND, V16, P117; WOODRUFF DS, 1990, PRESERVATION VALUATI, P119; WRANGHAM RW, 1979, CURRENT PROBLEMS SOC, P481; WU CI, 1991, GENETICS, V127, P429; ZIHLMAN AL, 1978, NATURE, V275, P744, DOI 10.1038/275744a0; 1991, GLOBAL CAPTIVE ACTIO	98	424	441	1	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1193	1201		10.1126/science.7915048	http://dx.doi.org/10.1126/science.7915048			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7915048				2022-12-28	WOS:A1994PD42200025
J	WEISSMAN, JS; KASHI, Y; FENTON, WA; HORWICH, AL				WEISSMAN, JS; KASHI, Y; FENTON, WA; HORWICH, AL			GROEL-MEDIATED PROTEIN-FOLDING PROCEEDS BY MULTIPLE ROUNDS OF BINDING AND RELEASE OF NONNATIVE FORMS	CELL			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; ORNITHINE TRANSCARBAMYLASE; ESCHERICHIA-COLI; CENTRAL CAVITY; RHODANESE; INTERMEDIATE; HYDROLYSIS; TRANSLOCATION; PRECURSOR	The chaperonin GroEL is a ribosome-sized double-ring structure that assists in folding a diverse set of polypeptides. We have examined the fate of a polypeptide during a chaperonin-mediated folding reaction. Strikingly, we find that, upon addition of ATP and the cochaperonin GroES, polypeptide is released rapidly from GroEL in a predominantly nonnative conformation that can be trapped by mutant forms of GroEL that are capable of binding but not releasing substrate. Released polypeptide undergoes kinetic partitioning: a fraction completes folding while the remainder is rebound rapidly by other GroEL molecules. Folding appears to occur in an all-or-none manner, as proteolysis and tryptophan fluorescence indicate that after rebinding, polypeptide has the same structure as in the original complex. These observations suggest that GroEL functions by carrying out multiple rounds of binding aggregation-prone or kinetically trapped intermediates, maintaining them in an unfolded state, and releasing them to attempt to fold in solution.	YALE UNIV, SCH MED, BOYER CTR MOLEC MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University	WEISSMAN, JS (corresponding author), YALE UNIV, SCH MED, BOYER CTR MOLEC MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA.		Kashi, Yechezkel/D-5433-2013					ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHAN HS, 1993, J CHEM PHYS, V99, P2116, DOI 10.1063/1.465277; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DOERING D, 1992, THESIS MIT CAMBRIDGE; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KALOUSEK F, 1978, J BIOL CHEM, V253, P3939; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEFHABER T, 1992, PROTEINS, V12, P171, DOI 10.1002/prot.340120210; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; TANDON S, 1989, J BIOL CHEM, V264, P9859; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; VLITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WANG Z, 1992, PROTEIN SCI, V1, P522; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	52	341	346	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					693	702		10.1016/0092-8674(94)90533-9	http://dx.doi.org/10.1016/0092-8674(94)90533-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915201				2022-12-28	WOS:A1994PD69300017
J	GRINES, CL; WEAVER, WD				GRINES, CL; WEAVER, WD			TREATING MYOCARDIAL-INFARCTION - AND IMPORTANCE OF EARLY REPERFUSION	LANCET			English	Editorial Material							THROMBOLYSIS; ANGIOPLASTY		UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	GRINES, CL (corresponding author), WILLIAM BEAUMONT HOSP, DEPT MED, DIV CARDIOL, ROYAL OAK, MI 48072 USA.							BADIMON L, 1991, TRENDS CARDIOVAS MED, V1, P261, DOI 10.1016/1050-1738(91)90032-A; BECKER RC, 1991, CARDIOLOGY, V79, P49, DOI 10.1159/000174860; Cannon Christopher P., 1993, Journal of the American College of Cardiology, V21, p136A; DEBONO DP, 1992, BRIT HEART J, V67, P122; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HERLITZ J, 1992, EUR HEART J, V13, P171, DOI 10.1093/oxfordjournals.eurheartj.a060142; KLEIMAN NS, 1992, CIRCULATION, V86, P260; LIDON RM, 1994, CIRCULATION, V89, P1567, DOI 10.1161/01.CIR.89.4.1567; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROUX S, 1992, J AM COLL CARDIOL, V19, P671, DOI 10.1016/S0735-1097(10)80290-6; TCHENG JE, 1993, CIRCULATION, V88, P1; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1994, CIRCULATION, V89, P1557, DOI 10.1161/01.CIR.89.4.1557; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1993, EUR HEART J        S, V14, P48	17	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	1994	344	8921					490	491		10.1016/S0140-6736(94)91893-7	http://dx.doi.org/10.1016/S0140-6736(94)91893-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914609				2022-12-28	WOS:A1994PC53500004
J	YUEN, KY; WONG, SSY; TSANG, DNCT; CHAU, PY				YUEN, KY; WONG, SSY; TSANG, DNCT; CHAU, PY			SERODIAGNOSIS OF PENICILLIUM-MARNEFFEI INFECTION	LANCET			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS	Diagnosis of Penicillium marneffei infection is often made late. We evaluated an indirect immunofluorescent antibody test for P marneffei in serum from 103 patients with persistent fever and from 78 normal subjects. Germinating conidia (initial tissue-invasion phase) and yeast-hyphae (tissue multiplication phase) forms were used as antigen. All 8 documented P marneffei cases (8%) had an IgG titre of 160 or more; the other 95 patients and all the healthy controls had an IgG titre of 40 or below. Blood culture was positive in only 1 case with HIV infection. Biopsy and culture of tissues were necessary for confirmation in the other 7 cases. The test could provide rapid presumptive diagnosis and supplement conventional culture.	QUEEN ELIZABETH HOSP,KOWLOON,HONG KONG		YUEN, KY (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT MICROBIOL,UNIV PATHOL BLDG,POKFULAM RD,HONG KONG,HONG KONG.		Yuen, Kwok Yung/C-4465-2009; Wong, Samson/C-4446-2009	Yuen, Kwok-yung/0000-0002-2083-1552				DISALVO AF, 1973, AM J CLIN PATHOL, V60, P259; HILMARSDOTTIR I, 1993, J ACQ IMMUN DEF SYND, V6, P466; QUINDOS G, 1990, EUR J CLIN MICROBIOL, V9, P178, DOI 10.1007/BF01963834; SALTINI C, 1993, J INFECT DIS, V168, P1409, DOI 10.1093/infdis/168.6.1409; SEKHON AS, 1982, MYCOPATHOLOGIA, V77, P51, DOI 10.1007/BF00588658; SO SY, 1985, AM REV RESPIR DIS, V131, P662, DOI 10.1164/arrd.1985.131.4.662; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; TSANG DNC, 1991, REV INFECT DIS, V13, P766; VIVIANI MA, 1993, EUR J EPIDEMIOL, V9, P79, DOI 10.1007/BF00463094; YUEN KY, 1992, J INFECTION, V25, P29, DOI 10.1016/0163-4453(92)93441-R	10	76	79	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					444	445		10.1016/S0140-6736(94)91771-X	http://dx.doi.org/10.1016/S0140-6736(94)91771-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914566				2022-12-28	WOS:A1994PB76100011
J	HULL, M; JONES, R; BENDALL, M				HULL, M; JONES, R; BENDALL, M			FATAL HEPATIC-NECROSIS ASSOCIATED WITH TRAZODONE AND NEUROLEPTIC DRUGS	BRITISH MEDICAL JOURNAL			English	Letter											HULL, M (corresponding author), UNIV NOTTINGHAM HOSP,NOTTINGHAM NG7 2UH,ENGLAND.							CHU AG, 1983, ANN INTERN MED, V99, P128, DOI 10.7326/0003-4819-99-1-128_3; SHEIKH KH, 1983, ANN INTERN MED, V99, P572, DOI 10.7326/0003-4819-99-4-572_1	2	20	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					378	378						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	7915924				2022-12-28	WOS:A1994PB31600022
J	SWALES, JD				SWALES, JD			PHARMACOLOGICAL TREATMENT OF HYPERTENSION	LANCET			English	Article							HIGH BLOOD-PRESSURE; CORONARY HEART-DISEASE; EUROPEAN-WORKING-PARTY; MYOCARDIAL-INFARCTION; MORTALITY; MANAGEMENT; MORBIDITY; TRIALS; GUIDELINES; STROKE				SWALES, JD (corresponding author), LEICESTER ROYAL INFIRM,DEPT MED,CLIN SCI BLDG,POB 65,LEICESTER LE2 7LX,ENGLAND.							ALDERMAN MH, 1993, ANN INTERN MED, V119, P329, DOI 10.7326/0003-4819-119-4-199308150-00013; AMERY A, 1985, LANCET, V1, P1349; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BING RF, 1986, J HYPERTENS, V4, pS42; CARLSEN JE, 1990, BRIT MED J, V300, P975, DOI 10.1136/bmj.300.6730.975; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COLLINS R, 1994, TXB HYPERTENSION, P1156; COOPE J, 1987, LANCET, V1, P1380; CORONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JOHANNESSON M, 1992, J HYPERTENS, V10, P1063; KAWACHI I, 1991, J HYPERTENS, V9, P199, DOI 10.1097/00004872-199103000-00002; KENNEDY M, 1992, ADVERSE DRUG REACT, V156, P587; LEDINGHAM JGG, 1979, Q J MED, V48, P25; LINDHOLM L, 1984, ACTA MED SCAND, V216, P251; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MANCIA G, 1990, J HYPERTENS, V8, pS1; MIALL WE, 1987, MILD HYPERTENSION IS; MOGENSEN CE, 1992, BRIT MED J, V304, P327, DOI 10.1136/bmj.304.6823.327; SAGIE A, 1993, NEW ENGL J MED, V329, P1912, DOI 10.1056/NEJM199312233292602; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; Stamler J, 1989, Hypertension, V13, pI2; SWALES JD, 1991, BRIT HEART J, V66, P409; SWALES JD, 1993, J HYPERTENS, V11, P899, DOI 10.1097/00004872-199309000-00003; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P732; WHITE WB, 1989, JAMA-J AM MED ASSOC, V261, P873; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; WILHEMSEN L, 1987, J HYPERTENS, V300, P975; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; 1993, ARCH INTERN MED, V153, P154; 1991, JAMA-J AM MED ASSOC, V265, P255; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1984, HYPERTENSION S1, V6, P198; 1992, BRIT MED J, V304, P405; 1993, BLOOD PRESSURE, V2, P62; 1985, J HYPERTENS, V3, P379; 1993, J HYPERTENS, V11, P905	44	39	39	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					380	385						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914311				2022-12-28	WOS:A1994PA30300014
J	CRANSTON, I; LOMAS, J; MARAN, A; MACDONALD, I; AMIEL, SA				CRANSTON, I; LOMAS, J; MARAN, A; MACDONALD, I; AMIEL, SA			RESTORATION OF HYPOGLYCEMIA AWARENESS IN PATIENTS WITH LONG-DURATION INSULIN-DEPENDENT DIABETES	LANCET			English	Article							NOCTURNAL HYPOGLYCEMIA; UNAWARENESS; COUNTERREGULATION; RESPONSES; SYMPTOMS; HUMANS; IDDM; NEUROENDOCRINE; REVERSIBILITY; PREVALENCE	Hypoglycaemia without warning is a dangerous complication of insulin-dependent diabetes mellitus and it limits the use of intensified insulin therapy to reduce chronic diabetic complications. To investigate the possibility of restoring awareness; symptomatic, cognitive, and hormonal responses to controlled hypoglycaemia were studied in insulin-dependent diabetic patients with long disease duration (6 with good glycaemic control and 6 with poor control) before and after hypoglycaemia avoidance. At the start of the study, all had loss of hypoglycaemia awareness. Responses to the initial challenge were small (pooled area under curve [AUC] adrenaline 5.75 [SE 0.07] nmol/L per 260 min, pooled AUC symptom score 80 [1.3]) and only started when plasma glucose was significantly lower than the 2.8 (0.1) mmol/L at which cognitive function deteriorated. After 4.1 (1.1) months' scrupulous hypoglycaemia avoidance, hormone and symptom responses to the challenge were increased (AUC adrenaline 15.9 [0.1] nmol/L per 260 min, p = 0.01; AUC symptom score 275 [7], p < 0.001), starting at plasma glucose concentrations significantly higher than that causing cognitive dysfunction. Glycosylated haemoglobin did not deteriorate significantly. We conclude that the normal hierarchy of subjective awareness before cognitive dysfunction during hypoglycaemia can be restored by avoiding hypoglycaemia. This is independent of disease duration or initial metabolic control.	CATTEDRA MALATTIE RICAMBIO, PADUA, ITALY; UNIV NOTTINGHAM, QUEENS MED CTR, DEPT PHYSIOL & PHARMACOL, NOTTINGHAM NG7 2RD, ENGLAND	University of Nottingham	CRANSTON, I (corresponding author), GUYS HOSP, METAB MED UNIT, LONDON SE1 9RT, ENGLAND.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Macdonald, Ian/0000-0002-7540-9850				AMIEL SA, 1991, DIABETES CARE, V14, P109, DOI 10.2337/diacare.14.2.109; AMIEL SA, 1987, DIABETES, V36, P518, DOI 10.2337/diabetes.36.4.518; BIGGERS DW, 1989, DIABETES, V38, P7, DOI 10.2337/diabetes.38.1.7; CASPARIE AF, 1985, DIABETES CARE, V8, P141, DOI 10.2337/diacare.8.2.141; CLARKE WL, 1991, DIABETES, V40, P680, DOI 10.2337/diabetes.40.6.680; COX D, 1993, DIABETES, V42, pA126; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; FANELLI CG, 1993, DIABETES, V42, P1683, DOI 10.2337/diabetes.42.11.1683; GALE EAM, 1979, LANCET, V1, P1049; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HEPBURN DA, 1991, DIABETES CARE, V14, P949, DOI 10.2337/diacare.14.11.949; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; LAGER I, 1986, DIABETIC MED, V3, P322, DOI 10.1111/j.1464-5491.1986.tb00772.x; LIU D, 1992, DIABETOLOGIA, V35, P287, DOI 10.1007/BF00400932; MACDONALD IA, 1985, J NEUROSCI METH, V13, P239, DOI 10.1016/0165-0270(85)90072-X; MARAN A, 1992, DIABETIC MED, V9, P765, DOI 10.1111/j.1464-5491.1992.tb01889.x; MARAN A, 1993, DIABETES, V42, pA17; MARAN A, 1994, DIABETIC MED, V11, P114; MAZLAN M, 1989, THESIS U LONDON LOND; MCCALL AL, 1986, AM J PHYSIOL, V251, pE442, DOI 10.1152/ajpendo.1986.251.4.E442; MITRAKOU A, 1993, NEW ENGL J MED, V329, P834, DOI 10.1056/NEJM199309163291203; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NAGY RJ, 1992, DIABETES, V41, P69; RYDER RJ, 1980, BRIT MED J, V301, P783; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SJOBOM NC, 1989, DIABETOLOGIA, V32, P818; TCHOBROUTSKY G, 1981, DIABETOLOGIA, V21, P335; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233; WIDOM B, 1990, DIABETOLOGIA, V33, P84; WISE JK, 1973, NEW ENGL J MED, V288, P487, DOI 10.1056/NEJM197303082881003	30	315	314	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	1994	344	8918					283	287		10.1016/S0140-6736(94)91336-6	http://dx.doi.org/10.1016/S0140-6736(94)91336-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914259				2022-12-28	WOS:A1994NZ23300005
J	HANENBERG, RS; ROJANAPITHAYAKORN, W; KUNASOL, P; SOKAL, DC				HANENBERG, RS; ROJANAPITHAYAKORN, W; KUNASOL, P; SOKAL, DC			IMPACT OF THAILAND HIV-CONTROL PROGRAM AS INDICATED BY THE DECLINE OF SEXUALLY-TRANSMITTED DISEASES	LANCET			English	Article								The Thai government began an HIV-control programme in 1989. The programme had the following parts: the government bought and distributed sufficient condoms to protect much of the commercial sex in the country; sanctions were brought against commercial sex establishments where condoms were not used consistently; and a media campaign bluntly advised men to use condoms with prostitutes. Between 1989 and 1993 the use of condoms in commercial sex in Thailand increased from 14 to 94%, according to surveys of prostitutes, and the number of cases of the five major sexually transmitted diseases declined by 79% in men. We estimate that sex acts with prostitutes where there was a risk of HIV transmission declined from about 2.6% in June, 1989, to about 1.6% in June, 1993. If condom use in commercial sex stays high, future cohorts of young men and women may experience lower HIV incidence rates than those of the recent past. However, although condom use is high, there are many more infected prostitutes than before and many infected men who will pass HIV to their wives.	FAMILY HLTH INT,RES TRIANGLE PK,NC 27709; MINIST PUBL HLTH,DEPT COMMUNICABLE DIS CONTROL,BANGKOK,THAILAND	Ministry of Public Health - Thailand								ROJANAPITHAYAKO.W, 1991, 100 PERCENT CONDOM P; ROJANAPITHAYAKO.W, 1993, 100 PERCENT CONDOM U; Ungchusak K., 1990, Thai AIDS Journal, V2, P45; Ungchusak K., 1989, Thai AIDS Journal, V1, P57; 1991, STATUS TRENDS AIDS E	5	347	348	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					243	245		10.1016/S0140-6736(94)93004-X	http://dx.doi.org/10.1016/S0140-6736(94)93004-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913163				2022-12-28	WOS:A1994NY06000016
J	RAPHAEL, JC; CHEVRET, S; CHASTANG, C; BOUVET, F				RAPHAEL, JC; CHEVRET, S; CHASTANG, C; BOUVET, F			RANDOMIZED TRIAL OF PREVENTIVE NASAL VENTILATION IN DUCHENNE MUSCULAR-DYSTROPHY	LANCET			English	Article							RESPIRATORY MUSCLE WEAKNESS; FAILURE; PREDNISONE; MANAGEMENT; THERAPY; DISEASE; SLEEP	Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy in children. Paralysis of respiratory muscles causes a decrease in forced vital capacity (FVC) from age 12 years, and death occurs between 20 and 25 years old and is usually related to respiratory insufficiency. Uncontrolled studies suggest that early home use of nasal intermittent positive-pressure ventilation (NIPPV) in DMD patients free of respiratory failure could limit progression of the restrictive syndrome and therefore improve survival Because efficacy of preventive NIPPV has not been demonstrated in a controlled trial, we undertook a randomised multicentre study in which 70 patients with DMD were included. Patients were free of daytime respiratory failure and FVC was between 20 and 50% of predicted values. At least 6 h of nocturnal NIPPV (n=35) was compared with conventional treatment (n=35). During a mean follow-up of 52 months, 10 patients died, 8 in the NIPPV group and 2 in the control group (p=0.05, log-rank test). No differences were observed between the two groups for occurrence of hypercapnia, decrease of FVC below 20% of initial values, or use of necessary mechanical ventilation. Preventive NIPPV did not improve respiratory handicap and reduced survival of DMD patients. Use of NIPPV for preventive purposes should be avoided in patients with FVC between 20 and 50% of predicted values.	HOP ST LOUIS,DEPT BIOSTAT & INFORMAT MED,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	RAPHAEL, JC (corresponding author), HOP RAY POINCARE,SERV REANIMAT MED,F-92380 GARCHES,FRANCE.			chevret, sylvie/0000-0001-6449-4730				BACH JR, 1990, CHEST, V97, P52, DOI 10.1378/chest.97.1.52; BRAUN NMT, 1979, AM REV RESPIR DIS, V119, P123; BROOKE MH, 1989, NEUROLOGY, V39, P475, DOI 10.1212/WNL.39.4.475; BYE PTP, 1990, THORAX, V45, P241, DOI 10.1136/thx.45.4.241; CHERNIACK RM, 1972, AM REV RESPIR DIS, V106, P38, DOI 10.1164/arrd.1972.106.1.38; Delaubier A, 1987, Agressologie, V28, P737; DEMEDTS M, 1982, EUR J RESPIR DIS, V63, P62; DETROYER A, 1980, THORAX, V35, P603, DOI 10.1136/thx.35.8.603; DETROYER A, 1981, AM REV RESPIR DIS, V124, P132; ESTENNE M, 1983, AM REV RESPIR DIS, V128, P1002; FENICHEL GM, 1991, NEUROLOGY, V41, P1874, DOI 10.1212/WNL.41.12.1874; FERRIS BG, 1960, J CLIN INVEST, V39, P143, DOI 10.1172/JCI104012; GAFFNEY JF, 1989, ARCH NEUROL-CHICAGO, V46, P1249, DOI 10.1001/archneur.1989.00520470123039; GEORGE SL, 1974, J CHRON DIS, V27, P15, DOI 10.1016/0021-9681(74)90004-6; GILGOFF I, 1989, CHEST, V95, P519, DOI 10.1378/chest.95.3.519; GRANATA C, 1989, SEM HOP PARIS, V65, P1037; HECKMATT JZ, 1987, BRIT MED J, V295, P1014, DOI 10.1136/bmj.295.6605.1014; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; INKLEY SR, 1974, AM J MED, V56, P297, DOI 10.1016/0002-9343(74)90611-1; MENDELL JR, 1989, NEW ENGL J MED, V320, P1592, DOI 10.1056/NEJM198906153202405; MILLER JR, 1988, DEV MED CHILD NEUROL, V30, P200; NAGAI T, 1989, JPN CIRC J, V53, P406, DOI 10.1253/jcj.53.406; NOLTE D, 1983, EUR J RESPIR DIS, V64, P110; RAPHAEL JC, 1987, REV MAL RESPIR, V4, P195; Raphael JC, 1992, EUR RESPIR REV, V2, P312; RIDEAU Y, 1988, MUSCLE NERVE, V11, P407; SMITH PEM, 1989, CHEST, V96, P1346, DOI 10.1378/chest.96.6.1346; SMITH PEM, 1988, AM REV RESPIR DIS, V137, P884, DOI 10.1164/ajrccm/137.4.884; YAN K, 1983, EUR J RESPIR DIS, V64, P105	29	171	174	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1600	1604						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911921				2022-12-28	WOS:A1994NU35400011
J	HEALY, DL; TROUNSON, AO; ANDERSEN, AN				HEALY, DL; TROUNSON, AO; ANDERSEN, AN			FEMALE INFERTILITY - CAUSES AND TREATMENT	LANCET			English	Review							ENDOMETRIOSIS-ASSOCIATED INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; GONADOTROPIN-RELEASING HORMONE; INVITRO FERTILIZATION; LUTEINIZING-HORMONE; BALLOON TUBOPLASTY; FOLLICULAR PHASE; EMBRYO TRANSFER; PREGNANCY; WOMEN		UNIV COPENHAGEN,HERLEV HOSP,DEPT OBSTET & GYNAECOL,FERTIL CLIN,DK-2730 HERLEV,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	HEALY, DL (corresponding author), MONASH UNIV,MONASH MED CTR,DEPT OBSTET & GYNAECOL,LEVEL 5,246 CLAYTON RD,CLAYTON,VIC 3168,AUSTRALIA.			Trounson, Alan/0000-0001-5469-0500				ANGELL RR, 1994, CYTOGENET CELL GENET, V65, P194, DOI 10.1159/000133631; BATISTA MC, 1993, FERTIL STERIL, V59, P294; CATES W, 1985, LANCET, V2, P596; CLIFFORD KA, 1993, HUM REPROD S1, V8, P388; COHEN J, 1993, HUM REPROD, V8, P996, DOI 10.1093/oxfordjournals.humrep.a138216; CONFINO E, 1990, JAMA-J AM MED ASSOC, V264, P2079, DOI 10.1001/jama.264.16.2079; DICKER D, 1990, HUM REPROD, V5, P418, DOI 10.1093/oxfordjournals.humrep.a137114; FAYEZ JA, 1983, FERTIL STERIL, V39, P476; GOMEL V, 1983, FERTIL STERIL, V40, P607; HANEY AF, 1993, BAILLIERE CLIN OB GY, V7, P791, DOI 10.1016/S0950-3552(05)80464-X; Hassiakos D K, 1990, Obstet Gynecol Surv, V45, P165, DOI 10.1097/00006254-199003000-00004; HEALY DL, 1992, CURR OBSTET GYNAECOL, V2, P8; HUGHES EG, 1993, FERTIL STERIL, V59, P963; HULL ME, 1987, FERTIL STERIL, V47, P40; HURLEY DM, 1984, NEW ENGL J MED, V310, P1069, DOI 10.1056/NEJM198404263101702; JANSEN RPS, 1987, LANCET, V2, P309; JANSEN RPS, 1993, FERTIL STERIL, V59, P1041; KERIN J, 1990, J REPROD MED, V35, P606; KLENTZERIS LD, 1993, HUM REPROD, V8, P1223, DOI 10.1093/oxfordjournals.humrep.a138231; KNUDSEN LB, 1993, 44 DANM STAT STAT UN; KOLA I, 1993, HDB IN VITRO FERTILI, P173; KOVACS GT, 1986, MED J AUSTRALIA, V144, P682, DOI 10.5694/j.1326-5377.1986.tb113694.x; LEETON J, 1991, HUM REPROD, V6, P299, DOI 10.1093/oxfordjournals.humrep.a137326; MCCLURE N, 1993, FERTIL STERIL, V59, P729; MOSHER WD, 1990, 1965 1988 ADV DATA V; NAVOT D, 1991, LANCET, V337, P1375, DOI 10.1016/0140-6736(91)93060-M; NULSEN JC, 1993, OBSTET GYNECOL, V82, P780; OEHNINGER S, 1988, J IN VITRO FERTIL EM, V5, P249, DOI 10.1007/BF01132172; OLSON J, 1983, INT J EPIDEMIOL, V12, P179; PATTON GW, 1982, FERTIL STERIL, V37, P150; REGAN L, 1990, LANCET, V336, P1141, DOI 10.1016/0140-6736(90)92765-A; RISQUEZ F, 1993, FERTIL STERIL, V60, P211; ROSEVEAR SK, 1992, LANCET, V340, P1195, DOI 10.1016/0140-6736(92)92895-M; ROWLAND AS, 1992, NEW ENGL J MED, V327, P993, DOI 10.1056/NEJM199210013271405; SHOHAM Z, 1993, FERTIL STERIL, V59, P1153; SKAKKEBAEK NE, 1994, LANCET, V343, P1473, DOI 10.1016/S0140-6736(94)92586-0; TAN SL, 1992, LANCET, V339, P1390, DOI 10.1016/0140-6736(92)91205-M; TEVELDE E, 1992, TIJDSCHRIFT FERTILIT, V6, P5; THONNEAU P, 1991, HUM REPROD, V6, P811, DOI 10.1093/oxfordjournals.humrep.a137433; TUMMON IS, 1991, J IN VITRO FERTIL EM, V8, P149, DOI 10.1007/BF01131705; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1055, DOI 10.1093/oxfordjournals.humrep.a138191; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1175, DOI 10.1093/oxfordjournals.aje.a116426; WILLEMSEN W, 1993, LANCET, V341, P986, DOI 10.1016/0140-6736(93)91071-S; WINGIFELD MB, 1993, 12 FERT SOC AUSTR AN; WRIGHT J, 1989, INT J FERTIL, V34, P126; YOVICH JL, 1988, FERTIL STERIL, V50, P308; 1990, IVF GIFT PREGNANCIES; 1991, LANCET, V337, P888	50	135	141	1	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1539	1544		10.1016/S0140-6736(94)92941-6	http://dx.doi.org/10.1016/S0140-6736(94)92941-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911874				2022-12-28	WOS:A1994NR32900011
J	KATAN, MB				KATAN, MB			FATS FOR DIABETICS	LANCET			English	Editorial Material							DIET				KATAN, MB (corresponding author), AGR UNIV WAGENINGEN,DEPT HUMAN NUTR,WAGENINGEN,NETHERLANDS.							Bose RKC, 1907, BRIT MED J, V2, P1053; BURR ML, 1989, LANCET, V2, P757; CRAPO PA, 1985, ANNU REV NUTR, V5, P95, DOI 10.1146/annurev.nutr.5.1.95; GARG A, 1994, JAMA-J AM MED ASSOC, V271, P1421, DOI 10.1001/jama.271.18.1421; GLATZ JFC, 1989, AM J CLIN NUTR, V49, P269, DOI 10.1093/ajcn/49.2.269; GLAUBER H, 1988, ANN INTERN MED, V108, P663, DOI 10.7326/0003-4819-108-5-663; TAYLOR R, 1983, DIABETES EPIDEMIOLOG, P58; VESSBY B, 1994, AM J CLIN NUTR, V59, p742S, DOI 10.1093/ajcn/59.3.742S	8	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1518	1518		10.1016/S0140-6736(94)92934-3	http://dx.doi.org/10.1016/S0140-6736(94)92934-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911867				2022-12-28	WOS:A1994NR32900004
J	SYM, M; ENGEBRECHT, J; ROEDER, GS				SYM, M; ENGEBRECHT, J; ROEDER, GS			ZIP1 IS A SYNAPTONEMAL COMPLEX PROTEIN REQUIRED FOR MEIOTIC CHROMOSOME SYNAPSIS	CELL			English	Article							DNA TOPOISOMERASE-II; AMINO-ACID-SEQUENCE; GLUTATHIONE-S-TRANSFERASE; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE CONVERSION; YEAST CHROMOSOMES; MYOSIN ROD; MEIOSIS	ZIP1 is a novel meiosis-specific gene required for chromosome synapsis and cell cycle progression in S. cerevisiae. zip1 strains undergo homologous chromosome pairing, but are defective in synaptonemal complex (SC) formation. The zip1 mutation confers a uniform arrest in meiosis prior to the first division. zip1 strains display nearly wild-type levels of commitment to melotic recombination; however, mature reciprocal recombinants are not formed until cells are released from meiotic arrest by return to growth medium. DNA sequence analysis of ZIP1 reveals structural homology to a number of proteins containing coiled coils. Immunofluorescence experiments using anti-ZIP1 antibodies demonstrate that the ZIP1 protein localizes to synapsed meiotic chromosomes but not to unsynapsed axial elements. Taken together, these data suggest that ZIP1 is a component of the central region of the SC. We propose a model in which ZIP1 acts as a molecular zipper to bring homologous chromosomes in close apposition.			SYM, M (corresponding author), YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA.		Engebrecht, JoAnne/K-3355-2019	Engebrecht, JoAnne/0000-0002-2733-7506	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904, T32GM007223] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28904, 2 T32 GM07223-18] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1989, GENETICS, V122, P47; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BORTS RH, 1986, GENETICS, V113, P551; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DAVIDOW LS, 1984, GENETICS, V106, P165; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; Fraser R.D.B., 1973, CONFORMATION FIBROUS; Game J., 1983, YEAST GENETICS FUNDA, P109; GIROUX CN, 1988, GENETIC RECOMBINATIO, P465; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HESLOPHARRISON JS, 1985, J CELL SCI, V75, P85; HEYTING C, 1987, EUR J CELL BIOL, V43, P148; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES GH, 1984, CONTROLLING EVENTS M, P293; KLECKNER N, 1991, COLD SH Q B, V56, P729; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LUCHE RM, 1990, MOL CELL BIOL, V10, P3884, DOI 10.1128/MCB.10.8.3884; MAGUIRE MP, 1972, GENETICS, V70, P353; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MENEES TM, 1989, GENETICS, V123, P675; MOENS PB, 1985, CHROMOSOMA, V91, P113, DOI 10.1007/BF00294054; MOENS PB, 1987, J CELL BIOL, V105, P93, DOI 10.1083/jcb.105.1.93; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PARRY DAD, 1977, J MOL BIOL, V113, P449, DOI 10.1016/0022-2836(77)90153-X; PETES TD, 1991, MOL BIOL YEAST SACCH, P406; RASMUSSEN SW, 1986, CARLSBERG RES COMMUN, V51, P401, DOI 10.1007/BF02907315; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1991, GENE DEV, V5, P2392, DOI 10.1101/gad.5.12b.2392; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAEZ L, 1986, NUCLEIC ACIDS RES, V14, P2951, DOI 10.1093/nar/14.7.2951; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; Sherman F., 1986, METHODS YEAST GENETI; SHUSTER EO, 1989, GENETICS, V123, P29; SMITH A, 1992, EXP CELL RES, V198, P291, DOI 10.1016/0014-4827(92)90382-I; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SOLARI AJ, 1973, J CELL BIOL, V56, P145, DOI 10.1083/jcb.56.1.145; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE D, 1978, J BIOL CHEM, V253, P1137; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; VOELKELMEIMAN K, 1990, GENETICS, V124, P561; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WEBER L, 1992, GENETICS, V131, P55; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; ZICKLER D, 1992, GENETICS, V132, P135	71	495	502	3	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					365	378		10.1016/0092-8674(93)90114-6	http://dx.doi.org/10.1016/0092-8674(93)90114-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	7916652	hybrid			2022-12-28	WOS:A1993KM16200007
J	BARER, D				BARER, D			PATIENTS PREFERENCES AND RANDOMIZED TRIALS	LANCET			English	Letter											BARER, D (corresponding author), NEWCASTLE GEN HOSP, DEPT MED ELDERLY, NEWCASTLE UPON TYNE NE4 6BE, TYNE & WEAR, ENGLAND.		Strang, John/H-5460-2011; Farrell, Michael P/A-4769-2012	Strang, John/0000-0002-5413-2725; Farrell, Michael P/0000-0001-7008-8130				LANGLEY GB, 1984, RHEUMATOL INT, V4, P119, DOI 10.1007/BF00541180; SILVERMAN WA, 1994, LANCET, V343, P1586, DOI 10.1016/S0140-6736(94)93053-8; Williams C, 1992, INTRO NEW TREATMENTS, P49; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	4	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 3	1994	344	8923					688	688		10.1016/S0140-6736(94)92124-5	http://dx.doi.org/10.1016/S0140-6736(94)92124-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915376				2022-12-28	WOS:A1994PE38600052
J	FINCH, E; GOSSOP, M; HANKINSON, L; TAYLOR, C; FARRELL, M; STRANG, J				FINCH, E; GOSSOP, M; HANKINSON, L; TAYLOR, C; FARRELL, M; STRANG, J			PATIENTS PREFERENCES AND RANDOMIZED TRIALS	LANCET			English	Letter											FINCH, E (corresponding author), NATL ADDICT CTR,4 WINDSOR WALK,LONDON SE5 8AF,ENGLAND.		Strang, John/H-5460-2011; Farrell, Michael P/A-4769-2012	Strang, John/0000-0002-5413-2725; Farrell, Michael P/0000-0001-7008-8130				GOSSOP M, 1986, BRIT MED J, V293, P103, DOI 10.1136/bmj.293.6539.103; ZELEN M, 1990, STAT MED, V9, P645, DOI 10.1002/sim.4780090611	2	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					688	689		10.1016/S0140-6736(94)92124-5	http://dx.doi.org/10.1016/S0140-6736(94)92124-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915376				2022-12-28	WOS:A1994PE38600053
